Dear Colleagues,

Welcome to ACG 2007, ACG’s Annual Scientific Meeting and Postgraduate Course, the premier GI clinical event of the year. This year’s program features internationally recognized experts and rising stars in the field of gastroenterology providing the latest clinical updates plus what is on the horizon that may impact your practice.

You’ll find several new features to this year’s meeting. ACG offers a new Allied Health Professionals Symposium, “A Case Based Approach to the Management of Common GI Diseases,” on Sunday, October 14, from 2:00 pm–5:00 pm. If your support staff of physician assistants, nurse practitioners and nurses are joining you at the meeting, we encourage you to attend this symposium with them.

ACG will also feature Poster Rounds with the Experts. Each day of the poster sessions a well-known expert will lead attendees around to posters of interest. Day one will feature some of the Journal editorial leaders; day two, ACG Board of Trustee members; and day three, ACG Educational Affairs Committee members. This is a great opportunity to discuss posters, garner insight from the expert, and make new contacts with other attendees in a low-key, relaxed atmosphere. Poster Rounds with the Experts runs from Sunday–Tuesday. You’ll find more information included as a flyer in your registration bag or visit the Information Booth or Registration for more details.

This year marks a historic milestone for ACG as we celebrate our 75th Anniversary. In celebration of our anniversary, ACG has published a book, American College of Gastroenterology: Seventy-Five Years of Commitment to Clinical Gastroenterology, Gastroenterologists, and Patient Health. The book is offered free to any ACG member attending ACG 2007. A ticket is included with your name badge and you can pick up your book at the ACG booth, #1518. We’ve also created a special 75th Anniversary exhibit display that may be found in the Grand Hall.

Don’t miss the social event of the meeting, the President’s Reception, which will take place on Monday evening from 7:00 pm–9:00 pm at the Marriott Salon CDE. Reconnect with old colleagues and make new contacts.

In closing, I want to thank you for the opportunity to serve you this year. It has been my pleasure to be the ACG President and I welcome everyone to the ACG 2007 Annual Scientific Meeting and Postgraduate Course.

Sincerely,

David A. Johnson, MD, FACG
ACG President
## Schedule at a Glance

<table>
<thead>
<tr>
<th>Friday, October 12</th>
<th>Saturday, October 13</th>
<th>Sunday, October 14</th>
<th>Monday, October 15</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Continental Breakfast</strong>&lt;br&gt;6:30 am-8:00 am</td>
<td><strong>Continental Breakfast</strong>&lt;br&gt;Grand Hall&lt;br&gt;7:00 am-7:45 am</td>
<td><strong>Continental Breakfast</strong>&lt;br&gt;Grand Hall&lt;br&gt;7:00 am-7:45 am</td>
<td><strong>Registration</strong>&lt;br&gt;Bridge Area&lt;br&gt;7:00 am-5:15 pm</td>
</tr>
<tr>
<td><strong>Registration</strong>&lt;br&gt;Bridge Area&lt;br&gt;6:30 am-8:00 pm</td>
<td><strong>Registration</strong>&lt;br&gt;Bridge Area&lt;br&gt;7:00 am-5:15 pm</td>
<td><strong>Registration</strong>&lt;br&gt;Bridge Area&lt;br&gt;7:00 am-6:30 pm</td>
<td><strong>Auxiliary Registration/ Hospitality Suite</strong>&lt;br&gt;Marriott Room 304&lt;br&gt;8:00 am-12:00 noon</td>
</tr>
<tr>
<td><strong>Review of GI Structure and Function Course</strong>&lt;br&gt;Lecture Hall&lt;br&gt;7:00 am-12:30 pm</td>
<td><strong>Postgraduate Course</strong>&lt;br&gt;Ballroom AB&lt;br&gt;7:50 am-5:15 pm</td>
<td><strong>Postgraduate Course</strong>&lt;br&gt;Ballroom AB&lt;br&gt;7:50 am-5:15 pm</td>
<td><strong>ACG Store</strong>&lt;br&gt;Grand Hall&lt;br&gt;8:00 am-5:00 pm</td>
</tr>
<tr>
<td><strong>Practice Management Course</strong>&lt;br&gt;Room 108 AB&lt;br&gt;7:00 am-6:00 pm</td>
<td><strong>ACG Store</strong>&lt;br&gt;Grand Hall&lt;br&gt;8:00 am-4:30 pm</td>
<td><strong>ACG Store</strong>&lt;br&gt;Grand Hall&lt;br&gt;8:00 am-4:30 pm</td>
<td><strong>Annual Meeting</strong>&lt;br&gt;Ballroom AB&lt;br&gt;8:00 am-5:15 pm</td>
</tr>
<tr>
<td><strong>ASGE-Sponsored Endoscopy Course</strong>&lt;br&gt;Room 103 ABC&lt;br&gt;8:00 am-5:15 pm</td>
<td><strong>David Sun Lecture</strong>&lt;br&gt;Ballroom AB&lt;br&gt;10:20 am-10:50 am</td>
<td><strong>Optional Learning Luncheons</strong>&lt;br&gt;(Ticket required. See ticket for room assignment.)&lt;br&gt;12:40 pm-1:55 pm</td>
<td><strong>Presidential Address</strong>&lt;br&gt;Ballroom AB&lt;br&gt;9:00 am-9:30 am</td>
</tr>
<tr>
<td><strong>GI Pharmacology Course</strong>&lt;br&gt;Lecture Hall&lt;br&gt;1:45 pm-4:45 pm</td>
<td><strong>Career Opportunities for Women in GI Luncheon</strong>&lt;br&gt;Room 104 AB&lt;br&gt;12:40 pm-1:55 pm</td>
<td><strong>Career Opportunities for Women in GI Luncheon</strong>&lt;br&gt;Room 104 AB&lt;br&gt;12:40 pm-1:55 pm</td>
<td><strong>Exhibit Hall Open</strong>&lt;br&gt;Exhibit Hall AB&lt;br&gt;9:30 am-4:00 pm</td>
</tr>
<tr>
<td><strong>ACG Store</strong>&lt;br&gt;Grand Hall&lt;br&gt;2:00 pm-6:00 pm</td>
<td><strong>Optional Learning Luncheons</strong>&lt;br&gt;(Ticket required. See ticket for room assignment.)&lt;br&gt;12:20 pm-1:35 pm</td>
<td><strong>Optional Learning Luncheons</strong>&lt;br&gt;(Ticket required. See ticket for room assignment.)&lt;br&gt;12:20 pm-1:35 pm</td>
<td><strong>Poster Sessions</strong>&lt;br&gt;Exhibit Hall AB&lt;br&gt;10:30 am-4:00 pm</td>
</tr>
<tr>
<td><strong>Recertification Preparation and Update Course</strong>&lt;br&gt;Room 111 AB&lt;br&gt;5:15 pm-8:15 pm</td>
<td><strong>NEW! Trainees Luncheon</strong>&lt;br&gt;(Ticket required.)&lt;br&gt;Room 110 AB&lt;br&gt;12:40 pm-1:55 pm</td>
<td><strong>NEW! ACG Allied Health Professionals Symposium</strong>&lt;br&gt;Room 104 A&lt;br&gt;2:00 pm-5:00 pm</td>
<td><strong>Lunch Break</strong>&lt;br&gt;Food available for purchase in Exhibit Hall AB.&lt;br&gt;12:15 pm-2:00 pm</td>
</tr>
<tr>
<td><strong>GI Jeopardy</strong>&lt;br&gt;Room 204 ABC&lt;br&gt;5:30 pm-7:00 pm</td>
<td><strong>GI Jeopardy</strong>&lt;br&gt;Room 204 ABC&lt;br&gt;5:30 pm-7:00 pm</td>
<td><strong>Poster Sessions</strong>&lt;br&gt;Exhibit Hall AB&lt;br&gt;3:30 pm-7:00 pm</td>
<td><strong>FAQ Session – Esophagus</strong>&lt;br&gt;Exhibit Hall AB&lt;br&gt;12:30 pm-1:00 pm</td>
</tr>
<tr>
<td><strong>FAQ Session – Pancreas</strong>&lt;br&gt;Exhibit Hall AB&lt;br&gt;1:15 pm-1:45 pm</td>
<td><strong>Exhibit Hall Open</strong>&lt;br&gt;Exhibit Hall AB&lt;br&gt;3:30 pm-7:00 pm</td>
<td><strong>Exhibit Hall Open</strong>&lt;br&gt;Exhibit Hall AB&lt;br&gt;3:30 pm-7:00 pm</td>
<td><strong>FAQ Session – Pancreas</strong>&lt;br&gt;Exhibit Hall AB&lt;br&gt;1:15 pm-1:45 pm</td>
</tr>
<tr>
<td><strong>Trainees’ Forum</strong>&lt;br&gt;Room 103 AB&lt;br&gt;5:30 pm-7:00 pm</td>
<td><strong>Alumni Receptions</strong>&lt;br&gt;Consult ACG Registration Area for room locations.&lt;br&gt;6:00 pm-7:00 pm</td>
<td><strong>Alumni Receptions</strong>&lt;br&gt;Consult ACG Registration Area for room locations.&lt;br&gt;6:00 pm-7:00 pm</td>
<td><strong>The American Journal of Gastroenterology Lecture</strong>&lt;br&gt;Ballroom B&lt;br&gt;2:40 pm-3:20 pm</td>
</tr>
<tr>
<td><strong>Women and Minorities in GI Reception</strong>&lt;br&gt;Marriott Room 309&lt;br&gt;6:00 pm-7:00 pm</td>
<td><strong>Women and Minorities in GI Reception</strong>&lt;br&gt;Marriott Room 309&lt;br&gt;6:00 pm-7:00 pm</td>
<td><strong>Women and Minorities in GI Reception</strong>&lt;br&gt;Marriott Room 309&lt;br&gt;6:00 pm-7:00 pm</td>
<td><strong>ACG Business Meeting</strong>&lt;br&gt;Ballroom B&lt;br&gt;5:30 pm-6:00 pm</td>
</tr>
<tr>
<td><strong>International Attendee Reception</strong>&lt;br&gt;Marriott Room 309/310&lt;br&gt;6:00 pm-7:00 pm</td>
<td><strong>International Attendee Reception</strong>&lt;br&gt;Marriott Room 309/310&lt;br&gt;6:00 pm-7:00 pm</td>
<td><strong>International Attendee Reception</strong>&lt;br&gt;Marriott Room 309/310&lt;br&gt;6:00 pm-7:00 pm</td>
<td><strong>President’s Reception</strong>&lt;br&gt;Marriott Salon CDE&lt;br&gt;7:00 pm-9:00 pm</td>
</tr>
</tbody>
</table>

### Attention ACG Members

Looking to hire qualified candidates? Post your job openings for free at the ACG 2007 Job Forum. You can schedule on-site interviews or follow up with prospective employees after the meeting. For more information on how you can participate in the ACG 2007 Job Forum, visit www.acgmeetings.org/jobforum.
Optional Breakfast Sessions
(Ticket required. See ticket for room assignment.)
6:45 am-8:30 am

Registration
Bridge Area
6:45 am-6:00 pm

Auxiliary Registration/ Hospitality Suite
Marriott Room 304
8:00 am-12:00 noon

ACG Store
Grand Hall
8:00 am-4:30 pm

Job Forum
Room 203 B
8:00 am-5:00 pm

Annual Meeting
Ballroom AB
8:30 am-11:00 am

Exhibit Hall
Exhibit Hall AB
9:30 am-4:00 pm

J. Edward Berk Distinguished Lecture
Exhibit Hall AB
10:00 am-10:30 am

Poster Sessions
Exhibit Hall AB
10:30 am-4:00 pm

Lunch Break
Food available for purchase in Exhibit Hall AB.
12:15 pm-2:00 pm

FAQ Session – Liver
Exhibit Hall AB
12:30 pm-1:00 pm

FAQ Session – IBD
Exhibit Hall AB
1:15 pm-1:45 pm

Emily Couric Memorial Lecture
Ballroom AB
2:00 pm-2:30 pm

Optional Breakfast Sessions
(Ticket required. See ticket for room assignment.)
6:45 am-8:30 am

Registration
Bridge Area
6:45 am-6:00 pm

Auxiliary Registration/ Hospitality Suite
Marriott Room 304
8:00 am-12:00 noon

ACG Store
Grand Hall
8:00 am-12:00 noon

Job Forum
Room 203 B
8:00 am-12:00 noon

Annual Meeting
Ballroom AB
8:30 am-12:30 pm

Exhibit Hall
Exhibit Hall AB
9:30 am-12:00 noon

David Y. Graham Lecture
Ballroom B
10:15 am-10:45 am

ACKNOWLEDGEMENTS
The American College of Gastroenterology acknowledges with thanks contributions in support of this year’s program from the following:

Abbott Labs
AstraZeneca
Braintree
Ganeden Biotech
TAP Pharmaceutical Products, Inc.
Fleet Laboratories
Shire Pharmaceuticals
Sucampo/Takeda Pharmaceuticals
UCB, Inc.
Elan Pharmaceuticals/Biogen
ProPath
Ethicon Endo-Surgery
Dannon Company
Axcan Pharma
Friday Optional Courses, Postgraduate Course Learning Luncheons and Annual Meeting Breakfast Sessions

Exhibits, Poster Sessions, FAQ Sessions

Postgraduate Course and Annual Meeting Sessions

Existing Ballrooms Above Level 2

ACG Information Booth and ACG Store

Speaker Ready Room, Press Room, and Annual Meeting Simultaneous Plenary and Symposia Sessions
### Event Locations — Friday, October 12

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45–8:00 am</td>
<td>Continental Breakfast</td>
<td>Outside course room</td>
</tr>
<tr>
<td>7:00 am–12:30 pm</td>
<td>Review of GI Structure and Function Course</td>
<td>Lecture Hall</td>
</tr>
<tr>
<td></td>
<td>Registration is required. Visit ACG Registration to register, however</td>
<td></td>
</tr>
<tr>
<td></td>
<td>session may be sold out.</td>
<td></td>
</tr>
<tr>
<td>7:00 am–6:00 pm</td>
<td>Practice Management Course</td>
<td>Room 108 AB</td>
</tr>
<tr>
<td></td>
<td>Registration is required. Visit ACG Registration to register, however</td>
<td></td>
</tr>
<tr>
<td></td>
<td>session may be sold out.</td>
<td></td>
</tr>
<tr>
<td>8:00 am–5:15 pm</td>
<td>ASGE-sponsored Endoscopy Course</td>
<td>Room 103 ABC</td>
</tr>
<tr>
<td></td>
<td>Registration is required. Visit ACG Registration to register, however</td>
<td></td>
</tr>
<tr>
<td></td>
<td>session may be sold out.</td>
<td></td>
</tr>
<tr>
<td>1:45–4:45 pm</td>
<td>What’s New in GI Pharmacology Course</td>
<td>Lecture Hall</td>
</tr>
<tr>
<td></td>
<td>Registration is required. Visit ACG Registration to register, however</td>
<td></td>
</tr>
<tr>
<td></td>
<td>session may be sold out.</td>
<td></td>
</tr>
<tr>
<td>5:15–8:15 pm</td>
<td>Recertification Preparation and Update Course</td>
<td>Room 111 AB</td>
</tr>
<tr>
<td></td>
<td>Registration is required. Visit ACG Registration to register, however</td>
<td></td>
</tr>
<tr>
<td></td>
<td>session may be sold out.</td>
<td></td>
</tr>
</tbody>
</table>

### Event Locations — Saturday, October 13

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00–7:45 am</td>
<td>Continental Breakfast</td>
<td>Grand Hall</td>
</tr>
<tr>
<td>7:50 am–5:15 pm</td>
<td>Postgraduate Course</td>
<td>Ballroom AB</td>
</tr>
<tr>
<td>10:20–10:50 am</td>
<td>David Sun Lecture&lt;br&gt;Esophageal Dilation: A Perspective of 45 Years of</td>
<td>Ballroom AB</td>
</tr>
<tr>
<td></td>
<td>Experience: Pearls, Perils and Pitfalls&lt;br&gt;&lt;i&gt;H. Worth Boyle, Jr., MD, MACG&lt;/i&gt;</td>
<td></td>
</tr>
<tr>
<td>12:40–1:55 pm</td>
<td>OPTIONAL LEARNING LUNCHEONS&lt;br&gt;Cost is $50 person/per session. Visit ACG</td>
<td>Room location on ticket</td>
</tr>
<tr>
<td></td>
<td>Registration to purchase tickets, however some sessions may be sold out.</td>
<td></td>
</tr>
<tr>
<td>12:40–1:55 pm</td>
<td>Career Opportunities for Women in GI Luncheon&lt;br&gt;Advanced registration</td>
<td>Room 104 AB</td>
</tr>
<tr>
<td></td>
<td>required.</td>
<td></td>
</tr>
<tr>
<td>12:40–1:55 pm</td>
<td>Trainees Luncheon&lt;br&gt;Cost is $25 person. Visit ACG Registration to</td>
<td>Room 110 AB</td>
</tr>
<tr>
<td></td>
<td>purchase ticket, however this event may be sold out.</td>
<td></td>
</tr>
<tr>
<td>5:30–7:00 pm</td>
<td>GI Jeopardy Competition • All attendees are invited</td>
<td>Room 204 ABC</td>
</tr>
</tbody>
</table>
### Event Locations — Sunday, October 14

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Location</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00–7:45 am</td>
<td>Continental Breakfast</td>
<td>Grand Hall</td>
<td>6</td>
</tr>
<tr>
<td>7:50 am–5:15 pm</td>
<td>Postgraduate Course</td>
<td>Ballroom AB</td>
<td></td>
</tr>
<tr>
<td>12:20–1:35 pm</td>
<td><strong>OPTIONAL LEARNING LUNCHEONS</strong></td>
<td>Room location on ticket</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cost is $50 person/per session. Visit ACG Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>to purchase tickets, however some sessions may be sold</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00–5:00 pm</td>
<td><strong>ACG Allied Health Professionals Symposium</strong></td>
<td>Room 104 A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Registration is required. Visit ACG Registration to</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>register, however session may be sold out.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30–7:00 pm</td>
<td>Poster Sessions Open</td>
<td>Exhibit Hall</td>
<td></td>
</tr>
<tr>
<td>3:30–7:00 pm</td>
<td>Exhibit Hall Opens</td>
<td>Exhibit Hall</td>
<td></td>
</tr>
<tr>
<td>5:30–7:00 pm</td>
<td><strong>Trainees Forum</strong> • All Trainees are invited</td>
<td>Room 103 AB</td>
<td></td>
</tr>
<tr>
<td>6:00–7:00 pm</td>
<td><strong>Alumni Receptions</strong> • ???</td>
<td>Room ???</td>
<td></td>
</tr>
<tr>
<td>6:00–7:00 pm</td>
<td><strong>Women and Minorities in GI Reception</strong> • All</td>
<td>Marriott Hotel Room</td>
<td></td>
</tr>
<tr>
<td></td>
<td>attendees are invited</td>
<td>309/310</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Location</td>
<td>Page</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------</td>
<td>-------------------</td>
<td>------</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Opening Remarks</td>
<td>Ballroom AB</td>
<td>19</td>
</tr>
<tr>
<td>8:00–9:00 am</td>
<td>President’s Plenary Session</td>
<td>Ballroom AB</td>
<td>19</td>
</tr>
<tr>
<td>9:00–9:25 am</td>
<td>Presidential Address [David A. Johnson, MD, FACG]</td>
<td>Ballroom AB</td>
<td>19 &amp; 29</td>
</tr>
<tr>
<td>9:25–9:30 am</td>
<td>Awards Program</td>
<td>Ballroom AB</td>
<td>19</td>
</tr>
<tr>
<td>9:30–10:30 am</td>
<td>President’s Plenary Session</td>
<td>Ballroom AB</td>
<td>19</td>
</tr>
<tr>
<td>10:30–11:00 am</td>
<td>Coffee Break • Visit Exhibits</td>
<td>Exhibit Hall AB</td>
<td>3</td>
</tr>
<tr>
<td>11:00 am–12:15 pm</td>
<td>SIMULTANEOUS SYMPOSIA 1</td>
<td>Ballroom A, Ballroom B</td>
<td>20 &amp; 20</td>
</tr>
<tr>
<td></td>
<td>1A: Top Down or Step Up Therapy in Crohn’s Disease: Which is Right?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1B: Complications from Cirrhosis: We’re Making Progress</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15–2:00 pm</td>
<td>Lunch Break • Visit Poster Session</td>
<td>Exhibit Hall AB</td>
<td>3</td>
</tr>
<tr>
<td>12:30–1:00 pm</td>
<td>FAQ Session: Esophagus</td>
<td>Exhibit Hall AB</td>
<td>20</td>
</tr>
<tr>
<td>1:15–1:45 pm</td>
<td>FAQ Session: Pancreas</td>
<td>Exhibit Hall AB</td>
<td>20</td>
</tr>
<tr>
<td>2:00–2:40 pm</td>
<td>SIMULTANEOUS PLENARY SESSIONS</td>
<td>Room 204 ABC, Room 201 ABC</td>
<td>20 &amp; 20</td>
</tr>
<tr>
<td></td>
<td>Session 1: Colorectal Cancer Prevention/Small Intestine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session 2: Pancreatic/Biliary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:40–3:20 pm</td>
<td>The American Journal of Gastroenterology Lecture</td>
<td>Ballroom B</td>
<td>4 &amp; 21</td>
</tr>
<tr>
<td></td>
<td>NOTES: Just Because We Can, Should We?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anthony N. Kalloo, MD, FACG &amp; Jeffrey L. Ponsky, MD, FACG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:20–3:50 pm</td>
<td>Break • Visit Exhibits</td>
<td>Exhibit Hall AB</td>
<td>3</td>
</tr>
<tr>
<td>3:50–5:15 pm</td>
<td>SIMULTANEOUS SYMPOSIA 2</td>
<td>Ballroom A, Ballroom B</td>
<td>21 &amp; 21</td>
</tr>
<tr>
<td></td>
<td>2A: Colon Cancer Screening: What You Need to Know for the Future</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2B: How and When to Intervene for Biliary Symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:30–6:00 pm</td>
<td>Annual Business Meeting • College Members and Fellows invited</td>
<td>Ballroom B</td>
<td>21 &amp; 29</td>
</tr>
<tr>
<td>6:00–7:00 pm</td>
<td>International Reception • All International attendees are invited</td>
<td>Marriott Rooms 309/310</td>
<td>21 &amp; 29</td>
</tr>
<tr>
<td>7:00–9:00 pm</td>
<td>President’s Reception • All attendees are invited</td>
<td>Marriott Salon CDE</td>
<td>21 &amp; 29</td>
</tr>
</tbody>
</table>
**Event Locations — Tuesday, October 16**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Location</th>
<th>Page</th>
</tr>
</thead>
</table>
| 6:45–8:00 am | **BREAKFAST SESSIONS**  
Cost is $40 per person/per session. Visit ACG Registration to purchase tickets, however some sessions may be sold out. | Room location on ticket | 8
| 8:30–10:00 am| Plenary Session: IBD/Endoscopy                                                      | Ballroom AB  | 8
| 10:00–10:30 am | **J. Edward Berk Distinguished Lecture**  
Alice in Wonderland: The Endoscopist of the Future and the Gastrointestinal Mucosa Through the “New” Looking Glass  
*M. Brian Fennerty, MD, FACG* | Ballroom B | 8
| 10:30–11:00 am | Coffee Break • Visit Exhibits                                                       | Exhibit Hall | 8
| 11:00 am–12:15 pm | **SIMULTANEOUS SYMPOSIA 3**  
3A: Irritable Bowel Syndrome: SIBO or “Pla-SIBO”?  
3B: Esophagus: Burning Issues in 2007  
3C: Screening for GI Malignancies: An International Perspective | Ballroom B, Ballroom A, Room 204 ABC | 8
| 12:15–2:00 pm | Lunch Break • Visit Poster Session                                                  | Exhibit Hall | 8
| 12:30–1:00 pm | **FAQ Session: Liver**                                                              | Exhibit Hall | 8
| 1:15–1:45 pm | **FAQ Session: IBD**                                                                | Exhibit Hall | 8
| 2:00–2:45 pm | Emily Couric Memorial Lecture  
Pancreatic Cancer: Present Understanding and Future Prospects  
*Peter A. Banks, MD, MACG* | Ballroom B | 8
| 2:45–4:15 pm | **SIMULTANEOUS PLENARY SESSIONS**  
Session 1: Outcomes/Research/Stomach  
Session 2: Liver/Esophagus | Room 204 ABC, Room 201 ABC | 8
| 4:15–4:45 pm | Break • Visit Exhibits                                                              | Exhibit Hall | 8
| 4:45–6:00 pm | **SIMULTANEOUS SYMPOSIA 4**  
4A: Advances in Therapy for Ulcerative Colitis  
4B: HGI Bleeding: What Do You Do When the EGD & Colonoscopy are Normal?  
4C: Spotlight on Obesity | Ballroom A, Ballroom B, Room 204 ABC | 8
# Event Locations — Wednesday, October 17

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45–8:00 am</td>
<td><strong>BREAKFAST SESSIONS</strong>&lt;br&gt;Cost is $40 per person/per session. Visit ACG Registration to purchase tickets, however some sessions may be sold out.</td>
<td>Room location on ticket</td>
<td>##</td>
</tr>
<tr>
<td>8:30–10:15 am</td>
<td><strong>SIMULTANEOUS PLENARY SESSIONS</strong>&lt;br&gt;Session 1: Colon/Functional Bowel Disorders&lt;br&gt;Session 2: IBD/Esophagus/Endoscopy</td>
<td>Room 204 ABC &lt;br&gt;Room 201 ABC</td>
<td>##</td>
</tr>
<tr>
<td>10:15–10:45 am</td>
<td><strong>David Y. Graham Lecture</strong>&lt;br&gt;Evidence-Based Medicine: What Does it Mean for Gastroenterology—Present and Future&lt;br&gt;<em>Walter L. “Pete” Peterson, MD, FACP</em></td>
<td>Ballroom B</td>
<td>##</td>
</tr>
<tr>
<td>10:45–11:15 am</td>
<td><strong>Coffee Break • Visit Exhibits</strong></td>
<td>Exhibit Hall AB</td>
<td>##</td>
</tr>
<tr>
<td>11:15 am–12:30 pm</td>
<td><strong>SIMULTANEOUS SYMPOSIA 5</strong>&lt;br&gt;5A: Hepatitis C: New Insights&lt;br&gt;5B: The Ins and Outs of the Difficult Colonoscopy</td>
<td>Ballroom A &lt;br&gt;Ballroom B</td>
<td>##</td>
</tr>
<tr>
<td>12:30 pm</td>
<td><strong>Meeting Adjourns</strong></td>
<td>Room 109 AB</td>
<td>##</td>
</tr>
<tr>
<td>12:30–5:30 pm</td>
<td><strong>Women’s Networking, Negotiating and Leadership Skills Workshop</strong>&lt;br&gt;Advanced registration required. Visit ACG Registration to register, however session may be sold out.</td>
<td>Room 109 AB</td>
<td>##</td>
</tr>
</tbody>
</table>
# ACG Officers

## Officers 2006–2007

**President**  
David A. Johnson, MD, FACG • Norfolk, Virginia

**President-Elect**  
Amy E. Foxx-Orenstein, DO, FACG • Rochester, Minnesota

**Vice President**  
Eamonn M.M. Quigley, MD, FACG • Cork, Ireland

**Secretary**  
Delbert L. Chumley, MD, FACG • San Antonio, Texas

**Treasurer**  
Philip O. Katz, MD, FACG • Philadelphia, Pennsylvania

**Immediate Past President**  
Jack A. DiPalma MD, FACG • Mobile, Alabama

**Past President**  
John W. Popp, Jr., MD, FACG • Columbia, South Carolina

**Director, ACG Institute for Clinical Research and Education**  
Edgar Achkar, MD, FACG • Cleveland, Ohio

**Chair, Board of Governors**  
Francis A. Farraye, MD, FACG • Boston, Massachusetts

**Vice Chair, Board of Governors**  
Samir A. Shah, MD, FACG • Providence, Rhode Island

**Co-Editors, The American Journal of Gastroenterology**  
Joel E. Richter, MD, MACG • Philadelphia, Pennsylvania  
Nicholas J. Talley, MD, PhD, FACG • Rochester, Minnesota

## ACG Past Presidents

<table>
<thead>
<tr>
<th>Name</th>
<th>Years of Service</th>
<th>City, State</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack A. DiPalma</td>
<td>2005-2006</td>
<td>Mobile, AL</td>
</tr>
<tr>
<td>John W. Popp, Jr.</td>
<td>2004-2005</td>
<td>Columbia, SC</td>
</tr>
<tr>
<td>Douglas K. Rex</td>
<td>2003-2004</td>
<td>Indianapolis, IN</td>
</tr>
<tr>
<td>Frank L. Lanza</td>
<td>2002-2003</td>
<td>Houston, TX</td>
</tr>
<tr>
<td>Edgar Achkar</td>
<td>2001-2002</td>
<td>Cleveland, OH</td>
</tr>
<tr>
<td>Rowen K. Zetterman</td>
<td>2000-2001</td>
<td>Omaha, NE</td>
</tr>
<tr>
<td>Luis A. Balart</td>
<td>1999-2000</td>
<td>New Orleans, LA</td>
</tr>
<tr>
<td>Christina M. Surawicz</td>
<td>1998-1999</td>
<td>Seattle, WA</td>
</tr>
<tr>
<td>Sankis J. Chobanian</td>
<td>1997-1998</td>
<td>Knoxville, TN</td>
</tr>
<tr>
<td>Marvin M. Schuster</td>
<td>1996-1997</td>
<td>Baltimore, MD</td>
</tr>
<tr>
<td>Seymour Katz</td>
<td>1995-1996</td>
<td>Great Neck, NY</td>
</tr>
<tr>
<td>Joel E. Richter</td>
<td>1994-1995</td>
<td>Cleveland, OH</td>
</tr>
<tr>
<td>William D. Carey</td>
<td>1993-1994</td>
<td>Bronx, NY</td>
</tr>
<tr>
<td>Lawrence J. Brandt</td>
<td>1992-1993</td>
<td>Miami, FL</td>
</tr>
<tr>
<td>Arvei I. Rogers</td>
<td>1991-1992</td>
<td>Houston, TX</td>
</tr>
<tr>
<td>David Y. Graham</td>
<td>1990-1991</td>
<td>Miami, FL</td>
</tr>
<tr>
<td>Jamie S. Barkin</td>
<td>1989-1990</td>
<td>New Orleans, LA</td>
</tr>
<tr>
<td>Chesley Hines, Jr.</td>
<td>1988-1989</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Myron Lewis, MD</td>
<td>1987-1988</td>
<td>Philadelphia, PA</td>
</tr>
<tr>
<td>John P. Papp, MD</td>
<td>1985-1986</td>
<td>Grand Rapids, MI</td>
</tr>
<tr>
<td>Walter H. Jacobs</td>
<td>1984-1985</td>
<td>Kansas City, MO</td>
</tr>
<tr>
<td>James L. Achord</td>
<td>1983-1984</td>
<td>Jackson, MS</td>
</tr>
<tr>
<td>Jerome D. Waye</td>
<td>1982-1983</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Franz Goldstein</td>
<td>1981-1982</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Sidney J. Winawer</td>
<td>1979-1980</td>
<td>Washington, DC</td>
</tr>
<tr>
<td>Richard G. Farmer</td>
<td>1978-1979</td>
<td>New York, NY</td>
</tr>
<tr>
<td>*F. Warren Nugent</td>
<td>1976-1977</td>
<td>Burlington, MA</td>
</tr>
<tr>
<td>J. Edward Berk</td>
<td>1975-1976</td>
<td>Irvine, CA</td>
</tr>
<tr>
<td>John T. Galambos</td>
<td>1974-1975</td>
<td>Atlanta, GA</td>
</tr>
<tr>
<td>*Angelo E. Dagradi</td>
<td>1973-1974</td>
<td>Palm Desert, CA</td>
</tr>
<tr>
<td>*Mitchell A. Spellberg</td>
<td>1971-1972</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>*Joseph E. Walther</td>
<td>1970-1971</td>
<td>Indianapolis, IN</td>
</tr>
<tr>
<td>*David A. Dreiling</td>
<td>1968-1969</td>
<td>New York, NY</td>
</tr>
<tr>
<td>*John M. McMahon</td>
<td>1966-1967</td>
<td>Bessemer, AL</td>
</tr>
<tr>
<td>*Maxwell R. Berry</td>
<td>1965-1966</td>
<td>Big Canoe, GA</td>
</tr>
<tr>
<td>*Milton J. Matzner</td>
<td>1964-1965</td>
<td>Brooklyn, NY</td>
</tr>
<tr>
<td>*Robert R. Bartunek</td>
<td>1963-1964</td>
<td>Cleveland, OH</td>
</tr>
<tr>
<td>*Edward J. Krol</td>
<td>1962-1963</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>*Theodore S. Heineneck</td>
<td>1962</td>
<td>Glen Ridge, NJ</td>
</tr>
<tr>
<td>*Louis Ochs, Jr.</td>
<td>1961</td>
<td>New Orleans, LA</td>
</tr>
<tr>
<td>*Henry Baker, MD</td>
<td>1960-1961</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>*Joseph Shaiken</td>
<td>1959-1960</td>
<td>Milwaukee, WI</td>
</tr>
<tr>
<td>*Frank J. Borrelli</td>
<td>1958-1959</td>
<td>New York, NY</td>
</tr>
<tr>
<td>*C. William Wirts</td>
<td>1957-1958</td>
<td>Philadelphia, PA</td>
</tr>
<tr>
<td>*Arthur A. Kirchner</td>
<td>1956-1957</td>
<td>Los Angeles, CA</td>
</tr>
<tr>
<td>*James T. Nix</td>
<td>1955-1956</td>
<td>New Orleans, LA</td>
</tr>
<tr>
<td>*Lynn A. Ferguson</td>
<td>1954-1955</td>
<td>Grand Rapids, MI</td>
</tr>
<tr>
<td>*Sigurd W. Johnsen</td>
<td>1953-1954</td>
<td>Passaic, NJ</td>
</tr>
<tr>
<td>*Felix Cunha, MD</td>
<td>1952-1953</td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td>*William W. Lermann</td>
<td>1951-1952</td>
<td>Pittsburgh, PA</td>
</tr>
<tr>
<td>*C.J. Tidmarsh, MD</td>
<td>1950-1951</td>
<td>Montreal, Canada</td>
</tr>
<tr>
<td>*Horace W. Soper</td>
<td>1949-1950</td>
<td>St. Louis, MO</td>
</tr>
<tr>
<td>*William R. Morrison</td>
<td>1948-1949</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>*Anthony Bassler</td>
<td>1936-1948</td>
<td>New York, NY</td>
</tr>
<tr>
<td>*G. Randolph Manning</td>
<td>1932-1936</td>
<td>New York, NY</td>
</tr>
<tr>
<td>*Isidor L. Ritter</td>
<td>1932</td>
<td>New York, NY</td>
</tr>
</tbody>
</table>

*Deceased

---

**Trustees**

Carol A. Burke, MD, FACG • Cleveland, Ohio  
Ira L. Flax, MD, FACG • Houston, Texas  
Anthony N. Kalloo, MD, FACG • Baltimore, Maryland  
W. Elwyn Lyles, MD, FACG • Alexandria, Louisiana  
Dawn Provenzale, MD, FACG • Durham, North Carolina  
Harry E. Sarles, Jr., MD, FACG • Dallas, Texas  
Lawrence R. Schiller, MD, FACG • Dallas, Texas  
Mitchell L. Shiffman, MD, FACG • Richmond, Virginia  
Ronald L. Vender, MD, FACG • Hamden, Connecticut  
Roy K.H. Wong, MD, FACG • Washington, DC
ACG BOARD OF GOVERNORS 2006–2007
Chair: Francis A. Farraye, MD, FACG
Vice Chair: Samir A. Shah, MD, FACG

REGION I
Regional Councillor
Scott M. Tenner, MD, FACG (2009) Brooklyn
Burton S. Aronoff, MD, FACG (2009) Delaware
Matthew J. McKinley, MD, FACG (2007) Long Island
Andreas M. Stefan, MD, FACG (2009) Maine
Jerome H. Siegel, MD, MACG (2008) Manhattan
John R. Saltzman, MD, FACG (2008) Massachusetts
Kiron M. Das, MD, PhD, FACG (2008) New Jersey
Peter F. Purcell, MD, FACG (2007) Northern New York
Alyn L. Adrain, MD, FACG (2009) Rhode Island
James A. Vecchio, MD, FACG (2009) Vermont

REGION II
Daniel J. Pambianco, MD, FACG (2008) Virginia
Regional Councillor
Jorge L. Herrera, MD, FACG (2008) Alabama
R. Martin Bashir, MD, FACG (2009) District of Columbia
J. Patrick Waring, MD, FACG (2008) Georgia
Walter T. Boone, MD, FACG (2007) Mississippi
Sami R. Achem, MD, FACG (2009) Northern Florida
Rafael E. Medina-Rivera, MD, FACG (2008) Puerto Rico
March E. Seabrook, MD, FACG (2009) South Carolina
James S. Leavitt, MD, FACG (2009) Southern Florida

REGION III
R. Bruce Cameron, MD, FACG (2008) Northern Ohio
Regional Councillor
Naga P. Chalasani, MD, FACG (2007) Indiana
William B. Silverman, MD, FACG (2009) Iowa
Owen J. Smith, MD, FACG (2007) Kansas
Edward C. Adler, MD, FACG (2009) Kentucky
Stephen C. Hauser, MD, FACG (2009) Minnesota
Allan P. Weston, MD, FACG (2009) Missouri
Gary W. Varilek, MD, FACG (2009) Nebraska
Somasundaram Bharath, MD, FACG (2009) North Dakota
Jeffrey A. Murray, MD, FACG (2009) South Dakota
Norman H. Gilinsky, MD, FACG (2007) Southern Ohio
Michael J. Schmalz, MD, FACG (2007) Wisconsin

REGION IV
Michael K. Bay, MD, FACG (2009) Southern Texas
Regional Councillor
Steven A. Clift, MD, FACG (2008) Arkansas
W. Elwyn Lyles, MD, FACG (2008) Louisiana
Gulsan Parasher, MD, FACG (2009) New Mexico
Stephen J. Ferney, MD, FACG (2009) Northern Texas

REGION V
Joseph W. Leung, MD, FACG (2007) Northern California
Regional Councillor
Richard E. Sampiner, MD, MACG (2009) Arizona
John S. Sabel, MD, FACG (2008) Colorado
Fernando V. Ona, MD, FACG (2008) Hawaii
Stephen M. Schultz, MD, FACG (2007) Idaho
Brian K. Landsverk, MD, FACG (2008) Montana
Kandice L. Knigge, MD, FACG (2007) Oregon
Simon K. Lo, MD, FACG (2007) Southern California A
Paul J. Pockros, MD, FACG (2009) Southern California B
Duane V. Bohman, MD, FACG (2008) Utah
Klaus Mergener, MD, PhD, FACG (2007) Washington

REGION VI
Hugh Chaun, MD, FACG (2007) Western Province, Canada
Regional Councillor
Franz Josef Schweiger, MD, FACG (2007) Maritime Provinces, Canada
Alvin Newman, MD, FACG (2009) Ontario Provinces, Canada
Pierre Paré, MD, FACG (2007) Quebec Province, Canada

INTERNATIONAL
Franz Josef Schweiger, MD, FACG (2007) Maritime Provinces, Canada
Alvin Newman, MD, FACG (2009) Ontario Provinces, Canada
Pierre Paré, MD, FACG (2007) Quebec Province, Canada

PAST CHAIRS ACG BOARD OF GOVERNORS
2005-2006 .......................................................... Francis A. Farraye, MD, FACG
2004-2005 .......................................................... Richard P. MacDermott, MD, FACG
2002-2004 .......................................................... Harry E. Sarles, Jr., MD, FACG
2000-2002 .......................................................... Roy K.H. Wong, MD, FACG
1998-2000 .......................................................... Edgar Achkar, MD, FACG
1996-1998 .......................................................... Douglas K. Rex, MD, FACG
1994-1996 .......................................................... P. Gregory Foutch, DO, FACG
1992-1994 .......................................................... Luis A. Balart, MD, FACG
1990-1992 .......................................................... David A. Peura, MD, FACG
1988-1990 .......................................................... William D. Carey, MD, FACG
1986-1988 .......................................................... Albert C. Svoboda, Jr., MD, FACG
1984-1986 .......................................................... E. Marvin Sokol, MD, FACG
1982-1984 .......................................................... Gerald H. Becker, MD, FACG
1981-1982 .......................................................... E. Marvin Sokol, MD, FACG
1980-1981 .......................................................... Alvin M. Collar, MD, FACG
1976-1980 .......................................................... Robert L. Berger, MD, FACG
1973-1976 .......................................................... Richard N. Meyers, MD, FACG
1970-1973 .......................................................... Albert M. Yunich, MD, FACG
1969-1970 .......................................................... Edward I. Melich, MD, FACG
1968-1969 .......................................................... Manuel Sklar, MD, FACG
1967-1968 .......................................................... Edward I. Melich, MD, FACG
1966-1967 .......................................................... Warren Breidenbach, MD, FACG
1965-1966 .......................................................... Edward I. Melich, MD, FACG
1964-1965 .......................................................... Edward J. Nightingale, MD, FACG
1962-1964 .......................................................... Stanley Sidenberg, MD, FACG
1959-1962 .......................................................... Libby Pulsifer, MD, FACG
1958-1959 .......................................................... Dale W. Creek, MD, FACG
1955-1958 .......................................................... Henry G. Rudner, Sr., MD, FACG
1954-1955 .......................................................... Henry Baker, MD, FACG
### ACG Committees

#### Archives Committee
Chair: Kevin W. Olden, MD, FACP (2007) Little Rock, AR
James L. Achord, MD, MACG (2007) Brandon, MS
V. Alik Botoman, MD, FACP (2009) Fort Lauderdale, FL
Mitchell S. Cappell, MD, PhD, FACP (2008) Royal Oak, MI
Arvey I. Rogers, MD, MACG (2007) Miami, FL
Sidney J. Winawer, MD, MACG (2009) New York, NY
Alvin M. Zfass, MD, MACG (2009) Richmond, VA

#### Awards Committee
Chair: Christina M. Surawicz, MD, FACP (2007) Seattle, WA
Peter A. Banks, MD, MACG (2009) Boston, MA
Jamie S. Bankin, MD, MACG (2009) Miami Beach, FL
Seymour Katz, MD, MACG (2009) Great Neck, NY
Frank L. Lanza, MD, FACG (2008) Houston, TX
Daniel Pelot, MD, MACG (2008) Orange, CA
Marvin M. Schuster, MD, MACG (2008) Baltimore, MD

#### Constitution & Bylaws Committee
Chair: Daniel J. Pambianco, MD, FACP (2007) Charlottesville, VA
Carolyn H. Cegielski, DO (2008) Laurel, MD
Adil M. Choudhary, MD, FACP (2009) Roswell, NM
Harvey B. Lefton, MD, FACP (2008) Huntington, WA
V. Raman Muthusamy, MD (2009) Irvine, CA
Patricia L. Raymond, MD, FACP (2008) Chesapeake, VA
S. Todd Threadgill, MD (2008) Oxford, MS

#### Credentials Committee
Chair: David A. Gremse, MD, MACG (2007) Las Vegas, NV
Delbert L. Chumley, MD, FACP (2007) San Antonio, TX
John D. Horwath, MD, FACP (2009) Rockville, MD
Paul E. Hoyle, PhD (2008) Avondale, PA
Priya Jamidar, MD, FACP (2008) New Haven, CT
Mitchell A. Mahmoud, MD, FACP (2009) Rocky Mount, NC
Arif M. Muslim, MD, FACP (2008) New Windsor, NY
Timothy T. Nostrand, MD, FACP (2008) Ann Arbor, MI
William B. Silverman, MD, FACP (2008) Iowa City, IA
Paul R. Tarnasky, MD, FACP (2007) Dallas, TX
Vedapuwaran Viswanathan, MD, FACP (2009) Bel Air, MD

#### Educational Affairs Committee
Chair: Carol A. Burke, MD, FACP (2007) Cleveland, OH
Maria T. Abreu, MD, FACP (2007) New York, NY
Jean-Paul Achkar, MD, FACP (2007) Cleveland, OH
Marie L. Borum, MD, MPH, FACP (2008) Fairfax Station, VA
Michael D. Brown, MD, FACP (2008) Oak Park, IL
Ron Yustein, MD, ODE (2007) San Antonio, TX
Joyce Korvick, MD, MPH (FDA)
Ron Yustein, MD, ODE (FDA)

#### Finance and Budget Committee
Chair: Frank A. Hamilton, MD, MACG (2007) Bethesda, MD
Alberto O. Barroso, MD, FACP (2008) Houston, TX
Manooop S. Bhutani, MD, FACP (2008) Houston, TX
Sita S. Chokhavatia, MD, FACP (2008) Paramus, NJ
Massimo Crespi, MD, FACP (2008) Rome, Italy
Cristian Gheorghe, MD, FACP (2008) Bucharest, Romania
Toshifumi Hibi, MD, PhD, FACP (2008) Tokyo, Japan
Sripathi R. Kethu, MD, FACP (2009) Warwick, RI
Christopher Y. Kim, MD, FACP (2009) Baltimore, MD
Kenji Kobayashi, MD, FACP (2009) Minato-ku, Tokyo, Japan
Paul Y. Kwo, MD (2007) Indianapolis, IN
J. Estuardo Ligoria, MD, FACP (2009) Miami, FL
Maribel Lizarralba, MD, FACP (2008) Zulia, Venezuela
Anand Madan, MD (2008) Houston, TX
Tarun Mulpick, MD (2007) St. Charles, IL
Flavio Steinwurz, MD, FACP (2007) Sao Paulo, Brazil
Sander J. Van Zanten, MD, FACP (2009) Edmonton, AB, Canada
Nadia P. Williams, MD, FACP (2009) Mona, Kingston 7, Jamaica
Victor Witten, MD, PhD, FACP (2007) Rockville, MD
Richard A. Wright, MD, FACP (2007) Louisville, KY

#### International Relations Committee
Chair: Fumiaki Ueno, MD, FACP (2007) Kanagawa, Japan
Alberto O. Barroso, MD, FACP (2008) Houston, TX
Sangita Agrawal, MD (2009) Centerville, OH
Prateek Sharma, MD, FACP (2007) Kansas City, MO
Kirti Shetty, MD, FACP (2008) Mclean, VA
Sander J. Van Zanten, MD, FACP (2009) Edmonton, AB, Canada
Kenneth K. Wang, MD, FACP (2009) Rochester, NY
Patrick E. Young (2007) Gaithersburg, MD
Atif Zaman, MD, FACP (2009) Portland, OR

#### Minorities Affairs and Cultural Diversity Committee
Chair: Frank A. Hamilton, MD, MPh, MACG (2007) Bethesda, MD
Sam R. Achem, MD, FACP (2009) Jacksonville, FL
Sangeeta Agrawal, MD (2009) Centerville, OH
Luis A. Balart, MD, MACG (2008) New Orleans, LA

---

For detailed information on the work that the ACG Committees have performed during this past year, see the ACG Committees brochure distributed with your registration materials.
National Affairs Committee
Chair: Edward L. Cattau, Jr., MD, FACC (2007) Germantown, TN
Aala Abou-Saif, MD (2007) Mt. Vernon, WA
Eugene M. Bozymski, MD, FACC (2009) Chapel Hill, NC
Myron H. Brand, MD, FACC (2009) New Haven, CT
W. Scott Brooks, Jr., MD, MACG (2009) Atlanta, GA
R. Bruce Cameron, MD, FACC (2008) South Euclid, OH
Walter J. Coyle, MD, FACC (2009) San Diego, CA
Suzanne K. Daly, MD (2009) Salt Lake City, UT
Stephen E. Deal, MD, FACC (2009) Charlotte, NC
Dawn D. Ferguson, MD (2007) Rochester, MN
Barbara B. Frank, MD, FACC (2009) Philadelphia, PA
Paul J. Limburg, MD (2008) Rochester, MN
Klaus Mergener, MD, PhD, FACC (2009) Seattle, WA
Peter J. Molloy, MD, FACC (2009) Pittsburgh, PA
Peter M. Pardill, MD, MACG (2008) Treasure Island, FL
Charlene Prather, MD, MPH, FACP (2007) Saint Louis, MO
Colleen Schmitt, MD, MHS, FACC (2009) Chattanooga, TN
Jeffrey D. Stahl, MD, FACC (2007) West Des Moines, IA
Waring Tribble, Jr., MD, FACC (2009) Fredericksburg, VA
Jeff R. Willis, MD (2009) Norfolk, VA
Nominating Committee
John W. Popp, Jr., MD, FACC (2008) Columbia, SC
Edward C. Adler, MD, FACC (2008) Louisville, KY
David A. Greenwald, MD, FACC (2007) Bronx, NY
Douglas K. Rex, MD, FACC (2007) Indianapolis, IN

Patient Care Committee
Chair: Rajeev Vasudeva, MD, FACC (2007) West Columbia, SC
George G. Abdelasyed, MD, FACC (2009) Union City, NJ
K. Julian Billings, MD (2008) Huntsville, AL
Faisal Bukeirat, MD, FACC (2009) Morgantown, WV
Michael J. Callahan, PhD (2009) Mansfield, CT
John R. Gangemi, MD (2007) Jacksonville, FL
Lin Chang, MD (2007) Los Angeles, CA
C. Neal Ellis, MD, FACC (2008) Mobile, AL
Jean C. Fox, MD (2008) Rochester, MN
Amonn Gotian, MD (2009) Riverdale, NY
David A. Greenwald, MD, FACC (2009) Bronx, NY
Immanuel K.H. Ho, MD, FACC (2009) Upland, PA
Brenda J. Hoffman, MD, FACC (2009) Charleston, SC
Costas H. Kefalas, MD, FACC (2009) Akron, OH
Ronald P. Kotlia, MD (2008) Jackson, MS
Myron Lewis, MD, MACG (2009) Germantown, TN
Paul J. Limburg, MD (2008) Rochester, MN
Thomas C. Liu, MD (2009) New York, NY
Chandra Prakash, MD, MRCGP (2009) Saint Louis, MO
S. Devi Ramaprabhu, MD (2007) Hershey, PA
William Sanchez, MD (2008) Rochester, MN
Theodore W. Schafer, MD (2009) Corona, CA
Felice Schnoll-Sussman, MD (2009) New York, NY
Jeremy Spector, MD (2008) Providence, RI
Ira A. Tepler, MD (2009) New Rochelle, NY

Pediatric Gastroenterology Committee
Chair: Benjamin D. Gold, MD, FACC (2008) Atlanta, GA
Denesh K. Chitkara, MD (2009) Chapel Hill, NC
Steven J. Czinn, MD, FACC (2009) Baltimore, MD
Marla C. Dubinsky, MD (2009) Los Angeles, CA
Jonathan S. Evans, MD, FACC (2009) Jacksonville, FL
Ivor D. Hill, MD, FACC (2009) Winston-Salem, NC
Dinesh S. Pashankar, MD (2007) New Haven, CT
Vasundhara Tolia, MD, FACC (2009) Farmington Hills, MI
Harland S. Winter, MD, FACC (2009) Boston, MA

Practice Management Committee
Chair: Irving M. Pike, MD, FACC (2007) Virginia Beach, VA
Douglas G. Adler, MD, FACC (2008) Salt Lake City, UT
Steven L. Brint, MD, FACC (2007) Ocoee, FL
R. Bruce Cameron, MD, FACC (2009) South Euclid, OH
Lawrence B. Cohen, MD, FACC (2009) New York, NY
Chesley Hines, Jr., MD, MACG (2009) New Orleans, LA
Lin Huang, MD, PhD (2009) Issaquah, WA
Joshua A. Katz, MD, FACP (2009) Rockville, MD
James S. Leavitt, MD, FACC (2009) Miami, FL
Victor Levy, MD, FACC (2009) Clearwater, FL
Edward V. loftus, Jr., MD, FACC (2008) Rochester, MN
Gil Y. Meled, MD (2009) Los Angeles, CA
Klaus Mergener, MD, PhD, FACC (2009) Seattle, WA
Venkatatala Mohan, MD (2007) Bellevue, WA
Ece A. Mutlu, MD (2008) Chicago, IL
Jeffry L. Nestler, MD (2008) Hartford, CT
Chalmers M. Nunn, Jr., MD, FACC (2008) Lynchburg, VA
Peter M. Pardill, MD, MACG (2009) Treasure Island, FL
Ingram M. Roberts, MD, FACC (2008) Bridgeport, CT
Bruce A. Salzberg, MD, FACC (2007) Atlanta, GA
Harry E. Sarles, Jr., MD, FACC (2009) Garland, TX
Karen L. Woods, MD, FACC (2009) Houston, TX

Practice Parameters Committee
Darren S. Baron, MD (2007) Annandale, VA
David E. Bernstein, MD, FACC (2007) Roslyn, NY
William R. Brugge, MD, FACC (2009) Boston, MA
Lin Chang, MD (2009) Los Angeles, CA
William D. Chey, MD, FACC (2007) Ann Arbor, MI
John T. Cunningham, MD, FACC (2009) Tucson, AZ
Steven A. Edmundowicz, MD (2009) St. Louis, MO
Kelvin Hornbuckle, MD (2009) Norfolk, VA
Costas H. Kefalas, MD, FACG (2009) Akron, OH
Jennifer F. Lehrer, MD (2009) Bala Cynwyd, PA
Anthony J. Lembo, MD (2009) Boston, MA
John T. O'Brien, MD (2009) Omaha, NE
Steven J. Czinn, MD, FACG (2009) Baltimore, MD
Amnon Sonnenberg, MD, FACG (2009) Portland, OR
General Information
The 72nd Annual Scientific Meeting of the American College of Gastroenterology will be conducted on Monday, Tuesday and Wednesday, October 15–17, 2007, in conjunction with the Annual Postgraduate Course on Saturday and Sunday, October 13–14, 2007, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. The optional Annual Practice Management Course will be held on Friday, October 12 for a full day of practice management tips. Four additional optional programs will be held on Friday, October 12: (1) a half-day Review of GI Structure and Function course, (2) a full-day ASGE-sponsored endoscopy course, (3) a half-day GI Pharmacology course, and (4) a half-day course focusing on recertification preparation.

Registration (Bridge Area on Level 2 outside Exhibit Hall)
Registration will be open in the Bridge Area of the Pennsylvania Convention Center during the following hours:
- Friday, October 12: 6:30 am - 8:00 pm
- Saturday, October 13: 7:00 am - 5:15 pm
- Sunday, October 14: 7:00 am - 6:30 pm
- Monday, October 15: 7:00 am - 5:15 pm
- Tuesday, October 16: 6:45 am - 6:00 pm
- Wednesday, October 17: 6:45 am - 12:30 pm

Meeting Materials
Meeting materials (including name badges and optional event tickets) will be available for pick-up on-site at the ACG Registration Desk beginning on Friday, October 12 at 6:30 am in the Bridge Area.

Cancellation
Written notice of cancellation and requests for refunds must be received by the College’s office by September 21, 2007. After this date, no refunds will be possible. Registration cancellations are not accepted by telephone. An explanation must be provided in writing.

Annual Scientific Meeting (Ballroom AB)
There is no registration fee for ACG Members (including FACG and MACG), Residents/Trainee/Candidate Members, and Allied Health Members. In addition, Non-Member Residents/Trainees will have their registration fee waived if they provide a letter from their Program Director indicating they are currently in training. Guests/Non-Member Physicians/Exhibitors are required to submit a registration fee. Non-Member Allied Health Professionals are also required to submit a registration fee. Tickets for the optional breakfast sessions on Tuesday and Wednesday may be purchased for $40. Please visit the ACG Registration Desk in the Bridge Area to purchase tickets. All registrants of the Annual Scientific Meeting will receive a copy of the meeting syllabus. Attendees of the optional Breakfast Sessions will receive a syllabus which includes the presentations for all breakfast sessions. For course details, see page ##.

Annual Postgraduate Course (Ballroom AB)
A comprehensive syllabus with a separate self-assessment examination will be included. The Postgraduate Course again offers registrants the opportunity to participate in the optional Learning Luncheon programs. There are a limited number of participants who may attend each Learning Luncheon. There is a separate charge of $50 per ticket for the Learning Luncheons. Please visit the ACG Registration Desk in the Bridge Area to purchase tickets. For course details, see page ##.

Optional Friday Courses – Friday, October 12
Details for optional Friday courses begin on page ##.

Accreditation
The American College of Gastroenterology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American College of Gastroenterology designates these educational activities for a maximum as noted below of AMA PRA Category 1 Credits™. Each physician should claim credit commensurate with the extent of their participation in the activity.

- Annual Scientific Meeting: 16.5 AMA PRA Category 1 Credits™
- Postgraduate Course: 14 AMA PRA Category 1 Credits™
- Practice Management Course: 9 AMA PRA Category 1 Credits™
- GI Structure and Function Course: 5 AMA PRA Category 1 Credits™
- What's New in GI Pharmacology?: 3 AMA PRA Category 1 Credits™
- Recertification Course: 3 AMA PRA Category 1 Credits™
- Allied Health Professionals Symposium: 3 AMA PRA Category 1 Credits™

Exhibit Hall (Exhibit Hall AB)
The science and technology of medicine is ever changing and advancing the practice of gastroenterology. Showcasing these latest advances in technology and therapeutics is the ACG 2007 Exhibit Hall where more than 150 companies will display and demonstrate their products and services. With the variety of exhibitors expected to participate, there are certain to be displays of interest for all attendees. Companies who exhibit include pharmaceutical manufacturers, medical instrument suppliers, research companies, technology companies, publishers, non-profit organizations, recruiters and many others.

Exhibit Hall Scavenger Hunt. Again this year ACG will offer the Exhibit Hall Scavenger Hunt. The vast amount of new information available in the Hall is reason enough to visit, but attendees now have the opportunity to be entered into a drawing to win fabulous prizes by visiting certain areas of the Hall. The Exhibit Hall will be open from Sunday, October 14 to Wednesday, October 17. Don’t miss the chance to benefit your practice by exploring what the Exhibit Hall has to offer, and have some fun while doing so! Exhibit Hall hours are:

- Sunday, October 14: 3:30 pm - 7:00 pm
- Monday, October 15: 9:30 am - 4:00 pm
- Tuesday, October 16: 9:30 am - 4:00 pm
- Wednesday, October 17: 9:30 am - 12:00 noon

The ACG Store (Grand Hall)
Postgraduate Course and Annual Meeting syllabi, as well as other educational materials will be available for purchase at the ACG Store. ACG logo items, such as jackets, golf shirts, mugs, and mouse pads will also be available. ACG Store hours are:

- Friday, October 12: 2:00 pm - 6:00 pm
- Saturday, October 13: 8:00 am - 4:30 pm
- Sunday, October 14: 8:00 am - 4:30 pm
- Monday, October 15: 8:00 am - 4:30 pm
- Tuesday, October 16: 8:00 am - 4:30 pm
- Wednesday, October 17: 8:00 am - 12:00 noon
Americans With Disability Act (ADA)
Attendees at the ACG Annual Scientific Meeting and Postgraduate Course who need additional reasonable accommodations or who have special needs should contact the ACG office no later than October 1, 2007.

On-Site Child Care Information
The American College of Gastroenterology will again be offering child care services during its 2007 Annual Meeting and Postgraduate Course. The service will be available from Saturday, October 13 through Wednesday, October 17 at the Philadelphia Downtown Marriott. A child care attendant will be on duty from 7:00 am until 5:00 pm on Saturday, Sunday, Monday and Tuesday, and from 7:00 am until 12:30 pm on Wednesday. Please visit the ACG Registration Desk in the Bridge Area for more information.

The Scientific Poster Sessions (Exhibit Hall AB)
The Scientific Poster Programs will be conducted in the Exhibit Hall of the Pennsylvania Convention Center during the following hours:

- Sunday, October 14 . . . . . . . 3:30 pm-7:00 pm
- Monday, October 15 . . . . . . .9:30 am-4:00 pm
- Tuesday, October 16 . . . . . . .9:30 am-4:00 pm
- Wednesday, October 17 . . . .9:30 am-12:00 noon

Speaker Ready Room (Room 203 A)
All faculty members are requested to check in their slides at least 30 minutes prior to the opening of the session in which they are to speak. The Speaker Ready Room will be open beginning on Thursday, October 11 from 2:00 pm – 5:00 pm, on Friday, October 12 from 6:00 am – 5:00 pm, on Saturday, October 13 through Tuesday, October 16 from 6:00 am – 5:00 pm, and on Wednesday, October 25 from 6:30 am – 12:30 pm.

Press Room (Room 202 A)
The Press Room will be open on the following days: Thursday, October 11 from 6:00 pm – 8:00 pm; Friday, October 12 from 6:00 am – 5:00 pm; Saturday, October 13 from 7:00 am – 5:00 pm; Sunday, October 14 from 7:00 am – 5:00 pm; Monday, October 15 from 7:00 am – 5:00 pm; Tuesday, October 16 from 6:30 am – 6:00 pm; and Wednesday, October 17 from 6:30 am – 12:30 pm. Authors are requested to check in to the Press Board for interviews. No announcements will be made in the Scientific Sessions.

ASGE Learning Center (Exhibit Hall AB)
The American College of Gastroenterology is once again pleased to have the opportunity to include at its 2007 Annual Scientific Meeting highlights from the ASGE Learning Center. This program will be available in the Exhibit Hall at the Pennsylvania Convention Center and will be open on Sunday, October 14 from 3:30 pm – 7:00 pm, on Monday and Tuesday, October 15–16 from 9:30 am – 4:00 pm and on Wednesday, October 17 from 9:30 am – 12:00 noon.

NEW ACG Information Booth (Grand Hall)
Located in the Grand Hall, ACG's new Information Booth will offer help with questions about room locations, CME credits, membership issues, area dining venues, and a variety of other topics.

ACG thanks Fleet for their support of the ACG Information Booth.

ACG Internet Cafés Now three locations!
Stay in touch with the home and office. Visit the ACG 2007 Internet Cafés. E-mail family and colleagues back home and surf the web. Now with three locations to serve you throughout the meeting.

Location 1: Exhibit Hall, Booth #1616
Location 2: Grand Hall
Location 3: Main floor in the 200 Hallway before registration

ACG thanks Elan Pharmaceuticals/Biogen and UCB, Inc. for their support of the ACG Internet Cafés.

ONLINE Self-Assessment Test
Beginning Monday, October 15, the ONLINE Self-Assessment Test will be available for purchase. The online version of the popular print resource from ACG allows you to answer questions at your own pace. Start and stop the exam as often as you need. Your work is saved each time you access the online test. The test is organized by organ system and includes more than 300 multiple-choice questions. The test tracks your responses, indicates correct answers with detailed discussion and supporting references, and provides your overall/category scores. Complete the test and earn a maximum of 12 AMA PRA Category 1 Credits™. In addition, after you’ve finished the test you can continue to go back and review, re-read, and check on linked references for further study. $75 for members, $100 for non-members. For more information and to purchase, visit www.acg.gi.org.

ACG’s Self-Assessment Program for Maintenance of Certification
The American Board of Internal Medicine has approved ACG’s Self-Assessment Program (SAP) for credit in the ABIM Maintenance of Certification (MOC) program. ABIM diplomates enrolled in the MOC program who successfully complete the program will be awarded 20 self-evaluation of medical knowledge points by ABIM. ACG’s web-based module, a comprehensive educational program dedicated to providing clinical updates in specific topic areas in gastroenterology, is comprised of 60 case-based, multiple-choice questions. Upon completion, users are able to access detailed explanations and linked references to other educational resources, and earn up to 4 AMA PRA Category 1 Credits™. ACG members will pay $60 for the MOC module, non-members will pay $80. Available October 15, 2007. For more information and to purchase, visit www.acg.gi.org.

CD-ROMs
AstraZeneca is sponsoring CD-ROMs from the 2007 Postgraduate Course and Annual Meeting which will be made available to participants.

Postgraduate Course on CD-ROM: Pick up your order form at the designated CD-ROM desk in the Grand Hall. A $10 shipping and handling fee applies. Allow 6-8 weeks for delivery.

Annual Meeting Abstracts on CD-ROM: Contains all abstracts in the plenary and poster sessions. Return the coupon distributed in your registration bag either to the ACG Exhibit Booth, #1518, or to the ACG Store, Sunday through Wednesday. Limited quantities available. First come, first served.

ACG thanks AstraZeneca LP for their unrestricted grant support of these products.
Featured Lectures

David Sun Lecture

*Esophageal Dilation: A Perspective of 45 Years of Experience: Pearls, Perils and Pitfalls*

Saturday, October 13
10:20 am – 10:50 am • Ballroom AB

This year’s David Sun Lecture has been awarded to H. Worth Boyce, Jr., MD, MACG, who will present “Esophageal Dilation: A Perspective of 45 Years of Experience: Pearls, Perils and Pitfalls.” Held during the Annual Postgraduate Course, The David Sun Lectureship in Postgraduate Education was established by Mrs. Sun in memory of her husband, Dr. David Sun, an outstanding gastroenterologist and investigator. The Lecturer, with a distinguished background in gastroenterology or an allied field, is chosen by the Course Directors of the Postgraduate Program subject to the approval of the Educational Affairs Committee and the Board of Trustees. All who are registered for the Postgraduate Course are invited to attend.

The American Journal of Gastroenterology Lecture

*NOTES: Just Because We Can, Should We?*

Monday, October 15
2:40 pm – 3:20 pm • Ballroom B

Join colleagues for a lively debate, “NOTES: Just Because We Can, Should We?” Leading experts on the subject, Anthony N. Kalloo, MD, FACG, and Jeffrey L. Ponsky, MD, FACG, will provide point/counterpoint views on whether NOTES should become part of our everyday practice, the benefits to patients of NOTES vs. traditional or laparoscopic surgery, if patients will be receptive to this type of surgery, and whether we leave it up to the surgeons. This event is sponsored by ACG and Blackwell Publishing, co-publishers of *The American Journal of Gastroenterology*. You can view previous AJG lectures and learn more about the upcoming lecture by visiting www.amjgastro.com.

J. Edward Berk Distinguished Lecture

*Alice in Wonderland: The Endoscopist of the Future and the Gastrointestinal Mucosa Through the “New” Looking Glass*

Tuesday, October 16
10:00 am – 10:30 am • Ballroom AB

This year’s J. Edward Berk Distinguished Lecture has been awarded to M. Brian Fennerty, MD, FACG, who will present “Alice in Wonderland: The Endoscopist of the Future and the Gastrointestinal Mucosa Through the ‘New’ Looking Glass.” Awarded to individuals prominent in gastroenterology or a related area, the J. Edward Berk Distinguished Lecturer is nominated by the President and the appointment is subject to approval by the Board of Trustees. The lectureship was established in recognition of the significant contributions made by J. Edward Berk, MD, MACG, to clinical gastroenterology during his long and distinguished clinical and academic career. A nationally and internationally renowned physician and teacher, Dr. Berk also served as ACG President from 1975-1976. All who are registered for the Annual Meeting are encouraged to attend.

Emily Couric Memorial Lecture

*Pancreatic Cancer: Present Understanding and Future Prospects*

Tuesday, October 16
2:00 pm – 2:30 pm • Ballroom AB

Peter A. Banks, MD, MACG, has been designated to deliver the Emily Couric Memorial Lecture. The title of his presentation will be “Pancreatic Cancer: Present Understanding and Future Prospects.” This new lecture was developed by the ACG, the Virginia Gastroenterological Society and the Old Dominion Society of Gastroenterology Nurses and Associates to honor Virginia State Senator Emily Couric who died of pancreatic cancer in October of 2001. Senator Couric was a strong advocate for health care issues, particularly in her instrumental work to pass the nation’s first legislation mandating health insurance coverage for colorectal cancer screening. All who are registered for the Annual Meeting are encouraged to attend.

David Y. Graham Lecture

*Evidence Based Medicine: What Does it Mean for Gastroenterology—Present and Future?*

Wednesday, October 17
10:15 am – 10:45 am • Ballroom B

Walter L. “Pete” Peterson, MD, FACG, is being honored this year as presenter of the David Y. Graham Lecture, “Evidence Based Medicine: What Does it Mean for Gastroenterology—Present and Future?” The presenter is chosen by the President and is subject to approval by the Board of Trustees. This named lectureship was established in 2004 in recognition of the many contributions to clinical gastroenterology made by David Y. Graham, MD, MACG. The lectureship was made possible through a donation by Otsuka Pharmaceutical Co., Inc., and Meretek Diagnostics, Inc. Dr. Graham gave the inaugural presentation. All who are registered for the Annual Meeting are encouraged to attend.
There are numerous opportunities at ACG 2007 to network with your peers. Here are a few of the events taking place this year at ACG 2007.

**ACG Presidential Address**

**ACG Presidential Address**
Monday, October 15  
9:00 am – 9:30 am • Ballroom AB

David A. Johnson, MD, FACG, ACG President, will address attendees during the Presidential Address to mark the beginning of the Annual Meeting. The President uses this opportunity to welcome members, highlight ACG’s accomplishments over the past year, and bid farewell as he passes leadership of the ACG on to the President-Elect.

**Receptions**

**Allied Health Professionals Symposium Reception**
Sunday, October 14  
5:00 pm – 6:00 pm • Room 104 B

All attendees who registered for the Allied Health Professionals Symposium are invited to attend and enjoy cocktails and hors d’oeuvres while meeting colleagues.

**Women and Minorities in Gastroenterology Reception**
Sunday, October 14  
6:00 pm – 7:00 pm • Marriott Hotel Room 309/310

All those interested in the issues facing women and minorities in the GI field are invited to attend and enjoy cocktails and hors d’oeuvres while meeting colleagues.

**International Reception**
Monday, October 15  
6:00 pm – 7:00 pm • Marriott Hotel Room 309/310

All International attendees are invited to attend and enjoy cocktails and hors d’oeuvres while meeting colleagues.

**President’s Reception**
Monday, October 15  
7:00 pm – 9:00 pm • Marriott Hotel Salon CDE

The President’s Reception is a light-hearted, social gathering open to all meeting attendees. Join us for refreshments and a chance to network and mingle with your fellow professionals.

**Alumni Receptions**

Every year, several Alumni Receptions are planned for alumni of various medical schools. Invited attendees will receive an invitation by mail from their alumni group.

**Additional Events**

**Career Opportunities for Women in GI Luncheon**
Saturday, October 13  
12:40 pm-1:55 pm • Room 104 AB

The Women in Gastroenterology Committee is hosting a program on Sunday, October 13, from 12:40 pm–1:55 pm geared to medical students and residents who are facing difficult decisions in the future of their medical careers. Female gastroenterologists from a variety of medical backgrounds will address the issues of being a female subspecialist, balancing career and family, and opportunities for women in medicine and more specifically, gastroenterology. Advanced registration is required and space is limited. Please contact Maria Susano in the ACG office at 301-263-9000 for more information.

**ACG Annual Business Meeting**
Monday, October 15  
5:30 pm-6:00 pm • Ballroom B

All ACG Members and Fellows (FACG) are encouraged to attend the College’s Annual Business Meeting, where College business will be discussed and voted on. The meeting will be held on Monday, October 15 from 5:30 pm–6:00 pm, immediately following that day’s Annual Scientific Session.

**Women’s Networking, Negotiating and Leadership Skills Workshop**
Wednesday, October 17  
12:30 pm-5:30 pm • Room 109 AB

The Women in Gastroenterology Committee is hosting a program on Wednesday, October 17, from 12:30 pm–5:30 pm geared to Senior GI Fellows and Junior Faculty discussing networking, negotiation and leadership skills for women. Advanced registration is required and space is limited. Please contact Maria Susano in the ACG office at 301-263-9000 for more information.

**ACG Auxiliary**
Sunday – Tuesday, 8:00 am-12:00 noon  
Wednesday, 8:00 am-11:00 am  
Marriott Hotel Room 304

The ACG Auxiliary will provide a Hospitality Suite for spouses during the ACG Annual Meeting, offering a place to relax and unwind, review tour and visitor information, or just chat with friends. Registration for Auxiliary members will also be available in the suite.

All Auxiliary members are invited to attend the Auxiliary Board Meeting on Monday, October 15 from 10:00 am–11:00 am. The Auxiliary will also offer special tours for adults and children. Please visit the ACG Physician Registration Desk at the Pennsylvania Convention Center for more information about the Auxiliary and the tours.
Trainees’ Luncheon: What I Learned My First Year in Practice
Saturday, October 13
12:40 pm–1:55 pm • Room 110 AB

Before you enter your first year of practice, learn from the experience of someone who just recently completed his first year. Larry E. Clark, MD, will discuss lessons learned from personal interactions, financial matters, prioritizing busy schedules, and focusing on quality of life issues for newly practicing gastroenterologists.

*A separate fee of $25 is required for this event. See page 87 for information on how to register.*

GI Jeopardy: Buzz In for Your Training Program
Saturday, October 13
5:30 pm–7:00 pm • Room 204 ABC

ACG’s favorite quiz show, GI Jeopardy, will be back again in 2007. To become a contestant, you must be a fellow-in-training, but all are welcome to attend the competitive final round, a spirited GI version of the television classic. The competition begins in July with a preliminary round open to all GI training programs. Groups of fellows will take a 45-question online test on a variety of GI organs and diseases. The top five scoring programs will then be invited to send two-person teams to compete in front of a live audience at the 2007 ACG Postgraduate Course. Travel expenses for the teams will be covered by ACG. Last year’s GI Jeopardy finalists were supported by more than 300 lively audience members giving the event a real game show atmosphere. Visit the Trainees’ section of the ACG website for further details on how to participate. Following the conclusion of the GI Jeopardy competition, a reception will be held to allow fellows to network with their peers.

Trainees’ Forum: Scoping Out Your Future: Finding a Job and Transitioning into Practice
Sunday, October 14
5:30 pm–7:00 pm • Room 103 AB

Don’t miss this year’s Trainees’ Forum, “Scoping Out Your Future: Finding a Job and Transitioning to Practice.” All trainees should attend this event, scheduled for Sunday, October 14, from 5:30 pm–7:00 pm, immediately following the Sunday session of the ACG Postgraduate Course. The program will include information on finding the right job, finances, ASCs, and transitioning into the first year of practice. The panel will include experts in the field as well as recent graduates. Short presentations will be accompanied by ample time for questions. The program, available without charge to all trainees in gastroenterology and hepatology, will offer an opportunity for social interchange. Don’t miss out on this important information; it can help you take control of your career. Light hors d’oeuvres and beverages will be served.

Job Forum: Where Candidates and Employers Meet
Sunday – Tuesday, October 14–16, 8:00 am–5:00 pm and Wednesday, October 17, 8:00 am–12:30 pm • Room 203 B

Looking for a job? ACG’s Job Forum offers valuable networking opportunities. With so many GI professionals convening in Philadelphia, the ACG Job Forum provides an ideal setting for applicants to share their credentials with employers and to review position openings across the U.S. and Canada. The Job Forum includes a mechanism for the exchange of CVs and a message service to connect employers and job candidates. Visit www.acgmeetings.org to take advantage of this opportunity and fill out the necessary online forms.
J. EDWARD BERK DISTINGUISHED LECTURERS
formerly ACG Distinguished Lecture

2007  M. Brian Fennerty, MD, FACG: Alice in Wonderland: The Endoscopist of the Future and the Gastrointestinal Mucosa Through the ‘New’ Looking Glass

2006  Joel E. Richter, MD, MACG: Eosinophilic Esophagitis: New Disease or Old Friend in Disguise?

2005  Bruce R. Bacon, MD, FACG: Hereditary Hemochromatosis – What We Have Learned Since the Discovery of HFE

2004  Brian Saunders, MBBS, MD, MRCP: Colonoscopy in Evolution

2003  Earle M. Quigley, MD, FACG: Demystifying Motility; Gut Motor Dysfunction in Clinical Practice

2002  Roger Williams, CBE, MD: Improved Treatments for Decompensated Liver Disease Including Liver Support Devices

2001  Richard P. MacDermott, MD, FACG: Immunology and Therapy of IBD

2000  Lawrence J. Brandt, MD, MACG: Patients’ Attitudes and Apprehensions About Endoscopy: Calming Troubled Waters

1999  Marcia Angell, MD: Evaluating Medical Stories of Health Risk

1998  Kees Huibregtsme, MD: The Endoscopic Approach to Benign Bile Duct Strictures and Leaks

1997  David Wingate, MD: Small Bowel Motility – Out of the Closet and into the Clinic

1996  Guido Tytgat, MD: Conditions Mimicking Crohn’s Disease

1995  David Y. Graham, MD, MACG: Peptic Ulcer Disease: The Rest of the Story

1994  Eugene R. Schiff, MD, FACG: Long Term Treatment of Chronic Viral C Hepatitis

1993  Jerome Kassirer, MD, FACG: Making Decisions with Patients: Fixing the Flaws

1992  Waltis C. Maddrey, MD, FACG: Chronic Hepatitis – 1992


1990  Vay Liang Go, MD: Brain-Gut Interaction: Relevance to Clinical Gastroenterology

1989  Professor Dame Sheila Sherlock: Liver Disease – The Next Decade

1988  Thomas Almy, MD (Hon.): The Gastroenterologist and The Graying of America

1987  John Fordtran, MD, FACG (Hon.): Recent Insights into the Pathogenesis of Chronic Diarrhea

1986  Henry D. Janowitz, MD, FACG: The Natural History of Inflammatory Bowel Disease and Therapeutic Decisions

1985  Norton J. Greenberger, MD, FACG (Hon.): Pathophysiological Approach to the Patient with a Diarrheal Disorder

1984  Henri Sarles, MD: Management of Pain in Chronic Pancreatitis

1983  Denis P. Burkitt, MD: The Role of Fibre in the Prevention of Common Intestinal Disease

1982  Howie A. Spiro, MD, FACG: From Parsnips to Pomegranates – A Look Back at Gastroenterology

1981  Basil I. Hirschowitz, MD, FACG: Clinical Perspectives of Gastrointestinal Secretion

1980  Charles E. Code, MD, FACG (Hon.): The InterDigestive Gastrointestinal Housekeeper

1979  Baruch S. Blumberg, MD, FACG (Hon.): The Relation Between HBsAG and Hepatic Carcinoma

1978  Charles S. Lieber, MD, FACG: Alcohol and the Liver: Progress Through 1978

1977  Joseph B. Kirsner, MD, FACG (Hon.): The Biomedical Problems Presented by Inflammatory Bowel Disease

1976  Basil C. Morson, MD, FACG (Hon.): Biopsy of the Colon and Rectum in Inflammatory Disease

1975  Thomas C. Chalmers, MD, FACG (Hon.): What Should Distinguish a Gastroenterologist?

1974  Lloyd M. Nyhus, MD, FACG (Hon.): New Frontiers in Treatment of Duodenal Ulcer

1973  Henry L. Bockus, MD, FACG (Hon.): The Doctor Image

1972  Henry Colcher, MD, FACG: Gastrointestinal Endoscopy, 1972

1971  Irving M. Arias, MD, FACG (Hon.): Jaundice–1972

1970  Hans Popper, MD, FACG (Hon.): The Problem of Hepatitis

1969  Richard H. Marshak, MD, FACG: Ulcerative Granulomas and Ischemic Colitis

1968  David A. Dreiling, MD, FACG: Basic Mechanism in Pancreatic Secretion

BAKER PRESIDENTIAL LECTURESHIP

2003  Loren A. Laine, MD, FACG: Reducing NSAID-Induced GI Injury: Keeping the Gastroenterologist Home at Night

2002  David A. Lieberman, MD, FACG: Colonoscopy for Cancer Screening and Surveillance: Do We Have the Resources to Do Both?

2001  Bruce R. Bacon, MD, FACG: Hereditary Hemochromatosis: Implication of Gene Discovery on Pathophysiology and Clinical Practice


1999  Sum P. Lee, MD, FACG: A Tale of Two Oppossums and a Discussion on Gallstones

1998  Willis C. Maddrey, MD, MACG: Reflections on the Emergence of Hepatology

1997  Joseph B. Kirsner, MD: The Impact of Research on Clinical Gastroenterology During the 20th Century

1996  Barry J. Marshall, MD, FACG: H. pylori in the Year 2000

1995  Donald O. Castell, MD, FACG: Reflections of an Esophagogastroduodenologist

1994  Peter A. Banks, MD, FACG: Acute Necrotizing Pancreatitis

1993  Daniel Present, MD, FACG: Immunosuppressive Therapy for IBD

1992  Sidney J. Winawer, MD, FACG: The Prevention of Colorectal Cancer: Progress and Prospects

1991  Lawrence J. Brandt, MD, FACG: Colitis in the Elderly

1990  Paul D. Webster, III, MD, FACG: Pancreatic Function and Disease at the Cellular Level

1989  David B. Sachar, MD, FACG: Inflammatory Bowel Disease: Back to the Future

1988  Melvin Schapiro, MD, FACG: The Community Hospital Gastroenterologist: Survival of the Species

1987  James L. Achord, MD, FACG: Nutrition, Alcohol and the Liver

1986  H. Worth Boyce, Jr., MD, FACG: Peroral Endoscopic Mucosal Resection (PEMR): A New Technique for the Diagnosis and Treatment of Intra-abdominal Mucosal Lesions

1985  Jerome D. Waye, MD, FACG: The Colon Polyp – Promises and Prospects

1984  Burton I. Korelitz, MD, FACG: Pregnancy, Fertility and IBD

1983  David Y. Graham, MD, FACG: The Role of the Clinical Gastroenterologist in Research

1982  Bergein E. Overholt, MD, FACG: Socioeconomic and Political Issues in Gastroenterology

1981  Frank P. Brooks, MD, FACG: Cortical Secretion: Implication of Gene Discovery on Pathophysiology and Clinical Practice

1980  Richard G. Farmer, MD, FACG: Factors in the Long-Term Management of Celiac Disease

1979  Richard H. Marshak, MD, FACG: Ulcerative Granulomas and Ischemic Colitis

1978  Charles S. Lieber, MD, FACG: Alcohol and the Liver: Progress Through 1978

1977  Joseph B. Kirsner, MD, FACG (Hon.): The Biomedical Problems Presented by Inflammatory Bowel Disease

1976  Basil C. Morson, MD, FACG (Hon.): Biopsy of the Colon and Rectum in Inflammatory Disease

1975  Thomas C. Chalmers, MD, FACG (Hon.): What Should Distinguish a Gastroenterologist?

1974  Lloyd M. Nyhus, MD, FACG (Hon.): New Frontiers in Treatment of Duodenal Ulcer

1973  Henry L. Bockus, MD, FACG (Hon.): The Doctor Image

1972  Henry Colcher, MD, FACG: Gastrointestinal Endoscopy, 1972

1971  Irving M. Arias, MD, FACG (Hon.): Jaundice–1972

1970  Hans Popper, MD, FACG (Hon.): The Problem of Hepatitis

1969  Richard H. Marshak, MD, FACG: Ulcerative Granulomas and Ischemic Colitis

1968  David A. Dreiling, MD, FACG: Basic Mechanism in Pancreatic Secretion


1966  Hans Popper, MD, FACG: The Problem of Hepatitis

1965  Richard H. Marshak, MD, FACG: Ulcerative Granulomas and Ischemic Colitis
DAVID SUN LECTURESHIP IN POSTGRADUATE EDUCATION

2007 H. Worth Boyce, Jr., MD, MACG: Esophageal Dilation: A Perspective of 45 Years of Experience: Pearls, Perils and Pitfalls

2006 Anthony N. Kalloo, MD, FACG: Natural Office Transgastric Endoscopic Surgery: Dawn of a New Era
2005 Douglas K. Rex, MD, FACP: Optimizing the Impact and Safety of Colonoscopy in Colon Cancer Prevention
2004 Richard L. Sampliner, MD, FACP: Current Controversies in Barrett’s Esophagus
2003 Lawrence J. Brandt, MD, MACG: Superior Mesenteric Arterial Emboli and Acute Mesenteric Ischemia: An Update
2002 Christina M. Surawicz, MD, FACP: The Differential Diagnosis of Colitis
2001 Lawrence R. Schiller, MD, FACP: Chronic Diarrhea
2000 Teresa Wright, MD: Hepatitis C in the Next Decade
1999 Stephen B. Hanauer, MD, FACP: New Therapies for the Treatment of IBD
1997 Rowen K. Zetterman, MD, FACP: Alcoholic Liver Disease
1996 Rodger Haggitt, MD, FACP: Dysplasia in Ulcerative Colitis: A 20-Year Odyssey
1994 Thomas Starzl, MD: Gastrointestinal Organ Transplantation for the 1990’s – An Outcome Analysis. Can We Afford the Technology in the Era of Cost Containment?
1993 Cyrus E. Rubin, MD, FACP: Small Bowel Pathology
1992 Peter Cotton, MD, FACP: Malignant Obstructive Jaundice: A Real Challenge
1991 Sum P. Lee, MD, FACP: Pathophysiology of Gallstone Formation: Romancing the Stone
1990 Marvin Slesinger, MD: GI Diseases in the Immunocompromised Host
1989 Laszlo Safary, MD, FACP: Bile Ducts, Common Duct Stones, and Pancreatitis
1988 Scott J. Boley, MD: Colon Ischemia – The First 25 Years
1987 William Y. Chey, MD, FACP: Ulcerogenic Tumor Syndrome in 1987
1986 David H. Van Thiel, MD, FACP: Liver Transplant – The Role of the Gastroenterologist
1985 James W. Freston, MD, FACP: The Therapy of Peptic Ulcer Disease: Where are We?
1984 Henri Sarles, MD: Pathogenesis of Alcoholic Chronic Pancreatitis – A Secretory Concept
1983 Thomas C. Chalmers, MD, FACP: The Clinical Trial
1982 Sidney J. Winawer, MD, FACP: Surveillance of GI Cancer
1981 Paul D. Webster, III, MD, FACP: Acute and Chronic Pancreatitis
1980 Paul Sherlock, MD, FACP: Current Concepts of the Epidemiology and Etiology of Colorectal Cancer
1979 I. N. Marks, MD, FACP: Crossroads in Peptic Ulcer Therapy
1978 Rosalyn S. Yalow, PhD: Radioimmunoassay in Gastroenterology
1977 J. Edward Berk, MD, FACP: New Dimensions in the Laboratory Diagnosis of Pancreatic Disease

AMERICAN JOURNAL OF GASTROENTEROLOGY LECTURE

2007 Anthony N. Kalloo, MD, FACG, & Jeffrey L. Ponsky, MD, FACG: NOTES: Just Because We Can, Should We?
2006 David A. Johnson, MD, FACG, Robert E. Schoen, MD, MPH & Gregory S. Cooper, MD, FACP: Colon Cancer Screening: When to Start and Stop
2005 Stephen B. Hanauer, MD, FACG & William J. Sandborn, MD, FACP: Steroid-Refractory Severe Acute Ulcerative Colitis: Infliximab or Cyclosporine
2004 Arthur Boudreaux, MD, Douglas K. Rex, MD, FACP & Gregory Zuccaro, Jr., MD, FACP: The Use of Anesthesia in Endoscopy – A Critical Examination
2003 David Y. Graham, MD, MACG & Jay L. Goldstein, MD, FACP: Emerging Data on NSAIDs, GI Complications and Implications for Your Practice

DAVID Y. GRAHAM LECTURE

2007 Walter L. Peterson, MD, FACG: Evidence Based Medicine: What Does it Mean for Gastroenterology—Present and Future?
2006 Amnon Sonnenberg, MD, MSc, FACG: The “Incredibly Simple” Solution to the Cohort Phenomenon of Peptic Ulcer Disease
2005 Francis K.L. Chan, MD: Use of NSAIDs in a COX-2 Restricted Environment

EMILY COURIC ANNUAL LECTURE

2007 Peter A. Banks, MD, MACG: Pancreatic Cancer: Present Understanding and Future Prospects
2006 Douglas K. Rex, MD, FACP: What is Needed to Transform Colonoscopy into a Truly Protective Strategy Against Colorectal Cancer?

BERK/FISE CLINICAL ACHIEVEMENT AWARD

(formerly the ACG Clinical Achievement Award)

2007 Joel E. Richter, MD, MACG
2006 Seymour Katz, MD, MACG
2005 David B. Sachar, MD, MACG
2004 Alvin M. Zfass, MD, MACG
2003 Arthur H. Aufses, Jr., MD, MACG
2002 Cyrus Rubin, MD, FACG
2001 Jerome D. Waye, MD, MACG
2000 Bergein Overholt, MD, MACG
1999 Lawrence J. Brandt, MD, MACG
1998 Leslie H. Bernstein, MD, FACG
1997 Sidney J. Winawer, MD, MACG
1996 Burton I. Korelitz, MD, MACG
1995 David Y. Graham, MD, MACG
1994 Howard Spiro, MD, FACG
1993 F. Warren Nugent, MD, FACG
1992 Henry D. Janowitz, MD, FACG
1991 John T. Galambos, MD, FACG
1990 Francis K. Chan, MD, FACG
1989 James L. A. Roth, MD, FACG
1988 J. Edward Berk, MD, MACG
1987 Leonidas Berry, MD, FACG
1986 Paul D. Webster, III, MD, FACG
1985 Francis K. Chan, MD, FACG
1984 Henrik Spicher, MD, FACG
1983 J. Edward Berk, MD, MACG
1982 Heidrun Rotterdam, MD: Contribution of Gastrointestinal Biopsy to an Understanding of Gastrointestinal Disease
1981 Eleanor E. Deschner, MD: Early Proliferative Changes in Gastrointestinal Cancer
1980 Dame Sheila Sherlock, MD: Primary Biliary Cirrhosis
1979 Elizabeth Barrett-Conner, MD: Traveler’s Disease
1978 Margot Shiner, MD: Contribution of Electron Microscopy to Our Knowledge of Small Intestinal Disease

AUXILIARY LECTURES

1982 Heidrun Rotterdam, MD: Contribution of Gastrointestinal Biopsy to an Understanding of Gastrointestinal Disease
1981 Eleanor E. Deschner, MD: Early Proliferative Changes in Gastrointestinal Cancer
1980 Dame Sheila Sherlock, MD: Primary Biliary Cirrhosis
1979 Elizabeth Barrett-Conner, MD: Traveler’s Disease
1978 Margot Shiner, MD: Contribution of Electron Microscopy to Our Knowledge of Small Intestinal Disease
THE SAMUEL S. WEISS AWARD FOR OUTSTANDING SERVICE TO THE AMERICAN COLLEGE OF GASTROENTEROLOGY

2006  William D. Carey, MD, MACG  
2005  David Y. Graham, MD, MACG  
2004  Edgar Achkar, MD, FACG  
2002  Lawrence J. Brandt, MD, MACG  
2001  Joel E. Richter, MD, MACG  
2000  Seymour Katz, MD, FACG  
1998  Rowen K. Zetterman, MD, FACG  
1997  Arthur H. Aufses, Jr., MD, MACG  
1996  Arvey I. Rogers, MD, MACG  
1995  Jerome D. Waye, MD, MACG  
1994  J. Edward Berk, MD, MACG  
1993  Arthur Lindner, MD, MACG  
1992  Franz Goldstein, MD, MACG  
1991  James L. Achord, MD, MACG  
1990  Robert L. Berger, MD, FACG  
1989  Angelo E. DaGradi, MD, MACG  
1987  Joseph E. Walther, MD, MACG  
1986  Richard L. Wechsler, MD, FACG  
1984  John P. Papp, MD, MACG  
1982  Daniel Weiss, B.S., M.A.  
1980  David A. Dreiling, MD, MACG  
1978  Henry Colcher, MD, MACG  
1976  Murrel H. Kaplan, MD, FACG  
1974  Robert R. Bartunek, MD, FACG  
1972  Milton J. Matzner, MD, FACG

MINORITY HEALTH CARE

This new ACG achievement award recognizes an ACG Member or Fellow whose work in the areas of clinical investigation or clinical practice has improved the digestive health of minorities or other underserved populations of the United States.

2007  LaSalle D. Leffall, Jr., MD, FACG

2007 ACG MASTERS RECIPIENTS

Eugene M. Bozymski, MD, FACG  
James T. Frakes, MD, FACG  
Linda Rabeneck, MD, FACG  
Ashok N. Shah, MD, FACG

For more information about this year’s ACG award recipients, see the ACG Awards brochure distributed with your registration materials.
Abstract Award Recipients

2007 ACG Auxiliary Award Recipient (Trainee)

Constipation: Is it a Colonic Versus Generalized Gastrointestinal Tract Disorder, the Temple Experience
Shahana Shabih, MD, Henry Parkman, MD, Robert S. Fisher, MD,
Department of Gastroenterology, Temple University Hospital, Philadelphia, PA
Paper 48, page ##.

2007 ACG Auxiliary Award Recipient (ACG Member/Fellow)

Cost-Benefit of PPI Gastroprotection Among Elderly NSAID Users
Neena S. Abraham, MD, MSCE, Jennifer Hasche, MSic, and Christine Hartmann, PhD, Gastroenterology, Michael E. DeBakey VAMC, Baylor College of Medicine, Houston, TX and Health Services Research, Houston Center of Quality of Care and Utilization Studies; Michael E. DeBakey VAMC, Houston, TX
Paper 33, page .

2007 ACG Governors Award Recipient for Excellence in Clinical Research

Ethanol Pancreatic Injection of Cysts: Results of a Prospective Multicenter, Randomized Double Blinded Study
William R. Brugge, MD, Kerry Collier, MA, Kathleen McGreevy, RN, C. Max Schmidt, MD, John DeWitt, MD, Gastroenterology, Indiana University, Indianapolis, IN; Gastroenterology, Massachusetts General Hospital, Boston, MA; and Surgery, Indiana University, Indianapolis, IN
Paper 18, page .

Cytokeratin 18 Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients
Dima Diab, MD, Lisa Yerian, MD, Phillip Schauer, MD, Sangeeta R. Kashyap, MD, Rocio Lopez, MS, and Aarion E. Feldstein, MD, Endocrinology, Pediatric Gastroenterology, General Surgery, Anatomical Pathology, and Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
Paper 12, page .

Toward Better Prognostic Modeling in Acute Liver Failure
Julie Polson, MD, Nick Rogers, MD, Linda S. Hynan, PhD, A.J. Naylor, BS, and William M. Lee, MD, Internal Medicine, and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX
Paper 39, page .

High Cortisol Levels are Correlated to Low Esophageal Pain Threshold to Balloon Distention in Patients with NERD and Functional Heartburn
Sheila Rodriguez-Stanley, PhD, Maggie Wolff, Tisha Adams and Philip B. Miner, Jr., The Oklahoma Foundation for Digestive Research, Oklahoma City, OK
Paper 55, page .

Primary Sclerosing Cholangitis is a More Common Indication for Orthotopic Liver Transplantation Among African American than Non-African American Patients
Alastair D. Smith, MD, ChB and Judith W. Gentile, RN, ANP, Medicine, Duke University, Durham, NC
Paper 4, page .

2007 ACG/Radhika Srinivasan Gender Based Research Award Recipient

Disparity in Gastroenterology: Is it Just “Academic” or a Significant Problem? A 10 Year Prospective Cohort Study
Aparajita Singh, MD, Carol A. Burke, MD, for the Women in GI Committee of ACG, Gastroenterology, Cleveland Clinic, Cleveland OH

2007 ACG/AstraZeneca Clinical Vignette Award Recipient

Severe Pulmonary Hypertension in Whipple’s Disease*
Patricia A. Sanchez, MD, Joel Camilo, MD, Wendell K. Clarkston, MD, Gastroenterology, University of Missouri at Kansas City School of Medicine, Kansas City, MO
Poster 900, page .

Hereditary Gastric Carcinoma- At Management Cross Roads*
Jawaid Ahmed Shaw, MD, Motaz Al Hafnawi, MD, Tarun Kothari, MD, Kevin Casey, MD, Gastroenterology, Rochester General Hospital, and Gastroenterology, Unity Hospital, Rochester, NY
Poster 810, page .

2007 ACG/AstraZeneca Senior Fellow Abstract Award Recipient

Adenosine—A Key Neuromediator in the Pathogenesis of Functional Chest Pain
Ashok Attaluri, MD, Jose Remes-Troche, MD, Satish Rao, MD, Gastroenterology, University of Iowa, Iowa City, IA
Paper 1, page .

Early Oral Feeding in Mild Acute Pancreatitis: A Randomized Prospective Trial
Nisar B. Badalov, MD, Zankhana Mehta, MD, Himso Satyavolu, MD, Tejal Shah, MD, Jian-Jun Li, MD, Robin Baradarian, M.D, Kadirawel Iswara, MD, Scott Tenner, MD, MPH, Division of Gastroenterology, Department of Medicine, Maimonides Medical Center, Brooklyn, NY
Paper 10, page .

Dysplasia in Fundic Gland Polyps in FAP: Prevalence, Risk Factors and Optimal Biopsy Technique
Laura K. Bianchi, MD, Ana E. Bennett, MD, Rocio Lopez, MS, Hennie Hasson, RN and Carol A. Burke, MD, Gastroenterology, Anatomic Pathology, and Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
Paper 32, page .

Learning Curve for Double-Balloon Enteroscopy (DBE) at a U.S. Center
Seth A. Gross, MD, Mark E. Stark, MD, Gastroenterology, Mayo Clinic Jacksonville, FL
Paper 26, page .

Endomysial Antibody Testing Improves Sensitivity in Screening for Celiac Disease in Your Children, A Five Year Single Center Experience
Muralidhar Jalia, MD, Caroline Kieserman-Shmoker and Ritu Verma, MD, Division of Gastroenterology and Nutrition, The Children’s Hospital of Philadelphia, Philadelphia, PA
Paper 3, page .

A Prospective Study of Factors Associated with Increased Gluten-Free Diet Adherence in Adults with Celiac Disease
Daniel A. Leffler, MD, Jessica B. Edwards George, PhD, Melinda D. Dennis, RD, Hanif P. Abdullah, MD, Ciaran P. Kelly, MD, The Celiac Center, Beth Israel Deaconess Medical Center, Boston, MA
Paper 11, page .

Missed Cancers vs Procedure-Related Complications: Balancing the Medico-Legal Risks of Surveillance Colonoscopy
D. Saini, MD, Sandeep Vian, MD, Philip S. Schoenfeld, MD, Gastroenterology, University of Michigan, Ann Arbor, MI and Internal Medicine, University of Michigan, Ann Arbor, MI
Paper 37, page .

Comparison of Sensed Acid Reflux Event Characteristics Among the Different GERD Groups
Ron Schey, MD, Tomas Navarro-Rodriguez, MD, Michael Shapiro, MD, Christopher Wendel, MS and Ronnie Fass, MD, The Neuroenteric Clinical Research Group, Southern Arizona 111 VA Health Care System and University of Arizona, Tucson, AZ
Paper 47, page .

* Indicates a 2007 ACG Presidential Poster Award Recipient.
Abstract Award Recipients

Does Tandem Colonoscopy Affect the Adenoma Detection Rate Described with Narrow Band Imaging?  
Sally Sttpho, MD, Nooman Gilani, MD, FACC and Francisco C. Ramirez, MD, FACC, Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix, AZ  
Paper 6, page .

Functional Dyspepsia: The Economic Impact to Patients  
Kirsten T. Weiser, MD, Abigail T Kennedy, BA, Brian E. Lacy, MD, PhD, Michael D. Crowell, PhD, and Nicholas J. Talley, MD, PhD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, Mayo Medical Center, Scottsdale, AZ, and Mayo Medical Center, Rochester, MN  
Paper 2, page .

2007 ACG/Centocor IBD Abstract Award Recipient

Incidence of Post-Surgical Complications Among Ulcerative Colitis (UC) Patients: A Population-Based Study  
Salma Akram, MD, Steven B. Ingle, MD, Shamina Dhillon, MD, W. Scott Harbman, RS, Alan L. MacManus, MD, William J. Tremaine, MD, William J. Sandborn, MD, Edward V. Loftus, MD, Mayo Clinic, Rochester, MN  
Paper 57, page .

A Prospective, Controlled Longitudinal Study of the Effects of Oral Steroids at 3 and 5 Months on Bone Mineral Density (BMD) in Patients with IBD  
Jae Gaun Hyun, MD, Asher Kornbluth, MD, James George, MD, Peter Legnani, MD, Simon Lichtiger, MD, Meredith Lewis, MS, Gastroenterology, Mount Sinai Medical Center, New York, NY  
Paper 23, page .

Adenocarcinoma in Ileal Pouch-Anal Anastomosis: The Cleveland Experience  
Revital Kariv, MD, Ana Bennett, MD, Yehuda Kariv, MD, Victor Fazio, MD, Ian Lavery, MD, Brett Lashner, MD, Bo Shen, MD, and Feza Remzi, MD, Digestive Disease Center, Cleveland Clinic, Cleveland, OH  
Paper 22, page .

Exposing the Weaknesses: A Systematic Review of Azathioprine Efficacy in Ulcerative Colitis  
Yvette Leung, MD, Remo Panaccione, MD, Brenda Hemmellgarn, PhD, and Jennifer Jones, Medicine, Division of Gastroenterology, University of Calgary, Alberta, Canada  
Paper 59, page .

Mesalazine Protects Against Colorectal Cancer in Inflammatory Bowel Disease  
Jeffrey Tang, MD, Gena Kucera, PhD, Omar Sharif, MD, Chetan Pai, DO and Ann L. Silverman, MD, Internal Medicine, Division of Gastroenterology, Henry Ford Hospital, Detroit, MI  
Paper 5, page .

2007 ACG/Naomi Nakao Gender Based Research Award Recipient

Gender Differences and Bariatric Surgery Outcome  
Inessa Khaykis, MD, Christine J. Ren, MD, George A. Fielding, MD, Warren Huberman, PhD, Barrie Wolfe, MD, Heekoung Youn, RN, Stefanie Hong, Fritz Francois Francois, MD, Elizabeth Weinshel, MD, Gastroenterology, Surgery, and Psychiatry, New York University Hospital, New York, NY  
Paper 38, page .

2007 ACG Motility Award Recipient

Prevalence and Impact of Co-Morbid Psychological Distress on Response to PPI Therapy in Patients with GERD  
William D. Chey, MD, Borko Nokiov, MD, Joel R. Rubenstein, MD, Susan A. Adlis, MS, Michael J. Shaw, MD, Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI and Park Nicollet Institute, Minneapolis, MN.  
Poster 374, page .

How Useful is Digital Rectal Examination in the Diagnosis of Dyssynergia?  
Priyanka Rao, Kasaya Tantilphichiva, MD, Ashok Attaluri, MD, Satish Rao, MD, University of Iowa, Iowa City, IA  
Paper 51, page .

Investigation of Wireless Capsule (SmartPill) for Colonic Transit: A Comparative Study with Radiopaque Markers in Health and Constipation  
S. Rao, MD, FACC, B. Kuo, MD, W. Chey, MD, FACC. J. DiBaise, MD, FACC, L. Katz, MD, K. Koch, MD, FACC, J. Lackner, PsyD, SmartPill Research Group  
Paper 54, page .

Gastric Emptying Scintigraphy Results in the ROME III Subgroup Classifications for Functional Gastro-Duodenal Disorders  
Richard L. Walters, MD, Alan H. Maurer, MD, Henry P. Parkman, MD, Medicine, Temple University, School of Medicine, Philadelphia, PA  

2007 ACG/Olympus Colorectal Cancer Prevention Award Recipient

Which Adenoma Characteristic Has the Strongest Effect on Predicting Advanced Neoplasia or Numerous Adenomas on Follow-up Colonoscopy?  
Carol A. Burke, MD, FACC, Leila Mott, John Baron, MD, Doug Robertson, MD, The Polyp Prevention Study Group, Gastroenterology, Cleveland Clinic, Cleveland, OH  
Paper 9, page .

Role of Resistant Starch in Colorectal Cancer Prevention: A Prospective Randomized Controlled Trial  
Shridhar S. Dronamraju, MD, Jonathan M. Coxhead, PhD, Seamus B. Kelly, MD, John G. Mathers, PhD, Human Nutrition Research Centre, School of Clinical Medical Sciences, Newcastle University, Newcastle Upon Tyne, Tyne and Wear, United Kingdom and Department of General Surgery, North Tyneside General Hospital, North Shields, Tyne and Wear, United Kingdom  
Paper 13, page .

Elevated HbA1c is an Independent Predictor of Aggressive Clinical Behavior in Patients with Adenomatous Colonic Polyps  
Ali A. Siddiqui, Haripriya Maddur, Suraj Naik, MD, Byron Cryer, Gastroenterology, Dallas VA Medical Center, Dallas, TX  
Paper 7, page .

Effect of Initial Polypectomy Versus Surveillance Polypectomy on Colorectal Cancer Mortality Reduction: Micro-Simulation Modeling of the National Polyp Study  
Ann G. Zauber, PhD, Sidney J. Winawer, MD, Iris Lamsdorf-Vogelaar, MS, Marjolein van Ballegooijen, MD, PhD, Michael J. O’Brien, MD, Epidemiology and Biostatistics, Memorial Sloan- Kettering Cancer Center, New York, NY  
Paper 14, page .

2007 ACG/Wyeth Gender Based Research Award Recipient

Statin Use and the Risk of Cholecystectomy in Women  
Chung-Jiy Tsai, MD, Michael Leitzmann, MD, Walter Willett, MD, Edward Giovannucci, MD, Division of Digestive Diseases and Nutrition, University of Kentucky Medical Center; Division of Cancer Epidemiology and Genetics, National Institute of Health and Channing Lab, Department of Medicine, Harvard Medical School  
Paper 34, page .

2007 Lawlor Resident Award Recipient

Gastric Electrical Stimulation for GastroparesisThe Temple Experience  
Varadarajan Subbiah, MD, Sean Harbison, MD, John Meilahn, MD, Vanessa Lytes, GRNP, Robert S. Fisher, MD, Henry P. Parkman, MD, Medicine, Temple University, Philadelphia, PA  
Paper 8, page .
The ACG Auxiliary will provide a Hospitality Suite for spouses during the ACG Annual Meeting, offering a place to relax and unwind, review tour and visitor information, or just chat with friends. Registration for Auxiliary members will also be available in the suite. All Auxiliary members are invited to attend the Auxiliary Board Meeting on Monday, October 15 from 7:00 am - 12:00 noon. The Auxiliary will also offer special tours for adults and children. Please visit the ACG Physician Registration Desk at the Pennsylvania Convention Center for more information about the Auxiliary and the tours.

**Tour Lobby Entrance of the Venetian Resort Hotel and Casino.**

All admissions, taxes and gratuities. All tours depart from the executive motorcoach, narration by professional tour guide, and

- Tour tickets will be distributed at the Physician Registration Desk. All tours include exclusive round trip transportation by executive motorcoach, narration by professional tour guide, and all admissions, taxes and gratuities. All tours depart from the Tour Lobby Entrance of the Venetian Resort Hotel and Casino.

---

### Auxiliary Schedule at a Glance

<table>
<thead>
<tr>
<th>SUNDAY, OCTOBER 14</th>
<th>TUESDAY, OCTOBER 16</th>
</tr>
</thead>
</table>
| Physician Registration  
Bridge Area, Convention Ctr  
7:00 am - 6:30 pm  
Auxiliary Registration/  
Hospitality Suite  
Marriott Room 304  
8:00 am - 12:00 noon  
TOUR 1: Barnes Foundation*  
Depart from Tour Lobby  
Entrance  
12:30 pm - 4:30 pm  | Physician Registration  
Bridge Area, Convention Ctr  
6:45 am - 6:00 pm  
Hospitality Suite  
Marriott Room 304  
8:00 am - 12:00 noon  
TOUR 2: Ron Avery Guided Bus Tour*  
Depart from Tour Lobby  
Entrance  
2:30 pm - 5:30 pm |
| MONDAY, OCTOBER 15 | WEDNESDAY, OCTOBER 17 |
| Physician Registration  
Bridge Area, Convention Ctr  
7:00 am - 5:15 pm  
Auxiliary Registration/  
Hospitality Suite  
Marriott Room 304  
8:00 am - 12:00 noon  
Auxiliary Board Meeting  
See Physician Registration Desk for Location  
8:30 am - 10:00 am  
TOUR 2: Medicine in Colonial Philadelphia*  
Depart from Tour Lobby  
Entrance  
12:00 noon - 4:00 pm  
President’s Reception  
Marriott Salon CDE  
7:00 pm - 9:00 pm | Physician Registration  
Bridge Area, Convention Ctr  
6:45 am - 12:30 pm  
Hospitality Suite  
Marriott Room 304  
8:00 am - 12:00 noon  |
| TOUR 1: The Barnes Foundation Tour  
Sunday, October 14, 12:30 pm – 4:30 pm  
Cost: $52.00 per person  
The Barnes Foundation houses one of the world’s finest private collections of Post-Impressionist and early French modern art, including works by Renoir (180), Cezanne (69), Matisse (60), Picasso, Monet and Manet. Art from every corner of the globe is grouped with fine examples of antique furniture, ceramics, hand-wrought iron and Native American jewelry. Visit the Arboretum of the Barnes Foundation, which features an exceptional collection of rare and unusual trees and woody plants from all over the world. The 12-acre Arboretum surrounds the Foundation’s Gallery and includes a fern collection, formal rose and perennial gardens, lilac groves, and groupings of mature trees, including specimens not usually grown in the Mid-Atlantic region. Some highlights include: an Araucaria araucana, or monkey puzzle tree, native to Chile; Parrobia persica, or Persian ironwood, indigenous to northern Iran; and Sequoia sempervirens, or coast redwood, native to a narrow strip of land along the Pacific coast of North America.  
TOUR 2: Medicine in Colonial Philadelphia Tour  
Monday, October 15, 12:00 noon – 4:00 pm  
Cost: $55.00 per person  
Explore Philadelphia’s rich medical history while visiting the Pennsylvania Hospital, the nation’s oldest hospital. The hospital was founded in 1751 by Benjamin Franklin and Dr. Thomas Bond and features a medicinal garden and medical library. The tour will also visit the Physick House, an elegant freestanding Federal mansion built in 1786 by Henry Hill, a wealthy importer of Madeira wine. In 1815, the house was purchased by Dr. Philip Syng Physick, who was known during his lifetime as the “Father of American Surgery.” He was responsible for advancement of surgical methods and improvements in surgical instrumentation. Finally, guests will visit The Mutter Museum, the oldest honorary medical academy in the nation. The museum is one of the few pathological and medical artifact museums that still exist. Its collection includes “The Soap Lady,” the death cast of Siamese twins, Chang and Eng, a tumor removed from President Cleveland’s jaw, skeletons and more!  
TOUR 3: Ron Avery Guided Bus Tour  
Tuesday, October 16, 2:30 pm – 5:30 pm  
Cost: $22.00 per person  
See Philadelphia through the eyes of leading historian and native of Philadelphia, Ron Avery. A history major in college, Ron Avery worked as a newspaper reporter for more than 30 years in Philadelphia and the suburbs and has written three books about Philadelphia and produced three video tours of the city. Stops will include: The Benjamin Franklin Parkway (Rodin Museum, Cathedral of Saints Peter and Paul, Washington Monument). There may even be a climb to the top of the “Rocky Steps” for a panoramic view of the city! The tour will also visit South Broad Street, including the Kimmel Center, the Academy of Music, Bellevue-Stratford Hotel and the Union League Club. A short walk in historic Society Hill will include a visit to St. Peters Church and many houses that have been standing since George Washington was president. The tour will also stop by the Delaware River waterfront, where several historic ships are kept. Lastly, the tour will drive by Independence Hall, Carpenters Hall, Franklin Court, Christ Church Burial Ground, Constitution Center, Betsy Ross House, Federal Reserve Building and the First and Second Banks of the United States. |
NEEDS ASSESSMENT

The practice of clinical gastroenterology is facing an enormous ever increasing array of options both in treatments and technology. These advancements apply to all elements of diagnosis and treatment, including pharmacological agents and enhancements to technology options for interventions. The pressure to include new and ever changing administrative requirements by policymakers and payors continues to create unique challenges for the busy gastroenterology clinician. Finally, patients are more educated than ever when they walk into their physician's office – even if all of the information they have is not of the highest quality. The result, for busy clinicians is a significant set of challenges that make knowledge of the full array of state of the art science and treatment options more important than ever. While the traditional goals of thorough diagnostics and sound therapeutic options continue to remain in place, the place for outcomes measurement and turning these findings into evidence-based care continues to grow.

The reimbursement limitation and work force challenges that have been apparent in recent years have continued unabated. For GI clinicians and their practices, the imperative is to find more efficient ways to gain the latest therapeutic knowledge and institute it without compromising the highest quality of patient care. Notwithstanding research indicating that different venues present significantly different safety profiles for patients, over the past several years, a host of large payors have attempted to step in and substitute judgment regarding the appropriate venue for treatment and procedures. Unfortunately, these changes have been made largely based on financial considerations and without the input of clinicians or against their recommendations. The risk of inconsistent outcomes as a result of these changes is an area of concern and the latest data regarding safety and technical developments will be critical to assuring continued high quality patient care. This attempt to substitute judgment of the clinician is not limited to issues such as venue for care delivery. There have been efforts focused on details such as which sedatives can or should be used or even which equipment or accessories should be used for various procedures. The multi-faceted pressures of new and increasing scientific developments, pressures from payors and policymakers and demands by patients with ever greater amounts of information of various levels of quality mandate that the clinical gastroenterologists find ways to constantly reevaluate the treatments used and mechanisms for delivery in their practices, regardless of the specific practice setting to guarantee that each individual patient obtains the treatment and services that are the best possible options for their specific needs.

The emphasis of ACG's educational efforts continues to reflect the objective of obtaining the timeliest diagnosis through screening for myriad gastroenterological diseases and conditions so that appropriate interventions, treatments and disease management can begin in the most timely fashion possible. Specifically, encouraging screening for liver diseases including the various forms of hepatitis and NAFLD, screening surveillance and treatment of colon cancer, GERD, eosinophilic esophagitis and Barrett's Esophagus; management and treatment of the family of inflammatory bowel diseases and the related conditions that can develop in this patient population; meeting the unique needs of patients who have undergone some form of obesity surgery or liver transplantation; and helping patients deal with the significant challenges presented by various functional GI disorders.

Recognizing that pancreaticobiliary diseases are amongst the most difficult to treat, education on identification, treatment and management of various forms of pancreatitis, pancreatic cysts and biliary disorders is critical to obtaining the best patient outcomes.

As the survival rate from the full range gastroenterological cancers across the board improves, there is an increasing need to keep educating the clinicians who will be following post-surgical patients. This important, evolving educational need must be met in a way that touches on the impact of various forms of cancer to the overall health of the patient's GI tract.

There is no area of GI that has seen more significant developments in pharmacological therapy options than inflammatory bowel disease. The GI clinician must be fully aware of the latest developments in biologics therapy and administration and patient management options in this area as well as advances that are being made in genetics as it relates to testing and diagnosis.

The constant technological advancements that are seen in endoscopic and other technologies employed in GI procedures creates a need to communicate the latest strategies for dealing with everything from patients with altered anatomy to removal of large and difficult polyps using endoscopic technology to the developing practice of natural orifice transluminal endoscopic surgery. In addition to using the same technology in a more efficient manner, developments of new technologies permit the gastroenterologist to observe areas that have not traditionally been viewable, such as the small bowel. Clinicians in a variety of practice settings can learn to integrate new therapies into their practice regime using technologies they are already using to provide cutting edge services to their patients.

Developments in understanding the underlying causes or motility disorders have been moving forward at a quick pace as the amount of clinical research in this area expands. In some cases, the result has been that effective treatments have become available for a variety of manifestations of these disorders. Understanding the latest science in the area of motility is critical to opening the door to treatment for a large group of patients who have been among the most difficult to treat. Exposure to the latest data will assist in the identification of the incidence of disorders such as celiac sprue and other nutritional disorders, new treatments, both pharmacological and device based, for well known but difficult to treat problems such as gastroparesis, cyclical vomiting and irritable bowel syndrome.

GI bleeding remains one of the most common and most challenging issues confronted by the clinical gastroenterologist. Be it the result of pain management techniques or cardiac care or patients with chronic liver disease or even occult bleeding of unknown origins, the clinician must be up to date on the latest information on strategies and techniques to prevent and treat bleeding all through the GI tract. This will include providing accurate, practical information directly to patients and referring physicians.

The continuing problem of C. difficile disease and other chronic and acute causes of diarrhea create a need for practitioners to have complete updates on state of the art research and care to meet the needs of their patients. The challenges of risk reduction are clear in this area and the clinical gastroenterologist is going to need to be equipped as a primary resource for their community for dealing with these patients and the issues that arise.

The demand for increased practice efficiency across all settings continues to drive the search for practical tools to positively impact care delivery and patient outcomes. Through the use of evidence based approaches to treatment and rational public health policy, clinicians need to identify new and innovative ways to deliver care across the community.

FACULTY DISCLOSURES

It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. Individuals participating in the planning or implementation of a sponsored activity are required to disclose to ACG any relevant financial relationship held within the past 12 months that may pose a potential commercial bias. Conflicts of interest will be identified and resolved prior to the beginning of the activity. ACG also requires presenters to disclose to participants any uses of drugs or devices mentioned in their presentations that are off-label or investigational.
NEW!

THE FIRST ANNUAL ACG ALLIED HEALTH PROFESSIONALS SYMPOSIUM!

A Case Based Approach to the Management of Common GI Diseases

Sunday, October 14, 2007 • 2:00 pm – 5:00 pm • Room: 104A

Course Co-Directors: Carol A. Burke, MD, FACG and Jan Santisi, RN

AGENDA

2:00 pm  Abnormal LFTs
  K. Rajender Reddy, MD, FACG

2:20 pm  GERD
  Joel E. Richter, MD, MACG

2:40 pm  Ulcerative and Crohn's Colitis
  Sunanda V. Kane, MD, MSPH, FACG

3:00 pm  Q & A

3:15 pm  P4P – Government and Private Payors: What Does this Mean...How Do I Prepare?
  David A. Johnson, MD, FACG

3:45 pm  CRC Screening
  Carol A. Burke, MD, FACG

4:05 pm  Capsule Endoscopy: A Nurse's Perspective on Implementation and Interpretation
  Jan Santisi, RN

4:25 pm  IBS and Functional Dyspepsia
  Brian E. Lacy, MD, PhD, FACG

4:45 pm  Q & A

5:00 pm  Adjourn to Allied Health Professionals Reception

Members/Fellows (includes Allied Health Members): $0
Non-Members registered for any other ACG course: $0
Non-Members not registered for any other ACG course: $75

New in 2007, ACG will offer a three-hour symposium designed specifically with allied health professionals in mind. Leading experts will speak on hot topics in GI. After the symposium, join colleagues for a special reception and then visit the Exhibit Hall to see the latest in technology and therapeutics. ACG members may attend the symposium for free. Non-Members who are also registered for any other ACG 2007 course may attend the symposium for free. Any Non-Member who has not registered for any other ACG 2007 course will pay $75.

Course Description

Allied health professionals caring for patients with digestive diseases will be able to increase their knowledge about the current status of diagnostic tests and evidenced based treatments for some of the most common and chronic GI disorders including abnormal liver function tests, gastroesophageal reflux and Barrett's esophagus, Inflammatory Bowel Disease, Irritable Bowel Syndrome and Functional Dyspepsia. In addition, they will understand the benefits and limitations of current modalities for colorectal cancer screening and the use of emerging capsule technology which they will need to be familiar with in their day to day contact with patients with GI disorders. Using a fun and interesting case based approach, this symposium is designed for nurses, physician assistants, nurse practitioners and other allied health professionals interested in the latest information on diagnostic gastroenterology and state of the art treatment of gastroenterologic illnesses. Physicians are strongly encouraged to attend this symposium with their allied health personnel, as the optimal management of patients with digestive diseases often requires a dedicated and knowledgeable “team” of health care providers.

Accreditation

The American College of Gastroenterology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American College of Gastroenterology designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This program has been reviewed and is approved for a maximum of three hours of AAPA Category I (Preapproved) CME credit by the Physician Assistant Review Panel. Physician assistants should claim only those hours actually spent participating in the CME activity. This program was planned in accordance with AAPA's CME Standards for Live Programs and for Commercial Support of Live Programs.

This continuing nursing education activity was approved by the Society of Gastroenterology Nurses and Associates, Inc., an accredited approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is approved for 3 contact hours.

Program Objectives

At the conclusion of this program, participants will be able to:

- Recognize the common laboratory abnormalities associated with liver injury and link the patterns to a potential underlying cause of the hepatic disorder.
- Appreciate the etiology, natural history and treatment strategies of the common functional GI disorders including Irritable Bowel Syndrome and Functional Dyspepsia.
- Recognize the symptoms of IBD, the appropriate work up to make the diagnosis and understand a rational approach to guide treatment of IBD.
- Evaluate the current status of the payors’ (including the federal government) programs to enhance the quality of medical care and standardize treatment for gastrointestinal diseases.
- Understand the current options and benefit of colorectal cancer screening.
- Understand the utility of capsule endoscopy (CE) in GI practice and understand the nursing perspective on implementation and interpretation of CE.
- Evaluate the medical and surgical options for GERD management.
Faculty Listing and Disclosure Information

It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are required to disclose to ACG any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias and to assist in resolving any conflict of interest that may arise from the relationship. The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

Faculty have noted the following relationships related to their Allied Health Professionals Symposium presentations.

Carol A. Burke, MD, FACG
Director, Center for Colon Polyps & Cancer, Cleveland Clinic Foundation, Cleveland, OH
Dr. Burke has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.

David A. Johnson, MD, FACG
Professor of Medicine & Chief of Gastro, Eastern VA School of Medicine, Norfolk, VA
Dr. Johnson has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Sunanda V. Kane, MD, MSPH, FACG
Assistant Professor of Medicine, Mayo Clinic, Rochester, MN
Speakers’ Bureau: Prometheus Labs

Brian E. Lacy, MD, PhD, FACG
Associate Professor of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Speakers’ Bureau: Novartis, Takeda
Research grant (investigator initiated): Novartis

K. Rajender Reddy, MD, FACG
Director, Hepatology; Medical Director, Liver Transplantation, Hospital of the University of Pennsylvania, Philadelphia, PA
Dr. Reddy has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Joel E. Richter, MD, MACG
Chairman, Department of Medicine, Temple University School of Medicine, Philadelphia, PA
Dr. Richter has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Jan Santisi, RN
RN, Cleveland Clinic Foundation, Cleveland, OH
Consultant/Speaker: Olympus Intl., Given Imaging

Investigational Use Disclosure

ACG’s disclosure policy maintains that if any unapproved or off-label use of a product is to be referenced in a CME program, the faculty member is required to disclose that the product is either investigational or it is not labeled for the usage being discussed. The following faculty member has indicated he may reference an off-label use in his Allied Health Symposium presentation.

Dr. Lacy – tricyclic antidepressants, SSRIs for IBS and dyspepsia
ACG’s 2007 Educational Programs

Practice Management Course
Friday, October 12, 2007 • 7:00 am – 6:00 pm • Room: 108 AB
Course Co-Directors: Stephen E. Deal, MD, FACG and Chalmers M. Nunn, Jr., MD, MMM

Course Description
Learn ways to improve efficiency and increase profitability in your practice by attending the 20th Annual Practice Management Course. Course Directors Stephen E. Deal, MD, FACG, and Chalmers M. Nunn, Jr., MD, MMM, have organized a course that focuses on efficient practices and updates in areas of interest to the clinical gastroenterologist.

The ACG Practice Management Course will feature several physicians who are running successful practices PLUS a noted expert on negotiating, Roger Dawson. You’ll walk away from the course with the skills to become a power negotiator.

The negotiating sessions are new to this year’s program. Few are born with the knowledge on how to best negotiate, but it is a skill that can be learned. Roger Dawson, a leading expert on negotiating will lead the keynote session, “How to Become a Power Negotiator.” In addition, he’ll also present on such topics as using negotiating when dealing with payors, hospitals and your patients, resolving conflict and influencing your partners, and how to effectively deal with others. Attend and you’ll walk away armed with the knowledge and confidence to negotiate the best solution for you, your practice and your patients. Other sessions will guide you on paying staff based on productivity, where to make an investment in IT and how to develop your practice website, quality of life issues for mid-level providers, managing a difficult physician, how to make your practice unique, and preparing for 2008.

Faculty
Stephen E. Deal, MD, FACG, Course Co-Director
Chalmers M. Nunn, Jr., MD, MMM, Course Co-Director
Roger Dawson, CPAE, CSP
Philip Grossman, MD, FACP
Klaus Mergener, MD, PhD, FACP
Irving M. Pike, MD, FACP
Karen L. Woods, MD, FACP

Program Description
Medical school, residency and fellowship did not prepare you for the challenges you face today. Reimbursement is declining, you are having to learn to be more productive and quite often you find yourself having a hard time dealing with your hospital, vendors, payors and even your partners. This course is designed to help you learn to deal more effectively with the practice management challenges you face and create a more positive outlook on the future. The main focus of the course is to transfer to you the most important business skill you can have—the ability to negotiate effectively. To achieve this, we have invited a premier instructor of negotiation, Roger Dawson, to be the keynote speaker. Throughout the course of the day, Mr. Dawson will be teaching you the skills you need to become a savvier negotiator.

Another important business skill is that of networking and learning from each other. We have speakers who have learned a great deal from the school of hard knocks in running their practice and they will share what they have learned on topics such as dealing with a difficult partner, information technology, avoiding the commodity trap, how to pay your staff based on productivity and using physician extenders more effectively. There will be ample breakout sessions where you will have the opportunity to interact more closely with the speakers. The lunch session is designed for you to learn from each other and meet members of the College who serve on the Practice Management Committee. The course will wrap up using the clinical performance data you are collecting on yourself to negotiate for better outcomes.

Program Objectives
Upon completion of this program attendees will:
• Improve their negotiation skills to more effectively deal with payors, vendors, hospitals and their partners.
• Learn how to use data and time to their and their patients’ advantage.
• Run their practices more effectively through appropriate use of physician extenders to enhance the patient experience, avoiding the mistakes others have made and developing more effective pay practices.
• Develop a competitive differential advantage for their practice in the evolving business environment of consumerism where the burden of payment is now coming more from the patient rather than the payor.
• Learn how to more effectively deal with a difficult partner.
• Gain the newest perspective on how to incorporate information technology into your practice to improve patient care.

Accreditation
The American College of Gastroenterology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American College of Gastroenterology designates this educational activity for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Practice Management Course
Friday, October 12, 2007 • 7:00 am – 6:00 pm • Room: 108 AB
Course Co-Directors: Stephen E. Deal, MD, FACG and Chalmers M. Nunn, Jr., MD, MMM

Members/Fellows: $225
Resident/Trainee/Candidate Members: $0*/$150
Allied Health Members: $150
Non-Members: $275
Practice Managers: $150

7:00 am • Continental Breakfast
Topic Table Discussions (committee members will facilitate discussion)

8:00 am • Welcome and Introduction of Keynote Session
Stephen E. Deal, MD, FACG
and Chalmers M. Nunn, Jr., MD, MMM

8:10 am • Keynote Session: Becoming a Power Negotiator
Roger Dawson, CPAE, CSP, Power Negotiating Institute
Negotiation is the most important business skill you can acquire, and Roger Dawson is a premier instructor in teaching negotiation techniques to physicians. Mr. Dawson will teach you powerful negotiation skills that physicians use in every contractual interaction to get more than they ever thought possible. You will leave this workshop with new strategies and tactics so that you can strengthen your practice and patient care as a savvy negotiator.
  • Learn the five things that make you a power negotiator.
  • Learn negotiating tactics that lead to win-win solutions.
  • Learn how to gather information that gives you control.
  • Learn how to negotiate the best deal possible from your payors.
  • Learn how to negotiate win-win agreements with hospitals.
  • Learn how to negotiate better deals with your vendors.
  • Learn how to negotiate better for yourself and your patients.

10:00 am • Break

10:10 am • Using Negotiation in Your Practice to Deal with Payors — A Case Based Approach
Roger Dawson, CPAE, CSP, Power Negotiating Institute

11:40 am • Break

11:50 am • Lunch — Learning from Each Other: Round Table Discussions About the Greatest Challenges Faced by Your Practice

1:30 pm • IT Issues in GI: Where Do I Make the Investment?
Philip Grossman, MD, FACP

2:00 pm • Managing the Difficult Physician
Chalmers M. Nunn, Jr., MD, MMM

2:30 pm • Mid-Level Providers (NP/PA) in GI: Is it About Quality of Life, Income or BOTH?
Klaus Mergener, MD, PhD, FACP

3:00 pm • Break

3:10 pm • Breakout Session I (choose one)
A. Resolving Conflict and Influencing Your Partners (Room 111AB)
Roger Dawson, CPAE, CSP, Power Negotiating Institute
B. How Much Should I Develop my Website? (Room 109AB)
Philip Grossman, MD, FACP
C. Running Your Practice: Lessons Learned in the School of Hard Knocks (Room 113AB)
Karen L. Woods, MD, FACP
D. Avoiding the Commodity Trap: Making Your Practice Unique (Room 108AB)
Stephen E. Deal, MD, FACG

4:05 pm • Breakout Session II (choose one)
A. Resolving Conflict and Influencing Your Partners (Room 111AB)
Roger Dawson, CPAE, CSP, Power Negotiating Institute
B. How Much Should I Develop my Website? (Room 109AB)
Philip Grossman, MD, FACP
C. Running Your Practice: Lessons Learned in the School of Hard Knocks (Room 113AB)
Karen L. Woods, MD, FACP
D. Avoiding the Commodity Trap: Making Your Practice Unique (Room 108AB)
Stephen E. Deal, MD, FACG

4:50 pm • Break

5:00 pm • Preparing for 2008: Collecting Data on Yourself
Irving M. Pike, MD, FACG

5:30 pm • Knowing Thyself and Using that to Deal Effectively with Others
Roger Dawson, CPAE, CSP, Power Negotiating Institute

6:00 pm Adjourn

* ACG Resident/Trainee and Candidate Members ONLY. ACG will waive the usual $150 Resident/Trainee/Candidate Member Practice Management Course registration fee only if registration is received and processed by September 21, 2007. The $150 fee will apply to any registration received and/or processed after September 21.
ACG’s 2007 Educational Programs

Practice Management Course
Friday, October 12, 2007 • 7:00 am – 6:00 pm • Room: 108 AB

Course Co-Directors: Stephen E. Deal, MD, FAccG and Chalmers M. Nunn, Jr., MD, MMM

Faculty Listing and Disclosure Information
It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are required to disclose to ACG any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias and to assist in resolving any conflict of interest that may arise from the relationship. The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

Faculty have noted the following relationships related to their Practice Management Course presentations.

Stephen E. Deal, MD, FAccG
Carolina Digestive Health Associates, Charlotte, NC
Dr. Deal has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Roger Dawson, CPAE, CSP
Power Negotiating Institute, Inc., Placentia, CA
Dr. Dawson has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Philip Grossman, MD, FAccG
President, Drs. Grossman and Price PA, Miami, FL
Dr. Grossman has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Klaus Mergener, MD, PhD, FAccG
Digestive Health Specialists, Tacoma, WA
Dr. Mergener has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Chalmers M. Nunn, Jr., MD, MMM
CEO, Gastroenterology Associates of Central Virginia, Lynchburg, VA
Dr. Nunn has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Irving M. Pike, MD, FAccG
Gastrointestinal & Liver Specialists of Tidewater, PLLC, Virginia Beach, VA
Dr. Pike has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Karen L. Woods, MD, FAccG
Clinical Associate Professor of Medicine, Baylor College of Medicine, Houston, TX
Dr. Woods has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.
Course Description
Progress in the development and application of gastrointestinal endoscopy, like other technologies, may evolve from the solid, deliberate accumulation of knowledge through science, and from unexpected discoveries and attitudes that alter the way we approach clinical problems. These paradigm shifts offer new opportunities for adaptation to the challenges and disruptive changes facing endoscopists of the future. The purpose of the ASGE 2007 Interim Course is to examine the various facets of diagnostic and therapeutic endoscopy that may be impacted by future changes in health care, and to explore opportunities for practicing gastroenterologists to adjust to these changes.

Intended Audience
This course has been specifically designed for those practitioners in gastrointestinal endoscopy, especially gastroenterologists and gastrointestinal surgeons as well as fellows in training. The program will educate on state-of-the-art endoscopic techniques and devices as well as quality indicators in endoscopic procedures. This course is equally relevant to those in private practice and academic practice.

Course Objectives
At the conclusion of this course, participants should be able to:

- Describe next generation diagnostic endoscopy
- Explain proposed quality measures for physician volunteer reporting and demonstration (or lack) on outcomes
- Illustrate the potential for future turf battles, and the position of practicing gastroenterologists in these contests
- Explore opportunities for practicing gastroenterologists to adapt to changes predicted for the future
- Review the technologies that can be embraced by practicing gastroenterologists now and in the near future

Course Co-Directors
Jonathan Cohen, MD, FACG, FASGE and Colleen Schmitt, MD, MHS, FACG, FASGE

Faculty
Thomas M. Deas, Jr., MD, FACP, FASGE, Gastroenterology Associates of North Texas, LLP, Fort Worth, TX
Glenn M. Eisen, MD, MPH, FASGE, Oregon Health and Science University, Portland, OR
Grace H. Elta, MD, FACP, FASGE, University of Michigan, Ann Arbor, MI
Martin L. Freeman, MD, FACP, Hennepin County Medical Center, Minneapolis, MN
Robert A. Ganz, MD, FACP, Minnesota Gastroenterology, Minneapolis, MN
Lauren B. Gerson, MD, Stanford University Hospital, Stanford, CA
Ian M. Gralnek, MD, MSHS, FASGE, Technion Institute of Technology & Rambam Medical Center, Haifa, Israel
Douglas A. Howell, MD, FACP, FASGE, Portland Endoscopy Center, Portland, ME
Peter Kelsey, MD, Massachusetts General Hospital, Boston, MA
Irving M. Pike, MD, FACP, Gastroenterology Consultants, Virginia Beach, VA
Douglas K. Rex, MD, FACP, FASGE, Indiana University Medical Center, Indianapolis, IN
Richard I. Rothstein, MD, FACP, Dartmouth-Hitchcock Medical Center, Lebanon, NH
C. Paul Swain, MD, Royal London Hospital, London, England
Recertification Preparation and Update Course
Friday, October 12, 2007 • 5:15 pm – 8:15 pm • Room: 111 AB
Course Director: Brooks D. Cash, MD, FACG

Registration fee: $100

Course Description
The challenges of quality patient care and optimal patient outcomes seem to increase exponentially from year to year through a combination of increased demand and burgeoning information/treatment options relating to disease guidelines, disease management recommendations, introduction of new pharmacotherapeutic agents and devices. The clinical gastroenterologist needs to build on his/her educational foundation regarding GI anatomy and disease states that lead to their board certification and re-certification while distilling the essence of new information and integrating it into their day-to-day practice. The requirement for recertification has posed an educational challenge for board certified gastroenterologists who are trying to manage their practice with their educational needs. This program is designed for physicians studying for their recertification exam who seek to increase their comfort level with the nature of the information they will be required to know as they take the exam.

Using a module developed by the ACG under the leadership of Philip O. Katz, MD, FACG, and approved for self-evaluation credit toward ABIM Maintenance of Certification, faculty comprised of gastroenterologists with expertise in selected areas will review some of the types of question topics and scientific rationale you will need to achieve awareness of/command over and be prepared to answer to be successful in specific recertification component areas.

Program Objectives
Upon completion of this program attendees will:

- Learn the scope of the substantive areas in organ systems and disease management that they will need to be fully conversant in to successfully complete the exam.
- Obtain a clear understanding of the most effective test taking approaches.

Accreditation
The American College of Gastroenterology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American College of Gastroenterology designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Attendee Requirements
Registrants are required to purchase the ACG’s Self-Assessment Program for Maintenance of Certification credit ($60 ACG members; $80 non-members). Once registered, participants will be contacted regarding how to purchase the required module. Attendees enrolled in the ABIM’s MOC program who successfully complete this ACG module will be awarded 20 self-evaluation of medical knowledge points by ABIM.

Faculty
Course Director – Brooks D. Cash, MD, FACG
Randall E. Brand, MD, FACG
William D. Chey, MD, FACG
Sunanda V. Kane, MD, MSPH, FACG
Philip O. Katz, MD, FACG
Paul Y. Kwo, MD
Darrell S. Pardi, MD, FACG

Self-Evaluation Module:
ACG’s Self-Assessment Program for Maintenance of Certification
Required in Conjunction with the 2007 ACG Recertification Preparation Course

Earn 20 self-evaluation of medical knowledge points toward your ABIM Maintenance of Certification. ACG’s online Self-Assessment Program is a 60-question module developed by ACG. When you complete the program, you’ll earn a maximum of 4 Category 1 CME credits.

ACG member price: $60 Non-member price: $80

For more information on how to purchase the module, see General Information on page ##.
Recertification Preparation and Update Course
Friday, October 12, 2007 • 5:15 pm – 8:15 pm • Room: 111 AB
Course Director: Brooks D. Cash, MD, FACP

Faculty Listing and Disclosure Information
It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are required to disclose to ACG any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias and to assist in resolving any conflict of interest that may arise from the relationship. The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

Faculty have noted the following relationships related to their Recertification Course presentations.

Randall E. Brand, MD, FACP
Visiting Professor of Medicine, University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, PA
Dr. Brand has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Brooks D. Cash, MD, FACP
Associate Professor of Medicine, National Naval Medical Center, Gaithersburg, MD
Dr. Cash has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

William D. Chey, MD, FACP
Associate Professor of Medicine, Director GI Physiology Lab, University of Michigan Medical Center, Ann Arbor, MI
Dr. Chey has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Sunanda V. Kane, MD, MSPH, FACP
Assistant Professor of Medicine, Mayo Clinic, Rochester, MN
Consultant: Centocor, Abbott, Procter & Gamble, Shire
Research Support: Procter & Gamble

Philip O. Katz, MD, FACP
Chairman, Division of Gastroenterology, Albert Einstein Medical Center, Philadelphia, PA
Dr. Katz has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Paul Y. Kwo, MD
Associate Professor of Clinical Medicine, Indiana University Department of Medicine, Indianapolis, IN
Speakers’ Bureau: Gilead, Idenix, Novartis
Grant Support: GSK

Darrell S. Pardi, MD, FACP
Assistant Professor of Medicine, Mayo Clinic, Rochester, MN
Research: AstraZeneca
Review of GI Structure and Function Course
Friday, October 12, 2007 • 7:00 am – 12:30 pm
Room: Lecture Hall
Course Co-Directors: John F. Reinus, MD, FACG and Douglas M. Simon, MD, FACG

Members/Fellows: $150
Resident/Trainee/Candidate Members: $110
Allied Health Members: $125
All Non-Members: $175

Attend ACG’s Review of GI Structure and Function Course for a thorough review of the physiological, basic science underpinnings that are the basis for the Postgraduate Course review of pathophysiology, diagnosis and therapeutic measures.

Developed as an essential course for Board review, Review of GI Structure and Function will be presented by leading experts in the field.

AGENDA
7:00 am  The Structure of the Hollow Viscera
Elizabeth Montgomery, MD
7:30 am  Gastrointestinal Motility
Ikuo Hirano, MD, FACG
8:10 am  Gastrointestinal Endocrinology
John Del Valle, MD
8:30 am Break
8:50 am  Gastric Secretion
Michael Wolfe, MD, FACG
9:10 am  Pancreatic Structure and Function
James H. Grendell, MD
9:30 am  Intestinal Absorption and Secretion
Lawrence R. Schiller, MD, FACG
10:15 am  Gastrointestinal Immunology
Maria T. Abreu, MD
10:30 am Break
10:50 am  Hepatic Structure and Function
Paul Martin, MD, FACG
11:20 am  The Composition and Circulation of Bile
Michael Fuchs, MD, PhD
11:50 am  Bilirubin Metabolism
Jayanta Roy Chowdhury, MD
12:20 pm Adjourn

What’s New in GI Pharmacology Course
Friday, October 12, 2007 • 1:45 pm – 4:45 pm
Room: Lecture Hall
Course Director: Philip O. Katz, MD, FACG

Members/Fellows: $150
Resident/Trainees/Candidate Members: $110
Allied Health Members: $125
All Non-Members: $175

There is an ever-increasing demand on a physician’s time to keep up with the expanding list of pharmacologic treatment for GI and liver disorders. What’s New in GI Pharmacology provides an intensive review of key GI pharmacology issues. Attendees will learn treatment options for such disorders as eosinophilic esophagitis, Barrett’s esophagus, IBD, use of statins in patients with chronic liver disease, management of IBS, and treatments for obesity. This course is an essential component of the three-day Board Review.

AGENDA
1:45 pm  Management of Eosinophilic Esophagitis 2007
David A. Katzka, MD
2:15 pm  Chemoprevention for Barrett’s: PPIs, NSAIDs, Aspirin
Stuart J. Spechler, MD, FACG
2:45 pm  Optimizing Medical Therapy for IBD
Stephen B. Hanauer, MD, FACG
3:15 pm  Use of Statins in Patients with Chronic Liver Disease
Mitchell L. Shiffman, MD, FACG
3:45 pm  Management of Irritable Bowel Syndrome
William D. Chey, MD, FACG
4:15 pm  Treating Obesity: Reshaping the Future
Amy E. Foxx-Orenstein, DO, FACG
4:45 pm Adjourn

Accreditation — What’s New in GI Pharmacology
The American College of Gastroenterology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American College of Gastroenterology designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Accreditation — GI Structure and Function
The American College of Gastroenterology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American College of Gastroenterology designates this educational activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
TWO-DAY BOARD REVIEW

Designed as a board review for the young specialist preparing for the exam, the Three-Day Board Review includes the Review of GI Structure and Function Course, What’s New in GI Pharmacology Course, and the Annual Postgraduate Course. This collection of courses is designed to provide a comprehensive update in basic science and help prepare attendees for specific topics covered in the exam. Additionally, through the Postgraduate Course, you will learn better ways to integrate the newest tools in diagnosis with the latest therapeutic/treatment alternatives to achieve optimal outcomes, improve your awareness and ability to incorporate patient care decision-making issues relating to common and not-so-common GI patient conditions, and enhance your overall capacity to frame effective disease management strategies in your practice. When you sign up for the Three-Day Board Review, you will automatically be enrolled in the three designated courses. See the Registration Form on page 87 for complete pricing information.

Program Description

With the volume of patients continuing to increase as the population ages and the research and information available in gastroenterology does as well, the demands on the clinical gastroenterologist seem to be increasing at an incredible pace. The complexity of the research and treatment options necessary to maximize positive outcomes means that the need to identify ways to maximize knowledge and provide tools to integrate this knowledge into practice is in greater demand than ever. To be successful, educational programming has to build on the key foundation and clinical skills of the attendees and offer practical methods and solutions for treating patients and obtaining positive outcomes that can be put into practice with a wide variety of patient profiles with minimal disruption to all parties. These principles are the basis for this year’s educational programming from the ACG. The Course’s fundamental objective is to improve the gastroenterologist’s overall capacity to frame effective disease management strategies. Workshops, symposia and lunches provide updated perspectives on key GI and liver conditions/disorders and the procedural/technological baseline for sound diagnosis and treatment. This program is designed primarily for gastroenterologists and allied health professionals with significant involvement in diagnosis and treatment of GI and liver conditions and disorders who are interested in an aggressive but scientifically sound approach to management of the treatment needs of GI patients with these conditions. A comprehensive review will be conducted in didactic presentations from expert faculty, which collectively will provide broad coverage of organ systems. Optional, smaller group, “Meet the Professor” Learning Luncheons, together with question periods interspersed in the didactic sessions, and the choice among a series of breakout sessions in GI and liver clinical care will provide ample opportunities for exploration of specific issues and greater depth in focused areas and GI procedures and treatments.

This year’s faculty comprises a collection of true leaders in each of their respected fields. Learning from the “Masters” adds a different dimension to the traditional didactic format of postgraduate courses.

Program Objectives

Upon completion of this program, attendees will:

• Integrate new information about hepatitis C and non-alcoholic liver disease into current practice patterns along with redefining established care patterns for patients with fulminating hepatic failure and those status post liver transplant.
• Develop a systematic approach to the management of acute and chronic pancreatitis, the approach to cystic lesions and fluid collections of the pancreas and comprehending the evolving issues in the management of pancreatitis.
• Identify current issues/controversies in the management of patients with GI cancers, including tests for colorectal cancer, polyp surveillance strategies, detection of Barrett’s esophagus, and screening issues for hepatocellular carcinoma in the setting of cirrhosis.
• Incorporate into patient care decision-making new data regarding the biologics in the treatment of IBD, the management of fistulizing disease and the use of diagnostic testing and markers.
• Evaluate management tips from experts in a range of common practice issues such as taking out large polyps, managing ascites, using immunomodulators in IBD, and diagnosing celiac disease.
• Discuss approaches to managing gastrointestinal disease in the obese patient, managing the long-standing IBD patient and using new technologies in endoscopy.
• Identify evaluation and treatment options for functional disorders including IBS, functional dyspepsia, non-cardiac chest pain and chronic constipation.
• Analyze current treatment strategies for common gastrointestinal conditions such as IBD, pancreaticobiliary disease, IBS, viral hepatitis and chronic diarrhea.
• Assimilate appropriate diagnostic and treatment options for esophageal conditions including GERD, motility disorders, eosinophilic esophagitis and extra-esophageal reflux disease.
• Expand knowledge base regarding the management of gastroparesis, anorectal diseases, Barrett’s esophagus and endoscopy-related issues including sedation, monitoring and efficiency.

ACG 2007 Self-Assessment Test ONLINE

Advance purchase is available for Annual Postgraduate Course registrants only. See page ## for details.
Review of GI Structure and Function Course
Friday, October 12, 2007 • 7:00 am – 12:30 pm • Room: Lecture Hall

Course Co-Directors: John F. Reinus, MD, FACG and Douglas M. Simon, MD, FACG

Faculty Listing and Disclosure Information
It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are required to disclose to ACG any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias and to assist in resolving any conflict of interest that may arise from the relationship. The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

Faculty have noted the following relationships related to their GI Pathology and Imaging Course presentations.

Maria T. Abreu, MD
Associate Professor of Medicine, Mount Sinai Medical Center, New York, NY
Consultant: Abbott, Berlex, Centocor, Procter & Gamble, Prometheus, UCB
Research Grant: Procter & Gamble
Speaker’s Bureau: Abbott, Procter & Gamble, Prometheus, Salix

Jayanta Roy Chowdhury, MD
Professor, Albert Einstein College of Medicine, Bronx, NY
Dr. Chowdhury has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

John Del Valle, MD
Professor, Department of Internal Medicine, University of Michigan, Ann Arbor, MI
Dr. Del Valle has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Michael Fuchs, MD, PhD
Associate Professor of Medicine, Virginia Commonwealth University Medical Center, Richmond, VA
Dr. Fuchs has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

James H. Grendell, MD
Professor of Medicine, SUNY at Stony Brook School of Medicine, Mineola, NY
Dr. Grendell has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Ikou Hirano, MD, FACG
Associate Professor, Northwestern University Medical School, Chicago, IL
Dr. Hirano has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Paul Martin, MD, FACG
Professor of Medicine, Mount Sinai School of Medicine, New York, NY
Dr. Martin has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Elizabeth Montgomery, MD
Professor of Pathology & Oncology, Johns Hopkins Hospital, Baltimore, MD
Dr. Montgomery has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.

Lawrence R. Schiller, MD, FACG
Program Director, GI Fellowship, Baylor University Medical Center, Dallas, TX
Dr. Schiller has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Michael Wolfe, MD, FACG
Chief, Section of Gastroenterology, Boston University School of Medicine, Boston, MA
Dr. Wolfe has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.
What’s New in GI Pharmacology Course
Friday, October 12, 2007 • 1:45 pm – 4:45 pm • Room: Lecture Hall
Course Director: Philip O. Katz, MD, FACG

Faculty Listing and Disclosure Information
It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are required to disclose to ACG any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias and to assist in resolving any conflict of interest that may arise from the relationship. The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

Faculty have noted the following relationships related to their GI Pharmacology Course presentations.

William D. Chey, MD, FACG
Associate Professor of Medicine, Director GI Physiology Lab, University of Michigan Medical Center, Ann Arbor, MI
Consultant and/or Speakers’ Bureau: AGI, GSK, Microbia, Novartis, Procter & Gamble, Salix, Takeda, Pharmos

Amy E. Foxx-Orenstein, DO, FACG
Associate Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN
Dr. Foxx-Orenstein has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.

Stephen B. Hanauer, MD, FACG
Professor of Medicine, University of Chicago, Chicago, IL
Consultant: Abbott Labs, Alevan, Centocor, Elan, Ferring, Genentech, Millennium Pharmaceuticals, Otsuka, Protein Design Labs, Procter & Gamble, Prometheus, Salix, Shire, UCB Pharma (Celltech)
Clinical Research: Abbott Labs, Centocor, Elan, Ferring, Genentech, Otsuka, Protein Design Labs, Procter & Gamble, Prometheus, Salix, Shire, UCB Pharma (Celltech)
Speaker: Centocor, Ferring, Procter & Gamble, Prometheus, Salix, UCB Pharma (Celltech)

Philip O. Katz, MD, FACG
Chairman, Division of Gastroenterology, Albert Einstein Medical Center, Philadelphia, PA
Dr. Katz has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

David A. Katzka, MD
Co-Director, GI Motility/Physiology Program; Director, Swallowing Program, Hospital of the University of Pennsylvania, Philadelphia, PA
Dr. Katzka has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Mitchell L. Shiffman, MD, FACG
Chief, Hepatology Section; Medical Director, Liver Transplant Program, Virginia Commonwealth University Medical Center, Richmond, VA
Dr. Shiffman has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Stuart J. Spechler, MD, FACG
Chief, Division of Gastroenterology, Dallas VA Medical Center, Dallas, TX
Grant Support: AstraZeneca, TAP, BARRX Medical

Investigational Use Disclosure
ACG’s disclosure policy maintains that if any unapproved or off-label use of a product is to be referenced in a CME program, the faculty member is required to disclose that the product is either investigational or it is not labeled for the usage being discussed. The following faculty members have indicated they may reference an off-label use in their Pharmacology Course presentation.

Dr. Chey – renzapride, lubiprostone, linaclotide, asimadoline, alvimopan, methylnaltrexone, crefelemem, dextofisopam, AGN 203818, rifaximin, r-verapamil in the management of IBS.
ACG’s 2007 Postgraduate Course — Saturday, October 13

Annual Postgraduate Course
Saturday and Sunday, October 13 and 14, 2007 • Room: Ballroom AB
Course Co-Directors: Stephen B. Hanauer, MD, FACP, Sunanda V. Kane, MD, MSPH, FACP and Nicholas J. Shaheen, MD, FACP

SATURDAY, OCTOBER 13, 2007
7:50 am – 5:15 pm

Session 1A: Liver Disease (Ballroom AB)
Moderator: Michael W. Fried, MD

7:50 am Introduction
Stephen B. Hanauer, MD, FACP
Sunanda V. Kane, MD, MSPH, FACP
Nicholas J. Shaheen, MD, FACP

8:00 am Setting the Stage: Hepatitis C – Where Have We Been, Where Are We Going?
Willis C. Maddrey, MD, MACG

8:20 am Non-Alcoholic Fatty Liver Disease
Arun J. Sanyal, MD

8:40 am Hereditary Hemochromatosis and Other Metabolic Liver Disease
Kris V. Kowdley, MD, FACG

9:00 am Fulminant Hepatic Failure
Rowen K. Zetterman, MD, MACG

9:20 am Care of the Post-Transplant Patient
Mitchell L. Shiffman, MD, FACG

9:40 am Panel Q & A

10:00 am BREAK

10:20 am David Sun Lecture – Esophageal Dilation: A Perspective of 45 Years of Experience: Pearls, Perils and Pitfalls
H. Worth Boyce, Jr., MD, MACG

Session 1B: Pancreatic Disease (Ballroom AB)
Moderator: Michael B. Wallace, MD, MPH, FACP

10:50 am Setting the Stage: Evolving Issues in the Management of Pancreatitis
Peter A. Banks, MD, MACG

11:10 am Management of Chronic Pancreatitis
Glen A. Lehman, MD, FACP

11:30 am Pancreatic Cysts and Fluid Collections
Stuart Sherman, MD, FACG

11:50 am Evidence-based Approach to Acute Pancreatitis
Scott M. Tenner, MD, MPH, FACP

12:10 pm Panel Q & A

12:40 pm BREAK FOR LEARNING LUNCHEONS
Saturday Learning Luncheons – “How I Do It”
12:40 pm – 1:55 pm
Cost is $50.00 per person/per luncheon. Separate registration is required. If you have not registered, visit the ACG Registration Desk.

1. Take Out Large Polyps
   Jerome D. Waye, MD, MACG

2. Use New Testing Modalities in Esophageal Disease
   Kenneth R. DeVault, MD, FACP

3. Manage Ascites
   Arun J. Sanyal, MD

4. Achieve the Hard Cannulation
   John Baille, MB, ChB, FACP

5. Drain a Pancreatic Cyst
   Stuart Sherman, MD, FACP

6. Use Immunomodulators in IBD
   William J. Sandborn, MD, FACP

7. Endoscopic Mucosal Resection
   Kenneth K. Wang, MD, FACP

8. Manage Achalasia
   Joel E. Richter, MD, MACG

9. Evaluate the Transplant Candidate
   Robert S. Brown, Jr., MD, MPH, FACP

10. Find Celiac Sprue
    Sheila E. Crowe, MD, FACG

11. Treat Post-Nissen Complications
    John E. Pandolfino, MD, FACP

12. Run an Efficient Office Practice
    James T. Frakes, MD, FACG

The 2007 Self-Assessment Test ONLINE

Enhance your learning by purchasing the 2007 ONLINE Self-Assessment Test. The online version to the popular print resource tracks user responses, indicates the correct answer and provides overall/category scores. It also provides detailed explanations and bibliography, with links to PubMed and resources like ACG’s practice guidelines. For more information, see General Information on page ##. $75 members; $100 non-members.
Session 1C: GI Oncology (Ballroom AB)
Moderator: Stuart J. Spechler, MD, FACG

2:10 pm Setting the Stage: Colorectal Cancer Screening – How Good are the Tests, and Which Will “Win”?
Sidney J. Winawer, MD, MACG

2:30 pm Update on Polyp Surveillance Strategies
Douglas K. Rex, MD, FACG

2:50 pm Barrett’s Esophagus: New Methods of Detection and Surveillance
Prateek Sharma, MD, FACG

3:10 pm Screening for Hepatocellular Carcinoma in Cirrhosis: Yes? And If So, How?
Gregory J. Gores, MD, FACG

3:30 pm Panel Q & A

3:50 pm–5:15 pm SIMULTANEOUS SYMPOSIA

Symposium A – GI Disease in the Obese Patient
(Room 201 ABC)
Moderator: Carol E. Semrad, MD, FACG

3:50 pm Managing Complications of Gastric Bypass
John P. Cello, MD

4:20 pm GERD and Adenocarcinoma of the Esophagus
Hashem B. El-Serag, MD, MPH

4:50 pm Endoscopy/Procedural Considerations in the Very Obese
John J. Vargo, MD, MPH, FACG

Symposium B – Managing Longstanding IBD
(Ballroom B)
Moderator: Sunanda V. Kane, MD, MSPH, FACG

3:50 pm Bone Density Issues
Maria T. Abreu, MD

4:20 pm Cancer Risk with Chronic Disease and Risks Associated with Chronic Immunosuppression
William J. Sandborn, MD, FACG

4:50 pm Pregnancy Issues
Sunanda V. Kane, MD, MSPH, FACG

Symposium C – Evolving Technology in GI Endoscopy
(Ballroom A)
Moderator: Douglas K. Rex, MD, FACG

3:50 pm Shapelock and Double-Balloon
Simon K. Lo, MD, FACG

4:20 pm Capsule Endoscopy
Blair S. Lewis, MD, FACG

4:50 pm NOTES
Jeffrey L. Ponsky, MD, FACG

5:15 pm Adjourn

SUNDAY OCTOBER 14, 2007
7:50 am – 5:15 pm

Session 2A: Inflammatory Bowel Disease
(Ballroom AB)
Moderator: William J. Tremaine, MD, FACG

7:50 am Introduction
Stephen B. Hanauer, MD, FACG
Sunanda V. Kane, MD, MSPH, FACG
Nicholas J. Shaheen, MD, FACG

8:00 am Setting the Stage: IBD
Daniel H. Present, MD, MACG

8:40 am Making Sense of the Data on Biologics
Stephen B. Hanauer, MD, FACG

9:00 am Treating Fistulous Disease
William J. Sandborn, MD, FACG

9:20 am Panel Q & A

9:40 am BREAK

Session 2B: Functional Bowel Disease
(Ballroom AB)
Moderator: Douglas A. Drossman, MD, MACG

10:00 am Setting the Stage: Irritable Bowel Syndrome — Common Phenotypes Due to Several Defined Disease Entities?
Michael Camilleri, MD, FACG

10:20 am Functional Dyspepsia — Evidence Based Management
Nicholas J. Talley, MD, PhD, FACG

11:00 am Developing Therapy for Chronic Constipation
William D. Chey, MD, FACG

11:20 am Panel Q & A

11:40 am State of the Art Lecture: NSAIDs and the Gut: Toward Rational Therapy
Loren A. Laine, MD, FACG

12:20 pm BREAK FOR LEARNING LUNCHEONS
(See listing on next page.)

Accreditation
The American College of Gastroenterology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American College of Gastroenterology designates this educational activity for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Sunday Learning Luncheons – “You Make the Call”
12:20 pm – 1:35 pm
Cost is $50.00 per person/per luncheon. Separate registration is required. If you have not registered, visit the ACG Registration Desk.

13. Inflammatory Bowel Disease
   David T. Rubin, MD

14. Pancreaticobiliary Disease
   John Bailie, MB, CHB, FACG

15. Nutritional Disorders
   Carol E. Semrad, MD, FACG

16. Upper GI Bleeding
   Loren A. Laine, MD, FACG

17. Irritable Bowel Syndrome
   Eamonn M.M. Quigley, MD, FACG

18. Colorectal Cancer Screening and Surveillance
   Linda Rabeneck, MD, MPH, FACG

19. Barrett’s Esophagus
   Prateek Sharma, MD, FACG

20. Viral Hepatitis
    Luis A. Balart, MD, MACG

21. Liver Transplant
    Mitchell L. Schiffman, MD, FACG

22. C. difficile
    Christina M. Surawicz, MD, FACG

23. Chronic and Acute Diarrhea
    Lawrence J. Brandt, MD, MACG

24. Management of Pancreatic Masses
    Michael B. Wallace, MD, MPH, FACG

25. Chronic Nausea and Vomiting Work-up
    Kenneth L. Koch, MD, FACG

Session 2C: Esophageal Disease  (Ballroom A)
Moderator: David A. Johnson, MD, FACG

1:45 pm  Setting the Stage: GERD Pathogenesis and Treatment — Beyond the PPIs
         Donald O. Castell, MD, MACG

2:05 pm  Motility Disorders of the Esophagus
         Peter J. Kahrilas, MD, FACG

2:25 pm  Eosinophilic Esophagitis
         Joel E. Richter, MD, MACG

2:45 pm  Recognizing and Treating Extra-Esophageal Reflux Disease
         Philip O. Katz, MD, FACG

3:05 pm  Panel Q & A

3:25 pm  Break

3:45 pm – 5:00 pm  SIMULTANEOUS ENDOSCOPY WORKSHOPS

Symposium D: Gastroparesis: Beyond Metaclopramide  (Room 201 ABC)
Moderator: Henry P. Parkman, MD, FACG

3:45 pm  Pathogenesis and Pathophysiology
         Pankaj J. Pasricha, MD

4:10 pm  Therapy Beyond Metaclopramide and Prochlorperazine
         Henry P. Parkman, MD, FACG

4:35 pm  Gastric Pacing
         Kenneth L. Koch, MD, FACG

Symposium E: Management of Anorectal Diseases and Incontinence  (Room 204 ABC)
Moderator: Satish S.C. Rao, MD, PhD, FACG

3:45 pm  Therapy of Incontinence
         Satish S.C. Rao, MD, PhD, FACG

4:10 pm  Management of Hemorrhoids
         Dennis M. Jensen, MD, FACG

4:35 pm  Pelvic Floor Dysynergia
         William E. Whitehead, MD, PhD, FACG

Symposium F: Sedation, Monitoring, and Efficiency Issues in Endoscopy  (Ballroom B)
Moderator: John J. Vargo, MD, MPH, FACG

3:45 pm  Propofol and Other Alternative Sedation Regimens
         Douglas K. Rex, MD, FACG

4:10 pm  Monitoring the Patient Undergoing Endoscopy
         John J. Vargo, MD, MPH, FACG

4:35 pm  Efficient Office Endoscopy
         James T. Frakes, MD, FACG

Symposium G: Controversies in the Management of Barrett’s  (Ballroom A)
Moderator: Nicholas J. Shaheen, MD, FACG

3:45 pm  Is Endoscopic Surveillance Worth the Effort?
         John M. Inadomi, MD, FACG

4:10 pm  High-Grade Dysplasia: Cut, Burn, or Just Watch
         Gary W. Falk, MD, FACG

4:35 pm  Biomarkers in BE: Improving on Dysplasia
         Rhonda Souza, MD

5:00 pm  Conclusion
         Stephen B. Hanauer, MD, FACG
         Sunanda V. Kane, MD, MSPH, FACG
         Nicholas J. Shaheen, MD, FACG

5:15 pm  Adjourn
Faculty Listing and Disclosure Information

It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are required to disclose to ACG any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias and to assist in resolving any conflict of interest that may arise from the relationship. The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

Faculty have noted the following relationships related to their Postgraduate Course presentations.
ACG's 2007 Postgraduate Course — Faculty Listing

John M. Inadomi, MD, FACG
Dean M. Craig Endowed Chair in Gastrointestinal Medicine, University of California San Francisco, San Francisco, CA
Research Grant: SARX
Consultant: Given Imaging

Dennis M. Jensen, MD, FACG
Professor of Medicine, CURE Digestive Diseases Research Center, Los Angeles, CA
Research Grant: Olympus, Boston Scientific
Speakers' Bureau: Boston Scientific

Peter J. Kahrihas, MD, FACG
Professor of Medicine, Northwestern University Medical School, Chicago, IL
Dr. Kahrihas has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Sunanda V. Kane, MD, MSPH, FACG
Mayo Clinic College of Medicine, Rochester, MN
Consultant: Centocor, Abbott, Procter & Gamble, Shire
Research Support: Procter & Gamble

Philip O. Katz, MD, FACG
Chair, Division of Gastroenterology, Albert Einstein Medical Center, Philadelphia, PA
Honoria: AstraZeneca, Santarus, TAP
Consultant: Negma-Lerads, AstraZeneca, Prometheus, TAP

Kenneth L. Koch, MD, FACG
Professor of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
Speakers' Bureau: Novartis
Scientific Advisory Board: Sandhill Corp.

Kris V. Kowdley, MD, FACG
Professor of Medicine, University of Washington, Seattle, WA
Dr. Kowdley has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Loren A. Laine, MD, FACG
Professor of Medicine, USC School of Medicine, Los Angeles, CA
Consultant: Merck, Novartis, TAP, Ethicon
Observational Study Monitoring Board: Pfizer

Glen A. Lehman, MD, FACG
Professor of Medicine, Indiana University, Indianapolis, IN
Dr. Lehman has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Blair S. Lewis, MD, FACG
Clinical Professor of Medicine, Mount Sinai School of Medicine, New York, NY
Consultant/Speakers Bureau/Research Support: Given Imaging

Simon K. Lo, MD, FACG
Director, GI Endoscopy, Cedars Sinai Medical Center, Los Angeles, CA
Research Grant: Fujinon, Inc.

Willis C. Maddrey, MD, MACG
Professor of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
Consultant: Schering, Isis, Intarcia, Valeant

John E. Pandolfin, MD, FACG
Assistant Professor of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL
Dr. Pandolfin has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Henry P. Parkman, MD, FACG
Associate Professor of Medicine, Temple University, Philadelphia, PA
Consultant: SmartPill
Research Grant: Medtronic

Pankaj J. Pasricha, MD
Professor of Medicine, University of Texas Medical Branch, Galveston, TX
Dr. Pasricha has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Jeffrey L. Ponsky, MD, FACG
Oliver H. Payne Professor, Case Western Reserve University School of Medicine, Cleveland, OH
Dr. Ponsky has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Daniel H. Present, MD, MACG
Present, Chapman, Marion, MD, PC, New York, NY
Grant/Research Support: Procter & Gamble, CCFA, Otsuka, Centocor, Mayo Clinic, Celltech, Human Genome Sciences, Abbott, Elan, Salix, Schering, Jacobus, Ocsa
Consultant: NIH (U. of Pennsylvania), Tech Lab, UCB, NPS
Speakers' Bureau: Procter & Gamble, Prometheus, Salix, Shire USA, Elan, Axcan

Eamonn M.M. Quigley, MD, FACG
Professor of Medicine & Human Physiology, National University of Ireland at Cork, Cork, Ireland
Stockholder/Ownership: Alimentary Health
Speakers' Bureau: Procter & Gamble
Consultant: AGI Therapeutics

Linda Rabeneck, MD, FACG
Professor of Medicine, University of Toronto, Toronto, ON, Canada
Dr. Rabeneck has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.

Satish S.C. Rao, MD, PhD, FACG
Professor of Medicine, University of Iowa Hospitals & Clinics, Iowa City, IA
Unrestricted and/or Research Grants: SmartPill, Sucampo Pharmaceuticals, Takeda Pharmaceuticals, Procter & Gamble
Consultant/Advisory Board: SmartPill, Novartis, Takeda Pharmaceuticals, Theravance Inc., Johnson & Johnson, Forest Laboratories, Salix

Douglas K. Rex, MD, FACG
Professor of Medicine, Indiana University Hospital, Indianapolis, IN
Speakers' Bureau: TAP, Novartis, CB Fleet, Salix, Olympus
Research Support: Olympus, CB Fleet, Salix, MGI Pharma, Given Imaging
Scientific Advisory Boards: Given Imaging, Avantis, Neo Guide, CB Fleet, Salix, GI View, MG Pharma

Joel E. Richter, MD, MACG
Chairman, Department of Medicine, Temple University School of Medicine, Philadelphia, PA
Dr. Richter has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

David T. Rubin, MD
Assistant Professor of Medicine, University of Chicago School of Medicine, Chicago, IL
Grant Support: Procter & Gamble, Salix, Prometheus, Given Imaging
Consultant: Procter & Gamble, Salix, Prometheus, Abbott Immunology, UCB Pharma, Given Imaging, Shire
Speakers' Bureau: Procter & Gamble, Salix, Prometheus, Abbott Immunology, Centocor

William J. Sandborn, MD, FACG
Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN
Consultant: Prometheus, Centocor, Abbott Laboratories, UCB Pharma
Research Support: Centocor, Abbott Laboratories, UCB Pharma
Indirect Support of Continuing Medical Education Events: Prometheus, Centocor, Abbott Laboratories, UCB Pharma

Arun J. Sanyal, MD
Professor of Medicine, Virginia Commonwealth University Medical Center, Richmond, VA
Dr. Sanyal has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Carol E. Semrad, MD, FACG
Associate Professor of Medicine, University of Chicago, Chicago, IL
Dr. Semrad has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.
Nicholas J. Shaheen, MD, FACG
Associate Professor of Medicine & Epidemiology, University of North Carolina, Chapel Hill, NC
Dr. Shaheen has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Prateek Sharma, MD, FACG
Professor of Medicine, University of Kansas School of Medicine, Kansas City, MO
Speakers’ Bureau: AstraZeneca, TAP, Olympus, Santarus
Research Grants: AstraZeneca, TAP, Olympus, Santarus

Stuart Sherman, MD, FACG
Professor of Medicine & Radiology, Indiana University Medical Center, Indianapolis, IN
Dr. Sherman has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Mitchell L. Shiffman, MD, FACG
Professor of Medicine, Virginia Commonwealth University Medical Center, Richmond, VA
Dr. Shiffman has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Rhonda Souza, MD
Associate Professor of Medicine, UT Southwestern Medical School, Dallas, TX
Dr. Souza has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.

Stuart J. Spechler, MD, FACG
Professor of Medicine, University of Texas Southwestern Medical Center, Dallas, TX
Grant Support: AstraZeneca, TAP, BARRx Medical

Christina M. Surawicz, MD, FACG
Professor of Medicine, University of Washington School of Medicine, Seattle, WA
Speakers’ Bureau: Biocodex, Viopharma

Nicholas J. Talley, MD, PhD, FACG
Chair, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL
Research Support: Novartis, Takeda

Scott M. Tenner, MD, MPH, FACG
Director, Medical Education and Research, Maimonides Medical Center, SUNY, Brooklyn, NY
Dr. Tenner has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

William J. Tremaine, MD, FACG
Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN
Research Grant: Procter & Gamble
Consultant: AstraZeneca

John J. Vargo, MD, MPH, FACG
Clinical Assistant Professor of Medicine, Cleveland Clinic, Cleveland, OH
Dr. Vargo has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Michael B. Wallace, MD, MPH, FACG
Associate Professor of Medicine, Mayo Clinic, Jacksonville, FL
Research Grant: Olympus, Cook, Fujinon

Kenneth K. Wang, MD, FACG
Associate Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN
Education Grant Support: Wilson Cook, Olympus

Jerome D. Wave, MD, MAGG
Clinical Professor, Mt. Sinai School of Medicine, New York, NY
Dr. Wave has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

William E. Whitehead, MD, PhD, FACG
Professor of Medicine, University of NC at Chapel Hill, Chapel Hill, NC
Dr. Whitehead has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Sidney J. Winawer, MD, MACG
Paul Sherlock Chair in Medicine & Professor of Medicine, Weill Cornell College of Medicine, New York, NY
Advisory Committee: Exact Sciences, Enterix

Rowen K. Zetterman, MD, MACG
Professor of Medicine, University of Nebraska Medical Center, Omaha, NE
Dr. Zetterman has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

ACG’s 2007 Postgraduate Course — Faculty Listing

Investigational Use Disclosures
ACG’s disclosure policy maintains that if any unapproved or off-label use of a product is to be referenced in a CME program, the faculty member is required to disclose that the product is either investigational or it is not labeled for the usage being discussed. The following faculty members have indicated they may reference an off-label use in their PG Course presentation(s).

Dr. Castell: BID PPI therapy for treatment of GERD
Dr. Choy: colchicine, misoprostol, renzapride, linaclotide, alvimopan, methyllylartuxone for therapy of chronic constipation
Dr. Fass: PPIs, tricyclics, botox, SSRI’s for non-cardiac chest pain
Dr. Fried: multiple HCV therapeutics
Dr. Hanauer: use of adalimumab and infliximab in IBD
Dr. Katz: high dose PPI in treatment of extra-esophageal reflux disease
Dr. Laine: PPIs
Dr. Lewis: capsule colonoscopy
Dr. Lo: unapproved devices for small bowel endoscopy usage
Dr. Maddrey: EPO in hepatitis C, modafinil for fatigue, ritalin and ondansetron for fatigue
Dr. Parkman: domperidone
Dr. Pena: AGE croslink breakers
Dr. Quigley: verapamil, Bifidobacterium infantis 35624, rifaximin, anti-depressants for IBS
Dr. Sandborn: azathioprine, 6-mercaptopurine, methotrexate: Crohn’s disease and ulcerative colitis; adalimumab: ulcerative colitis; certolizumab pegol, ciprofloxacin, metronidazole, tacrolimus, cyclosporine: Crohn’s disease
Dr. Surawicz: rifaximin, nitazoxanide, metronidazole for treatment of C. difficile-associated disease
Dr. Tremaine: mesalamine for Crohn’s disease, adalimumab for ulcerative colitis

Support
The American College of Gastroenterology acknowledges an educational grant in support of this activity from Procter & Gamble.
Join GI physicians from around the U.S. and the world for the ACG Annual Scientific Meeting. The meeting promises to deliver the latest clinical information on timely topics in gastroenterology. As an ACG member, you can attend the three-day Annual Meeting for free – there is no registration fee. Choose from 12 symposia, networking events, and see the latest advances in technology and therapeutics from exhibitors from around the globe. Additional breakfast sessions, 14 in total, will be offered for a nominal fee. Register today!

**Program Description**

Clinical GI medicine — remaining abreast of the refinements in treatments of long-standing GI disorders, integrating paradigm shifts about new technologies and pharmacologic treatments of both major as well as less prevalent digestive diseases, and endoscopic treatment could pose a never-ending challenge and quandary for the general gastrointestinal practitioner. Diagnostic and therapeutic options in GI patient care proliferate unabated. Staying updated in GI and disease management skills is a central objective, attainable only with a focus on grasping the essence of new advances, both the scientific and technological, and persistently evaluating pros and cons of new technologies are essential to being able to apply these new modalities to achieve the most desirable patient diagnostic and therapeutic outcomes. Changes and refinements in science continue to challenge the capacity of clinical practitioners to absorb new information and integrate it into the framework of their patient care and decision-making.

Detailed coverage of refinements and new advances across the spectrum of GI diseases/conditions will be explicated in the 12 plenary state-of-the-art symposia, and 14 optional breakfast symposia which form the core curriculum of this year’s program. The program is designed primarily for gastroenterologists and others with significant involvement in diagnosis and treatment of GI conditions and disorders who are interested in an aggressive but scientifically sound approach to management of the treatment needs of GI patients with these conditions.

**Program Objectives**

Upon completion of this program attendees will:

- Develop a rational approach to the integration and application of traditional and new therapies for Crohn’s disease and ulcerative colitis in your practice which maximizes patient safety and outcome with special attention to the underserved, adolescent and childbearing patient.

- Detail the important characteristics of your patient with liver disease due to hepatitis B, C, and non alcoholic fatty liver disease to tailor optimal strategies for treatment with current and emerging therapies and incorporate the latest options for the management of the complications of cirrhosis including ascites, varices and hepatocellular cancer.

- Attain a solid foundation for understanding the performance characteristics, measures to enhance quality and effectiveness, and minimize and manage the complications of diagnostic and therapeutic ERCP and colonoscopy.

- Incorporate strategies to identify the etiology and optimal evidenced-based treatment of highly prevalent gastrointestinal symptoms which may underlie the neuroenteric disorders; gastroparesis, IBS, functional dyspepsia, sphincter of Oddi dysfunction, and colonic and pelvic dysmotility.

- Evaluate the medical and surgical options for weight loss in the obese patient and the impact of post-operative complications on the performance of endoscopy.

- Deliberate the evidence and utility of some of the complimentary and alternative treatments employed by patients for the improvement of common gastrointestinal symptoms and identify a prudent approach to the confirmation and therapy of food and allergy-based gastrointestinal diseases.

- Distinguish the utility of EUS and radiologic options to define the origin of pancreatic and liver lesions and be facile in the generation of the approach to their treatment.

- Comprehend the evolution of novel gastrointestinal devices and therapies such as capsule endoscopy and Natural Orifice Transluminal Endoscopic Surgery (NOTES) and how it may impact on optimal patient management and the field of Gastroenterology.

- Integrate strategies to devise a variety of services that your practice can offer to your patients and partners that will solidify its performance today and into the future.
MONDAY, OCTOBER 15, 2007
8:00 am – 5:15 pm

7:00 am-5:15 pm  Registration

8:00 am  Opening Remarks
David A. Johnson, MD, FACG
ACG President

8:00 am-9:00 am  President’s Plenary Session (Ballroom AB)
Moderators:
David A. Johnson, MD, FACG
Carol A. Burke, MD, FACG

1. Adenosine—A Key Neuromediator in the Pathogenesis of Functional Chest Pain
★ 2007 ACG/AstraZeneca Senior Fellow Abstract Award Recipient
Ashok Attaluri, MD, Jose Remes-Troche, MD, Satish Rao, MD, Gastroenterology, University of Iowa, Iowa City, IA

2. Functional Dyspepsia: The Economic Impact to Patients
★ 2007 ACG/AstraZeneca Senior Fellow Abstract Award Recipient
Kirsten T. Weiser, MD, PhD, Michael D. Crowell, PhD, and Nicholas J. Talley, MD, PhD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, Mayo Medical Center, Scottsdale, AZ, and Mayo Medical Center, Rochester, MN

3. Endomysial Antibody Testing Improves Sensitivity in Screening for Celiac Disease in Your Children, A Five Year Single Center Experience
★ 2007 ACG/AstraZeneca Senior Fellow Abstract Award Recipient
Muralidhar Jaila, MD, Caroline Kieserman-Shmokler and Ritu Verma, MD, Division of Gastroenterology and Nutrition, The Children’s Hospital of Philadelphia, Philadelphia, PA

4. Primary Sclerosing Cholangitis is a More Common Indication for Orthotopic Liver Transplantation Among African American than Non-African American Patients
★ 2007 ACG Governors Award Recipient for Excellence in Clinical Research
Alastair D. Smith, MD, ChB and Judith W. Gentile, RN, ANP, Medicine, Duke University, Durham, NC

5. Mesalamine Protects Against Colorectal Cancer in Inflammatory Bowel Disease
★ 2007 ACG/Centocor IBD Abstract Award Recipient
Jeffrey Tang, MD, Gena Kucera, PhD, Omar Sharif, MD, Chetan Pai, DO and Ann L. Silverman, MD, Internal Medicine, Division of Gastroenterology, Henry Ford Hospital, Detroit, MI

6. Does Tandem Colonoscopy Affect the Adenoma Detection Rate Described with Narrow Band Imaging?
★ 2007 ACG/AstraZeneca Senior Fellow Abstract Award Recipient
Sally Stiphos, MD, Noeman Gilani, MD, FACG and Francisco C. Ramirez, MD, FACG, Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix, AZ

9:00 am-9:25 am  Presidential Address (Ballroom AB)
David A. Johnson, MD, FACG
Introduced by:
Amy E. Foxx-Orenstein, DO, FACG, ACG President-Elect

9:25 am-9:30 am  Awards Program (Ballroom AB)

9:30 am-10:30 am  President’s Plenary Session (Ballroom AB)
Moderators:
Amy E. Foxx-Orenstein, DO, FACG
Carol A. Burke, MD, FACG

7. Elevated HbA1c is an Independent Predictor of Aggressive Clinical Behavior in Patients with Adenomatous Colonic Polyps
★ 2007 ACG/Olympus Colorectal Cancer Prevention Award Recipient
Ali A. Siddiqui, Haripriya Maddur, Suraj Naik, MD, Byron Cryer, Gastroenterology, Dallas VA Medical Center, Dallas, TX

8. Gastric Electrical Stimulation for Gastroparesis—The Temple Experience
★ 2007 Lawlor Resident Award Recipient
Varadaraj Subbiah, MD, Sean Harbison, MD, John Meilahn, MD, Vanessa Lytes, GRNP, Robert S. Fisher, MD, Henry P. Parkman, MD, Medicine, Temple University, Philadelphia, PA

9. Which Adenoma Characteristic Has the Strongest Effect on Predicting Advanced Neoplasia or Numerous Adenomas on Follow-up Colonoscopy?
★ 2007 ACG/Olympus Colorectal Cancer Prevention Award Recipient
Carol A. Burke, MD, FACG, Leila Mott, John Baron, MD, Doug Robertson, MD, The Polyp Prevention Study Group, Gastroenterology, Cleveland Clinic, Cleveland, OH

10. Early Oral Feeding in Mild Acute Pancreatitis: A Randomized Prospective Trial
★ 2007 ACG/AstraZeneca Senior Fellow Abstract Award Recipient
Nison L. Badalov, MD, Zankhana Mehta, MD, Hima Satyavolu, MD, Tejal Shah, MD, Jian-Jun Li, MD, Robin Baradarian, MD, Kadirawel Iswara, MD, Scott Tenner, MD, MPH, Division of Gastroenterology, Department of Medicine, Maimonides Medical Center, Brooklyn, NY

11. A Prospective Study of Factors Associated with Increased Gluten-Free Diet Adherence in Adults with Celiac Disease
★ 2007 ACG/AstraZeneca Senior Fellow Abstract Award Recipient
Daniel A. Leffler, MD, Jessica B. Edwards George, PhD, Melinda D. Dennis, RD, Hani Abdullah, MD, Ciaran P. Kelly, MD, The Celiac Center, Beth Israel Deaconess Medical Center, Boston, MA

12. Cytokeratin 18 Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients
★ 2007 ACG Governors Award Recipient for Excellence in Clinical Research
Dima Diab, MD, Lisa Yerian, MD, Phillip Schauer, MD, Sangeeta R. Kashyap, MD, Rocío Lopez, MS, and Aariel E. Feldstein, MD, Endocrinology, Pediatric Gastroenterology, General Surgery, Anatomical Pathology, and Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

10:30 am-11:00 am  Coffee Break – Visit Exhibits

11:00 am-12:15 pm  SIMULTANEOUS SYMPOSIA 1

Annual Scientific Meeting — Monday, October 15
11:00 am-12:15 pm SIMULTANEOUS SYMPOSIA 1

Simultaneous Symposia 1A: Top Down or Step Up Therapy in Crohn's Disease: Which is Right? (Ballroom A)
Moderator: William J. Tremaine, MD, FACG
1. Top Down Therapy Alters Natural History
   Gary R. Lichtenstein, MD, FACG
2. Step up is Better: Primum Non Nocere
   William J. Tremaine, MD, FACG
3. Balancing Efficacy and Risk: What do we Tell our Patients?
   Corey A. Siegel, MD

Simultaneous Symposia 1B: Complications from Cirrhosis: We're Making Progress (Ballroom B)
Moderator: Arun J. Sanyal, MD
1. Refractory Ascites: What to Expect and How to Treat
   Arun J. Sanyal, MD
2. Esophageal Varices: To Band or Block
   William D. Carey, MD, MACG
3. A Rational Guide to TIPS
   Thomas D. Boyer, MD, FACG

12:15 pm-2:00 pm Lunch Break
12:15 pm-2:00 pm Poster Session (Exhibit Hall)
12:30 pm-1:00 pm FAQ Session: Esophagus (Exhibit Hall)
   Philip O. Katz, MD, FACG
1:15 pm-1:45 pm FAQ Session: Pancreas (Exhibit Hall)
   Peter A. Banks, MD, MACG
2:00 pm-2:40 pm SIMULTANEOUS PLENARY SESSIONS

SESSION 1: Colorectal Cancer Prevention/Small Intestine (Room 204 ABC)
Moderators: Douglas K. Rex, MD, FACG
            Jack A. DiPalma, MD, FACG

13. Role of Resistant Starch in Colorectal Cancer Prevention: A Prospective Randomized Controlled Trial
   ★ 2007 ACG/Olympus Colorectal Cancer Prevention Award Recipient
   Shridhar S. Dronamraju, MD, Jonathan M. Coxhead, PhD,
   Seamus B. Kelly, MD, John G. Mathers, PhD, Human Nutrition
   Research Centre, School of Clinical Medical Sciences,
   Newcastle University, Newcastle Upon Tyne, Tyne and Wear,
   United Kingdom and Department of General Surgery, North
   Tyneside General Hospital, North Shields, Tyne and Wear, United

SESSION 2: Pancreatic/Biliary (Room 201 ABC)
Moderators: John Baillie, MB, ChB, FACG
            Scott M. Tenner, MD, MPH, FACG

17. The Severity of Pancreatic Ductal Changes on Standard MRCP According to Cambridge Classification Correlate with the Maximum Bicarbonate Level Achieved During Secretin Stimulated Exocrine Pancreatic Functional Testing (ePFT)
   Samer Alkaade, MD, Numan C. Balci, MD, Amir J. Mordtahan,
   MD, Frank R. Burton, MD, Internal Medicine, and Radiology,
   St. Louis University School of Medicine, St. Louis, MO

18. Ethanol Pancreatic Injection of Cysts: Results of a Prospective Multicenter, Randomized Double Blinded Study
   ★ 2007 ACG Governors Award Recipient for Excellence in Clinical Research
   William R. Brugge, MD, Kerry Collier, MA, Kathleen McGreevy,
   RN, C. Max Schmidt, MD, John DeWitt, MD, Gastroenterology,
   Indiana University, Indianapolis, IN; Gastroenterology, Massa-
   chusetts General Hospital, Boston, MA; and Surgery, Indiana
   University, Indianapolis, IN

19. Long-term Follow-up of Endoscopic Papillary Balloon Dilation Compared to Endoscopic Sphincterotomy for the Extraction of Bile Duct Stones
   James A. DiSario, MD, Maydeen M. Ogara, Steven Price,
   Kristen Hilden and EDES Group, Internal Medicine, GI Division,
   University of Utah Health Sciences Center, Salt Lake City, UT

20. Hypertriglyceridemic Acute Pancreatitis is Different
   Jagdish S. Nachnani, MD, Donald R. Campbell, MD, Department
   of Medicine – Gastroenterology Division, Saint Luke's
   Hospital, Kansas City, MO

2:40 pm-3:20 pm The American Journal of Gastroenterology Lecture (Ballroom B)
NOTES: Just Because We Can, Should We?
   Anthony N. Kalloo, MD, FACG
   Jeffrey L. Ponsky, MD, FACG
   See page ## for more information.

3:20 pm-3:50 pm Break/Visit Exhibits
Annual Scientific Meeting Agenda – Monday, October 15 & Tuesday, October 16

3:50 pm-5:15 pm  SIMULTANEOUS SYMPOSIA 2

Simultaneous Symposia 2A: Colon Cancer Screening: What You Need to Know for the Future (Ballroom B)
Moderator: Irving M. Pike, MD, FACG

1. What is a Quality Colonoscopy and Why You Should Care
   Irving M. Pike, MD, FACG

2. Enhancing Compliance to Colonoscopy in Your Practice
   John M. Inadomi, MD, FACG

3. CT Colonography: Is it Coming to Your Practice?
   Inku Hwang, MD, FACG

Simultaneous Symposia 2B: How and When to Intervene for Biliary Symptoms (Ballroom A)
Moderator: John Baillie, MB, ChB, FACG

1. Suspected SOD: When and How to Approach It (or Not!)
   Martin L. Freeman, MD, FACG

2. Management of Bile Duct Stones in Relation to Lap Chole
   John Baillie, MB, ChB, FACG

3. You Too Can Cannulate Like Me! 10 Tips for the ERCP Endoscopist
   Firas H. Al-Kawas, MD, FACG

5:30 pm-6:00 pm  Annual Business Meeting (Ballroom B)
College Members and Fellows invited

6:00 pm-7:00 pm  International Reception (Marriott 309/310)
All International attendees are invited

7:00 pm-9:00 pm  President’s Reception (Marriott Salon CDE)
All attendees are invited

TUESDAY, OCTOBER 16, 2007
6:45 am – 6:00 pm

BREAKFAST SESSIONS
6:45 am-8:30 am
Cost is $40 per person/per session. If you have not registered, visit the ACG Registration Desk.

Breakfast Session A: Increasing Your Bottom Line
Moderator: Harry E. Sarles, Jr., MD, FACG

1. Being an Expert Witness
   Peter M. Pardoll, MD, MACG

2. Clinical Research: Is It for Your Practice?
   Colleen Schmitt, MD, MHS, FACG

3. Offering More: Pathology/Radiology Services, Renting Space
   Harry E. Sarles, Jr., MD, FACG

Breakfast Session B: Gastric Motor Disorders: Gastroparesis and Beyond
Moderator: Kenneth L. Koch, MD, FACG

1. Gastroparesis
   Kenneth L. Koch, MD, FACG

2. Functional Dyspepsia
   Brian E. Lacy, MD, PhD

3. Rumination
   Denesh K. Chitkara, MD

Breakfast Session C: Hot Issues in Acute Pancreatitis
Moderator: Scott M. Tenner, MD, MPH, FACG

1. Investigation and Management of Idiopathic, Acute, Recurrent Pancreatitis
   Darwin L. Conwell, MD

2. Prevention and Management of Severe Post-ERCP Pancreatitis
   Scott M. Tenner, MD, MPH, FACG

3. What Does EUS Offer in Management of Fluid Collections Following Acute Pancreatitis?
   Michelle A. Anderson, MD

Breakfast Session D: NOTES: Will Surgeons Become Extinct?
Moderator: Richard I. Rothstein, MD, FACG

1. Theory, Practice, Oversight and Training
   Pankaj J. Pasricha, MD

2. Video Show: Bariatric Surgery
   Richard I. Rothstein, MD, FACG

3. Video Show: Gallbladder, Colon, Appendix
   Jeffrey L. Ponsky, MD, FACG
21. Infliximab Reduces Colectomy in Patients with Moderate-to-Severe Ulcerative Colitis: Analysis From Act 1 and Act 2
W. J. Sandborn, MD, P. Rutgeerts, MD, B. G. Feagan, MD, W. Reinisch, MD, A. Olson, MD, J. Johanns, PhD, J. Lu, PhD, D. Rachmilewitz, MD, S. Hanauer, MD, G. Lichtenstein, MD, W. deVilliers, MD, D. Present, MD, B. Sands, MD, J. Colombel, MD, Gastro, Mayo Clinic, Rochester, MN, Gastro, Univ Hosp Gasthuisberg, Leuven, Belgium; Robarts Research Institute, Univ Western Ontario, Canada; Internal Medicine, Univ Hosp Vienna, Vienna, Austria; Centocor, Inc. Malvern, PA; Shaara Zedak Medical Center, Jerusalem, Israel; Gastro & Nutrition, Univ Chicago, Chicago, IL; Center for IBD, Univ Penna, Philadelphia, PA; Internal Medicine, Univ Kentucky, Lexington, KY; Medicine, Mt. Sinai, New York, NY; Gastro Unit, MGH, Boston, MA; and Pr Gastroenterologie, Hopital Huriez Lille, France

22. A Prospective, Controlled Longitudinal Study of the Effects of Oral Steroids at 3 and 5 Months on Bone Mineral Density (BMD) in Patients with IBD
★ 2007 ACG/Centocor IBD Abstract Award Recipient
Jae Gaun Hyun, MD, Asher Kornbluth, MD, James George, MD, Peter Legnani, MD, Simon Lichtiger, MD, Meredith Lewis, MS, Gastroenterology, Mount Sinai Medical Center, New York, NY

23. Adenocarcinoma in Ileal Pouch-Anal Anastomosis: The Cleveland Experience
★ 2007 ACG/Centocor IBD Abstract Award Recipient
Revital Kariv, MD, Ana Bennett, MD, Yehuda Kariv, MD, Victor Fazio, MD, Ian Lavery, MD, Bret Lashner, MD, Bo Shen, MD, and Feza Remzi, MD, Digestive Disease Center, Cleveland Clinic, Cleveland, OH

24A. Natalizumab Induces Sustained Response and Remission in the Absence of Concomitant Immunosuppressants in Patients with Crohn’s Disease Who Failed Prior Anti-TNF Therapy
B. Lashner, J.F. Colombel, R. Enns, B. Feagan, R.N. Fedorak, S.B. Hanauer, I.C. Lawrence, R. Panaccione, D. Present, P. Rutgeerts, W.J. Sandborn, M. Sanders, S. Schreiber, M.E. Spehlmann, Z. Tulassay, S. van Deventer, M. Volfova, D.C. Wolf, S. Targan, Cleveland Clinic, Cleveland, OH; Hôpital Claude Huriez, Lille, France; St Paul’s Hospital, University of British Columbia, Vancouver, Canada; Roberts Research Institute, University of Western Ontario, London, Canada; University of Alberta, Edmonton, Canada; University of Chicago, Chicago, IL; University of Western Australia, Western Australia, Australia; University of Calgary, Calgary, Canada; Mount Sinai School of Medicine, New York, NY; University Hospital Gasthuisberg, Leuven, Belgium; Mayo Clinic, Rochester, MN; University of Virginia Health Systems, Charlottesville, VA; Christian-Albrechts University, Kiel, Germany; Asklepios Westklinikum, Hamburg, Germany; Semmelweis University, Budapest, Hungary; University of Amsterdam Medical School, Amsterdam, Netherlands; Hepato-Gastroenterology, Hradec Králové, Czech Republic; Atlanta Gastroenterology Associates, Atlanta, GA; Cedars Sinai, Los Angeles, CA

24B. Natalizumab Does Not Require the Concomitant Use of Immunosuppressants or Corticosteroids for the Induction of Sustained Response and Remission in Patients with Crohn’s Disease
D.C. Wolf, J.F. Colombel, R. Enns, B. Feagan, R.N. Fedorak, S.B. Hanauer, B. Lashner, I.C. Lawrence, R. Panaccione, D. Present, P. Rutgeerts, W.J. Sandborn, M. Sanders, S. Schreiber, M.E. Spehlmann, Z. Tulassay, S. van Deventer, M. Volfova, S. Targan. Atlanta Gastroenterology Associates, Atlanta, GA; Hôpital Claude Huriez, Lille, France; St Paul’s Hospital, University of British Columbia, Vancouver, Canada; Roberts Research Institute, University of Western Ontario, London, Canada; University of Alberta, Edmonton, Canada; University of Chicago, Chicago, IL; Cleveland Clinic, Cleveland, OH; University of Western Australia, Western Australia, Australia; University of Calgary, Calgary, Canada; Mount Sinai School of Medicine, New York, NY; University Hospital Gasthuisberg, Leuven, Belgium; Mayo Clinic, Rochester, MN; University of Virginia Health Systems, Charlottesville, VA; Christian-Albrechts University, Kiel, Germany; Asklepios Westklinikum, Hamburg, Germany; Semmelweis University, Budapest, Hungary; University of Amsterdam Medical School, Amsterdam, Netherlands; Hepato-Gastroenterology, Hradec Králové, Czech Republic; Atlanta Gastroenterology Associates, Atlanta, GA; Cedars Sinai, Los Angeles, CA
Simultaneous Symposia 3B: Esophagus: Burning Issues in 2007 (Ballroom A)  
**Moderator: Ronnie Fass, MD, FACG**

1. **Natural Course of GERD: Will We all Burn?**  
   Ronnie Fass, MD, FACG

2. **Obesity and GERD: Which to Treat First?**  
   John E. Pandolfino, MD, FACG

3. **So You Have Barrett’s, What Do You Do Now?**  
   Kenneth K. Wang, MD, FACG

Simultaneous Symposia 3C: Screening for GI Malignancies: An International Perspective (Room 204 ABC)  
**Moderator: Lewis R. Roberts, MB, ChB, PhD**

1. **Colorectal Cancer: Not Just a Western Disease**  
   Massimo Crespi, MD, FACG (Italy)

2. **Esophageal and Gastric Cancer: Are We Doing Any Better?**  
   Hidekazu Suzuki, MD, PhD (Japan)

3. **Hepatocellular Carcinoma: A World-Wide Problem**  
   Lewis R. Roberts, MB, ChB, PhD (United States)

12:15 pm-2:00 pm Lunch Break

12:15 pm-2:00 pm Poster Session (Exhibit Hall)

12:30 pm-1:00 pm FAQ Session: Liver (Exhibit Hall)  
**William D. Carey, MD, MACG**

1:15 pm-1:45 pm FAQ Session: IBD (Exhibit Hall)  
**Gary R. Lichtenstein, MD, FACG**

2:00 pm-2:45 pm Emily Couric Memorial Lecture  
(Ballroom B)  
**Pancreatic Cancer: Present Understanding and Future Prospects**  
**Peter A. Banks, MD, MACG**

Sponsored by the ACG, the Virginia Gastroenterological Society and the Old Dominion Society of Gastroenterology Nurses and Associates  
See page ## for more information.

2:45 pm-4:15 pm SIMULTANEOUS PLENARY SESSIONS

**SESSION 1: Outcomes Research/Stomach** (Room 204 ABC)  
**Moderators: Eamonn M.M. Quigley, MD, FACG  
Nicholas J. Shaheen, MD, FACG**

Jay L. Goldstein, MD, Barbara J. Hunt, MS, Justin R. Boike, BS, Byron Cryer, MD, Department of Medicine, University of Illinois at Chicago, Chicago, IL, TAP Pharmaceutical Products Inc., Lake Forest, IL and Department of Medicine, University of Texas Southwest Medical Center, Dallas, TX
31. Adjudication of GI Events from Long-term Placebo-Controlled Trials Provides Evidence for GI Safety and Tolerability of Celecoxib vs Placebo
N. Arber, MD, D. Lieberman, MD, M. Bertagnolli, MD, E. Hawk, MD, A. Rustgi, MD, T. Wang, MD, J. Coindreau, MD, C. Eagle, MD, B. Levin, MD, Tel Aviv MC, Israel, Oregon University, Harvard Cancer Center, National Cancer Institute, University of Pennsylvania, Columbia University, Pfizer Inc, and University of Texas

32. Dysplasia in Fundic Gland Polyps in FAP: Prevalence, Risk Factors and Optimal Biopsy Technique
★ 2007 ACG/AstraZeneca Senior Fellow Abstract Award Recipient
Laura K. Bianchi, MD, Ana E. Bennett, MD, Rocio Lopez, MS, Hennie Hasson, RN and Carol A. Burke, MD, Gastroenterology, Anatomic Pathology, and Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

33. Cost-Benefit of PPI Gastroprotection Among Elderly NSAID Users
★ 2007 ACG Auxiliary Award Recipient (ACG Member/Fellow)
Neena S. Abraham, MD, MSCE, Jennifer Hasche, MSc, and Christine Hartman, PhD, Gastroenterology, Michael E. DeBakey VAMC; Baylor College of Medicine, Houston, TX and Health Services Research, Houston Center of Quality of Care and Utilization Studies; Michael E. DeBakey VAMC, Houston, TX

34. Statin Use and the Risk of Cholecystectomy in Women
★ 2007 ACG/Wyeth Gender Based Research Award Research Award Recipient
Chung-Jyi Tsai, MD, Michael Leitzmann, MD, Walter Willett, MD, Edward Giovannucci, MD, Division of Digestive Diseases and Nutrition, University of Kentucky Medical Center; Division of Cancer Epidemiology and Genetics, National Institute of Health and Channing Lab, Department of Medicine, Harvard Medical School

35. Disparity in Gastroenterology: Is it Just “Academic” or a Significant Problem? A 10 Year Prospective Cohort Study
★ 2007 ACG/Radhika Srinivasan Gender Based Research Award Recipient
Aparajita Singh, MD, Carol A. Burke, MD, for the Women in GI Committee of ACG, Gastroenterology, Cleveland Clinic, Cleveland OH

36. Sequential Therapy is Superior to Standard Therapy for Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis
Nadim S. Jafri, MD, Carlton A. Hornung, PhD, and Colin W. Howden, MD, University of Louisville, Louisville, KY and Northwestern University, Chicago, IL

37. Missed Cancers vs Procedure-Related Complications: Balancing the Medico-Legal Risks of Surveillance Colonoscopy
★ 2007 ACG/AstraZeneca Senior Fellow Abstract Award Recipient
Sameer D. Saini, MD, Gastroenterology, University of Michigan, Ann Arbor, MI and Medical University of South Carolina, Charleston, SC

38. Gender Differences and Bariatric Surgery Outcome
★ 2007 ACG/Naoko Nakao Gender Based Research Award Recipient
Inessa Khaykis, MD, Christine J. Ren, MD, George A. Fielding, MD, Warren Huberman, PhD, Barrie Wolfe, RD, Heekoung Youn, RN, Stefanie Hong, Fritz Francois Francois, MD, Elizabeth Weinsch, MD, Gastroenterology, Surgery, and Psychiatry, New York University Hospital, New York, NY

2:45 pm-4:15 pm SIMULTANEOUS PLENARY SESSIONS

SESSION 2: Liver/Esophagus (Room 201 ABC)
Moderators: Mitchell L. Shiffman, MD, FACG
Philip O. Katz, MD, FACG

39. Toward Better Prognostic Modeling in Acute Liver Failure
★ 2007 ACG Governors Award Research Award for Excellence in Clinical Research
Julie Polson, MD, Nick Rogers, MD, Linda S. Hyman, PhD, A.J. Naylor, BS, and William M. Lee, MD, Internal Medicine, and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX

40. Venous Thromboembolism in Patients with Cirrhosis
David D. Gulley, MD, Evgenia Teal, MA, Naga Chalasani, MD, Suthat Liangpunsakui, MD, MPH, Department of Medicine, Indiana University, Indianapolis, IN and Regenstrief Institute, Indianapolis, IN

Arash Farhadi, MD, James H. Lewis, MD, Omar S. Khokhar, MD, Lisa H. McGrall, MD, Gastroenterology/Hepatology, George-town University Medical Center, Washington, DC and Medical Oncology, Sibley Memorial Hospital, Washington, DC

42. Systemic and Pulmonary Hemodynamics in Patients with Extra-Hepatic Portal Vein Obstruction (EHPVO)
Ashish Kumar, MD, DM, Sanjeev K. Jha, MD, Barjesh C. Sharma, MD, DM and Shiv K. Sarin, MD, DM, Gastroenterology, G.B. Pant Hospital, New Delhi, Delhi, India

43. N-Butyl-2-Cyanoacrylate in Gastric Variceal Bleeding—A Randomized Controlled Trial
Chandana Pande, MBBS, Ashish Kumar, MD, DM, Sharda Patra, MS, Popy H. Hazarika, MBBS, Atiqat Batul, MBBS, Johan Amin, FCP, Rafaa Chaudhry and Asim Malik, FRCSEd, Gastroenterology, Fatima Memorial Hospital, Lahore, Punjab, Pakistan

44. Efficacy of Recombinant Hepatitis B Vaccine (rHBV) Alone in Preventing Perinatal Transmission of Hepatitis B is Similar to Combination of rHBV Plus Hepatitis B Immunoglobulin (HBIG): A Randomized Controlled Trial
Arif Amir Nawaz, FACP, FACC, A. Nawaz, FACP, FACC, Shahid Sarwar, FCPS, Salwa Hussain, MBBS, Atiqat Batul, MBBS, Johan Amin, FCP, Raifa Chaudhry and Asim Malik, FRCS, Gastroenterology, Fatima Memorial Hospital, Lahore, Punjab, Pakistan

45. Endoscopic Full-Thickness Plication for the Treatment of GERD: Five Year Multi-Center Results
Douglas Pleskow, MD, Richard Rothstein, MD, Richard Koza-rek, MD, Gregory Haber, MD, Christopher Costout, MD, Simon Lo, MD, Robert Hawes, MD, Anthony Lembo, MD, Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Virginia Mason Medical Center, Seattle, WA; Lenox Hill Hospital, New York, NY; Mayo Clinic, Rochester, MN; Cedars Sinai Medical Center, Los Angeles, CA and Medical University of South Carolina, Charleston, SC

46. Comparison of Eosphageal Motility Parameters as Measured by the New High Resolution Manometry (HRM) vs Traditional Manometry™
Muhammad Hasan, MD, Sheila Rodriguez-Stanley, PhD, Susan Riley, RN, Sattar Zubaidi and Philip B. Miner, Jr., MD, Gastroenterology, The University of Oklahoma Health Sciences Center, and The Oklahoma Foundation for Digestive Research, Oklahoma City, OK
47. Comparison of Sensed Acid Reflux Event Characteristics Among the Different GERD Groups

2007 ACG/AstraZeneca Senior Fellow Abstract Award Recipient
Ron Schey, MD, Tomas Navarro-Rodriguez, MD, Michael Shapiro, MD, Christopher Wendel, MS and Ronnie Fass, MD, The Neuroenteric Clinical Research Group, Southern Arizona VA Health Care System and University of Arizona, Tucson, AZ

4:15 pm-4:45 pm   Break
4:45 pm-6:00 pm   SIMULTANEOUS SYMPOSIA

Simultaneous Symposia 4A: Advances in Therapy for Ulcerative Colitis (Ballroom A)
Moderator: Stephen B. Hanauer, MD, FACG
1. First Line Therapy for Ulcerative Colitis: What’s New and Do We Care?
   Stephen B. Hanauer, MD, FACG
2. Biologics for Ulcerative Colitis: When Is a Colon Worth the Expense?
   Miguel D. Regueiro, MD
3. A Primer on Management of Severe Ulcerative Colitis
   Asher Kornbluth, MD

Simultaneous Symposia 4B: GI Bleeding: What Do You Do When the EGD and Colonoscopy Are Normal? (Ballroom B)
Moderator: Jonathan A. Leighton, MD
   Carol E. Semrad, MD, FACG
2. Non-endoscopic Approach: We Can Go Thru It All, But Do We See It All?
   Blair S. Lewis, MD, FACG
3. When All Is Seen and Done, What Should We Do?
   Jonathan A. Leighton, MD

Simultaneous Symposia 4C: Spotlight on Obesity (Room 204 ABC)
Moderator: Amy E. Foxx-Orenstein, DO, FACG
1. Appetite Regulation: Are We Programmed to Be Fat?
   Amy E. Foxx-Orenstein, DO, FACG
2. BMI >30: What Next?
   Philip R. Schauer, MD
3. GI Complications of Bariatric Surgery: What the Endoscopist Needs to Know—Anatomy, Strictures, Ulcers
   David A. Johnson, MD, FACG

WEDNESDAY, OCTOBER 17, 2007
6:45 am – 12:30 pm

BREAKFAST SESSIONS
6:45 am-8:30 am
Cost is $40 per person/per session. If you have not registered, visit the ACG Registration Desk.

Breakfast Session H: Satisfaction Guaranteed: Primer on Evacuation and Colonic Motility
Moderator: Philip F. Caushaj, MD, FACG
1. Fecal Incontinence
   Philip F. Caushaj, MD, FACG
2. Pelvic Floor Disorders
   Satish S.C. Rao, MD, PhD, FACG
3. Colonic Dysmotility
   Nicholas J. Talley, MD, PhD, FACG

Breakfast Session I: Advances in EUS: Beyond the Shadows
Moderator: Kenneth J. Chang, MD, FACG
1. When Tissue is the Issue: FNA, Truecut
   Michael J. Levy, MD, FACG
2. Cystic Lesions of the Pancreas
   William R. Brugge, MD, FACG
3. What’s New in EUS Guided Therapy?
   Kenneth J. Chang, MD, FACG

Breakfast Session J: Inflammatory Bowel Disease in Special Populations
Moderator: Kim L. Isaacs, MD, PhD
1. The Childbearing Couple: Fertility and Conception in IBD
   Uma Mahadevan, MD
2. The Young and the Restless: Treatment of Children and Adolescents
   Marla C. Dubinsky, MD
3. Treating the “Have-nots:” Challenges in the Underserved
   Kim L. Isaacs, MD, PhD

Breakfast Session K: Approach to Liver Masses
Moderator: K. Rajender Reddy, MD, FACG
1. Beyond a Shadow of a Doubt: Clinical and Radiologic Diagnosis
   K. Rajender Reddy, MD, FACG
2. To Biopsy or Not to Biopsy: Invasive Diagnosis of Liver Masses
   Kirti Shetty, MD, FACG
3. Management Options: Observe, Ablate, Operate
   Paul Martin, MD, FACG
Breakfast Session L: Alternative Treatments: What is the Evidence for What Your Patients Are Doing?  
Moderator: Eamonn M.M. Quigley, MD, FACG  
1. Probiotics: Are These Placebo or Standard of Care?  
   Eamonn M.M. Quigley, MD, FACG  
2. Acupuncture  
   Anthony J. Lembo, MD  
3. Hypnotherapy, Digestive Enzymes and High Colonics  
   Michael P. Jones, MD, FACG

Breakfast Session M: Don't Forget These Colitides  
Moderator: Lawrence R. Schiller, MD, FACG  
1. Microscopic Colitis  
   Lawrence R. Schiller, MD, FACG  
2. Diverticular Disease  
   Martin H. Floch, MD, MACG  
3. Recurrent and Refractory C. difficile  
   Frank K. Friedenberg, MD

Breakfast Session N: Food For Thought  
Moderator: Ali Keshavarzian, MD, FACG  
1. Eosinophilic Esophagitis: Establishing the Cause  
   Nirmala Gonsalves, MD  
2. Food Allergy Wannabes: When Is It Real?  
   Ali Keshavarzian, MD, FACG  
3. Celiac Disease: Don't Be a Glutton for Gluten  
   Peter H.R. Green, MD, FACG

6:45 am-12:30 pm  Registration  
8:30 am-10:15 am  SIMULTANEOUS PLENARY SESSIONS

SESSION 1: Colon/Functional Bowel Disorders  
Moderators: Nicholas J. Talley, MD, PhD, FACG  
Lawrence R. Schiller, MD, FACG  
48. Constipation: Is it a Colonic Versus Generalized Gastrointestinal Tract Disorder, the Temple Experience  
   ★ 2007 ACG Auxiliary Award Recipient (Trainee)  
   Shabana Shahid, MD, Henry Parkman, MD, Robert S. Fisher, MD, Department of Gastroenterology, Temple University Hospital, Philadelphia, PA

49. A Cost Comparison of Metronidazole and Vancomycin in the Treatment of Clostridium difficile-Associated Diarrhea  
   Kristen L. Thomas, BS, Kyland R. Holmes, MS, Brian R. Jackson, MD, MS, Mae Go, MD, John C. Fang, MD, Kathryn A. Peterson, MD, MsCi, Gastroenterology, University of Utah, ARUP, and Gastroenterology, VA Medical Center, Salt Lake City, UT

50. A Comparison of Polyethylene Glycol Laxative and Placebo for Relief of Constipation from Constipating Medications  
   Jack A. DiPalma, MD, Mark V.B. Cleveland, PhD, John McGowan, and Jorge L. Herrera, MD, Division of Gastroenterology, University of South Alabama, Mobile, AL, and Braintree Laboratories, Inc., Braintree, MA

51. How Useful is Digital Rectal Examination in the Diagnosis of Dyssynergia?  
   ★ 2007 ACG Motility Award Recipient  
   Priyanka Rao, Kasaya Tantiphlachiva, MD, Ashok Attaluri, MD, Satish Rao, MD, University of Iowa, Iowa City, IA

52. A Randomized Double-Blind, Placebo-Controlled Study of R-Verapamil in Non-Constipated Irritable Bowel Syndrome  
   Eamonn M.M. Quigley, MD, John Devane, PhD, David Young, PhD, and Jackie Butler, PhD, Alimentary Pharmabiotic Centre, National University of Ireland, Cork, Ireland; AGI Therapeutics Research Ltd., Athlone County Westmeath, Ireland, and AGI Therapeutics Inc., Columbia, MD

53. Gastric Emptying Scintigraphy Results in the ROME III Subgroup Classifications for Functional Gastro-Duodenal Disorders  
   ★ 2007 ACG Motility Award Recipient  
   Richard L. Walters, MD, Alan H. Maurer, MD, Henry P. Parkman, MD, Medicine, Temple University, School of Medicine, Philadelphia, PA

54. Investigation of Wireless Capsule (SmartPill®) for Colonic Transit: A Comparative Study with Radioopaque Markers in Health and Constipation  
   ★ 2007 ACG Motility Award Recipient  
   S. Rao, MD, FACG, B. Kuo, MD, W. Chey, MD, FACG, J. DiBaise, MD, FACG, L. Katz, MD, K. Koch, MD, FACG, J. Lackner, PsyD, SmartPill Research Group

55. High Cortisol Levels are Correlated to Low Esophageal Pain Threshold to Balloon Distention in Patients with NERD and Functional Heartburn  
   ★ 2007 ACG Governors Award Recipient for Excellence in Clinical Research  
   Sheila Rodriguez-Stanley, PhD, Maggie Wolff, Tisha Adams and Philip B. Miner, Jr., The Oklahoma Foundation for Digestive Research, Oklahoma City, OK

Late-Breaking Abstract

56. In Patients with Chronic Constipation, TD-5108, a Selective 5-HT4 Agonist with High Intrinsic Activity, Increases Bowel Movement Frequency and the Proportion of Patients with Adequate Relief  
   Michael Goldberg, MD, Yu-Ping Li, PhD, Brage Garofalo, MA, Allan Valmonte, BA, John Johanson,* MD, Allen Mangel,** MD, Michael Kitt, MD, Theravance, Inc., So. San Francisco, CA, *University of Illinois College of Medicine, Rockford, IL, and **RTI-Health Solutions, Research Triangle Park, NC
SESSION 2: IBD/Esophagus/Endoscopy (Room 201 ABC)

Moderators: Jean-Paul Achkar, MD, FACG
Ronnie Fass, MD, FACG

57. Incidence of Post-Surgical Complications Among Ulcerative Colitis (UC) Patients: A Population-Based Study
* 2007 ACG/Centocor IBD Abstract Award Recipient
Salma Akram, MD, Steven B. Ingle, MD, Shamina Dhillon, MD, W. Scott Harmsen, MS, Alan R. Zinsmeister, PhD, William J. Tremaine, MD, William J. Sandborn, MD, Edward V. Loftus, MD, Mayo Clinic, Rochester, MN

58. Adverse Events Related to the Use of Corticosteroids, Immunosuppressants, and Anti-TNF Therapy in Crohn’s Disease Patients

59. Exposing the Weaknesses: A Systematic Review of Azathioprine Efficacy in Ulcerative Colitis
* 2007 ACG/Centocor IBD Abstract Award Recipient
Yvette Leung, MD, Remo Panaccione, MD, Brenda Hemmelgarn, PhD, and Jennifer Jones, Medicine, Division of Gastroenterology, University of Alberta, Calgary, Alberta, Canada

60. Authorship and Industry Sponsorship in Treatment Trials in Inflammatory Bowel Disease
William J. Tremaine, MD, Mayo Clinic and Rochester, Rochester, MN

61. A New Surgical Approach to Gastroesophageal Reflux Disease: Nissen Fundoplication with Highly Selective Vagotomy
Savio Reddymasu, MD, Niazy Selim, MD, Michael Moncure, MD, Jeffrey Piehler, MD, Daniel Buckles, MD, Richard McCallum, MD, Medicine and Surgery, Kansas University Medical Center, Kansas City, KS

62. Cost-Effectiveness of MII-ph Testing in Persistent Reflux-Related Cough Despite Acid Suppressive Therapy
Deepika Laxmi Koya, MD, MSCR, Marcelo A. Vela Aquino, MD, MSCR, Donald O. Castell, MD, Kit N. Simpson, DrPH, Internal Medicine and Health Administration and Policy, Medical University of South Carolina, Charleston, SC

63. Proton Pump Inhibitor and Nonsteroidal Anti-Inflammatory Use and the Development of Neoplasia in Barrett’s Esophagus
John Kuczynski, MD, Hashem El-Serag, MD, Stephanie Davis, PharmD, Adam Wachter, Daniel J. Stein, MD, Richard E. Sampliner, MD, Southern Arizona VA Medical Center and Baylor College of Medicine, Houston, TX

64. Successful Ablation of Barrett’s Esophagus and Dysplasia Using the Halo Ablation System in a Prospective Cohort
Virender K. Sharma, MD, Christopher Wells, MD, Hack J. Kim, MD, Ananya Das, MD, Giovanni DePetris, MD, Roxane McLaughlin, RN and David E. Fleischer, MD, Mayo Clinic Arizona, Scottsdale, AZ

65. Accuracy and Clinical Impact of EUS—FNA as the Definitive Diagnostic or Staging Study in Patients with Suspected or Known Lung Cancer
R. Srinivasan, MD, P. Gupta, MD, S. Jaganmohan, MD, J.B. Zwischenberger, MD, M.S. Bhutani, MD, Division of Gastroenterology, UTMB, Galveston, TX and Division of Gastroenterology, M.D. Anderson Cancer Center, Houston, TX

10:15 am-10:45 am  David Y. Graham Lecture (Ballroom B)
Evidence-Based Medicine: What Does it Mean for Gastroenterology—Present and Future?
Walter L. “Pete” Peterson, MD, FACG
See page ## for more information.

10:45 am-11:15 am  Coffee Break/Visit Exhibits

11:15 am-12:30 pm  SIMULTANEOUS SYMPOSIA 5

Simultaneous Symposia 5A: Hepatitis C: New Insights (Ballroom A)
Moderator: Mitchell L. Shiffman, MD, FACG

1. Updated Strategies for Therapy
Mitchell L. Shiffman, MD, FACG

2. HCV and NAFLD: Do They Go Together?
Stephen A. Harrison, MD, FACG

Ira M. Jacobson, MD, FACG

Simultaneous Symposia 5B: The Ins and Outs of the Difficult Colonoscopy (Ballroom B)
Moderator: Douglas K. Rex, MD, FACG

1. Intubation Techniques and Devices for the Tough Colon
Jerome D. Waye, MD, MACG

2. How to Manage the Difficult Polypectomy
Douglas K. Rex, MD, FACG

3. How to Manage and Prevent Complications: Clips, Loops, etc.
Gregory G. Ginsberg, MD, FACG

12:30 pm  ANNUAL SCIENTIFIC MEETING ADJOURNS
Annual Scientific Meeting
Monday – Wednesday, October 15 through 17, 2007 • Room: Ballroom AB

Faculty Listing and Disclosure Information
It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are required to disclose to ACG any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias and to assist in resolving any conflict of interest that may arise from the relationship. The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

Faculty have noted the following relationships related to their Annual Meeting presentations.

Edgar Ackers, MD, FACG
Vice Chairman, Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, OH
Dr. Ackers has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Sanjeev Arora, MD, FACP
Professor Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM
Speakers’ Bureau/Grant Support: Boston Scientific, Cook
Research Grants: Roche, Schering.ヤtalent Pharmaceuticals, Veralto Pharmaceuticals

John Baillie, MB, ChB, FACG
Division Head, Division of Gastroenterology, Henry Ford Hospital, Detroit, MI

Kimberly A. Brown, MD
Director, Center for Pancreatic Disease, Brigham & Women’s Hospital, Boston, MA
Dr. Banks has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Todd H. Boren, MD
Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN
Consultant/Grant Support: Boston Scientific, Avondale, Boston Scientific, CoeXendoscopy

Wallace F. Berman, MD, FACP
Professor, Division of Pediatric Gastroenterology and Nutrition, Duke University Medical Center, Durham, NC
Dr. Berman has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

R. Bruce Cameron, MD, FACP
Associate Clinical Professor, Case Western Reserve University, University Suburban Health Center, South Euclid, OH
Dr. Cameron has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

William D. Carey, MD, FACG
Professor of Medicine, The Cleveland Clinic Foundation, Cleveland, OH
Dr. Carey has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Amitabh Chak, MD, FACG
Professor Medicine, University of Alabama, Mobile, AL
Consultant/Research Grant/Speakers’ Bureau: Alveolus, Boston Scientific, Cook

Robynne K. Chutkan, MD
Assistant Professor, Georgetown University Medical Center, Washington, DC
Speakers’ Bureau: Genentech Imaging

Gregory S. Cooper, MD, FACG
Professor of Medicine, Duke School of Medicine, Durham, NC
Dr. Cooper has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Sheila E. Crowe, MD, FACP
Associate Professor of Internal Medicine, University of Virginia Health System, Charlottesville, VA
Dr. Crowe has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.

Andrew D. Decker, MD
Professor and Chair of Pediatrics, University of Maryland School of Medicine, Baltimore, MD
Dr. Decker has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

G. Anton Decker, MD
Instructor of Medicine, Mayo Clinic, Scottsdale, AZ
Dr. Decker has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Jackson A. DiPalma, MD, FACP
Professor of Medicine and Director, Division of Gastroenterology, University of South Alabama, Mobile, AL
Consultant/Grant Director: Bransome Labs

Steven A. Edmundowicz, MD
Professor of Medicine, Washington University School of Medicine, St. Louis, MO
Consultant/Grant Support: Prometheus Labs

Gary W. Falk, MD, FACP
Director, Center for Swallowing and Esophageal Disorders, Cleveland Clinic Foundation, Cleveland, OH
Consultant/Grant Support: AstaZeneca

Ronnie Foss, MD, FACP
Associate Professor of Medicine, Southern Arizona VA Health Care System, Tucson, AZ
Research Support: AstaZeneca, Finex
Speakers’ Bureau: AstaZeneca

Andrew D. Feld, MD, JD, FACP
Clinical Associate Professor, University of Washington, Seattle, WA
Dr. Feld has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

David R. Fleisher, MD
Associate Professor of Child Health, University of Missouri Health Care, Columbia, MO
Dr. Fleisher has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Frank K. Friedenberg, MD
Associate Professor of Medicine, Temple University Hospital, Philadelphia, PA
Dr. Friedenberg has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Daniele N. Gerding, MD
Professor of Medicine, Loyola University Stritch School of Medicine, Chicago, IL
Dr. Gerding has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Hidekazu Suzuki is MD, PhD
Professor of Medicine, Mayo Clinic, Scottsdale, AZ
Consultant/Stockholder: Satiety
Consultant: Inscope
Grant Support: Boston Scientific, Wilson Cook, Olympus

Sanjeev Arora, MD, FACP
Professor Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM
Speakers’ Bureau/Grant Support: Boston Scientific, Cook
Research Grants: Roche, Schering.ヤtalent Pharmaceuticals, Veralto Pharmaceuticals

Gary W. Falk, MD, FACP
Director, Center for Swallowing and Esophageal Disorders, Cleveland Clinic Foundation, Cleveland, OH
Consultant/Grant Support: AstaZeneca

Ronnie Foss, MD, FACP
Associate Professor of Medicine, Southern Arizona VA Health Care System, Tucson, AZ
Research Support: AstaZeneca, Finex
Speakers’ Bureau: AstaZeneca

Andrew D. Feld, MD, JD, FACP
Clinical Associate Professor, University of Washington, Seattle, WA
Dr. Feld has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

David R. Fleisher, MD
Associate Professor of Child Health, University of Missouri Health Care, Columbia, MO
Dr. Fleisher has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Frank K. Friedenberg, MD
Associate Professor of Medicine, Temple University Hospital, Philadelphia, PA
Dr. Friedenberg has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Daniele N. Gerding, MD
Professor of Medicine, Loyola University Stritch School of Medicine, Chicago, IL
Dr. Gerding has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.
Annual Scientific Meeting — Faculty Listing

Christopher J. Gustot, MD, FACC
Associate Professor of Medicine, Mayo Clinic, Rochester, MN.
Research Consultant: Abbott Laboratories, Canady Tech, Boston Scientific
Consultant: Wilson Cook
Speaker: Canady Tech

David A. Greenwald, MD, FACC
Associate Division Director, Montefiore Medical Center, Bronx, NY.
Dr. Greenwald has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Stephen B. Hanauer, MD, FACC
Professor of Medicine, University of Chicago, Chicago, IL.
Consultant: Abbott Laboratories, UCB Pharmaceuticals (Celltech), Canady Tech, Elan, Proctor & Gamble, Salix, Schering-Plough.
Clinical Research: Abbott Laboratories, UCB Pharmaceuticals (Celltech), Canady Tech, Elan, Proctor & Gamble, Salix, Schering-Plough.
Speaker: UCB Pharmaceuticals (Celltech), Canady Tech, Elan, Proctor & Gamble, Salix

Eileen Hoy, MD, FACC
Professor of Medicine, Mayo Clinic, Rochester, MN.
Dr. Hoy has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.

Brands J. Hoffman, MD, FACC
Professor of Medicine, Medical University of South Carolina, Charleston, SC.
Dr. Hoffman has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.

Kim L. Isaacs, MD, PhD
Professor of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Grants/Research Funds: AstraZeneca

Steven H. Itzkowitz, MD, FACC
Associate Director, GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Clinical Research: Abbott Laboratories, UCB Pharmaceuticals (Celltech), Canady Tech, Proctor & Gamble, Schering-Plough.

Sunanda V. Kane, MD, MSPH, FACC
Assistant Professor of Medicine, University of Chicago, Chicago, IL.
Dr. Kane has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.

Philip O. Katz, MD, FACC
Chairman, Division of Gastroenterology, Albert Einstein Medical Center, Philadelphia, PA.
Consultant: Axcan Pharma, Astellas, Genentech, Gilead, Janssen, Merck, Novartis, Pfizer, Schering-Plough, Shire, TAP, Teva, Wyeth

Donald Kirby, MD, FACC
Chief, Department of Nutrition, Virginia Commonwealth University, Medical Center, Richmond, VA.
Dr. Kirby has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Samuel A. Koocheshi, MD, FACC
Assistant Professor of Medicine, University of Virginia Health System, Charlottesville, VA.
Dr. Koocheshi has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Paul Y. Kwo, MD
Associate Professor of Clinical Medicine, Indiana University Department of Medicine, Indianapolis, IN.
Dr. Kwo has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Glen A. Lehman, MD, FACC
Professor of Medicine and Radiology, Indiana University Medical Center, Indianapolis, IN.
Dr. Lehman has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

James D. Lewis, MD, MScE
Assistant Professor of Medicine and Epidemiology, University of Pennsylvania, Philadelphia, PA.
Grant Research Support: Canady Tech, Wilson Cook

Gary R. Lichterstein, MD, FACC
Professor of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.

David A. Lieberman, MD, FACC
Professor of Medicine, Division of Gastroenterology, Oregon Health and Science University, Portland, OR.
Scientific Advisory Board: Exact

Edward S. Lotfs, Jr., MD, FACC
Associate Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN.
Consultant: Prometheus Labs
Research Support: TechLab

Uma Mahadevan, MD
Assistant Professor of Medicine, University of California, San Francisco, San Francisco, CA.
Consultant: Canady Tech

Paul Martin, MD, FACC
Professor of Medicine, Mount Sinai School of Medicine, New York, NY.
Dr. Martin has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Kevin M. McGrath, MD
Assistant Professor of Medicine, UPMC Presbyterian, Pittsburgh, PA.
Dr. McGrath has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Kevin W. Olden, MD, FACC
Director of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR.
Dr. Olden has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Gulshan Parasar, MD, FACC
Assistant Professor of Medicine, University of New Mexico, Albuquerque, NM.
Dr. Parasar has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Robert E. Peterson, MD, FACC
Professor of Gastroenterology, University of California, Santa Barbara, CA.
Dr. Peterson has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

John L. Petris, MD, FACC
Professor of Clinical Medicine, University of Southern California, Los Angeles, CA.
Dr. Petris has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Mark Pimentel, MD
Co-Director, GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA.
Consultant: Salix Pharmaceuticals, Schering-Plough, Shire Pharmaceuticals
Speaker: Salix Pharmaceuticals

F. Fred Poordad, MD
Assistant Professor of Medicine, UCLA School of Medicine, Los Angeles, CA.
Research Support: Canady Tech, Wilson Cook

John J. Peto, MD, FACC
Associate Professor of Medicine, Mayo Clinic, Rochester, MN.
Dr. Peto has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Charline Prather, MD
Associate Professor of Internal Medicine, St. Louis University, St. Louis, MO.
Dr. Prather has indicated that she has no relationship which, in the context of her presentation, could be perceived as a potential conflict of interest.

Eamon M.M. Quigley, MD, FACC
Professor of Medicine, National University of Ireland at Cork, Cork, Ireland.
Dr. Quigley has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest.

Waqar A. Qureshi, MD, FACC
Associate Professor of Medicine, Baylor College of Medicine, Houston, TX.
Speakers’ Bureau/Research Support: Canady Tech
Investigational Use Disclosures

ACG members are reminded that if any unapproved or off-label use of a product is to be referenced, an IUD program must be implemented at the time of the reference. The aim is to disclose that the product is either investigational or it is not labeled for the use being discussed. The following faculty members indicated they will reference the following off-label uses in their Annual Meeting presentations.

Dr. Brown – investigational changes in length of therapy
Dr. Gerding – metronidazole for C. difficile disease
Dr. Isaacs – azathioprine/6MP for IBD therapy; cyclosporin, antibiotics for IBD
Dr. Kocoshis – the use of antidepressants for the management of visceral pain
Dr. Mahadevan – cyclosporin and antibiotics for C. difficile disease

Support
The American college of Gastroenterology acknowledges an educational grant in support of this activity from AstraZeneca.
Disclosure of Potential Conflicts of Interest

It is the policy of the American College of Gastroenterology to ensure objectivity, balance, independence, transparency, and scientific rigor in all its sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are required to disclose to ACG any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias and to assist in resolving any conflict of interest that may arise from the relationship. The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

Planning Committee Members have noted the following relationships.

Carol Burke, MD, FACG
Chair, ACG Educational Affairs Committee
Director, Center for Colon Polyps & Cancer, Cleveland Clinic Foundation, Cleveland, OH
Dr. Burke has indicated no relevant financial relationships.

Maria Abreu, MD
Associate Professor of Medicine, Mount Sinai Medical Center, New York, NY
Consultant: Abbott, UCB

Jean-Paul Achkar, MD, FACG
Director, Gastroenterology Fellowship Program, Cleveland Clinic Foundation, Cleveland, OH
Dr. Achkar has indicated no relevant financial relationships.

Marie L. Borum, MD, FACG
Professor of Medicine, Director, Division of Gastroenterology, George Washington University, Washington, DC
Dr. Borum has indicated no relevant financial relationships.

Ronnie Fass, MD, FACG
Professor of Medicine, Southern Arizona VA Health Care System, Tucson, AZ
Research: Wyeth, TAP, AstraZeneca, Altana
Consultant: Wyeth, TAP, AstraZeneca, Altana
Speaker: TAP, AstraZeneca, Novartis

Martin L. Freeman, MD, FACG
Professor of Medicine, Hennepin County Medical Center, Minneapolis, MN
Fellowship Program Support: Boston Scientific, Cook Endoscopy

David Greenwald, MD, FACG
Associate Division Director, Montefiore Medical Center, Bronx, NY
Dr. Greenwald has indicated no relevant financial relationships.

Inku Hwang, MD
Associate Professor of Medicine, Walter Reed Army Medical Center, Washington, DC
Stockholder: Merck, Pfizer

Sunanda V. Kane, MD, MSPH, FACG
Assistant Professor of Medicine, Mayo Clinic, Rochester, MN
Speakers’ Bureau: Centocor, Novartis, Procter & Gamble, Shire, Solvay, Prometheus, TAP
Consultant: Centocor, Elan, Abbott, UCB, Prometheus, Procter & Gamble, Shire
Investigator: Abbott, UCB

Kenneth L. Koch, MD, FACG
Chief, Section of Gastroenterology, Wake Forest University School of Medicine, Winston-Salem, NC
Stockholder: 3CPM Company
Consultant: SmartPill Corp., Tranzyme Corp.
Scientific Advisory Board: SmartPill Corp.

Paul Kwo, MD
Associate Professor of Clinical Medicine, Indiana University Department of Medicine, Indianapolis, IN
Grant Support: Roche, Schering Plough, Vertex, Valeant, Coley, GlaxoSmithKline, Idenix

Brian E. Lacy, MD, PhD
Associate Professor of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Research Support: Novartis, AstraZeneca
Speakers’ Bureau: Novartis, Takeda

Jonathan A. Leighton, MD, FACG
Associate Professor of Medicine, Mayo Clinic Scottsdale, Scottsdale, AZ
Consultant: Given Imaging, NPS Pharma
Research support: Otsuka, Olympus, Fujinon, Given Imaging

Edward V. Loftus, Jr., MD, FACG
Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN
Consultant: Abbott Labs, UCB Pharma
Research Support: Abbott Labs, Schering Plough

Peter J. Molloy, MD, FACG
Associate Professor, Medicine, Temple University, Pittsburgh, PA
Dr. Molloy has indicated no relevant financial relationships.

Waqar Qureshi, MD, FACG
Associate Professor of Medicine, Baylor College of Medicine, Houston, TX
Dr. Qureshi has indicated no relevant financial relationships.

Francisco Ramirez, MD, FACG
Professor of Clinical Medicine, University of Arizona, Phoenix, AZ
Dr. Ramirez has indicated no relevant financial relationships.

K. Rajender Reddy, MD, FACG
Medical Director, Liver Transplantation, Hospital of the University of Pennsylvania, Philadelphia, PA
Advisor: Roche, Idenix, BMS, Gilead
Speaker: Roche
Investigator: Roche, Schering, Gilead, Vertex

Lawrence R. Schiller, MD, FACG
Program Director, GI Fellowship, Baylor University Medical Center, Dallas, TX
Consultant: Novartis, Takeda, Sucampo, Napo Pharmaceuticals, Procter & Gamble, McNeil
Speakers’ Bureau: Novartis, Takeda, Sucampo, Procter & Gamble, Prometheus, Salix, AstraZeneca, TAP

Kirti Shetty, MD
Medical Director, Liver Transplantation, Georgetown University Hospital, Washington, DC
Speakers’ Bureau: Schering, Gilead

Kenneth Wang, MD, FACG
Associate Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN
Research Support: AstraZeneca, BARRX
Poster Presentations

Sunday, October 14, 2007
3:30 pm — 7:00 pm
Authors will be present from 3:30 pm — 4:30 pm

Esophagus ......................................................... P1-P30
Stomach .......................................................... P31-P42
Pancreatic/Biliary .............................................. P43-P60
Small Intestine/Unclassified. .............................. P61-P72
Liver ................................................................. P73-P97
Colon ................................................................. P98-P112
Clinical Vignettes .............................................. P113-P233
Outcomes Research ........................................... P234-P262
Inflammatory Bowel Disease ............................... P263-P291
Functional Bowel Disorders ............................... P292-P306
Endoscopy ....................................................... P307-P329
Pediatrics ......................................................... P330-P337
Colorectal Cancer Prevention ............................. P338-P347

Monday, October 15, 2007
10:30 am — 4:00 pm
Authors will be present from 11:15 am — 1:00 pm

Esophagus ......................................................... P348-P375
Stomach .......................................................... P376-P388
Pancreatic/Biliary .............................................. P389-P406
Small Intestine/Unclassified. .............................. P407-P418
Liver ................................................................. P419-P443
Colon ................................................................. P444-P458
Clinical Vignettes .............................................. P459-P578
Outcomes Research ........................................... P579-P594
Inflammatory Bowel Disease ............................... P595-P625
Functional Bowel Disorders ............................... P626-P640
Endoscopy ....................................................... P641-P663
Pediatrics ......................................................... P664-P671
Colorectal Cancer Prevention ............................. P672-P684

Tuesday, October 16, 2007
10:30 am — 4:00 pm
Authors will be present from 11:15 am — 1:00 pm

Esophagus ......................................................... P685-P709
Stomach .......................................................... P710-P721
Pancreatic/Biliary .............................................. P722-P739
Small Intestine/Unclassified. .............................. P740-P749
Liver ................................................................. P750-P774
Colon ................................................................. P775-P789
Clinical Vignettes .............................................. P790-P907
Outcomes Research ........................................... P908-P932
Inflammatory Bowel Disease ............................... P933-P959
Functional Bowel Disorders ............................... P960-P973
Endoscopy ....................................................... P974-P995
Colorectal Cancer Prevention ............................. P996-P1007
P1. Tissue Ingrowth in a Fully Covered Self-Expandable Metallic Stent
Sathya Jaganmohan, MD, Joseph Zwischenberger, MD, Gottumukkal S. Raju, MD, FACG, Gastroenterology & Surgery, UTMB, Galveston, TX.

P2. Yo-Yo Lipoma in My Esophagus
Daniald M. Rodrigues, MD, Rakish Parikh, MD, Satish Maryala, MD, Joseph L. Kinzie, MD, Internal Medicine, and Division of Gastroenterology, Wayne State University, Detroit, MI.

P3. An Unusual Case of Esophageal Histoplasmosis
Kanai Sharma, MD, Pallavi K. Rao, MD, Lisa Stone, MD, Dept. of Gastroenterology, Wright State University, Dayton, OH.

P4. Black Esophagus Associated with Malignancy and Use of FOLFOX/Avastin
Olivia C. Forys, MD, Dawn D. Ferguson, MD, Internal Medicine, Mayo Clinic, Rochester, MN and Gastroenterology, Mayo Clinic, Rochester, MN.

P5. Cervical Inlet Patch in Twins: Is It All in the Genes?
Shailaja Jamma, MD, Krishna Rao Tangella, MD, Davendra P. Ramkumar, MD, Internal Medicine, University of Illinois at Urbana Champaign, IL; Pathology, UIUC, IL.

P6. Prevalence of Gastroesophageal Reflux Disease in Patients with Non-Cardiac Chest Pain Presenting to the Emergency Department
Stephanie E. Thompson, MD, Julia J. Liu, MD, John R. Saltzman, Ling Hu, Richard Zane, Division of Gastroenterology, University of Alberta Hospital, Edmonton, AB, Canada and Division of Gastroenterology, Emergency, and Cardiology, Brigham and Women’s Hospital, Boston, MA.

P7. Atypical GERD Symptoms on PPI Therapy Are More Likely in an Older Female Patient Group
Neeraj Sharma, MD, Amit Agrawal, MD, Marcelo Vela, MD, Donald O. Castell, MD, Department of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC.

P8. A Case of Severe Heartburn
Krysla L. Zancosky, DO, Sean Connelly, DO, Peter J. Molloy, MD, Gastroenterology, The Western Pennsylvania Hospital, Pittsburgh, PA.

P9. Esophageal Capsule Endoscopy for Evaluation of Gastroesophageal Reflux Disease
Disaya Chavalitdhamrong, MD, Oren Goltzer, Capsule Endoscopy Services Study Group, Los Angeles, CA.

P10. Inter-Observer Agreement between Multi-Channel Intraluminal Impedance-pH (MII-pH) Software Analysis and an Experienced MII-pH Test Reviewer
Dawn D. Ferguson, MD, MHS, Kenneth R. DeVault, MD, Internal Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN and Internal Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL.

P11. Prevalence of Esophageal Dystmotility in a Cohort of Patients with Biopsy Proven Eosinophilic Esophagitis: A Prospective Study
John T. Bassett, MD, Joseph L. Perry, MD, Eric M. Osgard, MD, Connie L. Maydonovitch, Leslie H. Sobin, MD, Roy H. Wong, MD, Gastroenterology, National Naval Medical Center, Bethesda, MD; Gastroenterology, Walter Reed Army Medical Center, Washington, DC and Haptic and Gastrointestinal Pathology, Armed Forces Institute of Pathology, Washington, DC.

P12. Exclusion of the Meal Period Does Not Improve the Diagnostic Accuracy of 48-Hour Ambulatory Catheter-Free Esophageal pH Testing
Stephanie L. Hansel, MD, John K. DiBaise, MD, Isaac Malagon, BS, Marie Haywood, BSN, Jana G. Stoa, BSN, Virender K. Sharma, MD, H. Jae Kim, MD, Michael D. Crowell, PhD, Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ.

P13. Refractory ENT/GERD Symptoms – Is Upper Esophageal Sphincter (UES) or Esophageal Body the Culprit?
Ginish Anand, MD, Matthew R. Gideon, Philip O. Katz, MD, Gastroenterology, Albert Einstein Medical Center, Philadelphia, PA.

P14. Use of Pillcam ESO™ Endoscopy for Early Detection of Esophageal Injury after Radiofrequency Ablation Therapy for Atrial Fibrillation
Milan Dodig, MD, Andrea Natale, MD, Madhusudhan R. Sanaka, MD, Alan Siu, Janice Santissi, RN, Stacy Poe, RN, Department of Gastroenterology and Hepatology, and Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH.

P15. Clinical Utility of the Bravo Capsule
Brian E. Lacy, PhD, MD, Andrew C. Dukowicz, MD, Lisa Piquette, RN, Douglas J. Robertson, MD, MPH, Julia Weiss, MS, Maurice L. Kelley, Jr., MD, Gastroenterology, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Gastroenterology, WRJ VA Medical Center, White River Junction, VT and Community and Family Medicine, Dartmouth Medical School, Hanover, NH.

P16. Utility of Catheter-Free Ambulatory pH Testing on PPI Therapy
Lydell C. Horine, MD, Sami R. Achem, MD, Ernest P. Bouras, MD, Mark E. Stark, MD, Dawn D. Ferguson, MD, Kenneth R. DeVault, MD, Medicine, Mayo Clinic, Rochester, MN.

P17. Eosinophilic Esophagitis/Ringed Esophagus: The Diagnostic Conundrum
Fatima Gangotena, MD, Scott Mackenzie, MD, Mae Go, MD, Kristen Thomas, BS, John Fang, MD, Kathryn Peterson, MD, Gastroenterology, University of Utah, Salt Lake City, UT and Gastroenterology, VAMC, Salt Lake City, UT.

P18. Omeprazole Induces a Transepithelial Leak in Gastric Mucosa
James M. Mullin, PhD, Mary C. Valenzano, Marysue Whitby, Deborah Lurie, PhD, Vishal Jain, MD, Owen Tully, MD, Paul Allegretti, DO, Daniel Lazowick, DO, J. David Schmidt, MD, James J. Thornton, MD, Giancarlo Mercogliano, MD, Lankenau Institute for Medical Research, Wynnewood, PA; Mathematics, St. Joseph’s University, Philadelphia, PA; Medicine and Gastroenterology, Lankenau Hospital, Wynnewood, PA.

P19. Low Grade Esophageal Eosinophilia in Adults: An Unrecognized Part of the Spectrum of Eosinophilic Esophagitis?
Karthik Ravi, MD, Jeffrey A. Alexander, MD, David A. Neumann, MD, Nicholas J. Talley, MD, Thomas C. Smyrk, MD, Ganapathy A. Prasad, MD, Yvonne Romero, MD, Amindra S. Arora, MD, Internal Medicine, Gastroenterology and Hepatology, and Pathology, Mayo Clinic, Rochester, MN.

P20. Associated Risk Factors for GERD in Native Americans
Adam Randolph, MD, Lila Ammour, MD, Richard Gerkin, MD, Francisco Ramirez, MD, Michele Young, MD, Gastroenterology and Hepatology, Carl T. Hayden VA Medical Center, Phoenix, AZ and Medicine, Banner Good Samaritan Medical Center, Phoenix, AZ.
P21. Clinical Efficacy and Problems of a Simple Questionnaire (FScale) for the Diagnosis of GERD in the Elderly
Toshiyasu Watanabe, Yoshihisu Urita, Tadashi Maeda, Kaoru Domon, Susumu Ishihara, Asuka Nakayama, Makie Nanami, Tomohiro Arita, Tatsuhiro Yamamoto, Takamasu Ishii, Akiko Kugahara, Hirohito Kato, Kazuo Hike, Nonko Hara, Yoshiho Honda, Yoko Nagai, Shuji Watanabe, Kazushige Nakanishi, Nagato Shimada, Motonobu Sugimoto, Kazumasa Miki, Division of Gastroenterology and Hepatology, Department of General Medicine and Emergency Care, and Department of Hematology, Toho University, Tokyo, Japan.

P22. What Is the Incidence of Acidic and Nonacidic Gastroesophageal Reflux (GER) in Lung Transplant Recipients (LTR)?
Anne F. Peery, MD, Ryan D. Madanick, MD, Joseph A. Galanko, PhD, Peadar Noone, MD, Thomas Egan, MD, Isabel Neuringer, MD, Nicholas J. Shaheen, MD, University of North Carolina, Chapel Hill, NC.

P23. ADHERE Study: Application of Dx-pH Catheters in the Evaluation of Patients without Gastroesophageal Reflux Disease (GERD)
George Sun, MD, Sean Casey, MD, Eric Hill, MD, Farnoosh Farrokhi, MD, Michael Vaezi, MD, Digestive Disease Center, Vanderbilt University Medical Center, Nashville, TN.

P24. Dx-pH Monitoring: How Does It Compare to the Standard pH Probe?
Farnoosh Farrokhi, MD, Eric M. Hill, MD, George Sun, MD, Sean P. Casey, MD, Milton O. Ochieng, Gregory D. Ayers, BS, Michael F. Vaezi, MD, FACC, Gastroenterology, Vanderbilt University Medical Center, Nashville, TN.

P25. Are There Differences in Sensitivity Thresholds to Balloon Distention in the Upper and Lower Esophagus?
Muhammad Hasan, MD, Sheila Rodriguez-Stanley, PhD, Susan Riley, RN, Sattar Zubaidi, Philip B. Miner, Jr., MD, Gastroenterology, The University of Oklahoma Health Sciences Center, and The Oklahoma Foundation for Digestive Research, Oklahoma City, OK.

P26. Value of a Novel Multi-Factorial Scoring System as a Diagnostic Aid in the Prospective Evaluation of Patients with Reflux-Like Dyspepsia
Andrew K. Roorda, MD, Samuel N. Marcus, MD, PhD, George Triadafilopoulos, MD, Internal Medicine, St. Mary's Medical Center, San Francisco, CA; Gastroenterology, El Camino Hospital, Mountain View, CA and Gastroenterology, Stanford University, Stanford, CA.

P27. Gastroesophageal Reflux during Sleep: Does REM Sleep Provide a Protective Effect?
Srirarsha Damera, MD, Suanne Goodrich, PhD, Paula Fernstrom, BS, Goran Hasselgren, MD, William C. Orr, PhD, Lynn Health Science Institute, Oklahoma City, OK; AstraZeneca, Molndal, Sweden and University of Oklahoma Health Sciences Center, Oklahoma City, OK.

P28. Ethnic Variation in Lower Esophageal Sphincter Pressure and Length
Kenneth J. Vega, MD, M. Mazen Jamal, MD, Division of Gastroenterology, University of Florida/Jacksonville, Jacksonville, FL and Division of Gastroenterology, Veterans Affairs Medical Center, Long Beach, CA.

P29. A Novel Partial 5HT Agonist DDP733 after a Standard Refluxogenic Meal Reduces Reflux Events: A Randomized, Double-Blind, Placebo-Controlled Pharmacodynamic Study
Rok Seon Choung, MD, Dawn D. Ferguson, MD, Joseph A. Murray, MD, Patricia P. Kammerer, Ross A. Dierkhising, MS, Alan R. Zinsmeister, PhD, Suhail Nurbhai, MRCP, Steven B. Landau, MD, Nicholas J. Talley, MD, PhD, Division of Gastroenterology and Hepatology; Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, MN and Dynogen Pharmaceuticals, Inc., Waltham, MA.

P30. Effect of Obesity on Symptom Resolution in Patients with Gastroesophageal Reflux Disease (GERD)
★ 2007 ACG Presidential Poster Award Recipient
Prateek Sharma, MD, FACG, Nimish Vakil, MD, FACG, John T. Myryak, PhD, Debra G. Silberg, MD, FACC, University of Kansas Medical Center, Kansas City, MO; University of Wisconsin Medical Center, Milwaukee, WI and AstraZeneca LP, Wilmington, DE.

STOMACH

P31. Aspirin Use in the Setting of Acute Myocardial Infarction and Peptic Ulcer Bleeding Does Not Increase the Rebleeding Rate
★ 2007 ACG Presidential Poster Award Recipient
Justin Cheung, MD, Jennifer Rajala, MD, Daniel Moroz, Gurpal Sandha, MD, Medicine, University of Alberta, Edmonton, AB, Canada.

P32. Primary Prevention by Omeprazole 20mg Daily of the Adverse Gastrointestinal Effects of Short-Term Non-Steroidal Anti-Inflammatory Drug Use in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Study
★ 2007 ACG Presidential Poster Award Recipient
Jay C. Desai, BA, Shelifai M. Sanyal, BA, Tyralee Goo, BA, Ariel A. Benson, BA, Carol A. Bodian, DrPH, Kenneth M. Miller, MD, Lawrence B. Cohen, MD, James Aisenberg, MD, Internal Medicine (Gastroenterology), Mount Sinai School of Medicine, New York, NY and Anesthesia (Biostatistics), Mount Sinai School of Medicine, New York, NY.

P33. Risk Factors Involved in Patients with Bleeding Peptic Ulcers—A Community Based Study
Sesha S. Uppalapati, MD, James D. Boylan, MD, Jill Stoltzfus, PhD, Internal Medicine, and Gastroenterology, St. Luke's Hospital, Bethlehem, PA.

P34. Drug Utilization Review of Acid Suppressants for Bleeding and Other Indications (Durable)—An Audit To Assess the Utilization of Proton Pump Inhibitors and Histamine H2-Receptor Antagonists in Canadian Hospitals
Alan Barkun, MD, Robert Enns, MD, Joseph Romagnuolo, MD, Tanja Muller, MD, Bruce Kalmin, MD, Ian A. Hawes, BSc, Yao Lei, PhD, the DURABLE Group of Investigators, Division of Gastroenterology, McGill University, Canada; Division of Gastroenterology, University of British Columbia, Canada; Division of Gastroenterology, Medical University of South Carolina, and Medical Affairs, AstraZeneca Canada Inc, Canada.

P35. Incidence of Endoscopic Gastric and Duodenal Ulcers (GDUs) in Randomized Placebo-Controlled NSAIDs Trials: A Meta-Analysis
Yuhong Yuan, MD, Changcheng Wang, MD, Richard H. Hunt, MD, FRCP, FRCPG, Gastroenterology, McMaster University Health Science Centre, Hamilton, ON, Canada and 2nd Affiliated Hospital of Sun Yet-Sen University, Guangzhou, China.
P36. Case Report: Zantac 300 mg BID Controls Gastric Acid Secretion vs Nexium 75 mg BID in a Patient with Gastric Bypass and Clinically Significant Vomiting
Sheila Rodriguez-Stanley, PhD, Susan Riley, RN, Philip B. Miner, Jr., MD, The Oklahoma Foundation for Digestive Research, Oklahoma City, OK.

P37. Effects of Cobiprostone on Indomethacin- and Stress-Induced Gastric Ulcers in Rats
Hiroyoshi Osaka, Sachiko Kuno, PhD, Birgit Roerig, PhD, Ryuji Ueno, MD, Sucampo Pharma Ltd., Osaka, Japan and Sucampo Pharmaceuticals, Inc., Bethesda, MD.

P38. Iron Pill Gastropathy: A Case Report and Review of the Literature
Nirmal Kaur, MD, Bryan N. Coffing, MD, Joel Greenson, MD, William D. Chey, MD, Division of Gastroenterology and Department of Pathology, University of Michigan, Ann Arbor, MI.

P39. Two Cases Involving Gastric Ulceration and Bleeding from Recent Placement of Gastrostomy Tubes with T-Fasteners
Rajesh Dhirmalani, DO, Dengda Tang, MD, Zamir Breivi, MD, Gastroenterology, UMDNJ, Newark, NJ.

P40. Cobiprostone is a Type-2 Chloride Channel Activator That Protects Against NSAID-Induced Cellular Damage
John Cuppoletti, PhD, Katrin Mende, PhD, Danuta H. Malinowska, PhD, Ryuji Ueno, MD, University of Cincinnati, Cincinnati, OH and Sucampo Pharmaceuticals, Inc., Bethesda, MD.

P41. Eosinophilic Gastritis: A Case Report
Sumit Sharma, MD, Preeti Agrawal, MD, Jack Garon, MD, Arun Verma, MD, Department of Medicine and Department of Pathology, Mt. Sinai Hospital, Sinai Health System, Chicago, IL.

P42. Does Increased Primary Resistance to Recommended Antibiotics Really Affect Helicobacter pylori Eradication?
Christina C. Eclissato, MD, Sergio Mendonça, PhD, Marcelo L. Ribeiro, PhD, José Pedroazzoli, Jr., PhD, Clinical Pharmacology and Gastroenterology Unit, São Francisco University, Bragança Paulista, SP, Brazil.

PANCREATIC/BILIARY

P43. Failure of Antibiotics To Prevent Infection in Patients with Necrotizing Pancreatitits: A Meta-Analisis
★ 2007 ACG Presidential Poster Award Recipient
Nisson Badalov, MD, Robin Baradarian, MD, Ilan Aharoni, MD, Jian Jun Li, MD, Scott Tenner, MD, MPH, Division of Gastroenterology, Dept of Medicine, Maimonides Medical Center, Brooklyn, NY and Division of Gastroenterology, State University of New York, Brooklyn, NY.

P44. Prophylactic Antibiotics in Necrotizing Pancreatitis: A Meta-Analysis
★ 2007 ACG Presidential Poster Award Recipient
Phil A. Hart, MD, Matthew L. Bechtold, MD, Abhishek Choudhary, MD, Shrivas R. Puli, MD, Mohamed O. Othman, MD, John B. Marshall, MD, Praveen K. Roy, MD, Division of Gastroenterology, University of Missouri, Columbia, MO.

P45. Prevalence of Fungal Infection in Patients with Severe Acute Pancreatitis and Its Outcome
Rakesh Kochhar, MD, Mahiuddin S.K. Ahammed, MD, Arunakolee Chakraborti, MD, Pallab Ray, MD, Usha Dutta, MD, Jai Dev Wig, MS, FRCS, Gastroenterology, Microbiology & General Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

P46. Efficacy and Safety of a Fully Covered Self Expandable Metal Stents (CSEMS) for Distal Biliary Neoplasia: Preliminary Data of a Multicenter Study
Michel Kahaleh, MD, Lee McHenry, MD, Pat G. Northup, MD, Don Wakelin, MD, Stuart Sherman, MD, Glen A. Lehman, MD, John Cunningham, MD, Paul Yeaton, MD, Digestive Health, University of Virginia, Charlottesville, VA; Department of Gastroenterology, Indiana University, Indianapolis, IN and Division of Gastroenterology and Hepatology, University of Arizona, Tucson, AZ.

P47. Long-Term Follow up of Endoscopic Sphincterotomy for Bile Duct Stone Removal: A North American Perspective
Milan E. Folkers, MD, Maydeen Ogar, Kathy Peterson, MD, James DiSario, MD, Gastroenterology, University of Utah, Salt Lake City, UT.

P48. Lack of Correlation between Liver Enzymes and the Presence of a Bile Leak Following Laparoscopic Cholecystectomy
R. Martin Bashir, MD, Biju K. Alex, MD, Gastroenterology, Washington Hospital Center, Washington, DC.

P49. Clinical Outcomes, and Long-Term Stent Patency in Patients with Malignant Biliary Obstruction: A Systematic Review and Meta-Analysis
Faisal A. Bukeyrat, MD, Rubayat Rahman, MD, Digestive Diseases, WVU School of Medicine, Morgantown, WV.

P50. Biliary Tract Complications in Orthotopic Liver Transplant Patients: A Single Center Retrospective Observational Study
Victor J. Torres, MD, Glenn W. Gross, MD, Sandeep Patel, DO, Gastroenterology and Nutrition, The University of Texas Health Science Center at San Antonio, San Antonio, TX.

P51. Asymptomatic Common Bile Duct Dilatation in Chronic Hepatitis C Patients on Methadone
Atif Shahzad, MD, Srisna Jasti, MD, Ayse Aytaman, MD, Gerald Fruchter, MD, Gastroenterology, State University of New York Downstate Medical Center, Brooklyn, NY and Gastroenterology, VA NY Harbor Healthcare System, Brooklyn, NY.

P52. The Effects of Alcohol and Substance Abuse on Sedation during ERCP
Ami K. Naik, MD, Yasmin Alishahi, MD, Muhammad Bilal, MD, Jim Y. Wan, PhD, Claudio R. Tombazzi, MD, Department of Gastroenterology and Hepatology, The University of Tennessee, Memphis, Memphis, TN.

P53. Prognostic Factors in Patients with Advanced Cholangiocarcinoma: Role of Surgery, Chemotherapy, and Body Mass Index
Mirna H. Farhat, MD, Ali I. Shamseddine, MD, Kassem A. Barada, MD, Internal Medicine–Division of Hematology/Oncology and Internal Medicine–Division of Gastroenterology, American University of Beirut-Medical Center, Beirut, Lebanon.

P54. Management of Acute Cholangitis with Periampullary Diverticula—Is Endoscopic Sphincterotomy Really Effective for Recurrence Prevention?
Susumu Shinoura, MD, Tomiaki Kubota, MD, Yutaka Yamaguchi, MD, Yoshihiko Shimabukuro, MD, Kazoru Kikuchi, MD, Yoshihide Keida, MD, Department of Internal Medicine, Division of Gastroenterology, Okayama Chubu Hospital, Uruma, Okinawa, Japan.

P55. Correlation between MRCP and ERCP Findings in Patients Undergoing an ERCP at a Tertiary Care Hospital
Rubayat Rahman, MD, Uma Sundaram, MD, Section of Digestive Diseases, West Virginia University School of Medicine, Morgantown, WV.
P56. GI Assistants’ Evaluation of the Impact of Hands-On Practice Workshop for ERCP Training
Joseph W. Leung, MD, FACG, Rebeck Gutierrez, RN, Brian Lim, MD, Kanat Ransibrahmanakul, MD, Robert Wilson, BVD, Felix W. Leung, MD, Gastroenterology, Sacramento VA Medical Center, Mather, CA; Division of Gastroenterology and Hepatology, UC Davis Medical Center, Sacramento, CA and Gastroenterology, Sepulveda ACC, VAGLAHS and David Geffen School of Medicine at UCLA, North Hills, CA.

P57. Comparison of MRCP with the Gold Standard, ERCP, for Evaluation of the Hepatobiliary Tract in a Large Urban Community Hospital
Jennifer Lee, MD, Dana A. Sloane, MD, Mahmood Abedi, MD, R.M. Bashir, MD, Timothy R. Koch, MD, Medicine/Gastroenterology, Washington Hospital Center, Washington, DC and Gastroenterology, Washington Hospital Center and Georgetown University School of Medicine, Washington, DC.

P58. Magnetic Resonance Cholangiopancreatography Versus Endoscopic Retrograde Cholangiopancreatography in the Evaluation of Patients with Suspected Biliary Strictures and Choledocholithiasis
Emaid Qayed, MD, Qiang Cai, MD, FACG, Department of Medicine, Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA.

P59. Selected Diagnostic and Therapeutic ERCP and EUS Cases Can Be Safely and Effectively Performed in an Ambulatory Surgery Center Setting
Nicholas Karypis, MD, Rudolph Bedford, MD, Gastrointestinal Biosciences, Beverly Hills, CA; Linden Crest Surgery Center, Beverly Hills, CA and Medicine, UCLA, Los Angeles, CA.

P60. Septic Pylephlebitis Mimicking Acute Biliary Obstruction
Raffat Jaber, MD, Chriistian Holand, MD, Ronald Griffin, MD, Division of Gastroenterology, Medicine, Loma Linda University, Loma Linda, CA.

SMALL INTESTINE/UNCLASSIFIED

P61. Mechanism of Zinc Deficiency in Patients with Roux-en-Y Gastric Bypass Surgery
Hiral N. Shah, MD, Bikram Bal, MD, Frederick C. Finelli, MD, JD, Nancy M. Carroll, MD, John R. Kirkpatrick, MD, Timothy R. Koch, MD, Medicine, Surgery, and Gastroenterology, Washington Hospital Center and Georgetown University School of Medicine, Washington, DC.

Reza Koshini, MD, Dai Sun-Chuan, MD, Sheila Lezcano, BS, Mark Pimentel, MD, Division of Gastroenterology, Harbor/UCLA Medical Center, Torrance, CA and GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA.

P63. Calcium Deficiency Is Associated with Small Intestinal Bacterial Overgrowth after Roux-en-Y Gastric Bypass Surgery
Bikram S. Bal, MD, Hiral N. Shah, MD, Frederick C. Finelli, MD, JD, Nancy M. Carroll, MD, John R. Kirkpatrick, MD, Timothy R. Koch, MD, Medicine, Surgery, and Gastroenterology, Washington Hospital Center and Georgetown University School of Medicine, Washington, DC.

P64. Pathomorphologic and Functional Alteration of Duodenal Mucosa in Patients with Chronic Alcoholic Pancreatitis
Kartar Singh, DM, Chander Kamal Nain, PhD, Department of Gastroenterology, Postgraduate Institute of Medical Education & Research, Chandigarh, Union Territory, India.

P65. Relationship between Atrophic Gastritis and Fasting Breath Hydrogen and Methane Levels in the Elderly
Yoshiihsa Urita, Toshiyasu Watanabe, Tadashi Maeda, Kaoru Domon, Susumu Ishihara, Toshihiro Arita, Asuka Nakayama, Makie Nanami, Tatsuhiro Yamamoto, Akira Kugahara, Takamasa Ishii, Hirohito Kato, Kazuo Hike, Noriko Hara, Yoshiko Honda, Shuji Watanabe, Kazushige Nakashii, Nagiio Shimada, Motonobu Sugimoto, Kazumasa Miki, Department of General Medicine and Emergency Care, Division of Gastroenterology and Hepatology, and Department of Hematology, Toho University, Tokyo, Japan.

P66. Treatment of Symptomatic Small Intestinal Bacterial Overgrowth and Weight Gain after Gastric Bypass Surgery
Hiral N. Shah, MD, Frederick C. Finelli, MD, John R. Kirkpatrick, MD, Nancy M. Carroll, MD, Timothy R. Koch, MD, Medicine, Surgery, and Gastroenterology, Washington Hospital Center and Georgetown University School of Medicine, Washington, DC.

P67. Nitazoxanide for the Treatment of IBS and SIBO Related Gastrointestinal Symptoms
Isaac Rajman, MD, Susana Escalante-Glorsky, MD, Matthew Bandres, PharmD, Digestive Associates of Houston, P.A., Houston, TX and Department of Medical Science, Romark Laboratories, L.C., Tampa, FL.

P68. Nitazoxanide for the Treatment of SIBO Related Gastrointestinal Symptoms in Pediatric Population
Youhanna Al-Tawil, MD, Alexandre Edelwein, MD, Clarisa Cuevas, MD, Anthony S. Jackson, PharmD, Children’s Hospital Pediatric Gastroenterology, Knoxville, TN and Department of Medical Science, Romark Laboratories, L.C., Tampa, FL.

P69. Nitazoxanide for the Treatment of SIBO-Related Gastrointestinal Symptoms
Harry Moulis, MD, Gregory J. Stella, MD, Louis M. Agnone, MD, Donato R. Ricci, MD, Sunil P. Pasricha, MD, David B. Mostellar, PharmD, Gastrointestinal Associates, P.A., Port Orange, FL and Department of Medical Science, Romark Laboratories, L.C., Tampa, FL.

P70. A Case of Large Hookworm Infestation
Gourisankar P. Degala, MD, Osama Alaradi, MD, Gastroenterology, Henry Ford Health System, Detroit, MI.

P71. Is Pre-Albumin an Accurate Marker of Nutritional Status in Acutely Ill Patients?
Kandarp R. Patel, DO, Lin Shu, Richard Gerkin, MD, Rakesh Nanda, MD, Department of Gastroenterology, Carl T. Hayden VA Medical Center, and Department of Medicine, Good Samaritan Regional Medical Center, Phoenix, AZ.

P72. Primary Aortoduodenal Fistula Caused by Mycobacterium Avium Complex
Pallavi K. Rao, MD, Kanan Sharma, MD, Christopher Barde, MD, Department of Gastroenterology, Wright State University, Dayton, OH.

LIVER

P73. Erythropoietic Protophorya (EPP) with Acute Hepatic Failure
Xingqin Fan, MD, Gagan Sood, MD, Shuyuan Xiao, MD, Karl Anderson, MD, Gastroenterology and Hepatology and Pathology, University of Texas Medical Branch, Galveston, TX.
P74. Tumor Necrosis Factor (TNF)/Tumor Necrosis Factor Receptor (TNFR) Interactions Are Critical for the Development and Effect of Hepatic and Splenic Cytoxic T Cells in MHC Class I Disparate GVHD
Sabina A. Ali, MD, Giri Brown, MD, Pediatrics: Division of Gastroenterology and Internal Medicine; Division of Gastroenterology, University of Texas Southwestern, Dallas, TX.

P75. Tolerability of an Optimal PEG IFN Alpha + Ribavirin Regimen for Patients with Decompensated Liver Disease Due to Hepatitis C
Joseph Ahn, MD, MS, Steven Flamm, MD, Hepatology, Rush University Medical Center, Chicago, IL and Hepatology, Northwestern University, Chicago, IL.

P76. Patients with Hypertension and Diabetes Mellitus Undergoing Interferon Therapy for Treatment of HCV Are Not at Higher Risk to Develop Ophthalmologic Complications
James D. Panetta, DO, Cameron Kifar, DO, Elizabeth A. Evanich, NP, Nooman Gilani, MD, FACG, Department of Medicine and Research, Section of Gastroenterology, Carl T. Hayden VAMC, Phoenix, AZ.

P77. Sustained Virological Response to Interferon-Based Antiviral Therapy by Viral Genotype in Recurrent Hepatitis C Patients Following Liver Transplantation
Anastacia Waechter, MD, Jason Williams, MD, Jason Lee, MPH, Lynn Shapiro, MD, Maximilian Lee, MD, Ahmad Kamal, MD, MSc, Emmet B. Keeffe, MD, Aijaz Ahmed, MD, Division of Gastroenterology and Hepatology, Liver Transplant Program, and Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, CA and Division of Gastroenterology, Santa Clara Valley Medical Center, San Jose, CA.

Iryna S. Hepburn, MD, Rassa Shahidzadeh, MD, Theodore S. Johnson, MD, Andrew Pearson, MD, Jeffrey R. Lee, MD, David Munir, MD, Robert R. Schade, MD, FACG, Sect. of Gastroenterology/Hepatology, Dept. of Pediatrics, and Immunotherapy Center, Medical College of Georgia, and Dept. of Pathology, Veterans Affairs Medical Center, Augusta, GA.

P79. Role of Antigen Processing and Presentation Genes in Development of Acute and Chronic Hepatic Viral Infections
Sukriti Baweja, Nirupma T. Pati, Sujoy Bose, Syed S. Hissar, Manoj Kumar, Puja Sakhija, Shiv K. Sarin, Department of Gastroenterology and Department of Pathology, G.B. Pant Hospital, New Delhi, India.

P80. Independent Predictors of Histologic Disease Severity in Asian Indian Patients with Nonalcoholic Steatohepatitis
Deepak Kumar Singh, MD, Puja Sakhija, MD, Veena Malhotra, MD, Ajay Kumar Chaudhary, MD, Ranjana Gondal, MD, Shiv Kumar Sarin, MD, Pathology, and Gastroenterology, G. B. Pant Hospital, New Delhi, India.

P81. The Risk of Analgesics in Cirrhosis
Roger N. Coron, MD, Victor J. Navarro, MD, Medicine, and Gastroenterology and Hepatology, Thomas Jefferson University School of Medicine, Philadelphia, PA.

P82. Hepatic Vein Pressure Gradient (HVPG) Is a Predictor of the Degree of Liver Fibrosis (LF) in Patients with Chronic Liver Disease (CLD) Due to Hepatitis B Virus (HBV)
Manoj Kumar, MD, DM, Hissar Syed, MD, Ashish Kumar, MD, DM, Pankaj Jain, MD, Archana Rastogi, MD, Deepak Singh, MD, Puja Sakhija, MD, Shiv Sarin, MD, DM, Department of Gastroenterology and Department of Pathology, G. B. Pant Hospital, New Delhi, India.

P83. Role of Pentoxifylline in PRE-Hepatorenal Syndrome State
Pankaj Tyagi, MD, DM, Smruti Ranjan Mishra, MD, Manoj Sharma, MD, DM, Praveen Sharma, MD, Amarendra Puri, MD, DM, Shiv Kumar Sarin, MD, DM, Gastroenterology, G B Pant Hospital, New Delhi, India.

P84. Association of Nonalcoholic Fatty Liver Disease with Metabolic Syndrome in Indian Population
M.G. Sanal, Ajay K, Chowdhary, MD, Shiv K. Sarin, DM, Special Center for Molecular Medicine, New Delhi, Delhi, India and Gastroenterology, GB Pant Hospital, Delhi, India.

P85. Improvement of Metabolic Syndrome (MS) in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) after Bariatric Surgery
Chunhong Bai, MS, Clare Nugent, MBChB, Michael Garone, Jr., Priya Gopalakrishnan, Caitlin Quigley, Zarah Younoszai, Mariam Afendi, Ari describe, Rochelle S. Collins, MPH, MD, Manirath Shroshord, RN, BSN, Hazem Elanny, MD, PhD, Zobair M. Younossi, MD, MPH, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA.

P86. Splanchic Hemodynamics in Cirrhotic Patients: Relationship to Esophageal Varices and the Severity of Hepatic Failure
Tary A. Salmon, MD, Inas Kurayim, MD, Naglaa A.A. Allam, MD, Khaled Abuela, MD, Hepatology, Radiology, and Surgery, National Liver Institute, Shebeen, Menofeya, Egypt.

P87. Genetic Variation in the Peroxisome Proliferator Activated Receptor-gamma Gene Is Associated with NAFLD and Its Histological Phenotypes
Samir Gawrieh, Miranda Marion, Kristen Smith, Richard Komorowski, James Wallace, Peter Nutterman, Deborah Andris, Ahmed Kissebab, Carl Langefeld, Michael Olivier, Medical College of Wisconsin, Milwaukee, WI; Zablocki VA Medical Center, Milwaukee, WI and Wake Forest University, Winston-Salem, NC.

P88. Limited Value of Leukocyte Esterase Reagent Strips for the Quick Diagnosis of Spontaneous Bacterial Peritonitis
Matthew Eidem, MD, Sunil Dwivedi, MD, Hector Nazario, MD, Alfredo Espinoza, MD, Anastacio Hoyumpa, MD, Department of Medicine, Division of Gastroenterology and Nutrition, University of Texas Health Science Center at San Antonio, San Antonio, TX.

P89. Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Budd-Chiari Syndrome (BCS): Experience at a Tertiary Health Center

P90. Recent Application of AASLD Practice Guidelines and US Algorithm for Treatment of Chronic Hepatitis B
Denis V. Kapkov, MD, Trinh B. Meyer, MD, Douglas Meyer, MD, David J. Clain, MD, Henry C. Bodenheimer, Jr., MD, Albert D. Min, MD, Digestive Diseases, Beth Israel Medical Center, New York, NY.

P91. Can Metabolic and Hepatic Abnormalities Be Improved by Intragastric Balloon Treatment for Obesity?
Giorgio Ricci, MD, Flavia Pigò, MD, Angelo Rossi, MD, Gianluca Bersani, MD, Vittorio Alvisi, MD, Postgraduate School of Gastroenterology, University of Ferrara, Ferrara, ER, Italy.

P92. Factors Influencing Participation in Hepatitis C Research Trials
★ 2007 ACG Presidential Poster Award Recipient
Katina D. Robertson, BA, Cynthia A. Moylan, MD, Carla W. Brady, MD, Andrew J. Muir, MD, Division of Gastroenterology, Duke University Medical Center, Durham, NC.
P93. Clinico-pathological Predictors of Sustained Viral Response Rates in Patients with Chronic Hepatitis C Infection
Jagdish S. Nachnani, MD, Raja Gidwani, MD, Esmat Sadeeddin, MD, Wendell K. Clarkston, MD, Russell Fiorella, MD, MBA, Laura M. Alba, MD, Internal Medicine, University of Missouri Kansas City, Kansas City, MO; Pathology, Truman Medical Center, Kansas City, MO and Gastroenterology, University of Missouri Kansas City, Kansas City, MO.

P94. Factors Associated with Low Platelet Count in Veterans with Chronic Hepatitis C
Samir Parekh, MD, Andrew Simpson, MD, Mohammad Wehbi, MD, Aasma Shaukat, MD, Kamil Obideen, MD, Digestive Diseases, Emory University School of Medicine, Atlanta, GA.

P95. Hepatic Neuro-Endocrine Tumor: A Case Report
Sumit Sharma, MD, Preeth Agrawal, MD, Rami Haddad, MD, Department of Medicine, Rosalind Franklin University of Medicine and Sciences, North Chicago, IL and Department of Oncology, Rosalind Franklin University of Medicine and Sciences, North Chicago, IL.

P96. 34 Year Old Pregnant Female Presents with Abdominal Pain
Baiseer Qazi, MD, Naser M. Khan, MD, Mani Mahdavian, MD, Medicine, Division of Gastroenterology, Advocate Lutheran General Hospital, Park Ridge, IL.

P97. Frequency of Hepatitis B Core Antibodies in Chronic Active Hepatitis C Patients in a Pakistani Cohort
Muhammad Umar, FACS, Zahid Mahmood Minhas, MD, Muhammad Ali Asghar, MBBS, Saima Aimbreen, FCPs, Muhammad Usman Yaqoob, MBBS, Hamama Tul Bushra, FCPS, Usman Hakeem, MBBS, Munibashir Aziz, MBBS, Fiza Binte Ismail, MBBS, Gastroenterology & Hepatology Division of Department of Medicine, Holy Family Hospital, Rawalpindi, Punjab, Pakistan.

P98. Increased Risk of Colon Adenomatous Polyps in Patients Infected with Helicobacter pylori
Trinh Meyer, MD, Vindushi Golla, MD, Curtis Coley, MD, Albert Min, MD, Division of Digestive Diseases, Beth Israel Medical Center, New York, NY.

P99. Is Survival for Rectal Cancer Patients Downstaged to Stage I after Neoadjuvant Radiation Determined by Their Pretreatment Stage? A 10 Year Analysis
Ravi P. Kiran, MD, Naveen Pokala, MD, Victor W. Fazio, MD, Colorectal Surgery, Cleveland Clinic Foundation, Cleveland, OH.

P100. Safety of Colonoscopy during Pregnancy
Steven R. Fox, MD, Navakanth Gorrepati, MD, Mitchell S. Cappell, MD, Gastroenterology, William Beaumont Hospital, Royal Oak, MI.

P101. Simultaneous Assessment of Colonic Transit Using Wireless Capsule (SmartPill®) and Radiopaque Markers in Healthy Subjects and Effects of Gender
S. Rao, MD, FACG, B. Kuo, MD, W. Chey, MD, FACG, J. Dibaise, MD, FACG, L. Katz, MD, K. Koch, MD, FACG, J. Lackner, PsyD, R. McCallum, MD, R. Saad, MD, K. Selover, J. Semler, PhD, M. Sitrin, MD, G. Wilding, PhD, H. Parkman, MD, FACG, SmartPill Research Group.

P102. Characterization of Colon Cancer in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis
Erin W. Thackeray, MD, Phunchai Charatcharoenwitthaya, MD, Keith D. Lindor, MD, Internal Medicine, and Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

P103. Fermentation of Wheat Dextrin, Psyllium, and Inulin Are Altered but Not Improved by the Addition of Lactobacillus reuteri
Joanne L. Slavin, PhD, Ashley Januszewski, BS, Alberto Paredes-Diaz, MD, Vincenzo Savarino, MD, Maria L. Stewart, MS, Food Science and Nutrition, University of Minnesota, St. Paul, MN; Novartis Consumer Health, Parsippany, NJ and Gastroenterology Unit, Dipartimento di Medicina Interna, Genova, Italy.

P104. Colonoscopy Scheduling for Elderly Patients: Morning or Afternoon Sessions and Does It Make a Difference?
Anthia Gapotoulou, MD, Elmuhtady Said, MBBS, Anastasios Koulaouzidis, MD, MRCP, Anand Reddy, MRCP, Jitendra N. Singh, MRCP, Athar A. Saeed, FRCP, Gastroenterology, Queen Elizabeth Hospital, Gateshead, United Kingdom and Gastroenterology, Llandudno Hospital, Llandudno, United Kingdom.

P105. Dyssynergia—Key Pathophysiological Mechanism for Fecal Incontinence (FI) in Nursing Home Residents

P106. Two Pathways of Carcinogenesis: MSI vs CIN in Iranian Patients with Colorectal Cancer
Manso Molaei, MD, Babak Noorinayer, MD, Ali Ghanbarimotlagh, MD, S. Alireza Emami, MD, Somaye Ghiasi, MD, Mohamadreza Zali, MD, Pathology and Gastroenterology, Research Center for Gastroenterology and Liver Disease, Shahed Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.

P107. Association of GSTM1, P1, T1 and CYP2E1 Single Nucleotide Polymorphisms with Colorectal Cancer in Iran
Saeideh Ebrahimkhani, MS, Babak Noorinayer, MD, Pedram Kharaziha, MD, Katoyuon Aghajani, MD, Mohammad Reza Zali, MD, FACC, Shaheed Beheshti Medical University, Research Center for Gastroenterology and Liver Disease, Tehran, Islamic Republic of Iran.

P108. POSTER WITHDRAWN

P109. Expandable Metal Stents for Obstructing Lesions of the Colon as Bridge Therapy: An Alternative to Emergent Surgery
Aravind S. Vijayapal, MD, Kiely M. James, MD, Albert J. Karen, MD, Dua S. Kulwinder, MD, Medicine, Division of GI & Hepatology, and Surgery, Medical College of WI, Milwaukee, WI.

P110. Assessment of Methane Breath Testing
Sattar Zubaidi, MD, Sheila Rodriguez-Stanley, PhD, FACC, Susan Riley, RN, Philip B. Miner, Jr., MD, FACC, Oklahoma Foundation for Digestive Research, Oklahoma City, OK.

P111. C-Reactive Protein and the Risk of Colorectal Adenoma in Apparently Healthy Populations
Sung Keun Park, Dong Il Park, Hong Ju Kim, Chong Il Shon, Byung Ik Kim, Woo Kyu Jeon, Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.

P112. Colon Cancer: Protein Biomarkers in Tissue and Body Fluids
M. Momeni, MD, P. Pevsner, MD, D. Vecchione, BS, B. Stall, AAS, K. Zaalook, MD, S. Duddempudi, MD, M. Joseph, MD, S. Anand, MD, Gastroenterology, The Brooklyn Hospital Center, Brooklyn, NY and NYU School of Medicine Department of Pharmacology, New York, NY.
CLINICAL VIGNETTES

P113. Post Herpetic Esophageal Neuralgia: A New Entity?
Kiran Jagarlamudi, MD, Pragathi Ravi, MD, George Protopapas, Ashok Gupta, MD, Walid Baddoura, MD, Gastroenterology, St. Joseph’s Regional Medical Center, Paterson, NJ and Seton Hall University School of GME, S. Orange, NJ.

P114. An Unusual Case of Severe Pill Esophagitis Mimicking Herpetic Esophagitis, Caused by a New OTC NSAID – Containing Sleeping Aid
Jennifer L. Wellington, Darlene Bonior, RN, V. Alin Botoman, MD, Biological Sciences, Florida Atlantic University, Boca Raton, FL; GI Institute of Fort Lauderdale, Fort Lauderdale, FL and Gastroenterology, University of Miami, Miami, FL.

P115. An Unusual Case of Dysphagia Caught on 3-D CT
Brian S. Lim, MD, Walter Trudeau, MD, John Rosenquist, MD, Gastroenterology & Radiology, UC Davis Med Ctr, Sacramento, CA.

P116. Enteryx: Migration into the Lymphatics and Beyond
Ganesh R. Veerappan, MD, Jonathan M. Koff, MD, Milton T. Smith, MD, Gastroenterology, Walter Reed Army Medical Center, Washington, DC.

P117. The First Reported Case of Disseminated Coccidioides Involving the Esophagus and Presenting with Severe Iron-Deficiency Anemia
Julie T. Yang, MD, Hanson Kwok, MD, David S. Condon, MD, Internal Medicine/Gastroenterology, Loma Linda University Medical Center, Loma Linda, CA.

P118. Lung Cancer Presenting with Dysphagia Due to Esophageal Metastasis
Vineeta Sood, MD, Fred L. Hardwicke, MD, Parupudi V.J. Sriram, MD, Internal Medicine, Internal Medicine (Hematology & Oncology), and Internal Medicine (Gastroenterology), Texas Tech Univ Health Sciences Center, Lubbock, TX.

P119. Dysphagia in a Patient after Cervical Spine Surgery
Ravi V. Nadimpalli, MD, Mark Blumenkohl, MD, Gastroenterology, Henry Ford Health System, Detroit, MI.

P120. Zenker’s Bezoar as a Cause of False-Negative Modified Barium Swallow in a Patient with Dysphagia
Andrew N. Pearson, MD, Rassa Shahidzadeh, MD, Sherman M. Chamberlain, MD, Section of Gastroenterology, Medical College of Georgia, Augusta, GA.

P121. Successful Endoscopic Dilation of Cervical Esophageal Webs: Two Case Reports
Ali Lankarani, MD, Vivek Kumar, MD, Sam Yoselevitz, MD, Sudhir K. Dutta, MD, Gastroenterology, Sinai Hospital, Baltimore, MD and Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD.

P122. The Importance of Belching: Pharmacologcal Inhibition of Erection Presenting as Bloating and Abdominal Pain
Andrew D. Rhim, MD, Gastroenterology Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.

P123. Unusual Pulmonary Complication from Maloney Dilation
David S. Hodges, MD, Rishi Raj, MD, Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX.

P124. Colonic Polyps in the “Esophagus”
Jessica Widmer, DO, Paul Panzarella, MD, William Gusten, MD, Kavita Kongara, MD, James Grendell, MD, Gastroenterology, Winthrop University Hospital, Mineola, NY.

P125. Oro-Nasal Fistula: An Usual Etiology of Dysphagia after Treatment for Tonsillar Cancer
Joseph M. McKinley, MD, Brice Taylor, MD, Prasad Kulkarni, MD, Department of Gastroenterology, University of South Florida, Tampa, FL.

P126. Dysphagia Lusoria Due to an Aberrant Right Subclavian Artery and a Dilated Diverticulum of Kommerell
Srikanth Vallurupalli, MD, Juan Jimenez, MD, Internal Medicine and Radiology, University of Illinois at Urbana Champaign, Urbana, IL.

P127. Safe Use of the PillCam ESO in a Patient with an Implantable Cardioverter Defibrillator
Daniel S. Mishkin, MD, CM, Gastroenterology, Boston University, Boston, MA.

P128. The GIST (Gastrointestinal Stromal Tumor) of the Gastroesophageal Junction (GEJ)
Wanwarat Ananthapanyasut, MD, Sammy Nawas, MD, Jue-lin Tang, MD, Andrea Blumenstein, MD, Charles Berkelhammer, MD, Gastroenterology/Internal Medicine, University of Illinois, Oak Lawn, IL.

P129. Gastric Cancer Recurrence in Small Bowel after Subtotal Gastrectomy with Billroth II Gastrojejunostomy
Albert J. Pahk, MD, Shahid Mehboob, MD, Gastroenterology, University of Buffalo, Buffalo, NY.

P130. Isolated Gastric Malakoplaikia Associated with Helicobacter pylori Infection: A Case Report and Review of Literature
Shoba Mendu, MD, Michael Piper, MD, Ved Singla, MD, Gastroenterology, St. John Providence Hospital, Southfield, MI.

P131. Fine Needle Aspiration Biopsy (FNAB) of a Rare Case of Malignant Seeding of Percutaneous Endoscopic Gastrostomy (PEG) Tract: Direct Implantation during PEG insertion or Seeding Via Hematogenous Spread?
Anwer M. Siddiqi, MD, Robert D. Hamilton, MD, Mithra Baliga, MD, Rhyme Flowers, MD, Anil Minocha, MD, Pathology, Medicine, Division of Oncology, and Medicine, Division of Gastroenterology, University of Mississippi Medical Center, Jackson, MS.

P132. Metastatic Melanoma in a Dialysis Patient with Vomiting Diagnosed by Gastric Polyp Biopsy
Maria Lufrano, DO, Ian Storch, DO, Richard Feldstein, MD, John Costabile, MD, Michael Gitman, MD, Gastroenterology, Northshore University Hospital, Manhasset, NY.

P133. DIC as a Complication of HHT or Osler-Weber-Rendu Syndrome
Humam Javedan, MD, Nausheen Naz, MD, Manish Tandon, MD, Julio C. Ayala, MD, Internal Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA.

P134. Metastatic Melanoma Presenting as Massive Upper Gastrointestinal Bleeding
Nison L. Badalov, MD, Matthew Tangorra, DO, Anita Torok, MD, JianJun Li, MD, Kadirawel Iswara, MD, Scott Tenner, MD, MPH, Division of Gastroenterology, Department of Medicine, Maimonides Medical Center, Brooklyn, NY.
P136. Schistosoma Mansoni in the Stomach—A Rare Find!
Rohit Jindal, MD, Jie Ouyang, MD, Rosemary L. Wieczorek, MD, Mohit Jindal, MD, Ayse Ayteman, MD, Gastroenterology, VA NYHHCS, Gastroenterology, SUNY Downstate Medical Center, and Pathology, VA NYHHCS, Brooklyn, NY.

P137. Dramatic Decrease of Gastrin Levels after Extirpation of Metastatic Gastrinoma Lymph Nodes in a Patient with Multicentric Carcinoid and MEN 1
Alejandra Castillo-Roth, MD, Jonathan Erber, MD, Wilbur Bowne, MD, Rosemary Wieczorek, MD, Gerald Fruchter, MD, NY VA NY Harbor Health Care System, Brooklyn, NY and SUNY Downstate Medical Center, Brooklyn, NY.

P138. Isolated Neurofibroma of the Pylorus Presenting as “Idiopathic” Gastropareasis, Refractory to Standard Medical Management
Irene Sarosiek, Jameson Forster, Savio Reddymasu, Pernilla Foran, Katherine Roesser, Jerzy Sarosiek, Richard McCallum, Motility Center and Surgery, KUMC, Kansas City, KS.

P139. Granulocytic (Myeloid) Sarcoma of Stomach Presenting with Upper Gastrointestinal Bleeding
M. Singh, MD, Haifawi, MD, Baitdano, MD, C. Zanardi, MD, P. Hollzapfl, MD, Gastroenterology, Pathology, SUNY Upstate Medical University, Syracuse, NY.

P140. Severe Copper Deficiency in a Patient with History of Gastric Bypass Leading to CNS Demyelination, Severe Azafrax and Peripheral Neuropathy
Motaz K, Al-Hafnawi, MD, Jawaid Shaw, MD, Kevin Casey, MD, Department of Medicine, Gastroenterology Division, Rochester General Hospital, Rochester, NY.

P141. An Unusual “PPI-Refractory” Symptomatic Gastric Ulcer Successfully Treated with Corticosteroids and Azathioprine: Eosinophilic Mural Ulcer
Tasma Harindhanavudhi, MD, Wanwarat Anathapanysut, MD, Waqar Mian, MD, David Olmstead, MD, Rogelio G. Silva, MD, Hareth Raddawi, MD, Internal Medicine/GI, University of Illinois, Advocate Christ Med Ctr, Chicago/Oak Lawn, IL.

P142. Eosinophilic Gastritis Due to Infection from a Non-Gas-Producing Bacteria
Manju P. Paul, MD, Savio John, MD, Nilesh Mehta, MD, Preeti Mehta, MD, Uma K. Murthy, MD, Medicine, SUNY Upstate Medical University, Syracuse, NY.

P143. The Buried Bumper Syndrome and Gas in the Portal Venous System
Jocelyn V. de Jesus, MD, Dean Silas, MD, Gastroenterology, Advocate Lutheran General Hospital, Park Ridge, IL.

P144. Gastric Myeloma
Aman Ali, MD, Louis Rosainz, MD, Eric Rosen, MD, Knarik Arakun, MD, Peter J. Baioccy, MD, Gastroenterology and Hepatology, Lenox Hill Hospital, New York, NY.

P145. Penetrating Gastric Ulcer: An Usual Route for Liver Biopsy
William A. Mourad, MD, Stacy Pratt, DO, Komar Mike, MD, Gastroenterology, Geisinger Medical Center, Danville, PA.

P146. Profound Gastroparesis Presenting with Isolated Intrapерitoneal Amyloidosis
Hui Hing Jack Tin, MD, Jai Mirchandani, MD, JianJun Li, MD, Kadirawel Iswara, MD, Scott Tenner, MD, MPH, Division of Gastroenterology, Dept of Medicine, Maimonides Medical Center, Brooklyn, NY.

P147. Nitazoxanide and Treatment of *Helicobacter pylori*
William P. Stuppy, MD, Private Practice, Los Angeles, CA.

P148. Chronic Mesenteric Ischemia Presenting as *Helicobacter pylori*-Negative Duodenal and Gastric Ulcers. Case Report and Literature Review
M. Fuad Azrak, MD, Gihad Gaith, MD, Department of Internal Medicine Medicine, William Beaumont Hospital, Royal Oak, MI.

P149. Giant Hyperplastic Gastric Polypos: Precursor Lesions to Adenocarcinoma?
Vivek Kumar, MD, Ali Lankarani, MD, Sam Yoselevitz, MD, Gerald Hofkin, MD, Gastroenterology, Sinai Hospital, Baltimore, MD and Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD.

P150. Treatment of Symptomatic Cystic Duct Stone in a Pretransplant Cirrhotic Patient
Timothy M. Saettele, Megan Saettele, Priyanka Tiwari, MD, Matthew L. Bechtold, MD, Srinivas R. Puli, MD, Mainor R. Antillon, MD, Division of Gastroenterology, University of Missouri, Columbia, MO.

P151. Sign of Leser-Trélat
Audrey H. Calderwood, MD, Robert C. Lowe, MD, Gastroenterology, Boston Medical Center, Boston, MA.

P152. A Pancreatic Pseudocyst Presenting as Dysphagia and Review of the Literature
Sandra M. Jara, MD, Francene Martin, MD, Patrick Brady, MD, Division of Digestive Diseases, University of South Florida, Tampa, FL.

P153. Case Series on Hepatic Portal Venous Gas
Debapiya De, MD, Mitesh Patel, MD, Rishi Pawa, MD, Krishnarao V. Tangella, MD, Davendra P. Ramkumar, MD, Internal Medicine, University of Illinois at Urbana Champaign, Urbana, IL; Gastroenterology, Columbia University College of Physicians & Surgeons, Harlem Hospital Center, New York, NY; Pathology, Provena Covenant Medical Center, and Gastroenterology, University of Illinois College at Urbana Champaign, Urbana, IL.

P154. Acute Pancreatitis: An Unusual Complication of Double Balloon Enteroscopy
Rahul Pannala, MD, Ganapathy A. Prasad, MD, Suresh T. Chari, MD, Louis M. Wong Kee Song, MD, Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

P155. Insulin Therapy for Hypertriglyceridemia (>6,000mg/dl) and Hyperglycemia (>500mg/dl) in the Setting of Acute Pancreatitis
Wayne Tsuang, Luis Ruiz, MD, Smrutl Mohanty, MD, Jesse Hall, MD, Pritzker School of Medicine, Section of Pulmonary and Critical Care Medicine, and Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL.

P156. *Clostridium difficile* Sepsis Associated with an Enterocolic Hepatic Abscess
Patricia A. Sanchez, MD, Michael Selden, MD, Owen J. Smith, MD, Wendell K. Clarkston, MD, Department of Medicine, Division of Gastroenterology, University of Missouri at Kansas City School of Medicine, Kansas City, MO.

P157. Insulin and Dextrose in the Treatment of Hypertriglyceridemia Induced Pancreatitis (HIP)
Debapiya De, MD, Rishi Pawa, MD, Benjamin L. Jacobson, MD, Ali Alizadehsovari, MD, Davendra P. Ramkumar, MD, Internal Medicine, University of Illinois at Urbana Champaign, Urbana, IL; Gastroenterology, Columbia University College of Physicians & Surgeons, Harlem Hospital Center, New York, NY; and Gastroenterology, University of Illinois at Urbana Champaign, Urbana, IL.
P181. Evaluation of an Inpatient with Obscure Gastrointestinal Bleeding in the Community Hospital Setting
Keith S. Sultan, MD, Joseph S. DeVito, MD, Robert J. Ward, MD, Gastrointestinal Associates, Plainview, NY; Massapequa, NY and Lake Success, NY.

P182. Primary Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma Treated with Rituximab
Brent J. Prosser, MD, Praveena G. Velamati, MD, Mack C. Mitchell, MD, Department of Digestive Diseases, Johns Hopkins Bayview Medical Center, Baltimore, MD.

P183. Mycobacterium Avium Complex Infection of the Duodenum
Josh Forman, MD, Roderick Kreisberg, MD, Eric Goldberg, MD, Division of Gastroenterology, University of Maryland School of Medicine, Baltimore, MD.

P184. Metastatic Soft Tissue Sarcoma Detected by Small Bowel Video Capsule Endoscopy
Jennifer Weiss, MD, Sharon Weber, MD, Mark Reichelider, MD, Deepak Gopal, MD, Section of Gastroenterology & Hepatology & Dept. of General Surgery, University of Wisconsin - School of Medicine & Public Health, Madison, WI.

P185. Four Different Presentations of a Rare Disease—Whipple’s Disease
Bogdan Cristescu, MD, Safak Reka, MD, Digestive Diseases, SUNY Downstate Medical Center, Brooklyn, NY.

P186. Small Bowel Metastasis from Lung Cancer
Mario Tapia, Bielose C. Konwe, Margie Cornwell, Muhammad G. Nathani, Internal Medicine, UTHSCSA, Regional Academic Health Center, Harlingen, TX.

P187. Medical Management of Jejunal Diverticulitis
Valerie J. Rader, MD, Noel Fajardo, MD, John A. Schaffner, MD, Internal Medicine, Mayo Clinic School of Graduate Medical Education, Rochester, MN and Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

P188. Mystery in the Desert
Shayan Alam, MD, Jonathan A. Leighton, MD, Jerry Smilack, MD, Thomas Colby, MD, Internal Medicine, Gastroenterology, NNMC, Bethesda, MD; Pathology and Division of Surgery, Division of Colon and Rectal Surgery, and Department of Anatomic Pathology, Mayo Clinic, Rochester, MN.

P189. A Case of Common Variable Immunodeficiency Mimicking Refractory Celiac Sprue
Tanvi A. Dhere, MD, Alexander Lee, Mohammed Wehbi, MD, Kamil Obideen, MD, Department of Digestive Diseases, Emory University, Atlanta, GA.

P190. Metastatic Breast Cancer Mimicking Small Bowel Crohn’s Disease
Marian S. Sauer, MD, Sherri Yong, MD, James Richter, MD, Khondker Islam, MD, Department of Medicine and Department of Pathology, Loyola University Medical Center, Maywood, IL.

P191. Ischemic Duodenal Ulceration in a Sickle Cell Patient with Sickle Cell Crisis
Rahul N. Julka, MD, Laura W. Lamps, MD, Kevin W. Olden, MD, Gastroenterology/Hepatology and Pathology, University of Arkansas for Medical Sciences, Little Rock, AR.

P192. Chronic Diarrhea, Alopecia Totalis and Muscle Cramps in a 36 Year Old Female
Samar Harris, MBBS, Kathrin Czarnecki, MD, Harris V.K. Naina, MBBS, Internal Medicine, Mayo Clinic, College of Medicine, Rochester, MN.

P193. VIPoma—A Case of Abrupt Onset Diarrhea in an Elderly Patient
Amil P. Patel, MD, Mohammad Wehbi, MD, Kamil Obideen, MD, Department of Gastroenterology, Emory University, Atlanta, GA.

P194. Cronkhite-Canada Syndrome Presenting as Acute Colitis; Confirmed by Colonoscopy, Upper Endoscopy, Capsule Endoscopy, and Pathology
Greg Nesmith, MD, Ryan Ford, MD, Kelly Crawford, MD, Digestive Diseases, Emory University School of Medicine, Atlanta, GA.

P195. Adult T-Cell Leukemia/Lymphoma with Terminal Ileal Involvement
Biju K. Alex, MD, Atoussa Farough, MD, Roshan M. Bashir, MD, Department of Medicine, Washington Hospital Center, Washington, DC.

P196. Perforated Meckel’s Diverticulum Mimicking Crohn’s Disease Presenting with Bowel and Urinary Obstruction
Banny S. Wong, MD, David W. Larson, MD, Schuyler O. Sanderson, MD, Amy S. Oxentenko, MD, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Department of Surgery, Division of Colon and Rectal Surgery, and Department of Anatomic Pathology, Mayo Clinic, Rochester, MN.

P197. Gastrointestinal Stromal Tumor and Papillary Renal Cell Carcinoma: A Case Report
Illya Diamond, DO, Saphwat Eskaros, MD, Chethana Kanaparthi, MD, Andrea Culliford, MD, Sury Anand, MD, Gastroenterology, Brooklyn Hospital, Brooklyn, NY and Gastroenterology, St. Barnabas, Bronx, NY.

P198. Severe Anemia as the Presenting Feature of Small Bowel Melanoma
Rushabh J. Modi, BA, Samir A. Shah, MD, David Schreiber, MD, Edward Feller, MD, Medicine, Division of Gastroenterology, The Warren Alpert Medical School of Brown University, Providence, RI and The Warren Alpert Medical School of Brown University, Providence, RI.

P199. Intestinal Occlusion Caused by Meckel’s Diverticulum with Ileoileal Intussusception in an Elderly Patient: A Rare Case Report
Jianfeng Cheng, MD, PhD, Naga Vemula, MD, Jeffrey Brensilver, MD, FACG, Internal Medicine, Sound Shore Medical Center of Westchester, New Rochelle, NY.

P200. Intermittent Jejunosotomy Tube Obstruction Due to Ascaris Lumbricoides Infection
Camron Kiafar, DO, Deepa Shah, MD, Nooman Gilani, MD, FAGC, Medicine, Medical Center Valley Hospital, Phoenix, AZ.

P201. A Rare Cause of Nausea, Vomiting and Diarrhea: Eosinophilic Gastroenteritis
Amer Skopic, DO, Joel Moncur, MD, Jonathan Koff, MD, Gastroenterology, NNNMC, Bethesda, MD; Pathology and Gastroenterology, WRAMC, Washington, DC.

P202. Pneumatosis Intestinalis of Small Bowel Due to Acute Pancreatitis Induced Ileus
Suresh Jayatilaka, MD, Gurpreet Singh, MD, Chintan Modi, MD, Robert Spira, MD, Gastroenterology, St. Michael’s Medical Center/Seton Hall University, Newark, NJ.

P203. Celiac Disease and Chronic Infectious Enteritis
William P. Stuppy, MD, Private Practice, Los Angeles, CA.
P204. Wireless Capsule Endoscopy in a Patient with Intermittent Obstructive Symptoms—A New Indication
Daniel A. Sussman, MD, Jamie S. Barkin, MD, Gastroenterology, University of Miami/Leonard Miller School of Medicine, Miami, FL and Gastroenterology, Mount Sinai Medical Center, Miami Beach, FL.

P205. A Simple Twist of Fate?
Ryan M. Ford, MD, Kristina R. Chacko, MD, Tanvi Dhere, MD, Greg Nesmith, MD, Henry Olejeme, MD, Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA.

P206. Recurrent Lymphoma Presenting as Incarcerated Umbilical Hernia
Eyong J. Ly, BA, Edward R. Feller, MD, Fred J. Schiffman, MD, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI.

P207. Acute Myelomonocytic Leukemia Manifesting as Ileus
Tal B. Hazan, MD, Fernando N. Gamarra, MD, James C. Shanks, MD, Luis C. Maas, MD, Robert Bloom, MD, Gastroenterology/Hepatology, Internal Medicine, and Hematology/Oncology, Providence Hospital and Medical Centers, Southfield, MI.

P208. Clinical Utility of Adjunctive Naturopathic Products To Improve the Tolerability of Interferon Based Regimens for Hepatic B and C: A Report on Four Patients
Srinivas S. Vasireddi, MD, Advanced Digestive Center, Metuchen, NJ.

P209. Endoscopic Management of Esophageal Varices with Band Ligation in Hepatitis C Patients Receiving Pegylated Interferon/Ribavirin Therapy: Safety and Success of This Approach in Three Patients
Alexander T. Lalo, MD, Gastrointestinal Consultants of NEPA, Scranton, PA.

P210. Facial Hyperpigmentation in Association with Peginterferon alpha-2a and Ribavirin Treatment for Chronic Hepatitis C Patient: A Case Report
Mandeep Singh, MD, Muhammad Y. Sheikh, MD, Mary Reyes, MD, Marie L. Borum, MD, Gastroenterology, George Washington University, Washington, DC.

P211. A Case of Interferon-Induced Anti-Jo1 Positive Polymyositis with Pulmonary Fibrosis
Matthew B. Chandler, MD, David L. Jager, MD, Mary Reyes, MD, Marie L. Borum, MD, Gastroenterology, George Washington University, Washington, DC.

P212. Primary Sclerosing Cholangitis and Autoimmune Hemolytic Anemia: A Casual Association?
Marie B. Wiles, PA-C, Charles H. Parker, MD, Alastair D. Smith, MB, ChB, Medicine, Halifax Regional Hospital, South Boston, VA and Medicine, Duke University, Durham, NC.

P213. Ciprofloxacin-Induced Acute Cholestatic Liver Injury and Associated Renal Failure from Acute Tubular Necrosis
Amy J. DiChiara, MD, Matt Atkinson, MD, Kenneth E. Sherman, MD, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH.

P214. Elevated Alpha Fetoprotein: Looking beyond Hepatocellular Carcinoma
Mamata Ravipati, MD, Navneet Attri, MD, Rami Y. Haddad, MD, Department of Internal Medicine, North Chicago VA Medical Center, North Chicago, IL and Department of Hematology/Oncology, North Chicago VA Medical Center, North Chicago, IL.

P215. Multifocal Splenic Steatosis in End Stage Cholestatic Liver Disease
Jeffrey Tang, MD, Chetan Pai, DO, Stuart C. Gordon, MD, Internal Medicine, Division of Gastroenterology, Henry Ford Hospital, Detroit, MI.

P216. An Unusual Case of Right Upper Quadrant Pain
Christopher B. Keller, DO, Jorge L. Herrera, MD, Internal Medicine and Division of Gastroenterology, University of South Alabama, Mobile, AL.

P217. Liver Transplantation for Infliximab-Induced Fulminant Hepatic Failure
John L. Gosserand, MD, Shamita Shah, MD, K. Shiva Kumar, MD, Division of Gastroenterology & Hepatology, Ochsner Clinic Foundation, New Orleans, LA.

P218. Case of Chronic Hepatitis C Presenting with Right Axillary Lymphadenopathy
Biju K. Alex, MD, Roshan M. Bashir, MD, Department of Medicine, Washington Hospital Center, Washington, DC.

P219. A Case of Thyrotoxic Crisis Leading to Fulminating Hepatic Failure
Thomas Birris, MD, Michael Heavey, MD, Ashish Arora, MD, Sonu Dhillon, MD, Claus Fimmel, MD, Gastroenterology, Hepatology, and Nutrition, Loyola University Medical Center, Maywood, IL.

P220. Effectiveness of EUS in Liver Lesions of Unclear Etiology
Priyanka Tiwari, MD, Timothy M. Saettele, Matthew L. Bechtold, MD, Srinivas R. Puli, MD, Mairon R. Antillon, MD, Division of Gastroenterology, University of Missouri, Columbia, MO.

P221. Endometriosis Presenting as Recurrent Massive Ascites
Hui Hing Jack Tin, MD, Hima Satyawal, MD, Jai Mirchandani, MD, Kadirawel Iswara, MD, JianJun Li, MD, Scott Tenner, MD, MPH, Division of Gastroenterology, Department of Medicine, Maimonides Medical Center, Brooklyn, NY.

P222. Encapsulating Peritoneal Sclerosis: A Rare, but Recognized Cause of Ascites in Patients with Renal Failure
Alastair D. Smith, MB, ChB, Andrew I. Wolf, MD, Keyur Patel, MD, Medicine, Duke University, Durham, NC.

P223. Hepatocellular Carcinoma in a Patient with Hepatitis C in the Absence of Cirrhosis
Javid Fazili, MD, Mohammad Madhoun, MD, Lary Pennington, MD, Digestive Diseases/Internal Medicine and General Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK.

P224. A Rare Case of Hepatotoxicity
Sohail Asfandiyar, MD, Chan Ma, MD, Mary Ann H. Sherbondy, MD, Gastroenterology, Henry Ford Hospital, Detroit, MI and Pathology, Henry Ford Hospital, Detroit, MI.

P225. Endophthalmitis Complicating Klebsiella Pneumoniae Liver Abscess: An Infrequently Recognized Complication
David W. Victor, MD, Rebeckah Lemann, MD, Jacob Feagans, MD, Virendra Joshi, MD, Digestive Diseases/Internal Medicine and General Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK.

P226. Hepatic Adenomatosis: A Rare Clinical Entity with Unique Characteristics
Kashif Ahmed, MD, Muslim Atiq, MD, Kamran Safdar, MD, Nyingi Kemmer, MD, Guy Neff, MD, Division of Digestive Diseases, Dept of Internal Medicine, University of Cincinnati, Cincinnati, OH.

P227. Tanned Lady with Skin Lesions and Liver Disease
Rajeswari Anaparthy, MD, Internal Medicine, University of Texas Medical Branch, Galveston, TX.
P228. Massive Pleural Effusion as Initial Presentation of Advanced Liver Cirrhosis
Michelle Rivera, Jahaira Serrano, Yohanna de Jesus, Victor L. Carlo, Internal Medicine, Division of Gastroenterology, UPR Medical Science Campus, School of Medicine, San Juan, Puerto Rico.

P229. Fusobacterium Nucleatum: An Uncommon Cause of Pyogenic Liver Abscess
Amil P. Patel, MD, Jesse Jacob, MD, Mohammad Wehbi, MD, Kamil Obideon, MD, Department of Gastroenterology, Emory University, Atlanta, GA.

P230. Ischemic Liver Insult in a Patient with Sickle Beta Thalassemia O: First Reported Case
Rajat Gulati, MD, Tasma Harindhanavudhi, MD, Imran Ali, MD, Rafal G. Ciecierski, MD, Hareth Raddawi, MD, Internal Medicine/GI, University of Illinois/Advocate Christ Med Ctr, Chicago/Oak Lawn, IL.

P231. Advanced Liver Disease in a Patient with PiMZ alpha-1 Antitrypsin (A,AT) Phenotype and Normal Serum A,AT Level
Meena Narayan, MD, Swetha Kandula, MD, Frank A. Mitros, MD, Jatinder P. Ahluwalia, MD, Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL and Pathology, Univ. of Iowa, Iowa City, IA.

P232. Fever of Unknown Origin: Pylephlebitis
Julie Yang, MD, Eugene R. Schiff, MD, MACG, Division of Gastroenterology and Hepatology, University of Miami Miller School of Medicine, Miami, FL.

P233. Case Series: Lactulose Retention Enema Associated with Massive Gastrointestinal Hemorrhage in Three Patients
William R. Kessler, MD, Gastroenterology, Indiana University Medical Center, Indianapolis, IN.

OUTCOMES RESEARCH

P234. Utility of Screening Coagulation Studies in Gastrointestinal Bleeding Patients without Risk Factors for Coagulopathy Admitted to the Intensive Care Unit
Angelo H. Paredes, MD, Viet-Nhan H. Nguyen, DO, Corrine L. Maydonovitch, BS, Department of Gastroenterology, Walter Reed Army Medical Center, Washington, DC.

P235. Management of Iron Deficiency Anaemia: Are We Meeting the Guidelines?
Sindhu Ramamurthy, MBBS, Peter Reid, FRCP, Department of Medicine, Countess of Chester Hospital NHS Foundation Trust, Chester, Merseyside, United Kingdom.

P236. Stress Ulcer Prophylaxis for the Acutely-Ill Patient: What Do Residents Know?
Bassel Alasi, MD, Henri Godbold, MD, Kurtis Moodie, MD, Louay Shawesh, MD, Soley Seren, MD, Jorge Guzman, MD, Internal Medicine/Pediatrics, Wayne State University, Detroit, MI.

P237. Gastroenterology and CME: How Do We Want To Learn in an Urban Landscape?
Seth F. Tatel, MD, Justin R. Boike, BS, BS, Christopher J. Shoemaker, MD, Ben M. Stickan, MBA, Jay L. Goldstein, MD, Department of Medicine, University of Illinois at Chicago, Chicago, IL.

P238. Outcomes of Recurrent Abdominal Pain (RAP) in Children and Responses to a Multidimensional Measure for RAP (MM-RAP): A Follow-Up Study
Hoda M. Malaty, MD, PhD, Suhail Abudayyeh, MD, Kimberly O’Malley, PhD, David Y. Graham, MD, Mark A. Gilger, MD, Department of Medicine, Baylor College of Medicine, Houston, TX; Medicine, Veterans Affairs Medical Center, Houston, TX and Pediatrics, Baylor College of Medicine, Houston, TX.

P239. Patients Discharged from a Chest Pain Center—Are They Followed up and Treated Appropriately?
Mark Mellow, MD, Charles Bethea, MD, Gayle Sturgis, RN, Linda Pitchford, RN, Digestive Health Center, INTEGRIS Baptist Medical Center, Oklahoma City, OK.

P240. Exploratory Study Examining the Risk of Gastrointestinal Bleeding for Patients on Selective Serotonin Reuptake Inhibitor Therapy
Smita Kothari, PhD, Michael Jones, MD, Stacey Long, MS, TAP Pharmaceuticals Products, Inc., Lake Forest, IL; Northwestern University, Chicago, IL and Thomson Healthcare, Cambridge, MA.

P241. Comparison of Lactose Versus Lactulose Breath Tests in Subjects Suspected with Small Intestinal Bacterial Overgrowth
Kelly Cushing, BS, Rana Abraham, MD, Mary Kwansky, ScD, Ali Keshavarzian, MD, Ece Mutlu, MD, Digestive Diseases, Rush University Medical Center, Chicago, IL and Rush College of Nursing, Chicago, IL.

P242. Does Abnormal Computed Tomography (CT) of the Gastrointestinal (GI) Tract Correlate with Endoscopic Findings?
Rekha Cheruvattath, MD, Stacy G. Prall, DO, Robert E. Smith, MD, Michael J. Komar, MD, Nicholas A. Inverso, MD, Gastroenterology, Geisinger Medical Center, Danville, PA.

P243. Non-Cutaneous Head and Neck Cancer in Solid Organ Transplant Recipients
Saurabh S. Dhawan, MD, Thomas H. Costello, MD, Agnes Lo Costello, BSP, PharmD, Merri E. Sebelik, MD, Brea Olson, BSc, A. Osama Gaber, MD, Internal Medicine, Otolaryngology, Head and Neck Surgery, Pharmacy, and Transplant Surgery, University of Tennessee Health Science Center, Memphis, TN.

P244. Statin Use and the Risk of Colorectal Cancer in Patients with Diabetes
Christine Yeh, MD, Robert Morgan, PhD, Michael Johnson, PhD, Mark Kuebeler, MS, Hashem El-Serag, MD, MPH, Health Services Research, Baylor College of Medicine, Houston, TX.

P245. Infliximab Is Clinically Effective in Reducing the Need for Steroids in Inflammatory Bowel Disease
H.C. Thompson, MBA, B. Meissner, PhD, M.I. Rahman, MD, O. Dabbous, MD, B. Tang, MD, HECOR, Centocor, Inc., Horsham, PA and Applied Health Outcomes, Xcenda, LLC, Palm Harbor, FL.

P246. The Pre-Operative Utility of Dobutamine Stress Echocardiography in Patients Undergoing Liver Transplantation
Lynn Shapiro, MD, Maximilian Lee, MD, Jason Lee, MPH, Alex S. Lapasaran, MSN, MSN, William Fearon, MD, Ahmad Kamai, MD, MSc, Aijaz Ahmed, MD, Division of Gastroenterology and Hepatology, Liver Transplant Program, Center for Primary Care and Outcomes Research, and Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, and Division of Gastroenterology, Santa Clara Valley Medical Center, San Jose, CA.

P247. Prevalence of Gastrointestinal Symptoms and the Influence of Demographic Factors
Afsaneh Zarghi, MD, MPH, Mohammad Amin Pourhoseingholi, PhD, Manijeh Habibi, MS, Ali Akbar Haghdoost, MD, PhD, Ali Solhpour, MD, Mehdi Moazezi, MD, Ali Ramezankhani, PhD, Mohammad Rostaminejad, BS, Mohammad Reza Zali, MD, FACG, HSR, Research Center for Gastroenterology & Liver Diseases, Shaheed Beheshti Medical Sciences University, Tehran, Islamic Republic of Iran.
P248. Collagenous and Lymphocytic Colitis in Celiac Disease: Evaluation of Standardized Morbidity Ratios
Jianfeng Cheng, MD, PhD, Jun Yang, MD, Govind Bhagat, MD, Peter Green, MD, Internal Medicine, Sound Shore Medical Center, New Rochelle, NY; Medicine-Digestive and Liver Disease, and Pathology, Columbia University, New York, NY.

P249. Feeding Decisions in Patients with Advanced Dementia—Formative Research
Donald A. Garrow, MD, Jane G. Zapka, ScD, Elaine Amella, PhD, Mark DeLegge, MD, GI and Hepatology, MUSC, Charleston, SC.

P250. Gastrointestinal Bleeding in Biopsy-Proven Graft-Versus-Host Disease of the GI Tract: Risk Factors and Effect on Mortality
Hazem T. Hammad, MD, Natalieya Razumilava, MD, Nolan E. Perez, MD, Murray N. Ehrinpreis, MD, Division of Gastroenterology, Wayne State University, Detroit, MI.

P251. Can the Occurrence of Septic Complications after Restorative Proctocolectomy Be Predicted?
Ravi P. Kiran, MD, Feza H. Remzi, MD, Victor W. Fazio, MD, Andre D. Moreira, MD, James M. Church, MD, Ian C. Lavery, MD, Tracy L. Hull, MD, Scott A. Strong, MD, Colorectal Surgery, Cleveland Clinic Foundation, Cleveland, OH.

P252. A Model To Predict Rebleeding Following Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Hemorrhage
Anne T. Wolf, MD, Sharmee K. Wasan, MD, John R. Saltzman, MD, Gastroenterology and Medicine, Brigham and Women's Hospital, Boston, MA.

P253. Derivation and Validation of an Algorithm To Identify Helicobacter pylori Infected Patients Using Administrative Data
Neena S. Abraham, MD, MSCE, Ranil DeSilva, MD, Peter Richardson, PhD, Gastroenterology, Baylor College of Medicine; Micheal E. DeBakey VAMC, Houston, TX; Health Services Research, Houston Center of Quality of Care and Utilization Studies; Micheal E. DeBakey VAMC, Houston, TX and Department of Medicine, Baylor College of Medicine, Houston, TX.

P254. Knowledge of Hepatocellular Carcinoma (HCC) Screening Guidelines and Current Practices: Results of a National Survey
Gary Panjabi, Health Benchmarks, Woodland Hills, CA and Elan Pharmaceuticals, San Diego, CA.

P255. Patient Underreported Use of NSAIDs in GI Practice: Guidelines and Current Practices; Results of a National Survey
Raj T. Majithia, MD, David A. Johnson, MD, Internal Medicine/Gastroenterology Division, Eastern Virginia Medical School, Norfolk, VA.

P256. Prevalence of Gastroesophageal Reflux Disease as Assessed by the National Ambulatory Medical Care Survey
Frank K. Friedenberg, MD, David Nehemia, MD, Jorge Marrero, MD, Hazem T. Hammad, MD, Peter Green, MD, Internal Medicine, Mayo Clinic, Rochester, MN and Graduate School of Public Health, Temple University, Philadelphia, PA.

P257. Frequency and Indications for Performance of Repeat Colonoscopy within Sixty Days
Hazem Hammad, MD, Bret T. Petersen, MD, Beverly Ott, Felicity Enders, PhD, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN and Internal Medicine, Wayne State University, Detroit, MI.

P258. Administrative Data for Colonoscopy with Polypectomy Have a High Level of Accuracy
Collins N. Okolie, MD, Gregory Cooper, MD, Department of Gastroenterology, University Hospitals of Cleveland Case Medical Center, Cleveland, OH.

P259. Patients That Do Not Speak English Miss Fewer Clinic Appointments Than English Speaking Patients
Justin L. Sewell, MD, MPH, John M. Inadomi, MD, Hal F. Yee, Jr., MD, PhD, Medicine, University of California, San Francisco, San Francisco, CA.

P260. The Readability of Hepatitis C Health Education Materials
Noel M. Lee, MD, Andrew J. Muir, MD, MHS, Carla W. Brady, MD, MHS, Department of Medicine and Division of Gastroenterology, Duke University Medical Center, Durham, NC.

P261. Impact of an Internet-Based Educational Program on Colonoscopy Attendance and Quality
Tojo Thomas, MD, Prashant Kedia, MD, Russell D. Cohen, MD, Medicine/Gastroenterology, The University of Chicago, Chicago, IL.

P262. GI Endoscopy Nurse Experience Predicts Polyp Detection during Screening Colonoscopy
Evan S. Dellow, MD, Robert S. Sandler, MD, MPH, Nicholas J. Shaheen, MD, MPH, Medicine, University of North Carolina, Chapel Hill, NC.

INFLAMMATORY BOWEL DISEASE

P263. Distal Location of Dysplasia and Colorectal Cancer in Longstanding Ulcerative Colitis (UC)

P264. Cost of Treating Crohn's Disease

P265. The Direct and Indirect Cost Burden of Illness of Ulcerative Colitis
Eliza Ng, MD, Teresa B. Gibson, PhD, Ronald J. Ozminkowski, PhD, Global Outcomes Research, UCB, Smyrna, GA; School of Pharmacy, University of Arizona, Tucson, AZ; 4Clinics, All4IT, Waterloo, Belgium and Global Outcomes Research, Modis International, London, United Kingdom.

P266. Impact of Crohn's Disease Severity on Healthcare Costs and Utilization
Patricia Grossman, PharmD, Edward Armstrong, PharmD, Lionel Van Holle, MA, Andrea Beyer, MA, Vincent Bauchau, PhD, Global Outcomes Research, UCB, Smyrna, GA; School of Pharmacy, University of Arizona, Tucson, AZ; 4Clinics, All4IT, Waterloo, Belgium and Global Outcomes Research, Modis International, London, United Kingdom.

P267. Assessment of the Validity of Computed Tomographic Enterography for Diagnosing Active Crohn's Disease
Patricia Burgunder, ARNP, Ira Shafran, MD, Shafran Gastroenterology Center, Winter Park, FL.

P268. POSTER WITHDRAWN
P270. Infliximab Therapy Is Associated with Unexpected Weight Gain in Patients with Crohn's Disease as Compared to Those with Rheumatoid Arthritis

Cristal L. Brown, Kim L. Isaacs, MD, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC.

P271. Clinical Features of Patients with Crohn's Disease on Home Parenteral Nutrition

Razvi M. Razack, MD, Douglas Seidner, MD, Cindy Hamilton, MS, Ana Rocío Lopez, MS, Bret A. Lashner, MD, Section of Clinical Nutrition and IBD, Department of Gastroenterology and Hepatology, The Cleveland Clinic, Cleveland, OH.

P272. Gender Influences Time to Diagnosis for Patients with Crohn's Disease Confined to the Ileum

Sunanda V. Kane, MD, MSPH, Enn Aronson, BSc, Department of Medicine, University of Chicago, Chicago, IL and Department of Medicine, Mayo Clinic, Rochester, MN.

P273. Safety and Efficacy of Adalimumab in Pediatric Crohn's Disease Patients

Alex Green, DO, Matthew Wyneski, MD, Robert Wylie, MD, Marsha Kay, MD, Lori Mahajan, MD, Pediatric Gastroenterology, Cleveland Clinic, OH and Pediatrics, MetroHealth Medical Center, Cleveland, OH.

P274. Immunization for Vaccine-Preventable Illnesses in Patients with Inflammatory Bowel Disease

Shamita Shah, MD, John L. Gosserand, MD, Rahul Jasti, MD, Sandra Kemmerly, MD, K. Shiva Kumar, MD, James W. Smith, MD, Division of Gastroenterology & Hepatology, Ochsner Clinic Foundation, New Orleans, LA.

P275. Comparable Pharmacokinetics (PK) of Two Delayed Release Formulations of Oral Mesalamine

William J. Sandborn, MD, Guhan Balan, PhD, Barbara Kuzmak, PhD, Stephen B. Hanauer, MD, Mayo Clinic, Rochester, MN; P&G Pharmaceuticals, Mason, OH and University of Chicago, Chicago, IL.

P276. Long-Term Efficacy of Adalimumab Treatment in Patients with Moderately to Severely Active Luminal Crohn's Disease Who Lost Response or Showed Intolerance to Infliximab

J. Hinojosa, MD, F. Gomollón, MD, S. Garcia, MD, G. Bastida, MD, C. Saro, MD, J. Cabriada, MD, M. Gassull, MD, Hospital de Sagunto, Sagunto, Spain; Hospital Clínic de Lozano Blesa, Zaragoza, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital La Fe, Valencia, Spain; Hospital de Cabuenes, Gijón, Spain; Hospital de Galdakao, Vizcaya, Spain and On Behalf of GETECCU, Hospital Germans Trias I Pujol, Barcelona.

P277. Observations on a Large Sample Set Using Serologic Markers To Predict Inflammatory Bowel Disease, Ulcerative Colitis (UC), and Crohn's (CD)

Bruce Neri, PhD, Augusto Lois, PhD, Susan Carroll, PhD, Richard Bogardt, PhD, R&D, Prometheus Laboratories, San Diego, CA.

P278. Rapid Clinical Remission Is Significant for the Well-Being of Ulcerative Colitis Patients Treated with Delayed-Release Mesalamine

E. Jan Irvine, MD, Simon Magowan, MD, Margaret Pasquale, PhD, Seymour Katz, MD, St. Michael's Hospital/University of Toronto, Toronto, ON, Canada; P&G Pharmaceuticals, Mason, OH and Nassau Gastroenterology Associates, Great Neck, NY.

P279. Long-Term Safety of 5 Aminosalicylates (Mesalamine) in the Treatment of Inflammatory Bowel Disease

Chirag D. Trivedi, DO, Sima Mithani, MD, Eswarya Chichili, MD, Danli Xing, Kiron M. Das, MD, PhD, Department of Gastroenterology, Robert Wood Johnson Medical School, New Brunswick, NJ.

P280. Is Laparotomy Warranted at the Closure of Temporary Ileostomy? A Review of 571 Patients with Bowel Obstruction Following Restorative Proctocolectomy with Ileal Pouch

Renyu Zhang, MD, Victor Fazio, MD, Feza Remzi, MD, James Church, MD, colorectal Surgery, The Cleveland Clinic Foundation, Cleveland, OH.

P281. Inflammatory Bowel Disease in Afro-Caribbeans: Does It Differ from Other Ethnic Groups?

Alejandra I. Castillo-Roth, MD, Joanne M. Matthews, MD, Kapil Gupta, MD, Safak Reka, MD, Swaminath Iyer, MD, Gastroenterology and Hepatology, SUNY Downstate, Brooklyn, NY.

P282. High Rates of Vitamin D Deficiency and Osteopenia in Crohn's Disease Are Associated with Abnormal Absorption of Vitamin D

Kleanthis G. Dendrinos, MD, Arthur F. Stucchi, PhD, James Becker, MD, Timothy Heeren, PhD, Zhiren Lu, MS, Jeffrey Mathieu, MS, Tai C. Chen, PhD, Michael F. Holick, MD, Francis A. Faryaye, MD, Section of Gastroenterology Department of Surgery, and Section of Endocrinology, Boston University School of Medicine, Boston, MA, and Biostatistics, Boston University School of Public Health, Boston, MA.

P283. MMX™ Mesalamine Is Effective for the Maintenance of Remission of Mild-to-Moderate Ulcerative Colitis Irrespective of Patients' Previous Relapse History

William J. Sandborn, MD, Robyn Karlstadt, MD, Karen Barrett, MSc, Raymond E. Joseph, MD, Inflammatory Bowel Disease Clinic, Mayo Clinic, Rochester, MN; Shire Pharmaceuticals Inc., Wayne, PA and Shire Pharmaceuticals Inc., Basingstoke, Hampshire, United Kingdom.

P284. A Comprehensive Evaluation of the Impact of Crohn's Disease and Its Treatment on Patients Is Achieved Using a Combination of the CDAI and IBDQ

Brian G. Feagan, MD, Geoffrey Coteur, PhD, Dorothy L. Keininger, MS, Robarts Research Institute, London, ON, Canada; SGS, SGS Life Science Services, Mechelen, Belgium and Global Health Outcomes Research, UCB SA, Braine-l’Alleud, Belgium.

P285. Changes in Utility Scores of Patients with Active Crohn's Disease after Cetirizolium Pegol 400mg Induction and Maintenance (PRECISE 2)

Seng Tan, MSc, Brian G. Feagan, MD, Stefan Schreiber, MD, Martin C.J. Brown, MSc, Laetitia C. Gerlier, MSc, Robarts Clinical Trials, Robarts Research Institute, London, ON, Canada; Medicine, Christian-Albrechts University, Kiel, Germany, Global Health Outcomes Research, UCB, Slough, United Kingdom and Keyrus Biopharma, Levallois-Perret, France.

P286. Severe Crohn's Disease Symptoms Are Relieved by Cetirizolium Pegol

Brian G. Feagan, MD, Geoffrey Coteur, PhD, Dorothy L. Keininger, MS, Robarts Clinical Trials, Robarts Research Institute, London, ON, Canada; SGS, SGS Life Science Services, Mechelen, Belgium and Global Health Outcomes Research, UCB SA, Braine-l’Alleud, Belgium.
P287. Chromoendoscopy Is Superior to Standard Colonoscopic Surveillance for Detecting Dysplasia in Patients with IBD: A Continuing, Long-Term, Prospective Endoscopic Trial
James F. Manon, MD, Jerome D. Waye, MD, MACG, Daniel H. Present, MD, MACG, Yumi Israel, BS, Carol Bodian, DrPH, Naam Harpaz, MD, Maria T. Abreu, MD, Thomas A. Ullman, MD, Lloyd Mayer, MD, Gastroenterology and Pathology, Mount Sinai School of Medicine, New York, NY.

P288. Absence of NOD2 Polymorphisms in Crohn's Disease Patients with Ulcers
LuLu Iles-Shih, MD, Elisa Takalo, Judith F. Collins, MD, Tamara M. Martin, PhD, Casey Eye Institute, Department of Medicine, and Department of Gastroenterology, Oregon Health and Science University, Portland, OR.

P289. Prevalence of Cytomegalovirus and Epstein Barr Virus in Inflamed Colon Tissue of Patients with Mild to Moderate Inflammatory Bowel Disease—Preliminary Results
Paul A. Feldman, MD, MSc, Stephen Vernon, MD, Daniel L. Cohen, MD, Jeffrey B. Raskin, MD, Nevis Fregien, PhD, Division of Gastroenterology, Pathology, and Anatomy and Cell Biology, University of Miami, School of Medicine, Miami, FL.

P290. Previous History of Steroid Use Does Not Preclude Treatment with Mesalamine in Ulcerative Colitis (UC)
Seymour Katz, MD, Bruce R. Yacyshyn, MD, David L. Ramsey, MS, Gary R. Lichtenstein, Nassau Gastroenterology Associates, Great Neck, NY; Procter & Gamble Pharmaceuticals, Mason, OH and Hospital of the University of Pennsylvania, Philadelphia, PA.

P291. Crohn's Disease Diagnosed by Capsule Endoscopy in Patients with Obstructive Gastrointestinal Bleeding
Saketha Crowder, MD, Richard Bloomfield, MD, Gastroenterology, Wake Forest University Baptist Medical Center, Winston-Salem, NC.

FUNCTIONAL BOWEL DISORDERS

P292. Safety Testing: Effects of Nutrient and Water Loading on Gastric Volume and Emptying ★ 2007 ACG Presidential Poster Award Recipient
Siva Doma, MD, Steve Kantor, Robert S. Fisher, MD, Linda C. Knight, PhD, Alan H. Maurer, MD, Henry P. Parkman, MD, Medicine, Temple University School of Medicine, Philadelphia, PA.

P293. High Dose Dexamethasone for Acute Idiopathic Gastroapresis
Eugene M. Cooper, MD, Jamie Barkin, MD, Division of Gastroenterology, University of Miami/Jackson Memorial Hospital, Miami, FL and Division of Gastroenterology, Mount Sinai Medical Center, Miami Beach, FL.

P294. Transition of Gastroesophageal Reflux Disease Symptoms into Other Gastrointestinal Symptoms: Six Month Prospective Study
Giles R. Locke, MD, Suzanne Clark, MS, Annamaria Cerulli, MPH, Josh Marehban, MPH, Kristjan H. Kahler, PhD, RPh, Michael A. Shetzline, MD, PhD, Mayo Clinic College of Medicine, Rochester, MN; Health Benchmarks, Inc., Woodland Hills, CA and Novartis Pharmaceuticals Corporation, East Hanover, NJ.

P295. Methane Production in IBS Subjects Is Associated with a Constellation of Symptoms: Not Just Constipation
Mark Pimentel, MD, FRCP(C), Sheila Lezcano, BS, Kimberly Low, BS, GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA.

P296. Male Sex Hormone May Influence on Irritable Bowel Syndrome in Young Men
Beom Jin Kim, Poong-Lyul Rhee, Hee Jung Son, Young-Ho Kim, Dong Kyung Chang, Jae J. Kim, Jong Chul Rhee, Hyuk Lee, Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea and Medicine, The Armed Forces Capital Hospital, Seoul, Republic of Korea.

P297. Type D Personality Is Associated with Impaired Health-Related Quality of Life in Patients with Functional Bowel Disorders (FBDs)
Stephanie L. Hansel, MD, MS, Sarah B. Wessinger, MD, V. Ann Schettler, RN, MHL, John K. DiBaise, MD, Michael P. Jones, MD, Michael D. Crowell, PhD, Gastroenterology & Hepatology, Mayo Clinic Arizona, Scottsdale, AZ and Gastroenterology, Northwestern University, Chicago, IL.

P298. Familial Aggregation of Functional Dyspepsia: A Case-Control Study
Smita L.S. Halder, MRCP, Meredythe A. McNally, MD, Giles R. Locke, MD, Judy A. Peterson, Prabin Thapa, MS, Scott Harmsen, MS, Alan R. Zinsmeister, PhD, Nicholas J. Talley, MD, Department of Gastroenterology, University of Manchester, Manchester, United Kingdom; Dyspepsia Center and Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN.

P299. Prevalence of Irritable Bowel Syndrome in an Older Bi-Racial Population
Carline Quander, MD, MS, Marta Clara Morris, ScD, Julia L. Biennias, ScD, Denis A. Evans, MD, Internal Medicine, Rush University Medical Center and Rush Institute for Healthy Aging, Rush University Medical Center, Chicago, IL.

P300. Predictors of Response in Gastroparesis
Rajeswari Anaparthy, MD, Nonco Pehlivanov, MD, Sonia Price, RN, Pankaj Jay Pasricha, MD, Department of Internal Medicine and Department of Gastroenterology, Internal Medicine, University of Texas Medical Branch, Galveston, TX.

P301. Risk Factors for Chronic Diarrhea Not Related to Irritable Bowel Syndrome
Joseph Y. Chang, MD, MPH, Giles R. Locke, III, MD, Cathy D. Schleck, BSc, Alan R. Zinsmeister, PhD, Nicholas J. Talley, MD, PhD, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; Division of Gastroenterology and Internal Medicine, and Division of Biostatistics, Mayo Clinic, Rochester, MN.

P302. Functional Gastrointestinal Disorder Comorbidities: Comparisons of Prevalence and Costs in the 6 Months before and after Diagnoses of Constipation (C) and Irritable Bowel Syndrome and Constipation (IBS+C)
R.A. Brook, MS, N.J. Talley, MD, N.L. Kleinman, PhD, R.W. Baran, PharmD, JeSTARx Group, NJ; Dept Medicine, Mayo Clinic, MN; HCMS, WY and Takeda Global R&D, IL.

P303. Nightly Tegaserod Prevents the Clinical Recurrence of Bacterial Overgrowth Symptoms
Mark Pimentel, MD, FACG, Walter Morales, BS, Sheila Lezcano, BS, Sun-Chuan Dai, MD, Kimberly Low, BA, Reza Khoshini, MD, Janet Yang, MD, GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA.

P304. Tegaserod (Zelnorm) Safety Profile in Pediatric Patients
Aileen F. Har, MD, Rita Steffen, MD, Barbara Kaplan, MD, Lori Mahajan, MD, Pediatrics, Cleveland Clinic, Cleveland, OH.

P305. The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review
Darren M. Brenner, MD, Matthew Moeller, MD, William D. Chey, MD, Philip Schoenfeld, MD, Department of Gastroenterology and Department of Internal Medicine, University of Michigan Hospitals, Ann Arbor, MI.
P306. Clinical Characteristics, Diagnostic Features, and Response to Therapy in Patients with Rumination Syndrome
Christopher D. Miller, MD, Jiten D. Patel, MD, Farid Namin, MD, Richard W. McCallum, MD, Division of Gastroenterology and Hepatology, University of Tennessee Health Science Center, Memphis, TN and Center for Gastrointestinal Nerve & Muscle Function, University of Kansas, Kansas City, KS.

ENDOSCOPY

P307. A Single-Center Experience with 652 Cases of Wireless Capsule Endoscopy over a Period of 5 Years
Adnan Muhammad, MD, Shivani Sharma, MD, Yogandhar Akula, MD, Sandeep Bhargava, MD, C.S. Pitchumoni, MACG, Gastroenterology, Hepatology and Clinical Nutrition, Saint Peter's University Hospital, New Brunswick, NJ.

P308. Problems, Complications and Failures of Wireless Capsule Endoscopy: A Single-Center Experience with 652 Cases
Adnan Muhammad, MD, Sandeep Bhargava, MD, C.S. Pitchumoni, MACG, Gastroenterology, Hepatology and Clinical Nutrition, Saint Peter's University Hospital, New Brunswick, NJ.

P309. Diagnostic Yield of Wireless Capsule Endoscopy for the Evaluation of Iron Deficiency Anemia in Different Age Groups
Adnan Muhammad, MD, Yogandhar Akula, MD, Shivani Sharma, MD, C.S. Pitchumoni, MD, Gastroenterology, Hepatology and Clinical Nutrition, Saint Peter's University Hospital, New Brunswick, NJ.

P310. Role of Endoscopic Ultrasonography in the Evaluation of Gastric Submucosal Lesions: A Single Center Experience
Shailender Singh, MD, Srinivas Pulil, MD, Jyotsna Talapaneni, MD, Melissa Oropeza-Vail, RN, Mojtaba Olyaee, MD, Medicine, Kansas University Medical Center, Kansas City, KS.

P311. Endoscopic Ultrasonography Findings in Patients with Nonspecific Changes of the Pancreas on Computed Tomography: A Single-Center Experience
Sana Waheed, MD, Shailender Singh, MD, Savio Reddyrasu, MD, Jyotsna Talapaneni, MD, Benjamin Alsop, Melissa Oropeza-Vail, RN, Mojtaba Olyaee, MD, Medicine, Kansas University Medical Center, Kansas City, KS.

P312. Utility of EUS-Guided Trucut Biopsy To Distinguish Pancreatic Rests from Gastrointestinal Stromal Tumors (A Case Series)
Junaid Siddiqui, MD, Andrew D. Vanderheyden, MD, Chris S. Jensen, MD, Henning Gerke, MD, Internal Medicine/Gastroenterology and Hepatology, and Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA.

P313. Socioeconomic Status Directly Affects the Probability of Percutaneous Endoscopic Gastrostomy Placement
Roberto Gamarra, MD, Rahil Shah, MD, Alan Cutler, MD, Gastro-enterology & Hepatology, Providence Hospital, Southfield, MI.

P314. A Retrospective Comparison of Percutaneous Endoscopic and Radiologic Gastrostomy Tube Feeding
Saleh Alqahtani, FRCPC, Medicine, University of Calgary, Calgary, AB, Canada.

P315. Comparison of Direct Endoscopic Guided Placement of the Bravo Capsule with the Conventional Method
Isam Daboul, MD, Vikas Ghai, MD, Sriniv Hejeebu, DO, Adeel Husain, Gastroenterology and Medicine, University of Toledo, Toledo, OH.

Isam Daboul, MD, Vikas Ghai, MD, Sriniv Hejeebu, DO, Adeel Husain, Gastroenterology and Medicine, University of Toledo, Toledo, OH.

P317. Laparoscopic-Assisted Double Balloon Enteroscopy in Persistent Obscure GI Bleeding
Erika M. Lee, MD, Vivek N. Prachand, MD, Carol E. Semrad, MD, Dept. of Medicine, Section of Gastroenterology, and Dept. of General Surgery, The University of Chicago, Chicago, IL.

P318. Application of Cyanoacrylate for Hemostasis in a Patient with Refractory Post-Sphincterotomy Hemorrhage
Olivia C. Forsy, MD, Dawn D. Ferguson, MD, Navtej Buttar, MD, Internal Medicine and Gastroenterology, Mayo Clinic, Rochester, MN.

P319. ERCP Training: Too Little, Too Late and Too Lax
Stacy Tong, MD, Michael Brown, MD, Gastroenterology and Nutrition, Rush University Medical Center, Chicago, IL.

P320. Is ERCP Necessary for Removal of Biliary Stent?
Yevgeniy Ostinsky, MD, Swapa Gayam, MD, Uma Sundaram, MD, Department of Medicine, Division of Digestive Diseases, West Virginia University School of Medicine, Morgantown, WV.

P321. Radiation Exposure in Endoscopic Retrograde Cholangiopancreatography
Vasu Appalaneni, Tammy Glenn, Donald G. Frey, Christopher Lawrence, Brenda J. Hoffman, Digestive Disease Center, Medical University of South Carolina, Charleston, SC.

P322. Community-Based Helicobacter pylori Screening in Patients with Endoscopic Evidence of Peptic Ulcer Disease
William J. Salyers, Jr., MD, Boutros El-Haddad, MD, Ali Mansour, MD, K. James Kallial, PhD, Esteban N. Zayat, MD, Internal Medicine, University of Kansas School of Medicine–Wichita, Wichita, KS.

P323. Combined Endoscopic Assisted Laparoscopic Resection of Upper and Lower Gastrointestinal Adenomas, Carcinoids, and Stromal Tumors—An Effective and More Targeted Resection of GI Tract Lesions
David M. Poppers, MD, Michael D. Lieberman, MD, Felice Schnoll-Sussman, MD, Mark B. Pochapin, MD, Division of Gastroenterology and Hepatology, and Department of Surgery, New York Presbyterian Hospital–Weill Cornell, New York, NY.

P324. Endoscopic Full-Thickness Suturing in the Management of Gastric Wall Defects
Daniel van Renteln, MD, Bettina Riecken, MD, Arthur Schmidt, MD, Karel Caca, MD, Department of Gastroenterology, Klinikum Ludwigsburg, Ludwigsburg, Baden-Württemberg, Germany.

P325. Does Pre-Procedural Counseling by Peers Improve Completion Rates?
Igal Khorshidi, MD, Eleazer Yousefzadeh, MD, Verenice Mackey, RN, David Greenwald, MD, Gastroenterology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

P326. Risk Factors for Hypoxemia during Elective Outpatient Endoscopy
Mohammed A. Qadeer, MD, John J. Vargo, MD, Rocío Lopez, MPH, John A. Dumot, MD, Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

P327. Do “No-Shows” Share Common Characteristics?
S.R.R. Muthavarapu, MD, Mohammad Erfani, MD, Pramod Joseph, MD, Nejat Kiyici, MD, Hilary Hertan, MD, Edward P. Norkus, PhD, Division of Gastroenterology, Our Lady of Mercy Medical Center, Bronx, NY.
P328. Utility of Endoscopy in Evaluating Abnormal Findings of the Gastrointestinal Tract on CT Scan
Muhammad S. Karim, MD, Uma Sundaram, MD, Section of Digestive Diseases, West Virginia University School of Medicine, Morgantown, WV.

P329. Trimming of Migrated Metal Stent for Malignant Colonic Stricture Using Argon Plasma Coagulation (APC)
Kirn V. Rao, MD, Gagan D. Beri, MD, Weizheng Wang, MD, Department of Medicine, University of Medicine and Dentistry of NJ, Newark, NJ.

P330. POSTER WITHDRAWN

P331. Impedance-pH Measuring in Preterm Infants with Apparently Life-Threatening Events
Barbara Bizzarri, MD, Giulio Bevilacqua, Prof, Fabiola Fornaroli, MD, Nicola de’ Angelis, MD, Barbara Magiteri, MD, Gian Luigi de’ Angelis, Prof, Pediatric Gastroenterology Unit, Neonatal Intensive Care Unit, and General Surgery, University of Parma, Parma, Italy.

P332. Prevalence of Gastroesophageal Reflux in Children Aged 2–15 Years Old with Chronic Abdominal Pain: 9 Years Experience
Bashir Chomeili, MD, Pooya Chomeili, MD, Pediatrics, School of Medicine, Jundishapur University of Medical Sciences, and Pediatrics Gastroenterology Ward, Abuzoor Children’s Hospital, Ahwaz, Khuzestan, Islamic Republic of Iran.

P333. Pediatric Patients Have Shorter Lansoprazole Half-Life Than Previously Reported
Jeffrey O. Phillips, PharmD, Jane E. Burnett, Shan H. Siddiqui, Marcela R. Bothwell, MD, Surgery–Applied Research, University of Missouri School of Medicine, Columbia, MO and Rady Children’s Hospital, San Diego, CA.

P334. Pneumatic Dilation with a 35mm Balloon, a Safe and Effective Initial Therapy in Pediatric Achalasia
Inna Novak, MD, Tuvia Marciano, DO, Theresa Guerin, RN, Yolanda Rivas, MD, Pediatric Gastroenterology and Nutrition, Children’s Hospital at Montefiore, Bronx, NY.

P335. POSTER WITHDRAWN

P336. Transient Neonatal Achalasia
Daniel Gelfond, MD, Samira S. Blanchard, MD, Anjali Malkani, MD, Pediatric Gastroenterology, University of Maryland, Baltimore, MD.

P337. Proof That Some Kids Really Do Like Their Vegetables: A New Flavor Option for PEG Solution
Pramodha Muniyappa, MD, Lori Mahajan, MD, Pediatric Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH.

P338. Mismatch Repair Gene Mutations in Iranian HNPCC Families
Katayoun Aghajani, MD, Babak Norrinayer, MD, Mohsen Chiani, MS, Somayeh Ghiasi, MD, Mehrnoosh Tashakori, MD, Navaz Karimianpour, MS, Nasim Rahnamaye Chitsaz, MD, Mahsa Molaei, MD, Farzam Darakhshan, MD, Maurizio Ponz de Leon, MD, Mohammad Reza Zali, MD, FACG, Research Center for Gastroenterology and Liver Diseases, Shaheed Beheshti Medical University, Tehran, Islamic Republic of Iran and Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy.

P339. Role of Tumor Necrosis Factor Gene Polymorphism (-308 and -238) in Colorectal Cancer Susceptibility
Mehrnosha Tashakori, MD, Babak Norrinayer, MD, Azadeh Safaei, MS, Faramarz Darakhshan, MD, Mohammad Reza Zali, MD, FACG, Research Center for Gastroenterology and Liver Diseases, Shaheed Beheshti Medical University, Tehran, Islamic Republic of Iran.

P340. Mechanisms of Polyethylene Glycol (PEG) Anti-Proliferative Effects: Implications for Colon Cancer Chemoprevention
Sabana Siddiqi, MD, Jennifer Koetsier, Mary Nyhuis, Ramesh Wali, PhD, Dhananjay Kunte, PhD, Hemant K. Roy, MD, Research, Evanston Northwestern Healthcare, Evanston, IL.

P341. Should Colonoscope Withdrawal Time Recommendations Be Adjusted for Patient or Procedure Factors?
Audrey H. Calderwood, MD, Edwin J. Lai, MD, Gheorghe Doros, PhD, Sauri Gupta, Brian C. Jacobson, MD, Gastroenterology, Boston University Medical Center, and Biostatistics, Boston University, Boston, MA.

P342. Findings on Surveillance Colonoscopy in Patients with Low-Risk Polyps on Initial Colonoscopy
Neli Mehta, MD, Josephine Miller, MD, Michael Feldman, MD, Emma Furth, MD, Gregory Ginsberg, MD, James D. Lewis, MD, University of Pennsylvania, Philadelphia, PA.

P343. Colorectal Cancer Screening in HIV-Infected Patients: Are They Still Being Ignored?
Shahzad Iqbal, MD, Veron Brown-McDonald, MD, Mehjabin Zahir, MD, Hashem Vahabzadeh-Monshie, MD, Bishnu Sapkota, MD, Rekha Khurana Khurana, MD, Eric A. Jaffe, MD, Maurice A. Cerulli, MD, FACG, Gastroenterology & Hepatology, NY Methodist Hospital, Brooklyn, NY and Internal Medicine, Interfaith Medical Center, Brooklyn, NY.

P344. Colon Cancer Screening at an HIV Outpatient Clinic: 2000-2006
Ryan M. Ford, MD, Matthew M. McMahon, MD, Jeffrey L. Lennox, MD, Kamil Obideen, MD, Mohammad A. Wehbi, MD, Division of Digestive Diseases and Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA.

P345. Feasibility and Results of a Colorectal Cancer Screening Program Targeting Uninsured Patients
Gregory A. Cote, MD, Laura Michalski, BS, Christian S. Jackson, MD, James Webster, MD, Babs Waldman, MD, Robert M. Craig, MD, Gastroenterology, Northwestern University, Chicago, IL and Lederman Family Health Center, Chicago, IL.

P346. Open Access Colonoscopy: An Acceptable Strategy To Boost Colon Cancer Screening Rates
Ian Logan, MD, Amar Al-Juburi, MD, Michele Limognes, Jacob Wegelin, PhD, Juan Garcia, MD, Department of Internal Medicine, Division of Gastroenterology and Division of Biostatistics, UC Davis Medical Center, Sacramento, CA.

P347. Strategies To Improve Scheduling and Completion of Screening Colonoscopy in a VA Setting
Francisco C. Ramirez, MD, Samuel F. Castillo, MD, Felix W. Leung, MD, Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix, AZ and Medicine & Research, Sepulveda ACC, VAGLAHS, UCLA, North Hills, CA.
**ESOPHAGUS**

**P348. PPI Efficacy in Overweight/Obese Patients with Erosive GERD: Rabeprozole (RAB) 20 mg vs Omeprazole (OME) 20 mg**

Brian C. Jacobson, MD, Byron DeLemos, MD, Yijun Sun, PhD, Jim Xiang, PhD, John LoCoco, MBA, Honglan Li, PhD, Stefania Casalini, Boston University Medical Center, Boston, MA; Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ; Eisai Inc., Woodcliff Lake, NJ and Janssen-Cilag, Cologno Monzese, Italy.

**P349. PillCam ESO for Evaluating the Esophagus in the Workplace: Making It Even Easier To Swallow**

Daniel S. Mishkin, MD, CM, Joan Pemberton, RN, James E. Scharback, MD, Sandra L. Marwill, MD, MPH, Gastroenterology, Boston University, Boston, MA and Internal Medicine, Gillette Medical Department, South Boston, MA.

**P350. Pantoprazole is Significantly More Effective in Relieving GERD Symptoms Than Esomeprazole**

György Rumi, MD, Luciana Camacho Lobato, MD, Bernd Rosenstock, PhD, Hartmut Heinze, MD, Internal Medicine, Kapos Mór Oktatókórház, Kaposvár, Hungary; Gastroenterology, Hosp. Sao Paulo da Univ. Federal de S.P., Sao Paulo-SP, Brazil; Clinical Operations and Clinical Development, ALTANA Pharma AG, Konstanz, Germany.

**P351. Are There Any Motility Disturbances in Eosinophilic Esophagitis?**

Savio Reddymasu, MD, Mojaba Oyae, MD, Paul Hyman, MD, Daniel Buckles, MD, Scott Grisolano, MD, Richard McCullum, MD, Medicine and Pediatrics, Kansas University Medical Center, Kansas City, KS.

**P352. High Prevalence of Eosinophilic Esophagitis in Inflammatory Bowel Disease**

Souheil Gebara, MD, Robert M. Truding, MD, Saleha Khanum, MD, Sandra L. Hodges, RN, Chung-Ho Chang, MD, Neal S. Goldstein, MD, Pediatrics and Anatomic Pathology, William Beaumont Hospital, Royal Oak, MI.

**P353. Gender-Related Difference in Composition of Secretion from Esophageal Submucosal Mucous Glands, in Response to Stimulation of Serotonergic Pathway, in Patients with Gastroesophageal Reflux Disease**

Marek Majewski, MD, Tomasz Jaworski, MD, Irene Sarosiek, MD, Sandra Sostarich, Katherine Roesser, Stanley Edlatch, PhD, Richard W. McCullum, MD, Grzegorz Wallner, MD, PhD, Jerzy Sarosiek, MD, PhD, GI Research Laboratory, Motility Center, KUMC, Kansas City, KS; Epidemiology, UMSOM, Kansas City, MO and Surgery, Medical University, Lublin, Poland.

**P354. Current Trends in Clinical Utility of Esophageal Motility Studies**

Vaibhav Mehendiratta, MD, Anthony J. DiMarino, MD, Sidney Cohen, MD, Department of Medicine, and Department of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA.

**P355. Measurement of Lower Esophageal Sphincter (LES) Characteristics during Esophageal Manometry Does Not Differ with Severity of Ineffective Esophageal Motility**

Vishal Jain, MD, Neeraj Sharma, MD, Marcelo Vela, MD, Donald Castell, MD, Department of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC.

**P356. Ineffective Esophageal Motility (IEM) and Prolonged Nocturnal Gastroesophageal Acid Reflux**

Monjur Ahmed, MD, Girma Mesheha, MD, Frezgi Kebreab, MD, Fikadu Gebreyesus, MD, Internal Medicine, Marshall University, Huntington, WV.

**P357. Comparison of Serum Pepsinogens between Patients with and without Reflux Esophagitis**

Yoshihisa Urita, Toshiyasu Watanabe, Tadashi Maeda, Kaoru Domon, Susumu Ishihara, Tomohiro Arita, Asuka Nakayama, Makie Nanami, Tatsuhito Yamamoto, Akiko Kugahara, Takamasa Ishii, Hirohito Kato, Kazuo Hike, Noriko Hara, Yoshiko Honda, Shuji Watanabe, Kazushige Nakanishi, Nagato Shimada, Motonobu Sugimoto, Kazumasa Miki, Department of General Medicine and Emergency Care, Division of Gastroenterology and Hepatology, and Department of Hematology, Toho University, Tokyo, Japan.

**P358. Factors Predictive of a Poor Outcome in Patients with Esophageal Atresia**

Julie Castilloux, MD, Angela Noble, MD, Chanei Belanger, Christophe Faure, MD, Pediatric Gastroenterology, Hospital Ste-Justine, Montreal, QC, Canada.

**P359. Esophageal Histology in Patients with Gastroesophageal Reflux Disease (GERD) and Symptom Resolution after 4 Weeks of Esomeprazole Treatment**

Wilfred M. Weinstein, MD, John T. Monyak, PhD, Debra G. Silberg, MD, FAGC, David Geffen School of Medicine at UCLA, Los Angeles, CA and AstraZeneca LP, Wilmington, DE.

**P360. The Effect and Timing of Food on the Pharmacokinetics and Pharmacodynamics of TAK-390MR (Modified Release): Evidence for Dosing Flexibility**

R.D. Lee, PhD, M. Valky, PhD, J. Wu, PhD, S. Atkinson, PhD, TAP Pharmaceutical Products Inc, Lake Forest, IL.

**P361. Derivation and Validation of a Short Reflux Symptom Questionnaire (ReQuest in Practice™) in Patients with GERD**

Greg Rubin, MD, Peter Uebel, MD, Amelia Brimo-Hayek, MD, Karl-Heinz Hey, MD, Hubert Doerfler, MD, Robert C. Heading, MD, Primary Care, University of Sunderland, United Kingdom; Private Practice, Ludwigshafen, Germany; Private Practice, Dortmund, Germany; Private Practice, Paderborn, Germany; Gastroenterology, ALTANA Pharma, Konstanz, Germany and Gastroenterology, Royal Infirmary, Glasgow, United Kingdom.

**P362. Nocturnal Gastric Acidity and Nocturnal Esophageal Acidity Are Lower with Immediate-Release Omeprazole Than with Lansoprazole or Esomeprazole in GERD Patients Treated with a Proton Pump Inhibitor**


**P363. Clinical Utility of Impedance in Evaluation of Noncardiac Chest Pain**

Mary Kovalak, MD, Kristen Thomas, BS, Mae Go, MD, Fatima Gangotena, MD, John Fang, MD, Kathryn Peterson, MD, Division of Gastroenterology, University of Utah, and Division of Gastroenterology, VA Medical Center, Salt Lake City, UT.

**P364. Rebamipide Improves Salivary Gland Function and Saliva Transit to the Distal Esophagus**

Yoshihisa Urita, Toshiyasu Watanabe, Tadashi Maeda, Kaoru Domon, Susumu Ishihara, Tomohiro Arita, Asuka Nakayama, Makie Nanami, Tatsuhito Yamamoto, Akiko Kugahara, Takamasa Ishii, Hirohito Kato, Kazuo Hike, Noriko Hara, Yoshiko Honda, Shuji Watanabe, Kazushige Nakanishi, Nagato Shimada, Motonobu Sugimoto, Kazumasa Miki, Department of General Medicine and Emergency Care, Division of Gastroenterology and Hepatology, and Department of Hematology, Toho University, Tokyo, Japan.

**P365. TAK-390MR vs. Lansoprazole (LAN) for Maintenance of Drug Concentration above a Threshold Which Corresponds to Higher %-Time pH>4**

J. Wu, PhD, M. Valky, PhD, G. Witt, MS, D. Mulford, PhD, TAP Pharmaceutical Products Inc, Lake Forest, IL.
P366. Esophageal Impedance Detection of Cycling, a Specific Finding in GERD
Ryan D. Madanick, MD, Nicole L. Cheng, PA-C, Sheila Crawford, RN, Douglas Morgan, MD, Nicholas J. Shaheen, MD, Center for Esophageal Diseases and Swallowing, Division of GI/Hepatology, and GI Motility Laboratory, UNC Hospitals, Chapel Hill, NC.

P367. What Is the Truth? Sleep Disturbance as Assessed by Investigators or a Validated Instrument (ReQuest™) in Patients with GERD
Gerald Holtmann, MD, Richard Hunt, MD, Peter Katelaris, MD, Peter Berghoefer, PhD, Hubert Doerfler, MD, Jan Tack, MD, Gastroenterology, Royal Adelaide Hospital, Adelaide, SA, Australia; Gastroenterology, McMaster University, Hamilton, ON, Canada; Gastroenterology, University of Sydney, Concord Hospital, Sydney, Australia; Gastroenterology, ALTANA Pharma AG, Konstanz, Germany and Gastroenterology, University of Leuven, Leuven, Belgium.

P368. Rabeprazole Sodium 20 mg BID Improves Symptoms in Patients with Chronic Persistent Asthma
Frank K. Friedenberg, MD, Kellie Simmons, MSN, Amiya Palit, MD, Gastroenterology, Temple University School of Medicine, Phila, PA.

P369. Multichannel Intraluminal Impedance (MII) Can Make a Diagnosis of Achalasia; A Comparison of MII in Achalasia Versus Normals
Harsh V. Iyer, MD, Girish Anand, MD, Matthew Gideon, Philip O. Katz, MD, Department of Internal Medicine, Albert Einstein Medical Center, Philadelphia, PA and Department of Gastroenterology, Albert Einstein Medical Center, Philadelphia, PA.

P370. Objective Documentation of the Link between Gastroesophageal Reflux Disease and Obesity
Shahin Ayazi, MD, Peter F. Crookes, MD, Christian G. Peyre, MD, Jeffrey A. Hagen, MD, Jessica M. Leers, MD, Andrew L. Tang, MD, Nuttha Ungnapatanin, MD, Steven R. DeMeester, MD, John C. Lipham, MD, Tom R. DeMeester, MD, Surgery, University of Southern California, Los Angeles, Ca.

P371. Predictors of Heartburn (HB) Resolution in Patients with Gastroesophageal Reflux Disease (GERD) Symptoms
Roy C. Orlando, MD, FACC, John T. Monyak, PhD, Debra G. Silberg, MD, FACC, Tulane University Health Sciences Center, New Orleans, LA and AstraZeneca LP, Wilmington, DE.

P372. Eotaxin-3 Immunofluorescence in Adults with Dysphagia: Is There More to Eosinophilic Esophagitis Than Meets the Microscopic Eye?
Edward J. Frech, Scott K. Kuwada, Mae F. Go, Kristen L. Thomas, Frederic C. Clayton, Phillip Gray, Gerald J. Gleich, John C. Fang, Kathryn A. Peterson, GI, Pathology and Dermatology, UUMC, and GI, VAMC, Salt Lake City, UT.

P373. Predictors of Erosive Esophagitis in Patients with Symptoms of Gastroesophageal Reflux Disease (GERD)
Roy C. Orlando, MD, FACC, John T. Monyak, PhD, Debra G. Silberg, MD, FACC, Tulane University Health Sciences Center, New Orleans, LA and AstraZeneca LP, Wilmington, DE.

P374. Prevalence and Impact of Co-Morbid Psychological Distress on Response to PPI Therapy in Patients with GERD
William D. Chey, MD, Borko Nojko, MD, Joel R. Rubenstein, MD, Susan A. Adlis, MS, Michael J. Shaw, MD, Division of Gastroenterology, University of Michigan Health System, Ann Arbor, MI and Park Nicollet Institute, Minneapolis, MN.

P375. A PPI Is a PPI! Similar Results for Continuous Reflux on Therapy
★ 2007 ACG Presidential Poster Award Recipient
Amit Agrawal, MD, Neeraj Sharma, MD, Donald O. Castell, MD, Department of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC.

STOMACH

P376. Effect of Prokinetics (PK) on Gastric Emptying (GE) and Symptoms in Placebo-Controlled Trials of Gastroparesis: A Systematic Analysis
Preet Bagi, MD, Michael D. Crowell, PhD, Nicholas J. Talley, MD, Michael P. Jones, MD, Division of Gastroenterology, Northwestern University, Chicago, IL; Division of Gastroenterology, Mayo Clinic, Rochester, MN and Division of Gastroenterology, Mayo Clinic, Scottsdale, AZ.

P377. T Regulatory Cells Are Abnormal in Gastroparesis (GP)
Vikram Taruga, MD, William Johnson, PhD, Mark Runnels, MS, Phillips Jenkins, MD, Gailen Marshall, MD, PhD, Thomas Abell, MD, Dept. of Digestive Diseases, University of Mississippi Medical Center, Jackson, MS.

P378. Relationship of Symptoms to Quality of Life in Patients with Gastroparesis
Pooja Sukthanki, MD, Siva Doma, MD, Henry P. Parkman, MD, Medicine, Temple University School of Medicine, Philadelphia, PA.

P379. Comparisons of Alimentary Tract Transit Times among Normal Subjects from Two Multicenter Trials Using SmartPill Wireless pH/Pressure Recording Capsule: Its Clinical Implication
I. Sarosiek, MD, J. Sarosiek, MD, S. Rao, MD, H. Parkman, MD, B. Kuo, MD, J. Lackner, PsD, L. Katz, MD, M. Sitrin, MD, W. Chey, MD, W. Hasler, MD, J. DiBaise, MD, J. Wo, MD, K. Koch, MD, J. Semler, PhD, R. McCallum, MD, KUMC, Kansas City, KS; UI, Iowa City, IA; TU, Philadelphia, PA; MGH, Boston, MA; UB, Buffalo, NY; MC, Scottsdale, AZ; UL, Louisville, KY; UM, Ann Arbor, MI; WFU, Winston Salem, NC and The SP Corp., Buffalo, NY.

P380. The Effect of Tegaserod on Gastric Accommodation and Gastric Emptying in Patients with Functional Dyspepsia and Comparison with Domperidone
Mohamed N.A. Al-Aghbar, PhD, Internal Medicine, Basel Medical Centre, Abu Dhabi, United Arab Emirates.

P381. Implanted Gastric Pacemaker for the Treatment of Diabetic Gastroparesis: A University Hospital Experience
Rassa Shahidzadeh, MD, John D. Mellingier, MD, Bruce V. MacFadyen, MD, Ayaz J. Chaudhary, MD, FACC, Section of Gastroenterology/Hepatology and Section of Gastrointestinal Surgery, Medical College of Georgia, Augusta, GA.

P382. A Cost Analysis of GERD and Dyspepsia in Iran
Mohammadreza Rezailashkajani, MD, Deiniz Roshandel, MD, Sepideh Shafaei, MD, Mohammad Reza Zali, MD, FACC, Health Informatics, Research Center for Gastroenterology and Liver Disease, Tehran, Islamic Republic of Iran.

P383. Assessment of Reasons for Non-Adherence to Nonvariceal Upper Gastrointestinal Bleeding (NVUGIB) Guidelines
Sean M. Hayes, PsyD, Ian A. Hawes, BSP, Martin Dawes, MD, Alan Barkun, MD, Performance and Education Research Division, AXDEV Group Inc, Canada; Medical Affairs, AstraZeneca Canada Inc, Canada; Department of Family Medicine and Division of Gastroenterology, McGill University, Canada.
P384. Novel Biopsy Technique for Diagnosis of Gastric Subepithelial Lesions
Shashin Shah, MD, Mark J. Sterling, MD, Division of Gastroenterology and Hepatology, UMDNJ-New Jersey Medical School, Newark, NJ.

P385. Clinical Presentation and Endoscopic Management of Dieulafoy’s Lesions in an Urban Community Hospital
SriKrishna Nagri, Sury Anand, Yashpal Arya, Gastroenterology, Brooklyn Hospital Center, and Gastroenterology, Wyckoff Heights Medical Center, Brooklyn, NY.

P386. A Retrospective Study on the Role of Helicobacter pylori in Positive Fecal Occult Blood Tests in Hispanic Veterans
Manuel Salcedo, MD, Doris H. Tor, MD, Javier Pou, MD, Carol L. Torres, MD, Gastroenterology, VA Caribbean Healthcare System, San Juan, Puerto Rico.

P387. Fasting Gastric Leptin Levels Are Elevated in Diabetics Independent of BMI
Benjamin Young, MD, Jatin Roper, MD, Michelle Mourad, MD, Asalia Z. Olives de Perez, MS, Guillermo I. Perez-Perez, DSc, Zhiheng Pei, MD, PhD, Martin J. Blaser, MD, Fritz Francois, MD, Sanjiv J. Agarwal, MD, MSc, Medicine, NYU School of Medicine, New York, NY; Medicine, University of California San Francisco, San Francisco, CA and Medicine, Beth Israel Deaconess Medical Center, Boston, MA.

P388. Ischemic Gastritis; an Unusual Cause of Abdominal Pain and Gastric Ulcers
Steven Kaptik, MD, Yasser Jamal, MD, B. Kay Jackson, MD, Claudio R. Tombazzi, MD, Medicine, University of Tennessee, Memphis, TN.

P389. Hemoconcentration Alone Is an Unreliable Predictor of Mortality in Acute Pancreatitis
★ 2007 ACG Presidential Poster Award Recipient
Bechien U. Wu, MD, Richard S. Johannes, MD, Xiaowu Sun, PhD, Peter A. Banks, MD, Division of Gastroenterology, Center for Pancreatic Disease, Brigham and Women’s Hospital, Boston, MA and Cardiac Health-MediQual, Marlborough, MA.

P390. Admission Apache II for Prediction of In-Hospital Mortality in Acute Pancreatitis
Bechien U. Wu, MD, Richard S. Johannes, MD, Xiaowu Sun, PhD, Peter A. Banks, MD, Division of Gastroenterology, Center for Pancreatic Disease, Brigham & Women’s Hospital, Boston, MA and Cardiac Health-MediQual, Marlborough, MA.

P391. Endoscopic Drainage of Pancreatic Fluid Collections Using Fully Covered Metallic Stents (CSEMS): A Feasibility Study
Michel Kahaleh, MD, Jayant P. Taleja, MD, Diklar Makola, MD, Tanya D. Morris, RN, Vanessa M. Shami, MD, Paul Yeaton, MD, Digestive Health Center, University of Virginia, Charlottesville, VA.

P392. Perceived Cancer Risk among Patients with Pancreatic Cysts
Ketan Kulkarni, MD, Savreet Sarkaria, MD, Mark Pochapin, MD, Felice Schnoll-Sussman, MD, Division of Gastroenterology and Hepatology, Weill Cornell Medical Center, New York, NY.

P393. Utility of the SPYGLASS Cholangiopancreatoscope (SCPS): An Initial Series of 26 Cases at a Tertiary Care Center
Diego I. Kuperschmit, MD, Franklin E. Kasmin, MD, Seth A. Cohen, MD, Jerome H. Singel, MD, Gastroenterology, Beth Israel Medical Center, New York, NY.

P394. Dissociation in the Sensitivity of Magnetic Resonance Cholangiopancreatography in the Diagnosis of Biliary and Pancreatic Diseases
Emad Qayed, MD, Qiang Cai, MD, FACP, Department of Medicine Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA.

P395. Multiple Biliary Stenting—An In Vitro Comparison Using a Novel ERCP Mechanical Simulator
Joseph W. Leung, MD, Brian Lim, MD, Chhaya Hasyagar, MD, Robert Wilson, BVD, Felix W. Leung, MD, Gastroenterology, Sacramento VA Medical Center, Mather, CA; Division of Gastroenterology and Hepatology, UC Davis Medical Center, Sacramento, CA and Gastroenterology, Sepulveda ACC, VAGLAHCS and David Geffen School of Medicine at UCLA, North Hills, CA.

P396. Trends and Experiences with ERCP and MRCP in Maryland
Josh Forman, MD, Eric Goldberg, MD, Peter Darwin, MD, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD.

P397. Trainers’ Assessment of Mechanical Simulator Practice in ERCP Training
Brian S. Lim, MD, Joseph W. Leung, MD, Robert Wilson, BVD, Felix Leung, MD, Gastroenterology, UC Davis Med Cntr, Sacramento, CA; Sacramento VA Med Cntr, Mather, CA and Sepulveda ACC/David Geffen School of Medicine at UCLA, Sepulveda, CA.

P398. Efficacy and Safety of ERCP in the Pediatric Population When Performed by Adult Gastroenterologists: A 6 Year Review
Simona Meca, MD, Brian Schwender, MD, Ari Wiesen, MD, Bernard Stark, MD, Sideridis Kostas, DO, Simmy Bank, MD, Gastroenterology, Long Island Jewish Medical Center, New Hyde Park, NY.

P399. Detection of Patients at Increased Risk of Pancreatic Cancer Utilizing Electronic Databases
Brandon A. Conkling, DO, James T. Sing, DO, Richard A. Erickson, MD, Gastroenterology, Scott & White Hospital, Texas A&M Health Sciences Center, Temple, TX.

P400. Comparison of Cyst Fluid DNA Analysis Utilizing Two Different DNA Interpretations
Mustafa Alnournou, MD, Sirish Sanaka, MD, Jeffrey Tokar, MD, Oleh Haluszka, MD, Fox Chase Cancer Center, Philadelphia, PA.

P401. Pancreatic Cyst Size and Malignancy: An Endoscopic Ultrasound Perspective
Jayaprakash Sreenarasaiah, MD, Luis A. Armstrong, MD, Luis F. Lara, MD, Shou J. Tang, MD, Division of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, TX.

P402. Inferior Vena Cava Compression Due to Biloma: A Case Report
Shailaja Jamma, MD, Michael Aref, MD, Andrew Batey, MD, Thomas Huber, MD, Internal Medicine, University of Illinois at Urbana Champaign, IL and Gastroenterology, UIUC, IL.

P403. Metastatic Cholangiocarcinoma Masquerading as Mesenteric Ischemia
Andrew N. Pearson, MD, Rassa Shahidzadeh, MD, Vinayasekhara Reddy, MD, Section of Gastroenterology, Medical College of Georgia, Augusta, GA.

P404. Comparison of Abdominal Ultrasound and ERCP in Determining the Etiology of Obstructive Jaundice
Arif Amir Nawaz, FACP, FACG, Shahid Sarwar, FCPS, Salwa Hussain, MBBS, Atiqa Batul, MBBS, Khubaih Shahid, FCPS, Gastroenterology and Hepatology, Fatima Memorial Hospital Shadman, Lahore, Punjab, Pakistan.
P405. A Single Institution’s Initial Experience with Spyglass™ in the Diagnosis and Management of Biliary Disease during ERCP
Karen R. Canlas, MD, Malcolm S. Branch, MD, Paul S. Jowell, MD, Darren A. Pavey, MD, Jorge V. Obando, MD, John A. Evans, MD, Department of Gastroenterology, Duke University Medical Center, Durham, NC.

P406. A Patient with Choledochal Cyst
Nausheer A. Khan-Bitni, MD, Kaleem M. Rizvon, MD, Omer K. Masood, MD, Paul J. Mustacchia, MD, Gastroenterology, Nassau University Medical Center, East Meadow, NY.

Nilesh P. Patel, MD, Jason D. Conway, MD, MPH, James O. Cappellari, MD, Kathleen G. Gibson, Pathology, Wake Forest University School of Medicine, Winston-Salem, NC and Internal Medicine, Section on Gastroenterology, Wake Forest University School of Medicine, Winston-Salem, NC.

P408. Double Balloon Enteroscopy, Virginia Commonwealth University Health System Experience

**2007 ACG Presidential Poster Award Recipient**
Amrita Sethi, MD, Doumit S. BouHaidar, MD, Bimaljit Sandhu, MD, Alvin Zfass, MD, Gastroenterology, Virginia Commonwealth University, Richmond, VA.

P409. POSTER WITHDRAWN

P410. Magnetic Resonance Imaging (MRI) of the Small Intestine: Utility of This Modality in a Large Urban Community Hospital
Nalini K. Sharma, MD, Dana A. Sloane, MD, Jennifer Lee, MD, I.D. Shocket, MD, Julio A. Salcedo, MD, J.D. McFadden, MD, Gastroenterology/Medicine and Radiology, Washington Hospital Center, Washington, DC.

P411. Enteroscopy Using the New 47F Discovery SB and Fujinon Entroscope
Paul A. Akerman, MD, Daniel Cantero, MD, Jose Avila, MD, University Gastroenterology, Providence, RI; Hospital Francais, Ascuncion, Paraguay and Rhode Island Hospital, Providence, RI.

P412. Mantle Cell Lymphoma of the GI Tract: Is It Distinctive from Other Gastrointestinal Lymphomas?
Adrienne LaJoie, MD, Williamson B. Strum, MD, Gastroenterology and Hepatology, Scripps Clinic and Research Institute, La Jolla, CA.

P413. Clostridium difficile Small Bowel Enteritis
Harry A. Lazarte, MD, Syed Bin-Sagheer, MD, Kelli Peterson, MD, Department of Gastroenterology, Creighton University Medical Center, Omaha, NE.

P414. Continuous Intravenous Administration of Teduglutide (ALX-0600), a Glucagon-like Peptide-2 (GLP-2) Analog Induces Intestinotrophic Activity
Lidia L. Demchynshyn, Nathan Teuscher, David S. Wells, Dept of Drug Discovery, NPS Pharmaceuticals, Toronto, ON, Canada.

P415. Pharmacokinetics and Safety Profile of a Range of Teduglutide Doses Given for Eight Days in Healthy Volunteers
Nanko Pehlivanov, MD, John Wallens, Jay Yang, PhD, Jane Cyran, PhD, David Wells, PhD, NPS Pharmaceuticals, Parsippany, NJ.

P416. The Significance of Antineutrophil Cytoplasmic Antibody in Adult Patients with Henoch-Schönlein Purpura Presenting Mainly with Gastrointestinal Symptoms
Yan Zhang, MD, Yongkang Wu, MSB, Mattew Ciocarpa, MD, Qin Ouyang, MD, Division of Gastroenterology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Department of Laboratory Medicine2, West China Hospital of Sichuan University, Chengdu, Sichuan, China and Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO.

P417. Kaposi’s Sarcoma Presenting as Small Bowel Intussusception: Case Presentation and Review of the Literature
Khursheed Haider, MD, Vijay Nkhate, MD, Shahid Ahmed, MD, Victoria Bengualid, MD, Internal Medicine, St. Barnabas Hospital, Bronx, NY.

P418. Revisiting Capsule Endoscopy in the Diagnosis of Small Bowel Malignancy
Anthony Aghenta, MD, Ayodele Osowo, MD, Tarun Kohthi, MD FACG, FACP, Internal Medicine, Unity Health System, Rochester, NY.

P419. Etiological, Clinical and Radiological Profile of Suppurative Lesions in Solid Abdominal Visceras

P420. Factors Associated with Treatment Failure in Patients with Genotype 3 Hepatitis C Virus Infection
Xinyu Zhao, MD, Gulam M. Khan, MD, Tinghui Hsieh, MD, Kumaravel Perumalsamy, MD, Michael Bernstein, MD, Kadiwarel Iswara, MD, Scott Tenner, MD, Xiaoli Ma, MD, Jianjun Li, MD, Gastroenterology, Maimonides Medical Center, Brooklyn, NY and Gastroenterology and Hepatology, Temple University, Philadelphia, PA.

P421. Statins and Hepatitis C Therapy: A Retrospective Analysis in a Veteran Medical Center
Andrew Simpson, MD, Kamil Obdeen, MD, Samir Parekh, MD, Sakaria Sonali, MD, Patel Minal, MD, Kristina Chacko, MD, Mohamad Wehbi, MD, Medicine/Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA.

P422. Safety of Bioelectrical Impedance Analysis in Evaluation of Patients with Liver Cirrhosis and Relation with Severity of Disease
Daniele Torres, MD, Gaspare Parrinello, MD, Salvatore Paterna, MD, Pietro Di Psquale, MD, Giuseppe Licata, MD, Internal Medicine Department, University Hospital, Palermo, Italy.

P423. Single Dose of Infliximab Is Safe and Effective in Severe Alcoholic Hepatitis: An Open Label Study
Praveen Sharma, MD, DM, Ashish Kumar, MD, DM, Ajay Kumar, MD, Hitendra Garg, MD, Barjesh C. Sharma, MD, DM, Shiv K. Sarin, MD, DM, Gastroenterology, G B Pant Hospital, New Delhi, India.

P424. Liver Transplant Patients with Hepatitis C Who Do Not Respond to Pegylated Interferon Plus Ribavirin Do Respond to Consensus Interferon Plus Ribavirin
Shobha N. Joshi, MD, Fredric G. Regenstein, MD, Abdominal Transplant, Tulane University School of Medicine, New Orleans, LA.
P425. MyD88-Dependent Bone Marrow-Derived Cells Mediate Sensitization to Lipopolysaccharide-Induced Acute Liver Injury
Arumugam Velayutham, MD, Istvan Hritz, MD, Angela Dolganiuc, MD, Pranoti Mandrekar, PhD, Evelyn Kurt-Jones, MD, Gyongyi Szabo, MD, Department of Medicine, Division of Gastroenterology, University of Massachusetts Medical School, Worcester, MA.

P426. Effects of Pentoxifylline and Weight Reduction on Liver Histology in Patients with Non-Alcoholic Steatohepatitis (NASH)
Ajay Kumar, MD, Ashish Kumar, MD, DM, Puja Sekhjua, MD, Deepak K. Singh, MD, Barjesh C. Sharma, MD, DM, Shiv K. Sarin, MD, DM, Gastroenterology, and Pathology, G B Pant Hospital, New Delhi, Delhi, India.

P427. Cryptococcus and Cirrhosis. Have We Been Missing the Association?
Rajasekhar R. Mummid, MD, Krishna S. Kasturi, MD, Audrey Nguyen, MD, Division of Gastroenterology, The University of Texas Medical Branch, Galveston, TX.

P428. To Investigate the Utility of a Week-4 Virological Response for SVR Prediction in Hepatitis C Virus (HCV) Genotype 3 Patients Treated with Pegylated Interferon and Ribavirin for 24 Weeks
Shamail Zafar, MBBS, FCPS, Israr Ul Haque Toor, MBBS, FCPS, Nusrat Ullah Chaudhry, MBBS, MRCP, Department of Gastro-Enterology & Hepatology, Lahore Medical & Dental College, Lahore, Punjab, Pakistan.

P429. Adequacy of Liver Biopsy Specimens Performed by Gastroenterologists and Radiologists
Muhammad Y. Sheikh, MD, Muhammad H. Bashir, MD, Jasjit Singh, MBBS, Farheen A. Khan, Humaira Sadiq, MD, Mandeep Singh, MD, William C. Pitts, MD, Kandarp K. Shah, MD, Division of Gastroenterology and Hepatology, University of California, San Francisco-Fresno Education Program, Fresno, CA.

P430. The APR Is a Fair Estimator of Fibrosis in NALFD, and May Be Enhanced by the Use of Age
Karen O. Steffer, MD, Shu-Yuan Xiao, MD, John Petersen, PhD, Ned Snyder, MD, Internal Medicine, and Pathology, University of Texas Medical Branch, Galveston, TX.

P431. Screening, Diagnosis and Treatment Strategies Used by the Gastroenterologists in Ohio for NASH/NAFLD
Thomas Sodeman, MD, Isam Daboul, MD, Charles Filipiak, MD, Sirin Hejeebeu, DO, Vikas Ghai, MD, Department of Gastroenterology and Department of Medicine, University of Toledo, Toledo, OH.

P432. Non-Invasive Predictors of Large Varices in Patients Hospitalized with Gastroesophageal Variceal Hemorrhage
Faisal W. Ismail, MD, Hasnain A. Shah, FRCP, Saeed S. Hamid, FRCP, Shahab Abid, MD, Wasiq Jafari, FRCP, Medicine, Aga Khan University Hospital, Karachi, Sind, Pakistan.

P433. Leucocyte Esterase Reagent Strips for the Diagnosis of Spontaneous Bacterial Peritonitis: A Systematic Review
Anastasios Koulouzidis, MD, MRCP, Grigoris I. Leoniadis, MD, PhD, Elmuhtady Said, MBBS, Jaber Gasem, MBBCch, MRCP, Athar A. Saeed, FRCP, Eystatros Maltezos, MD, PhD, Gastroenterology, Bangor Hospital, Bangor, North Wales, UK; Gastroenterology, Medical School 'Democritus' University, Alexandropolis, Thrace, Greece and Gastroenterology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, UK.

P434. The Effect of Statins on PEG-Interferon/Ribavirin Treatment for Chronic Hepatitis C

P435. Predictive Values of HOMA and Metabolic Syndrome by Different Definitions in Identifying NASH and Liver Fibrosis in a Population with High Prevalence of Obesity and Diabetes
Ibrahim A. Hanoun, MD, Tamal Bhattacharya, MD, Hesham M. Elgouhari, MD, Nizar Z. Zain, MD, Arthur J. McCullough, MD, Ariel E. Feldstein, MD, Internal Medicine, Cell Biology, Gastroenterology and Hepatology, and Pediatric Gastroenterology and Cell Biology, Cleveland Clinic, Cleveland, OH.

P436. Anticoagulation Therapy Using with Danaparoid Sodium for Portal Venous Thrombosis
Ryushi Shudo, MD, Yasuyuki Yazaki, MD, Mitsunori Honda, MD, Kenji Sugawara, MD, Shuichi Maeda, MD, Haruyasu Yoshizaki, MD, Shigeto Muranaka, MD, Akihito Imada, MD, Gastroenterology, Kurosawa Hospital, Obihiro, Hokkaido, Japan and Gastroenterology, Kobayashi Hospital, Kitami, Hokkaido, Japan.

P437. Detection of Caspase Activity in the Plasma of Patients with Various Liver Diseases as a Novel Biomarker of Hepatic Fibrosis
Hesham M. Elgouhari, Nizar Z. Zain, Lisa Yerian, Ibrahim A. Hanoun, Rocio Lopez, Ariel E. Feldstein, Gastroenterology, Anatomic Pathology, Biostatistics and Epidemiology, Internal Medicine, and Pediatric Gastroenterology and Cell Biology, Cleveland Clinic, Cleveland, OH.

P438. Large Volume Paracentesis Can Be Performed Safely by a Nurse Practitioner and Can Reduce Physician Work-Load in a Busy GI Practice
Kandarp Patel, DO, Erin Tharalson, NP, Tony Merill, Nooman Gian, MD, FACG, Department of Gastroenterology, Carl T. Hayden VAMC, Phoenix, AZ and Department of Medicine, Good Samaritan Regional Medical Center, Phoenix, AZ.

P439. In Hospital Mortality Rates of Patients Admitted for Esophageal Variceal Hemorrhage over a 15 Year Period: MELD as a Predictor
Amanda D. Fehring, DO, Toan Ngyuen, MD, Kenneth D. Rothstein, MD, Department Gastroenterology & Hepatology, Albert Einstein Medical Center, Philadelphia, PA.

P440. High MELD Score and Type of Immunosuppression Are Predictors of Gastrointestinal Bleeding after Liver Transplantation
Julian Perez, MD, Mauricio Orrego, MD, Oscar Martinez, MD, Ramesh Koja, MD, Cosme Manzerbeitia, MD, Philip Katz, MD, Internal Medicine, Liver Transplant, and Gastroenterology, Albert Einstein Medical Center, Philadelphia, PA.

Carlos Romero-Marrero, MD, Ana P. Ortiz, PhD, Graciela Nogueras, MPH, William Calo, MPH, Eduardo Hernandez, MPH, Nayda Figueroa, MD, Esther A. Torres, MD, MACG, Erick Suarez, PhD, Medicine Division of Gastroenterology, and Biostatistics and Epidemiology, University of Puerto Rico School of Public Health, and Puerto Rico Cancer Center, University of Puerto Rico, San Juan, Puerto Rico.

P442. Capsule Endoscopy Can Discriminate between Large/ Medium Varices and Small or No Varices: Defining the Threshold
Kevin P. Meltz, DO, Ian R. Schreibman, MD, Thomas R. Riley, MD, Tri H. Le, MD, Gastroenterology & Hepatology, Hershey Medical Center/Penn State University, Hershey, PA.
P443. Hepatic Infarct Following TIPS with a ePFTET-Covered Stent and Review of the Literature
Sandra M. Jara, MD, Joseph McKinley, MD, John M. Coleman, MD, William Boyd, MD, Division of Digestive Diseases & Nutrition, and Division of Interventional Radiology, James A. Haley VA Hospital, Tampa, FL.

P444. Narrow-Band Imaging for Differentiating Neoplastic and Nonneoplastic Colon Polyps during Colonoscopy in Clinical Practice
★ 2007 ACG Presidential Poster Award Recipient
Ananth Vadee, MD, Colin Swales, MD, Curuchi Anand, MD, Gastroenterology, Saint Vincent Hospital, Worcester, MA and Gastroenterology, University of Massachusetts Medical Center, Worcester, MA.

P445. In Vivo Prediction of Polyp Histology Using High Definition/Magnification and Narrow Band Imaging (NBI)
Anu K. Mathew, MD, Francisco C. Ramirez, MD, FACG, Nooman Gilani, MD, FACG, Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix, AZ.

P446. Normal Anorectal Biomechanics Analyzed with Concurrent Intraluminal Manometry, Surface EMG and Fluoroscopy
Ann Ouyang, MD, Sung-Yup Kim, David S. Hartman, MD, James G. Brasseur, PhD, Medicine and Radiology, Hershey Medical Center, Penn State University, Hershey, PA, and Mechanical Engineering, Penn State University, University Park, PA.

P447. Predicting Obstructive Defecation: Symptoms and Physiologic Tests
Kian Makipour, MD, Siva Doma, MD, Henry P. Parkman, MD, Medicine, Temple University, Philadelphia, PA.

P448. Comparison of Anorectal Manometry to Endoanal Ultrasound in the Evaluation of Fecal Incontinence
Savio Reddydasu, MD, Sana Waheed, MD, Shailender Singh, MD, Benjamin Alsop, Melissa Oroppeza-Vail, RN, Richard McCallum, MD, Mojtaba Olyaee, MD, Gastroenterology, Temple University, Philadelphia, PA.

P449. A Novel Artificial Magnetic Sphincter To Prevent Fecal Incontinence
Mauro Bortolotti, MD, Giampaolo Ugolini, MD, Ann Ouyang, MD, Siva Doma, MD, Henry P. Parkman, MD, Medicine, Temple University, Philadelphia, PA.

P450. Relationship between Sporadic Hyperplastic Polyps and Colorectal Neoplasia in Hispanic Veterans
Rafael Perez, MD, Arnaldo Lasa, MD, Doris H. Toro, MD, Marcia Cruz-Correa, MD, PhD, Jaime Martinez-Sousa, MD, Gastroenterology Section, VA Caribbean Healthcare System, and Comprehensive Cancer Center, University of Puerto Rico, San Juan, Puerto Rico.

P451. Do ACG Guidelines Still Predict C. difficile Diarrhea in Hospitalized Patients?
Michael Kaczanowski, MD, David Peretz, MD, Jonathan A. White, MD, William B. Haie, MD, Gastroenterology, Norwalk Hospital, Yale University School of Medicine, Norwalk, CT.

P452. Intravenous Immunoglobulins for Clostridium difficile Infection—A Systematic Review
Anastasios Koulouzidis, MD, MRCP, Syed Habib, MBBS, Saeed Ur Rehman, MBBS, Naveen Hornappa, MBBS, DV, John Moschos, MD, PhD, Athar A. Saeed, FRCP, Gastroenterology, Llandudno Hospital, Llandudno, Conwy, United Kingdom; Gastroenterology, 424 Army Hospital, Thessaloniki, Greece and Gastroenterology, Queen Elizabeth Hospital, Gateshead, United Kingdom.

P453. Fospropofol Disodium Is Effective and Safe for Sedation during Colonoscopy
Douglas K. Rex, MD, Lawrence B. Cohen, MD, Indiana University Medical Center, Indianapolis, IN and The Mount Sinai Hospital, New York, NY.

P454. Diagnostic Yield of Colonoscopy in Patients Referred with Iron Deficiency Anaemia. Do Patients under 50 Years of Age Merit Such Indication?
Mahboob Ali, MBBS, Linga Devi Thanasekaran, MBBS, Abdur Rafeh Khan, MBBS, Irfan Maqsood, MBBS, Nosheen Khawaja, MBBS, Irum Telay, MBBS, Muhammad Naeeem Khan, MBBS, Nicholas Russell, FRCP, Babur Javaid, FRCP, Medicine, North Cumbria Acute Hospitals NHS Trust, Whitehaven, England, United Kingdom.

P455. Nurses Who Assist in Colonoscopy with Sedation On-Demand and a Novel Technique of Water Infusion without Air Insufflation Evaluate the Combination as Credible Options for Patient Care
Rodelei Siao-Salena, BSN, RN, Hazel Cabrera, RN, Joseph W. Leung, MD, FACG, Dannie Prather, RN, Lee Toomsen, RN, Rafeh Khan, MD, FACG, Kanat Ransibrahmanakul, MD, Felix W. Leung, MD, Gastroenterology, Sacramento VA Medical Center, VANCHCS, Mather, CA and Gastroenterology, Sepulveda ACC, VAGLAHS and David Geffen School of Medicine at UCLA, North Hills, CA.

P456. Mismatch Repair Proteins and Clinicopathologic Factors in Colorectal Cancer
Mansla Molaei, MD, Babak Noorinayer, MD, Ali Ghanbanimitlagh, MD, Somayeh Ghiassi, MD, S. Alireza Emami, MD, Katayoon Aghajani, MD, Mohamadreza Zali, Pathology and Gastroenterology, Research Center for Gastroenterology and Liver Disease, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.

P457. The Association of Diabetes Mellitus and Colorectal Cancers
Samir L. Habashi, MD, Juan C. Munoz, MD, Kenneth Vega, MD, Gastroenterology, University of Florida Health Science Center/Jacksonville, Jacksonville, FL.

P458. Small (<5mm) Right Sided Polyps (P) Are More Likely Adenomatous (A) Than Small Left Sided Polyps during Colonoscopy (G)
John M. Haydek, MD, John P. Haydek, Chris M. Haydek, Gastrointestinal Associates, Knoxville, TN.

CLINICAL VIGNETTES

P459. Cholestatic Hepatitis Associated with Hyperthyroidism, and Exacerbated by Methimazole Therapy
Erick H. Chinga-Alayo, MD, Bashar M. Attar, MD, PhD, Frida Abrahamian, MD, Gastroenterology, Cook County - John H. Stroger Hospital, Chicago, IL and Gastroenterology, Rush University Medical School, Chicago, IL.

P460. Methotrexate in Autoimmune Hepatitis
Roger Montenegro, MD, Gijo Vetthiakal, MD, Melchor Demetria, MD, Bashar M. Attar, MD, PhD, Gastroenterology, Cook County - John H. Stroger Hospital and Rush University Medical School, Chicago, IL.
P461. Type 1 Acute Autoimmune Hepatitis in a Male Patient
Navakanth Gorrepati, MD, Atulkumar Patel, MD, Department of Internal Medicine and Division of Gastroenterology, William Beaumont Hospital, Royal Oak, MI.

P462. Sinusoidal Occulsion Syndrome Following Exposure to Gemtuzumab: Unsuccessful Treatment with Defibrotide
Alastair D. Smith, MB, ChB, Daniel J. Hampton, MD, Joseph O. Moore, MD, Louis F. Diehl, MD, Gastroenterology & Hepatology, Duke University, Durham, NC and Hematology, Duke University, Durham, NC.

P463. MALTOMA of the Colon Presenting as Autoimmune Hemolytic Anemia
Amanpal Singh, MD, MS, Jack B. Alperin, MD, Alvah R. Cass, MD, Guillermo Gomez, MD, G.S. Raju, MD, Internal Medicine, Family Medicine and Surgery, University of Texas Medical Branch, Galveston, TX.

P464. Acute Hemorrhagic Colitis in 25 Year Old Man Treated for Flu like Symptoms
Dana M. Kaplan, Jianlin Xie, MD, PhD, Anisha Thadani, MD, Sita Chokhavatia, MD, Gastroenterology, The Mount Sinai Medical Center, New York, NY.

P465. Recurrent Signet-Cell Type Gastric Cancer Simulating Ulcerative Colitis
Matthew Mukherjee, MD, A. Brodsky, MD, Irwin M. Grosman, MD, Gastroenterology, Long Island College Hospital, Brooklyn, NY.

P466. Ischemic Colitis in a Patient Receiving Carboplatin and Paclitaxel for Non-Small Cell Carcinoma of the Lung
Sumanta K. Pal, MD, Donald David, MD, Department of Medical Oncology and Department of Gastroenterology, City of Hope National Medical Center, Duarte, CA.

P467. Delayed Colonic Perforation after ESD in a Patient with Ulcerative Colitis
Matthew L. Bechtold, MD, Ajitinder Grewal, MD, Todd W. Kilgore, MD, Srinivas R. Pull, MD, Mainor R. Antillon, MD, Division of Gastroenterology, University of Missouri, Columbia, MO.

P468. Toxic Megacolon with Perforation: A Complication of Salmonella Colitis in the U.S.
Isam Daboul, MD, Vikas Ghai, MD, Adeel Husain, Srini Hejeebu, DO, Gastroenterology and Medicine, University of Toledo, Toledo, OH.

P469. Intra Abdominal Pathology in Polyomylgia Rheumatica Presenting as Exacerbation of Rheumatic Disease
Punyanganie de Silva, MRCP, Nagarajan Pranesh, MRCS, Guy Vautier, FRCP, Department of Gastroenterology and Department of Surgery, James Paget University Hospital, United Kingdom.

P470. Heat Stress and Exercise Induced Ischemic Colitis in a 21 Year Old
Riffat Meraz, MD, Namita Chittoria, MD, Preeti Mehta, MD, Uma Murthy, MD, Internal Medicine, SUNY Upstate Medical University, Syracuse, NY.

P471. Delayed Post-Polypectomy Bleeding Associated with Use of Bilberry (Vaccinium Myrtillus) Extract
Mitchell Duterte, MD, Shawn Waugh, PA-C, Rizwana Thanawala, MD, Lake City, FL.

P472. Mycophenolate Mofetil (MMF) Induced Cecal Ulceration in a Patient with Lupus Nephritis
Ehteshamul H. Anjum, MD, Prabodh Ranjan, MD, Jinil Yoo, MD, Pramod Joseph, MD, Nephrology, Our Lady of Mercy Medical Center/New York Medical College, Bronx, NY and Gastroenterology, Our Lady of Mercy Medical Center/New York Medical College, Bronx, NY.

P473. Isolated Polyomylgia Rheumatica of the Sigmoid Colon
Debapriya De, MD, James Kumar, MD, Srikanth Vallurupalli, MD, Krishnarao V. Tangle, MD, Davendra P. Ramkumar, MD, Internal Medicine, University of Illinois at Urbana Champaign, Urbana, IL; Pathology, Provena Covenant Medical Center, Urbana, IL and Gastroenterology, University of Illinois at Urbana Champaign, Urbana, IL.

P474. Complicated Periappendiceal Abscess Diagnosed on Colonoscopy
Raja S. Vadlamudi, MD, Puneeth Goenka, MD, Department of Internal Medicine, East Tennessee State University, Johnson City, TN.

P475. Cisplatin Induced Ischemic Colitis: A Case Report
Kanwar R.S. Gill, MD, Seth A. Gross, MD, Mohammad Al-Haddad, MD, Tejal Patel, James S. Scopolio, MD, Division of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, FL.

P476. A Rare Mimic of Colon Cancer: Ameboma
Malini Madhavan, MBBS, Chenni S. Srim, MD, Gautam Kumar, MBBS, MRCP(UK), Department of Internal Medicine and Molecular Pharmacology/Experimental Therapeutics, Mayo Clinic, Rochester, MN.

P477. Isolated Cecal Infarction with the Radiological Picture of a Mass Lesion in a Patient with an Acute Abdomen and No Obvious Predisposing Factors
M. Momeni, MD, P. Basi, MD, G. Martin, MD, S. Anand, MD, V. Rovito, MD, GI, Lutheran Medical Center, Brooklyn, NY.

P478. Recurrent Hematochezia—A Rare Presentation of the Klippel-Trenaunay-Weber Syndrome
Bhavesh B. Shah, MD, Geanina Anghel, MD, Joseph C. Young, MD, Anthony R. Lupelini, MD, Katie F. Farah, MD, Division of Gastroenterology, Allegheny General Hospital, Drexel University College of Medicine, Surgery and Dept. of Diagnostic Radiology, Allegheny General Hospital, Pittsburgh, PA.

P479. An Unusual Cause for Rectal Mass
Mahindra Shrut, MD, Saad F. Jazrawi, MD, Nicholas Gualtieri, MD, James Robilotti, MD, Peter Bloom, MD, Internal Medicine–Gastroenterology, Saint Vincent Hospital–Manhattan, New York Medical College, New York, NY.

P480. Carcinoid Tumor of Small Bowel and Colonic Adenocarcinoma, a Concurrent Occurrence in a 77 Year Old Male
Alka Farmer, MD, Howard Benn, MD, Internal Medicine, St. Joseph Regional Medical Center, Paterson, NJ.

P481. Certolizumab Pegol Treatment of Crohn’s Disease in a Patient with Lactose Intolerance
Marianne J. Mendenhall, MD, Gastroenterology, The Mount Sinai Hospital, New York, NY.

P482. Strongyloidiasis Manifesting as Colonic Polyps Successfully Treated with Ivermectin
Raymond Bou Assaf, MD, Nassim El-Hajj, MD, Ayse Aytaan, MD, Andrew W. Seymour, MD, Jie Ouyang, MD, Gerald Frucht, MD, State University of New York, Brooklyn, NY and New York Harbor VA, Brooklyn Campus, Brooklyn, NY.
P483. Fatal Small Bowel and Colonic Ischemia after Sodium Phosphate Bowel Preparation
Praveena G. Velamati, MD, Kimberly E. Steele, MD, Mack C. Mitchell, MD, Department of Digestive Diseases and Department of Surgery, Johns Hopkins Bayview Medical Center, Baltimore, MD.

P484. TB or Not TB: An Atypical Etiology of Colitis
David H. Kerman, MD, Jeffrey B. Raskin, MD, Medicine–Gastroenterology, University of Miami/Jackson Memorial Hospital, Miami, FL.

P485. Unusual Presentation of a Cecal Volvulus
Sohail N. Shaikh, MD, Hamed Shaaban, MD, Robert S. Spira, MD, Joseph R. DePasquale, MD, Gastroenterology, Seton Hall University School of Graduate Medical Education, South Orange, NJ.

P486. Adenocarcinoma of the Colon Associated with Esophageal Dysmotility
M. Mukherjee, MD, A. Khdair, MD, T. Soora, MD, I.M. Grosman, MD, Gastroenterology, Long Island College Hospital, Brooklyn, NY.

P487. Collagenous Colitis Associated with Common Variable Immunodeficiency
Soren Gandhi, David M. Chaletsky, MD, Christopher C. Ashley, MD, Gastroenterology, Albany Medical College, Albany, NY.

P488. Ischemic Colitis Masquerading as Crohn's Colitis in a Patient with Protein C Deficiency
S. Gopaluni, MD, V. Muthu, MD, N. Mehta, MD, P. Holtzapple, Medicine, SUNY Upstate University, Syracuse, NY.

P489. Segmental Arterial Mediolysis: An Unusual Cause of Ischemic Colitis
Robert E. Kraichely, MD, Amy S. Oxentenko, MD, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

P490. Isolated Histoplasma Colitis Masquerading as Idiopathic Inflammatory Bowel Disease
Pavan Chepyala, MD, Prasuna Madhavaram, MD, Kevin W. Olden, MD, Gastroenterology & Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR.

P491. An Unusual Case of Disseminated Histoplasmosis in an Immunocompetent Patient
Elliott Jou, MD, Matthew M. Tsushima, MD, Michael Walter, MD, Internal Medicine and Gastroenterology, Loma Linda University Medical Center, Loma Linda, CA.

P492. Amebiasis Mimicking Metastatic Colon Cancer
Aman Ali, MD, Mylon Satchi, MD, Adam Palance, MD, Berhanu Gemon, MD, Sujit Kulkarni, MD, Eric Rosen, MD, Peter Kim, MD, Gastroenterology and Hepatology, Lenox Hill Hospital, New York, NY.

P493. Chronic Intestinal Schistosomiasis
Rishi Pawa, MD, Vishal Gupta, PhD, Rohan Clarke, MD, Jay Cowan, MD, Lisa Ozick, MD, Department of Gastroenterology, Columbia University College of Physicians and Surgeons, Harlem Hospital Center, New York, NY.

P494. Ulcerative Colitis Diagnosed in a Patient with Venous Thromboembolism
Seong K. Choi, MD, Afshin Tavakoly, MD, Leelavathi Kasturi, MD, Henry Saifer, MD, Internal Medicine, Mount Sinai School of Medicine at Queens Hospital Center, Jamaica, NY.

P495. Pulmonary Nodules in Ulcerative Colitis
ThanhTam N. Nguyen, BA, Chris Shepela, MD, Patnaik Mrinal, MD, Gastroenterology, Hepatology and Nutrition & General Internal Medicine, University of Minnesota, Minneapolis, MN.

P496. Henoch-Schönlein Purpura with Terminal Ileitis Masquerading as Crohn's Disease
Eric R. Wollins, MD, Antoinette Saddler, MD, Marie L. Borum, MD, Division of Gastroenterology and Liver Diseases, George Washington University Medical Center, Washington, DC.

P497. Two Primary Adenocarcinomas in a Crohn's Patient with Infliximab Therapy
Christina A. Tennyson, MD, Divyesh Sejpai, MD, Daniel Labow, MD, Michael Lewis, MD, Maria T. Abreu, MD, Gastroenterology, Surgery, and Pathology, Mount Sinai School of Medicine, New York, NY.

P498. Azathioprine Induced Sweets Syndrome in a Patient with Crohn's Disease
Nicholas C. Boetticher, MD, El-Azhary A. Rokea, MD, Carryer W. Peter, MD, Santhi S. Vege, MD, Gastroenterology and Hepatology, and Dermatology, Mayo Clinic-Rochester, Rochester, MN.

P499. Infectious Colitis Mimicking Crohn's Disease
Thomas Park, MD, Ashok N. Shah, MD, Division of Gastroenterology and Hepatology, University of Rochester, Rochester, NY.

P500. Rifaximin for the Treatment of Newly Diagnosed Crohn's Disease
Ira Shafra, MD, Patricia Burgunder, ARNP, Shafra Gastroenterology Center, Winter Park, FL.

P501. Is it Time To Perform HIV Screening among Patients Prior to Receiving Infliximab (Remicade) Therapy?
Ketul Patel, MD, Shoba Mendu, MD, Michael Piper, MD, Gastroenterology, Providence Hospital Medical Center, Southfield, MI.

P502. Improvement of Cardiomyopathy after Infliximab Treatment for Crohn's Disease (CD)
Roberto E. Mera, MD, Hector Banch, MD, Esther A. Torres, MD, MACG, Department of Medicine, Division of Gastroenterology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico.

P503. Vaginal Crohn's Disease Successfully Treated with Adalimumab
Patricia L. Kozuch, MD, Anthony J. DiMarino, MD, Kent Wilson, BS, Cynthia Miller, RN, Anthony Infantolino, MD, Digestive Disease Institute, Thomas Jefferson University Hospital, Philadelphia, PA.

P504. Pancytopenia in a Patient Treated with 6MP and Fluconazole: A Novel Drug Interaction
Jonathan Z. Potack, MD, Lloyd Mayer, MD, Thomas A. Ulman, MD, Dr. Henry D. Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY.

P505. Adalimumab (ADA) Treatment of Hidradenitis Suppurativa (HS) in a Crohn's Disease (CD) Patient
Jeffrey T. Wenzke, MD, Ashok Shah, MD, Gastroenterology and Hepatology Division, University of Rochester, Rochester, NY.

P506. Adenocarcinoma at the Colostomy Site in a Patient Presenting for Ulcerative Colitis Dysplasia Surveillance
Armitpal S. Johal, MD, Michael J. Komar, MD, Gastroenterology, Geisinger Medical Center, Danville, PA.
P507. False Negative Test for Gastroparesis from Technicium (Tc) Oatmeal Radionuclide Gastric Emptying (GE) Study: Lack of Standardized Updated Protocols for Tc GE in Community Hospitals
Jennifer L. Wellington, Jon Kotler, MD, Soumendu K. Das, MD, V. Alin Botoman, MD, Biological Sciences, Florida Atlantic University, Boca Raton, FL; Nuclear Medicine, Holy Cross Hospital, and GI Institute of Fort Lauderdale, Fort Lauderdale, FL, and Gastroenterology, University of Miami, Miami, FL.

P508. Therapeutic Success of Rifaximin in the Setting of Clostridium Difficile Diarrhea Refractory to Metronidazole and Vancomycin: Case Report
George C. Tannous, BA, Guy Neff, MD, Terry O’Toole, MD, Nathan Schmulewitz, MD, Christopher Duncan, MD, Victoria Zacharias, MS, Nyingi Kemmer, MD, Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH.

P509. Retrieval of Distally Migrated Esophageal Stent Using Enteroscopy
Raja S. Vadamudi, MD, Mark F. Young, MD, Department of Internal Medicine, East Tennessee State University, Johnson City, TN.

P510. Pneumatosis Intestinalis. The Question Is To Be or Not To Be—A Polyp?
Aman Ali, MD, Hagit Manor, MD, Eric Rosen, MD, Rukhsar Ahmed, MD, Knarik Arunk, MD, Gregory Haber, MD, Gastroenterology and Hepatology, Lenox Hill Hospital, New York, NY.

P511. Endoscopic Hemostasis of Massive Hematochezia after Transrectal Prostate Biopsy: A Case Series
Teresa A. Tacopina, MD, Irwin M. Grosman, MD, Adnan Khair, MD, Gastroenterology, Long Island College Hospital, Brooklyn, NY.

P512. Diagnosis of Mediastinal Tuberculosis with EUS Guided FNA
Alla Grigorian, MD, Houssam Mardini, MD, Nicholas Nickl, MD, Division of Digestive Diseases and Nutrition, University of Cincinnati College of Medicine, Cincinnati, OH and Tristate Surgical Weight Loss Center, St. Luke Hospital, Florence, KY.

P513. Intragastric Balloon for Obesity Causing Gastric Outlet Obstruction
Natalee S. Sansone, MD, Liberato Salvatore, MD, Internal Medicine, Division of Gastroenterology, New York Hospital of Queens, Flushing, NY.

P514. A Late Presentation of Blue Rubber Bleb Nevus Syndrome Diagnosed by Laparoscopic-Assisted Double Balloon Enteroscopy
Nidhi Singh, MD, Vivek Prachand, MD, Carol Semrad, MD, Gastroenterology, University of Michigan, Ann Arbor, MI.

P515. Massive Upper GI Bleed Secondary to Splenic Artery Pseudoaneurysm
Susan Ramchany, MD, Ajay Malhotra, MD, Safak Reka, MD, Michael Herskowitz, MD, Frank Gress, MD, Gastroenterology, Radiology, SUNY Downstate Medical Center and Kings County Hospital, Brooklyn, NY.

P516. Uncommon Presentation of PTLD in the Esophagus
Syed Abbas Fehmi, MD, Sameer Saini, MD, William Chey, MD, Gastroenterology, University of Michigan, Ann Arbor, MI.

P517. Endoscopic Ultrasound (EUS) Findings in Tropical Pancreatitis
Laith H. Jamil, MD, Amulya Konda, MD, Steven Fox, MD, Gehad Ghait, MD, Veslav Stecevic, MD, GI, William Beaumont Hospital, Royal Oak, MI.

P518. Jejunal Ulcerations and Ascites as Presenting Manifestations of Henoch-Schonlein Purpura
Suzanne K. Morrissey, MD, Katie Farah, MD, Division of Gastroenterology, Allegheny General Hospital, Drexel University College of Medicine, Pittsburgh, PA.

P519. Bread Bag Clip Ingestion: A Rare Cause of Upper Gastrointestinal Bleed
Suzanne K. Morrissey, MD, M. Lance Weaver, MD, Katie Farah, MD, Shyam J. Thakker, MD, Division of Gastroenterology and Department of General Surgery, Allegheny General Hospital, Drexel University College of Medicine, Pittsburgh, PA.

P520. Delayed Life Threatening Rectal Bleeding after Trus-Guided Prostatic Biopsy
Wael El Darawy, MD, Won Sohn, MD, Maurice A. Cerulli, MD, Methodist Hospital, Brooklyn, NY.

P521. The Misplaced Shoe Polish Bottle!
Rohit Jindal, MD, Edmond Bouassaf, MD, Ayse Ayteman, MD, Gastroenterology, VA NYHHS, and Gastroenterology, SUNY Downstate Medical Center, Brooklyn, NY.

P522. EUS with Trucut Biopsy for Diagnosis of Intra-Abdominal Tuberculosis
Kaumudi Somnay, MD, Nataya Belova, MD, Department of Gastroenterology, New York Hospital Queens, Flushing, NY.

P523. Rare Anatomic Variation of Ampulla of Vater
Patricia Laurel, Rahat Hussain, Muhammed G. Nathani, Internal Medicine, UTHSCSA, Regional Academic Health Center, Harlingen, TX.

P524. Long Biliary Stent Causing Sigmoid Colon Perforation
Pavan Manchikalapati, MD, Noel Martins, MD, Kanishka Bhattacharya, MD, Gastroenterology, University of Massachusetts, Worcester, MA.

P525. Endoscopic Mucosal Resection of H. pylori Negative Esophageal MALT Lymphoma
Michael J. Gilbert, MD, Ashok Shah, MD, Asad Ullah, MD, Gastroenterology and Hepatology, University of Rochester, Rochester, NY.

P526. Successful Removal of a Migrated Esophageal Self-Expanding Metallic Stent from the Stomach with the Aid of an Esophageal Self-Expanding Plastic Stent
Gene L. Chang, MD, Yogesh Patel, DO, Timothy Laurie, DO, Mani Mahdavian, MD, Gastroenterology, Advocate Lutheran General Hospital, Park Ridge, IL.

P527. Endotherapy for Massive GI Bleeding Due to Duodenal Lipoma
Parupudi V.J. Sriram, MD, Easwaran Varyiam, MD, Internal Medicine (Gastroenterology), Texas Tech Univ Health Sci Center, Lubbock, TX.

P528. Trouble Shooting in the Endoscopy Unit: Successful Management of Gastro-Gastric Fistula and Gastro-Jejunal Anastomosis Obstruction Using a Polylflex Stent
Paramvir Singh, MD, Thomas Sonnarstine, MD, Andres Gelrud, MD, Digestive Diseases, University of Cincinnati, Cincinnati, OH and Tristate Surgical Weight Loss Center, St. Luke Hospital, Florence, KY.

P529. Dissection of an Unusual Gastric Mass Using Rat-Tooth Forceps
Patrick J. McDevitt, DO, Arnab Biswas, DO, Abraham Mathew, MD, Department of Internal Medicine, and Department of Gastroenterology and Hepatology, The Penn State Hershey Medical Center, Hershey, PA.
P530. Unusual Complication of a Colonic Interposition with an Unusual Solution
Paramvir Singh, MD, Andres Gelrud, MD, Digestive Diseases, University of Cincinnati, Cincinnati, OH.

P531. EUS Guided Diagnosis of New-Onset Sarcoïdosis in a Patient with Cervical Cancer
Rabin Rahmani, MD, David Hass, MD, Sammy Ho, MD, Gastroenterology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

P532. Investigation of the Excluded Stomach after Roux-en-Y Gastric Bypass: The Role of Percutaneous Endoscopy
Kanwar R.S. Gill, MD, Mark J. McKinney, MD, Ernest P. Bouras, MD, Gastroenterology, Mayo Clinic, Jacksonville, FL.

P533. Rectal Stent Revision Using Argon Plasma Coagulation
Amil Patel, MD, Kamal Obideen, MD, Medicine/Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA.

P534. Balantidium Coli and Trichuris Trichiura Co-Infection Presented with Lower Gastrointestinal Bleeding—A Case Report
Bogdan Cristescu, MD, Safak Reka, MD, Digestive Diseases, SUNY Downstate Medical Center, Brooklyn, NY.

P535. Pyogenic Liver Abscess Complicating Colonoscopic Polypectomy
Rebekah G. Gross, MD, Bruce Reiter, MD, Mark A. Korsten, MD, Gastroenterology, Mount Sinai School of Medicine, New York, NY. Radiology, James J. Peters Veterans Affairs Medical Center, Bronx, NY and Gastroenterology, James J. Peters Veterans Affairs Medical Center, Bronx, NY.

P536. Henoch-Schonlein Purpura in an Adult Presenting Initially as Acute Gastrointestinal Illness without Skin Manifestations
Siddharth Mathur, MD, Mukul Araya, MD, Internal Medicine, Gastroenterology, Indiana University, Indianapolis, IN.

P537. Case Report: Argon Plasma Coagulation for the Treatment of Hemorrhagic Radiation Sigmoiditis
Mindy C.W. Lam, MSc, Clarence K.W. Wong, MD, FRCP, Gastroenterology, University of Alberta, Edmonton, AB, Canada.

P538. Identification of Unsuspected Parasitic Disease on Video Capsule Endoscopy
Nirmala M. Sivaprakasapillai, MD, Thomas Judge, MD, Gastroenterology, Cooper University Hospital, Camden, NJ.

P539. Delivery of Agile Patency Capsule Using an Endoscopic Delivery Device
Janice Freeman, RN, Deepika Koya, MD, Brenda J. Hoffman, MD, Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC.

P540. Conservative Management of Inadvertent Colon Penetration during Percutaneous Gastrostomy Tube Placement
Hansen Kwok, MD, Wichit Srikureja, MD, Ronald Griffin, MD, Gastroenterology, Loma Linda University Medical Center, and Gastroenterology, Loma Linda VA Medical Center, Loma Linda, CA.

P541. Narrow-Band Imaging in the Identification of Sessile Serrated Adenomas
Manuel Y. Lam, BA, Edward Feller, MD, Baishali Bhattacharya, MD, Samir A. Shah, MD, Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI.

P542. Diagnosis of Shwachman-Diamond Syndrome in a 24-Year-Old Woman with Abdominal Pain and Fatty Replacement of the Pancreas
Jaya R. Agrawal, MD, MPH, John R. Saltzman, MD, FACG, Elena M. Stoffel, MD, MPH, Gastroenterology, Brigham and Women's Hospital, Boston, MA.

P543. Collagenous Gastroenterocolitis in a Two Year Old Boy with Cerbellar Ataxia
Alicja A. Leby, MD, Seema Khan, MD, Diana A. Corao, MD, Gastroenterology and Pathology, A.I. Dupont Hospital for Children, Wilmington, DE.

P544. The Buried Bumper Syndrome in Children
Sabina A. Ali, MD, Meghanah Sathe, MD, Michael A. Russo, MD, Pediatrics, Division of Pediatric Gastroenterology and Nutrition, University of Texas Southwestern/Children's Medical Center of Dallas, Dallas, TX.

P545. Exophytic Splenic Cyst Mimicking a Gastric Mass
Christine Carter-Kent, MD, Pramodha Muniyappa, MD, Matthew Wyneski, MD, Orhan Atay, MD, Lori Mahajan, MD, Pediatric Gastroenterology, Cleveland Clinic, Cleveland, OH.

P546. Endoscopic Closure of a Gastrocutaneous Fistula
Zahid Afzal, MD, Ajay Bajaj, MD, Internal Medicine/ Gastroenterology, Advocate Christ Medical Center, Oak Lawn, IL.

P547. Severe Gastrointestinal Bleeding Due to Isolated CMV Enteritis Diagnosed by Double-Balloon Enteroscopy
Monika Fischer, MD, Michael V. Chiorean, MD, Internal Medicine, Gastroenterology, Indiana University, Indianapolis, IN.

P548. Leakage from Surgical Jejunostomy Tube Due to Sharp Angle of Efferent Limb
Kendrick M. Che, DO, Snorri Olafsson, MD, Gastroenterology, Loma Linda University Medical Center, Loma Linda, CA.

P549. Use of Endoscopic Ultrasound Guided Fine Needle Aspiration (EUS-FNA) with Aspirate Parathormone (PTH) Assay To Diagnose Medialastial Parathyroid Adenomas
Duc H. Vu, MD, Richard A. Erickson, MD, FACG, Gastroenterology, Scott & White Memorial Hospital and Clinic, Temple, TX.

P550. Hepatic Artery Pseudoaneurysm: A Unique Cause of Obscure Upper GI Bleeding
Siddharth Mathur, MD, Mukul Araya, MD, Niket Sonpal, BS, Mohammed Aladdin, MD, Sandeep Patil, MD, Internal Medicine, Wyckoff Heights Medical Center, Brooklyn, NY.

P551. Thumbs Up: Endoscopist's Thumb as an Occupational Hazard Related to High Volume Endoscopy
Joy Tsai, MD, Charles Berkelhammer, MD, Gastroenterology, University of Illinois, Oak Lawn, IL.

P552. Hemorrhagic Small Bowel Renal Cell Metastasis Diagnosed by Double Balloon Enteroscopy
Adam L. Palance, MD, Sejal Patel, MD, Gregory Haber, MD, Evin J. McCabe, MD, Parest Shah, MD, Department of Medicine, and Department of Surgery, Lenox Hill Hospital, New York, NY.

P553. Successful Late Treatment of Boerhaave's Syndrome with Esophageal Stenting
Adam L. Palance, MD, Eric Rosen, DO, Gregory Haber, MD, Jeevan Vinod, MD, Aman Ali, MD, Division of Gastroenterology, Lenox Hill Hospital, New York, NY.
**Poster Presentations — Monday, October 15**

**P554. Obscure-Overt Gastrointestinal Hemorrhage: A Rare Case of Bleeding Ectopic Ileal Varices Managed by Double Balloon Enteroscopy**

Adam L. Palance, MD, Evin J. McCabe, MD, Gregory Haber, MD, Department of Medicine, Division of Gastroenterology, Lenox Hill Hospital, New York, NY.

**P555. A Novel Endoscopic Treatment of a Gastric Duplication Cyst**

Evin J. McCabe, MD, Adam L. Palance, MD, Gregory B. Haber, MD, Stephen Machnicki, MD, Division of Gastroenterology, Department of Medicine, and Department of Radiology, Lenox Hill Hospital, New York, NY.

**P556. Botulinum Toxin Injection for the Treatment of Gastric Stasis in Patients with Prior Gastric Surgery**

Steven R. Fox, MD, Laith H. Jamil, MD, Tushar K. Desai, MD, Gastroenterology, William Beaumont Hospital, Royal Oak, MI.

**P557. Unusual Cause of Chronic Diarrhea: Cronkhite-Canada Syndrome**

Manmeet Padda, MD, Jenica Ryu, MD, Nahid Molaie, MD, Eric Olsen, MD, Viktor Eysselein, MD, David Chung, MD, Binh V. Pham, MD, Family Medicine and Pathology, Harbor-UCLA Medical Center, Torrance, CA.

**P558. Hemoclip for Severe Post-Prostate Biopsy Rectal Hemorrhage: Case Series**

Joy Tsai, MD, Robert User, MD, Charles Berkelhammer, MD, Gastroenterology & Urology, University of Illinois, Oak Lawn, IL.

**P559. Diagnosis of Appendiceal Adenocarcinoma during Screening Colonoscopy**

Jaya R. Agrawal, MD, MPH, John R. Saltzman, MD, FACP, Gastroenterology, Brigham and Women's Hospital, Boston, MA.

**P560. Gastrointestinal Bleeding in a Patient with Pancreatico-Jejunostomy Diagnosed and Treated with Double-Balloon Endoscopy**

Abdo Saad, MD, Michael V. Chiorean, MD, Debra Helper, MD, Julia K. LeBlanc, MD, David Agarwal, MD, Internal Medicine, and Radiology, Indiana University, Indianapolis, IN.

**P561. Recto-Sigmoid Colon Perforation during Retroflexion in a Patient with Rectal Prolapse: Is This a Safe Practice**

Robert P. Svoboda, MD, Kevin W. Olden, MD, Gastroenterology, and Radiology, Mayo Clinic Arizona, Scottsdale, AZ.

**P562. Sigmod Endometriosis Diagnosed by Endoscopic Ultrasound Fine Needle Aspirate**

Bennett S. Hooks, MD, Peter Jelsma, MD, Howard R. Mertz, MD, Gastroenterology, University of South Alabama College of Medicine, Mobile, AL and St. Thomas Hospital, Nashville, TN.

**P563. Gossypiboma: An Unusual Cause of Gastric Outlet Obstruction Diagnosed by Endoscopy**

Urooj Ahmed, MD, Mohy El-Deen Attia, MD, Nouhad Hamade, MD, Alain Giguere, MD, Shaista Ahmed, MD, Medicine/Gastroenterology, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.

**P564. “Mark and Clip” in Difficult Cases of Gastrointestinal Hemorrhage**

Joseph C. Yarze, MD, FACG, FACG FASGE, GI Division, Gastroenterology Associates of Northern New York, Glens Falls, NY.

**P565. Proximal Black Esophagus: A Case Report**

David A. Neumann, II, MD, Dawn D. Ferguson, MD, Todd H. Baron, MD, Department of Internal Medicine, and Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

**P566. An Unusual Complication of Nissen Fundoplication**

Simon C. Chan, MD, Ashok Shah, MD, Gastroenterology, University of Rochester Medical Center, Rochester, NY.

**P567. Localized Aspergillus Esophagitis: A Difficult Diagnosis of Persistent Odynophagia Leading to a Diagnosis of AIDS**

Syed-Mohammed Jafri, MD, Anand Madan, MD, Division of Gastroenterology, University of Texas Health Science Center, Houston, TX.

**P568. An Unusual Presentation of Eosinophilic Esphagitis**

Adam J. Spiegel, DO, Kirk Sperber, MD, David C. Wolf, MD, Division of Gastroenterology, and Division of Allergy and Immunology, New York Medical College, Valhalla, NY.

**P569. Acute Esophageal Necrosis: Two Cases of a Rare Endoscopic Finding**

Leon S. Maratchi, MD, Ammon Gotian, MD, Ira A. Tepler, MD, Luocuan Wang, MD, Albert D. Kramer, MD, Gastroenterology, and Pathology, Montefiore Medical Center, Bronx, NY.

**P570. Eosinophilic Esophagitis in a Patient with Sjogren’s Syndrome**

Susan G. Coe, MD, Michelle D. Bishop, MD, Dawn D.F. Ferguson, MD, Internal Medicine and Gastroenterology, Mayo Clinic, Jacksonville, FL, and Gastroenterology, Mayo Clinic, Rochester, MN.

**P571. Achalasia Cardia in an Adult with Acute Renal Failure, Lung Abscess and Spontaneous Pneumomediastinum, a Rare Combination**

Asokh K. Sharma, MD, Lokesh K. Jha, MD, Shradhha Pandey, MD, Carl Guillaume, MD, Christopher Taurani, MD, Gastroenterology, St. Barnabas Hospital, Bronx, NY.

**P572. Esophageal Lymphangioma**

Stephanie L. Hansel, MD, MS, Cuong C. Nguyen, MD, Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ.

**P573. New Method for Esophageal Foreign Body Removal**

Yaser Al-Solaiman, MD, Yaman Suleiman, MD, Mohammad Alsolaiman, MD, Gastroenterology Dept., Central Utah Clinic, Provo, UT and Internal Medicine, Rosalind Franklin University, North Chicago, IL.

**P574. Liver Abscess as a Complication of Esophageal Balloon Dilatation**

Yaman Suleiman, MD, Samah Bassas, MD, Mohammad Alsolaiman, MD, Gastroenterology Dept., Central Utah Clinic, Provo, UT.

**P575. The Use of a Self-Expanding Plastic Stent for an Iatrogenic Esophageal Perforation**

John M. Petersen, DO, Gastroenterology, Baptist Medical Center/Borland-Groover Clinic, Jacksonville, FL.

**P576. Suspected Asymptomatic Large Colon Lipoma: Biopsy?**

Yaser Al-Solaiman, MD, Mohammad Alsolaiman, MD, Gastroenterology Dept., Central Utah Clinic, Provo, UT.

**P577. Large Descending Colon Lipoma Causing Intussusception and Mimicking Malignancy**

Patrick D. Martin, MD, Bradford Sklow, MD, Douglas G. Adler, MD, Gastroenterology, University of Utah, Salt Lake City, UT.

**P578. Infiltrating Ductal Breast Carcinoma Metastasis to Rectum, an Uncommon Occurrence**

Suresh Jayatilaka, MD, Alka Farmer, MD, Gurpreet Singh, MD, Hossam Elfarra, MD, Gastroenterology, St. Joseph’s Hospital Medical Center, Paterson, NJ.
OUTCOMES RESEARCH

P579. Systemic Antibiotic Prophylaxis for Percutaneous Endoscopic Gastrostomy: A Meta-Analysis
Abhishek Choudhary, MD, Matthew L. Bechtold, MD, Mohamed O. Othman, MD, Srinivas R. Puli, MD, John B. Marshall, MD, Praveen K. Roy, MD, Division of Gastroenterology, University of Missouri, Columbia, MO.

P580. Efficacy of Proton Pump Inhibitors in Reflux Laryngitis: A Meta-Analysis and Systematic Review
Srinivas R. Puli, MD, Abhishek Choudhary, MBBS, Jyojtsa Batapati Krishna Reddy, MBBS, Matthew L. Bechtold, MD, Ajitinder Grewal, MD, Christoper Bartalos, MD, Jack D. Bragg, MD, Praveen K. Roy, MD, Department of Gastroenterology and Hepatology, University of Missouri-Columbia, Columbia, MO.

P581. Proton Pump Inhibitors vs. Histamine2 Receptor Antagonist in Treatment of Non Variceal Upper Gastrointestinal Bleed: A Meta-Analysis
Ruchi Gupta, MD, Praveen Garg, MD, Medicine, University of Florida College of Medicine, Jacksonville, FL.

P582. Gastric Acid Analysis is a Reliable and Reproducible Measure of Acid Secretion in GERD Patients Treated with Placebo or Pantoprazole
Vijaya Pratha, MD, Daniel L. Hogan, MD, Richard B. Lynn, MD, Gail Conner, MD, David C. Metz, MD, Clinical Applications Laboratories, San Diego, CA; Wyeth Pharmaceuticals, Collegeville, PA and University of Pennsylvania Medical Center, Philadelphia, PA.

P583. Use of Acid Suppression Therapy in Hospitalized Patients – Going beyond the Indications
Ruchi Gupta, MD, Ravi Kottoor, MD, Juan C. Munoz, MD, Louis R. Lambiase, MD, Medicine, Division of Gastroenterology, University of Florida College of Medicine, Jacksonville, FL.

P584. Are Proton-Pump Inhibitors (PPIs) Associated with an Increased Risk of Community-Acquired Pneumonia (CAP)? A Nested Case-Control Study Investigating Recent PPI Exposure and CAP
Monika A. Sarkar, MD, Sean Hennessy, PharmD, Yu-Xiao Yang, MD, Department of Medicine, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA.

P585. Use and Abuse of Proton Pump Inhibitors
Erika Grigg, MD, J. Carter Balart, MD, Dianne B. Williams, PharmD, Robert R. Schade, MD, Medicine, Gastroenterology/Hepatology, Pharmacy, Medical College of Georgia, Augusta, GA.

P586. Healthcare Utilization and Cost in Pediatric Gastroesophageal Reflux Disease (GERD) Patients on Continuous vs. Intermittent Proton Pump Inhibitor (PPI) Treatment Regimens
Suzanne P. Nelson, MD, Smrita Kohari, PhD, Eric Q. Wu, PhD, Bjorn Persson, PhD, Nicolas Beaulieu, MA, Mateo Arana, MA, Mei Lu, MA, The Feinberg School of Medicine, Northwestern University, Chicago, IL; Health Economics & Outcomes Research, TAP Pharmaceutical Products, Inc., Lake Forest, IL and Analysis Group, Inc, Boston, MA.

P587. Comparison of Resource Consumption in GERD Care by Primary Care Providers and Gastroenterologists
Jay L. Goldstein, MD, FACC, Smrita Kohari, PhD, Rachel Halpert, PhD, Jenner Illinois at Chicago, Chicago, IL; TAP Pharmaceutical Products, Inc., Lake Forest, IL and i3 Innovus, Eden Prairie, MN.

P588. Development and Validation of the pH-Metry Impact Scale (pHIS) and pH-Metry Symptoms Scale (pHSS)
Angela G. Bradley, MD, Hack J. Kim, MD, John K. DiBaise, MD, Virender K. Sharma, MD, Michael D. Crowell, MD, Internal Medicine, and Gastroenterology, Mayo Clinic Scottsdale, Scottsdale, AZ.

P589. Influence of Esophagogastroduodenoscopy (EGD) on Prescription (Rx) Fill Patterns for Proton Pump Inhibitors (PPIs) and Nonselective Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) among Type-2 Diabetic (T2D) and Nondiabetic Patients
Linda C. Koo, PhD, Roger Luo, PhD, Jeremy Levinson, John T. Monyak, PhD, Debra G. Silberg, MD, FACC, AstraZeneca LP, Wilmington, DE.

P590. Frequent Nighttime Symptoms and Increased GERD Symptom Severity Are Associated with Impaired Functioning
James McGuigan, MD, Lawrence Johnson, MD, Daniel Aguilar, MPH, Bonnie Dean, PhD, James McGuigan, MD, Lawrence Johnson, MD, William Orr, PhD, Ning Yan, PhD, Diana Morgenstern, MD, Robert Dubois, MD, Cerner LifeSciences, Beverly Hills, CA; University of Alabama, Birmingham, AL; University of Arizona, Tucson, AZ and Wyeth Pharmaceuticals, Collegeville, PA.

P591. The Relationship between Atypical GERD Manifestations and Sleep Impairment
Ronnie Fass, MD, Brian Calimlim, MS, Daniel Aguilar, MPH, Bonnie Dean, PhD, James McGuigan, MD, Lawrence Johnson, MD, William Orr, PhD, Ning Yan, PhD, Diana Morgenstern, MD, Robert Dubois, MD, Cerner LifeSciences, Beverley Hills, CA; University of Alabama, Birmingham, AL; University of Florida, Gainesville, FL; Lynn Health Science Institute, Oklahoma City, OK; University of Arizona, Tucson, AZ and Wyeth Pharmaceuticals, Collegeville, PA.

P592. Prevalence of Sleep Impairment among Adults with GERD
William Orr, PhD, Brian Calimlim, MS, Daniel Aguilar, MPH, Bonnie Dean, PhD, Lawrence Johnson, MD, Ronnie Fass, MD, James McGuigan, MD, Ning Yan, PhD, Diana Morgenstern, MD, Robert Dubois, MD, Cerner LifeSciences, Beverley Hills, CA; University of Alabama, Birmingham, AL; University of Florida, Gainesville, FL; Lynn Health Science Institute, Oklahoma City, OK; University of Arizona, Tucson, AZ and Wyeth Pharmaceuticals, Collegeville, PA.

P593. Impact of Sleep Difficulties on Economic and Humanistic Outcomes in GERD/Heartburn Sufferers
Reema Mody, PhD, Susan Bolge, PhD, Hema Kannan, MPH, TAP Pharmaceutical Products Inc., Lake Forest, IL and Consumer Health Sciences, Princeton, NJ.

P594. Is Obesity the Cause of Reduced Healing Rates in Advanced Grades of Erosive Esophagitis (EE)?
Nimish Vakil, MD, FACC, Prateek Sharma, MD, FACG, John T. Monyak, PhD, Debra G. Silberg, MD, FACC, University of Wisconsin Medical Center, Milwaukee, WI; University of Kansas Medical Center, Kansas City, MO and AstraZeneca LP, Wilmington, DE.

INFLAMMATORY BOWEL DISEASE

P595. Crohn’s Disease-Associated Colonic Dysplasia Cancer: Lessons Learned from 93 Cases
Revital Kariv, MD, Ana Bennett, MD, Teyhuda Kariv, MD, Mary Brown, MD, Bo Shen, MD, Victor Fazio, MD, Ian Lavery, MD, Scott Strong, MD, Bret Lashner, MD, MPH, Digestive Disease Center, Cleveland Clinic, Cleveland, OH.
P596. Recurrent Colon Cancer or Dysplasia after Segmental Resection in Crohn's Colitis
Elana A. Maser, MD, David B. Sachar, MD, MACG, Thomas Ullman, MD, Esther Roth, BA, Daniel H. Present, MD, MACG, Noam Harpaz, MD, PhD, Joel Bauer, MD, Medicine, Pathology, Surgery, Mount Sinai Medical Center, New York, NY.

P597. Lactoferrin Assessment of Rectal Effluent as an Aid to Colonoscopy for Determining Intestinal Inflammation
Darcy A. Whitlock, MS, James H. Boone, MS, David M. Lyerly, PhD, Sunanda V. Kane, MD, Research & Development, TechLab, Inc., Blacksburg, VA and Dept. of Medicine, Gastroenterology, University of Chicago, Chicago, IL.

P598. Family Medicine Practitioners Often Uncomfortable Providing Preventive Care to Inflammatory Bowel Disease Patients
Lisbeth A. Selby, MD, John F. Wilson, PhD, Andrew Hoelllein, MD, Freddy Caldera, MD, Willem de Villiers, MD, PhD, Digestive Diseases and Nutrition, Behavioral Medicine, and Internal Medicine, University of Kentucky, Lexington, KY.

P599. Influence of Disease Duration and Severity on Inflammatory Bowel Disease Patients' Medication Preference
Deepthi Deconda, MD, Tamar Taddei, MD, Hannah L. Miller, MD, Judy H. Cho, MD, Deborah Proctor, MD, Medicine/Gastroenterology, Yale University School of Medicine, New Haven, CT.

P600. Characteristics of an Inflammatory Bowel Disease Population with Dysplasia and Adenocarcinoma
Bret A. Ancowitz, MD, Sally Stipho, MD, Samir Shah, MD, FACG, Division of Gastroenterology and Hepatology, Brown University Medical School, Providence, RI; University of Arizona, Phoenix, AZ and Gastroenterology Associates, Providence, RI.

P601. Willingness of Individuals with IBD To Use Complementary and Alternative Medicine
Delia Daian, MD, Ashkan Farhadi, MD, MS, Majid Afsharzadeh, MD, Ali Keshavarzian, MD, Division of Digestive Diseases, Rush University Medical Center, Chicago, IL.

P602. Do Patients with Inflammatory Bowel Disease Worry about Their Risk of Colon Cancer? A Study of Patients' Perception of Their Own Colon Cancer Risk
Sonia Friedman, MD, Adam Cheifitz, MD, Frank Farrary, MD, Medicine, Brigham and Women’s Hospital, Medicine, Beth Israel Medical Center, and Medicine, Boston University Medical Center, Boston, MA.

P603. NOD2/CARD15 Gene Exons Sequencing in Iranian Patients with Crohn's Disease
Nosratollah Naderi, MD, Alma Farnood, MD, Manijeh Habibi, Msc, Elham Vali Khoeini, MD, Hedieh Balai, BS, Faramarz Derakhshan, MD, Farzad Firouzi, MD, Mohammad Reza Zali, MD, FACG, Research Center for Gastroenterology and Liver Disease, Shaheed Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.

P604. Efficacy and Safety of Rifaximin as Maintenance Therapy for Mild–Moderate Crohn’s Disease Refractory to Multiple Medical Therapies
Asher Kornbluth, MD, Michele Kissous-Hunt, RPA, James George, MD, Peter Legnani, MD, Gastroenterology, Mt. Sinai Medical Center, New York, NY.

P605. Nutritional Changes in Crohn's Disease Patients Treated with Infliximab
Dawn Wiese, BS, Bret Lashner, MD, Douglas Seidner, MD, Gastroenterology, Cleveland Clinic, Cleveland, OH.

P606. Chronic Perceived Psychological Stress and the Regulation of Pro-Inflammatory Cytokines in Ulcerative Colitis
Gary E. Wild, MD, PhD, FRCP, Gastroenterology, McGill University Health Centre, Montreal, QC, Canada.

P607. Enterocutaneous Fistula after Closure of Temporary Ileostomy, Incidence, Management and Outcome
Renyu Zhang, MD, Victor Fazio, MD, Feza Remzi, MD, Colorectal Surgery, The Cleveland Clinic Foundation, Cleveland, OH.

P608. Long-Term Results of Adalimumab Treatment in Subjects with Moderately to Severely Active Fistulizing Crohn's Disease Who Have Failed Response or Showed Intolerance to Infliximab
F. Gornollon, MD, J. Hinojosa, MD, P. Nos, MD, M. Penate, MD, D. Ceballos, MD, M.A. Gassull, MD, Hospital Clinico Lozano Blesa, Zaragoza, Spain; Hospital Sagunto, Sagunto, Spain; Hospital La Fe, Valencia, Spain; Hospital Insular Las Palmas, Las Palmas, Spain; Hospital de Gran Canaria Dr. Negrín, Las Palmas, Spain and on Behalf of GETECCU, Hospital Germans Trias I Pujol, Barcelona, Spain.

P609. Adalimumab Therapy for Patients with Ulcerative Colitis Who Have Lost Response or Are intolerant of Infliximab
Eugene F. Yen, MD, Jonathan P. Terdiman, MD, Uma Mahadevan, MD, Division of Gastroenterology, University of California San Francisco, San Francisco, CA.

P610. Gastroenterologists' Tolerance for Crohn's Disease Treatment Risks
B. Sands, C. Siegel, S. Ozdemir, S. Hass, D. Miller, Massachusetts General Hospital, Boston, MA; Dartmouth-Hitchcock Medical Center, Lebanon, NH; RTI International, Research Triangle Park, NC; and Elan Pharmaceuticals, San Diego, CA.

P611. Comparison of the Penetration of Certolizumab Pegol and Adalimumab in Inflamed and Noninflamed Mouse Tissue
Andrew M. Nesbitt, PhD, Roger T. Palfman, PhD, Alex D. Vugler, MSc, Adrian R. Moore, PhD, Mark B. Baker, MSc, Roland Foulkes, PhD, Neil Gazzard, PhD, Celltech Antibody Biology Division, UCB, Slough, United Kingdom.

P612. Serologic Markers Are Associated with Subsequent Crohn's Disease Diagnosis and Fistulizing Complications in Ulcerative Colitis Patients Who Undergo Ileal Pouch Anal Anastomosis
Kleanthis G. Dendrinos, MD, Arthur F. Stucchi, PhD, James Becker, MD, Wayne LaMorte, MD, Francis A. Farrary, MD, Section of Gastroenterology and Department of Surgery, Boston University School of Medicine, and Biostatistics, Boston University School of Public Health, Boston, MA.

P613. Minimally Important Difference for WPAI:CD Scores: Defining Relevant Impact on Work Productivity in Active Crohn's Disease
William J. Sandborn, MD, Margaret C. Reilly, MA, Martin C.J. Brown, MSc, Yves Brabant, MSc, Laetitia C. Gerlier, MSc, Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN; Margaret Reilly Associates Inc., New York, NY; Global Health Outcomes Research, UCB Celltech, Slough, United Kingdom; AXEN, Brussels, Belgium and Keyrus Biopharma, Levallois-Perret, France.

P614. Long-Term Remission Rates in Patients with Mild-to-Moderate Ulcerative Colitis Who Require an MMX™ Mesalamine Dose Increase To Induce Initial Remission
Stephen B. Hanauer, MD, Michael A. Kamm, MD, Ron Diebold, PhD, Karen Barrett, MSc, Raymond E. Joseph, MD, Section of Gastroenterology and Nutrition, University of Chicago, Chicago, IL; Department of Gastroenterology, St. Mark’s Hospital, London, United Kingdom; Shire Pharmaceuticals Inc., Wayne, PA and Shire Pharmaceuticals Inc., Basingstoke, Hampshire, United Kingdom.
P615. A Randomized Prospective Trial of Endoscopic Ultrasound (EUS) To Guide Combination Medical and Surgical Treatment for Crohn’s Perianal Fistulas
Natalie M. Spradlin, MD, Paul Wise, MD, Alan Herline, MD, Roberta Muldoon, MD, David A. Schwartz, MD, Gastroenterology, Vanderbilt University Medical Center, Nashville, TN and Colon and Rectal Surgery, Vanderbilt University Medical Center, Nashville, TN.

P616. Surveillance Pouch Endoscopy for the Detection of Dysplasia in Ulcerative Colitis Patients with Ileal-Pouch Anal Anastomoses Is Cost-Effective (IPAAN)
Bo Shen, MD, Alex Z.H. Fu, PhD, Bret Lashner, MD, Feza H. Remzi, MD, Victor W. Fazio, MD, Digestive Disease Center, Cleveland Clinic, Cleveland, OH.

P617. Younger Age at Diagnosis Predicts Disease Severity in Ulcerative Colitis
Lee Roth, MD, Nileshe Chande, MD, Agatha Lau, MD, Maya Roth, MA, Terry Ponich, MD, Jamie Gregor, MD, Division of Gastroenterology, London Health Sciences Centre, London, ON, Canada.

P618. Risk Factors for Ulcerative Colitis (UC) Surgery in a Population-Based Cohort
Steven B. Ingle, MD, Shamima Dhillon, MD, W. Scott Harmsen, MS, Alan R. Zinsmeister, PhD, William J. Tremaine, MD, William J. Sandborn, MD, Edward V. Loftus, MD, Mayo Clinic, Rochester, MN.

P619. Time to Initial Symptom Resolution with MMX™ Mesalamine Therapy for Active, Mild-to-Moderate Ulcerative Colitis
William J. Sandborn, MD, Robyn Karlstadt, MD, Karen Barrett, MSc, Raymond E. Joseph, MD, Inflammatory Bowel Disease Clinic, Mayo Clinic, Rochester, MN; Shire Pharmaceuticals Inc., Wayne, PA and Shire Pharmaceuticals Inc., Basingstoke, Hampshire, United Kingdom.

P620. PROTECT-1: A Prospective Randomized Trial of CCX282-B (Traficit), a Novel Oral Therapy Targeting Chemokine Receptor 9 in Crohn's Disease
Salish Keshav, MD, Robert Petryka, MD, Tomas Vanásk, MD, Yaron Niv, MD, Krzysztof Marlicz, MD, PhD, Ole Haagen-Nielsen, MD, Marta Machado, MD, Jens Dahlherup, MD, Stefan Schreiber, MD, Pirow Bekker, MD, Sujata Sanith, PhD, Thomas J. Schall, PhD, Gastroenterology, Oxford University, Oxford, United Kingdom; Gastroenterology, NZOZ Vivamed, Warsau, Poland; Hepato-Gastroenterology, Edvarda Beneš 1549-Poliklinika III, Hradec Kralove, Czech Republic; Gastroenterology, Rabin Medical Center, Petach Tikva, Israel; Gastroenterology, Klinika Gastroenterologi i Chorób, Szczecin, Poland; Gastroenterological Dept, Herlev Hospital, Herlev, Denmark; Gastroenterology, Hospital Sào Lucas, Porto Allegre, Brazil; Medical Dept, Arhus University Hospital, Arhus, Denmark; Institute for Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany and ChemoCentryx, Mountain View.

P621. Sustainability of Adalimumab in Fistula Healing and Response: 2-Year Data from CHARM and 12-Month Open-Label Extension Follow-Up Study
J.F. Colombel, MD, M.A. Kamrn, MD, D. Schwartz, MD, W.J. Sandborn, MD, J. Li, PhD, K.G. Lomax, MD, P.F. Pollack, MD, CHU Lille, Lille, France; St. Mark’s Hospital, Harrow, United Kingdom; Vanderbilt University Medical Center, Nashville, TN; Mayo Clinic, Rochester, MA and Abbott, Parsippany, NJ.

P622. Sustained Efficacy and Tolerability of Certolizumab Pegol over 18 Months: Data from PRECiSE 2 and Its Extension Studies (PRECiSE 3 and 4)
Stefan Schreiber, MD, Julian Panes, MD, David Mason, MD, Gary R. Lichtenstein, MD, William J. Sandborn, MD, Medicine, Christian-Albrechts University, Kiel, Germany; Gastroenterology, Hospital Clinic de Barcelona, Barcelona, Spain; Clinical Development, UCB, Slough, United Kingdom; Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA and Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

P623. Validation of an Algorithm for Predicting IBD, CD and UC in a Comprehensive Population
Augusto Lois, PhD, Susan Carroll, PhD, Bruce Neri, PhD, Prometheus Laboratories, San Diego, CA.

P624. Clinical Predictors of Elevated C-Reactive Protein (CRP) among Patients with Active Inflammatory Bowel Disease
Houssam Mardini, MD, Razvan Arsenescu, MD, Trevor Winter, MD, Willem de Villiers, MD, Department of Digestive Diseases and Nutrition, University of Kentucky, Lexington, KY.

P625. Elevated CRP (C-Reactive Protein) Levels Can Predict Ileal Involvement in Patients with Inflammatory Bowel Disease
Prabhat P. Swaroop, MD, Naishadh Raghuwanshi, MD, Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, TX and Gastroenterology and Hepatology, Saint Louis University Hospital, Saint Louis, MO.

FUNCTIONAL BOWEL DISORDERS

P626. Can Thrombosis Be Predicted in Patients with Gastroparesis? 2007 ACG Presidential Poster Award Recipient
Bradley Creel, MD, Thomas L. Abell, MD, William Rock, MD, William Johnson, PhD, Department of Digestive Diseases, Department of Pathology, and Department of Preventive Medicine and Biostatistics, University of Mississippi Medical Center, Jackson, MS.

P627. Double Blind Randomized Study of Temporary Gastric Electrical Stimulation (GES): Preliminary Results of EndoStim Study and Correlation with Mucosal EGG
Stephen Weeks, MD, Janell Thompson, MD, William D. Johnson, MD, Thomas L. Abell, MD, Dept. of Digestive Diseases, University of Mississippi Medical Center, Jackson, MS.

P628. Complete Spontaneous Bowel Movement Frequency as Primary Outcome Measure in Patients with Chronic Constipation Treated with Linacolitide
Jeffrey M. Johnston, MD, James Mac Dougall, PhD, Bernard J. Lavins, MD, Caroline B. Kurtz, PhD, Microbia, Inc., Cambridge, MA.

P629. Pregabalin Ameliorates Abdominal Pain from Adhesions
Ann Silverman, MD, Helen Gikas, RN, Qiana Samuels, BA, Martin Zonca, MD, Dept. of Internal Medicine, Div. of Gastroenterology, Henry Ford Health System, Detroit, MI.

P630. Multi-Specialty Functional Bowel Center Outcomes in Irritable Bowel Syndrome
Yamini Subbiah, MD, Jorge Vazquez, MD, Kathy Sepesy, BSN, Paul J. Lebovitz, MD, Department of Gastroenterology, Allegheny General Hospital, Pittsburgh, PA.
Xuan Jiang, MD, Giles R. Locke, MD, FACG, Rok Seon Choung, MD, Alan R. Zinsmeister, PhD, Cathy D. Schleck, BSc, Nicholas J. Talley, MD, PhD, FACG, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN; Division of Gastroenterology and Hepatology, People’s Hospital, Peking University, Beijing, China, and Department of Health Sciences Research and Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, MN.

P632. Mucosal Cytokine Imbalance in Irritable Bowel Syndrome (IBS)
Eamonn M. Quigley, MD, John McSharry, PhD, Liam O’Mahony, PhD, Aine Fanning, PhD, Emer Bairead, PhD, Paul Scully, PhD, Jay Tiesman, PhD, Andy Fulmer, PhD, Timothy Dinan, MD, Graham Sherlock, PhD, Fergus Shanahan, MD, Alimentary Pharmacological Centre, University College Cork, Cork, Ireland; Alimentary Health Ltd, Kinsale, Cork, Ireland and Miami Valley Innovation Centre, Procter & Gamble, Cincinnati, OH.

P633. Impact of Combined Gastric and Sacral Stimulators on Upper/Lower Gastrointestinal and Urinary Symptoms
Chris Abrasley, MD, Shaily Jain, MD, Paige White, MD, Thomas Abell, MD, Dept. of Digestive Diseases, University of Mississippi Medical Center, Jackson, MS.

P634. Functional Dyspepsia: The Patient’s Perspective
Abigail T. Kennedy, BA, Kirsten T. Weiser, MD, Brian E. Lacy, PhD, MD, Michael D. Crowell, PhD, Nicholas J. Talley, PhD, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Mayo Medical Center, Scottsdale, AZ and Mayo Medical Center, Rochester, MN.

P635. A Long-Term Follow-Up Study of Children with Chronic Constipation
Kirin Goria, MD, Rita Steffen, MD, Gerard Banez, PhD, Pediatrics, MetroHealth Medical Center, Cleveland, OH; Pediatric Gastroenterology and Behavioral Pediatrics, Cleveland Clinic, Cleveland, OH.

P636. What Do Internal Medicine Residents Know about Irritable Bowel Syndrome?
Baseer Qazi, MD, Naser Khan, MD, Amit Gupta, MD, Kenneth O’Riordan, MD, Medicine, Division of Gastroenterology, Advocate Lutheran General Hospital, Park Ridge, IL.

P637. Predictors of Better Quality of Life Outcomes in Patients Suffering from IBS
Pierre Paré, MD, Robert Balshaw, PhD, Olaf Heisel, MD, PhD, Rose Liu, Martin Barbeau, Centre Hospitalier Affilie Universitaire de Quebec, Hospital du Saint-Sacrement, Quebec City, QC, Canada; Vancouver General Hospital, Vancouver, BC, Canada and Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.

P638. Work Productivity Is More Impaired in Functional Gastrointestinal Disorders Compared to GERD: Six-Month Data from Progress
Giles R. Locke, MD, Suzanne Clark, MS, Annamaria Cerulli, MPH, Josh Marehbian, MPH, Kristijan H. Kahler, PhD, RPh, Michael A. Shetzline, MD, PhD, Mayo Clinic College of Medicine, Rochester, MN; Health Benchmarks, Inc., Woodland Hills, CA and Novartis Pharmaceuticals Corporation, East Hanover, NJ.

P639. Pilot Study on Patient Centered Educational Intervention in Irritable Bowel Syndrome (IBS)
Albena Halpert, MD, Abha Verma, BA, Douglas Grossman, MD, Medicine/Gastroenterology, Boston University Medical Center, Boston, MA and UNC Center for Functional GI & Motility Disorders, University of North Carolina, Chapel Hill, NC.

P640. Satisfaction with Laxatives in Chronic Constipation (CC) and Irritable Bowel with Constipation (IBS-C)
Thao Nguyen, MD, Olafur S. Palsson, PsyD, Michael von Korff, ScD, Andrew D. Feld, MD, Rona L. Levy, PhD, Marsha J. Turner, MS, William E. Whitehead, PhD, University of North Carolina at Chapel Hill, NC; Group Health Cooperative of Puget Sound, Seattle, WA and University of Washington, Seattle, WA.

ENDOSCOPY

P641. Upper Gastrointestinal Tract Lesion Identification by Small Bowel Capsule Endoscopy
Sonia Z. Mian, MD, Milan Dodig, MD, Janice M. Santisi, RN, Division of Gastroenterology and Hepatology, Case Western Reserve at Metrohealth Medical Center, and Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation, Cleveland, OH.

P642. Safety Monitoring in a Phase 1 First-In-Human Study of the Anti-Viral Agent CMX001: A Novel Application of Wireless Capsule Endoscopy
H.S. Vanderveldt, MD, W. Painter, MD, A. Robertson, PhD, J.S. Barkin, MD, Div. of Gastroenterology, U. of MiamiMt. Sinai Med. Ctr., Miami, FL and Chimerix, Inc., Durham, NC.

P643. The Effect of Small Bowel Transit Time on the Yield of Video Capsule Endoscopy
Anthony Aghenta, MD, Ayodele Osowo, MD, Vinod Jeevanantham, MD, Tarun Kohli, MD, FACG, FACP, Internal Medicine, Unity Health System, Rochester, NY.

P644. Endoscopic Ultrasonographic Evaluation of Hemodynamics in Esophageal Variceal Patients Related to Early Variceal Relapse
Takahiro Sato, MD, Katsu Yamazaki, MD, Jouji Toyota, MD, Yoshiyasu Karino, MD, Takumi Ohmura, MD, Jun Akaide, MD, Gastroenterology, Sapporo Kosei General Hospital, Sapporo, Japan.

P645. The Frequency of Intraabdominal Metastasis Identified during EUS Staging for Lung Cancer in a Community Setting
John C. Deutsch, MD, Madeline S. Pokorney, BA, Kirk P. Bernadino, MD, Gastroenterology, St. Mary’s Duluth Clinic, Duluth, MN.

P646. Presence of Lymph Node Vasculature: A New EUS Criterion for Benign Nodes?
Joshua D. Hall, MD, Michel Kahaleh, MD, Grace White, RN, Patrick G. Northup, MD, Vanessa M. Shami, MD, Internal Medicine, University of Virginia, Charlottesville, VA.

P647. Colonc, Non-Rectal, Submucosal Lesions Referred for EUS Staging and Irritable Bowel with Constipation (IBS-C)
William E. Norris, MD, Bruce D. Greenwald, MD, Peter E. Darwin, MD, Scott Oosterveen, MD, Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD.

P648. Natural History of the Mallory Weiss Tear in African-American and Hispanic Patients
Abbasi J. Akhtar, MD, Internal Medicine/Gastroenterology, Charles R. Drew University of Medicine and Science, Los Angeles, CA.

P649. Predictors of Rebleed in Actively Bleeding Duodenal Ulcer after Endoscopic Intervention in a Developing Asian Country
Shahid Majid, FCPS, Asif Ali Ahmed, FCPS, Wasiem Jafri, FRCP, FACG, Adeel Nasir, MBBS, Medicine, Aga Khan University Hospital, Karachi, Pakistan.
P650. Endoscopic Necrosectomy as a Primary Treatment Modality for Pancreatic Abscess
Kevin P. Meitz, DO, Abraham Mathew, MD, Gastroenterology & Hepatology, Hershey Medical Center/Penn State University, Hershey, PA.

P651. Prophylactic Antibiotic Usage in Endoscopic Retrograde Cholangiopancreatography (ERCP): A Meta-Analysis and Systematic Overview
Faisal A. Bukenr, MD, Rubayat Rahman, MD, MPH, Digestive Diseases-Medicine, WVU School of Medicine, Morgantown, WV.

P652. ERCP-Associated Pancreatitis: Systematic Evaluation of 99,483 ERCP Procedures with Qualitative Meta-Analysis
Nirmal S. Mann, MD, FACP, John D. Ward, MD, Gastroenterology, UC Davis, Sacramento, CA and Med Library, UC Davis, Sacramento, CA.

P653. Endoscopic Management of Postcholecystectomy Biliary Leaks
Virendra Singh, MD, Rahul Gupta, MD, Gurpreet Singh, MS, Ganga Ram Verma, MS, Hepatology and Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

P654. Seizure-like Activity and Other Adverse Events While Using Propofol: A Retrospective Observational Study of 38,575 Sequential Endoscopies in an Outpatient Gastrointestinal Endoscopy Center
Ketul Patel, MD, Ryan Fauble, MD, Su-Linn Zywol, MS, Alan Clutter, MD, Gastroenterology, Providence Hospital and Medical Center, Southfield, MI and Michigan Endoscopy Center, Farmington Hills, MI.

P655. Biopsy Forceps-Guided Ileal Intubation (BIGII)
Tat-Kin Tsang, MD, Tiffany Graybill, MD, Department of Medicine, Feinberg School of Medicine, Northwestern University, Evanston, IL.

P656. Successful Endoscopic Closure of Postoperative Colocutaneous Fistula
Rajasekhar R. Mummadi, MD, Guillermo Gomez, MD, Gollumkkula S. Raju, MD, MRCP, Division of Gastroenterology and Department of Surgery, The University of Texas Medical Branch, Galveston, TX.

P657. Management of the Poorly Prepared Colonoscopy Patient: Colonoscopic Colon Enemas as a Preparation for Colonoscopy
Norman Sohn, MD, Michael A. Weinstein, MD, Surgery, Lenox Hill Hospital, New York, NY.

P658. Predicting Sedation Induced Respiratory Compromise during Colonoscopy
Suzanne B. Karan, MD, William Voter, MA, Ashok Shah, MD, William Sauer, BS, Denham S. Ward, MD, PhD, Anesthesiology and Gastroenterology, University of Rochester, Rochester, NY.

P659. Recall of Informed Consent and Patient Satisfaction with the Addition of an Educational Video Prior to Colonoscopy
Nirmala M. Sivaprakasapillai, MD, Aditi Nerurkar, MD, Gregory Seltzer, MD, Adam B. Elfant, MD, Gastroenterology/Internal Medicine, Cooper University Hospital, Camden, NJ.

P660. Can Colonoscopy Performed for Reason Other Than Screening Replace Screening Colonoscopy for Colorectal Carcinoma Screening
Hemal Patel, MD, Essam Quraishi, MD, Rana Sabbagh, MD, Osama Alaradi, MD, Internal Medicine, and Gastroenterology, Henry Ford Hospital, Detroit, MI.

Judy Oh, MD, Faroqoox Dastgir, MD, Toomas Sorra, MD, Adnan Khdair, MD, Irwin M. Grosman, MD, Gastroenterology, Long Island College Hospital, Brooklyn, NY.

P662. Identifying Barriers To Keeping Endoscopy Appointments
Raymond G. Duggan, DO, Dawn M. Sears, MD, Gastroenterology, Scott & White Memorial Hospital, Temple, TX.

P663. A Novel Use of Side-Viewing Endoscopy: Detection, Visualization, and Removal of Technically Difficult Left Sided Polypos
Jerry Martel, MD, Amar Deshpande, MD, Robert I. Goldberg, Division of Gastroenterology, Mount Sinai Medical Center, University of Miami Miller School of Medicine, Miami Beach, FL.

P664. Use of CO2 for Insufflation during Colonoscopy in Children
Eduardo Isbarguen-Secchia, MD, Pediatric Digestive Care, San Antonio, TX.

P665. pH Probe Indices in Infants with Gastroesophageal Reflux Presenting with or without Respiratory Symptoms
B. Muckova, MD, S. Rajeевич, RN, A. Shah, M. Shah, MD, Pediatric Gastroenterology, Loma Linda University, Loma Linda, CA.

P666. Demographic Profile of Children Diagnosed with Celiac Disease
Ajay Kaul, MD, Jose M. Garza, MD, Gastroenterology, Hepatology & Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

P667. Use of Rifaximin in Pediatric Patients with Inflammatory Bowel Disease
Pramodha Muniyappa, MD, Reema Gulati, MD, Hupertz Vera, MD, Pediatric Gastroenterology, Cleveland Clinic, Cleveland, OH and MetroHealth Medical Center, Cleveland, OH.

P668. Utilization of Nitazoxanide for the Empirical Treatment of Pediatric Diarrhea of Unknown Etiology
Youhanna Al-Tawil, MD, Alexandra Eidelwein, MD, Clarisa Cuevas, MD, Anthony S. Jackson, PharmD, Childrens Hospital Pediatric Gastroenterology, Knoxville, TN and Department of Medical Science, Romark Laboratories, L.C., Tampa, FL.

P669. Chromosomal 1p36 Deletion: Inflammatory Bowel Disease, Sclerosing Cholangitis and Annullar Pancreas
Samra S. Blanchard, MD, Rita Gnyawali, MD, Anjali Malkani, MD, Pediatric Gastroenterology, University of Maryland, Baltimore, MD.

P670. Pneumatosis Intestinalis: Rare Presentation of Crohn's Disease
Hershey, PA.

P671. The Constipated Child: Is There a Correlation between Symptoms and Manometric Findings?
Lisa A. Feinberg, MD, Lori Mahajan, MD, Rita M. Steffen, MD, Department of Pediatric Gastroenterology, Cleveland Clinic Children's Hospital, Cleveland, OH.
COLORECTAL CANCER PREVENTION

P672. Gender and Subsite Locations Modulate the Chemopreventive Efficacy of Celecoxib: A MIN Mouse Study
Mary Nyhuis, Jennifer Koetsier, Ramesh Wali, PhD, Dhananjay Kunte, PhD, Russ Pelham, PhD, Mark Cleveland, PhD, Hemant K. Roy, MD, Research, Evanston Northwestern Healthcare, Evanston, IL and Braintree Labs, Braintree, MA.

P673. Measuring Compliance with Routine Screening Recommendations in Health Care Workers
Zeba Anwar, MD, Nazif Chowdhury, MD, Leslie Bank, MD, Internal Medicine, Wilson Memorial Regional Medical Center, Johnson City, NY; and Gastroenterology, Wilson Memorial Regional Medical Center, Johnson City, NY.

P674. Endoscopists Recommend Shortened Surveillance Intervals
LeAnn C. Michaels, BS, Nora C. Mattek, MPH, Cynthia D. Morris, PhD, David A. Lieberman, MD, Gastroenterology, OHSU, Portland, OR.

P675. A Paid Day Off from Work Increased Willingness To Have Screening Colonoscopy
Kavitha Kumbum, MD, David Widjaja, MD, Kalyan C. Kanneganti, MD, Prospere Remy, MD, Sridhar S. Chilimuri, MD, Gastroenterology/Medicine, Bronx Lebanon Hospital Center, Bronx, NY.

P676. Marked Racial/Ethnic Differences in Acceptance of and Barriers to Colorectal Cancer Screening in a Primary Care Setting
Najm M. Soofi, MD, MPH, David Aizenberg, MD, Craig T. Tenner, MD, Michael Poles, MD, PhD, Edmund J. Bini, MD, MPH, Gastroenterology and Internal Medicine, New York University Medical Center, New York, NY.

P677. The Influence of Race and Gender on Colon Polyp Incidence after Polypectomy
Eli Penn, MD, Donald Garrow, MD, Joseph Romagnuolo, MD, General Internal Medicine, and GI and Hepatology, Medical University of South Carolina, Charleston, SC.

P678. Ethnic Differences in Findings on Screening Colonoscopy
Roy D. Yen, MD, Ognian Pomakov, MD, Michael Sitrin, MD, Shahid Mehboob, MD, Internal Medicine/Gastroenterology, Unv at Buffalo/Western NY VA, Buffalo, NY.

P679. Disparities in Colon Cancer Screening—A Population Study
Carline Quander, MD, MS, Steve Whitman, PhD, Ami M. Shah, MPH, Internal Medicine, Rush University Medical Center, and Urban Health Institute, Sinai Health System, Chicago, IL.

P680. An Elevated Rate of Adenoma Detection in an Urban Latin American Population Undergoing Colorectal Cancer Screening
K. Grover, MD, R.J. Bienwirth, MD, M.J. Sterling, MD, D.M. Rosenblum, PhD, G. Ashrafzadeh, MD, S.H. Weiss, MD, The Division of Gastroenterology and the Department of Preventative Medicine and Community Health, UMDNJ–New Jersey Medical School, Newark, NJ.

P681. Low Frequency of Colon Polyps in Association with Diverticulosis
Amol S. Rangnekar, MD, Aaron Z. Tokayer, MD, Gastroenterology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY.

P682. Gastroenterologists’ Patient Instructions for Oral Sodium Phosphate Solution for Colonoscopy Preparation: A Survey among Gastroenterologists in the State of Indiana
Veronika Gagovic, MD, Douglas K. Rex, MD, Department of Medicine, Division of Gastroenterology, Indiana University, Indianapolis, IN.

P683. Obesity (BMI > 30) Has Highest Attributable Risk for Colorectal Neoplasia in Asymptomatic Women
Benjamin N. Stein, MD, Joseph C. Anderson, MD, Zvi Alpern, MD, Carol M. Martin, ANP, Patricia Hubbard-Ells, ANP, Gastroenterology, Stony Brook University, Stony Brook, NY.

P684. Body Mass Index, Waist-to-Hip Ratio, Family History and Risk of Colorectal Cancer. A Prospective Study
Edson J. da Silva, MD, Alexandre D. Pelosi, MD, Glaucia R. de Freitas, MD, Marcelo R. da Camara, MD, Eleodoro C. de Almeida, MD, Proctology, Hospital dos Servidores do Estado, Rio de Janeiro, Brazil and Digestive Endoscopy, Casa de Portugal, Rio de Janeiro, Brazil.
**ESOPHAGUS**

P685. The Prevalence of Barrett’s Esophagus in Patient with or without GERD Symptoms
Xingqin Fan, MD, Ned Snyder, MD, Gastroenterology and Hepatology, University of Texas Medical Branch, Galveston, TX.

P686. Barrett’s Esophagus under Antisecretory Therapy: The Higher the Severity of Dysplasia, the Higher the Likelihood of Regression
Adewale B. Ajumobi, MD, Khaled Bahjri, MD, Sharma Rajiv, MD, Ronald A. Griffin, MD, Internal Medicine and Public Health, Loma Linda University, and Gastroenterology, Jerry L. Pettis VA Medical Center, Loma Linda, CA.

P687. Intragastric Acid Control in Patients Who Have Barrett’s Esophagus: Comparison of Once- and Twice-Daily Regimens of Esomeprazole and Lansoprazole
Stuart J. Spechler, MD, FACC, Peter N. Barker, PhD, Debra G. Silberg, MD, FACG, University of Texas Southwestern Medical Center, Dallas, TX and AstraZeneca LP, Wilmington, DE.

P688. Changes in Quality of Life over Time in Patients Registered on the Mayo Clinic Esophageal Adenocarcinoma and Barrett’s Esophagus Registry
Pamela J. Atherton, MS, Brian F. Kabat, BS, Robert C. Miller, MD, Yvonne Romero, MD, Mary Fredericksen, Jeff A. Sloan, PhD, Mayo Clinic Cancer Center Statistics, Radiology, and Digestive Diseases and Cancer Clinics, Mayo Clinic, Rochester, MN.

P689. Are Patients with Barrett’s Esophagus Likely To Develop Cancer or High Grade Dysplasia If They Miss Their Surveillance Endoscopy?
Adewale B. Ajumobi, MD, Khaled Bahjri, MD, Ronald A. Griffin, MD, Internal Medicine and Public Health, Loma Linda University, and Gastroenterology, Jerry L. Pettis VA Medical Center, Loma Linda, CA.

P690. Presentation and Prognosis of Esophageal Adenocarcinoma in Patients Below Age 50
Nikroo Hashemi, MD, Sidney Cohen, MD, Terry Hyslop, PhD, Anthony J. DiMarino, MD, David E. Loren, MD, Gastroenterology and Hepatology, and Biostatistics, Thomas Jefferson University Hospital, Philadelphia, PA.

P691. Coexistence of Barrett’s Esophagus and Eosinophilic Esophagitis
Cristina Alfonsana, MD, Herbert Wolfsen, MD, Kenneth Devault, MD, Sami R. Achem, MD, Gastroenterology, Mayo Clinic, Jacksonville, FL.

P692. Decreased GLIPR1 Expression in Esophageal Adenocarcinoma
Keith Brown, MD, Timothy C. Thompson, PhD, Chengzhen Ren, PhD, Mahdis Rahmani, MS, Mounom Younes, MD, Pathology and Scott Department of Urology, Baylor College of Medicine, Houston, TX.

P693. Use of Narrow Band Imaging (NBI) To Detect Esophagitis in Non Erosive Reflux Disease (NERD)
Daniel A. Ringold, MD, Sanjay Sikka, MD, Bhaskar Banerjee, MD, Division of Gastroenterology, Washington University School of Medicine, Saint Louis, MO.

P694. Barrett’s Esophagus and Helicobacter pylori Infection
Xiangwen Meng, PhD, Marc Scheer, MD, Tat-Kin Tsang, MD, Medicine, Evanston Northwestern Healthcare, and Medicine, Northwestern University, Feinberg School of Medicine, Evanston, IL.

P695. EGFR, p-Erk and p-AKT Expression in Barrett’s Esophagus (BE): A Prospective Pilot Study
Abha Rani, MD, Milind M. Javle, MD, Charles M. LeVea, MD, PhD, Jihnhee Yu, PhD, Michael Brattain, PhD, Jennifer D. Black, PhD, Michael Sitrin, MD, Department of Gastroenterology, State University of New York at Buffalo, and Roswell Park Cancer Institute, Buffalo, NY.

P696. The Evaluation of Definitive Radiation Therapy for Patients with Stage II-III Squamous Cell Carcinoma of the Esophagus
Tetsuo Nonaka, MD, PhD, Hideyuki Sakurai, MD, PhD, Hitoshi Ishikawa, MD, PhD, Mariko Shiroya, MD, Masumi Murata, MD, Katsuyuki Shirai, MD, Koichi Harashima, MD, PhD, Takeshi Ebara, MD, PhD, Takashi Nakano, MD, PhD, Hiroyuki Kato, MD, PhD, Hiroyuki Kuwano, MD, PhD, Radiation Oncology, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan and General Surgical Science (Surgery I), Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan.

Yize Wang, MD, PhD, Joel E. Richter, MD, MACG, Gastrointestinal Section, Department of Medicine, Temple University School of Medicine, Philadelphia, PA.

P698. Adenocarcinoma of Esophagus and Cardioesophageal Junction (CE): 10 Year Experience
Edward S. Friedman, MD, Anu K. Mathew, MD, Cameron Kifar, DO, Richard Gerkin, MD, Kathleen M. Rogers, CTR, Francisco C. Ramirez, MD, Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix, AZ and Medicine, Banner Health Samaritan Hospital, Phoenix, AZ.

P699. Is There a Difference in the Prevalence of Helicobacter pylori Infection between Short-Segment and Long-Segment Barrett’s Esophagus?
Changcheng Wang, MD, Yuhong Yuan, PhD, Richard H. Hunt, MD, FRCP, FRCPG, Division of Gastroenterology, McMaster University Health Science Centre, Hamilton, ON, Canada.

P700. Endoscopic Full-Thickness Plication for the Treatment of GERD: 12 Month Follow-Up in the Sham-Controlled Trial
Richard I. Rothstein, MD, Charles Filipi, MD, Karol Caca, MD, Ronald Pruitt, MD, Klaus Mergener, MD, Alfonso Torquati, MD, Gregory Haber, MD, Kenneth Chang, MD, David Wong, MD, Jacques Deviere, MD, Douglas Pleskow, MD, Charles Lightdale, MD, Alain Ades, MD, Richard Kozarek, MD, William Richards, MD, Anthony Lembo, MD, Dartmouth Medical School, Lebanon, NH; Creighton University Medical Center, Omaha, NE; Klinikum Ludwigsburg University Heidelberg, Ludwigsburg, Germany; Saint Thomas Hospital, Nashville, TN; Digestive Health Specialists, Tacoma, WA; Vanderbilt University Medical Center, Nashville, TN; Lenox Hill Hospital, New York, NY; University of California Irvine, Orange, CA; Tri Valley Gastroenterology, San Ramon, CA; Erasme Hospital, Brussels, Belgium; Beth Israel Deaconess Medical Center, Boston, MA; Columbia University Medical Center, New York, NY; Seacoast Gastroenterology, Exeter, NH and Virginia Mason Medical Center, Seattle, WA.

P701. Photodynamic Therapy Decreases DNA Content Abnormalities in Residual Non-Dysplastic Barrett’s Esophagus
Weitian Liu, MD, Jason L. Hornick, MD, Robert D. Odze, MD, Mari Mino-Kenudson, MD, Gregory Y. Lauwers, MD, Raj K. Goyal, MD, Gastroenterology, Hepatology and Endoscopy; Pathology, Brigham and Women’s Hospital, Harvard Medical School (HMS), Boston, MA; Pathology, Massachusetts General Hospital, HMS, Boston, MA and Medicine, Veterans Affairs Medical Center, HMS, West Roxbury, MA.
P702. Utility of Endoscopic Ultrasound Prior to Esophagectomy for High Grade Dysplasia in Barrett's Esophagus
G.A. Prasad, MD, K.K. Wang, MD, R.J. Badreddine, MD, N.S. BUTTER, MD, L.M. Wongkeesong, MD, K.T. Dunagan, L.S. LUTZKE, L.S. Borkenhagen, Barrett's Esophagus Unit, Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN.

P703. Insulin-Like Growth Factor-1 Pathway Activation in Barrett's Esophagus
Kayode Olowe, MD, Dawn Dawson, MD, Joseph Willis, MD, Larry Miller, MD, Jason Taylor, MD, Jennifer Kimble, MD, Aimitab Chak, MD, Division of Gastroenterology, and Pathology, University Hospitals-Case Medical Center/Case Western Reserve University, Cleveland, OH.

P704. Endoscopic Full-Thickness Plication with Two Serially Placed Implants Improves Esophagitis, GERD Symptoms and Reduces PPI Use and Esophageal Acid Exposure
Daniel von Renteln, MD, Ullrike Brey, MD, Bettina Riecken, MD, Karel Caca, MD, Department of Gastroenterology, Klinikum Ludwigsburg, Ludwigsburg, Germany.

P705. Endoscopic Full-Thickness Plication for the Treatment of GERD: 6 Month Data of the German Multi-Center Serial Implant Trial
Karel Caca, MD, Ingo Schiefke, MD, Karl-Herrmann Fuchs, MD, Daniel von Renteln, MD, Susanne Radczynski, MD, Michael Philipper, MD, Wolfram Breithaupt, MD, Horst Neuhaus, MD, Department of Gastroenterology, Klinikum Ludwigsburg, Germany; Department of Surgery, Markus-Krankenhaus Frankfurt, Germany and Department of Internal Medicine, EVK Dusseldorf, Germany.

P706. POSTER WITHDRAWN

P707. Long Term Follow up of Patients Treated with Stretta ★ 2007 ACG Presidential Poster Award Recipient
Robert P. Yatto, MD, Genevra Russell, CGRN, Deborah Hargis, CGRN, Nancie Gunter, CGRN, Endoscopy Department, Cumberland Medical Center, Crossville, TN.

P708. Cryotherapy Ablation for Barrett's Esophagus (BE) with High-Grade Dysplasia (HGD) and Intramuscosal Carcinoma (IMCA), and Early Esophageal Cancer (EEC) ★ 2007 ACG Presidential Poster Award Recipient
Bruce D. Greenwald, MD, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD.

P709. 5-ALA Photodynamic Therapy Eliminates Resistant Barrett's Cells
Kenneth K. Wang, MD, Ganapathy Prasad, MD, Michel WongKeesong, MD, Navtej S. Buttar, MD, Wiste Westra, MD, Rami Badreddine, MD, Marlys Anderson, Lori Lutzke, Kelly Duncan, Lynn Borkenhagen, Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

STOMACH

P710. The Role of Flow Cytometry in the Diagnosis and Surveillance of Gastrointestinal Lymphomas
Minhuyen T. Nguyen, MD, Heba Durra, MD, David S. Weinberg, MD, Harry S. Cooper, MD, Tahseen I. Al-Saleem, MD, Fox Chase Cancer Center, and Temple University Hospital, Philadelphia, PA.

P711. Effect of Helicobacter pylori Infection on Gastric Cancer Development
Marcelo L. Ribeiro, PhD, Waldemar Bartchewsky, Jr., MS, Mariana R. Martini, MS, Marisa C. Alvarez, MS, Daisy M. Salvadori, PhD, Marcelo S. Ladeira, PhD, José Pedrazzoli, Jr., PhD, Unidade Integrade de Farmacologia e Gastroenterologia, Universidade São Francisco, Bragança Paulista, SP, Brazil and Departamento de Clinica Medica, UNESP, Botucatu, SP, Brazil.

P712. Do Minorities Have a Worse Outcome from Primary Gastric Cancer Than Whites?
Thomas Birris, MD, Andrew Albert, MD, MPH, Sherri Yong, MD, Stephen Sontag, MD, Gastroenterology, Hepatology, and Nutrition, Loyola University Medical Center, Maywood, IL.

P713. Usefulness of Microvascular Diagnoses of Early Gastric Cancer Using Magnifying Endoscopy
Tomofumi Tanaka, Yasushi Oda, Makoto Yasunaga, Eisu Kaku, Kiwamu Hasuda, Seiji Ito, Hideyo Goto, Masahiro Hattori, Gastroenterology, Hattori G.I. Endoscopy and Oncology Clinic, Kumamoto, Japan.

P714. Helicobacter pylori Virulence Marker from an Area of High Prevalence, with Low Incidence of Gastric Carcinoma
Javed Yakob, PhD, Shahab Abid, FCPS, Zaigham Abbas, FACC, Jafri Wasim, FACC, Muhammad Islam, MSc, Rustam Khan, FCPS, Zubair Ahmad, FCPS, Medicine and Pathology, Aga Khan University, Karachi, Sindh, Pakistan.

P715. Expression of MUC5AC and TFF1 in Intestinal Metaplasia Subtypes
Byung Wook Kim, MD, Lee-So Maeng, MD, Kyong-Mee Kim, MD, In-Sik Chung, MD, Internal Medicine, and Pathology, The Catholic University of Korea, Seoul, Republic of Korea.

P716. Survival in Gastric Cancer Patients: Univariate and Multivariate Analysis
Bijan Moghimi Dethkordi, MSc of Epidemiology, Azadeh Saafaei, MSc of Epidemiology, Babak Noori Nayer, MD, Mohammad Reza Zali, MD, FACC, Cancer, Research Center of Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.

P717. Can Polaprezinc Be Attributed To Reduce the Risk of Gastric Carcinogenesis in Helicobacter pylori-Positive Young People?
Toshifumi Mitani, MD, Daisuke Shirasaka, MD, Hideyuki Miyachi, MD, Toshio Tanaka, MD, Naohisa Yahagi, MD, Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan and Department of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

P718. A Patient with Gastric Hodgkin's Lymphoma
Kaleem M. Rizvon, MD, Omer K. Masood, MD, Nausheur Khan-Bitni, MD, Paul J. Mustacchia, MD, Gastroenterology, Nutrition, Loyola University Medical Center, East Meadow, NY.

P719. Multiplex PCR To Detect H. pylori in MALToma and Its Role in Treatment and Prognosis: A Case Series
Xiangwen Meng, PhD, Veerpal Singh, MD, Tat-Kin Tsang, MD, ENH Research Institute, Evanston Northwestern Healthcare, Evanston, IL and Department of Medicine, Northwestern University, Feinberg School of Medicine, Evanston, IL.

P720. Helicobacter pylori (Hp) Seropositivity in Patients with Both Negative Rapid Urease Test (CLO) and No Histopathological Evidence of Hp
Kishore Maganty, MD, Adarsh Varma, MD, Swetha Kandula, MD, Larry F. Hughes, PhD, Jatinder P. Aihlwalia, MD, Division of Gastroenterology, Internal Medicine, and Surgery, Southern Illinois University School of Medicine, Springfield, IL.

P721. POSTER WITHDRAWN
P722. Longitudinal Study of Endoscopic Ultrasound-Guided Celiac Plexus Blockade (EUS-CPB) for Treatment of Painful Chronic Pancreatitis (CP)
Tyler Stevens, MD, Gregory Zuccaro, MD, John A, Dumot, DO, John J. Vargo, MD, MPH, Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, OH.

P723. Clinicopathologic Features of Surgically Resected Pancreatic Cystic Lesions
Michelle K. Kim, MD, Thomas Curran, BA, Daniel Labow, MD, Myron Schwartz, MD, Gabriel Levi, MD, Noam Harpaz, MD, PhD, Steven Itzkowitz, MD, Medicine, Surgery, and Pathology, Mount Sinai School of Medicine, New York, NY.

P724. Two Simple Vital Sign Measurements Plus Serum Albumin Are Strong Predictors of Disease Severity in Acute Pancreatitis?
Amit B. Schagia, MD, Raja Masood, MD, Rafiq Rehan, MD, Hiliary Hertan, MD, Nejat Kiyici, MD, Edward Norkus, PhD, Department of Gastroenterology & Medicine, Our Lady of Mercy Medical Center, Bronx, NY.

P725. Predictors of Morbidity from Local Complications in Severe Acute Pancreatitis
Hazem Hammad, MD, David Hough, MD, Santhi Swaroop Vege, MD, Brett T. Petersen, MD, Division of Gastroenterology and Hepatology, and Department of Radiology, Mayo Clinic College of Medicine, Rochester, MN and Department of Internal Medicine, Wayne State University, Detroit, MI.

P726. A Comparison of Ranson's Criteria Versus Sequential Organ Failure Assessment Score (SOFA) in Predicting Intensive Care Unit Admission, Morbidity and Mortality in Acute Pancreatitis in the Emergency Room
Mirela Meca, MD, Ari J. Wiesen, MD, Arkady Broder, MD, Brian Schwender, MD, Jonathan Wiesen, MS, Kostas Sideridis, DO, Prasun Jalal, MD, Steven Helft, MD, Simmy Bank, MD, Brian Schwender, MD, Jonathan Wiesen, MS, Kostas Sideridis, DO, Prasun Jalal, MD, Steven Helft, MD, Simmy Bank, MD, Gastroenterology, Long Island Jewish Medical Center, New Hyde Park, NY.

P727. Retrospective Comparison of Magnetic Resonance Cholangiopancreatography (MRCP) with Endoscopic Retrograde Cholangiopancreatography (ERCP) in the Diagnosis of Pancreaticobiliary Diseases
Emad Qayed, MD, Qiang Cai, MD, FACG, Department of Medicine Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA.

P728. Cluster of Cases of Gallstone Complications in Patients Less Than 31 Years of Age at UMC, Fresno, CA
Kandarp K. Shah, MD, Kalyani K. Shah, MD, Mandeep Singh, MD, Grace W. Huang, DO, Jasjit Singh, MBBS, Muhammad Y. Sheikh, MD, Gastroenterology, UCSF-Fresno, Fresno, CA.

P729. A Retrospective Comparison of ERCP Complications with Conventional ERCP vs. Wire Guided ERCP
Gregory J. Ward, MD, Leila Keyvani, MD, Donald R. Duerksen, MD, Internal Medicine, Section of Gastroenterology, University of Manitoba, Winnipeg, MB, Canada.

P730. Multiple Biliary Stent Placement Using Conventional Long Wire (OASIS) and Short Wire (Fusion OASIS with IDR) Stenting Systems for Benign Bile Duct Strictures (BBDS)—A Retrospective Study
Chhaya Hasyagar, MD, Brian S. Lim, MD, Kanat Ranisbrahmanakul, MD, Erina Foster, MD, Joseph W. Leung, MD, Gastroenterology, UC Davis Medical Center, Sacramento, CA and Sacramento VA Medical Center/VANCHCS, Mather, CA.

P731. Wire Controlled Cannulation Reduces the Risk of Post-ERCP Pancreatitis in Children by Initially Accessing the Bile Duct with a Soft-Tipped Guidewire, without Contrast Injection
R. Martin Bashir, MD; Bryan Fine, MD, Farvathi Mohan, MD, Ali Bader, MD, Sonia Sehgal, MD, Bernard Kerzner, MD, Gastro-enterology, Children's National Medical Center, Washington, DC.

P732. POSTER WITHDRAWN

P733. Recurrent Acute Pancreatitis Leads to Chronic Pancreatitis: A Prospective Case Series
Elie Aoun, MD, David C. Whitcomb, MD, Ferga C. Gleeson, MD, Dionysios J. Papachristou, MD, Adam Slivka, MD, Georgios I. Papachristou, MD, Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA; Medicine, Mayo Clinic, Rochester, MN and Medicine, Pittsburgh VA Health Care System, Pittsburgh, PA.

P734. Acute Experimental Pancreatitis in Rats Is Ameliorated by Treatment with Pramlintide, a Synthetic Analogue of the β-Cell Hormone Amylin
Bronislava Gedulin, MD, Pamela Smith, BS, Ginger Toschiaddi, Olara Polizzi, Andrew Young, MD, In Vivo Pharmacology, Amylin Pharmaceuticals, Inc., San Diego, CA.

P735. Painless Jaundice and an Extremely Elevated CA 19-9 Secondary to Choledocholithiasis, Not Malignancy
David L. Ulinch, MD, Saad Jazrawi, MD, Francis Lu, MD, James Robilotti, MD, Prim Chattoo, MD, Gastroenterology, Saint Vincents Medical Center, New York, NY.

P736. Adenocarcinoma of the Pancreas Presenting as Diabetic Ketoacidosis
Aly Lakhani, MB, BS, Michael Cannon, MD, Department of Internal Medicine, Gastroenterology Division, William Beaumont Hospital, Royal Oak, MI.

P737. Hepatic Resection Is a Safe and Effective Treatment for Bilateral Hepatolithiasis
Satoshi Nozawa, MD, Fumio Kimura, MD, Hiroaki Shimizu, MD, Hiroyuki Yoshidome, MD, Masayuki Ohtsuka, MD, Atsushi Kato, MD, Hideyuki Yoshitomi, MD, Katsunori Furukawa, MD, Noboru Mitsushima, MD, Dan Takeuchi, MD, Kousuke Suda, MD, Shigetsugu Takano, MD, Masaru Miyazaki, MD, Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

P738. Prevalence of Gall Bladder Dyskinesia in Gastroparesis
Savio Reddymsasu, MD, Harshal Patil, MD, Richard McCallum, MD, Medicine, Kansas University Medical Center, Kansas City, KS.

P739. Prevalence of the Calcium Sensing Receptor (CaSR) Gene Polymorphisms in Patients with Recurrent Acute and Chronic Pancreatitis with or without SPINK1 N34S
Venkat Muddana, MD, Michael M. Barnada, PhD, Janette Lamb, PhD, Beth Elinoff, MPH, Robert H. Hawes, MD, Peter B. Cotton, MD, Michelle Anderson, MD, Randall E. Brand, MD, Adam Slivika, MD, David C. Whitcomb, MD, Department of Medicine, UPMC Shadyside, Pittsburgh, PA; Department of Human Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA; Department of Medicine, UPMC Presbyterian, Pittsburgh, PA; Digestive Disorder Center, Medical University of South Carolina, Charleston, SC; Department of Medicine, University of Michigan Medical Center, Ann Arbor, MI and Department of Medicine, Evanston Northwestern Healthcare, Evanston, IL.
P740. The Yield of Routine Endoscopy with Duodenal Biopsies To Exclude Celiac Disease
Ramu P. Raju, MD, Daniel Moore, MD, Tolga Errim, DO, Fernando Castro, MD, Gastroenterology, Cleveland Clinic Florida, Weston, FL.

P741. Psychological Correlates of Gluten-Free Diet Adherence in Adults with Celiac Disease
Jessica B. Edwards George, PhD, Daniel A. Leffer, MD, Melinda Denis, RD, Ciaran P. Kelly, MD, Debra L. Franko, PhD, Jessica Blom-Hoffman, PhD, The Celiac Center, Beth Israel Deaconess Medical Center, and Applied Psychology, Northeastern University, Boston, MA.

P742. Histopathology Predicts Abnormal Liver Function Tests and Autoimmune Disorders in Celiac Disease
Kavita Singh, MD, Ece A. Mutlu, MD, Mark T. DeMeo, MD, Medicine, Rush University Medical Center, Chicago, IL.

P743. A Prospective Study of Five Measures of Gluten Free Diet Adherence in Adults with Celiac Disease
Daniel A. Leffer, MD, Jessica B. Edwards-George, PhD, Melinda Dennis, RD, Detlef Schuppan, MD, Ciaran P. Kelly, MD, Gastro-enterology, Beth Israel Deaconess Medical Center, Boston, MA.

P744. Positive Predictive Value of Tissue Transglutaminase: A Retrospective Review at Our Institution
Thomas Park, MD, Ibilola Fashoyin, MD, Marilyn A. Menegus, PhD, Arthur J. DeCross, MD, Division of Gastroenterology and Hepatology, and Division of Microbiology, University of Rochester, Rochester, NY.

P745. Clinical Characteristics and Prevalence of Celiac Disease and Non-Celiac Gluten Sensitivity Presenting to a Community Based Private Gastroenterology Clinic

P746. Celiac Disease in the Adult Community; Still a Rare Occurrence
Douglas J. Sprung, MD, Gregory M. Sprung, Maitland, FL.

P747. Genetic Testing Prior to Serologic Screening in Family Members of Patients with Celiac Disease as a Cost Containment Method
Matthew Chang, MD, Peter H. Green, MD, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY.

P748. Can Colorectal Cancer Screening Consultations Assist in Evaluating Physician Adherence to Management of Obese African American Patients?
Anita Mittal, MD, Rebecca Fausel, Marie L. Borum, MD, MPH, EdH, Internal Medicine, University of Hawaii, Honolulu, HI and Gastroenterology, The George Washington University School of Medicine, Washington, DC.

P749. Liver and Gastrointestinal Manifestations of Dengue Hemorrhagic Fever. An Analysis from a Cohort of 263 Hospitalized Patients
Antonio Ramos-De la Medina, MD, Tadeo Ceron, MD, Aurora Diaz-Vega, MD, Angelica Hernandez, MD, Jose M. Remes-Troche, MD, Gastroenterology and Gastrointestinal Surgery, Veracruz Regional Hospital, and Medical-Biological Research Institute, Universidad Veracruzana, Veracruz, Mexico.

P750. Severe Pulmonary Sarcoidosis Complicating Hepatitis C Therapy and Resolving after Treatment Withdrawal
Nalini K. Sharma, MD, Averell H. Sherker, MD, Gastroenterology, Washington Hospital Center, Washington, DC.

P751. Liver Histological Features of Randomly Selected Population with Abnormal Liver Sonography in Iran
Leila Pasharavesh, MD, Ziba Khorram, MD, Roshanak Roshanfek, MD, Kamran Shateri, MD, Ramin Tavazfzadeh, MD, Reza Mashayekhi, MD, Maryam Firoozi, BS, Amir Houshang Mohammad Alizadeh, MD, Farahnaz Fallahian, MD, Seyed Mohsen Mousavi, MD, Farzaneh Khadem Sameni, MD, Bahman Talebipoor, MD, Behnaz Mohabbbatian, MD, Mohammad Reza Zali, MD, FACG, Research Center of Gastroenterology and Liver Diseases, Shahid Beheshtee University of Medical Sciences, Tehran, Islamic Republic of Iran.

P752. Hepatic Fibrosis and Steatosis in Treatment Naive Chronic Hepatitis C Patients of Central California Valley
Muhammad Y. Sheikh, MD, Muhammad H. Bashir, MD, Humaira Sadiq, MD, Jaisj Stigl Singh, MBBS, Farheen A. Khan, William C. Pitts, MD, Kandarp K. Shah, MD, Division of Gastroenterology and Hepatology, University of California, San Francisco-Fresno Education Program, Fresno, CA.

P753. The Value of Serum Aminotransferases after Cardio-Pulmonary Resuscitation
Kavitha Kumbum, MD, David Widjaja, MD, Kalyan C. Kanneganti, MD, Pradeep R. Atia, MD, Prospere Remy, MD, Sridhar S. Chilumir Mit, MD, Gastroenterology/Medicine, Bronx Lebanon Hospital Center, Bronx, NY.

P754. Hepatic Fibrosis and Steatosis in Treatment Naive Chronic Hepatitis C Patients of Central California Valley
Muhammad Y. Sheikh, MD, Muhammad H. Bashir, MD, Humaira Sadiq, MD, Jaisj Stigl Singh, MBBS, Farheen A. Khan, William C. Pitts, MD, Kandarp K. Shah, MD, Division of Gastroenterology and Hepatology, University of California, San Francisco-Fresno Education Program, Fresno, CA.

P755. HBV Genotype in Northern Portugal
Susana Lopes, MD, Carla Rolanda, MD, Pedro Pereira, MD, Fernando Branca, MD, Mota Garcia, MD, Guilherme Macedo, MD, Gastroenterology Unit and Clinical Pathology, H.S. Marcos, Braga, Portugal.

P756. Retrospective Analysis of Treatment Outcome for Hepatitis C Genotype 4 in a Community Hospital
Abdulra. M. Malishki, MD, Omar A. Al-Shebae, MD, Iyad I. Subei, MD, FACP, FACG FASGE, Gastroenterology, ErfanBagedo Hospital, Jeddah, Saudi Arabia.

P757. Clinical and Histological Differences between Obese and Non-Obese Cryptogenic Cirrhosis
Shivangi Khara, MD, Arun Samanta, MD, Kenneth M. Klein, MD, Baburao Koneru, MD, Dorian Wilson, MD, Adrian Fisher, MD, Andrew De La Torre, MD, Milie Debrook, MD, Medicine, Pathology and Laboratory Medicine, and Surgery, University of Medicine and Dentistry of New Jersey, Newark, NJ.

P758. Iron Reduction by Phlebotomy Reduces alpha Fetoprotein in Patients with Advanced Chronic Hepatitis C: A Long Term Follow-Up Study
Steven R. Fox, MD, Navakanth Gorrepati, MD, MPH, Mamtha Balasubramaniam, MS, Tusal K. Desai, MD.

P759. Role of Vitamin E & Vitamin C in the Treatment of Nonalcoholic Steatohepatitis
Kavishkumar K. Patel, MD, Michael Babich, MD, Rad Agrawal, MD, Department of Gastroenterology, Allegheny General Hospital, Pittsburgh, PA.
P760. POSTER WITHDRAWN

P761. Long Term Sustained Virological Response among Hispanic Veterans Successfully Treated for Hepatitis C Virus

P762. Prevalence and Predictors of Steatosis in Patients with Chronic Hepatitis C (HCV) Infection
Jagdish S. Nachnani, MD, Alexandra Laya, MD, Esmat Sadeddin, MD, Owen J. Smith, MD, Laura M. Alba, MD, Wendell K. Clarkston, MD, Internal Medicine, and Gastroenterology, University of Missouri Kansas City, Kansas City, MO.

P763. The Effect of Statins on Viral Load in Patients with Chronic Hepatitis C

P764. Are Ethnicity and Gender Associated with Outcomes in Patients with Primary Sclerosing Cholangitis (PSC)?
Toya James-Stevenson, MD, Shaukat Asma, MD, Fuad Azrak, MD, Kristina Chacko, MD, Kamil Obideen, MD, Medicine/Digestive Diseases, Emory University SOM, Atlanta, GA; Medicine, GI, University of Minnesota, Minneapolis, MN and Medicine, William Beaumont Hospital, Royal Oak, MI.

P765. Autoimmune Hepatitis: A Risk Factor for Cryptogenic Cirrhosis
Malika Ahmad, MD, Arun Samanta, MD, Kenneth M. Klein, MD, Baburao Koneru, MD, Dorian Wilson, MD, Fisher Adrian, MD, Andrew De La Torre, MD, Milie Debroy, MD, Medicine, Pathology and Laboratory Medicine, and Surgery, University of Medicine and Dentistry of New Jersey, Newark, NJ.

P766. Transmission of Hepatitis B Virus (HBV) Infection Is Predominantly Perinatal in the Indian Subcontinent: A Large Prospective Study
Hissar Syed, MD, Manoj Kumar, MD, DM, Kazim N. Syed, PhD, Sanjay Satpathy, MD, DM, Tharon G. Kumar, MSc, Ranjeet Chauhan, MSc, Didar Singh, MBBS, Puja Sakhija, MD, Shiv K. Sarin, MD, DM, Gastroenterology and Pathology, G. B. Pant Hospital, New Delhi, India.

P767. Prediction of Histology in Nonalcoholic Fatty Liver Disease: Do Medications Matter?
Sri Naveen Surapaneni, MD, Charles Katopdes, MD, James Wallace, MD, Peter Nettlemann, MD, Deborah Andris, NP, Behmaran Behnaz, MD, Richard Komorowski, MD, Franco Jose, MD, Rajiv Varma, MD, Omar Massoud, MD, Kia Saean, MD, Samer Gawrieh, MD, Medical College of Wisconsin (MCW), and Zablocki VA Medical Center, Milwaukee, WI.

P768. 13C Breath Tests as Tools for the Assessment of Liver Diseases
Yoshisada Urita, Toshiyasu Watanabe, Tadashi Maeda, Kaoru Domon, Susumu Ishihara, Tomohiro Arita, Asuka Nakayama, Makie Nanami, Tatsuhiko Yamasaki, Akiko Kugahara, Takamasa Ishii, Hirohito Kato, Kazuo Hike, Shuji Watanabe, Kazushige Nakanishi, Nagato Shimada, Motonobu Sugimoto, Kazumasa Miki, Department of General Medicine and Emergency Care, Division of Gastroenterology and Hepatology, and Department of Hematology, Toho University, Tokyo, Japan.

P769. Results of 5 Years Experience of Liver Secondaries Treated by Radiofrequency Ablation
Rashmi Jaiswal, MBBS, Ajit Sewkani, MS, Swarna Vyas, MSc, Sandesh Sharma, MS, Saleem Naik, MS, Dipak Purohit, MS, Vikrant Singh, MS, K.K. Maudar, MS, PhD, Subodh Varshney, Harkirat Bains, PhD, GI Surgery, Bhopal Memorial Hospital and Research Centre, Bhopal, MP, India.

P770. Study of Serum Adiponectin in Chronic Liver Disease and Cholestasis
Tary A. Salaman, MD, Naglaa A.A. Allam, MD, Gasser I. Azab, MD, Ahmed Shaarawy, MD, Mona Hassouna, MD, Omkoeloum M. El-haddad, MD, Hepatology, National Liver Institute, Shebeen Al-koam, Menofeya, Egypt and Clinical Pathology, National Liver Institute, Shebeen Al-koam, Menofeya, Egypt.

P771. A Single Center Experience of the Use of Mycophenolate Mofetil (MMF) in the Maintenance Treatment of Autoimmune Hepatitis (AIH)
Jonathan T. Hlivko, MD, Mitchell L. Shiffman, MD, R. Todd Stratvitz, MD, Velimir A. Luketic, MD, Arun J. Sanyal, MD, Michael Fuchs, MD, Richard K. Sterling, MD, Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University Health System, Richmond, VA.

P772. Treatment Rates in Patients with Chronic Hepatitis B after Liver Biopsy
Denis V. Kapkov, MD, Trinh B. Meyer, MD, Douglas Meyer, MD, David J. Clain, MD, Neil D. Theise, MD, Henry C. Bodenheimer, Jr., MD, Albert D. Min, MD, Digestive Diseases, Beth Israel Medical Center, New York, NY.

P773. Serum Adipokine Profile in Indian Men with Nonalcoholic Steatohepatitis: Serum Adiponectin Is Paradoxically Decreased in Lean Versus Obese
M.G. Sanal, Shiv K. Sarin, DM, Ajay K. Chowdhary, MD, Special Center for Molecular Medicine, and Gastroenterology, GB Pant Hospital, New Delhi, Delhi, India.

P774. Zeaxanthin Reduces Fibrosis in a Gerbil Model of Non-Alcoholic Steatohepatitis
★ 2007 ACG Presidential Poster Award Recipient
Sherman M. Chamberlain, MD, Manuela Bartoli, PhD, Nancy Rodriguez, DVM, Jeffrey R. Lee, MD, Jigneshkumar Patel, MBBS, Subbaramiah Sridhar, MBBS, Dennis M. Marcus, MD, Section of Gastroenterology, Section of Vascular Medicine, Laboratory Animal Services, Department of Pathology, and Department of Medicine, Medical College of Georgia, Augusta, GA, and Southeast Retina Center, Augusta, GA.

P775. Antibacterial and Sporicidal Activity of Silver Against Clostridium difficile and Impact on Gut Colonization and Disease
★ 2007 ACG Presidential Poster Award Recipient
Jeffrey B. Lyczak, PhD, Wen Chen, PhD, Nicole Bellefeuille, BS, Katherine V. Thompson, MPH, Katherine J. Turner, PhD, Research & Development, Nucryst Pharmaceuticals, Inc., Wakefield, MA.

P776. Post-Surgical Clostridium difficile Infection
Rabin Rahmani, MD, William Southern, MD, Igal Khorshidi, MD, Andy Thanjan, MD, Christopher B. Ibrahim, MD, Lawrence J. Brandt, MD, MACG, Gastroenterology, Montefiore Medical Center, Bronx, NY.
P777. Clostridium difficile Colitis: A Shift from a Traditionally Hospital Acquired Infection to a Community and Nursing Home-Based Disease
Vivek Kumar, MD, Sam Yoselevitz, MD, Suchir K. Dutta, MD, Gastroenterology, Sinai Hospital, and Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD.

P778. Outcomes and Risk Factors for Development of Post-Polypectomy Hemorrhage Requiring Hospitalization
Essam R. Quraishi, MD, Omar Sharif, MD, Kim Brown, MD, Gastroenterology and Internal Medicine, Henry Ford Hospital, Detroit, MI.

P779. In-Patient Colonoscopy Preparation—Is Splitting the Dose the Solution?
Flor Mizrahi, MD, Ramesh Koka, MD, Jorge Uribe, MD, Stacey Zavala, MD, Girish Anand, MD, Philip Katz, MD, Gastroenterology, Albert Einstein Medical Center, Philadelphia, PA.

P780. Poor Prep Rate for Inpatient Colonoscopies Is Unacceptably High—Needs Attention
Krishna S. Kasturi, MD, MPH, Rajasekharra R. Mummadi, MD, Gottumukkala S. Raju, MD, Internal Medicine, University of Texas Medical Branch, Galveston, TX.

P781. Excellent Cecal Cleansing with Split Dose of Phosphosoda and 30 mg of Bisacodyl—A Retrospective Study Using Cecal Photograph as a Reflector of the Quality of Colon Cleansing
Sahil Mittal, MD, Rajasekharra R. Mummadi, MD, T. Trang, G.S. Raju, MD, Internal Medicine, University of Texas Medical Branch, Galveston, TX.

P782. Is Body Mass Index an Important Marker of Complicated Diverticulitis? A 10 Year Retrospective Review
Serge A. Sorser, MD, Tal B. Hazan, MD, Michael Piper, MD, Luis C. Maas, MD, Gastroenterology, Providence Hospital and Medical Center, Southfield, MI.

P783. The Impact of BMI and Ethnicity on the Course of Colonic Diverticulitis
Igal Khorshidi, MD, George Cherrnis, MD, Rabin Rahmani, MD, Lawrence J. Brandt, MD, Gastroenterology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

P784. Trainees’ Influence on Polyp Detection (TRIPOD). Does Trainee Participation Affect Polyp Detection Rates?
Colin T. Swales, MD, Alexander J. Eckardt, MD, Neil P. Phelan, MD, Sharif Zubair, MD, Nadeem Anwar, MD, Noel Martins, MD, Sunil Patel, MD, Brian Moquin, MD, Katherine Leung, MPH, Wahid Y. Wassell, MD, Kanishka Bhattacharya, MD, John M. Levey, MD, Division of Gastroenterology, University of Massachusetts, Worcesters, MA.

P785. 5-ASA Treatment Practices among Physician Subspecialties in HIV-Associated Diarrhea
Maribel Rodriguez-Torres, MD, Joel Scales, MA, Simon Magowan, MD, Fundacion De Investigacion De Diego, San Juan, Puerto Rico and Procter & Gamble Pharmaceuticals, Mason, OH.

P786. Environmental and Dietary Risk Factors in Microscopic Colitis: Preliminary Data from a Case-Control Study
Cyrus P. Tamboli, MD, FRCPC, Laura Aker, BSc, Jamison J. Engle, MD, Robert J. Caldwell, PA, M. Bridgez Zimmerman, PhD, Frank A. Mitros, MD, Internal Medicine, Gastroenterology, and Pathology, University of Iowa Carver College of Medicine, and Biostatistics, College of Public Health, University of Iowa, Iowa City, IA.

P787. Views and Practice of Gastroenterologists Regarding High Fiber Diet and Fiber Supplementation in Patients with Colonic Diverticulosis
Nirmal S. Mann, MD, FACG, Suk Seo, MD, Dept. of Gastroenterology, University of California Davis, School of Medicine, Sacramento, CA.

P788. Effect of Exercise and Obesity on Difficulty of Performing Colonoscopy
Syed T. Bin-Sagheer, MD, Asma Dajani, MD, Stephen Lanspa, MD, Gilev Haynatzki, PhD, Division of Gastroenterology, Creighton University Medical Center, Omaha, NE.

P789. Colonoscopy with Withdrawal Times (WT) > 6 Minutes Detects More Polyps That Are Mostly Small and Hyperplastic (H) but Also a Few That Are Larger and Neoplastic (A)
John M. Haydek, MD, John P. Haydek, Chris M. Haydek, Gastrointestinal Associates, Knoxville, TN.

CLINICAL VIGNETTES

P790. Rectal Perforation Caused by a Holistic Colonic Cleansing
Jennifer Lee, MD, Hiral N. Shah, MD, Mario Golosovsky, MD, Timothy R. Koch, MD, Medicine, Washington Hospital Center, Washington, DC; Surgery, Washington Hospital Center, Washington, DC and Gastroenterology, Washington Hospital Center and Georgetown University School of Medicine, Washington, DC.

P791. Intestinal Tuberculosis Masquerading as Crohn’s Disease
Jae Geun Hyun, MD, Eric S. Goldstein, MD, Patricia Sylia, MD, David Bub, MD, Gastroenterology, The Mount Sinai Medical Center, New York, NY and General Surgery, The Mount Sinai Medical Center, New York, NY.

P792. A Rare Case of Intussusception in a Patient with Typhilitis Managed Successfully by Barium Enema Reduction
Simon C. Chan, MD, Ashok Shah, MD, Department of Gastroenterology, University of Rochester Medical Center, Rochester, NY.

P793. Colonic Co-Infection of Histoplasma and CMV in an HIV/AIDS Patient Mimicking Carcinoma
Xingqin Fan, MD, Larry Scott, MD, Qiu Suimin, MD, Gastroenterology and Hepatology, and Department of Pathology, University of Texas Medical Branch, Galveston, TX.

P794. Methylnaltrexone (MNTX) for Constipation in a Patient on Opioids with Malignant Spinal Cord Compression
Neal E. Sladkin, MD, Michelle Rhiner, RN, NP, Robert J. Israel, MD, Palliative Care, City of Hope, Duarte, CA and Medical Affairs, Progenics Pharmaceuticals, Inc., Tarrytown, NY.

P795. An Unusual Case of Hematochezia in a Healthy 28 Year Old Female
Steven R. Fox, MD, Michael C. Duffy, MD, Gastroenterology, William Beaumont Hospital, Royal Oak, MI.

P796. Hemorrhagic Mantle Cell Lymphoma Diagnosed with Colonic Cold Biopsy
Jigneshkumar Patel, MBBS, Subbarmiah Sridhar, MBBS, Sherman M. Chamberlain, MD, Medicine and Section of Gastroenterology, Medical College of Georgia, Augusta, GA.

P797. Spontaneous Multiperforation in Lymphomatous Colitis Masquerading as Crohn’s Disease: Two Cases
A. Mohammed, MD, R. Stein, MD, G. Zalzaleh, MD, J. Grela, MD, C. Berkelhammer, MD, Gastroenterology-Internal Medicine, University of Illinois, Oak Lawn, IL.
P798. An Interesting Cecal Mass in a Patient with AIDS
Ashutosh Naniwadekar, MD, Adviya Malhotra, MD, Internal Medicine, University of Texas Medical Branch, Galveston, TX.

P799. Watermelon Colon: Can This Be an SLE Flare-Up?
Heather Sheets, MD, Krishna S. Kasturi, MD, Rajasekharar R. Mummid, MD, Internal Medicine, and Gastroenterology and Hepatology, University of Texas Medical Branch, Galveston, TX.

P800. Intestinal Spirochetosis: A Cause of Symptoms Resembling Irritable Bowel Syndrome
Meghashyam J. Koti, MD, Jawaid Shaw, MD, Jeffrey A. Goldstein, MD, FACG, Department of Internal Medicine and Department of Gastroenterology, Rochester General Hospital, Rochester, NY.

P801. Neutropenic Enterocolitis: An Unusual Complication of Hepatitis C Virus Combination Therapy
Krishna S. Kasturi, MD, Rajasekharar R. Mummid, MD, Gagan K. Sood, MD, Internal Medicine, and Gastroenterology and Hepatology, University of Texas Medical Branch, Galveston, TX.

P802. Diffuse Hemangiomatosis of Colon, Liver and Skin
Krisdeep S. Chadha, MD, Shahid Mehboob, MD, Department of Gastroenterology, State University of New York, Buffalo, NY.

P803. A Rare Case of Intraluminal Ureter Metastasis from Rectal Cancer
Vishal Gupta, MD, PhD, Rishi Pawa, MD, Jonathan Saniel, MD, Vaughan Whitaker, MD, Bryan Donaldson, MD, Jay Cowan, MD, Raja Sabbagh, MD, Division of Gastroenterology, Department of Pathology, and Section of Colorectal Surgery, Harlem Hospital Center/Columbia College of Physicians and Surgeons, New York, NY.

P804. Refractory Rectal Ulcer Secondary to Infrared Coagulation Treated with Canasa Suppository
Yaman Suleiman, MD, Samah Bassas, MD, Mohammad Alsolaiman, MD, Gastroenterology Dept, Central Utah Clinic, Provo, UT.

P805. Rare Case of Lung Cancer Metastatic to the Colon Incidentally Discovered at Screening Colonoscopy
Gennady Bakis, MD, Matthew M. Baichi, MD, Department of Gastroenterology, Division of Gastroenterology, Hepatology, and Nutrition, State University of New York, Buffalo, NY.

P806. Rectal Bleeding: A Case Report of Localized AL Amyloidosis of the Colon
Stephanie L. Hansel, MD, Arthur D. Shiff, MD, Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ.

P807. Addition of Rifaximin Enema Resolves Colitis Associated with Clostridium difficile Infection
Donald S. David, MD, FACG, City of Hope Cancer Center, Duarte, CA.

P808. A Rare Cause of Rectal Bleeding!
Mitesh B. Patel, MD, Shilpa R. Gowdapanu, MD, Rosena Custudio, MD, Jyothi A. Reddy, MD, FACG, Gastroenterology and Pathology, University of Illinois College of Medicine Urbana Champaign, Danville, IL.

P809. Gastric Antral Vascular Ectasia Associated with Sytemic Sclerosis: A Case Report and Review of the Literature
Sindu Stephen, MD, Marie L. Borum, MD, Department of Gastroenterology, George Washington University, Washington, DC.

P810. Hereditary Gastric Carcinoma: At Management Cross Roads
★ 2007 ACG Presidential Poster Award Recipient
★ 2007 ACG/AstraZeneca Clinical Vignette Award Recipient
Jawaid Ahmed Shaw, MD, Motaz Al Hafnawi, MD, Tarun Kothari, MD, Kevin Casey, MD, Gastroenterology, Rochester General Hospital, and Gastroenterology, Unity Hospital, Rochester, NY.

P811. An Unusual Case of Heterotopic Gastric Mucosa Followed for 5 Years
Deepthi Bollineni, MD, Prem Misra, MD, FACG, Division of Gastroenterology, Wyckoff Heights Medical Center, Brooklyn, NY.

P812. Recurrent Gastric Telangiectasias Despite Argon Plasma Coagulation in a Patient with Osler-Weber-Rendu Syndrome
Simon C. Chan, MD, Ashok Shah, MD, Gastroenterology, University of Rochester Medical Center, Rochester, NY.

P813. UGI Bleeding Secondary to Pseudoxanthoma Elasticum
Jae Geun Hyun, MD, Lauren K. Schwartz, MD, Aaron Walfish, MD, Gastroenterology, The Mount Sinai Medical Center, New York, NY.

P814. Gastric Adenocarcinoma in MEN-1
Jessica L. Widmer, DO, Jay P. Babich, MD, Biju Abraham, DO, Phillip Cassar, MD, Kavita R. Kongara, MD, James H. Grendell, MD, Gastroenterology, Winthrop University Hospital, Mineola, NY.

P815. Isolated Gastric Varices in Lymphoma
Mohamad Sankari, MD, Mark Duff, DO, James Pollack, MD, Angel Cinco, MD, Thomas Memorial Hospital, South Charleston, WV.

P816. Hiccups: A Subtle Sign of Gastric Volvulus?
David P. McElreath, DO, Farshad Adul, MD, Kevin W. Olden, MD, Gastroenterology, University of Arkansas for Medical Sciences, Little Rock, AR.

P817. Preventing Recurrent Gastro-Gastric Stricture as a Complication of Roux-en-Y Gastric Bypass Surgery
Bikram S. Bai, MD, Shilen V. Lakhan, MD, Hiral N. Shah, MD, Frederic C. Finelli, MD, JD, Timothy R. Koch, MD, Medicine/Gastroenterology, Surgery, and Gastroenterology, Washington Hospital Center, and Georgetown University School of Medicine, Washington, DC.

P818. Gastric Polyps Causing Intermittent Gastric Outlet Obstruction
Jan C. Prazak, MD, Ann Silverman, MD, Division of Gastroenterology, Henry Ford Hospital, Detroit, MI.

P819. Cola Dissolution Therapy in Gastric Bezoar
Falgun M. Modhia, MD, Camille F. Torbey, MD, Internal Medicine and Gastroenterology, Marshfield Clinic, Marshfield, WI.

P820. Gastric Perforation Due to a Trichobezoar in a Normal Healthy Woman
Amanpal Singh, MD, Tina Kochar, MD, Advitya Malhotra, MD, Internal Medicine, University of Texas Medical Branch, Galveston, TX.

P821. Steroid Injection for Benign Refractory Pyloric Stenosis
Yaman Suleiman, MD, Samah Bassas, MD, Mohammad Alsolaiman, MD, Gastroenterology Dept., Central Utah Clinic, Provo, UT.
P822. Rare Extra-Intestinal Manifestation of Ulcerative Colitis
Jeanette Smith, Eric Newton, Petr Protiva, Gastroenterology, University of Connecticut, Farmington, CT.

P823. The Use of Infliximab To Treat a Patient with Both Familial Mediterranean Fever and Crohn’s Disease
Alana P. Bunnag, AB, David T. Rubin, MD, University of Chicago, Chicago, IL.

P824. Bariatric Surgery in Patients with Crohn's Disease and Extreme Obesity
Kerry Wright, MBBS, Donald D. Hensrud, MD, William J. Tremaine, MD, Internal Medicine, Preventive Medicine, and Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

P825. Steroid Unresponsive Sweet's Syndrome in a Patient with Crohn's Disease
Christopher D. Gamble, MD, Prema R. Menon, MD, Internal Medicine, Ball Memorial Hospital, Muncie, IN.

P826. Development of Lymphomatoid Papulosis in a Patient with Crohn's Disease Treated with Infliximab—A Case Report
William Outlaw, MD, Alan Fleischer, MD, Richard Bloombeld, MD, Gastroenterology and Dermatology, Wake Forest University, Winston-Salem, NC.

P827. An Unusual Path to the Diagnosis of Crohn's Disease; from Gastric Outlet Obstruction to Fat Wrapping of the Terminal Ileum
Michael J. Viksjo, MD, Grace Noh, MD, Clara Yook, MD, Judy Lin, MD, Gastroenterology, UMDNJ New Jersey Medical School, Newark, NJ; Pathology and Gastroenterology, VA Medical Center, East Orange, NJ.

P828. An Unusual Case of Headache in a Patient with Ulcerative Colitis
Wanda Blanton, MD, Paul Schroy, MD, Francis A. Farraye, MD, Section of Gastroenterology, Boston Medical Center, Boston, MA.

P829. Acute Noncholestatic Azathioprine Induced Hepatotoxicity in a Female with Crohn's Disease
Charles P. Koczka, MD, Juan Diego Baltodano, MD, Robert Levine, MD, Medicine, SUNY Upstate Medical College, Syracuse, NY.

P830. POSTER WITHDRAWN

P831. Refractory and Coexistent Crohn's Disease with ITP: A Clinical Dilemma
Joshua E. Melson, MD, MS, Joseph Ahn, MD, Hepatology, Interventional Radiology, and Gastroenterology/Hepatology, Mayo Clinic, Rochester, MN.

P832. Patent Stent 10 Years Post Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Gurpreet Singh, MD, Ragu Kottam, MD, Suresh Jayatilaka, MD, Joseph DePasquale, MD, Gastroenterology, Saint Michael’s Medical Center, Newark, NJ and Seton Hall University School of GME, South Orange, NJ.

P833. Extensive Nonalcoholic Fatty Liver Disease and Cirrhosis in a Single Family: A Case Report
Stacy K. Tong, MD, Joseph Ahn, MD, Stanley M. Cohen, MD, Hepatology and Gastroenterology, Rush University Medical Center, Chicago, IL.

P834. Loratidine-Induced Hepatitis with Autoimmune Features Associated with Small Fiber Peripheral Neuropathy
Muaiad Kittaneh, MD, Sara Hanif, MD, Albert J. Czaja, MD, FACP, Arthur Itkin, MD, Charles Berkelhammer, MD, FACP, Internal Medicine, University of Illinois at Chicago, Oak Lawn, IL and Internal Medicine, Division of Gastroenterology, Mayo Clinic, Rochester, MN.

P835. “Downhill” Esophageal Varices Treated with Azygos Vein Embolization
Garth Swanson, MD, Joseph Ahn, MD, MS, Stanley Martin Cohen, MD, Hector Ferral, MD, Forrest Dodson, MD, David Van Thiel, MD, Hepatology, Interventional Radiology, and Abdominal Transplant Surgery, Rush University Medical Center, Chicago, IL.

P836. MRI Differentiates Anoxic Brain Injury from Liver Failure Associated Cerebral Edema in Ecstasy (MDMA) Toxicity
Joshua E. Melson, MD, Joseph Ahn, MD, MS, Shyam Prabhakaran, MD, MS, Stanley Martin Cohen, MD, Hepatology, and Neurology, Rush University Medical Center, Chicago, IL.

P837. Consequences of a “Dropped Pass”: Liver Abscess Due to Eikenella corrodens
Joanna M. Peloquin, MD, Gautam Kumar, MBBS, Stephen C. Hauser, MD, Medicine, Johns Hopkins Hospital, Baltimore, MD; Cardiology, and Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

P838. Prurigo Nodularis in a Patient with Hepatic Sarcoidosis
Suresh Jayatilaka, MD, Habib ElGhoul, MD, Theodore Dacosta, MD, Robert Spira, MD, Gastroenterology, St. Michael's Medical Center, Newark, NJ.

P839. Fatal Lactic Acidosis Associated with Combination Oral Antiviral Therapy for Hepatitis B Reactivation Following Chemotherapy
Ronald M. Levy, MD, Stanley M. Cohen, MD, David H. Van Thiel, MD, Joseph Ahn, MD, Hepatology and Gastroenterology, Rush University Medical Center, Chicago, IL.

P840. Life-Threatening Hepatic Failure Associated with Entecavir Resistance Mutations I269I/T and T184L Two Years after Discontinuation of Lamivudine
Maureen E. Morgan, MD, Walid Ayoub, MD, Aijaz Ahmed, MD, Emmet B. Keeffe, MD, Mindie H. Nguyen, MD, Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA.

P841. Inflammatory Pseudotumor of the Liver Mimicking Malignancy
Joseph Ahn, MD, MS, Joshua E. Melson, MD, Mariano S. Dy-Liacco, MD, Shiriam Jakate, MD, Stanley Martin Cohen, MD, Hepatology, Abdominal Transplant Surgery, and Pathology, Rush University Medical Center, Chicago, IL.

P842. Interferon-Alpha Induced Thyroid Disease in Patients Being Treated for Hepatitis C
Enika Grigg, MD, Edward Chin, MD, Robert Schade, MD, Medicine, Endocrinology, and Gastroenterology/Hepatology, Medical College of Georgia, Augusta, GA.

P843. Cytomegalovirus Infection Associated with Esophagitis and Esophageal Stricture after Liver Transplantation
Joseph Ahn, MD, MS, Hirano Ikuo, MD, Steven Flamm, MD, Hepatology, Rush University Medical Center, Gastroenterology and Hepatology, Northwestern University, Chicago, IL.
P844. Abernethy Malformation—A Rare Case and Method of Detection
Todd W. Kilgore, MD, Jason S. Ogden, MD, Ajitlinder Grewal, MD, Matthew L. Bechtold, MD, Srinivas R. Puli, MD, Maimon R. Antillon, MD, Jamal A. Ibda, MD, Division of Gastroenterology, University of Missouri, Columbia, MO.

P845. A Rare Cause of Granulomatous Hepatitis Presenting as Fever of Unknown Origin
Ryan M. O’Connor, MD, Adam L. Palance, MD, Gregory Haber, MD, Dennis K. Miller, MD, Department of Medicine, Lenox Hill Hospital, New York, NY.

P846. Duodenal Variceal Hemorrhage Treated with TIPS
Kevin S. Jo, MD, William Shaheen, MD, Asad Ullah, MD, Gastroenterology and Hepatology, University of Rochester, Rochester, NY.

P847. Acute Liver Dysfunction after Addition of Natalizumab to Interferon in Two Patients with MS
Michael E. Kader, MD, Thalia Mayes, MD, Philip Katzman, MD, Lawrence J. Saubermann, MD, Bushra Fazli, MD, Benedict Maliakkal, MD, Department of Gastroenterology and Hepatology, and Department of Pathology, University of Rochester, Rochester, NY.

P848. Experience Using Nitazoxanide in a U.S. Genotype 1 Hepatitis C Patient
William Kolozsi, MD, Department of Gastroenterology, Salem Community Hospital, Salem, OH.

P849. Rectus Sheath Hematoma Following Large Volume Paracentesis
Muhammad M. Amin, MD, Osama A. Yousef, MD, Patricia A. Sanchez, MD, Wendell K. Clarkston, MD, Gastroenterology, University of Missouri Kansas City, Kansas City, MO.

P850. Diarrhea: A Presenting Symptom of HCC
Paul S. Panzarella, MD, Jay P. Babich, MD, Robert Bonasera, MD, Kovita R. Kon, MD, James H. Grendell, MD, Gastroenterology, Winthrop University Hospital, Mineola, NY.

P851. Pyogenic Liver Abscess Secondary to Staphylococcus aureus Infection without Primary Source of Infection
Lokesh K. Jha, MD, Rahaman Mujibur, MD, Samer Alshaeba, MD, Internal Medicine, St. Barnabas Hospital, Bronx, NY.

P852. Concomitant Hemobilia and Hepatic Abscess after Radiofrequency Ablation
Cristina S. Marin, MD, Toyia N. James-Stevenson, MD, James R. Spivey, MD, Internal Medicine and Digestive Diseases, Emory University, Atlanta, GA.

P853. Primary Sclerosing Cholangitis in Association with Multiple Myeloma
Matthew Downey, MD, Christopher O’Brien, MD, Elizabeth Frauenhofer, MD, Nasrollah Ahmadpour, MD, Thomas Riley, MD, Ian Schreibman, MD, Gastroenterology and Hepatology, Penn State Milton S. Hershey Medical Center, Hershey, PA and Division of Hepatology, University of Miami School of Medicine, Miami, FL.

P854. Combined Hepatocellular Cholangiocarcinoma
Sam M. Nourani, MD, Emma Du, MD, Paul J. Pockros, MD, Gastroenterology and Pathology, Scripps Clinic, La Jolla, CA.

P855. Severe Systemic Lupus Erythematosus Induced by Antiviral Treatment for Hepatitis C
Vincent Ho, MBBS, Bsc(Med), Anna Mclean, MBBS, Shaughan Terry, MBChB, FRCPE, FACP, School of Medicine, James Cook University, and Gastroenterology, Cairns Base Hospital, Cairns, Queensland, Australia.

P856. Anidulafungin Induced Cholestasis Following Liver Transplant
Christopher C. Canale, MD, William R. Hutson, MD, Department of Gastroenterology, University of Utah, Salt Lake City, UT.

P857. An Atypical Presentation of Hepatocellular Carcinoma
Christopher C. Canale, MD, William R. Hutson, MD, Department of Gastroenterology, University of Utah, Salt Lake City, UT.

P858. Cholestatic Jaundice as a Paraneoplastic Presentation of Hodgkin’s Lymphoma
Julia Massaad, MD, Mohammad Wehbi, MD, Digestive Diseases, Emory University School of Medicine, Atlanta, GA.

P859. Carcinosarcoma: An Unusual Hepatic Metastasis
Anastasia C. Waechter, MD, Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA.

P860. Systemic Mastocytosis: A Rare Cause of Portal Hypertension
Seth Sweetser, MD, Patrick S. Kamath, MD, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN.

P861. “Delayed” Sustained Virologic Response after Treatment of Hepatitis C with Pegylated Interferon and Ribavirin
Joseph C. Yarze, MD, FACP, FACG FASGE, GI Division, Gastroenterology Associates of Northern New York, Glens Falls, NY.

P862. Massive Bilateral Hepatic Hydrothoraces with Minimal Ascites
Joseph C. Yarze, MD, FACP, FACG FASGE, David M. Markowitz, MD, GI Division, Gastroenterology Associates of Northern New York, and Department of Radiology, Glens Falls Hospital, Glens Falls, NY.

P863. Fleeting Hepatomegaly Due to Glycogenic Hepatopathy in Uncontrolled Type 1 Diabetes Mellitus
Rahul K. Chhablani, MD, Maria McIntire, MD, Shriram Jakate, MD, Stanley M. Cohen, MD, Joseph Ahn, MD, Hepatology, and Pathology, Rush University Medical Center, Chicago, IL.

P864. A Rare Case of Metastasis-Induced Acute Pancreatitis in a Patient with Small Cell Carcinoma of the Lung
Matthew M. Tsushima, MD, Wicht Srikureja, MD, Gastroenterology, Loma Linda University Medical Center, Loma Linda, CA.

P865. Autoimmune Pancreatitis Masquerading as Pancreatic Cancer
Rada Shakov, MD, Kiran Jagarlamudi, MD, Hossam Elfarra, MD, Walid Baddoura, MD, Gastroenterology, St. Joseph’s Regional Medical Center, Paterson, NJ and Seton Hall University School of GME, South Orange, NJ.
P866. Transient Pancreatic Hiatal Herniation Causing Acute Pancreatitis
Gupreet Singh, MD, Charbel Maksoud, MD, Suresh Jayatilaka, MD, George Pavlou, MD, Wald Baddoura, MD, Gastroenterology, St. Joseph’s Regional Medical Center, Paterson, NJ.

P867. Cystic Duct Remnant as a Cause of Post-Cholecystectomy Syndrome Diagnosed by Endoscopic Ultrasound
Anthony N. Schore, MD, Seth A. Gross, MD, Timothy Woodward, MD, Ernest Bouras, MD, David S. Loeb, MD, Massimo Raimondo, MD, Barry Rosser, MD, Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL.

P868. Pancreatic Sarcoirosis Diagnosed by EUS with FNA
Kevin S. Jo, MD, William Shaheen, MD, Asad Ullah, MD, Ashok Shah, MD, Gastroenterology and Hepatology, University of Rochester, Rochester, NY.

P869. Type III Choledochal Cyst Variant: First Description of a "Closed Choledochocele" with Biliary and Pancreatic Drainage Via the Accessory Duct
John M. Levenick, MD, Timothy B. Gardner, MD, Daniel L. Rath, MD, Stuart R. Gordon, MD, Gastroenterology, Dartmouth-Hitchcock Medical Center, Lebanon, NH and Gastroenterology, Cheshire Medical Center, Keene, NH.

P870. Metastatic Cholangiocarcinoma Presenting as Left Shoulder Pain
Harshinie Amaratunge, MD, Thomas Tran, MD, Lee Lu, MD, Waqar A. Qureshi, MD, Medicine, Baylor College of Medicine and VA Medical Ctr, Houston, TX.

P871. Successful Multi-Modality Endoscopic Treatment of Bouveret’s Syndrome without Surgery
Jason N. Rogart, MD, Melissa Perkal, MD, Anil Nagar, MD, Section of Digestive Diseases, Department of Internal Medicine, and Department of Surgery, Yale University School of Medicine, New Haven, CT.

P872. Primary Pancreatic Non-Hodgkin’s Lymphoma
Pedro R. Abanto, MD, Asif Zamir, MD, FACG, Muhammed G. Nathani, MD, FACG, Internal Medicine, UTHSCSA, Regional Academic Health Center, Harlingen, TX.

P873. A Case of Delayed-Onset Cholestasis Due to Lisinopril Use
Cristina Capanescu, MD, Christopher Deitch, MD, Cynthia McCleery, MD, William Rafferty, MD, Gastroenterology, Cooper University Hospital, Camden, NJ.

P874. Gallbladder Remnant: Rare Cause of Abdominal Pain Post Cholecystectomy
Ganesh R. Veerappan, MD, Matthew C. Wakefield, MD, Gilbert Aidnian, MD, Eric M. Osgard, MD, Gastroenterology and General Surgery, Walter Reed Army Medical Center, Washington, DC.

P875. Abdominal Wall Biloma Following Laparoscopic Cholecystectomy (LC)
Yaser Al-Solaiman, MD, Yaman Suleiman, MD, Mohammad Alsolaiman, MD, Gastroenterology Dept, Central Utah Clinic, Provo, UT and Internal Medicine, Rosalind Franklin University, North Chicago, IL.

P876. EUS in the Diagnosis of Pancreatic Duct Stone Presenting as Pancreas Divisum and Pancreatic Stricture
Kenneth Belitsis, MD, Rajiv Uppal, MD, Steven Gorcey, MD, Dawn Loveland, ANP, Monmouth Gastroenterology, Eatontown, NJ and Monmouth Medical Center, Long Branch, NJ.

P877. Hemobilia Post Intrabiliary Photodynamic Therapy (PDT) for Cholangiocarcinoma
Rami J. Badreddine, MD, Lewis R. Roberts, MBCB, Joseph J. McBride, MD, Ganapathy A. Prasad, MD, Lynn S. Borkenhagen, CNP, Lori S. Lutzke, Todd H. Baron, MD, Kenneth K. Wang, MD, Gastroenterology and Hepatology, and Interventional Radiology, Mayo Clinic, Rochester, MN.

P878. Microscopic Papillary Adenoma as a Cause of Recurrent Acute Pancreatitis
Ana Ignjatovic, MBCh, Anthony S. Mee, MD, Gastroenterology, Royal Berkshire Hospital, Reading, United Kingdom.

P879. A Broken Heart from Pancreatitis
Joseph Y. Chang, MD, MPH, Gautam Kumar, MBBS, Mayo Clinic College of Medicine, Rochester, MN.

P880. Meckel’s Diverticulum Active Bleeding Detected by Capsule Endoscopy
Guilherme Macedo, MD, PhD, Artur Machado, MD, Susana Lopes, MD, Raquel Goncalves, MD, Carla Rolanda, MD, Pedro Pereira, MD, Mesquita Rodrigues, MD, Mario Marcelino, MD, Gastroenterology Unit and Surgery Department, H.S. Marcos, Braga, Portugal.

P881. Pseudomelanosis Duodeni: An Unusual Rare Finding
Laura H. Yun, MD, Gastroenterology, University of California San Diego, La Jolla, CA.

P882. Ischemic Necrosis of the Terminal Ileum and Cecum with Oral Kayexalate
Srinivas R. Mummadi, MD, Ashutosh S. Naniwadekar, MD, Phong Tang, MD, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX.

P883. A Case of 300 Pound Weight Loss, Malabsorption, Malnutrition and Protein Losing Enteropathy Due to Systemic Lupus Erythematosis of the Small Intestine
Cindy Huang, MD, Richard MacDermott, MD, Jennifer Lindstrom, MD, Seth Richter, MD, Gastroenterology and Nutrition, Albany Medical College, Albany, NY.

P884. An Unusual Case of Three Synchronous Primary Gastrointestinal Carcinomas
Nan Sandar, MD, SriKrishna Nagri, MD, Zeyar Thet, MD, Richard Hwang, MD, Khalid Zalook, MD, Sury Anand, MD, Carl Guillaume, MD, Gastroenterology, The Brooklyn Hospital Center, Brooklyn, NY; Medicine, Long Island College Hospital, and Gastroenterology, St. Barnabas Hospital, Bronx, NY.

P885. Strongyloides: A Worm with Lethal Potential
Jawaid Ahmed Shaw, MD, Motaz Al Hafnawi, MD, Meghashyam Koti, MD, Kevin Casey, MD, Gastroenterology/ Internal Medicine, Rochester General Hospital, Rochester, NY.

P886. Wireless Capsule Endoscopy To Assess Extent of Small Bowel Involvement in Metastatic Melanoma
Sonia S. Kupfer, MD, David T. Rubin, MD, Section of Gastroenterology, University of Chicago Hospital, Chicago, IL.

P887. A Case of Obscure Gastrointestinal Bleeding
Neal J. Schamberg, MD, Brian Landzberg, MD, Felice H. Schnoll-Sussman, MD, Division of Gastroenterology and Hepatology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY.
P888. Early Detection of Diaphragm's Disease of the Small Bowel and Impact on Management
Houssam Al Kharrat, MD, Sammy Deeb, MD, Omar Shoukfeh, Department of Medicine, Covenant Medical Center, and Health Science Center, Texas Tech University, Medical School, Lubbock, TX.

P889. Systemic (AL) Amyloidosis Diagnosed on Duodenal Biopsies in a Patient Presenting with Mucosal Friability, Hepatomegaly and Weight Loss
Toyia N. James-Stevenson, MD, Robert A. Cohen, MD, Marina Mosunjac, MD, Department of Medicine/Digestive Diseases, and Pathology, Emory University School of Medicine, Atlanta, GA.

P890. Pneumatosis Cystoides Intestinalis in a Patient with Scleroderma and Idiopathic Pancreatic Exocrine Insufficiency
Karthik Ravi, MD, Dawn D.F. Ferguson, MD, Internal Medicine and Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

P891. Gastrointestinal CMV Disease in an Immunocompetent Host
Christopher Fyock, MD, Melissa Gaitanis, MD, John Gao, MD, PhD, Murray Resnick, MD, PhD, Samir A. Shah, MD, Medicine and Pathology, Brown Medical School, Providence, RI.

P892. Domperidone for the Treatment of Severe Hyperemesis Gravidarum
Sumona Saha, MD, Rosanna Moura, MD, Division of Women’s Digestive Disorders, Women & Infants’ Hospital, Providence, RI.

P893. A Case of Multiple Gastrointestinal Stromal Tumors of the Small Bowel in a Patient with Neurofibromatosis Type 1
Cindy Huang, MD, Jesse Green, MD, Kevin Mercure, MD, David Kuehler, MD, David Jones, MD, Gastroenterology, Surgery, and Pathology, Albany Medical College, Albany, NY.

P894. MALT Lymphoma of the Duodenum: A Rare Cause for Upper Gastrointestinal Bleeding and Pancreatitis
Michael Selden, MD, Patricia Sanchez, MD, Esmat Sadeddin, MD, Sandra Lay, MD, Wendell Clarkson, MD, Gastroenterology Department, Saint Luke’s Hospital/University of Missouri, Kansas City, Kansas City, MO.

P895. Efficacy Alendronate for Improving Bone Mineral Density in Celiac Disease
David Widjaja, MD, Kalyan C. Kannemanti, MD, Sridhar S. Chilimuri, MD, Gastroenterology, Bronx Lebanon Hospital Center, Bronx, NY.

P896. Spontaneous Large Intramural Hematoma in Roux Limb of Gastric Bypass
Wei tai Liu, MD, PhD, John R. Saltzman, MD, FACG, Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.

P897. Pandiceliac acidase and IgA Deficiency Diagnosed in Adulthood
★ 2007 ACG Presidential Poster Award Recipient
Vincent Ho, MBBS, Bsc(Med), John Ombiga, MBBS, FRACP, Peter Boyd, MBBS, FRACP, School of Medicine, James Cook University, and Gastroenterology, Cairns Base Hospital, Cairns, Queensland, Australia.

P898. Twist of Fate: Intestinal Non-Rotation and Intermittent Volvulus in an Adult Treated with Laparoscopic Lysis of Ladd’s Bands
Sara Hanif, MD, Eric Dozois, MD, Charles Berkelhammer, MD, Gastroenterology, University of Illinois, Oak Lawn, IL and Surgery, Mayo Clinic, Rochester, MN.

P899. A Case of Ileocecal Tuberculosis Found on Screening Colonoscopy
Christopher Fyock, MD, Alyn Adrain, MD, Internal Medicine, Brown Medical School/Rhode Island Hospital, and Gastroenterology Associates, Providence, RI.

P900. Severe Pulmonary Hypertension in Whipple’s Disease
★ 2007 ACG Presidential Poster Award Recipient
★ 2007 ACG/AstraZeneca Clinical Vignette Award Recipient
Patricia A. Sanchez, MD, Joel Camilo, MD, Wendell K. Clarkston, MD, Gastroenterology, University of Missouri at Kansas City School of Medicine, Kansas City, MO.

P901. EWS-CREB 1: A Novel Variant Gene Fusion Transcript in Clear Cell Sarcoma of the Ileum
Venkata Yalamanchili, MD, Melham Solh, MD, Doina David, MD, Geetha Krishnamoorathy, MD, Department of Medicine, Sinai Grace Hospital, Wayne State University, Detroit, MI.

P902. Inferior Pancreaticoduodenal Artery Pseudoaneurysm: A Rare Cause of Massive GI Hemorrhage
Krishna S. Kasturi, MD, Rajasekhar R. Mummad, MD, Aravind Sugumar, MD, Internal Medicine, and Gastroenterology and Hepatology, University of Texas Medical Branch, Galveston, TX.

P903. Superior Mesenteric Artery Syndrome
Angela M. Mills, MD, Dusan Stanojevic, Medical Student, Andrew D. Mills, MD, Syed T. Bin-Sagheer, MD, Internal Medicine, Division of Gastroenterology, Creighton University Medical Center, Omaha, NE.

P904. Human Small Intestinal Anisakiasis Due to Consumption of Raw Sardines
Masahiro Matsushita, MD, Kensisuke Kobayashi, MD, Koji Oba, MD, Raisuke Nishiyama, MD, Akihiko Seki, MD, Yoichiro Kawata, MD, Hidenori Sakai, MD, Yoshimasa Kobayashi, MD, Gastroenterology, Haibara General Hospital, Makinohara, Shizuoka, Japan; Surgery, Haibara General Hospital, Makinohara, Shizuoka, Japan; Radiology, Haibara General Hospital, Makinohara, Shizuoka, Japan; Medicine, Kawata Clinic, Yoshida, Shizuoka, Japan; Medicine, Sakai Clinic, Makinohara, Shizuoka, Japan and 2nd Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

P905. Gastrointestinal Histoplasmosis
Navin Paul, MD, Subramanian Swaminathan, MD, Alka Ganesh, MD, George Abdelsayed, MD, Bridgeport Hospital [Yale New Haven Health], Bridgeport, CT and Christian Medical College, Vellore, India.

P906. A Patient with Diarrhea and an Abnormal CT Enterography
Rami J. Badreddine, MD, Conor G. Loftus, MD, Santhi S. Vege, MD, Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, MN.

P907. Band of Cacophony
Gautam Dulta, MD, Aparna S. Chowdhury, MD, Mukta Panda, MD, FACP, Internal Medicine, University of Tennessee, Chattanooga, TN.
P924. Patient Reported Quality of Life Following Surgery in Ulcerative Colitis
H.C. Thompson, MBA, D. Eisenberg, PhD, M. Bala, PhD, M.I. Rahman, MD, Health Economics Clinical Outcomes Research, Centocor, Inc., Horsham, PA and Worldwide Health Economics Pricing, JJ Pharmaceutical Services, Malvern, PA.

P925. The Direct and Indirect Cost Burden of Crohn's Disease
Eliza Ng, MD, Teresa B. Gibson, PhD, Ronald J. Ozminkowski, PhD, Ron Z. Goetzl, PhD, Wayne Burton, MD, Sara Wang, PhD, Ross MacLean, MD, Global Outcomes Research Strategy, Bristol-Myers Squibb, Princeton, NJ; Health and Productivity Research, Thomson Healthcare, Ann Arbor, MI; Institute for Health and Productivity Studies, Cornell University, Washington, DC and Division of General Internal Medicine, Northwestern University, Chicago, IL.

P926. Increased Healthcare Utilization Following Colectomy in Ulcerative Colitis
Heidi C. Thompson, MBA, Brian Meissner, PhD, Mirza I. Rahman, MD, Omar Dabbous, MD, Boxiong Tang, MD, Health Economics & Clinical Outcomes Research, Centocor, Inc., Horsham, PA and Applied Health Outcomes, Xcenda, LLC, Palm Harbor, FL.

P927. Increased Inpatient Utilization Following Colectomy in Ulcerative Colitis in the Medicare Population

P928. Persistence with Infliximab Therapy Reduces Crohn's Disease Related Medical Costs
H.C. Thompson, MBA, M.I. Rahman, MD, B. Meissner, PhD, B. Tang, MD, O. Dabbous, MD, Health Economics & Clinical Outcomes Research, Centocor, Inc., Horsham, PA and Applied Health Outcomes, Xcenda, LLC, Palm Harbor, FL.

P929. Healthcare Costs and Clinical Sequelae Associated with Constipation in a Managed Care Population
Debanjali Mitra, MA, Keith L. Davis, MA, Robert W. Baran, PharmD, RTI Health Solutions, RTP, NC and Medical Outcomes Research, Thomson Healthcare, Ann Arbor, MI; Institute for Health and Productivity Studies, Cornell University, Washington, DC and Division of General Internal Medicine, Northwestern University, Chicago, IL.

P930. Patient Phone Calls: Activity-Based Cost Analysis related to Outpatient GI Practice
Raj T. Majithia, MD, David A. Johnson, MD, FACP, FACG, Internal Medicine/Gastroenterology Division, Eastern Virginia Medical School, Norfolk, VA.

P931. Timely Confirmation of Gastroesophageal Reflux Disease Via pH Monitoring: Budget Impact on Managed Care Organizations
Yu-Chen Yeh, MS, Won Chan Lee, PhD, Brian E. Lacy, PhD, MD, John E. Pandolfino, MD, Joel V. Brill, MD, Michael L. Weinstein, MD, Angelina M. Carlson, PhD, MD, Mary Jo Williams, BS, Michael R. Wittek, MSW, Chris L. Pashos, PhD, HERQuLES, Abt Associates Inc., Lexington, MA; HERQuLES, Abt Associates Inc., Bethesda, MD; Section of Gastroenterology, Dartmouth Hitchcock Medical Center, Lebanon, NH; Department of Gastroenterology, Northwestern University Medical School, Chicago, IL; Predictive Health, LLC., Phoenix, AZ; Metropolitan Gastroenterology Group, P.C., Chevy Chase, MD; Data Intelligence Consultants, LLC., Eden Prairie, MN and Medtronic, Inc., Minneapolis, MN.

P932. Prospective Assessment of Electronic Health Record (EHR) Implementation on Community Based GI Practice
Steve Carpenter, MD, Soha Taheri, MD, Lynn Marin, RN, MBA, Naresh Gunaratnam, MD, Andrew Cantanzaro, MD, Internal Medicine, Mercer University School of Medicine, Savannah, GA and Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor, MI.

INFLAMMATORY BOWEL DISEASE

P933. Prevalence and Predictors of Sexual Dysfunction in Patients with Inflammatory Bowel Disease
Viral Patel, Houssam Mardini, MD, Willem de Villiers, MD, Division of Digestive Diseases and Nutrition, University of Kentucky, Lexington, KY.

P934. Item Content Validation for Two New Measures To Assess Crohn's Disease Patients' Interest in Medication Change
M. Atkinson, R. Panaccione, S. Plevy, S. Kane, D. Wolf, S. Hass, S. Panjabi, PRO-Spectrus, Encinitas, CA; Univ. of Calgary, Calgary, Canada; Univ. of Pittsburgh, Pittsburgh, PA; Univ. of Chicago, Chicago, IL; Atlanta Gastroenterology Assoc., Atlanta, GA, and Elan Pharmaceuticals, San Diego, CA.

P935. Experience with Wireless Capsule Endoscopy in the Evaluation of Patients with Crohn's Disease
Adnan Muhammad, MD, Kiron M. Das, MD, PhD, C.S. Pitchumoni, MD, MACG, Gastroenterology, Hepatology and Clinical Nutrition, Saint Peter’s University Hospital, and Gastroenterology, Robert Wood Johnson University Hospital, New Brunswick, NJ.

P936. An Audit of Tolerability and Adverse Effects of Azathioprine and 6-Mercaptopurine in Patients with IBD
Mohammad A. Saeed, MBBS, Elmuhtady M. Said, MBBS, Jitendra N. Singh, MRCP, Anand V. Reddy, MRCP, Athar A. Saeed, FRCP, Gastroenterology, Queen Elizabeth Hospital, Gateshead, United Kingdom.

P937. Hospitalization Rates for Crohn's Disease Patients in Olmsted County, Minnesota, in the Pre-Biologic Era
Steven B. Ingle, MD, Edward V. Loftus, MD, W. Scott Harmsen, MS, Alan R. Zinsmeister, PhD, William J. Tremaine, MD, Brian G. Feagan, MD, William J. Sandborn, MD, Mayo Clinic College of Medicine, Rochester, MN and University of Western Ontario, London, ON, Canada.

P938. Gastroenterologists' Practices and Attitudes Regarding Inflammatory Bowel Disease
Andrea Altschuler, PhD, Fernando Velayos, MD, James E. Allison, MD, Liyan Liu, MD, Lisa J. Herrinton, PhD, Division of Research, Kaiser Permanente Northern California, Oakland, CA and Internal Medicine; Division of Gastroenterology, University of California, San Francisco, CA.

P939. Rifaximin Improves Symptoms in Patients with Crohn's Disease or Ulcerative Colitis
Paul L. Berenbaum, MD, FACG, Hahnemann University Hospital, Philadelphia, PA and Drexel University College of Medicine, Philadelphia, PA.

P940. Treatment of Inflammatory Bowel Disease with 6-Thioguanine (6-TG): Retrospective Case Series from a Tertiary Care Center
Chhaya P. Hasyagar, MD, Erina N. Foster, MD, Mark Gerich, MD, Thomas P. Prindiville, MD, Gastroenterology and Hepatology, UC Davis Medical Center, Sacramento, CA.
P941. MR Enterography in Crohn’s Disease: A Preliminary Experience
Samir A. Shah, MD, David J. Grand, MD, Medicine, Division of Gastroenterology and Department of Radiology, Brown Medical School, Providence, RI.

P942. Inflammatory Bowel Disease in the Setting of Autoimmune Pancreatitis
Karthyk Ravi, MD, Edward V. Loftus, MD, Suresh T. Char, MD, Santhi S. Vege, MD, William J. Sandborn, MD, Thomas C. Smyrk, MD, Internal Medicine, Gastroenterology and Hepatology, and Pathology, Mayo Clinic, Rochester, MN.

P943. The Apparent Increase in Apoptosis Reported for Adalimumab, Etanercept, and Infliximab Is Actually a Reduction in Cell Proliferation
Andrew M. Nesbitt, PhD, Gianluca Fossati, PhD, Derek T. Brown, PhD, Celltech Antibody Biology Division, UCB, Slough, United Kingdom.

P944. The Influence of Immune Modifier Therapy on the Development of Non-Melanoma Skin Cancer in Patients with Crohn’s Disease Under Age Fifty
Garfield Grandison, MBBS, William J. Tremaine, MD, Clark C. Otley, MD, Internal Medicine, Dermatology, and Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.

P945. A Pilot Study of the Efficacy and Tolerability of AST-120 in the Treatment of Active Pouchitis
Bo Shen, Darrell Pardi, Ana Bennett, Kerry Sherman, Gastroenterology, Cleveland Clinic, Cleveland, OH and Gastroenterology, Mayo Clinic, Rochester, MN.

P946. Biopsy Practices Following the Diagnosis of Neoplasia in Patients Undergoing Surveillance Colonoscopy in Ulcerative Colitis (UC)
Thomas Ullman, MD, Deepthi Deconda, MD, Yevgeniya Pashinsky, MD, Noam Harpaz, MD, Steven Itzkowitz, MD, Medicine and Pathology, The Mount Sinai School of Medicine.

P947. Prevalence of Epstein-Barr Virus in Patients with Inflammatory Bowel Disease
Kanat Ransibrahmanakul, MD, Pouria Kashkouli, MD, Erina Foster, MD, Thomas Prindiville, MD, Sumathi Sankaran, PhD, Irina Grishina, Satya Dandekar, PhD, Gastroenterology, University of California, Davis, Medical Center, Sacramento, CA and Medical Microbiology and Immunology, University of California, Davis, Davis, CA.

P948. Rapid Symptom Resolution with Delayed Release Mesalamine in Mildly and Moderately Active Crohn’s Disease
William J. Sandborn, MD, Seymour Katz, MD, David Ramsey, MS, Daniel H. Present, MD, Mayo Clinic, Rochester, MN; Nassau Gastroenterology Associates, Great Neck, NY; P G Pharmaceuticals, Mason, OH and Mount Sinai School of Medicine, New York, NY.

P949. MMX™ Mesalamine Is Effective for the Maintenance of Ulcerative Colitis Remission in Both Left-Sided and Extensive Disease
Gary R. Lichtenstein, MD, Michael A. Kamm, MD, Robyn Karlstad, MD, Ron Diebold, PhD, Karen Barrett, MSc, Raymond E. Joseph, MD, Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA; Department of Gastroenterology, St. Mark’s Hospital, London, United Kingdom; Shire Pharmaceuticals Inc., Wayne, PA and Shire Pharmaceuticals Inc., Basingstoke, Hampshire, United Kingdom.

P950. Once- or Twice-Daily MMX™ Mesalamine for the Maintenance of Remission of Mild or Moderate Ulcerative Colitis
Remo Panaccione, MD, Michael A. Kamm, MD, Robyn Karlstad, MD, Ron Diebold, PhD, Karen Barrett, MSc, Raymond E. Joseph, MD, Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, AB, Canada; Department of Gastroenterology, St. Mark’s Hospital, London, United Kingdom; Shire Pharmaceuticals Inc., Wayne, PA and Shire Pharmaceuticals Inc., Basingstoke, Hampshire, United Kingdom.

P951. Compassionate Use of Certolizumab Pegol in Patients with Crohn’s Disease for Whom Treatment with One or Two Anti-TNFs Failed
Suzanne Vermeire, MD, Benoît Collin, Krasimir Mitchev, MD, Stefanie Howaldt, MD, Daniel W. Hommes, MD, Paul J. Rutgeerts, MD, Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium; Global Medical Care, UCB, Braine L’Alleud, Belgium; Private Practice, Hamburg, Germany and Dept of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, Netherlands.

P952. Risk Factors for Pouchitis after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis or Indeterminate Colitis: A Population-Based Study
Paul E. Evans, MD, Darrell S. Pardi, MD, William J. Sandborn, MD, William J. Tremaine, MD, Eric J. Dozois, MD, Robert R. Cima, MD, David W. Larson, MD, John H. Pemberton, MD, Bruce G. Wolff, MD, William S. Harmsen, Alan R. Zinsmeister, PhD, Shamina Dhillon, MD, Patricia P. Kammer, Edward V. Loftus, MD, Division of Gastroenterology and Hepatology, Division of Colon and Rectal Surgery, and Divisions of Biostatistics and Epidemiology, Mayo Clinic, Rochester, MN.

P953. The Effect of Prolonged Therapy with MMX™ Mesalamine in Patients with Acute, Mild-to-Moderate Ulcerative Colitis
Gary R. Lichtenstein, MD, Michael A. Kamm, MD, Remo Panaccione, MD, Karen Barrett, MSc, Kirstin Lees, MA, Raymond E. Joseph, MD, Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA; Department of Gastroenterology, St. Mark’s Hospital, London, United Kingdom; Division of Gastroenterology, University of Calgary, Calgary, AB, Canada; Shire Pharmaceuticals Inc., Basingstoke, Hampshire, United Kingdom and Shire Pharmaceuticals Inc., Wayne, PA.

P954. Predictors of Short and Long Term Response to Azathioprine in Crohn’s Disease
Alla Grigorian, MD, Houssam Mardini, MD, Razvan Arsene, MD, Trevor Winter, MD, Willem de Villiers, MD, Division of Digestive Diseases and Nutrition, University of Kentucky, Lexington, KY.

P955. Predictors of 5-ASA Prescription Persistence during the Chronic Phase in Patients with Ulcerative Colitis (UC)
Sunanda Kane, MD, Simon Magowan, MD, Neil Accortt, PhD, Diana Brixner, PhD, University of Chicago, Chicago, IL; P G Pharmaceuticals, Mason, OH and University of Utah, Salt Lake City, UT.

P956. Efficacy and Safety of Certolizumab Pegol Do Not Appear To Be Affected by Neutralizing Antibodies in Patients with Crohn’s Disease
Sue Stephens, PhD, Ralph Bloomfield, MSc, Donna M. Devine, MSc, Andrew M. Nesbitt, PhD, Clinical Assay Department, Biometrics, and Antibody Biology Division, UCB Celltech, Slough, United Kingdom.
FUNCTIONAL BOWEL DISORDERS

Poster Presentations — Tuesday, October 16

P957. Adalimumab Safety in Crohn's Disease Patients: Open-Label Maintenance Following the Gain and CHARM Trials
J.F. Colombel, MD, P. Rutgeerts, MD, W.J. Sandborn, MD, R. Panaccione, MD, W. Lau, PhD, K.G. Lomax, MD, P.F. Pollack, MD, CHU Lille, Lille, France; University Hospital of Gasthuisberg, Leuven, Belgium; Mayo Clinic, Rochester, MN; Health Science Centre, Calgary, AB, Canada and Abbott, Parsippany, NJ.

P958. Participation in Colonoscopic Cancer Surveillance among Patients with Ulcerative Colitis: Meeting Expectations?
Fernando S, Velayos, MD, MPH, Liyan Liu, PhD, Jonathan P. Terdiman, MD, Bernie Collins, PhD, James A. Allison, MD, Lisa J. Herrinton, PhD, Gastroenterology and Hepatology, Center for Crohn's and Colitis, University of California San Francisco, San Francisco, CA and Division of Research, Northern California Kaiser Permanente, Oakland, CA.

P959. Non-Adherence to Surveillance Colonoscopy in Patients with Inflammatory Bowel Disease: Assessing the Risk
Sonia Friedman, MD, Adam Cheifitz, MD, Francis Farrayde, MD, Medicine, Brigham and Women's Hospital, Medicine, Beth Israel Medical Center, and Medicine, Boston Medical Center, Boston, MA.

P960. Expression of P2X Receptor in a Rat Model of Chronic Visceral Hyperalgesia
★ 2007 ACG Presidential Poster Award Recipient
Sahil Mittal, MD, Guang Yin Xu, PhD, John Winston, PhD, Mohan Shenoy, PhD, Pankaj J. Pasricha, MD, Division of Gastroenterology & Hepatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX.

P961. From Mouse Knockout to Investigational Drug: LX1031, a Novel Potential Treatment for Irritable Bowel Syndrome
Phil Brown, MD, Jessica Jackson, Kenny Frazier, Alex Turner, PhD, Jim Liu, PhD, Lexicon Pharmaceuticals, Inc., The Woodlands, TX.

P962. Effectiveness of a Behavioral Medicine Program on Adolescent Irritable Bowel Symptoms and Resource Utilization
Sriprya Balasubramanian, MD, Rhonda Gage, RN, Monica Randel, RD, Andre Shaw, Robert Randel, Alisa Lene, Shawn Visger, Michael Lawson, MD, Gastroenterology, Kaiser Permanente, Sacramento, CA.

P963. Effects of Mesalazine Alone or Associated with Lactobacillus boulardii on Diarrhea-Predominant Irritable Bowel Syndrome
Mauro Bafutto, Prof, Jose R. Almeida, Prof, Nayle V. Leite, MD, Maria C.F. Passos, Prof, Joffre R. Filho, Prof, Instituto Goiano de Gastroenterologia, Gastroenterology Division-Faculdade de Medicina UFGO, Goiania, Goias, Brazil; Gastroenterology Division, Faculdade de Medicina-UFPE, Recife, Pernambuco, Brazil and Gastroenterology Division, Faculdade de Medicina, Belo Horizonte, Minas Gerais, Brazil.

P964. A Randomized, Controlled, Double-Blind Trial of s-Pindolol
in Irritable Bowel Syndrome (IBS)
Eamonn M. Quigley, MD, John Devane, PhD, David Young, PhD, Jackie Butler, PhD, Alimentary Pharmacobiotic Centre, University College Cork, Cork, Ireland; AGI Therapeutics Research Ltd, Athlone, Westmeath, Ireland and AGI Therapeutics Inc, Columbia, MD.

P965. Do Autonomic Function and \( \alpha_2 \) Adrenergic Genotypes Predict IBS Phenotype?
Seth Sweetser, MD, Michael Camilleri, MD, Alan R. Zinsmeister, PhD, Philip A. Low, MD, Sanna McKinzie, MS, Clinical Enteric Neuroscience Translational and Epidemiological Research, Department of Health Sciences Research, Division of Biostatistics, and Department of Neurology, Mayo Clinic, Rochester, MN.

P966. Prevalence of Functional GI Disorders in Women with History of Domestic Violence. Does the Type of Abuse Matter?
Jose M. Remes-Troche, MD, Silvia Cid-Juarez, MD, Antonio Ramos-de-la-Medina, MD, Angelica Galmiche, MS, Max Schmulsion, MD, Federico Roesch, MD, Digestive Physiology and Motility Laboratory, Medical-Biological Research Instituto, Universidad Veracruzana, Medical Education, Hospital Regional de Veracruz, and La Casa de la Mujer, Veracruz, Mexico, and Department of Experimental Medicine, UNAM, Mexico City, Mexico.

P967. Does Maternal Predominance Exist in the Cyclic Vomiting Pattern in Gastroparesis?
Jane C. Williams, MD, Bradley Creel, MD, Thomas L. Abell, MD, Department of Digestive Diseases, University of Mississippi Medical Center, Jackson, MS.

P968. Colonic Diverticular Disease and Diarrhea-Predominant Irritable Bowel Syndrome: An Etiological Link?
Hye-kyung Jung, MD, PhD, G. Richard Locke, III, MD, Cathy D. Schleck, Alan R. Zinsmeister, PhD, Nicholas J. Talley, MD, PhD, Dyspepsia Center, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN; School of Medicine, Ewha Womans University, Seoul, Korea and Department of Health Sciences Research and Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, MN.

P969. Test of Brain-Gut Axis in Humans Using Cortical Evoked Potentials and Trans-Cranial, Trans-Lumbar, and Trans-Sacral Magnetic Stimulation and Its Reproducibility
Jose Remes-Troche, MD, Ashok Attaluri, MD, Jessica Paulson, Satish Rao, MD, Gastroenterology and Neurology, University of Iowa, Iowa City, IA.

P970. Prevalence and Predictors of Non-Consulting for Chronic Constipation
Olafur S. Palsson, Psyd, Marsha J. Turner, MS, Rona L. Levy, PhD, Andrew D. Feld, MD, Michael von Korff, ScD, William E. Whitehead, PhD, University of North Carolina at Chapel Hill, NC; University of Washington and Group Health Cooperative of Puget Sound, Seattle, WA.

P971. Development and Validation of the Bloating Symptom Impact Scale (B-SIS)
Sarah B. Wassinger, MD, Michael P. Jones, MD, Lucinda A. Harris, MD, John K. DiBaise, MD, Michael Crowell, PhD, Department of Gastroenterology and Hepatology, Mayo Clinic Scottsdale, Scottsdale, AZ and Department of Gastroenterology and Hepatology, Northwestern University Medical School, Chicago, IL.

P972. Self-Perceived Stigma in IBS: Relationship to Quality of Life, Self-Efficacy, Self-Esteem, and Psychiatric Distress
Michael P. Jones, MD, Jason Bratten, BS, Laurie Keefer, PhD, Greg Sayuk, MD, Sarah Wassinger, MD, Michael D. Crowell, PhD, Rona L. Levy, PhD, Olafur Palsson, PsyD, Northwestern University; Washington University; Mayo Clinic College of Medicine; University of Washington, and University of North Carolina.
P973. Quality of Life (QOL) but Not Symptom Reporting Is Significantly Determined by Psychosocial Factors: Implications for Outcomes Endpoints
Michael P. Jones, MD, Jason Bratten, BS, Laurie Keefer, PhD, Michael D. Crowell, PhD, Gastroenterology, Northwestern University, Chicago, IL and Gastroenterology, Mayo Clinic, Scottsdale, AZ.

P974. Lack of Education and Training in Video Capsule Endoscopy among Pediatric Gastroenterology Fellows
Neville D. Bamlji, MD, Brian P. Bosworth, MD, Robbyn E. Sockolow, MD, Aliza Solomon, MD, Melanie K. Greifer, MD, Felice H. Schnoll-Sussman, MD, Division of Gastroenterology and Hepatology, New York Presbyterian Hospital-Weill/Cornell Medical Center, New York, NY.

P975. A Retrospective Study of Capsule Endoscopy at a Tertiary Care Center: Inpatient Versus Outpatient Populations
Matthew A. Nikoloff, MD, Tri H. Le, MD, Department of Medicine, Division of Gastroenterology and Hepatology, Penn State Milton S. Hershey Medical Center, Hershey, PA.

P976. Capsule Endoscopy Performed for Small Bowel Obstruction: A Tertiary-Referral Center Experience
Mark H. Flasar, MD, Douglas R. Morgan, MD, Kim L. Isaacs, MD, Internal Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD and Internal Medicine, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC.

P977. CES E-Score for Esophageal Capsule Endoscopy Image Quality Assessment
Disaya Chavalitdhamrong, MD, Oren Goltzer, Capsule Endoscopy Services, Los Angeles, CA.

P978. Endosonographic Diagnosis of Gastric Variceal Bleeding
Sathya Jaganmohan, MD, Manoop Bhutani, MD, FACG, Gagan Sood, MD, Gastroenterology, UTMB, Galveston, TX and Gastroenterology, M.D. Anderson Cancer Center, Houston, TX.

P979. Prokinetics Infusion Prior to Endoscopy for Acute Upper Gastrointestinal Bleeding: A Randomized, Controlled, Double-Blind & Placebo-Controlled Trial
Samir L. Habashi, MD, Louis R. Lambiase, MD, Ravi Kottoor, MD, Gastroenterology, Bronx Lebanon Hospital Center, Bronx, NY.

P980. The Study of Associated Cellular DNA Damage in Proliferous Cells by Vital Dyes at Concentrations Used in Clinical Chromoendoscopy
Jihui Hao, PhD, Xiao Cang Cao, PhD, Qiang Liu, Wei Ting Du, Dept. of Abdominal Surgery, Tianjin Medical University Cancer Institute and Hospital, Dept. of Gastroenterology, Tianjin Medical University General Hospital, Institute of Radiation Medicine, CAMS PUMC, and State Key Lab. of Experimental Hematology, Institute of Haematology, CAMS PUMC, Tianjin, China.

P981. Disappointing Yield of Duodenal Biopsies for Celiac Disease in “At Risk” Patients
Rajasekharan R. Murmaddi, MD, Sahil Mittal, MD, Modar Shiban, MD, Krishna S. Kasturi, MD, Division of Gastroenterology, The University of Texas Medical Branch, Galveston, TX; and Tishreen University, Lattakia, Syrian Arab Republic.

P982. High-Definition White Light and High-Contrast Narrow-Band Imaging at Standard Magnification To Predict Polyp Histology: An In-Vivo Study
Daniel A. Ringold, MD, Sanjay K. Sikka, MD, Greg S. Sayuk, MD, Jonnalagadad Sreenivasa, MD, Chandra Prakash, MD, Bhaskar Banerjee, MD, Internal Medicine/Gastroenterology, Washington University, St. Louis, MO.

P983. Efficacy of Digital High Contrast Imaging Coupled with Standard Colonoscopes in Predicting Colon Polyp Histology
Sanjay Sikka, MD, Daniel Ringold, MD, Abdul Aadom, MD, Rajesh Shah, MD, Sreeni Jonnalagadda, MD, Bhaskar Banerjee, MD, Department of Medicine, Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO.

P984. The Study of Associated Cellular DNA Damage in Proliferous Cells by Vital Dyes at Concentrations Used in Clinical Chromoendoscopy
Jihui Hao, PhD, Xiao Cang Cao, PhD, Qiang Liu, Wei Ting Du, Dept. of Abdominal Surgery, Tianjin Medical University Cancer Institute and Hospital, Dept. of Gastroenterology, Tianjin Medical University General Hospital, Institute of Radiation Medicine, CAMS PUMC, and State Key Lab. of Experimental Hematology, Institute of Haematology, CAMS PUMC, Tianjin, China.

P985. Novel Endoscopic Techniques for Stoma Size Reduction Following Gastrojejunostomy
Richard I. Rothstein, MD, C. Alexander Mosse, PhD, C. Paul Swain, MD, Gastroenterology and Hepatology, Dartmouth Medical School, Lebanon, NH; University College London, London, United Kingdom and Surgical Oncology and Technology, Imperial College of Science Technology and Medicine, London, United Kingdom.

P986. Visualizing the Ampulla of Vater Using a Forward Viewing Endoscope
Jermaine C. Ralph, MD, Matthew J. McKinley, MD, FACP, Lisa Lih-Brody, MD, Paul S. Berg, MD, Robert Gal, MD, Gary S. Weissman, MD, Medicine, North Shore University Hospital, Manhasset, NY and Gastroenterology, PreHealthcare Associates, Lake Success, NY.

P987. Disappointing Yield of Duodenal Biopsies for Celiac Disease in “At Risk” Patients
Rajasekharan R. Murmaddi, MD, Sahil Mittal, MD, Modar Shiban, MD, Krishna S. Kasturi, MD, Division of Gastroenterology, The University of Texas Medical Branch, Galveston, TX; and Tishreen University, Lattakia, Syrian Arab Republic.

P988. Upper Gastrointestinal Findings in Hispanic Patients with Positive Fecal Occult Blood Test
Javier A. Pou, MD, Maria I. Dueno, MD, Manuel Salcedo, MD, Jaime Martinez-Souss, MD, Betty Chinea, MD, Doris Toro, MD, Gastroenterology, Veterans Affairs Caribbean Healthcare System, San Juan, Puerto Rico.

P989. Complications Requiring Hospitalization Following Primary Screening Colonoscopy
Omar Sharif, MD, Essam R. Quraishi, MD, Kim Brown, MD, Department of Internal Medicine and Department of Gastroenterology, Henry Ford Hospital, Detroit, MI.

P990. Irrigation Pump as an Aid to Colonoscopy
Kavitha Kumbum, MD, Myrta Daniel, MD, Prospere Remy, MD, Gastroenterology, Bronx Lebanon Hospital Center, Bronx, NY.
P991. Colonoscopy Outcome Can Be Improved by Using Multiple Assessment Criteria
Elmuhtady M. Said, MBBS, Rangarajan Kasturi, MRCP, Muhammad Ayub, MRCP, Muthurulandi Kasimanickam, MBBS, Anand Reddy, MRCP, Singh Jitendra, MRCP, Athar Saeed, FRCP, Gastroenterology, Queen Elizabeth Hospital, Gateshead, Tyne and Wear, United Kingdom and Gastroenterology, St. Luke's Health Campus, Middlesbrough, Cleveland, United Kingdom.

P992. Critical Evaluation of the Efficacy of 4 Different Colon Preparations
Manish Arora, MD, Patrick I. Okolo, III, MD, Ethan Dubin, MD, Sudhir K. Dutta, MD, Division of Gastroenterology, Department of Internal Medicine, Sinai Hospital of Baltimore, Division of Gastroenterology, Johns Hopkins School of Medicine, and Division of Gastroenterology, University of Maryland School of Medicine, Baltimore, MD.

P993. Colonoscopy Procedure Times and Obesity: A Retrospective Review
Andrew B. Gentry, MD, Patrick E. Young, MD, Cecilia H. Kim, PMH, Brooks D. Cash, MD, Gastroenterology, National Naval Medical Center, Bethesda, MD.

P994. Automated Video Capture for Quality Control during Colonoscopy: Real-Time Recognition of “Inside-the-Patient” Status
Piet C. de Groen, MD, Sean Stanek, Wallapak Tavanapong, PhD, Jung-Hwan Oh, PhD, Johnny Wong, PhD, Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN; Computer Science, Iowa State University, Ames, IA and Computer Science, University of North Texas, Denton, TX.

P995. Does Scheduling Time Matter? 30 Minute Versus 60 Minute Intervals for Colonoscopy
Yogesh J. Patel, DO, Akshay Trivedi, DO, Peter Sargon, MD, Dean Silas, MD, Department of Medicine, Lutheran General Hospital, Park Ridge, IL.

COLORECTAL CANCER PREVENTION

P996. CT Colonography (CTC) Reporting and Data System (CRADS): An Effective Method To Manage Extracolonic (EC) Findings
★ 2007 ACG Presidential Poster Award Recipient
Mazer R. Ally, MD, Ganesh R. Veerappan, MD, Jennifer S. Pak, Corinne L. Maydonovitch, Jong-Ho R. Choi, MD, Roy K.H. Wong, MD, Gastroenterology and Radiology, Walter Reed Army Medical Center, Washington, DC.

P997. Access to Colonoscopy for Positive FOBT or Blood Per Rectum: Gender Effect at a Veteran's Hospital
Andrew D. Rhim, MD, Mary A. Rambus, Michael Lawson, MD, Martin Tobi, MB, Gastroenterology Division, Univ of PA School of Medicine and Philadelphia VAMC, Philadelphia, PA; Detroit VAMC Wayne State School of Medicine, Detroit, MI and Kaiser Permanente, Sacramento, CA.

P998. Positive Predictive Value of Fecal Occult Blood Testing in Patients Taking Aspirin, Other NSAIDS, Warfarin or Clopidogrel
Heather E. McDougall, MD, Mandeep S. Sawhney, MBBS, Douglas B. Nelson, MD, John H. Bond, MD, Internal Medicine, Minneapolis VA Medical Center, Minneapolis, MN; Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA and Gastroenterology, Minneapolis VA Medical Center, Minneapolis, MN.

P999. Reasons for Delay in the Diagnosis of Colon Cancer under Colonoscopic Watch—Pilot Study
Amanpal Singh, MD, G.S. Raju, MD, Internal Medicine, UTMB, Galveston, TX.

P1000. Screening Colonoscopy in Patients Older Than 80 Years
Roy D. Yen, MD, Ognian Pomakov, MD, Michael Sitrin, MD, Matthew Baichi, MD, Gastroenterology, University at Buffalo/VA Western New York, Buffalo, NY.

P1001. Screening Colonoscopy in the Elderly, Is It Worthwhile?
Emily G. Singh, MD, Catherine T. Frenette, MD, Williamson B. Strum, MD, GI, Scripps Clinic, La Jolla, CA.

P1002. Comparing Adenoma Detection Rates among Colonoscopies Prepared by Bowel Lavage with Sodium Phosphate Solution vs Pegylated Electrolyte Lavage Solution
Michael J. Gilbert, MD, Arthur J. DeCross, MD, Division of Gastroenterology and Hepatology, University of Rochester, Rochester, NY.

P1003. Adenomas Are Detected More Often on Morning Than Afternoon Screening Colonoscopy
Madhusudhan R. Sanaka, MD, Fnu Deepinder, MD, Carol A. Burke, MD, Rocio Lopez, Gastroenterology, Cleveland Clinic, Cleveland, OH.

P1004. Location of Adenoma, Not Removal Method, Is Associated with Recurrent Neoplasia
Carol A. Burke, MD, Fnu Deepinder, MD, Madhu Sanaka, MD, Rocio Lopez, MS, Department of Gastroenterology, Cleveland Clinic, Cleveland, OH.

P1005. Exploring Fund of Knowledge, Beliefs and Attitudes about Colo-Rectal Cancer Screening, Results of a Patient Survey Undergoing Screening Colonoscopy
Samuel Castillo, MD, Felix W. Leung, MD, Francisco C. Ramirez, MD, Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix, AZ and Medicine and Research, Sepulveda ACC, VAGLAHS, UCLA, North Hills, CA.

P1006. Adherence to Screening Colonoscopy in a VA Setting
Samuel F. Castillo, MD, Felix W. Leung, MD, Francisco C. Ramirez, MD, Gastroenterology, Carl T. Hayden VA Medical Center, Phoenix, AZ and Medicine and Research, Sepulveda ACC, VAGLAHS, UCLA, North Hills, CA.

P1007. Physician Workforce, Socioeconomic Factors, and Colorectal Cancer Outcomes
Thad Wilkins, MD, Andria Thomas, PhD, Robert Schade, MD, D. Stephen Goggans, MD, Peggy Wagner, PhD, Denise Hodo, MPH, D. Douglas Miller, MD, Medical College of Georgia, Augusta, GA.
Information on the Genesis of Study Concepts and Design: Author Responsibility

This year, the American College of Gastroenterology has supplemented the current conflict of interest disclosure with an additional series of questions completed by the authors of abstracts indicating whether they have been actively and personally involved in developing the study’s concept and design and in collecting the data to assure that authors are not reporting data actually collected and developed by others, e.g., a pharmaceutical company or other commercial entity. An abstract not referenced below indicates that the authors reported no industry involvement took place in any aspect or phase of the research:

The research in the following abstracts was reported to be industry-initiated:

Papers: 10

The research in the following abstracts was reported to have been initiated and analyzed by industry:

Papers: 16, 36A, 36B, 52, 55
Posters: 24, 28, 276, 283, 284, 297, 304, 315, 326, 361, 413, 414, 436, 479, 704, 715, 716, 741, 761, 886, 1096, 1104, 1105, 1121, 1122

The research in the following abstracts was reported to have been initiated, analyzed and written by industry:

Papers: 8, 54
Posters: 36, 278, 279, 280, 281, 282, 285, 301, 307, 310, 321, 323, 342, 390, 412, 431, 482, 685, 697, 711, 712, 718, 725, 737, 780, 830, 922, 1061, 1068, 1069, 1070, 1071, 1075, 1083, 1096, 1094, 1097, 1101, 1107, 1114, 1144, 1145, 1153, 1171
FUNCTIONAL DYSPEPSIA: THE ECONOMIC IMPACT TO PATIENTS

Purpose: To determine the direct and indirect costs of functional dyspepsia (FD) and to document a patient's health care utilization patterns and to estimate direct and indirect costs of FD to patients.

Methods: ICD-9 codes identified patients ≥18 years with dyspepsia. Charts were individually reviewed to confirm patients met Rome III criteria for FD, and to document a normal upper endoscopy. A validated questionnaire was mailed to patients meeting these criteria. Responses were anonymous. Data was analyzed using SPSS statistical software.

Results: 297 patients met inclusion criteria, and 178/297 (60%) responded. The respondents' mean age was 51 (±14) years; 75% were women, 87% were Caucasian, and 16% earned more than $50,000 (US) per year. Respondents had a mean of 8 (±8) years of FD symptoms, which were self-rated as moderate (52%) or severe (20%). Patients reported a mean of 3 visits to the primary care clinic over the last 12 months. To further evaluate their FD symptoms, which were self-rated as moderate (52%) or severe (20%), patients reported having been hospitalized at least once in their lifetime for FD and to FD symptoms. To further evaluate their FD symptoms, which were self-rated as moderate (52%) or severe (20%), patients reported having been hospitalized at least once in their lifetime for FD and to FD symptoms.

Conclusion: This was the first study to estimate direct and indirect costs of FD to patients. This study suggests that FD patients incur significant direct costs related to evaluating, testing and treating FD as well as indirect cost related to absenteeism and decreased productivity.

FUNCTIONAL DYSPEPSIA: THE ECONOMIC IMPACT TO PATIENTS

Purpose: To determine the direct and indirect costs of functional dyspepsia (FD) and to document a patient's health care utilization patterns and to estimate direct and indirect costs of FD to patients.

Methods: ICD-9 codes identified patients ≥18 years with dyspepsia. Charts were individually reviewed to confirm patients met Rome III criteria for FD, and to document a normal upper endoscopy. A validated questionnaire was mailed to patients meeting these criteria. Responses were anonymous. Data was analyzed using SPSS statistical software.

Results: 297 patients met inclusion criteria, and 178/297 (60%) responded. The respondents' mean age was 51 (±14) years; 75% were women, 87% were Caucasian, and 16% earned more than $50,000 (US) per year. Respondents had a mean of 8 (±8) years of FD symptoms, which were self-rated as moderate (52%) or severe (20%). Patients reported a mean of 3 visits to the primary care clinic over the last 12 months. To further evaluate their FD symptoms, which were self-rated as moderate (52%) or severe (20%), patients reported having been hospitalized at least once in their lifetime for FD and to FD symptoms.

Conclusion: This was the first study to estimate direct and indirect costs of FD to patients. This study suggests that FD patients incur significant direct costs related to evaluating, testing and treating FD as well as indirect cost related to absenteeism and decreased productivity.
ELEVATED HbA1c IS AN INDEPENDENT PREDICTOR OF AGGRESSIVE CLINICAL BEHAVIOR IN PATIENTS WITH ADENOMATOUS COLON POLYPS

2007 ACG/Olympus Colorectal Cancer Prevention Award
Ali A. Siddiqui*, Harijipriya Maddar, Saraju Naik, MD, and Byron Creyer. Gastroenterology, Dallas VA Medical Center, Dallas, TX and University of Texas Southwestern Medical Center, Dallas, TX

Purpose: To determine if poor control of DM is associated with increased prevalence of colon adenomatous polyps (AP), especially advanced AP.

Methods: We performed a retrospective review of 652 patients with DM-2 and AP. HbA1c level was calculated as in index of glycemic control over the year that preceded diagnosis of AP. 40 factors were assessed in patients grouped into well controlled (HbA1c<7.5%) & poorly controlled DM (HbA1c>7.5%). Factors in each group were examined by univariate analysis and logistic regression analysis to determine independent predictors of aggressive AP behavior.

Results: Our results are summarized in table 1. Logistic regression showed that patients with HbA1c>7.5 presented with more advanced AP, greater right sided AP and a greater number of AP. Patients using NSAIDS had a lesser incidence of advanced AP (P = 0.01).

Conclusion: Concurrent use of insulin and NSAIDS appeared to negate any protective effect of NSAIDS.

Table 1

<table>
<thead>
<tr>
<th>Univariate Analysis</th>
<th>Normal HbA1c (n=339)</th>
<th>Elevated HbA1c (n=113)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present with Advanced Adenomatous Polyps, (%)</td>
<td>13.2</td>
<td>31.2</td>
<td>6.2 (2.4-15.5)</td>
</tr>
<tr>
<td>Right Sided Adenomatous Polyp (%)</td>
<td>15.4</td>
<td>32.9</td>
<td>5.6 (2.2-13.7)</td>
</tr>
<tr>
<td>Mean Age at Diagnosis of Adenomatous Polyp</td>
<td>67.8 (52.81)</td>
<td>64.1 (51.76)</td>
<td>0.001*</td>
</tr>
<tr>
<td>Mean polyp size, (mm)</td>
<td>6.7 (13-20)</td>
<td>10 (4-30)</td>
<td>0.005*</td>
</tr>
<tr>
<td>Mean Polyp Number</td>
<td>2.5 (11-7)</td>
<td>5.5 (2-20)</td>
<td>0.005*</td>
</tr>
<tr>
<td>Smoking</td>
<td>42.6</td>
<td>60.0</td>
<td>2.1 (0.89-4.79)</td>
</tr>
</tbody>
</table>

Multivariate Logistic Regression Analysis

<table>
<thead>
<tr>
<th>INDEPENDENT VARIABLES</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>AP site (Right sided)</td>
<td>0.04 - 0.07</td>
</tr>
<tr>
<td>Polyp Number</td>
<td>0.01 - 0.15</td>
</tr>
<tr>
<td>Age at Diagnosis</td>
<td>0.06 - 0.08</td>
</tr>
<tr>
<td>Smoke</td>
<td>0.14 - 0.84</td>
</tr>
<tr>
<td>Right Sided Polyps</td>
<td>0.06 - 1.04</td>
</tr>
<tr>
<td>Advanced Polyps</td>
<td>0.01 - 8.36</td>
</tr>
</tbody>
</table>

*Statistically significant

GASTRIC ELECTRICAL STIMULATION FOR GASTROPARESIS – THE TEMPLE EXPERIENCE

2007 Laval Resident award
Varadarajan Subbiah, MD, Sean Harbison, MD, John Mehall, MD, Vanessa Lytes, CRNP, Robert S. Fisher, MD, and Henry P. Parkman, MD*. Medicine, Temple University, Philadelphia, PA

Purpose: Gastric electric stimulation (GES) is used to treat patients with medically refractory gastroparesis. The aims of this study were: 1) to review our experience with GES for the treatment of refractory gastroparesis; and 2) to determine if there are factors that might favorably impact clinical outcome.

Methods: Patients with refractory gastroparesis have been treated with Enterra GES (Medtronic, Inc) at our institution over the last 6 years. At follow-up visits, patients were given the Patient Assessment of GI Symptoms (PAGI-SYM) questionnaire and asked to rank their symptoms using a Clinical Global Patient Assessment scale (CGPA) ranging from −7 (a very great deal worse) to +7 (a very great deal better).

Results: Of 100 patients implanted, 75 patients still had an active stimulator at the time of this analysis. 8 patients have died; 14 patients had stimulators explanted due to infection (4), gastronomy (2), lead/pacemaker erosion (3), MRI (4), shocks (1), and 3 patients had no follow-up. Average follow-up was 318 days (range 34-1473 days). 63 out of 75 patients (84% per protocol; 63% intention to treat) currently receiving GES reported symptomatic improvement, 6 remained the same, and 6 worsened. Average CGPA score of the 75 patients was 3.2±0.4 (SEM), falling in the “somewhat better” category. The 33 patients with diabetic gastroparesis had a higher average CGPA score than the 42 patients in the idiopathic group (4.2±0.5 vs 2.4±0.5: p=0.005). The 61 patients with nausea/vomiting as the primary symptom had a higher CGPA score than the 14 patients with abdominal pain (3.4±0.4 vs. 2.3±0.8: p=0.020). The 32 patients using narcotic analogues regularly had a lower CGPA score than the 43 patients in the non-narcotic group (2.3±0.6 vs 3.9±0.9: p=0.014). Among the diabetics, those with nausea/vomiting as their primary symptom felt more improvement than patients with abdominal pain (4.5±1.5 vs 3.3±1.08: p=0.027). The same trend was present among the idiopathic population (2.4±0.6 vs 0.7±1.2: p=0.034).

Conclusion: The majority of patients undergoing gastric electric stimulation stated their symptoms were better than prior to stimulation. Patients with nausea/vomiting as primary presenting symptom responded better than patients with other symptomatology. Patients with diabetic gastroparesis responded better than patients with idiopathic gastroparesis. Importantly, this study has delineated three factors that appear to impact on a favorable clinical response – etiology, preoperative symptom, and narcotic use.
WHICH ADENOMA CHARACTERISTIC HAS THE STRONGEST EFFECT ON PREDICTING ADVANCED NEOPLASIA OR NUMEROUS ADENOMAS ON FOLLOW UP COLONOSCOPY?  
2007 ACG/Olympus Colorectal Cancer Prevention Award  
Carol A. Burke, MD*, Leila Mott, John Baron, MD, Doug Roberston, MD, and The Polyp Prevention Study Group. Gastroenterology, Cleveland Clinic, Cleveland, OH and Biostatistics and Epidemiology, Dartmouth, Lebanon, NH  
Purpose: We concluded that patients with mild acute pancreatitis can safely be fed a regular diet as desired starting within 12 hours of admission. Patients were followed for pain medication requirements, complications, length of stay, and recurrence of disease.  
Results: To date, 33 patients have been enrolled in the study. Mean age 52±13, 12 male, 11 female. The three groups of patients did not differ regarding age, gender and etiology of acute pancreatitis. There were no differences in narcotic usage, complications and LOS among the three groups of patients. Morphine use was 6.1 mg/±2.8 mg per day for the first 3 days in Group 1, 5.5 ± 3.1 mg/day in Group 2 and 6.5 ± 2.8 mg per day in Group 3. The mean length of stay was 4.2 ± 1.1 days, 3.8 ± 2.5 days and 4.1 ± 1.7 days, respectively. Our aim was to determine the magnitude of the effect of each factor in predicting recurrent AN or being classified as HR at FU colonoscopy.  
Methods: Data from subjects in the placebo arm of 3 polypectomy chemoprevention trials were used. Subjects were divided into LR or HR based on MSTF criteria. AN was defined as adenoma >9 mm or with any villous component/SD. Multivariate regression analysis was used to obtain risk ratios for baseline adenoma factors, looking first at baseline risk status (HR vs LR) and then size, histology and number of adenomas in a second model. All models included age, sex, study, and follow-up time as covariates.  
Results: 800 subjects with a baseline adenoma(s) and who went complete polypectomy were included. The mean time to FU colonoscopy was 37 months. HR status at baseline was significantly associated with recurrent AN, RR 1.9 (1.3-2.3, p = 0.01) and HR status on FU, RR 2.1 (1.6-2.7, p<0.0001). When individual adenoma features were studied, adenoma multiplicity was associated with both outcomes, pathology was not associated with either outcome and large size was only associated with AN (Table).  
Conclusion: The number of adenomas (>2) is the strongest predictor of risk of recurrent AN and being classified as HR at FU. Colonoscopists should be diligent in efforts to detect synchronous neoplasia regardless of size in order to recommend the proper polypectomy interval.

<table>
<thead>
<tr>
<th>Effect of Adenoma features on Recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline Adenoma Factor</strong></td>
</tr>
<tr>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>Size (mm)</td>
</tr>
<tr>
<td>Avg vs &lt;5</td>
</tr>
<tr>
<td>&gt;5 vs &lt;6</td>
</tr>
<tr>
<td>Pathology</td>
</tr>
<tr>
<td>VA vs TA</td>
</tr>
<tr>
<td>&gt;2 vs &lt;5</td>
</tr>
<tr>
<td>*Adjusted</td>
</tr>
</tbody>
</table>

A PROSPECTIVE STUDY OF FACTORS ASSOCIATED WITH INCREASED GLUTEN-FREE DIET ADHENCE IN ADULTS WITH CELIAC DISEASE  
2007 ACG/AstraZeneca Senior Fellow Abstract Award  
Daniel A. Leffler, MD, Jessica B. Edwards George, PhD, Melinda D. Dennis, RD, Hani Abdulla, MD, and Ciaran P. Kelly, MD*. The Celiac Center; Beth Israel Deaconess Medical Center; Boston, MA  
Purpose: In recent years increasing number of individuals have been diagnosed with celiac disease (CD). The only treatment for CD is lifelong adherence to a strict gluten-free diet (GFD). Despite its efficacy, adherence to the GFD is poor and factors which influence this are poorly understood. We sought to determine which factors influence GFD adherence in adults with CD.  
Methods: A survey of items determined to be important in GFD adherence was developed by an expert committee and focus groups of patients with CD. The survey was administered to 154 adults with biopsy proven celiac disease who then underwent blood testing for IgA tissue transglutaminase (tTG) levels and a standardized GFD evaluation by a nutritionist skilled in CD. Univariate and multivariate analysis were conducted to determine factors associated with adherence level.  
Results: In the study population, GFD adherence was high with 44.2% following a strict gluten free diet. Gender, Age at participation, age at diagnosis of CD, length of time on GFD, marital status, educational achievement, and employment status were not correlated with level of adherence. Factors associated with GFD adherence are listed in the table below.  
Conclusion: A number of factors were found to be correlated with GFD adherence, including cost, ability to follow the diet outside the home, membership in a celiac disease advocacy group, belief in the importance of following the GFD, and the ability to follow the GFD despite changes in mood and stress. These results provide a foundation for the design of educational interventions that may be used to target individuals at high risk for non-adherence to the GFD.  
Factors Associated with GFD adherence  
<table>
<thead>
<tr>
<th>Factor</th>
<th>M Multivariable*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost makes GFD adherence difficult</td>
<td>0.001</td>
</tr>
<tr>
<td>Concern with purposeful gluten exposure</td>
<td>0.001</td>
</tr>
<tr>
<td>Concern with accidental gluten exposure</td>
<td>0.001</td>
</tr>
<tr>
<td>Understanding of GFD</td>
<td>0.002</td>
</tr>
<tr>
<td>Ability to follow GFD when traveling</td>
<td>0.013</td>
</tr>
<tr>
<td>Ability to follow GFD when dining out</td>
<td>0.001</td>
</tr>
<tr>
<td>Ability to follow GFD during social events</td>
<td>0.007</td>
</tr>
<tr>
<td>Membership in CD advocacy group</td>
<td>0.019</td>
</tr>
<tr>
<td>Comfort following GFD at work</td>
<td>0.003</td>
</tr>
<tr>
<td>Belief that avoiding gluten is important for health</td>
<td>0.027</td>
</tr>
<tr>
<td>Mood stress do not affect GFD adherence</td>
<td>0.001</td>
</tr>
<tr>
<td>Presence of other food intolerances</td>
<td>0.023</td>
</tr>
</tbody>
</table>

*Coring controlling for age, gender, education, age of diagnosis and marital status
ROLE OF RESISTANT STARCH IN COLORECTAL CANCER PREVENTION: A PROSPECTIVE RANDOMISED CONTROLLED TRIAL

2007 ACG/Olympus Colorectal Cancer Prevention Award
Shridhar S. Dronamraju, MD, Jonathan M. Coxehead, PhD, Seamus B. Kelly, MD, and John C. Mathers, PhD*. Human Nutrition Research Centre, School of Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom and Department of General Surgery, North Tyneside General Hospital, North Shields, Tyne and Wear, United Kingdom.

Purpose: Colorectal cancer (CRC) is the second most common cause of cancer related death in the western world. Resistant starch (RS), defined as starch that resists digestion in the small intestine of a healthy individual, gets converted to butyrate following bacterial fermentation in the colon. Butyrate is shown to have potent anti-neoplastic effects on colon cancer cells in vitro. This study investigated the anti-neoplastic effects of RS in patients with CRC and its potential role as a chemo-preventive agent.

Methods: A total of 65 (36 male) sporadic CRC patients were randomised to treatment (40gm/day) with RS or ordinary starch (OS) for 2-4 weeks. Pre-treatment and post-treatment biopsies were obtained from tumour and normal mucosa and the effects of the intervention on cell proliferation and expression of cell cycle regulatory genes CDK4 and GADD45A (using real time RT-PCR) were investigated.

Results: The expression of key cell cycle regulatory gene CDK4 was upregulated (p<0.01) while that of GADD45A was down regulated (p=0.001) in the tumour tissue compared with normal flat mucosa. RS treatment for 4-6 weeks in CRC patients tended to increase CDK4 expression (p=0.07) in tumour tissue. Expression of GADD45A, which was suppressed in expression (p=0.07) in tumour tissue. Expression of GADD45A, which was markedly reduced following RS treatment as compared with OS treatment (p=0.028) (Figure 1). There was no effect of RS treatment on crypt dimensions or tumour proliferation index.

Conclusion: RS modulates the colonic crypt cell kinetics and has potential as a chemo-preventive agent against CRC. The differential expression of key cell cycle regulatory genes may play a role in these cellular effects of RS.

EFFECT OF INITIAL POLYPECTOMY VERSUS SURVEILLANCE POLYPECTOMY ON COLORECTAL CANCER MORTALITY: REDUCTION; MICRO-SIMULATION MODELING OF THE NATIONAL POLYP STUDY

2007 ACG/Olympus Colorectal Cancer Prevention Award
Diane B. Peery, MD, MPH, M. Raiford Williams, Jr., MD, Sarah H. Thun, MD, PhD, and Nancy K. Reddy, MD. VAMC/VA-Portland, Portland, OR; Wake Forest School of Medicine, Winston-Salem, NC; University of Southern California, Los Angeles, CA; and University of Washington, Seattle, WA.

Purpose: Colorectal polypectomy with surveillance reduced colorectal cancer (CRC) incidence by 76-90% (Winawer, 1993) and colorectal cancer mortality by 69% to 92% (VanDyke et al., 1999) in most cases (n=3). However, after exenatide, all 3 patients no longer needed TPN. Despite the lack of TPN, no weight loss or biochemical nutritional deterioration was observed in any case. Previous attempts at ceasing TPN had resulted in immediate and life-threatening dehydration and malnutrition. Using normal bowel function as a goal, subjects described their improvement with exenatide as 65-100% improved. Antroduodenal manometry study was performed during fasting, after exenatide, and after a subsequent test meal. Each patient was then started on exenatide 5 to 10 mcg subcutaneously twice a day. Over the following month the baseline parameters measured were repeated.

Results: The subjects consisted of 4 males and 1 female, ages 46 to 69 (mean: 57.2). At baseline, all patients had severe diarrhea that ranged from 7 to 15 bowel movements per day, often occurring within 15 minutes of eating. After exenatide, all 5 patients had an immediate improvement in bowel frequency and form. In the most severely affected patient, the bowel movements reduced from 15 watery bowel movements per day to 2-3 formed stool. In all subjects, bowel movements were no longer meal related and often occurred hours after eating. At baseline, nutritional parameters were stable due to total parenteral nutrition (TPN), in most cases (n=3). However, after exenatide, all 5 patients no longer needed TPN. Despite the lack of TPN, no weight loss or biochemical nutritional deterioration was observed in any case. Previous attempts at ceasing TPN had resulted in immediate and life-threatening dehydration and malnutrition. Using normal bowel function as a goal, subjects described their improvement with exenatide as 65-100% improved. Antroduodenal manometry study was performed during fasting, after exenatide, and after a subsequent test meal. Each patient was then started on exenatide 5 to 10 mcg subcutaneously twice a day. Over the following month the baseline parameters measured were repeated.

Conclusion: Exenatide is a novel and safe treatment option for SBS. It normalizes bowel function and maintains nutritional status. Successful treatment with exenatide may significantly reduce the need for parenteral nutrition.

THE EFFICACY OF THE GLP-1 AGONIST EXENATIDE IN THE TREATMENT OF SHORT BOWEL SYNDROME

Mark Pimentel, MD*, Benjamin Basseri, MD, Sheila Lezcano, BS, Kimberly Low, BS, Vicky Lees-Kim, RN, Tess Consantino, RN, Jeffrey L. Conklin, MD, and Edy E. Soffer, MD. GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA.

Purpose: Short bowel syndrome (SBS) is a serious medical problem resulting in severe diarrhea and nutritional deprivation. The symptoms result from lack of absorptive surface and loss of the braking mechanisms controlling the proximal gut. One of the missing, distally produced, peptides that control the proximal gut is glucagon-like peptide-1 (GLP-1). In this study we test the effect of the GLP-1 receptor agonist, exenatide, on short bowel syndrome.

Methods: SBS subjects were selected based on clinical symptoms and greater than 50% distal small bowel resection. Before beginning exenatide treatment, each patient completed a questionnaire documenting stool frequency and consistency. In addition, SBS symptoms, CRC, chemistries and BMI were also obtained. An antroduodenal manometry study was performed during fasting, after exenatide, and after a subsequent test meal. Each patient was then started on exenatide 5 to 10 mcg subcutaneously twice a day. Over the following month the baseline parameters measured were repeated.

Results: The subjects consisted of 4 males and 1 female, ages 46 to 69 (mean: 57.2). At baseline, all patients had severe diarrhea that ranged from 7 to 15 bowel movements per day, often occurring within 15 minutes of eating. After exenatide, all 5 patients had an immediate improvement in bowel frequency and form. In the most severely affected patient, the bowel movements reduced from 15 watery bowel movements per day to 2-3 formed stool. In all subjects, bowel movements were no longer meal related and often occurred hours after eating. At baseline, nutritional parameters were stable due to total parenteral nutrition (TPN), in most cases (n=3). However, after exenatide, all 5 patients no longer needed TPN. Despite the lack of TPN, no weight loss or biochemical nutritional deterioration was observed in any case. Previous attempts at ceasing TPN had resulted in immediate and life-threatening dehydration and malnutrition. Using normal bowel function as a goal, subjects described their improvement with exenatide as 65-100% improved. Antroduodenal manometry study was performed during fasting, after exenatide, and after a subsequent test meal. Each patient was then started on exenatide 5 to 10 mcg subcutaneously twice a day. Over the following month the baseline parameters measured were repeated.

Conclusion: Exenatide is a novel and safe treatment option for SBS. It normalizes bowel function and maintains nutritional status. Successful treatment with exenatide may significantly reduce the need for parenteral nutrition.

RISK FACTORS FOR SMALL INTESTINAL BACTERIAL OVERGROWTH

Kristen M. Robson, MD*, and Rebecca Liberman, MPH. Gastroenterology, Lahey Clinic, Burlington, MA and Research, Lahey Clinic, Burlington, MA.

Purpose: Small intestinal bacterial overgrowth (SIBO) has been associated with various gastrointestinal disorders. Enteric bacterial flora are thought to play an important role in the pathogenesis of some gastrointestinal diseases. We aim to determine which patient characteristics, symptoms, and laboratory values are predictive of SIBO as defined by a positive glucose breath test.

Methods: The records of all patients who were referred for a glucose breath test between January 1, 2003, and December 31, 2006, were analyzed retrospectively. Breath samples were analyzed for hydrogen and methane using a Model DP Microlyzer (Quintron Instrument, Milwaukee, WI). A breath test was deemed positive when the baseline hydrogen or methane value increased by greater than 12 ppm after the ingestion of 50 g of glucose. Chi-square tests and Fisher’s exact test were used to determine associations between categorical variables. The independent sample t-test was used to compare groups of continuous variables.

Results: Of the 167 eligible patients who were referred for a glucose breath test, 139 patient records were available for analysis (49 male, 90 female; mean age 54±13 years). There were 40 patients (29%) with positive breath tests. Patient characteristics that were significantly associated with a positive glucose breath test were: age greater than 75 years (p<0.01), low serum albumin (p=0.04), and a history of cirrhosis (p=0.02). The OR for age greater than 75 years was 4.7 (95% CI 1.4, 15.4). A history of irritable bowel syndrome significantly lowered the risk of a positive test (OR=0.27; p=0.02). There was no association between a positive breath test and the use of proton pump inhibitors, histamine-2 receptor antagonists or antimotility drugs. Diarrhea was significantly associated with a positive breath test by hydrogen criteria (OR 2.9, p=0.01), but no similar association was found with constipation, abdominal pain, bloating or gas.
017

THE SEVERITY OF Pancreatic Ductal CHANGES ON STANDARD MRCP ACCORDING TO CAMBRIDGE CLASSIFICATION Correlated with the Maximum Bicarbonate LEVEL achieved during Secretin Stimulated EXOCRINE Pancreatic Functional Testing (ePFT)
Samer Alkaade, MD, Numan C. Balci, MD, Amir J. Momtahen, MD, and Frank R. Burton, MD*. Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO and Radiology, Saint Louis University School of Medicine, St. Louis, MO

Purpose: MRCP has shown comparable results to ERCP in detecting pancreatic ductal changes of chronic pancreatitis. ePFT is regarded as the gold standard for the detection of exocrine pancreatic insufficiency. The aim of this study is to evaluate the correlation between the severity of pancreatic ductal changes on MRCP according to Cambridge classification and the maximal bicarbonate levels achieved during secretin stimulated ePFT.

Methods: We retrospectively reviewed all the charts of patients who had secretin stimulated ePFT at our institution between January 2005 and March 2007. All patients who had MRCP and ePFT within four weeks time period were included in the study. All secretin stimulated ePTTs were performed in our endoscopy unit. The MRCP images were evaluated by our radiologist, who was blinded to ePFT results. Ductal changes of the pancreatic gland were assessed.

Results: 62 patients had ePFT at our institution between January 2005 and March 2007. 38 patients underwent MRCP and ePFT within four weeks time period. MRCP images revealed abnormal pancreatic ductal changes consistent with chronic pancreatitis (ranging from equivocal to severe according to Cambridge classification) in 16 patients. On ePFT testing 26 patients had maximum bicarbonate level above the cut off value of 80 mmol/L, and 12 patients had maximal bicarbonate level of 80 mmol/L or less. A strong correlation was found between the level of bicarbonate concentration on ePFT and MRCP scores according to Cambridge classification (Spearman 0.659, P value 0.00001). Also, there was a significant difference between the mean values of the maximum bicarbonate results during ePFT in patients with normal (Cambridge 0) and patients with equivocal/abnormal (Cambridge 1-4) MRCP findings (Mann-Whitney Test, P<0.0001).

Conclusion: A high degree of correlation exists between the pancreatic ductal changes as measured on MRCP according to Cambridge classification and maximum bicarbonate level achieved during ePFT testing. Further studies are needed to validate this correlation in a prospective manner.

018

ETHANOL Pancreatic INJECTION of CYSTS: RESULTS of a PROSPECTIVE MULTICENTER, RANDOMIZED, DOUBLE BLINDED STUDY
2007 ACG Governors Award Recipient Award Recipient for Excellence in Clinical Research William R. Brugge, MD*, Gerry Collier, MA, Kathleen McGreavy, RN, C. Max Schmidt, MD, and John DeWitt, MD. Gastroenterology, Indiana University, Indianapolis, IN; Gastroenterology, Massachusetts General Hospital, Boston, MA and Surgery, Indiana University, Indianapolis, IN

Purpose: Pancreatic cystic lesions (PCL) often represent a form of early malignancy (mucinous cystic lesions). Purpose: To determine the safety and effectiveness of Endoscopic Ultrasound (EUS)-guided ethanol lavage of PCLs. Hypothesis: The rate of cyst ablation as a result of ethanol (EUS-ETOH lavage with 80% ethanol) will be greater than the rate achieved with saline (EUS-SL lavage).

Methods: We performed a retrospective chart review of EUS-ETOH and EUS-SL performed on patients with pancreatic cystic tumors (4) and pseudocysts (3) between 10/04-6/07. PCLs with any complications were included, which led to at least 54 patients being enrolled. All patients underwent EUS-ETOH lavage of each lesion. A standardized lavage technique was used with 80% ethanol injected at 200ml per lesion. EUS-ETOH was repeated as necessary. EUS-SL was utilized as a control for each lesion. EUS was repeated as necessary. All patients were followed up for at least 3 months.

Results: 54 patients had EUS-ETOH and EUS-SL performed at our institution between January 2005 and March 2007. All patients who had EUS-ETOH and EUS-SL procedures within four weeks time period were included in the study. All secretin stimulated ePTTs were performed in our endoscopy unit. The MRCP images were evaluated by our radiologist, who was blinded to ePFT results. Ductal changes of the pancreatic gland were assessed.

Results: 62 patients had ePFT at our institution between January 2005 and March 2007. 38 patients underwent MRCP and ePFT within four weeks time period. MRCP images revealed abnormal pancreatic ductal changes consistent with chronic pancreatitis (ranging from equivocal to severe according to Cambridge classification) in 16 patients. On ePFT testing 26 patients had maximum bicarbonate level above the cut off value of 80 mmol/L, and 12 patients had maximal bicarbonate level of 80 mmol/L or less. A strong correlation was found between the level of bicarbonate concentration on ePFT and MRCP scores according to Cambridge classification (Spearman 0.659, P value 0.00001). Also, there was a significant difference between the mean values of the maximum bicarbonate results during ePFT in patients with normal (Cambridge 0) and patients with equivocal/abnormal (Cambridge 1-4) MRCP findings (Mann-Whitney Test, P<0.0001).

Conclusion: A high degree of correlation exists between the pancreatic ductal changes as measured on MRCP according to Cambridge classification and maximum bicarbonate level achieved during ePFT testing. Further studies are needed to validate this correlation in a prospective manner.

019

LONG-TERM FOLLOW-UP OF ENDOSCOPIC PAPILLARY BALLOON DILATION COMPARED TO ENDOSCOPIC SPHINCTEROTOMY FOR THE EXTRACTION OF BILE DUCT STONES
James A. DiSario, MD*, Maydeen M. Ogura, Steven Price, Kristen Ildiden, and EDES Group. Internal Medicine GI Division, University of Utah Health Sciences Center, Salt Lake City, UT

Purpose: Endoscopic papillary balloon dilation (ED) for the extraction of bile duct stones is proposed to prevent late-occurring complications compared to endoscopic sphincterotomy (ES). In our previous multi-center study, 237 patients were randomized to have ED or ES. 30 day morbidity occurred in 18% (7 severe, 2 deaths) of ED and 3% (0 severe) of ES patients (p=0.001) and the study was terminated at the 1st interim analysis. Our purpose is to determine the long-term outcomes of ED vs. ES in the same cohort.

Methods: Standardized telephone interviews and medical records review regarding 30 day morbidity beyond 30 days was performed by blinded personnel not involved in clinical management. Complications were stratified by consensus criteria. Patients crossed over from ED to ES were analyzed as ES.

Results: To date, 131 (51%) patients have been located and 34 (14%) are known dead. With a mean follow up of 9.7 (8.3-11.0) years, 63 (48%) ED and 68 (52%) ES participants have been located. 18 (14%) ED and 16 (12%) ES patients have died, but the causes are known in only 6 and none were pancreatobiliary-related. Reliable data are available on 97 (41%, 70 women, 27 men) with a mean age of 44 (26-95) years and the treatment groups are evenly matched. Results are shown in the table. A multivariate regression analysis was performed on age, gender, cholecystectomy status and percutaneous diverticulum, and none of these factors significantly contributed to complications in either treatment group.

Long-Term Complications

<table>
<thead>
<tr>
<th>Event</th>
<th>ED N=63</th>
<th>ES N=68</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with any complications</td>
<td>28 (28%)</td>
<td>24 (29%)</td>
<td>0.31</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>15 (24%)</td>
<td>13 (19%)</td>
<td>0.53</td>
</tr>
<tr>
<td>Recurrent stones</td>
<td>13 (21%)</td>
<td>15 (22%)</td>
<td></td>
</tr>
<tr>
<td>Complications</td>
<td>3 (5%)</td>
<td>1 (2%)</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: 1. Long-term complications of ED and ES occur at similar rates. 2. These findings do not support ED as preferential treatment for bile duct stones to prevent long-term complications of ES.

020

HYPERTRYGLIcidEMIdIC ACUTE Pancreatitis IS DIFFERENT Jagdish S. Nachman, MD, and Donald R. Campbell, MD*. Departments of Medicine - Gastroenterology Divisions, Saint Luke's Hospital, Kansas City, MO and University of Missouri/Kansas City, Kansas City, MO

Purpose: Although hypertriglyceridemia is a well known cause of acute pancreatitis, there are a limited number of studies characterizing hypertriglyceridemic acute pancreatitis (HAP). The aims of this study were to: a) compare the clinical course and severity of HAP and acute pancreatitis (AP) secondary to other causes, b) determine whether the admitting triglyceride level influences or predicts the course of HAP, c) determine how the severity of HAP in patients with diabetes mellitus (DM) compares to non-diabetics and d) evaluate serum amylase and lipase values in HAP.

Methods: During a 5 year period all inpatients discharged with pancreatitis and hypertriglyceridemia from two tertiary academic hospitals were identified using ICD-9 codes 577.0 and 272.1 respectively.

Results: 2,576 episodes of pancreatitis were identified. A cohort of 27 episodes (1.04%) comprising the fourth largest series of patients with AP attributable to HAP is characterized and described. Patients with HAP were younger (38.15 ± 11.24 years) compared to those with AP (45.78 ± 13.87 years, p<0.005) and had longer hospitalizations (10.44 ± 8.23 days vs. 3.96 ± 6.83 days, p<0.0001). The mean admission triglyceride levels of HAP were lower compared to diabetics with HAP (3.11 ± 2.85 v. 6.06 ± 3.54). However, non-diabetics with HAP had longer hospitalizations (12.67 ± 12.70 days) and required more ICU care (5.33 ± 7.47 days) compared to patients with HAP and DM (9.33 ± 4.87 hospital days and 2.56 ± 3.92 ICU days). The mean admission lipase value in patients presenting with HAP was 25,507 ± 6,889 U/L and mean amylase value was 266 ± 267 U/L. Serum amylase values were normal in 33% of the HAP cohort, 30% of the cohort had normal lipase values, and 11% of the cohort had both normal amylase and lipase values.

Conclusion: Patients with HAP were significantly younger and the length of their hospitalization was significantly longer compared to patients with non-HAP. Although 66% of HAP patients had diabetes mellitus, the longer hospitalizations associated with HAP were not attributable to DM. Up to one-third of HAP patients have a normal admission amylase or lipase value and admission lipase values are generally much higher than amylase values.
021 INFLXIMAB REDUCES COLESTCY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: ANALYSIS FROM ACT 1 AND ACT 2

W.J. Sandborn, MD*, P. Rutgeerts, MD, B.G. Feagan, MD, W. Reinsch, MD, A. Olson, MD, J. Johanns, PhD, J. Lu, PhD, D. Rachmilewitz, MD, S. Hanauer, MD, G. Lichtenschtitl, MD, W. de Villiers, MD, D. Present, MD, B. Sands, MD, and J. Colombel, MD. gastro, Mayo Clinic, Rochester, MN; gastro, Univ Hosp Gaschwitzburg, Leuven, Belgium; Roberts Research Institute, Univ Western Ontario, London, ON, Canada; Internal Medicine, Univ Hosp Vienna, Vienna; Austria; R&D, Centocor, Inc.; Malvern, PA; Pr, Shaare Zedak Medical Center, Jerusalem, Israel; gastro & Nutrition, Univ Chicago, Chicago, IL; Center for Ibd, Univ Penna, Phila, PA; Internal Medicine, Univ Kentucky, Lexington, KY, Medicine, Mt. Sinai, New York, NY; gastro Unit, MGH, Boston, MA, and Pr gastro Enterologtist, Hospital Huriez, lille, France

Purpose: We assessed the incidence of colectomy through 54 wks, a follow-up to ACT 1 & ACT 2.

Methods: The prespecified primary analysis was to colectomy in pts treated with infliximab (IFX) compared with placebo (PBO) (combined studies & IFX grups). Data were collected in ACT 1 & 2, ACT extension, and RESULTS-UC. Missing data were collected retrospectively. Rates of colectomy, UC-related hospitalizations, and UC-related surgeries and procedures were compared bw compared IFX and PBO. Stratified log-rank test was used for time to colectomy analysis, and Kaplan-Meier (K-M) product-limit estimated cumulative incidence of colectomy.

Results: 630 (86.5%) pts had complete colectomy follow-up; more IFX pts had complete colectomy follow-up (90.1%, 5 mg/kg; 86.8%, 10 mg/kg) than PBO pts (82.8%). 81 pts (36, PBO; 35, IFX) had below hip (BHF) x-rays at 18 months. A collection of PBO pts who received commercial IFX prior to colectomy was higher than that for combined IFX pts (15.7% vs 6.6%) at ACT 1, but similar in ACT 2 (6.5% vs 5.0%). Primary endpoint: Cumulative incidence of colectomy (K-M) was significant favoring the combined IFX, grp: p=0.012. The hazard ratio btw PBO and combined-IFX grps was 0.57 (95% CI: 0.37, 0.89), a 43% risk reduction in colectomy thru 54 wks. Major secondary endpoints: A significantly greater proportion of PBO pts (14.8%) had colectomy than combined IFX pts (9.3%, p=0.028) thru 54 weeks. The proportion of UC-related hospitalizations and surgeries were significantly higher in the PBO grps than those in the combined IFX grps (p=0.003 vs p=0.022) through 54 wks after first infusion.

Conclusion: IFX significantly reduced the incidence of colectomy and decreased UC-related hospitalizations and UC-related surgeries/procedures compared with PBO in UC. Disclosure. Dr. Sandborn-research support, consultant, speaker’s bureau-Centocor R&D, Inc. Dr. Rutgeerts-research support, consultant, speaker’s bureau-Centocor R&D, Inc. Dr. Feagan-research support, consultant, speaker’s bureau-Centocor R&D, Inc Dr. Reinitz-research support, consultant, speaker’s bureau-Centocor R&D, Inc. Dr. Olson-employee J&J, stockholder-Centocor R&D, Inc. Dr. Johanns-employee J&J, stockholder-Centocor R&D, Inc. Dr. Lu-employee J&J, stockholder-Centocor R&D, Inc. Dr. Rachmilewitz-research support, consultant, speaker’s bureau-Centocor R&D, Inc. Dr. Hanauer-research support, consultant, speaker’s bureau-Centocor R&D, Inc. Dr. Lichtenstein-research support, consultant, speaker’s bureau-Centocor R&D, Inc. Dr. De Villiers-research support, consultant, speaker’s bureau-Centocor R&D, Inc. Dr. Present-research support, consultant, speaker’s bureau-Centocor R&D, Inc. Dr. Sands-research support, consultant, speaker’s bureau-Centocor R&D, Inc. Dr. Colombel-research support, consultant, speaker’s bureau-Centocor R&D, Inc.

022 A PROSPECTIVE, CONTROLLED LONGITUDINAL STUDY OF THE EFFECTS OF ORAL STEROIDS AT 3 AND 6 MONTHS ON BONE MINERAL DENSITY (BMD) IN PATIENTS WITH IBD

Revival Kariv, MD, Ana Bennett, MD, Yehuda Kariv, MD, Victor Fazio, MD, Ian Lavery, MD, Brett Lashner, MD, Bo Shen, MD, and Feza Remzi, MD*. Digestive Disease Center, Cleveland Clinic, Cleveland, OH

Purpose: Total proctocolectomy with ileal pouch-anal anastomosis substantially reduces the risk for dysphagia and cancer associated with ulcerative colitis (UC). Cancer in ileal pouch-anal anastomosis (IPAA) patients with undergoing UC is a rare, which has only been reported as single cases. Natural history of IPAA cancer in these patients and its risk factors have not been investigated and there is lack of consensus for endoscopic cancer surveillance for these patients. The aim of the study was to characterize the natural history and clinical features, and histology in a group of patients with cancer of IPAA. Methods: Pouch database of 2,750 cases was searched. All patients had a preoperative diagnosis of UC or indeterminate colitis. Patients with cancer from the pouch and or/ and anatomic transition zone (ATZ) were identified. Clinical features of these patients were characterized. Results: Eight patients (0.29%) with adenocarcinoma of the pouch and/or ATZ were identified from the database. Average age at cancer diagnosis was 56.8 ± 11.25 (SD) years. The mean duration from IBID diagnosis to cancer and from ileostomy take-down after IPAA to cancer diagnosis was 22.8 ± 8.7 years, respectively. Most (5/8 [62.5%]) had regular pouch endoscopic-surveillance after IPAA. Six cases had ATZ cancers and 2 had cancers of the pouch.

Conclusion: The risk for cancer of IPAA is small but real, which can occur in UC patients with a proctocolectomy and pouch-anastomosis diagnosis of UC. Infrequent and non-proportional high number of these patients have had post-operative Crohn’s disease of the pouch. The majority of the patients had histologically-poorly differentiated cancer. Mucosectomy does not necessarily prevent cancers of the ATZ or pouch.

Demographic and Clinical Features of the 8 Patients with Cancer of IPAA

<table>
<thead>
<tr>
<th>Cases</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proctocolectomy performed for dysphagia or cancer</td>
<td>7</td>
</tr>
<tr>
<td>Pouch</td>
<td>7</td>
</tr>
<tr>
<td>Family history of colon cancer</td>
<td>5</td>
</tr>
<tr>
<td>Staged pouch surgery</td>
<td>7</td>
</tr>
<tr>
<td>Pouch and pouch anastomosis with mucosecetomy</td>
<td>6</td>
</tr>
<tr>
<td>Crohn’s disease of the pouch</td>
<td>3</td>
</tr>
<tr>
<td>Poorly differentiated cancer</td>
<td>7</td>
</tr>
<tr>
<td>Tumor metastasis at diagnosis</td>
<td>2</td>
</tr>
</tbody>
</table>

024A NATALIZUMAB INDUCES SUSTAINED RESPONSE AND REMISSION IN THE ABSENCE OF COMBONIT IMMUNOSUPPRESSANTS IN PATIENTS WITH CROHN’S DISEASE WHO FAILED PRIOR ANTI-TNF THERAPY

USE OF NATALIZUMAB IN PATIENTS WITH CROHN’S DISEASE WHO FAILED PRIOR ANTI-TNF THERAPY

W.J. Colombel, R. Emns, B.G. Feagan, R.N. Fedorak, S.H. Hanauer, J.C. Lawrenance, R. Panaccione, D. Present, P. Rutgeerts, W.J. Sandborn, M. Sanders, S. Schreiber, M.E. Spehlmann, Z. Tulasasy, S. van Deventer, M. Volfou, D.C. Wolf, and S. Targan. Cleveland Clinic, Cleveland; Hospital Claude Huriez, Lille, France; St Paul’s Hospital, University of British Columbia, Vancouver, Canada; Roberts Research Institute, University of Western Ontario, London, Canada; University of Alberta, Edmonton, Canada; University of Chicago, Chicago; University of Western Australia, Western Australia, Australia; University of Calgary, Calgary, Canada; Mount Sinai School of Medicine, New York; University Hospital Gashitzburg, Leuven, Belgium; Mayo Clinic, Rochester; University of Virginia Health Systems, Charlottesville; Christian-Albrechts University, Kiel, Germany; Asklepios Westklinikum, Hamburg, Germany; Semmelweis Univ, Budapest, Hungary; University of Amsterdam Medical School, Amsterdam, Netherlands; Hepato-Gastroenterology, Hradec Kralove, Czech Republic; Atlanta Gastroenterology Associates, Atlanta and Cedars Sinai, Los Angeles

Purpose: This post-hoc analysis assessed the need for concomitant immunosuppressants (Imm) for induction and maintenance of response and remission with natalizumab (NAT) in patients (pts) who failed prior anti-tumor necrosis factor α (TNF α) therapy. Methods: In the ENCORE induction trial, 599 pts with CDAI scores 420 and CRP levels ≥ 2.87 mg/L were randomized 1:1:1 to receive NAT (N=259) or placebo (PBO; N=250) at Mths 0, 1 and 2. In the ENACT2 maintenance trial, NAT-treated pts who had responded in ENACT1 and had a CDAI score ≤ 220 were randomized 1:1 to receive monthly NAT (N=168) or PBO (N=171) for up to 12 mths. Results: In ENCORE, 54 NAT and 51 PBO-treated pts failed prior anti-TNF α therapy and did not receive IMM at baseline. Within this subgroup a significantly greater proportion of NAT-treated pts were in clinical response at Mths 2 and 3 and at both timepoints combined, compared to PBO (Table 1). A significantly greater proportion of NAT-treated pts were in clinical remission at Mths 3 and maintained remission through Mths 2 and 3 compared to PBO (Table 1). In ENACT2 21 NAT and 19 PBO-treated pts failed prior anti-TNF α therapy and did not receive IMM at baseline. NAT treatment resulted in more pts in clinical response

Conclusion: A 3 month course of prednisone led to a greater decline in mean t scores at both the LSS and hip than in control patients by 3 months. However, in this group of patients who had discontinued of prednisone by 3 months, and maintained on calcium and vitamin D supplementation, there was no additional loss in BMD at the hip and a small number of patients had improvement at the LSS. A short course of prednisone, therefore did not lead to progressive bone loss beyond the duration of its use.

023 ADENOCARCINOMA IN ILEAL POUCH-ANAL ANASTOMOSIS: THE CLEVELAND CLINIC EXPERIENCE

2007 ACG Centor/CBD Abstract Award

Jae Geun Hyun, MD, Asher Kornbluth, MD*, James George, MD, Peter Legnani, Sinai Medical Center, New York, NY

 Forrest Huriez, Lille, France

Phila, PA; Internal Medicine, Univ Kentucky, Lexington, KY; Medicine, Mt. Sinai, New York, NY; gastro Unit, MGH, Boston, MA, and Pr gastro Enteroogtist, Hospital Huriez, lille, France
and remission throughout the study compared to PBO (Table 2). Significant differences in response and remission were observed, respectively, at Mths 9 through 12 and at Mths 6 through 12 (Table 2).

**Conclusion:** Analyses of these trials suggest that NAT was effective in inducing response and maintaining remission in CD pts who failed prior anti-TNF \\textit{f}t therapy and did not receive concomitant IMM.

**Table 1. ENCORE (Induction)**

<table>
<thead>
<tr>
<th>Month</th>
<th>Response</th>
<th>Remission</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBO</td>
<td>NAT</td>
<td>PBO</td>
</tr>
<tr>
<td>1</td>
<td>33</td>
<td>10</td>
</tr>
<tr>
<td>2</td>
<td>32</td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>28</td>
<td>10</td>
</tr>
<tr>
<td>2 &amp; 3</td>
<td>14</td>
<td>15*</td>
</tr>
</tbody>
</table>

*\(p<0.05\)

**Table 2. ENACT2 (Maintenance)**

<table>
<thead>
<tr>
<th>Month</th>
<th>Response</th>
<th>Remission</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>48</td>
<td>11</td>
</tr>
<tr>
<td>9</td>
<td>45*</td>
<td>11</td>
</tr>
<tr>
<td>12</td>
<td>43*</td>
<td>11</td>
</tr>
</tbody>
</table>

*\(p<0.05\)

Disclosure: Dr. Leehner-Elan Pharmaceuticals, consultant. Dr. Feagan-Elan Pharmaceuticals, consultant. Dr. Fedoruk-Elan Pharmaceuticals, consultant, speakers bureau, research support. Dr. Panaccione-Elan Pharmaceuticals, research support, speaker’s bureau. Dr. Rutgeerts-Elan Pharmaceuticals, consultant. Dr. Spehlmann-no disclosures. Dr. Tulassay-no disclosures. Dr. Wollina-no disclosures. Dr. Volvofa-no disclosures. Dr. Youngman-no disclosures. Dr. Targan-Elan Pharmaceuticals, consultant.

**02B NATALIZUMAB DOES NOT REQUIRE THE CONCOMITANT USE OF IMMUNOSUPPRESSANTS OR CORTICOSTEROIDS FOR THE INDUCTION OF SUSTAINED RESPONSE AND REMISSION IN PATIENTS WITH CROHN’S DISEASE**

D.C. Wolf, J.F. Colombel, R. Enns, B.G. Feagan, R.N. Fedorak, S.B. Hanauer, B. Lashner, I.C. Lawrance, R. Panaccione, D. Present, P. Rutgeerts, W.J. Sandborn, M. Sanders, S. Schreiber, M.E. Spehlmann, Z. Tulassay, S. van Deventer, M. Lashner, I.C. Lawrance, R. Panaccione, D. Present, P. Rutgeerts, W.J. Sandborn, M. Sanders, S. Schreiber, M.E. Spehlmann, Z. Tulassay, S. van Deventer, M. Volfova, and S. Targan*. Atlanta Gastroenterology Associates, Atlanta; Hospital Claude Huriez, Lille, France; St; Paul’s Hospital, University of British Columbia, Vancouver, Canada; Robert’s Research Institute, University of Western Ontario, London, Canada; University of Alberta, Edmonton, Canada; University of Chicago, Chicago; Cleveland Clinic, Cleveland; University of Western Australia; University of Calgary, Calgary, Canada; Mount Sinai Medical School, New York; University Hospital Gasthausberg, Leuven, Belgium; Mayo Clinic, Rochester, University of Virginia Health Systems, Charlottesville; Christian-Albrechts University, Kiel, Germany; Asklepion Westklinikum, Hamburg, Germany; Semmelweis University, Budapest, Hungary; University of Amsterdam Medical Center, Amsterdam, Netherlands; Hepato-Gastroenterology, Hradec Králové, Czech Republic and Cedars Sinai, Los Angeles

**Purpose:** This post-hoc analysis assessed the need for concomitant immunosuppressants (IMM) or corticosteroids (CS) for induction of response and remission with natalizumab (NAT) in the ENCORE and ENACT2 trials.

**Methods:** In the ENCORE induction trial, 509 patients (pts) with CDAI scores c\(\geq 220\) and ≤245 and CRP levels > 2.87 mg/L were randomized 1:1 to receive NAT 300 mg (N=259) or placebo (PBO; N=250) infusions at Mths 0, 1, and 2. In the ENACT2 maintenance trial, NAT-treated pts who responded in ENACT1 and had a CDAI score <220 were randomized 1:1 to receive monthly NAT (300 mg; N=168) or placebo (N=171) infusions for up to 12 mths.

**Results:** In ENCORE, 188 pts were not receiving IMM or CS at baseline, with 90 and 98 randomized to receive NAT and PBO, respectively. A significantly greater proportion of NAT-treated pts were in clinical response at both Months 2 and 3, and, individually, at Mths 1 through 3, compared to the PBO group (Table 1). NAT treatment also resulted in a significantly greater proportion of pts in clinical remission at both Mths 2 and 3 and, individually, at Mths 1 and 3 compared to PBO (Table 1). In ENACT2, 138 pts were not receiving IMM or CS at baseline, and following randomization, 70 and 68 pts received NAT and PBO, respectively. At Mths 6 through 12, a significantly greater proportion of NAT-treated patients were in clinical response and remission, compared to the PBO group (Table 2).

**Conclusion:** Analyses of these trials suggest that NAT was effective in inducing response and sustaining remission in CD pts in the absence of concomitant IMM or CS therapy.

**Table 1. ENCORE (Induction)**

<table>
<thead>
<tr>
<th>Month</th>
<th>Response</th>
<th>Remission</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>36</td>
<td>8</td>
</tr>
<tr>
<td>2</td>
<td>40</td>
<td>19</td>
</tr>
<tr>
<td>3</td>
<td>40</td>
<td>22</td>
</tr>
<tr>
<td>2 and 3</td>
<td>31</td>
<td>12</td>
</tr>
</tbody>
</table>

*\(p<0.05\)

Disclosure: Dr. Wolf-Elan Pharmaceuticals, consultant. Dr. Feagan-Elan Pharmaceuticals, consultant. Dr. Fedoruk-Elan Pharmaceuticals, consultant, speakers bureau, research support. Dr. Lashner-Elan Pharmaceuticals, research support, speaker’s bureau. Dr. Rutgeerts-Elan Pharmaceuticals, consultant. Dr. Spehlmann-no disclosures. Dr. Tulassay-no disclosures. Dr. Wollina-no disclosures. Dr. Volvofa-no disclosures. Dr. Youngman-no disclosures. Dr. Targan-Elan Pharmaceuticals, consultant.

**025 UPPER GI CANCER ASSESSMENT “STRAIGHT-TO-TEST” SERVICE: A SAFE, EFFICIENT, AND COST-EFFECTIVE APPROACH**

Ravi Maddotra, FRCP*, Pam Steer, RGN, Ana Ignjatovic, MRCP, and Chris Akubuine, MD. Department of Gastroenterology, Milton Keynes General Hospital, Milton Keynes, United Kingdom

**Purpose:** Rapid access to diagnostics is key to early diagnosis of upper gastro-intestinal (UGI) cancer. Due to rising healthcare costs, there is also increasing pressure on gastroenterologists to cut the costs of treatment. In the UK, Cancer Plan 2000 requires all suspected cancer patients to be seen by specialists within 2 weeks of referral, and diagnostics must be completed within 31 days. These targets put huge service delivery challenges for most hospitals with limited resources. We started a “straight-to-test” (STT) service to reduce time to diagnosis and staging of suspected UGI cancer. On receiving referrals, patients were booked directly for upper endoscopy or ultrasound as appropriate. Clinic appointment was booked after the test, if necessary. There were no extra costs for setting.

**Methods:** A prospective study of new STT service over 12 months to study safety, efficiency and cost-effectiveness. All consecutive patients referred by GPs for UGI cancer assessment were studied. The patients were followed up for 6 months after endoscopy by telephonic interview and/or review of hospital medical records. Data included demographics, symptoms, endoscopy findings, follow-up plans and clinical outcomes at 6 months. The cost savings were calculated using Outpatient Mandatory Tarriff Coding System.

**Results:** 241 patients (116 m, 125 f) were referred, of which 95% had endoscopy and/or imaging within 2 weeks. The commonest symptom was dyspepsia (68%), followed by dysphagia (48%), and anorexia (41%). The endoscopy diagnoses were Gastritis (32%), Hiatus hernia (26.9%), Oesophagitis (16.8%), duodenitis (12%), Cancer (27 (11.2%) and Gastric ulcers (2.7%). Cancers included oesophageal 15, gastric 4, pancreas 3, liver 2 and colon 3. 107 (44.3%) were discharged back to GP and 134 (55.7%) were followed back to GPs after cancer is excluded on gastroscopy and hence there is scope for more cost savings. STT model of cancer assessment service has potential for widespread use in NHS and other healthcare systems.
LEARNING CURVE FOR DOUBLE-BALLOON ENTEROSCOPY (DBE) AT A U.S. CENTER

Seth A. Gross, MD, and Mark E. Stark, MD*. Gastroenterology, Mayo Clinic, Jacksonville, FL

Purpose: Reports of DBE experience demonstrate the positive influence of DBE on management of small intestine disorders, but also note long procedure time, the use of special training, and a learning curve when endoscopists first perform DBE. Our aim was to examine the learning curve for a single endoscopist’s initial experience with DBE.

Methods: We analyzed the first 250 DBE performed at our center (905 – 437). DBE were performed by a single endoscopist using the Fujinon EN-450TS and P5 enteroscopes. Complications, procedure duration, length of small intestine examined, fluoroscopy time, rate of total enteroscopy, and proportion of DBE judged clinically “Helpful” were analyzed for sequential groups of 50 DBE, with comparison to the first 50 procedures.

Results: The only major complication was a self-contained perforation in a patient in the last group of 50 DBE. Procedure parameters for sequential groups of 50 DBE are shown in tables 1 and 2; the statistic (p) compares each group of 50 DBE to the first group.

Conclusion: There was no statistical decrease of DBE duration or fluoroscopy time with increasing experience. For oral DBE, the length of intestine examined did not increase with experience for up to 250 procedures, and increased for anal DBE after 100 DBE. The rate of total enteroscopy and proportion of “Helpful” procedures increased after 150 DBE. An endoscopist may be able to perform safe and useful DBE after limited training, expertise may require more than 150 procedures.

Table 1

<table>
<thead>
<tr>
<th>Position in DBE Series</th>
<th>n</th>
<th>DBE Duration (min) ±SD</th>
<th>Length examined (cm) ±SD</th>
<th>Fluoroscopy time (min) ±SD</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-90</td>
<td>28</td>
<td>196±24</td>
<td>320±86</td>
<td>4.6±2.1</td>
<td></td>
</tr>
<tr>
<td>51-100</td>
<td>23</td>
<td>108±38</td>
<td>42±29±52</td>
<td>62±5.1</td>
<td></td>
</tr>
<tr>
<td>101-150</td>
<td>24</td>
<td>112±19</td>
<td>107±37</td>
<td>46±1.1</td>
<td></td>
</tr>
<tr>
<td>151-200</td>
<td>24</td>
<td>112±37</td>
<td>107±37</td>
<td>46±1.1</td>
<td></td>
</tr>
<tr>
<td>201-250</td>
<td>24</td>
<td>107±32</td>
<td>104±61</td>
<td>45±1.6</td>
<td></td>
</tr>
<tr>
<td>Anal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-90</td>
<td>27</td>
<td>127±40</td>
<td>101±53</td>
<td>5.1±4.0</td>
<td></td>
</tr>
<tr>
<td>51-100</td>
<td>28</td>
<td>127±60</td>
<td>101±53</td>
<td>5.1±4.0</td>
<td></td>
</tr>
<tr>
<td>101-150</td>
<td>19</td>
<td>94±38</td>
<td>148±68</td>
<td>5±6.9</td>
<td></td>
</tr>
<tr>
<td>151-200</td>
<td>17</td>
<td>84±18</td>
<td>12±37</td>
<td>4.9±2.0</td>
<td></td>
</tr>
<tr>
<td>201-250</td>
<td>15</td>
<td>82±37</td>
<td>22±51</td>
<td>4.8±2.0</td>
<td></td>
</tr>
</tbody>
</table>

Note: p ≤ 0.05 was considered statistically significant.

Table 2

<table>
<thead>
<tr>
<th>Position in DBE Series</th>
<th>Successful Total Enteroscopy %</th>
<th>Clinically “Helpful” %</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-90</td>
<td>88 (1 of 13)</td>
<td>88</td>
</tr>
<tr>
<td>51-100</td>
<td>88 (1 of 12)</td>
<td>88</td>
</tr>
<tr>
<td>101-150</td>
<td>86 (5 of 5)</td>
<td>86</td>
</tr>
<tr>
<td>151-200</td>
<td>80 (10 of 12)</td>
<td>80</td>
</tr>
<tr>
<td>201-250</td>
<td>80 (10 of 13)</td>
<td>80</td>
</tr>
</tbody>
</table>

Note: p ≤ 0.05 was considered statistically significant.

ENDOSCOPIC TREATMENT OF MALIGNANT COLONIC OBSTRUCTION USING EXPANDABLE METAL STEMS: EXPERIENCE IN 169 PATIENTS

Aaron J. Small, BA, and Todd H. Baron, MD*. Dept of Medicine, Div of Gastroenterology, Mayo Clinic College of Medicine, Rochester, MN

Purpose: Self-expanding metal stent (SEMS) placement is a suitable therapeutic option for relief of colonic obstruction for both palliation and preoperative therapy. SEMS can be applied to both left and right-sided colon segments.

Methods: We analyzed the experience of 201 patients with malignant colonic obstruction at our U.S. center from April 1999 to August 2006. We monitored patients who had undergone SEMS placement for malignant colorectal obstruction. We analyzed the database. Enteral Wallstents and Ultraflex Precise Colonic stents (Boston Scientific) were used. Patients were characterized by age, malignant stricture location, stent-induced perforation. The median in situ time for the stents in the palliative group was 48.5 days (range, 43 to 291). There were no peri-interventional morbidity or mortality. One patient experienced an intra-procedural perforation.

Results: Palliative patients had a median survival time of 167 days (range, 43 to 291). The only major complication was a self-contained perforation in a patient in the first group. Rebleeding was documented either by convincing clinical picture or by endoscopic evidence.

Conclusion: A total of 213 patients met the inclusion criteria. 78 patients were placed in Group A; None of the patients in Group A had rebleeding (0/78). 135 patients fell into Group B. Eight patients in Group B (8/135, 5.9%) rebled, with one requiring surgery. This agrees with previously published data. The rebleeding rate of 0% in Group A was significantly lower than in Group B (p value <0.03 using one-sided Fisher’s exact test). Both groups A and B had comparable proportions of patients with visible vessel or active bleeding (44.87% for Group A compared to 45.19% for Group B).

Conclusion: In non-variceal acute UGIB, the use of endoscopic clips alone or in combination with injection therapy is associated with a lower in-hospital rebleeding rate than is thermocoagulation and/or injection therapy without endoscopic clip therapy. Endoscopic clips should be regarded as the therapy of choice in NVAUGIB. Injection therapy alone or combination therapy with injection therapy and thermocoagulation for NVAUGIB should be reserved for those situations where the application of endoscopic clips is not feasible or not successful and when the clips are not available.

029 Late Breaking Abstract

GENE EXPRESSION BIOMARKERS CAN PREDICT SUSTAINED VIROLOGIC RESPONSE (SVR) EARLY AFTER INITIATION OF Pegylated InterferON alpha-2a (PEG-INF) and RBV IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (CH-C)

Mandeep Singh, MD, Rochelle C. Plantes, MD, Ancha Banerova, PhD, Maria Stepanova, MS, Michael Garone Jr., Aimal Arsalia, Sambul Ahmed, MD, Christopher D. Santini, BS, Christopher L. Sigau, BS, Joanne Chan, BS, Ayuko A. Ivenson, BS, Sheng-Yung Fang, MD, and Michael E. Volmovitz, MD, Center for Liver Diseases at Inova Fairfax Hospital, Falls Church, VA, and Celera Diagnostics, Alameda, CA

Responsiveness to HCV therapy depends on both viral and host factors. Patients with HCV genotype 1 (G1) have lower SVR rates. Determining rapid virologic response (RVR) after 4 weeks of therapy and early virologic response (EVR) after 12 weeks of therapy can be helpful in the management of patients with CH-C. Nevertheless, an accurate biomarker to predict RVR early during the course of antiviral therapy is currently lacking. Aims: Develop a gene expression biomarker predicting SVR early during anti-viral therapy of patients with CH-C. Methods: 44 CH-C patients with G1 (19 treatment-naïve and 25 non-responders (NR) to previous treatment) were started on peg IFN-RBV (standard doses of PEG-INF alpha 2a or 2b and RBV). Blood samples were collected prior to treatment, 1 day, 1 week, 4 weeks, and 8 weeks after treatment. Treatment with antiviral therapy was continued for 48 weeks (if EVR was achieved and week-24 HCV RNA was undetectable). SVR was defined as undetectable HCV RNA 24 weeks after discontinuation of treatment. From the blood samples obtained at different time points, total RNA was extracted, quantified and used for one step RT-PCR to detect 317 mRNAs (160 genes consisting of interferon-inducible, interferon pathway, immune response, and housekeeping genes). Expression levels of mRNAs were normalized with 6 ‘housekeeping’ genes and a reference RNA. Multiple regression and stepwise selection were performed to test differences in gene expression at different time points and predictive performance was evaluated for each model. Results: Demographics: Patients were 49.1 ± 6.9 years old with 54.5% males and 68.2% Caucasians. After 24 hours of antiviral treatment, SVR was predicted by the IL1B and ADAM9 genes in G1-naive patients (Model p-value = 0.0091; area under curve (AUC) = 0.909, Sensitivity = 0.857, Specificity = 0.909) and by IFIT2 and JAK1 gene expression levels in G1-NR patients (Model p-value = 0.0005; AUC = 0.917, Sensitivity = 1.000, Specificity = 0.750). After 7 days of antiviral treatment, SVR for G1-naive patients was predicted by the gene expression of PRRKR (Model p-value = 0.009, AUC = 0.845, Sensitivity = 0.750, Specificity = 0.925) and by the gene expression of IREX, BAG1, SUCLG1, GMPR, LYN and SDCPB in G1-NR patients (Model p-value =0.004; AUC = 0.991, Sensitivity = 1.000, Specificity = 0.925). Conclusions: A panel of non-invasive gene expression biomarkers is developed to predict SVR in G1 CH-C patients. This biomarker panel can become very useful during treatment of patients with HCV.
DYSPEPTIC SYMPTOMS IN AN ASPIRIN (ASA)-USING POPULATION: CELECOXIB VERSUS NAPROXEN PLUS LANSPROZOLE

Jay L. Goldstein, MD, Barbara J. Hunt, MS, Justin R. Boike, BS, and Byron Cryer, MD* Department of Medicine, University of Illinois at Chicago, Chicago, IL; R&D, TAP Pharmaceutical Products Inc., Lake Forest, IL and Department of Medicine, University of Texas Southwest Medical Center, Dallas, TX

Purpose: To evaluate new or existing dyspepsia-like symptoms in patients taking ASA with either celecoxib or naproxen plus lansoprazole.

Methods: In a 12-week prospective, randomized, double-blind trial, prevalence of endoscopic ulcers was evaluated in 1045 subjects taking daily ≤325mg ASA and 200mg celecoxib QD (CEL) or 500mg naproxen b.i.d with 30mg lansoprazole QD (NAP/LAN). At baseline and after 4, 8, and 12 weeks of treatment, dyspepsia symptoms were assessed using both a 4-point scale [0 (none) to 3 (severe)] and Severity of Dyspepsia Questionnaire (SODA).

Results: As previously reported, endoscopically confirmed prevalence of gastrointestinal ulcer was 9.9% (CEL 42/426) and 8.9% (NAP/LAN 38/428). Baseline mean combined dyspepsia scores (sum of severities for abdominal pain, nausea, vomiting, and heartburn) were similar (CEL 1.8, NAP/LAN 1.7), and the mean increase from baseline was greater in CEL versus NAP/LAN at weeks 4 (+0.7 vs +0.3, p=0.012), 8 (+0.7 vs +0.5, p=NS) and 12 (+0.8 vs +0.5, p=0.043). Among those with dyspepsia at baseline (212 subjects; CEL 120/LAN 220 CEL), more subjects reported symptom resolution with NAP/LAN versus CEL at weeks 4, 8, and 12 (31 vs. 18%; 33 vs. 15%; and 22 vs. 19%, respectively; p≤0.003). Among those without dyspepsia at baseline, similar proportions developed new-onset dyspepsia (36-42% CEL, 36-38% NAP/LAN). More subjects treated with NAP/LAN reported improvement in heartburn and belching compared to those treated with CEL at weeks 4, 8, and 12 (p<0.05).

In the 299 subjects who completed SODA, mean baseline scores were similar between the NAP/LAN and CEL treatment groups (6.3 vs 5.8 pain intensity, 13.9 vs 14.0 nonpain severity). A greater mean improvement from baseline in the nonpain symptoms scales was observed at weeks 4 and 8 in NAP/LAN versus CEL (-0.5 vs -0.4 at wk 4, -0.7 vs -0.4 at wk 8; p≤0.025 for each). There were no other significant differences noted in NAP/LAN and CEL groups in SODA scores. There was no significant difference in the proportions of subjects who discontinued the study due to GI symptoms (CEL 1.2% vs NAP/LAN 1.3%).

Conclusion: While the incidence of new-onset dyspepsia symptoms in both groups of ASA-users was similar, subjects with baseline dyspepsia symptoms improved to a greater extent with NAP/LAN than with CEL.

Disclosure - Dr. Jay Goldstein—consultant to and has received honoraria, travel expenses, educational grants and research grants from TAP Pharmaceutical Products Inc., AstraZeneca, Merck, Novartis, Pﬁzer, and AstraZeneca. Dr. Byron Cryer—consultant to and has received honoraria from TAP Pharmaceutical Products Inc., Pfizer, Merck and AstraZeneca. Barbara Hunt—an employee of TAP Pharmaceutical Products Inc. Justin Boike has no conicts to disclose.

ADJUDICATION OF GI EVENTS FROM LONG-TERM PLACEBO-CONTROLLED TRIALS PROVIDES EVIDENCE FOR GI SAFETY AND TOLERABILITY OF CELECOXIB VS PLACEBO

N. Arber, MD*, D. Lieberman, MD, M. Bertagnolli, MD, E. Hawi, MD, A. Rustigi, MD, T. Wang, MD, J. Coindreau, MD, C. Eagle, MD, and B. Levin, MD Tel Aviv Mtz, Israel; Oregon University; Harvard Cancer Center; National Cancer Inst.; University of Pennsylvania; Columbia University; Pfizer Inc and University of Texas

Purpose: To analyze incidence of clinically signiﬁcant upper or lower gastrointestinal adverse events (CSULGIEs) of celecoxib vs placebo, using adjudicated gastrointestinal (GI) data from the Adenoma Prevention with Celecoxib (APC), and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) studies.

Methods: In APC, 2035 subjects were randomized to celecoxib 200 mg BD, 400 mg BD, or placebo for 3 years. In PreSAP, 1561 subjects were randomized to 400 mg QD or placebo for 3 years. Adverse events (AEs), bleeds, perforations, obstructions or ulcers were evaluated up to 30 days last dose by a blinded GI Endpoint Adjudication Committee (GIEAC).

Subjects with G I AEs, GI-related deaths, or Hb fall 3g from baseline were included. Time between ﬁrst dose and CSULGIE was analyzed by a Cox proportional hazards model, stratified by study, with aspirin as covariate. Age, gender, clinical history were also analyzed.

Results: Of total population reporting AEs (n=3588), 97 subjects met inclusion criteria and were reviewed by the GIEAC. 54 were adjudicated as having CSULGIEs (1.62% for celecoxib, 1.30% for placebo). Incidence of CSULGIEs was higher among aspirin-users in both groups (2.99% vs 1.17% celecoxib; 2.83% vs 0.81% placebo). No signiﬁcant difference was shown in hazard ratio (HR) or relative risk (RR) of CSULGIE vs placebo. HR of celecoxib vs placebo was 1.24 with upper 0.025 CI at 2.21 (β=0 non-inferiority). There were no signiﬁcant differences in RR of CSULGIEs between the APC and PreSAP treatment groups (RR 1.06, 95% CI 0.48, 2.34, P=0.849) or non-aspirin users (RR 1.44, 95% CI 0.64, 3.25, P=0.374). Aspirin and age were signiﬁcant contributors of toxicity.

Conclusion: In this pooled analysis, testing for non-inferior, incidence of CSULGIEs was equivalent for celecoxib and placebo. Importantly, there were few events and the analysis was underpowered. These ﬁndings support celecoxib’s long-term GI safety and tolerability, and show long-term aspirin use is associated with signiﬁcant GI toxicity.

<table>
<thead>
<tr>
<th>P-value</th>
<th>HR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celecoxib</td>
<td>0.62</td>
<td>0.47-0.8</td>
</tr>
<tr>
<td>Aspirin</td>
<td>0.0006</td>
<td>2.63</td>
</tr>
<tr>
<td>Age (≥ 65 y)</td>
<td>0.0366</td>
<td>1.79</td>
</tr>
<tr>
<td>Age (≤ 65 y)</td>
<td>1.04-3.08</td>
<td></td>
</tr>
</tbody>
</table>
033 COST-BENEFIT OF PPI GASTROPROTECTION AMONG ELDERLY NSAI D USERS

2007 ACG Auxiliary Award (ACG Member/Fellow)

Neena S. Abraham, MD, MSC*; Jennifer Hasche, MSc, and Christine Hartman, PhD. Gastroenterology, Michael E. DeBakey VAMC; Yale College of Medicine, Houston, TX and Health Services Research, Houston Center of Quality of Care and Utilization Studies; Michele E. DeBakey VAMC, Houston, TX

Purpose: Our aim was to quantify national cost-benefit of proton pump inhibitor (PPI) gastroprotection in a cohort of elderly NSAID users.

Methods: Veterans ≥ 65 years prescribed an NSAID or coxib at a VA facility (01/01/00-12/31/02) were identified from national prescription fill data and records linked to VA and Medicare inpatient, outpatient and death files. Using our published algorithm, we defined UGIE and assessed related endoscopic, radiological or surgical procedures, ambulatory visits and inpatient hospitalization days. The VA National Average Cost Dataset was used to assess healthcare utilization costs, apportioned as recommended by published methodology. Pharmacy costs, from the VA Pharmacy Benefits Management program, were considered cumulative from the index NSAID prescription to the UGIE. Each person-day of follow-up was assessed for exposure to NSAID, coxib and overlapping PPI. Regression models assessed whether PPI gastroprotection resulted in reduced healthcare use, while adjusting for demographics; UGIE risk factors; co-morbidity; prescription channeling (i.e., propensity score); geographic location and multiple time-dependent pharmacological covariates, including aspirin, anticoagulants, antipillets and statins.

Results: In 481,205 UGIE (97.3% male; 78.6% white; mean age, 73.9 [SD 5.7]), occurred in 293,594 person-years of follow-up. Of these UGIE, 36.9% were treated by the VA (i.e., VA-UGIE), costing $5.05 million, 97% of which ($4.9 million) was related to medical resources and $150,000 to pharmacy costs. Of VA-UGIE patients, 50% were ≥5 years of age; hospitalized, the 33.8% prescribed a PPI were less likely to be hospitalized (OR 0.93; 95% CI: 0.90-0.95) and had a lower median total medical cost than those not prescribed a PPI ($522.14 [IQR 1935] vs. $128.91 [IQR 4716]; p<0.001). PPI prophylaxis for an NSAID-related UGIE requires an additional $234 per veteran. However, this increase is offset by a $2,019 reduction in total medical costs per veteran.

Conclusion: PPI gastroprotection for high-risk elderly patients is associated with fewer NSAID-related UGIE and reduced hospitalization and associated resource costs. Reduced resource costs offset higher pharmacy-related costs, making PPI gastroprotection beneficial for elderly veterans.

034 STATIN USE AND THE RISK OF CHOLECYSTECTOMY IN WOMEN

2007 ACG/Wyeth Gender Based Research Award

Chung-Jyi Tsai, MD*, Michael Leitzmann, MD, Walter Willett, MD, and Edward Giovannucci, MD. Div. of Digestive Diseases and Nutrition, University of Kentucky Medical Center; Div. of Cancer Epidemiology and Genetics, National Institute of Health and Channing Lab., Dept.of Medicine, Harvard Medical School

Purpose: Statins are frequently used due to their well-established benefits on cardiovascular disease and their potential to reduce cholesterol, and have been shown to prevent gallstone formation in clinical studies. However, there is limited evidence regarding the putative benefits or concerns with statin use in women. Our study is the first to assess whether statin use is associated with a reduced risk of cholecystectomy.

Methods: We analyzed a retrospective cohort of women from the Nurses’ Health Study. Participants were followed from 1980 to 2004 (entry ages 30-55 years) and had a median follow-up period of 12 years. Women with gallstone disease or biliary tract surgery were excluded. Our primary outcome was the first occurrence of a cholecystectomy, a surrogate of symptomatic gallstone disease. A validation study was conducted to ensure that women who had no history of gallstone disease reported biennially if they had undergone a cholecystectomy, a surrogate of symptomatic gallstone disease. A validation study was conducted. Based on when the exposures of interest were queried, two follow-up periods were used: 2000 to 2004 and 2004 to 2007. We then analyzed the new data for potential gender differences in the association between statin use and cholecystectomy.

Results: Our data demonstrated disparity in incidence, family and practice patterns between men and women in GI. We sought to identify disparities between Private (PP) and Academic practice (AP) or between men & women within these practice types, 10 years after fellowship. Methods: A 36-question survey was sent originally to a cohort of 390 GI fellows at the time of fellowship, and 3,5 and 10 years later. We herein analyze the year 10 data for potential gender differences in the association between statin use and cholecystectomy.

Conclusion: Compared to AP, PP women were more often married to a physician (44% vs 22%, P =0.01) and childless (13% vs 1.5%, P<0.01). Women in PP worked less hrs/wk but made significantly higher income than those in AP.

035 DISPARITY IN GASTROENTEROLOGY: IS IT JUST “ACADEMIC” OR A SIGNIFICANT PROBLEM? A 10 YEAR PROSPECTIVE COHORT STUDY

2007 ACG/Radhika Srinivasan Gender Based Research Award

Aparajita Singh, MD, and Carol A. Burke, MD*. For the Women in GI Committee of ACG, Gastroenterology, Cleveland Clinic, Cleveland, OH

Purpose: Our previous data demonstrated disparity in income, family and practice patterns between men and women in GI. We sought to identify disparities between Private (PP) and Academic practice (AP) or between men & women within these practice types, 10 years after fellowship.

Methods: A 36-question survey was sent originally to a cohort of 390 GI fellows at the time of fellowship, and 3, 5 and 10 years later. We herein analyze the year 10 data for potential gender differences in the association between statin use and cholecystectomy.

Results: 171 individuals (149 men, 22 women) responded. 77% are in PP and 23% in AP. 81% of men and 56% of women are in PP. Compared to AP, PP women are more often married to a physician (44% vs 22%, P =0.01) and childless (13% vs 1.5%, P<0.01). Respondents in PP worked less hrs/wk but made significantly higher income than those in AP.

Table 1: PP vs AP

<table>
<thead>
<tr>
<th>Measure</th>
<th>PP</th>
<th>AP</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean income/yr</td>
<td>399K</td>
<td>317K</td>
<td>0.04</td>
</tr>
<tr>
<td>Dollars/hr income</td>
<td>14</td>
<td>10</td>
<td>0.01</td>
</tr>
<tr>
<td>Work hrs/wk</td>
<td>52</td>
<td>56</td>
<td>0.04</td>
</tr>
<tr>
<td>Call days/month</td>
<td>5</td>
<td>10</td>
<td>0.01</td>
</tr>
<tr>
<td>Vacation wks/yr</td>
<td>5</td>
<td>7</td>
<td>0.01</td>
</tr>
<tr>
<td>CME days/yr</td>
<td>0</td>
<td>1</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Gender Disparity in PP vs AP:
In both PP and AP women’s annual income was lower than men’s. In PP women work less hrs/wk, take less call days and more vacation than men. However, in AP, no significant difference in work-hr or vacation time was noted between men and women. Multivariate analysis adjusting for work hrs, vacation time, call days and practice ownership shows the annual income of women is $100K less than men in AP (P=0.003), and $60K less in PP (P=0.08).

Table 2: Gender Disparity PP vs AP

<table>
<thead>
<tr>
<th>Measure</th>
<th>PP</th>
<th>AP</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean income/yr</td>
<td>399K</td>
<td>317K</td>
<td>0.04</td>
</tr>
<tr>
<td>Dollars/hr income</td>
<td>14</td>
<td>10</td>
<td>0.01</td>
</tr>
<tr>
<td>Work hrs/wk</td>
<td>52</td>
<td>56</td>
<td>0.04</td>
</tr>
<tr>
<td>Call days/month</td>
<td>5</td>
<td>10</td>
<td>0.01</td>
</tr>
<tr>
<td>Vacation wks/yr</td>
<td>5</td>
<td>7</td>
<td>0.01</td>
</tr>
<tr>
<td>CME days/yr</td>
<td>0</td>
<td>1</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Conclusion: Gastroenterologists in AP workload longer hours but get paid significantly less than those in PP. Significant disparities in earnings and family structure exist for women in both PP and AP. While a greater proportion of women than men are in AP the disparity in income is greatest for women in that practice setting. Recognition of these disparities is imperative and steps to minimize these in both AP and PP are warranted.

036 SEQUENTIAL THERAPY IS SUPERIOR TO STANDARD THERAPY FOR TREATMENT OF HELICOBACTER PYLORI INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS

Nadim S. Jafri, MD, Carlton A. Hornung, PhD, and Colin W. Howden, MD*. University of Louisville, Louisville, KY and Northwestern University, Chicago, IL

Purpose: Authorities continue to recommend standard PPI-based triple or quadruple therapy for the treatment of H. pylori infection despite failure of eradication in around a quarter of patients. Sequential therapy (ST) (5 days of PPI + 1 antibiotic followed by 5 days of the other) is superior to standard therapy for H. pylori infection. We performed a systematic review of randomized controlled trials (RCTs) comparing standard therapy to sequential therapy to assess the cost-effectiveness of sequential therapy.

Methods: We performed a systematic search for randomized controlled trials (RCTs) comparing ST with standard therapy for H. pylori infection in Medline, EMBASE, and the Cochrane Central Register of Controlled Trials using PubMed, Google Scholar and Ovid as search engines without language restriction. We also hand searched the references of included studies for additional relevant studies.

Results: 8 RCTs comparing 2202 patients (1071 men) met eligibility criteria. Mean age ranged from 9.7-60 years. 1095 patients were randomized to sequential therapy and 1107 to standard therapy. ST was superior with respect to eradication rates; RRR=22% (95% CI: 18-27%), ARR=17% (14-20%), NNT=6 (5.7), and for ulcer healing; RRR=17% (10-25%), ARR=11% (7-16%), NNT= 9 (6-14). Compliance was similar in both arms. Side effect profile was similar in both arms.
Conclusion: ST appears superior to standard therapy for eradication of H pylori infection and ulcer healing. It also reduced ulcer recurrence risk in smokers and in patients with NUD. These outcomes were consistent by sensitivity analysis. However, all identified RCTs were from Italy, and results may not be replicable in the US. This approach should be tested in US-based RCTs.

037

MISSED CANCERS VS PROCEDURE-RELATED COMPLICATIONS: BALANCING THE MEDICO-LEGAL RISKS OF SURVEILLANCE COLONOSCOPY

2007 ACG/AstraZeneca Senior Fellow Abstract Award

Sameer D. Saini, MD, Sandeep Vijan, MD, and Philip S. Schoenfeld, MD*. Gastroenterology, University of Michigan, Ann Arbor, MI and Internal Medicine, University of Michigan, Ann Arbor, MI

Purpose: Data suggest that gastroenterologists perform surveillance colonoscopy more often than recommended by guidelines. This practice may be driven by medico-legal concerns over missed cancers. Though more frequent colonoscopy may reduce the risk of missed cancers, it also increases the risk of procedure-related complications. According to malpractice data, such complications, particularly colonic perforation, are the most common reason for litigation against gastroenterologists. Yet, no study has compared the frequency of missed cancers and colonic perforations in patients undergoing “intensive” vs. “recommended” colonoscopy surveillance.

Methods: We developed a Markov model to determine the number of opportunities for litigation in a cohort of 1000 men/women 50 yrs of age with a new diagnosis of colon adenoma. We modeled surveillance strategies: (1) an “intensive” strategy with colonoscopy every 3 years in all patients; and, (2) a “recommended” strategy with colonoscopy every 3-5 yrs based on current guidelines. The base-case assumptions (and ranges for sensitivity analysis) were: (1) risk of colonic perforation: 0.25% (0.1%-0.4%); (2) relative risk of litigation due to missed cancer vs perforation: 1.0 (1.0-3.0); and, (3) advanced adenoma miss rate: 6% (0%-12%).

Results: In the base-case analysis, the “intensive” strategy resulted in 46 opportunities for litigation over the lifetime of the cohort (32 perforations & 24 missed cancers). In contrast, the “recommended” strategy endorsed by current guidelines resulted in only 40 opportunities for litigation (14 perforations & 26 missed cancers). In sensitivity analysis, the number of opportunities for litigation under the “intensive” strategy was greater than under the “recommended” strategy even when the perforation rate was reduced (0.1%), while the relative risk of litigation due to an interval cancer was increased (3-fold), or when the advanced adenoma miss rate was increased (12%).

Conclusion: Compared to the recommended strategy, more intensive surveillance is associated with slighty fewer missed cancers but substantially more colonic perforations, resulting in more opportunities for litigation. This result was robust to a wide range of assumptions in sensitivity analysis. Endoscopists who disregard current guidelines and perform more intensive surveillance out of concern for missed neoplasia should carefully weigh the competing risk of procedure-related complications.

038

GENDER DIFFERENCES AND BARIATRIC SURGERY OUTCOME

ACG Naomi Nakao Gender Based Research Award

Inessa Khayikis, MD, Christine J. Ren, MD, George A. Fielding, MD, Warren Huberman, PhD, Barrie Wolfe, RD, Heekough Youn, RN, Stefanie Hong, Fritz Francois, MD, and Elizabeth Heinrich, MD*. Gastroenterology, New York University Hospital, New York, NY; Surgery, New York University Hospital, New York, NY and Psychiatry, New York University Hospital, New York, NY

Purpose: Bariatric surgery is an effective treatment for obesity, however it does not lead to equal result over the lifetime of the cohort (32 perforations & 24 missed cancers). In contrast, the “recommended” strategy endorsed by current guidelines resulted in only 40 opportunities for litigation (14 perforations & 26 missed cancers). In sensitivity analysis, the number of opportunities for litigation under the “intensive” strategy was greater than under the “recommended” strategy even when the perforation rate was reduced (0.1%), while the relative risk of litigation due to an interval cancer was increased (3-fold), or when the advanced adenoma miss rate was increased (12%).

Conclusion: Compared to the recommended strategy, more intensive surveillance is associated with slighty fewer missed cancers but substantially more colonic perforations, resulting in more opportunities for litigation. This result was robust to a wide range of assumptions in sensitivity analysis. Endoscopists who disregard current guidelines and perform more intensive surveillance out of concern for missed neoplasia should carefully weigh the competing risk of procedure-related complications.

040

VENOUS THROMBOEMBOLISM IN PATIENTS WITH CIRRHOSIS

David D. Gulley, MD, Evgenia Teal, MA, Naga Chalasani, MD, and Suthath Liangpunsakul, MD, MPH*. Dept of Medicine, Indiana University, Indianapolis, IN and Regenstrief Institute, Indianapolis, IN

Purpose: It is the general notion that cirrhotic patients do not suffer from DVT/PE as they are naturally anticoagulated. However, there are no studies that objectively addressed if patients with cirrhosis have lower frequency of venous thromboembolism (VTE). Therefore, we conducted a case-control study to examine the relationship between cirrhosis and VTE.

Methods: A case-control study of patients seen at Wishard Hospital between 1995-2005 was performed using the Regenstrief Medical Record System. Cases were hospitalized patients with biopsy and/or imaging plus clinical evidence of cirrhosis. Age, gender, and race-matched patients with no known evidence of cirrhosis seen during the same period served as controls. The development of VTE was identified by the ICD-9 codes followed by cross referencing studies with Doppler ultrasound, V/Q scan, and CT chest. Subjects previously hospitalized with VTE were excluded. Charlson Index was calculated to determine the comorbidity. Patients with cirrhosis were also compared to age, gender, race, and Charlson Index matched non-cirrhotic patients with other chronic illnesses including chronic kidney disease (CKD), congestive heart failure (CHF), and five most common cancers in the US. Logistic regressions were performed to identify variables with predictive value.

Results: This study consisted of 963 cirrhotics (51±11 yrs, females 34%, and Caucasians 66%) and 12,405 controls (51±11 yrs, females 36%, and Caucasians 60%). Patients with cirrhosis had VTE (1.8%) and this is significantly higher than the controls (0.9%); OR: 1.78, p = 0.007. The Charlson Index in cirrhotic patients was higher than that in controls (5.2±1.8 vs. 9.1±1.5, p < 0.0001). However, in the combined cohort, cirrhosis (OR: 0.87, 95%CI 0.2-2.6) and Acute Liver Failure (ALF) (OR: 0.88, 95%CI 0.4-1.7) were not independently associated with VTE. PTT (OR: 0.85; 95%CI 0.8-4.04) and serum albumin (OR: 0.97, 95%CI 0.23-0.93) were the independent predictors of VTE in the entire cohort. The risk of VTE in cirrhosis was much lower than those with other medical illnesses: 7.1% in CKD (OR 0.25; 95% CI 0.15-0.41), 7.8% in CHF (OR 0.23, 95%CI 0.14-0.37), and 6.1% in cancers (OR 0.29, 95%CI 0.17-0.52).

Conclusion: Underlying cirrhosis seems to be protective against VTE when compared to other chronic illnesses. However, patients with cirrhosis do not have lower risk of VTE compared to non-cirrhotic controls. PTT and albumin were independent predictors of VTE in cirrhotic patients.
HEPATITIS B (HBV) PATIENTS UNDERGOING CHEMOTHERAPY: WHO GETS SCREENED AND WHAT PROPHYLAXIS IS GIVEN? A QUESTIONNAIRE SURVEY OF ONCOLOGISTS

Ashar Farhad, MD, James H. Lewis, MD*, Omar S. Khokhar, MD, and Lisa H. McGraff, MD. Gastroenterology/Hematology, Georgetown University Medical Center, Washington, DC and Medical Oncology, Sibley Memorial Hospital, Washington, DC.

Purpose: Chemotherapy is well described as a risk factor for reactivation of HBV infection. We sought to ascertain their awareness of Hep B reactivation, their current practice of screening for HBV and their recommendations for giving antiviral prophylaxis to their chemotherapy patients.

Results: Respondents answer as follows: (1) Are you aware that reactivation of HBV can occur with chemotherapy? Yes 78%; No 22%. (2) Have you ever seen HBV reactivation in this setting? Yes 30%; No 70%. (3) Which patients do you screen for HBV: abnormal LFTs 70%; from Asia or Africa 32%; coinfected with HCV 70%; coinfected with HIV or Hx IVDU 58%; healthcare worker 50%; Hx of transfusions 54%; homosexual men 60%. (4) Which HBV pt should receive prophylaxis? Chronic carrier 46%; active infection 76%; resolved HBV 52%. (5) Do you prescribe prophylaxis yourself? Yes 28%; No 72%. (6) Which antiviral therapy would you use? Lamivudine 46%; adefovir 14%; not sure 48%. (7) How long did you recommend prophylaxis for? 4-6 weeks 48%; >6 weeks 38%; unsure 14%. Conclusion: Most practicing oncologists have not personally encountered HBV reactivation during chemotherapy, and relatively few currently screen universally for HBV or are aware that antiviral prophylaxis is available. Over 80% would defer treatment to a specialist. Raising awareness among oncologists of current recommendations for screening and providing HBV prophylaxis to chemotherapy patients is clearly warranted.


SYSTEMIC AND PULMONARY HEMODYNAMICS IN PATIENTS WITH EXTRA-HEPATIC PORTAL VEIN OBSTRUCTION (EHPVO)

Ashish Kumar, MD, DM, Sanjeev K. Jha, MD, Barjesh C. Sharma, MD, DM, and Shiv K. Sarin, MD, DM*, Gastroenterology, G B Pant Hospital, New Delhi, Delhi, India

Purpose: Extra-hepatic portal vein obstruction (EHPVO) is a common cause of portal hypertension and variceal bleeding. Few studies have been done on hemodynamic alterations in patients with non-cirrhotic portal hypertension especially EHPVO in contrast to many reports on hemodynamics in cirrhosis. We evaluated alterations of systemic and pulmonary vascular system in patients with EHPVO and compared them with patients with compensated cirrhosis.

Methods: Consecutive patients of EHPVO, ≥15 years of age were included. Controls were consecutively collected from patients with cirrhosis and history of variceal bleed in our hospital. Further, we compared changes in systemic and pulmonary vasculature in these patients with that of patients with compensated cirrhosis.

Results: The baseline parameters in the two groups were comparable. Both EHPVO and cirrhosis patients had similar values in all the measured hemodynamic parameters. The mean cardiac output in EHPVO was 6.5 (±2.6) L/min while it was 7.9 (±3.2) L/min in cirrhosis (p = 0.212). The systemic vascular resistance in EHPVO was 1242 (±494) dyn. cm⁻², which was similar to that in cirrhosis (1018 [±355], p = 0.167). The similarly the values of pulmonary vascular resistance were comparable in both the two groups (197 [±70] vs. 196 [±75], p = 0.905). A subgroup analysis was done of 8 patients of EHPVO and 8 age matched compensated cirrhosis which also revealed similar cardiac index, cardiac output, systemic vascular resistance index, systemic vascular resistance, pulmonary vascular resistance index, and pulmonary vascular resistance in the two groups.

Conclusion: EHPVO has features of hyperdynamic circulation, is increased cardiac output, decreased systemic and pulmonary vascular resistance. These changes are similar to that seen in patients with cirrhosis. This suggests a predominant role of increased resistance and thus increased portal-systemic collateral circulation which results in more than hepatohepatic injury in the genesis of these hemodynamic alterations.
045

ENDOSCOPIC FULL-THICKNESS PLICATION FOR THE TREATMENT OF GERD: FIVE YEAR MULTI-CENTER RESULTS
Douglas R. Kozlowski, MD, Gregory Haber, MD, Christopher Gostout, MD, Simon Lo, MD, Robert Hawkins, MD, and Anthony Lembo, MD. Beth Israel Deaconess Medical Center, Boston, MA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Virginia Mason Medical Center, Seattle, WA; Lenox Hill Hospital, New York, NY; Mayo Clinic, Rochester, MN; Cedars Sinai Medical Center, Los Angeles, CA and Medical University of Southern Carolina, Charlotte, SC.

Purpose: We previously reported the Plicator (NDO Surgical, Inc., Mansfield, MA) procedure, which is an endoscopic procedure that delivers a full-thickness plication, to be effective at reducing GERD symptoms and medication use for up to 3 years post-plication with no long-term procedural adverse events. The purpose of this study was to assess the long-term safety and treatment durability of the Plicator up to 5-years post-plication.

Methods: Subjects with chronic heartburn who had originally participated in the open-label study and received a single plication in the gastro esophageal junction were eligible. Subjects were evaluated at baseline for GERD symptoms and medication use. Long-term subject follow-up was completed to evaluate safety and long-term treatment durability.

Results: Twenty-eight subjects completed the long-term follow-up (mean follow-up interval: 5-years (58 months), range: 50-65 months). All procedure-related adverse events occurred acutely, as previously reported, and no new adverse events were observed during extended follow-up. At 5-years follow-procedure, 62% of baseline PPI-dependent patients remained off daily PPI therapy. Treatment effect remained stable from the 3 to 5-year follow-up interval, with 16/28 patients off daily PPI at 3-years compared to 15/24 patients at 5-years. Median GERD-HRQL scores remained significantly improved at 5-years versus baseline off-meds scores (10 vs. 19, p<0.001). In addition, the proportion of patients achieving ≥50% improvement in GERD-HRQL score was consistent from 3-years (55%) to 5-years (50%).

Conclusion: Endoscopic full-thickness plication can effectively reduce GERD symptoms and medication use for at least 5-years post-procedure. Treatment effect is stable for 5-years and there are no long-term procedural adverse events.

046

COMPARISON OF ESOPHAGEAL MOTILITY PARAMETERS AS MEASURED BY THE NEW HIGH RESOLUTION MANOMETRY (HRM) VS TRANSTHRUST MANNOMETRY
Muhammad Hasan, MD, Sheila Rodriguez-Stanley, PhD, Susan Riley, RN, Sattar Zabaida, and Philip B. Miner, Jr, MD*. Gastroenterology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK and The Oklahoma Foundation for Digestive Research, Oklahoma City, OK.

Purpose: The 36-channel Sierra esophageal motility catheter simultaneously measures pressure forces in the UES through the body and LES. This HRM provides an intuitive advance over the standard 4-channel Konigsberg catheter (TM). Before conclusions can be drawn regarding the efficacy of HRM, comparative manometry data needs to be acquired and analyzed to assure that current standards can be applied to this technical advance. The aims of this study were to compare LES measurement from the nares, LES residual pressure (relaxation), LES pressure, distal amplitude, velocity and duration as measured by HRM and TM in a control population.

Methods: Normal subjects were randomized to HRM or TM in a crossover design (7-d period between sessions, 48 h apart). Subjects were intubated via the nares. The station pull-through was performed with Konigsberg probe. The HRM probe was placed into the esophagus and LES without moving the probe. 10 water swallowing were performed and measurements were recorded. Physiologic data was compared using paired T-tests (P<0.05).

Results: Data were analyzed from 21 normal subjects (13 females, 8 males; mean age 27.6 years). Measurement of the distance of the LES from the nares was significantly different for the HRM vs TM probes (43.3 vs 41.7 cm; P=5.95x10^-10). Residual LES pressure, a reflection of LES relaxation with water swallowing, was significantly different as measure by the catheters (15.8 vs 18 mmHg; P=1.17x10^-3); HRM vs TM. Distal contractile pressure with water swallow was also significantly different between HRM vs TM (110.8 vs 94.9 mmHg; P=0.02). LES pressure (36.6 vs 32.1 mmHg; P=0.08), Velocity (4.8 vs 3.8 cm/sec; P=0.05) and Duration (3.7 vs 3.7sec; P=0.05) were not affected by the type of motility catheter.

Conclusion: HRM identifies the LES an average of 1.6 cm closer to the LES than with the TM method. Measurement differences would influence the placement of other probes for testing (ie: esophageal pH sensor, balloon distention), and may correlate to altered motility results. LES relaxation as well as distal contractile amplitude were also affected by catheter type. New normal values, as well as “pathologic” values need to be established using the HRM system in order to diagnose esophageal motility disorders accurately.

047

COMPARISON OF SENSED ACID REFUX EVENT CHARACTERISTICS AMONG THE DIFFERENT GERD GROUPS
Ron Schey, MD, Tomas Navarro-Rodriguez, MD, Michael Shapiro, MD, Christopher Wendel, MS, and Ronnie Fass, MD*. The Neuroenteric Clinical Research Group, Southern Arizona VA Health Care System and University of Arizona, Southern Arizona VA Health Care System, Tucson, AZ.

Purpose: Proximal migration, nadir of pH and duration of acid reflux have been shown to increase the likelihood of exposure to acid reflux event (SRE). Thus far, no studies compare SRE characteristics among different GERD groups.

Methods: Patients with typical heartburn symptoms at least 3 times a week for the last 3 months were recruited. Upper endoscopy and pH testing were used to classify the three groups: Erosive esophagitis (EE), Nonerosive reflux disease (NERD) and Functional heartburn (FH). Patients underwent esophageal pH testing using a multiple-sensor pH probe (6,11,16 cm<LES). All reflux events with pH<4 at sensor 6 cm<LES that correlated with symptoms were considered as SRE. Their characteristics were compared among GERD groups.

Results: A total of 22 patients had EE, 15 NERD, and 13 FH (M/F – 20/2, 12/3, 5/8, respectively). During the pH test, 97 SREs were detected at pH sensor 6 cm<LES. The proximal extent of SREs was significantly higher in the FH group compared to NERD and EE (16cm vs 14.26±0.76 cm, 16 cm vs 12.37±0.53 cm, respectively, p<0.03). The pH nadir of SREs was significantly higher in the FH group compared to NERD and EE (2.32±1.16 vs 1.31±0.18, and 2.31±1.16 vs 1.16±0.12 respectively, p<0.01). The duration and reduction in pH and number of preceding reflux events 1 hour before an SRE was similar among the groups. The number of preceding acid reflux events 2, 3, and 4 hours prior to an SRE was significantly lower in the FH group compared to NERD and EE, 2 hours (5.57±4.1 vs 15.64±9.2, 5.57±4.1vs 14.42±9.8 respectively, p<0.05), 3 hours (8.80±4 vs 25.60±12.5, 8.80±4 vs 21.19±12.4 respectively, p<0.01), and 4 hours (11.60±4 vs 31.30±15.9, 11.60±4 vs 26.64±15.7, respectively, p<0.01).

Conclusion: Patients with FH demonstrated the highest proximal extent of SREs but a higher pH nadir and fewer reflux episodes prior to an SRE compared to NERD and EE. The study suggests that proximal acid of an reflux event is the most important physiological factor for symptom generation.

048

CONSTIPATION: IS IT A COLONIC VERSUS GENERALIZED GASTROINTESTINAL TRACT DISORDER. THE TEMPLE EXPERIENCE
Shabana Shahid, MD, Henry Parkman, MD, and Robert S. Fisher, MD*. Department of Gastroenterology, Temple University Hospital, Philadelphia, PA

Purpose: Constipation is a common clinical condition affecting millions of Americans. Its prevalence ranges between 2 and 28% depending upon the definition. While the physiology of chronic constipation is examined, four subtypes exist: slow transit constipation (STC), dyssynergic defecation (pelvic floor dysfunction; DD), a combination of both (STC + DD), and normal colon transit with normal pelvic floor function. The purposes of this study were two-fold; first, to determine the percentage of constipated patients with STC, DD, STC/DD, or normal studies at a quaternary motility center; second, to evaluate what percentage of constipated patients have a diffuse gastrointestinal (GI) motility disorder as evidenced by a combination of upper and lower GI dysmotility.

Methods: This was a retrospective analysis of 488 patients who underwent anorectal manometry for the primary symptom of intractable constipation between 2001 and 2006 at Temple University Hospital’s Motility Center. Of these patients, anorectal manometry, whole gut transit scintigraphy, anal electromyography, balloon expulsion testing, and defecography results were reviewed.

Results: Of the 488 patients with chronic constipation who underwent AM, 212 patients met the inclusion criteria for the study. Of these, 91/212 (43%) had STC, 25/212 (12%) had DD, 53/212 (25%) had a combination of STC+DD, and 43/212 (20%) had normal colon transit and pelvic floor function. Of the patients with STC, 31/91 (34%) had delayed gastric emptying; 9/91 (10%) had delayed small bowel transit, 7/91 (8%) had a delay in both, while 44/91 (48%) had normal upper GI motility. A similar distribution was seen in patients with DD - 8/25 (32%) had delayed gastric emptying, 2/25 (8%) had delayed small bowel transit, 2/25 (8%) had transit delays in the stomach and small bowel, whereas 13/25 (52%) had no abnormalities. Examination of the STC/DD group showed 11/53 (21%) with gastric emptying delay, 7/53 (13%) with small bowel delay transit, 10/53 (19%) with a combination, and 25/53 (47%) had normal upper GI transit.

Conclusion: Patients presenting with a primary complaint of chronic constipation have a range of colonic motor disorders. The majority of patients had an identifiable abnormal pattern of colon transit, which included STC, DD, or a combination of STC and DD. In addition, many patients with chronic constipation have a generalized gastrointestinal tract disorder namely, delayed gastric emptying and/or delayed small bowel transit.
049

A COST COMPARISON OF METRONIDAZOLE AND VANCOMYCIN IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA

Kristen L. Thomas, BS, Kyland R. Holmes, MS, Brian R. Jackson, MD, MS, Mae Go, MD, John C. Fang, MD, and Kathryn A. Peterson, MD, MSc*. Gastroenterology, University of Utah, Salt Lake City, UT; PATHology, ARUP, Salt Lake City, UT and Gastroenterology, VA Medical Center, Salt Lake City, UT

Purpose: Clostridium difficile associated diarrhea (CDAD) is currently the leading cause of antibiotic associated diarrhea. Current guidelines recommend metronidazole as the first line therapy due to its low cost. The emergence of more virulent strains and increasing resistance rates of metronidazole have raised questions as to whether vancomycin should be used rather than metronidazole.

Aim: To determine whether metronidazole or vancomycin provides the most cost-effective treatment for CDAD.

Methods: TreeAge Pro 8.1 software was used to develop a cost comparison model of vancomycin versus metronidazole as first line therapy for CDAD. Separate Markov models were generated to evaluate the drugs' respective cost effectiveness for the treatment of CDAD.

Direct outpatient costs associated with CDAD were obtained from the Medicare database and included clinic visits, antibiotics (metronidazole and vancomycin), and stool tests (Toxin A and toxin B). Direct hospital costs were obtained from the US Medicare DRG’s for enteritis/complications.

Monte Carlo simulation was utilized in the comparison models. Patients were assumed to have no greater than 6 recurrences.

Results: Using recently reported resistance rates of 20% (metronidazole) and 1% (vancomycin) and a recurrence rate of 20% for each drug, the average treatment cost was $561 for metronidazole and $910 for vancomycin. Using probabilistic sensitivity modeling, equivalent costs between the groups were attained only once resistance rates of metronidazole approached 75%. As determined by cost-modeling, vancomycin expense would need to be reduced by 88% to achieve superiority to metronidazole.

Conclusion: Despite increasing resistance rates of CDAD to metronidazole, metronidazole outperforms vancomycin as first line therapy in the treatment of CDAD largely due to the expense of vancomycin. First line therapy for CDAD should remain as metronidazole unless resistance rates become substantial or the cost of vancomycin is significantly reduced.

050

A COMPARISON OF POLYETHYLENE GLYCOL LAXATIVE AND PLACEBO FOR RELIEF OF CONSTIPATION FROM CONSTIPATING MEDICATIONS

Jack A. DiPalma, MD*, Mark B. Cleveland, PhD, John McGowan, and Jorge L. Herrera, MD, Division of Gastroenterology, University of South Alabama, Mobile, AL and BRAINTREE LABORATORIES, INC., BRAINTREE, MA

Purpose: Medications often cause constipation and little data are available concerning treatment interventions. This study was designed to evaluate the safety and efficacy of polyethylene glycol (PEG) 3350 laxative (MiraLax) for relief of constipation from medicines associated with symptoms of constipation.

Methods: Study subjects were enrolled who met defined criteria for chronic constipation and were also taking medications that were associated with a reported side effect incidence of more than 3% constipation. Study subjects were randomized into a double-blind, parallel, multi-center study where they received 17 grams per day PEG laxative or placebo for 28 days. The primary efficacy variable, treatment success, was defined as relief of modified ROME criteria for constipation over the treatment period. Various secondary measures were also assessed. Daily bowel movement experience, patient perception of efficacy and safety information were recorded in a diary. Laboratory testing was performed at baseline and monthly for hematology and blood chemistry, including BUN, calcium, electrolytes, and TSH.

Results: 100 patients were enrolled in 4 study centers. Successful treatment according to the primary efficacy variable was seen in 78.3% of PEG and 39.1% of placebo subjects (p<0.001). Similar results were observed in a subgroup of 28 elderly subjects. Secondary measures of number of bowel movements, complete bowel movements, satisfactory bowel movements, straining at stool and stool consistency also showed statistically significant results in favor of PEG compared to placebo (p≤0.001) after the first week of treatment. There were no differences in patient reported scores for gas, cramping, or bloating between PEG and placebo. No significant differences in laboratory findings or adverse events, including the gastrointestinal category, were observed. Diarrhea, flatulence, and nausea occurred more frequently with PEG treatment, although they were not individually statistically different from placebo. Similar results were observed when these symptoms were analyzed for differences due to gender, race, or age.

Conclusion: PEG laxative is safe and effective for use in treating constipation in patients taking constipating medications.

Disclosure - Dr. DiPalma is a medical director consultant to BRAINTREE LABORATORIES. Dr. Herrera has been a paid advisory group member for BRAINTREE LABORATORIES. Dr. Cleveland and John McGowan are employees of BRAINTREE LABORATORIES.
GASTRIC EMPTYING SCINTIGRAPHY RESULTS IN THE ROME III SUBGROUP CLASIFICATIONS FOR FUNCTIONAL GASTRODUODENAL DISORDERS

2007 ACG Motility Award

Richard L. Walters, MD, Alan H. Maurer, MD, and Henry P. Parkman, MD.

Medicine, Temple University School of Medicine, Philadelphia, PA

Purpose: Delayed gastric emptying has been detected in 25–40% of patients with functional dyspepsia using gastric emptying scintigraphy (GES); however, the association of symptoms to alterations in gastric emptying has been difficult to delineate. ROME III criteria classify functional dyspepsia by “meal-related” and “meal-unrelated” symptoms into postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS), respectively. Additionally, new categories of chronic idiopathic nausea (CIN) and functional vomiting (FOV) have been recognized. Although these new classifications were devised to allow better understanding of the natural history and treatment pathways of these syndromes, the relationship between symptoms and specific patterns of abnormal gastric emptying in the ROME III subgroups has not been delineated. Aim: The aim of this study was to compare GES results to ROME III symptom subgroup classifications.

Methods: We designed a retrospective analysis of consecutive patients presenting to our tertiary care facility. GES was performed using 4 hour imaging after ingestion of a radiolabeled Eggbeaker sandwich. The PAGI-SYM questionnaire was completed at the time of imaging and used to classify patients into subgroups of FD, EPS, CIN, and FOV. Subgroup classifications were utilized to correlate to scintigraphic data.

Results: Of 99 consecutive patients undergoing GES from February 2007 to May 2007, 98 had analyzable GES data. GES revealed normal solid emptying in 58 patients, delayed solid emptying in 37, rapid emptying in 3, and not assessable GES data in 0. Of the 58 patients with normal gastric emptying, fullness/blotching was described as the predominant symptom(s) in 15, vomiting in 9, abdominal pain/discomfort in 8, nausea in 7, reflux/heartburn in 7, regurgitation in 2, constipation in 1, and no specific notches in 1. Classification of GES results revealed 61 patients with FD, 52 with EPS, 25 with CIN, 34 with FOV, and 27 with FOV. Of these delayed gastric emptying was seen in 25 of the 61 (41%) FD patients, 21 of the 52 (40%) EPS patients, 11 of the 25 (44%) CIN patients, 13 of 34 (38%) with FOV, and 14 of 27 (52%) with FOV. Twenty patients were found to have no definable ROME III disorder; of these, fourteen had normal GES and seven with delayed.

Conclusion: In this tertiary care center experience, use of meal-related and meal-unrelated symptoms did not identify a group with delayed gastric emptying. There was a significant prevalence of delayed gastric emptying in the ROME III classifications of the functional gastrointestinal disorders.

INVESTIGATION OF WIRELESS CAPSULE (SmartPill®) FOR COLON TRANIT AS A COMPARATIVE STUDY WITH RADIOPAQUE MARKERS IN HEALTH AND CONSTITUTION

2007 ACG Motility Award

S. Rao, MD, FACC*, B. Kuo, MD, W. Chey, MD, FACC, J. DiBiase, MD, FACC, L. Katz, MD, K. Koch, MD, FACC, J. Lockner, PsyD, R. McCullum, MD, R. Saud, MD, K. Selover, J. Semler, PhD, M. Strin, MD, G. Willing, PhD, and H. Parkman, MD, FACC. SmartPill Research Group

Purpose: Traditionally, colonic transit time (CTT) has been assessed with radiopaque marker (Sitzmarks® (SZ)) technique. Although useful, it requires radiation and is hindered by poor patient compliance and complex protocols. The aim was to simultaneously assess and compare CTT as measured by SmartPill® (SP)-wireless pressure and pressure recording capsule with that of Sitzmarks® in constipated (ROME II) and healthy subjects.

Methods: After overnight fast, subjects ingested a nutrient bar (260 kcal) followed by a Sitzmarks® (24 markers) and a SmartPill® capsule. Subjects wore a data receiver for 5 days or until SmartPill® was expelled and kept stool diary. Abdominal x-rays were obtained on days 2 & 5. SmartPill® tracing was examined to assess gastric emptying time (GET) (time to rise in pH>4), small bowel transit time (SBTT) (time to cecal entry with >1 pH drop in 24h), and whole gut transit time (WGTT). To account for the known influence of gender and age on CTT, analysis of covariance was used in the statistical examination of SmartPill® CTT.

Results: Table (mean ± SEM, **P<0.05). 92 constipated (n=38; 65) and 83 healthy (n=42;41) subjects participated. CTT, WGTT, day 2 Sitzmarks® transit, and day 5 Sitzmarks® transit were different (p<0.001) between constipated patients and controls, even after accounting for gender and age. CTT correlations between SmartPill® and % of markers expelled on day 5 were r=0.59 (p<0.0001) in patients and r=0.46 (p<0.001) in controls.

Conclusion: Traditionally, colonic transit time (CTT) has been assessed with radiopaque marker (Sitzmarks® (SZ)) technique. Although useful, it requires radiation and is hindered by poor patient compliance and complex protocols. The aim was to simultaneously assess and compare CTT as measured by SmartPill® (SP)-wireless pressure and pressure recording capsule with that of Sitzmarks® in constipated (ROME II) and healthy subjects.

HIGH CORTISOL LEVELS ARE CORRELATED TO LOW ESOPHAGEAL PAIN THRESHOLD TO BALLOON DISTENTION IN PATIENTS WITH NERD AND FUNCTIONAL HEARTBURN

2007 ACG Governors Award Recipient for Excellence in Clinical Research

Sheila Rodriguez-Stanley, PhD, Maggie Wolff, Tisha Adams, and Philip B. Miner, Jr.*. The Oklahoma Foundation for Digestive Research, Oklahoma City, OK

Purpose: The relationship between serum cortisol and esophageal pain sensitivity has been studied in published investigations. In patients with functional GI disorders (FGID), symptoms are often absent during the night when cortisol is low. However, patients with FGID and low awakening cortisol reported the greatest pain (Ehlen 2005). Recalbal balloon distention in patients with IBs vs chronic heartburn (CC) controls (C) indicated IBS patients had the lowest sensory thresholds than CC and C (Walter et al 2006). Our aims were: 1) To describe the relationship between serum Cortisol and maximum tolerable pain to balloon distention of the esophagus in patients with functional heartburn (FHB), 2) To compare Cortact, ACTH, and balloon sensitivity parameters in functional heartburn vs NERD.

Methods: 26 patients underwent esophageal balloon distention with MTD (volume and corresponding mean and maximum pressure). 14 patients fit criteria for FHB and were assessed on 4 occasions (n=56). 12 patients fit criteria for NERD and were assessed once (n=12). Blood samples for serum cortisol and ACTH were collected within 90 min prior to balloon distention. Regression analysis was performed between maximum tolerable pain (ml of balloon volume and corresponding mean and maximum mmHg pressure at MTD) and serum Cortisol levels (ug/dl), and between Cortisol and ACTH levels (pg/ml). Parameters were compared via t test (P<0.05 level of significance).

Results: There were no differences between FxHB and NERD in mean Cortisol (11.6 vs 9.5 mg/dl), mean ACTH (17.5 ± 16.4 pg/ml), or mean sensitivity parameters (22.7 ± 19.2 ml balloon volume; 29.3 vs 28 nmHg mean pressure; 48.9 vs 41.5 mmHg max pressure; all P > 0.05). Therefore all groups together (n=66) were compared to MTD. Sensitivity parameters were significantly related to cortisol levels (P<0.001). At MTD, maximum balloon pressure at MTD was also significantly and inversely related to cortisol levels (r=-0.60; P<0.001). As expected, Cortisol and ACTH were significantly related (r=0.60. P=1.8 x10^6).

Conclusion: Overall, higher cortisol levels were significantly related to lower pain thresholds to esophageal balloon distention. The significant positive relationship between ACTH and Cortisol indicate that patients had an intact HPA axis. These data imply that adrenal function may play a role in functional GI disease.

IN PATIENTS WITH CHRONIC CONSTIPATION, TD-5108, A SELECTIVE 5-HT4 AGONIST WITH HIGH INTRINSIC ACTIVITY, INCREASES BOWEL MOVEMENT FREQUENCY AND THE PROPORTION OF PATIENTS WITH ADEQUATE RELIEF

Michael Goldberg, MD, Yu-Ping Li, PhD, Brage Garfalto, MA, Allan Valmonte, BA, John Johnson*, MD, Allen Mangi¢* MD, Michael Kitt, MD, Tharavee, Inc., So. San Francisco, CA,. University of Illinois College of Medicine*, Rockford, IL, and RTI-Health Solutions**, Research Triangle Park, NC

TD-5108 is a potent, full agonist at the human 5-HT4 receptor that, unlike tegaserod, displays preferential binding to the 5-HT4 receptor compared with other 5-HT receptor subtypes. A Phase 2 dose-ranging clinical trial was conducted to investigate the efficacy and safety of TD-5108 in patients (pts) with chronic idiopathic constipation.

Methods: This double-blind, randomized, placebo-controlled, parallel-group, multicenter trial enrolled 401 adult pts (age 18-64 years) at 48 U.S.-based clinical centers (pts randomized to spontaneous bowel movements (SBM)week during a 2-week baseline period) were randomized to receive TD-5108 15, 30, or 50 mg, or placebo (PBO) once daily for 4 weeks. Bowel function as the measure of efficacy was recorded using a stool diary during daily Erys phone calls. Tolerability was monitored via biweekly questionnaires and adverse event clinical laboratory tests. ECGs.

Results: Treatment groups were balanced for clinical characteristics and constipation histories. The average number of SBM and complete SBM (CSBM) at baseline were 1.2 and 0.25/week, respectively.

Conclusion: In this study in pts with chronic constipation treated for 4 weeks, TD-5108 statistically and clinically significantly increased bowel movement frequency, provided adequate relief for significantly more patients. Moreover, the patients were generally well tolerated, particularly at the 15 mg dose.
5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*

5.48* 1.33 25.21*†
2.65* 1.10 4.82*
A NEW SURGICAL APPROACH TO GASTROESOPHAGEAL REFUX DISEASE: NISSEN FUNDOPLICATION WITH HIGHLY SELECTIVE VAGOTOMY
Savio Reddy, MD, Malya Selim, MD, Michael Moncure, MD, Jeffrey Pielcher, MD, Daniel Buckles, MD, and Richard McCullum, MD*. Medicine, Kansas University Medical Center, Kansas City, KS
Purpose: A standard Nissen fundoplication does not address gastric acid secretion; hence an accompanying highly selective vagotomy (HSV), which will reduce gastric acid secretion by 60%, could help sustain long-term symptom response. To assess this we measured the rate of proton-pump inhibitor (PPI) use postoperatively in a cohort of patients with gastroesophageal reflux disease (GERD) who underwent Nissen fundoplication with HSV in comparison to a group who did not undergo HSV during the procedure.
Methods: 14 patients (8 females) underwent a Nissen fundoplication with HSV, and 19 without HSV for refractory GERD symptoms, particularly nocturnal regurgitation. PPI use pre-operatively and during the postoperative follow up was recorded. Esophageal manometry, esophageal pH monitoring, and gastric emptying scintigraphy (GES) were performed preoperatively.
Results: Mean age of patients in both the groups was similar at 47 years. The mean lower esophageal sphincter pressure was 8 mmHg (95% CI: 6-10 mmHg) in the HSV and was not significantly different (p=0.44) than the non-HSV group (Mean 10 mmHg; 95% CI: 9-11 mmHg). The mean % of retained food after 4 hours on GES was also similar (p=0.44) in both groups- 8% (95% CI: 2-14%) in the HSV group and 12% (95% CI: 5-19%) in the non-HSV group. All patients in both groups were on a PPI (Usually double dose therapy) prior to the surgery. Median duration of follow up was 63 months (Range: 6-88 months). 1/14 (7%) patients in the HSV group and 9/19 (47%) in the non-HSV group either remained on a PPI post-operatively or were restarted, generally within the first 6 months after surgery. The odds ratio of being on a PPI in the HSV group after surgery as opposed to the non-HSV group was 0.08 (95% CI: 0.009-0.8). None of the patients in the HSV group had symptoms suggestive of gastroparesis postoperatively.
Conclusion: 1) Adding a HSV to the standard Nissen fundoplication procedure significantly reduced the use of PPI’s during long term post-operative follow up and was not associated with any adverse events. 2) This new surgical approach for refractory GERD warrants further objective studies to confirm these important observations.

062 COST-EFFECTIVENESS OF MI-PH TESTING IN PERSISTENT REFUX-RELATED COUGH DESPITE ACID SUPPRESSIVE THERAPY
Deepika Laxmi Koya, MD, MSCR, Marcelo A. Vela Aquino, MD, MSCR, Donald O. Castell, MD, and Kit N. Simpson, DrPH*. Internal Medicine, Medical University of South Carolina, Charleston, SC and Health Administration and Policy, Medical University of South Carolina, Charleston, SC
Purpose: GERD is a common cause of chronic cough. An empiric trial of high-dose proton pump inhibitor (PPI) is emerging as a diagnostic and therapeutic approach for suspected reflux-related chronic cough. In patients with persistent cough despite adequate acid suppression, symptoms may be due to non-acid reflux or may not be related to reflux. Combined multi-channel intraluminal impedance and pH (MI-PH) detects nonacid reflux and its temporal association with cough. A recent study showed that fundoplication successfully treats non-acid reflux associated cough diagnosed by MI-PH. Cost-effectiveness of this test to aid management of reflux-related persistent cough on PPI therapy has not been studied.
Methods: A decision tree was used to compare MI-PH testing to no testing. Cost-utility analysis was performed over a 3 yr time horizon. The published algorithm for management of patients with reflux-related cough refractory to acid suppression defined the care process. The analysis models a hypothetical population of 100 patients with reflux-related cough on acid suppression. We assumed two scenarios: MI-PH testing versus no testing. Costs and quality-adjusted life-years (QALY’s) for the two scenarios were examined. Outcome probabilities for the testing arm were derived from published literature (test positive 26%, probability of surgery in test positive arm 55%). We assumed that cough persisted in all patients in the no testing arm and those patients in the testing arm who did not have fundoplication. The expected costs for this group include PPI use and frequent physician visits. Utilities for persistent cough and no cough health states were obtained from the published literature. Estimated costs of surgery and office visits were obtained from a variety of resources. Drug costs represented the average wholesale price. The primary outcome measured was incremental cost-effectiveness ratio (ICER).
Results: MI-PH testing produced an ICER of $915 per QALY saved compared with no testing, over a 3 year horizon. The results are sensitive to probabilities and number of patients after surgery in test positive arm. If we assume that all the patients who are test positive would undergo surgery, the ICER would be $2 085,671.
Conclusion: MI-PH testing to evaluate persistent reflux-related cough refractory to acid suppression cost effectively identifies patients who would benefit from fundoplication.

063 PROTON PUMP INHIBITOR AND NONSTEROIDAL ANTI-INFLAMMATORY USE AND THE DEVELOPMENT OF NEOPLASIA IN BARRETT’S ESOPHAGUS
John Kaczkewicz, MD, Hashem El-Serag, MD, Stephanie Davis, PharmD, Adam Wucher, Daniel J. Stein, MD, and Richard E. Sampliner, MD*. Southern Arizona VA HealthCare System and Arizona Health Sciences Center, Tucson, AZ and Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX
Purpose: The role of chemoprevention in Barrett’s esophagus (BE) is unclear. Evidence suggests a protective role for proton pump inhibitors (PPI), but nonsteroidal anti-inflammatory agents (NSAIDs), and possibly statins. However, human data are limited.
Methods: This is a retrospective study of a well characterized large cohort of patients with documented BE diagnosed between 1985 and 2005. Prescription information was collected from pharmacy records before and after BE diagnosis. Patients were followed until the development of dysplasia, adenocarcinoma, death, or 12/2005. Cox regression analyses were performed to examine the association between NSAID, PPI, or statin prescription and the risk of developing dysplasia or cancer.
Results: We examined 408 patients with BE with a mean age of 61 at the time of BE diagnosis; Caucasian 91.2%, men 94.4%. The mean duration of follow-up was 6.6 years (SD 4.9). During 2690 patient-year follow-up, 125 developed dysplasia (20 high grade) yielding an incidence of 4.65 per 100 PY and 29 patients developed adenocarcinoma (1.08 per 100 PY). Approximately 38.4% were prescribed NSAIDs for a mean duration of 12.9 months, 66.4% were prescribed a PPI for a mean duration of 31.5 months, and 26.2% were prescribed for a mean duration of 16.5 years; median age 71 years; median length of follow-up in unadjusted analyses, only patients with BE segment > 3cm, and more recent time of BE diagnosis were associated with increased risk of dysplasia or cancer, whereas NSAID prescription was associated with reduction in that risk. This persisted in multivariable analysis (Table), and were examined for associations with the development of dysplasia or cancer after the first year of diagnosis; for example, PPI use (2.35, 95%CI: 1.02-0.61). No consistent associations were observed for NSAID or statin use where neither any suggestive effect (odds ratio > 12 months was associated with the risk of dysplasia or cancer.
Conclusion: PPI use seems to reduce the risk of neoplastic changes in patients with BE. NSAID or statin use is not associated with the risk of neoplasia.

Multivariable COX Ph model predicting the risk of dysplasia

<table>
<thead>
<tr>
<th>Hazard Ratio</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Caucasian</td>
<td>0.51</td>
</tr>
<tr>
<td>BE length &gt;3cm</td>
<td>1.53</td>
</tr>
<tr>
<td>PPI prescription</td>
<td>0.64</td>
</tr>
</tbody>
</table>

Disclosure - Dr. Sampliner: AstraZeneca speakers bureau and TAP grant support. Dr. El-Serag: TAP grant support.

064 SUCCESSFUL ABLATION OF BARRETT ESOPHAGUS WITH DYSPLASIA USING THE HALO ABLATION SYSTEM IN A PROSPECTIVE COHORT
Virender K. Sharma, MD, Christopher Wells, MD, Hack J. Kim, MD, Ananya Das, MD, Giovanni DePetris, MD, Roxane McLaughlin, RN*, and David E. Fleischer, MD. Gastroenterology, Mayo Clinic Arizona, Scottsdale, AZ
Purpose: To assess the safety and efficacy of a step-wise regimen of circumferential and focal ablation using the HALO ablation system (Barrx Medical Inc., Sunnyvale, CA) for the treatment of Barrett esophagus (BE) containing low-grade (LGD) or high-grade dysplasia (HGD).
Methods: HALO ablation system consists of a balloon based electrode array for circumferential and an endoscope -mounted, paddle-based electrode array for focal ablation of BE. Patients with BE and LGD or HGD, confirmed by 2 pathologists including 1 expert GI pathologists, were treated with circumferential ablation. Repeat ablation (circumferential or focal) was performed at 3 month intervals until BE was completely eradicated. Lugol’s chromoendoscopy with targeted biopsies from visible BE and random biopsies from the original BE region were obtained at regular follow-up intervals to assess for residual intestinal metaplasia (IM) and dysplasia. A complete response (CR) is defined as all biopsies for a patient negative for any dysplasia, HGD, LGD or IM (separate analyses) at last follow-up. All adverse events were recorded.
Results: Sixty-four patients were treated, 62 had at least one set of biopsies post ablation attempt included in the efficacy analyses (58 men; median age 71 years; median length of follow-up of BE 5 cm; 39 LGD, 25 HGD, median follow-up 12 months). Results from the last biopsy follow-up of 38 LGD patients; 25 (68%) normal squamous mucosa , 8 (21%) focal islands of non-dysplastic IM, 1 (3%) IM indefinite for dysplasia, 2 (5%) LGD, and 1 (3%) HGD in the cardia. Results from the last available biopsy follow-up of 24 HGD patients; 13 (54%) normal squamous mucosa, 4 (17%) focal islands of non-dysplastic IM, 3 (13%) IM indefinite for dysplasia, 1 (4%) LGD and 3 (12%) HGD. The CR for both LGD and HGD was 92% and 91% respectively. A total of 64 patients were included in the safety analyses. 1 (2%) patient each had self-limited GI bleed and mild esophageal stricture. There have been no instances of submucosal intestinal metaplasia, "buried Barrett," identified on review of >3000 biopsies.
Conclusion: Ablation of BE containing dysplasia using the HALO ablation system appears to be safe and effective, with CR for both LGD in the LGD cohort and HGD in the HGD cohort was 92% and 88%, respectively. Patient tolerance and safety with the procedure has been excellent. There has been no evidence of submucosal intestinal metaplasia, "Buried Barrett" post ablation.

Disclosure - Research support Barrx Medical.
ACCURACY AND CLINICAL IMPACT OF EUS–FNA AS THE DEFINITIVE DIAGNOSTIC OR STAGING STUDY IN PATIENTS WITH SUSPECTED OR KNOWN LUNG CANCER

R. Srinivasan, MD, P. Gupta, MD, S. Jagannnathan, MD, J.B. Zwischenberger, MD, and M.S. Bhutani, MD*. Division of Gastroenterology, UTMB, Galveston, TX and Division of Gastroenterology, UT MD Anderson Cancer Center, Houston, TX

Purpose: Prognosis and management of non-small cell lung cancers (NSCLC) are dependent on accurate staging for metastatic lymphadenopathy (LAD). Endoscopic ultrasound guided fine needle aspiration (EUS-FNA) of mediastinal nodes has emerged as a valuable minimally invasive alternative for staging. The objective of this study was to retrospectively determine the accuracy of EUS-FNA of mediastinal LNs in patients with known or suspected NSCLC and of mediastinal LAD of unknown etiology and review its clinical impact. Also, determine the diagnostic yield of using EUS-FNA as a primary modality for diagnosis and staging in patients with mediastinal LAD with lung mass on imaging.

Methods: A retrospective chart review was performed on all 107 patients that were identified. The EUS-FNA diagnosis was accepted as malignant mediastinal LNs when cytology was positive by EUS. When cytology was non-malignant, the results were compared with the final surgical pathology of the excised LNs.

Results: There were 79 patients who had mediastinal LAD with known or suspected lung cancer by CT and 69 patients underwent FNA of suspicious nodes. 32 of 69 patients (46%) received a diagnosis of metastatic disease with EUS-FNA and did not undergo further invasive workup. 37 patients had benign or non-diagnostic FNAs of which 26 patients underwent surgical staging. Sensitivity, specificity and accuracy for EUS-FNA of mediastinal LAD in patients with known or suspected lung cancer was 84%, 100% and 90% respectively. The negative predictive value was 79%, the false negative rate was 15% and the positive predictive value was 100%.

There were 20 patients with suspicious mediastinal LAD of uncertain etiology. The diagnostic yield of EGD/EUS-FNA in patients with mediastinal LAD of unknown etiology was 95% (19 of 20 patients).

27 patients had mediastinal LAD with lung mass on CT scan without a tissue diagnosis of the primary tumor. Diagnosis and staging was made in 15 patients (56%) thus avoiding further invasive workup.

Conclusion: EUS-FNA of mediastinal LNs has a high accuracy with a high NPV and low false negative rate. Our data supports the use of EUS-FNA early in the work-up of mediastinal LNs thus avoiding unnecessary imaging, more invasive mediastinal sampling procedures and potentially futile surgery.
Abbott Labs • Booth #1700 & 1705
200 Abbott Park Road, Abbott Park, IL 60064
Abbott is a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products to medical devices and pharmaceutical therapies. Our comprehensive product line encircles life itself – addressing important health needs for all ages.

Abbott Vascular • Booth #1711
3200 Lakeside Drive, Santa Clara, CA 95054
Abbott Vascular, a division of Abbott, is one of the world’s leading vascular care businesses. Abbott Vascular is uniquely focused on transforming the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development and advancing medicine through training and education. For more information, visit www.abbottvascular.com

Acupath Laboratories, Inc. • Booth #1119
28 South Terminal Drive, Plainview, NY 11803
Acupath Laboratories is a cutting-edge anatomic pathology laboratory with specialized gastroenterologic services. In addition to fellowship trained GI pathologists, we offer H. pylori testing by IHC, and facilities to work on GI lymphoma using molecular pathology and cytogenetic studies.

Advanced Medical Practice Management • Booth #848
25 Hanover Road, Suite 250, Building B, Florham Park, NJ 07932
Advanced Medical Practice Management is a full service medical billing company specializing in Gastroenterology, Orthopedic, Pain Management, and Ambulatory Surgical Center Billing. Let our team of experts reduce your overhead and increase your overall income! Visit us online at www.ampmbilling.com or contact us toll free at 866-516-AMPM.

Alaven Pharmaceutical • Booth #1338
2260 Northwest Parkway, Suite D, Marietta, GA 30067
Alaven Pharmaceutical is a privately held specialty pharmaceutical company located in Marietta, Georgia. We develop and market prescription and non-prescription products that treat women’s health and gastroenterological conditions. Gastroenterology products include: Rowasa® (mesalamine) Enema, Balneo™ (soothing perianal cleansing lotion), UniFiber® (all natural insoluble fiber supplement), and Calafol® Rx (micronutrients).

Alpine Biomed • Booth #842
17800 Newhope Street, Suite B, Fountain Valley, CA 92708
Alpine Biomed manufactures innovative diagnostic systems for the GI and related markets including the Digitrapper™400 pH recorder, and the Polygraf™ ID multi-parametric recorder for pH and manometry. We manufacture user-friendly pH/impedance systems and accessories including the IonTM Recorder and VersaFlex™ disposable catheters.

Ambry Genetics • Booth #1717
100 Columbia #200, Aliso Viejo, CA 92656
Ambry Genetics, a worldwide leader in diagnostic genetic testing, serves gastroenterologists through DNA sequence analysis and interpretation. We enable early, more accurate determination of the etiology of pancreatitis by providing comprehensive, full gene sequence analysis of the three genes that contribute significantly to this condition (CFTR, PRSS1, and SPINK1).

American Association of Ambulatory Surgery Centers • Booth #1339
P.O. Box 5271, Johnson City, TN 37626
The American Association of Ambulatory Surgery Centers (AAASC) is the national association dedicated to advancing high quality, physician led, and patient centered care in ambulatory surgical centers (ASC). AAASC diligently works to ensure physician ownership is protected and is the primary source for education and information for physician owned ASC. www.AAASC.org

American Association of Nurse Anesthetists • Booth #1304
222 South Prospect Avenue, Park Ridge, IL 60068-4001
The American Association of Nurse Anesthetists is the professional organization representing 36,000 Certified Registered Nurse Anesthetists (CRNAs). As advanced practice nurses, CRNAs practice with a high degree of autonomy and respect in every setting in which anesthesia is delivered. The field of nurse anesthesia is growing and career opportunities abound.

American College of Gastroenterology • Booth #1518
6400 Goldsboro Road, Suite 450, Bethesda, MD 20817
Welcome to ACG 2007, the premier GI clinical event of the year! ACG is a recognized leader in educating GI professionals and the general public about digestive disorders. In addition to providing a wide-range of educational programs focusing on clinically-oriented topics for the GI professional, ACG reaches out to policymakers to promote the interests of clinical gastroenterologists and the patients they serve.

American Express • Booth #926
20 Vesey Street, New York, NY 10285
American Express® Business Cards give you automatic access to the benefits and services that OPEN from American Express® has to offer, including benefits that can help you save money, gain control over your practice expenses, earn valuable rewards and much more.

American Gastroenterological Association • Booth #1231
4930 Del Ray Avenue, Bethesda, MD 20814
The AGA’s 15,000-plus members include physicians and scientists who research, diagnose and treat disorders of the gastrointestinal tract and liver. Stop by our booth (#1231) to learn more about membership as well as programs and products offered by the AGA Institute, which runs the organization’s practice, research and educational programs. View demonstrations of popular AGA Institute educational offerings.

American Neurogastroenterology & Motility Society • Booth #209
45665 Harmony Lane, Belleville, MI 48111
American Neurogastroenterology & Motility Society is a professional organization whose mission is to advance the understanding of gastroesophageal reflux, gastrointestinal motility and related enteric sciences, to translate the scientific advances to patient care, and to disseminate the knowledge to patients and care-givers in order to improve the diagnosis and treatment of patients with gastrointestinal motility and functional gastrointestinal disorders.

AmeriPath, Inc. • Booth #1400
7111 Fairway Drive, Suite 400, Palm Beach Gardens, FL 33418
AmeriPath GI Diagnostics provides gastrointestinal and liver pathol- ogy, consultations, and esoteric testing through our national network of local physician practices sub-specializing in GI Pathology and Digestive Disease. AmeriPath’s Institute of Gastrointestinal Pathology and Digestive Disease has a renowned team of GI and liver specialists who provide consultations, physician education and lecture programs nationwide.

AmSurf Corp • Booth #924
20 Burton Hills Boulevard, Suite 500, Nashville, TN 37215
Join the Endoscopy Center Leader: Since 1992, AmSurf has partnered with more than 500 GI’s to develop or acquire and manage more than 110 endoscopy centers across the country. Our experience and expertise will help you achieve your endoscopy center goals. Visit us at booth 924 or call (800) 945-2301.
Anesthesia Healthcare Partners, Inc. • Booth #1713
3079 Peachtree Industrial Boulevard, Atlanta, GA 30097
Leading provider of propofol-based anesthesia, administered in an Endoscopy Center setting, by our dedicated Anesthesiologist and CRNA teams. We are very proud of being one of the most respected anesthesia practice management companies in our industry. Visit us at Booth #1713 or online at www.ahphealthcare.com to discuss partnership opportunities.

Annals of Internal Medicine • Booth #417
190 N. Independence Mall West, Philadelphia, PA 19106-1572
Annals of Internal Medicine is published twice per month. Our impact factor is 14.78 with a circulation of 85,000. Through its publication of original research, reviews and commentary, Annals promotes excellence in the practice of internal medicine and in clinical research. We welcome submissions of new, original material from both the US and abroad.

ASGE • Booth #1251
1520 Kensington Road, Suite 202, Oak Brook, IL 60523
The American Society for Gastrointestinal Endoscopy (ASGE) is the preeminent professional organization dedicated to advancing patient care and digestive health by promoting excellence in endoscopy. Visit the ASGE exhibit booth to learn about the society's mission and goals, apply for membership and get information about upcoming educational activities.

AstraZeneca, LP • Booth #500
1800 Concord Pike, Wilmington, DE 19850
AstraZeneca produces a wide range of products that make significant contributions to treatment options and patient care. The company has one of the world’s leading portfolios to treat cancer and gastrointestinal disorders, in addition to the areas of anesthesia, pain management, cardiovascular disease, respiratory and central nervous system disorders. You are invited to visit our exhibit to speak with a representative about our products.

Axcan Pharma, Inc. • Booth #1206
597 Laurier Boulevard, Mont-Saint-Hilaire, Quebec J3H 6C4
Axcan is a leading multinational specialty pharmaceutical company focused on gastroenterology. The Company develops and markets a broad line of prescription products to treat a range of gastrointestinal diseases and disorders such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Bard Access Systems • Booth #1115
605 North 5600 West, Salt Lake City, UT 84116
Bard Access Systems welcomes you to our booth to see the NEW additions to our Fraxtrash® PEG Line. Fraxtrash® PEGs are now available in 14, 16, 20 and 24 Fr sizes. Also see our full line of Feeding Products including Jejunal Feeding Tubes.

BARRx, Inc. • Booth #816
540 Oakmead Parkway, Sunnyvale, CA 94085
The HALO360 System is designed to remove Barrett's esophagus epithelium in a short, well tolerated procedure and offers an alternative to "watchful waiting" for patients with intestinal metaplasia, low-grade Dysplasia, and high-grade Dysplasia. The HALO90 System is designed to be used independently or in conjunction with the commercially available HALO360 System, a balloon-based endoscopic ablation system for treating larger, circumferential areas of Barrett's esophagus.

Bi-Biomics • Booth #1806
1512 12th Avenue Road, Nampa, ID 83686
Bi-Biomics is based on improvements in high-resolution light microscopy that provide discovery tools for research and clinical applications. We provide histologic and enzyme information on a newly discovered secretory system in the colon, which has profound effects on digestion, and diagnostic testing for cases of unexplained chronic diarrhea.

Blackwell Publishing • Booth #300
350 Main Street, Malden, MA 02148
Blackwell Publishing merged with John Wiley & Sons, Inc.'s Scientific, Technical, and Medical business in February 2007 to become Wiley-Blackwell. Visit the #1 publisher in the field, at booth 300. Pick up your personal copy of The American Journal of Gastroenterology and get the “Best of the Best free CD!

Boston Scientific • Booth #824
100 Boston Scientific Way, Marlborough, MA 01752
Boston Scientific has pioneered the design, development and manufacturing devices for use in diagnostic, therapeutic, and palliative pancreaticobiliary, colorectal, and pulmonary endoscopic procedures. Boston Scientific is the leading provider of propofol-based anesthesia, administered in an Endoscopy Center setting, by our dedicated Anesthesiologist and CRNA teams. We are very proud of being one of the most respected anesthesia practice management companies in our industry. Visit us at Booth #1713 or online at www.ahphealthcare.com to discuss partnership opportunities.

Calmoseptine, Inc. • Booth #1300
60 Columbine Street West, Braintree, MA 02185-0929
Calmoseptine Ointment protects and helps heal skin irritations from moisture such as urinary and fecal incontinence. It is also effective for irritations from perspiration, wound drainage, fecal & vaginal fistulas and feeding tube site leakage. Calmoseptine temporarily relieves discomfort and itching. Free samples at our booth.

Caris Diagnostics • Booth #729
8400 Estes Boulevard., Suite 190, Irving, TX 75063
Caris Diagnostics delivers “world class” pathology diagnostic services and practice workflow solutions to GI physicians who perform endoscopies in free-standing facilities. We have combined medical and management professionals, processes, and technology to improve productivity and bring superior performance to our clients and their patients.

CBLPath, Inc. • Booth #1332
760 Westchester Avenue, Rye Brook, NY 10573
CBLPath is a specialized gastrointestinal pathology provider staffed by a group of experienced, board-certified and nationally recognized gastrointestinal pathologists. Features include: local representative; courier networks; rapid turn-around-time; clear/ Concise color diagnostic reports; auto-fax/remote-cts reduce procedural trauma, complexity, cost, time and risk to the patient.

Celiac Disease Foundation • Booth #207
3251 Ventura Boulevard, Suite 1, Studio City, CA 91604
Celiac Disease Foundation is a non-profit organization dedicated to raising awareness of this under diagnosed disease by providing educational programs and materials, services and support for patients, medical professionals and the general public. Free information available on celiac disease and dermatitis herpetiformis. Quarterly newsletter and Guidelines handbook included with annual membership. (818) 990-2354 www.celiac.org.

Centocor • Booth #700 & 600
800 Ridgeview Drive, Horsham, PA 19044
Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients’ lives. Centocor has already brought innovation to the treatment of Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn’s disease and psoriasis. The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune diseases. Centocor, Inc. is a wholly owned subsidiary of Johnson & Johnson.

Cleveland Clinic • Booth #2000
9500 Euclid Avenue, Cleveland, OH 44195
Cleveland Clinic has one of the world’s leading portfolios to treat cancer and gastrointestinal disorders, in addition to the areas of anesthesia, pain management, cardiovascular disease, respiratory and central nervous system disorders. You are invited to visit our exhibit to speak with a representative about our products.

Columbia Distributors • Booth #3000
1700 Broadway, New York, NY 10019
Columbia Distributors is a leading distributor of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #500
1440 E. Fort Harrison Avenue, Harrison, IN 46045
Columbia Laboratories is a leading manufacturer of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #2000
1700 Broadway, New York, NY 10019
Columbia Laboratories is a leading distributor of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #3000
1700 Broadway, New York, NY 10019
Columbia Laboratories is a leading distributor of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #500
1440 E. Fort Harrison Avenue, Harrison, IN 46045
Columbia Laboratories is a leading manufacturer of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #2000
1700 Broadway, New York, NY 10019
Columbia Laboratories is a leading distributor of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #3000
1700 Broadway, New York, NY 10019
Columbia Laboratories is a leading distributor of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #500
1440 E. Fort Harrison Avenue, Harrison, IN 46045
Columbia Laboratories is a leading manufacturer of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #2000
1700 Broadway, New York, NY 10019
Columbia Laboratories is a leading distributor of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #3000
1700 Broadway, New York, NY 10019
Columbia Laboratories is a leading distributor of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #500
1440 E. Fort Harrison Avenue, Harrison, IN 46045
Columbia Laboratories is a leading manufacturer of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #2000
1700 Broadway, New York, NY 10019
Columbia Laboratories is a leading distributor of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #3000
1700 Broadway, New York, NY 10019
Columbia Laboratories is a leading distributor of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #500
1440 E. Fort Harrison Avenue, Harrison, IN 46045
Columbia Laboratories is a leading manufacturer of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.

Columbia Laboratories, Inc. • Booth #2000
1700 Broadway, New York, NY 10019
Columbia Laboratories is a leading distributor of prescription pharmaceuticals, nonprescription products and healthcare supplies. Columbia is a wholly owned subsidiary of Johnson & Johnson.
ChirhoClin, Inc. • Booth #1442
4000 Blackburn Lane, Suite 270, Burtonsville, MD 20866
ChirhoClin, Inc. is the pharmaceutical manufacturer of porcine and human secretin. ChirhoClin’s mission is to develop orphan drug products that will aid, diagnose and treat gastrointestinal diseases. ChirhoClin’s lead product, ChirhoStim® (Human Secretin), is a diagnostic for pancreatic disease and is approved for Pancreatic Function Testing, ERCP, and Gastrinoma Testing.

Chronic Liver Disease Foundation • Booth #213
1199 Ritaran Road, Clark, NJ 07066
The Chronic Liver Disease Foundation is a nonprofit 501(c)(3) educational organization dedicated to increasing awareness of the effect of chronic liver disease (CLD) in the United States. The foundation’s goal is to provide health professionals with the most current education and information on CLD.

Community Health Systems, Inc. • Booth #1719
4000 Meridian Boulevard, Franklin, TN 37067
Community Health Systems is the largest publicly-traded hospital company in the United States and a leading operator of general acute care hospitals in non-urban and mid-size markets throughout the country. Through its subsidiaries, the company currently owns, leases or operates 132 hospitals in 28 states.

Conmed Endoscopic Technologies • Booth #1100
525 French Road, Utica, NY 13502
ConMed Endoscopic Technologies – Reaching for the greater potential in clinical endoscopy with innovative devices such as; GORE VIABIL® Biliary Endoprostheses & Flexxus™ Metal Biliary Stents, Entake™ Peg System, Nakao Spider-Net™ Retrieval Device, BiCap Super Conductor™ Probes and many more. Visit us at booth 1100.

Convention Research Studies • Booth #741
1333 A North Avenue, New Rochelle, NY 10804

Cook Endoscopy • Booth #1106
4900 Bethany Street, Winston-Salem, NC 27105
For over 25 years, COOK Medical has pioneered minimally invasive devices in the field of GI endoscopy. Today, COOK participates in all global markets, integrating device design, biopharma, gene and cell therapy and biotech. COOK collaborates with clinicians to ensure that our products are both patient and outcome focused. Visit us at www.cookmedical.com and click “Endoscopy.”

Crohn’s & Colitis Foundation of America • Booth #201
386 Park Avenue South, 17th Floor, New York, NY 10016
The Crohn’s & Colitis Foundation of America is a non-profit organization dedicated to raising funds to support biomedical research in Crohn’s disease and ulcerative colitis. The foundation also provides educational programs and materials for patients, medical professionals, and the general public. Conference participants may obtain copies of these educational materials at the CCFA booth.

CSA Medical • Booth #1701
1101 East 33rd Street, Baltimore, MD 21218
CryoSpray Ablation (CSA) is a safe, simple and effective treatment for unwanted tissues in the esophagus. CSA sprays field or focal lesions using low-pressure liquid nitrogen through a unique catheter placed in a standard endoscope. The rapid deep freeze and slow thaw achieves a deep injury in the submucosal layers.

Dannon Company • Booth #1218
27 Dickinson Lane, Wilmington, DE 19807
The Dannon Company, Inc. is a national leading producer of cultured yogurt and probiotic dairy products, including Activia™ and DanActive™. Probiotics are living microorganisms that, when administered in adequate amounts, provide benefits beyond basic nutrition. Dannon® produces about 6 million cups of yogurt each day in 100 flavors, styles and sizes.

Dianon Systems, Inc. • Booth #1316
200 Watson Boulevard, Stratford, CT 06615
DIANON is a leading nationwide provider of comprehensive Gastrointestinal diagnostic services. Our goal is to provide physicians with unparalleled, comprehensive anatomic and clinical pathology services, patient information, and business solutions for their practices. DIANON Systems supports the high level of service and efficiency that is the hallmark in an Endoscopy Center Environment.

Digestive Care, Inc. • Booth #1314
1120 Win Drive, Bethlehem, PA 18017-7059
Digestive Care, Inc. (DCI) is dedicated to developing unique pharmaceutical products to alleviate complications and symptoms of gastrointestinal disorders. DCI’s research into the controlled delivery of gastric acid resistant digestive enzymes and buffered bile acids through micro encapsulation led to the development of the highly successful drug product, PANCRECARB® (pancrelipsase).

Elan Pharmaceuticals, PLC • Booth #524
7475 Lusk Boulevard, San Diego, CA 92121
Elan Corporation, PLC is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating ourselves to bringing innovations into existence to fill significant unmet medical needs that continue to exist around the world. In autoimmune diseases, Elan is developing disease-modifying therapies in collaboration with Biogen Idec for multiple sclerosis, Crohn’s disease and rheumatoid arthritis.

Elsevier • Booth #413
1600 John F. Kennedy Boulevard, Suite 1800, Philadelphia, PA 19103
Elsevier, a combined premier worldwide health science publishing company, incorporating Saunders, Mosby, Churchill Livingstone, Butterworth Heinemann and Hanley-Belfus presents our latest titles in Gastroenterology. Visit and browse through our complete selection of publications including books, periodicals, and software.

e-MDs • Booth #1612
9900 Spectrum Drive, Austin, TX 78717
e-MDs Solution Series is an integrated suite of administrative, financial, workflow, and clinical software solutions which help create an efficient paperless medical practice. Purchased separately or together, e-MDs software solutions help transform your medical office by improving workflow and increasing physician income, while creating an environment that fosters optimum patient care.

EndoSoft – UTECH Products, Inc. • Booth #1324
135 Broadway, Schenectady, NY 12305
EndoSoft®, A Division of Utech Products, Inc. is a global leader in the development and sales of state-of-the-art GI procedure documentation systems. EndoSoft® offers solutions with true and complete EMR. Our applications are designed to manage patient flow, from scheduling, to billing, and every process in between. EndoSoft currently provides solutions for all types of medical facilities, from solo physician office solutions to large multi-site hospitals implementing enterprise wide applications. Learn more at www.endosoft.com.

ERBE USA, Inc. • Booth #1008
2225 Northwest Parkway, Suite 105, Marietta, GA 30067
ERBE USA, Inc. distributes Electrosurgical Generators, Argon Plasma Coagulation Units, Cryosurgery Units, Lavage Pumps, and the latest in water-jet technology, the HELIX Hydro-jet™, to the medical professionals in gastrointestinal suites and Operating Rooms across the USA and Canada markets.

Ethicon Endo-Surgery, Inc. • Booth #732
4545 Creek Road, Cincinnati, OH 45242
Ethicon Endo-Surgery, Inc. develops and markets advanced medical devices for minimally invasive and open surgical procedures, focusing on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as gastrointestinal health, gynecology and surgical oncology. More information can be found at www.ethiconendo.com.
E-Z-EM, Inc. • Booth #825
1111 Marcus Avenue, Lake Success, NY 11042

Ferndale Laboratories, Inc. • Booth #1215
780 West Eight Mile Road, Ferndale, MI 48220
Ferndale Laboratories, Inc. is dedicated to providing treatments for patients with anorectal disorders. Our products include: Analpram HC® (hydrocortisone acetate 1% or 2.5% and pramoxine hydrochloride 1%) – Cream, lotion, and kits offer patients relief of anorectal itching, burning, and inflammation. L.M.X. 5® (lidocaine 5%) – Anorectal cream providing temporary relief of pain, itching and discomfort associated with anorectal disorders.

Fleet Laboratories • Booth #1000
4615 Murray Place, Lynchburg, VA 24502
Fleet Laboratories™, a market leader in colon cancer screening preparations and consumer laxatives, is pleased to introduce the next generation of PHOSPHO-SODA®. The company provides the highest quality GI pathology diagnoses, made only by fellowship-trained gastrointestinal pathologists. Results are delivered back to its nationwide client base within an industry-leading 24 hours.

Fujinon Inc. • Booth #200
10 High Point Drive, Wayne, NJ 07470
Fujinon Inc., a member of the Fujifilm family, caters to the needs of every type of endoscopy facility. Fujinon is dedicated to providing cutting-edge technology, improving productivity and certified local service. Our new 4400 Fully Digital Endoscopy System brings you: High Definition (HD), Fuji Intelligent Color Enhancement™ (FICE)/ Multi Band Imaging™ and Super CCD.

Functional Brain-Gut Research Group • Booth #210
1820 Spruce Meadows Drive SE, Rochester, NY 55904

Ganedien Biotech, Inc. • Booth #1308
5915 Landerbrook Drive, Suite 304, Mayfield Heights, OH 44124
Ganedien Biotech Inc. is an OTC consumer health care company that markets Digestive Advantage and Sustenex. Our products are sold in over 40,000 U.S. retailers such as Wal-Mart, Walgreen’s, CVS Pharmacy, Rite-Aid and K-mart. Ganeden products contain a powerful, patented strain of bacteria known to help maintain proper gastrointestinal function.

Gastroenterology & Endoscopy News • Booth #1121
945 West 45th Street, 8th Floor, New York, NY 10036
Gastroenterology & Endoscopy News, founded in 1978, is an independent monthly newspaper providing up-to-date, comprehensive, and objective specialty-specific news to gastroenterologists, colon and rectal surgeons, and hepatologists.

Gastroenterology & Hepatology • Booth #1610
611 Broadway, Suite 310, New York, NY 10012
Gastroenterology & Hepatology (G&H) is a monthly, independent peer-reviewed journal that is circulated to all U.S. gastroenterologists, pediatric gastroenterologists, hepatologists, colon/rectal surgeons and high prescribing PCPs. Content for the publication is directed by the strong input of experts in the field. G&H is a practical and readable journal containing the most up-to-date clinical information in gastrointestinal disorders, including diseases of the liver and biliary tract.

Geisinger Health System • Booth #745
100 N. Academy Avenue, Danville, PA 17821
Geisinger is a physician-led academic institution with an excellent blend of clinical/academics/research, affording a balanced lifestyle. We have over 700 physicians employed in 75 medical and surgical specialties/sub specialties, along with 25 ACCME accredited residency and fellowship programs, including a Gastroenterology Fellowship Program. Among our excellent benefits is paid med-mal. Visit us at: www.geisinger.org

GeniusDoc • Booth #1513
9001 San Fernando Boulevard, Sun Valley, CA 91352
GeniusDoc Gastro HER offers a flexible approach to practicing medicine with a powerhouse of information physicians need to provide patient-specific care in a matter of a few mouse clicks. With GeniusDoc, physicians enjoy a fully-integrated clinical practice and financial management system that truly captures the workflow of a medical practice, offering diagnostic and therapeutic options with business intelligence at the point of care for electronic billing submission.

GI Focus Groups, LLC. • Booth #304
10 Dani Drive, Northfield, NJ 08225
GI Focus Groups, LLC is a market research organization engaged by pharmaceutical, technology and equipment companies to mine physician opinions. Physician-consultants are recruited by us to engage in peer group sessions to provide crucial information about physicians’ perception of medical therapies and market trends.

GI Pathology Partners, P.C. • Booth #308
150 Collins Street, Memphis, TN 38112
GI Pathology is the only physician-owned laboratory in the United States dedicated solely to the practice of gastrointestinal and liver pathology. The company provides the highest quality GI pathology diagnoses, made only by fellowship-trained gastrointestinal pathologists. Results are delivered back to its nationwide client base within an industry-leading 24 hours.

GI Supply • Booth #715
200 Grandview Road, Camp Hill, PA 17011
GI Supply manufactures endoscopic assist products for site/tissue identification, therapeutic relief, diagnostic testing and treatment. GI Supply’s product line includes: SPOT – endoscopic “tattoo” marker, HPFAST/HOONE – rapid urease tests, VIADUCT – biliary/pancreatic stents, POLARWAND – cryotherapy, and BITEBLOCKS.

Giilead Sciences, Inc. • Booth #932
333 Lakeside Drive, Foster City, CA 94404
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening disease worldwide. For more information, please visit www.gilead.com.

Given Imaging, Inc. • Booth #316
3950 Shackleford Road, Suite 500, Duluth, GA 30096
Given Imaging developed, produces and markets the Given® Diagnostic System, featuring the PillCam™ video capsule, a disposable, miniature video camera contained in a capsule which is ingested by the patient. The PillCam SB Video Capsule is the only naturally-ingested method for direct visualization of the entire small intestine. The PillCam ESO video capsule provides visual examination of the esophagus.

GlaxoSmithKline Consumer Healthcare • Booth #817
16 West State Street, P.O. Box 723, Sherburne, NY 13460
You are cordially invited to visit the GlaxoSmithKline Consumer Healthcare exhibit, where our professional sales representatives will provide product information and answer any questions you may have on our product. Citrucel® will be featured.

gMed • Booth #412
2125 N. Commerce Parkway, Weston, FL 33326
gMed offers an easy-to-use Gastroenterology digital charting system designed to automate, reduce costs and risks, increase revenues and improve care of the medical practice. Unlike others, gMed integrates reporting of specialty specific procedures that account for at least 40% of the Gastroenterologist’s revenues.

Group Financial Services • Booth #116
300 Park Avenue South, 10th Floor, New York, NY 10010
Group Financial Services has been a leading provider of financial products and services to the Health Care Industry for more than 30 years. We have serviced more than 40,000 health care facilities nationwide. We specialize in the development and operation of in-house (and often Private Label) vendor finance programs for our Health Care manufacturer/distributors partners.

Ganeden Biotech Inc. is an OTC consumer health care company that develops and commercializes therapeutics to advance the care of patients suffering from life-threatening disease worldwide. For more information, please visit www.gilead.com.
Hammond Law Group • Booth #1352
441 Vine Street, 3311 Carew Tower, Cincinnati, OH 45202
Hammond Law Group, LLC is one of the largest law firms in the United States dedicated to business immigration law. We specialize in healthcare immigration, including advising foreign medical graduates on nonimmigrant visa options (J-1, H-1B, O-1); immigrant visa options and J-1 waivers.

HRA Research • Booth #1306
400 Lanidex Plaza, Parsippany, NJ 07054
Our team of experienced interviewers will be distributing carefully developed questionnaires. We’ll be gathering the answers to vital marketing and clinical questions/answers that can affect the introduction of new products or the continuation of existing healthcare products and services.

IFFGD • Booth #113
121 East Silver Spring, 2nd Floor West, Milwaukee, WI 53217
The International Foundation for Functional Gastrointestinal Disorders (IFFGD) is a nonprofit education and research organization dedicated to informing, assisting and supporting people affected by functional gastrointestinal and motility disorders.

INOVIA Diagnostics • Booth #1511
9900 Old Grove Road, San Diego, CA 92131
INOVIA Diagnostics, Inc. develops, manufactures and sells a complete line of autoimmune disease diagnostic kits & components for screening and specific autoantibody determinations. INOVIA specializes in providing state-of-the-art proprietary testing products for celiac disease, including assays for autoantibodies to deamidated gliadin peptide and Tg. Other products groups include tests for gastrointestinal, autoimmune liver, rheumatoid arthritis, vasculitis, connective tissue disease, coagulation and endocrine diseases.

INOVERA Bioscience, Inc. • Booth #1808
P.O. Box 790, 921 Bethlehem Pike, Spring House, PA 19477
INOVERA Bioscience markets FORVIA® Multivitamin/Mineral TABLETS and CHEWABLES, the first patented non-prescription product designed specifically to meet the nutritional deficiencies of Crohn’s and ulcerative colitis patients. This fall, INOVERA introduces FORBONES calcium supplement, providing calcium, phosphorus and vitamin D in tablet form.

InScope, a Division of Ethicon Endo-Surgery, Inc. • Booth #718
4545 Creek Road, Cincinnati, OH 45242
InScope, a new division of Ethicon Endo-Surgery, Inc., is committed to the development of Endoscopic devices and accessories designed to make a difference in clinical practice. By creating practical, innovative, and procedure-enabling devices, InScope is dedicated to enhancing the future of everyday Endoscopy.

Ion Healthcare • Booth #1237
9011 Arborjeum Parkway, Suite 150, Richmond, VA 23236
Ion Healthcare is a patient care services company specializing in Sleep Apnea. Ion’s clinically proven turnkey pathway allows a Colonoscopy Center to comply with the new ASA practice guides. Patients with Sleep Apnea need special care. We can help.

The Joint Commission • Booth #1800
One Renaissance Boulevard, Oakbrook Terrace, IL 60181
Joint Commission accreditation is the gold standard for ambulatory care and office-based surgery. Over 1400 outpatient clinics, comprising over 40 different types of settings, have discovered the real value that accreditation brings to their organizations; competitive advantage, professional improvement, community confidence, and a more organized business.

Jordan Hospital • Booth #1820
275 Sandwich Street, Plymouth, MA 02360
Jordan Hospital is a non-profit, acute care, 160-bed Magnet hospital in coastal Plymouth, Massachusetts, 45 minutes from Boston. The Hospital has served 12 growing towns for a century. The 30+ departments, programs and services provide excellent, comprehensive inpatient and outpatient care during 300,000 encounters and 52,000 ED visits each year.

Kenwood Therapeutics • Booth #1418
383 Route 46 West, Fairfield, NJ 07004-2402
Kenwood Therapeutics, a division of Bradley Pharmaceuticals, Inc. has been providing quality therapies for more than 60 years to physicians who treat gastrointestinal disorders. Kenwood products include Peranex™ brand hemorrhoid therapies, Flora-Q® and Flora-Q™ 2 probiotics (dietary supplements) and Pamine® brand antispasmodic/anticholinergics.

L3 Healthcare Design, Inc. • Booth #415
375 Douglas Avenue, #209, Altamonte Springs, FL 32714
L3 Healthcare Design, Inc. is a nationally recognized professional provider of Design and Development services for Ambulatory Surgery Centers, Clinics and Imaging Centers. Our team includes Medical Planners, Architecture and Engineering as well as consulting for state Accreditation and Medicare Licensure.

Lakewood Pathology Associates • Booth #743
1200 River Avenue, Building 10, Lakewood, NJ 08701
Founded in 1990, Lakewood Pathology Associates is a national, full service anatomical pathology company providing pathology services tailored to the outpatient needs of gastroenterologists. Our facility is accredited by the College of American Pathologists with an award of distinction for exceptional service and quality.

Lippincott, Williams & Wilkins • Booth #737
1485 Tullamore Lane, Phoenixville, PA 19460
See new and current textbooks and journals in gastroenterology. Subscribe to Current Opinion in Gastroenterology and get 3 years for the price of 1!!!!

Market Access Partners • Booth #916
3236 Meadowview Road, Evergreen, CO 80439
Market Access Partners provides market research consulting to the medical device and pharmaceutical industries. We use innovative qualitative and quantitative methodologies to research opinions of physicians, nurses and patients. We offer a management-oriented approach to product development and marketing.

MD-Reports/ Infinite Software Solutions, Inc. • Booth #739
1110 South Avenue, Suite 303, Staten Island, NY 10314
MD-Reports offers Gastroenterologists Electronic Medical Records (EMR) solutions for documentation. Endoscopy module generates procedure reports with Images, Referral letters and Discharge Instructions in a quick and efficient manner EMR/Consultation offers comprehensive History & Physical, Follow-up notes, Organized Document Scanning, Paperless Patient Charts. MD-Reports Software eliminates transcription, imaging costs, increases efficiency and accuracy. www.md-reports.com

Medi-Capture • Booth #1709
580 West Germantown Pike, #103, Plymouth Meeting, PA 19462
Medi-Capture offers complete image capture solutions for the OR. The MediCap USB200 easily records digital video and still images to a USB flash drive from virtually any video source, including endoscopes, arthroscopes, surgical microscopes, etc. It’s affordable and easy to use. Come try the USB200 yourself at our booth and discover how simple video capture can be.

Medi-Corp, Inc. • Booth #383
25 Commerce Drive, Cranford, NJ 07016
Anesthesiology Billing Specialists – GI Centers and offices are utilizing our services to help them secure more revenue for themselves by billing for the anesthesia portion of the procedure. We have over 25 years experience in billing for anesthesia, so please give us a call to discuss your options.

MediPage Today, LLC. • Booth #1230
150 Clove Road, Little Falls, NJ 07424
MediPage Today is “News + CME.” We provide clinicians with real time medical news coverage that also offers CME/CE credit. The result is daily engagement with a highly loyal audience. Our news coverage is reviewed and approved by the University of Pennsylvania School of Medicine, which provides CME accreditation.
Medtronic • Booth #1811
8299 Central Avenue, NE, Minneapolis, MN 55432-2023
Medtronic is the global leader in medical technology—alleviating pain, restoring health and extending life for millions of people around the world. Products for the GI nurse include the Braw® pH monitoring system plus Enterra® Therapy, an implantable neurostimulation system to treat gastroparesis.

Meretek Diagnostics • Booth #814
2655 Crescent Drive, Suite C, Lafayette, CO 80026
Meretek Diagnostics provides the BreathTek™ System, which detects active H. pylori infection. Breath tek is CLIA non-regulated and cleared by the FDA for initial diagnosis and post-treatment monitoring of H. pylori. The test is easily administered in the office setting, with results in about 2 minutes.

MGI Pharma, Inc. • Booth #1205
5775 West Old Shakopee Road, #100, Bloomington, MN 55437
MGI Pharma, Inc. is a biopharmaceutical company focused on oncology and acute care that acquires, researches, develops, and commercializes proprietary products that address the unmet needs of patients. MGI Pharma markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® (polipepion 20 with carmustine implant) Wafer in the U.S.

Micro Direct, Inc. • Booth #208
803 Webster Street, Lewiston, ME 04240
Micro Direct will be displaying the MicroH2, Hydrogen Monitor. The MicroH2 is an innovative handheld unit designed for simple screening of lactose malabsorption and other sugars malabsorption. Combining accuracy and simplicity at an economical price, the MicroH2 provides a fast and easy-to-read display of expired Hydrogen levels in ppm.

National Digestive Diseases Information Clearinghouse • Booth #203
8280 Greensboro Drive, Suite 300, McLean, VA 22102
National Digestive Diseases Information Clearinghouse (NDDIC) is an information and referral service of the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), one of the National Institutes of Health. The clearinghouse responds to inquiries, develops and distributes publications, and provides referrals to digestive diseases organizations.

National Pancreas Foundation • Booth #111
364 Boylston Street, 4th Floor, Boston, MA 02116
NPF is the only national not-for-profit group dedicated to scientific research in all forms of pancreatic disease—both pancreatitis and pancreatic cancer. Over the past nine years, we have funded 56 research projects. We also support patients and doctors through our educational programs.

Natren, Inc. • Booth #1440
3105 Willow Lane, Westlake Village, CA 91361

Nature Publishing Group • Booth #849
75 Varick Street, 9th Floor, New York, NY 10013-1917
Nature Clinical Practice Gastroenterology & Hepatology provides physicians with authoritative, timely and accessible interpretations of key developments in the field, translating the latest findings into clinical practice. Coverage includes diagnosis and treatment of functional gastrointestinal disorders, inflammatory diseases, cancer, infection, and nutritional disorders. Complimentary Copies are available at booth 849.

Neoguide Systems • Booth #632
104 Cooper Court, Los Gatos, CA 95032
Neoguide Systems is developing and commercializing innovative technology designed to revolutionize the way physicians visualize and deliver therapies within the body. The company’s initial product, the NeoGuide Endoscopy System, is designed to address the major limitations of colonoscopy.

Neusys Imaging Systems Solutions • Booth #1348
1500 Pinecroft Road, Suite 212, Greensboro, NC 27407
Neusys is a leader in clinical diagnostic imaging products, representing Neusoft, a new manufacturer of high quality imaging systems, tailored to your clinical needs, scaled to fit your site, designed with the private practitioner in mind. Neusys provides total solutions including sales, consulting, project management, construction, service, financing and more.

Nueterra Healthcare • Booth #1721
11221 Roe Avenue, Suite 320, Leawood, KS 66211
Nueterra Healthcare’s Single Specialty Division provides a single-source development and management solution for endoscopic ambulatory surgical facilities. Our GI Division’s unique model offers physicians and ownership and ensures a physician’s control of clinical outcomes, operational efficiency, patient satisfaction and profitability.

The Oley Foundation • Booth #211
214 Hun Memorial Albany Medical Center, Albany, NY 12208
The Oley Foundation for home parenteral/enteral nutrition (homePEN) is a nonprofit organization which provides its 6,000+ members with critical information regarding research, health insurance, and medical advances. It is also a source of support, helping homePEN patients overcome the psycho-social challenges they face. All services are free to patients.

Olympus America Inc. • Booth #1124 & #1224
3900 Center Corporate Parkway, Center Valley, PA 18034
The Olympus Difference is clear to see with the most extensive endoscopy offering available. This year showcases the Olympus Difference with emphasis on new small bowel technologies, HDTV/Narrow Band Imaging (NBI), V-System, Autofluorescence Imaging (AFI), new EndoTherapy and EUS...all driven from a single platform. See it all in one place!

Omega Medical Imaging, Inc. • Booth #1738
675 Hickman Circle, Sanford, FL 32771
Omega Medical Imaging introduces eView, the only dedicated X-Ray Fluoro System designed from inception for performing ERCP studies. The eView eliminates drawbacks that occur when using the Radiology R/F Systems or Mobile C-Arms. Features include Low Dose Fluoro, High Power X-Ray Generator, Large Field of View, and Substantially Reduced Scatter Radiation. Addition information: Visit our Booth # 1738.

Osiris Therapeutics, Inc. • Booth #1343
7015 Albert Einstein Drive, Columbia, MD 21046
Osiris Therapeutics is a leading adult stem cell company developing products for patients with inflammatory, orthopedic and cardiovascular diseases. Mesenchymal Stem Cells are non-immunogenic, allowing the development of treatments derived from unrelated donors. We have two drug candidates in Phase 3 trials and a deep pipeline of earlier stage programs.

Pathology Solutions, LLC • Booth #1249
2-12 Cortett Way, Eatontown, NJ 07724
Pathology Solutions is a state-of-the-art anatomic pathology lab which has an expertise in setting up gastrointestinal with an office pathology program and allow them to practice better medicine for their patients. They offer their clients a quick turnaround time on processing their patient’s biopsies along with all the program and personal support needed to get practice in compliance with Stark Law regulations.

PathOptions • Booth #1336
709 St. Andrews Road, Hollywood, FL 33021
PathOptions is the leading provider of In-Office Pathology Solutions. Our labs are owned/staffed by GI-Fellowed Pathologists who support the TCP/PC business model. Integrated reports/24 hour turn-around/ access to top local Pathologists. Call Daniel Karlen at 954-347-5611 or email dkaren@pathoptions.com to learn more.
Commercial Exhibitors

Pentax • Booth #724
102 Chestnut Ridge Road, Montvale, NJ 07645-1856
Introducing the world’s most intuitive and powerful video processor, the PENTAX EPK-i. This innovative product offers a resolution of 1.25 mega pixels, providing the sharpest HD endoscopic images available. The EPK-i incorporates automatic physician customization, remote servicing and On-Demand Benchmarking tools that address individual demands and preferences for a more efficient lab!

Pfizer, Inc. • Booth #1710
235 E. 42nd Street, New York, NY 10017
Please visit the Pfizer Inc., U.S. Pharmaceuticals exhibit featuring CELEBREX® (celecoxib).

Philips • Booth #1207
3000 Minuteman Road, Andover, MA 01810
As a leading supplier of medical equipment and related services, Philips Medical Systems offers a patient-first approach to technology that makes sense for today’s clinical care environments. With Philips solutions, sophisticated technology becomes less intrusive, more intuitive and enhances the healthcare experience for clinicians and patients. Visit Booth 1207. 1-800-934-7372.
www.medical.philips.com

Physicians Endoscopy • Booth #1500
1456 Ferry Road, #305, Doylestown, PA 18901
Physicians Endoscopy develops and manages endoscopic ambulatory surgery centers in partnership with practicing GI physicians. Our 14 operating centers provide services to over 100,000 patients annually. The company has two additional centers under development. Our strategy is simple—SERVICE. Our company is forthright, reliable, and communicative, and we deliver upon expectations and promises.

Physicians RightPath, LLC • Booth #114
2500 S.W. 17th Road, Building 100, Ocala, FL 34474
Physicians RightPath provides comprehensive support services for the development, implementation, and operation of practice-based pathology laboratories for qualifying group practices. These services include feasibility determination; laboratory premises, equipment, and staff acquisition; billing, collections and data management. PRRP supported laboratories ensure superior diagnostic pathology services and optimize practice profitability.

Practical Gastroenterology • Booth #512
99 B Main Street, Westhampton Beach, NY 11978
Our exhibit will consist of journals.

PracticeMatch Integro • Booth #735
600 Emerson Road, Suite 450, St. Louis, MO 63141
PracticeMatch was chosen #1 among hospitals and clinics in 2006 for lists and data services. Physician recruiting services include: detailed physician profiles, online recruitment software, full-service physician recruitment (PracticeMatch Integro) and physician sourcing tools to aid in the healthcare recruitment process. For more information on our products and services contact us at 800.489.1440 or www.practicematch.com.

PracticeLink • Booth #820
415 Second Avenue, Hinton, WV 25951
PracticeLink® – The Online Physician Job Bank™ – is the leading physician employment website. There are more than 13,000 practice opportunities represented on the PracticeLink.com website. More than 18,000 residents, fellows and practicing physicians will use PracticeLink each year in their effort to find the right practice. Visit our website PracticeLink.com or call 1-800-776-8383.

PriCara • Booth #708
1000 Route 202, Raritan, NJ 08869
PriCara, Unit of Ortho-McNeil, Inc., is dedicated to serving Primary Care physicians. We currently market products to treat pain, acid reflux disease and infectious diseases.

Procter & Gamble • Booth #1112
8700 Mason-Montgomery Road, Mason, OH 45040
Procter & Gamble invites you to visit our exhibits to obtain the latest information about our brands: Asacol® (mesalamine), Metamucil, Fibersure, Align, and Prilosec OTC.

Prometheus • Booth #906
9410 Carroll Park Drive, San Diego, CA 92121
Prometheus Laboratories, Inc. is a specialty pharmaceutical company committed to developing new ways to help physicians individualize patient care. The Company focuses on the treatment, diagnosis and detection of gastrointestinal, autoimmune and inflammatory diseases and disorders by integrating therapeutics and diagnostic services.

ProVation Medical, Inc. • Booth #834
800 Washington Avenue N., #400, Minneapolis, MN 55401
ProVation’s Gastrointestinal Pathology Division, led by Cory A. Roberts, MD, is a premier provider of laboratory services to gastroenterologists and endoscopy centers nationwide. Our board certified gastrointestinal pathologists offer a complete list of testing capabilities, on-site advanced diagnostic technologies, rapid turnaround time, and state-of-the-art technology solutions for unmatched patient care.

QDx Pathology Services • Booth #1438
46 Jackson Drive, Cranford, NJ 07016
QDx Pathology Services is an independent, CLIA certified, state-of-the-art pathology company, specializing in anatomic pathology, as well as cytopathology, and a full range of ancillary services. Our staff of experienced board-certified pathologists and cytotecnologists are dedicated to providing clinicians and patients with diagnostic excellence.

QOL Medical, LLC • Booth #1436
10 Stoneleigh Drive, Scotch Plains, NJ 07076
QOL (quality of life) Medical is a specialty pharmaceutical company dedicated to acquiring FDA approved drugs that are essential for treating rare diseases. Please visit our booth to learn more about Nascobal® Nasal Spray (Cyanocobalamin USP), a breakthrough for B12 deficiency and SucraGen® (sacrosidase) oral solution for sucrase-isomaltase deficiency, a simple solution for a difficult disease.

Quest Diagnostics, Inc. • Booth #1214
16 W. State Street, Box 723, Sherrburne, NY 13460
Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. We offer the broadest access to health testing services. Each day, over half a million people rely on us to provide their doctors with medical information to help them assess whether their patients are healthy or ill.

QuinTron Instrument Company • Booth #719
3712 W. Pierce Street, Milwaukee, WI 53215
QuinTron’s NEW BreathTracker™ instruments are exceptionally accurate, offering hydrogen and methane analysis with carbon dioxide correction, helping aide physicians in diagnosing carbohydrate malabsorption and small intestinal bacterial overgrowth (SIBO). Breath-Tracker™ instrumentation utilizes long-life, solid-state detectors that save money and have a full three-year warranty. Free mail-in kits are also available.
Redfield Corporation • Booth #818
336 West Passaic Street, Rochelle Park, NJ 07662
The Redfield IRC2100 Infrared Coagulator is the leading non-surgical device for treating internal hemorrhoids. IRC treatments are easy to perform, well-tolerated by patients and offer excellent reimbursement. Redfield also sells a variety of anoscopes and other accessories. Visit us for a hands-on demonstration.

RedPath Integrated Pathology • Booth #312
816 Middle Street, Floor 2, Pittsburgh, PA 15212
RedPath Integrated Pathology, Inc. provides specialized cancer diagnostic testing. We are a commercial laboratory focused on facilitating superior disease diagnosis for pathologists, oncologists and clinicians. PathFinder®G, our patented molecular-based analysis, integrates with routine pathology review of fixed slides, cytology and fluid specimens to render a definitive diagnosis where none would otherwise exist, improving patient clinical management and outcomes.

Restech • Booth #548
10804 Willow Court, Suite B, San Diego, CA 92127
Restech’s Dx–pH Measurement SystemTM detects extragastric reflux in real time with its highly sensitive Dx–pH ProbeTM. Introduced as Oral Suspension, and DIP® Oral Suspension, the tip of the probe rests behind the soft palate for 24-48 hours. The Dx-System helps determine the significance of extragastric reflux and its relationship to patient symptoms.

Rheumatology Diagnostics Laboratory, Inc. • Booth #1707
10755 Venice Boulevard, Los Angeles, CA 90034
RDL Reference Laboratory specializes in esoteric testing and is known for maintaining exceptionally high standards in reliability and customer service. RDL offers testing for Inflammatory Bowel Disease, Crohn’s Disease and a Primary Biliary Cirrhosis panel exclusive to RDL.

Roche Laboratories, Inc. • Booth #900
340 Kingsland Street, Nutley, NJ 07110
Roche is a worldwide leader in the development of pharmaceuticals and diagnostics. Our people are engaged in the discovery, development, manufacturing and marketing of prescription medicines in a wide variety of therapeutic areas, including cancer, HIV/AIDS, hepatitis C, transplantation, influenza and osteoporosis. We invite you to our booth to learn more about Pegasys. www.rocheusa.com or www.roche.us.

Remark Pharmaceutical • Booth #436
3000 Bayport Drive, Suite 200, Tampa, FL 33607
Nitazoxanide (Alinia®, Remark Laboratories, LC) is a thiazolide anti-infective which has a broad spectrum of activity against parasites, anaerobic bacteria, and viruses. It is currently indicated in the United States for cryptosporidiosis and giardiasis in both pediatric and adult patients. Nitazoxanide is a safe medication, with a side-effect profile similar to placebo, and has been studied in children as young as five months of age (Rotavirus diarrhea).

Salix Pharmaceuticals, Inc. • Booth #1624
1700 Perimeter Park Drive, Morrisville, NC 27560
Salix Pharmaceuticals, Inc. follows a competitive strategy of in-licensing late-stage pharmaceutical products to treat GI diseases. The Salix portfolio includes COLAZAL®, XIFAXAN®, OsmoPrep™, MOVIPREP®, AZasan®, ANUSOL-HC®, PROCTOCORT®, PEP C® and TRANSCEND. Salix products are specially designed by a local Suspension, and fluid specimens to render a definitive diagnosis where none would otherwise exist, improving patient clinical management and outcomes.

Sandhill Scientific • Booth #1131
9150 Commerce Center Circle, #500, Highlands Ranch, CO 80129
Sandhill Scientific has been a world wide leader in the field of gastroenterology diagnostics for over 25 years. Known for innovative technologies, the company continues to lead the industry in high definitions GI diagnostic systems. For example, exclusive, cutting-edge impedance (Z) technology enables you to precisely differentiate at patient diseases presenting with similar esophageal symptoms.

Santarus Inc. • Booth #1901
10590 West Ocean Air Drive, Suite 200, San Diego, CA 92130
Santarus, Inc., is a specialty pharmaceutical company focused on acquiring, developing and commercializing products for the prevention and treatment of gastrointestinal diseases and disorders. Santarus launched the first and only immediate-release oral PPI for the treatment of symptomatic GERD, Erosive Esophagitis, Duodenal Ulcer, Gastric Ulcer, UGI Bleed in Critically Ill Patients.

Schering-Plough • Booth #808
2000 Galloping Hill Road, Kenilworth, NJ 07033
Schering Corporation is a research based pharmaceutical company with headquarters in Kenilworth, NJ. Visit the Schering-Plough booth to learn more about PEG-INTRON® (Peginterferon alfa-2b) Powder for Injection REDIPEN™ Single-dose Delivery System, REBETOL® (Ribavirin, USP) Capsules, and their numerous hepatitis support programs.

Schwarz Pharma • Booth #1239
6140 West Executive Drive, Mequon, WI 53092

Shire U.S., Inc. • Booth #324
725 Chesterbrook Boulevard, Wayne, PA 19087
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on central nervous system (CNS), gastrointestinal (GI), general products (GP) and human genetic therapies (HGT)—all being areas in which Shire has a commercial presence.

Sierra Scientific Instruments • Booth #820
5757 Century Boulevard, Suite 600, Los Angeles, CA 90045
Sierra Scientific Instruments, Inc. produces the ManoScan 360™ High-Resolution Manometry (HRM) system. A complete esophageal manometry study takes 10 minutes! It dramatically reduces patient discomfort, nurse and physician time commitments and costs/revenue ratios. The ManoScan 360™ is also available for anorectal manometry studies. SSI also produces the AccuTrac pH™ combined Impedance & pH reflux monitoring systems.

Sigma-Tau Pharmaceuticals, Inc. • Booth #948
8441 Washington Boulevard, Gaithersburg, MD 20878
VSL#3 is the probiotic medical food for the dietary management of Ulcerative Colitis (UC), Irritable Bowel Disease (IBS), or an Ileal Pouch. VSL#3 is imported by Sigma-Tau Pharmaceuticals, Inc., a subsidiary of Sigma-Tau S.p.A.

SLACK, Inc. • Booth #1302
6900 Grove Road, Thorofare, NJ 08086
SLACK Incorporated is a leading medical publisher that is renowned in the area of Gastroenterology. We are excited to present high-quality books for today’s gastroenterologist. Stop by our booth to see our new and best-selling titles.

SmartPill Corporation • Booth #418
847 Main Street, Buffalo, NY 14203
The SmartPill Corporation is a developer of ingestible, capsule-based medical devices, peripheral software and electronic components that aid in the diagnosis, definition and therapeutic intervention of gastrointestinal disorders and diseases. Contact us at 1.800.644.4162 or visit our website at www.smartpillcorp.com.

Solvay Pharmaceuticals, Inc. • Booth #800
901 Sawyer Road, Marietta, GA 30062
Solvay Pharmaceuticals, Inc., of Marietta, Georgia is the U.S. subsidiary of Solvay Pharmaceuticals, a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines, gastroenterology, specialized markets and men’s and women’s health.

Tushower • Booth #950
19 Pierce Road, Egg Harbor Township, NJ 08234

TUSHOWER® is designed to provide pain relief for those who suffer with hemorrhoids by keeping the affected area clean. The Tushower head is installed on the bottom rear of the toilet seat and provides a stream of fresh warm water to clean the tush of anyone sitting on the seat. Visit us at www.tushower.com.
### Industry Sponsored Symposia

#### Saturday, October 13

5:30 pm – 8:00 pm • Marriott Salon GKL  
**Centocor**  
Medical Crossfire: Update on Clinical Achievements in Inflammatory Bowel Diseases

Saturday, Oct. 13  
8:30 pm – 12:00 Midnight • Marriott Salon HIJ  
**Fleet Pharmaceuticals**  
Eliminating Inadequate Bowel Preparation: Practical Recommendations.

#### Sunday, October 14

Sunday, Oct. 14  
6:30 am – 7:45 am • Convention Center Room 201 ABC  
**Salix Pharmaceuticals, Inc.**  
Discontinued Products, Uncertain Data, Changing Options: Selecting Effective and Reliable Treatment for IBS

Sunday, Oct. 14  
5:00 pm – 7:00 pm • Marriott GKL  
**Abbott**  
Current Controversies in Biologic Therapy of Crohn’s Disease: Debating the Application of Emerging Clinical Data to Daily Treatment Decisions

Sunday, Oct. 14  
7:00 pm – 8:30 pm • Marriott Salon HIJ  
**Takeda**  
The Idiopathic Constipation and IBS-C Interface: Concepts, Controversies and Considerations for Clinical Practice

Sunday, Oct. 14  
8:30 pm – 12:00 Midnight • Loew’s Regency Ballroom  
**UCB**  
A Case-Based Discussion on Managing Crohn’s Disease: Integrating the New Generation of Anti-TNF-α Therapies

#### Monday, October 15

Monday, Oct. 15  
5:30 pm – 7:00 pm • Marriott HIJ  
**Procter & Gamble**  
FREEDOM FROM IBD: Keys to Personalized Management

Monday, Oct. 15  
9:00 pm – 11:00 pm • Marriott GKL  
**Braintree Laboratories**  
Desert with the Professors: An Interesting Set of Perspectives on Bowel Cleansing Options

#### Tuesday, October 16

Tuesday, Oct. 16  
6:30 pm – 8:00 pm • Marriott ECD  
**TAP Pharmaceuticals**  
Esophageal Diseases: Fast Track Issues to Watch For!

Tuesday, Oct. 16  
8:00 pm – 12:00 Midnight • Marriott AB  
**Dannon Company**  
Probiotic Applications in Gastrointestinal Health and Disease
Author Index

Abanto, P.R., P872
Abdelsayeed, G., P905
Abell, T., P377, P633
Abell, T. L., P542, P559
Abhiwaia, J. P., P321, P720
Abraham, N. S., 33, P253
Abrahams, C., P633
Abreu, M. T., P497
Achem, S. R., P691
Adler, D. G., P577
Adrain, A., P899
Afzal, Z., P546
Aghajani, K., P338
Aghenta, A., P418, P643
Agrawal, A., P375
Agrawal, J. R., P542, P559
Ahluwalia, J. P., P231, P720
Ahmad, M., P765
Ahmed, A., P77, P246
Ahmed, K., P226
Ahmed, M., P356
Ahmed, U., P563
Ahn, J., P836, P841, P843, P863
Aisenberg, J., P32
Ajumobi, A. B., P686, P689
Akerman, P. A., P411
Al Kharrat, H., P888
Al-Aghbar, M. N. A., P380
Al-Hafnawi, M. K., P140
Al-Saleem, T. I., P710
Al-Tawil, Y., P68, P668
Alam, S., P188
Alaradi, O., P70, P660
Alba, L. M., P93
Alex, B. K., P195, P218
Alexander, J. A., P19
Ali, A., P144, P492, P510
Ali, M., P454
Ali, S. A., P74, P544
Alkaade, S., 17
Ally, M. R., P996
Almansa, C., P691
Alnouou, M., P400
Alqahtani, S., P314
Alshaeba, S., P851
Alsolaaiman, M., P573, P574, P804, P821, P875
Altschuler, A., P938
Alvisi, V., P91
Amaratunge, H., P870
Amin, M. M., P949
Anand, C., P444
Anand, G., P13
Anand, S., P112, P171
Ananthapanayast, W., P128
Anaparthy, R., P227, P300
Anastassides, C. P., P159
Ancowitz, B. A., P600
Anderson, J. C., P683
Anderson, K., P73
Anjum, E. H., P472
Antillon, M. R., P150, P164, P220, P467
Anvar, Z., P673
Aoun, E., P733
Appalanan, V., P321
Arber, N., 31
Arora, M., P992
Arya, M., P550
Arya, Y., P385
Asfandiyar, S., P224
Ashley, C. S., P487
Atasi, B., P236
Atheron, P. J., P688
Atkinson, M., P934
Attaluri, A., 1
Attar, B. M., P459, P460
Badreddine, R. J., P877, P906
Bafutto, M., P963
Bagi, P., P376
Bai, C., P85
Baiocco, P. J., P144
Bakis, G., P805
Bal, B. S., P63, P817
Banks, P. A., P389, P390
Barada, K. A., P53
Barker, P., P203
Barkin, J., P175, P204, P642
Barkun, A., P34, P383
Baron, T. H., 27
Bashir, R. M., P48, P195, P218, P731
Bassett, J. T., P11
Bawjae, S., P79
Bechtold, M. L., P467
Belitsis, K., P476
Benguid, V., P417
Benard, H., P480
Berencenbaum, P. L., P939
Berkelhammer, C., P128, P551, P558, P797, P834, P898
Bhatchacharya, K., P524
Blunt, M. S., 65, P179
Bianchi, L. K., P2A, P2B
Bin-Sagheer, S. T., P788, P903
Biriss, T., P219, P712
Bishop, M. D., P570
Bizzarri, B., P331
Blanchard, S. S., P669
Blanton, W., P828
Bloom, R., P207
Bloomfield, R., P291, P826
Blumenkelh, M., P119
Boetticher, N. C., P498
Bollini, D., P811
Bortolotti, M., P449
Borunn, M. L., P211, P496, P748, P809
Botoman, V. A., P114, P507
Bou Assaf, E., P482
Bouras, E. P., P532
Boyd, P., P897
Boyd, W., P443
Bradley, A. G., P588
Brady, C. W., P260
Brady, P., P152
Bragg, J. D., P981
Brandt, L. J., P776, P783
Brevel, Z., P39
Brevel, Z. S., P162
Brenner, D. M., P305
Brensilver, J., P134, P199
Brixner, D., P955
Brook, R., P915
Brook, R. A., P302
Brown, C. L., P270
Brown, G., P74
Brown, K., P692, P778, P989
Brown, M., P319
Brown, P., P961
Brugge, W. R., 18
Buken, F. A., P49, P651
Bunag, A. P., P823
Burgunder, P., P267
Burke, C. A., 9, 32A, 32B, 35, P1004
Burton, F. R., 17
Caca, K., P324, P704, P705
Cai, Q., P58, P394, P727
Caldera, F., P176
Calderwood, A. H., P151, P341
Camilleri, M., P965
Campbell, D. R., 20
Canale, C. C., P856, P857
Canlas, K. R., P405
Cannon, M., P736
Cao, X. C., P984
Capanescu, C., P873
Cappell, M. S., P100, P168
Carlo, V. L., P228
Carpenter, S., P932
Carter-Kent, P., C45
Casey, K., P140, P810, P885
Cash, B. D., P993
Castell, D., P355
Castell, D. O., P7, P375
Castillo, S., P1005
Castillo, S. D., P1006
Castillo-Roth, A., P137
Castillo-Roth, A. I., P281
Castilloux, J., P358
Cerulli, M. A., P343
Chadha, K. S., P802
Author Index

Gosserand, J. L., P217
Gotian, A., P569
Grandison, G., P944
Green, A., P273
Green, J., P893
Green, P., P248
Green, P. H., P747
Greenwald, B. D., P708
Greenwald, D., P325
Gregor, J., P617
Grendell, J., P167
Grendell, J. H., P814, P850
Gress, F., P515
Grieger, D. L., P172
Griffin, R., P60, P540
Grigg, E., P585, P842
Grigorian, A., P512, P954
Grosman, I. M., P465, P486, P511, P661
Gross, R. G., P535
Gross, S. A., P26, P980
Grossman, P., P266
Grover, K., P680
Gualtieri, N., P479
Guillaume, C., P571, P884
Gulati, R., P230
Gulley, D. D., P40
Gunaratnam, N., P932
Gupta, R., P581, P583
Gupta, V., P803
Guslandi, M., P269
Habashi, S. L., P457, P979
Haber, G., P510, P552, P553, P554
Haber, G. B., P555
Haddad, R., P95
Haddad, R. Y., P214
Haider, K., P417
Halder, S. L. S., P298
Hale, W. B., P451
Hall, J., P155
Hall, J. D., P646
Halpert, A., P639
Haluszka, O., P400
Hammad, H., P257, P725
Hammad, H. T., P250
Hanauer, S. B., P275, P614
Hanif, S., P989
Hanouneh, I. A., P435
Hansel, S. L., P12, P297, P572, P806
Hao, J., P984
Har, A. F., P304
Harrindhanavudhi, T., P141
Harris, S., P192
Hart, P. A., P44
Hasan, M., P46, P25
Hashemi, N., P690
Hasyagar, C., P730
Hasyagar, C. P., P940
Hauser, S. C., P837
Haydek, J. M., P458, P789
Hayes, S. M., P383
Hazan, T. B., P207
Heading, R. C., P361
Heinze, H., P350
Hebbum, I. S., P78
Herrera, J. L., P216
Herrinton, L. J., P938, P958
Hinojosa, J., P276
Hlivoj, I. T., P771
Ho, S., P531
Ho, V., P855, P897
Hodges, D. S., P123
Hoffman, B. J., P312, P539
Hofkin, G., P149
Holtmann, G., P367
Holtzapple, P., P139, P488
Hooks, B. S., P562
Horine, L. C., P16
Howden, C. W., P36
Hoyumpa, A., P88
Huang, C., P883, P893
Huber, T., P402
Hunt, R. H., P35, P699
Hutson, W. R., P856, P857
Hyun, J. G., P22, P791, P813
Ibarguen-Secchia, E., P664
Ibdah, J. A., P721, P844
Ignjatovic, A., P878
Iles-Shih, L. L., P288
Ingle, S. B., P618, P937
Inverso, N. A., P242
Iqbal, S., P343
Irvin, E. J., P278
Isaacs, K. L., P270, P976
Islam, K., P910
Ismail, F. W., P432
Israel, R. J., P794
Itzkowitz, S., P723
Iyer, H. V., P369
Iyer, S., P281, P921
Jabeen, S. A., P160
Jaber, R., P60
Jacobson, B. C., P341, P348
Jafri, N. S., P36
Jafri, S.-M., P567
Jafri, W., P432, P649
Jagannnath, S., P1, P978
Jagarajandu, K., P113, P865
Jain, A. K., P419
Jain, V., P355
Jaiswal, R., P769
Jamal, M. M., P28
James-Steveson, J., P764
James-Steelman, T. N., P889
Jamil, L. H., P168, P517
Jamma, S., P5, P402
Jara, S. M., P152, P443
Jatla, M., P3
Javedan, H., P133
Javel, M. M., P695
Jayatilaka, S., P202, P578, P838
Jerzy, S., P353
Jha, L. K., P851
Jiang, X., P631
Jimenez, J., P126
Jindal, R., P136, P521
Jo, K. S., P846, P868
Johal, A. S., P506
Johnston, D. A., P255, P930
Johnston, J. M., P628
Jones, J., P9
Jones, J., P240
Jones, M. P., P376, P972, P973
Joo, E., P491
Joshi, S. N., P424
Joshi, V., P225
Judge, T., P538
Julka, R. N., P191
Jung, H., P968
Kaczanowskki, M., P451
Kader, M. E., P847
Kalaleh, M., P46, P391
Kamath, P. S., P860
Kandula, S., P536
Kane, S., P955
Kan, S. V., P272, P597
Kapkov, D. V., P90, P772
Kaplan, D. M., P464
Kapitik, S., P388
Karan, S. B., P658
Karim, M. S., P328
Kariv, R., P3, P595
Karyotakis, N., P59
Kasmin, F. E., P393
Kasturi, K. S., P780, P799, P801, P902
Katz, P., P440, P779
Katz, P. O., P13, P369
Katz, S., P278, P290, P830
Kaul, A., P666
Kaur, N., P38
Keida, Y., P54
Keller, C. B., P216
Kelly, C. P., P11, P741, P743
Kennedy, A. T., P634
Kerman, D. H., P484
Keshav, S., P620
Kessler, W. R., P233
Khan, S., P543
Khan-Blimi, N. A., P406
Khara, S., P757
Khaykis, L., P38
Khorshidi, I., P325, P783
Kiafar, C., P200
Kilgore, T. W., P844, P981
Kim, B. J., P296
Kim, B. W., P715
Kim, M. K., P723
Kim, P., P492
Kinzie, J. L., P2
Kiran, R. P., P99, P251
Kittaneh, M., P834
Kleinman, N., P915
Koch, T. R., P57, P61, P63, P66, P790, P817
Kochhar, R., P45
Koczka, C. P., P829
Koff, J., P201
Koloszi, W., P848
Komor, M. J., P506
Kongara, K., P124
Koo, L. C., P589
Korabluth, A., P22, P604
Korsten, M. A., P535
Koshire, R., P62
Kothari, S., P240
Kothari, T., P418, P643
Kotti, M. J., P809
Kottoor, R., P538, P979
Koulouzouidis, A., P433, P452
Kovalak, M., P363
Koya, D. L., P62
Kozuch, P. L., P503
Kraichely, R. E., P489
Krishnamoorthy, G., P901
Kuczynski, J., P36
Kulkarni, K., P392
Kulkarni, P., P125
Kulwinder, D. S., P109
Author Index

Kumar, A., 42, P426
Kumar, M., P82
Kumar, V., P149, P777
Kumbum, K., P675, P753, P990
Kaperschmidt, D. I., P393
Kupfer, S. S., P886
Kurayim, I., P86
Kwok, H., P540
Lacy, B. E., P15
LaJoie, A., P412
Lakhan, A., P736
Lalos, A. T., P209
Lam, M. C. W., P357
Lam, M. Y., P541
Lantikarani, A., P121
Laslner, B., 24A, P595
Latif, S. R., P177
Lamb, M. Y., P541
Lam, M. C. W., P537
Lam, M. Y., P541
Lovallo, M., P522
Lapin, J., P222
Levy, R. M., P839
Levine, R., P829
Levy, R. M., P839
Levy, S. M., P745
Lewis, J. D., P342
Lewis, J. H., 41
Lewis, J. D., P342
Levy, J., P576
Leve, J., P784
Levine, R., P829
Levy, R. M., P839
Levey, S. M., P745
Lewis, J. D., P342
Levey, J. H., 41
Li, J., P420
Liangpunsakul, S., 40
Lichtstein, G. R., P290, P949, P953
Lim, B. S., P115, P178, P397
Lin, J., P827
Lindor, K. D., P18
Liu, J. J., P6
Liu, W., P701, P896
Locke, G. R., P294, P638
Loeb, D. S., P867
Loftus, E. V., 57, P618, P909, P937, P942, P952
Logan, I., P346
Lois, A., P623
Lopes, S., P755
Loren, D. E., P690
Lowe, R. C., P151
Lufrano, M., P132, P158
Ly, E. J., P206
Lyczak, J. B., P775
Maas, L. C., P782
MacDermott, R., P883
Macedo, G., P755, P880
Madan, A., P567
Madanick, R. D., P366
Madhavan, M., P476
Madhottar, R., 25
Maganity, K., P720
Magowan, S., P785
Mahadevan, U., P609
Mahajan, L., P273, P304, P337, P545
Mahdavian, M., P96, P526
Mahi, T., P434, P763
Majewski, M., P353
Majid, S., P649
Majithia, R. T., P255, P930
Malipour, K., P447
Malaty, H. M., P238
Malhotra, H., P752, P798, P820
Malik, B., P847
Malkani, A., P336, P669, P670
Malliksho, A. M., P756
Manchikalapati, P., P524, P576
Mann, N. S., P652, P787
Mann, S. K., P178
Mardini, H., P512, P624, P933, P954
Marin, C. S., P852
Martel, J., P175, P663
Martin, P. D., P577
Martin, T. M., P288
Maser, E. A., P596
Massaad, J., P658
Mathers, J. C., 13
Mathew, A., P529, P650
Mathew, A. K., P445
Mathur, S., P550
Matsushita, M., P904
McCabe, E. J., P555
McCallum, R., 61, P138, P351, P379, P738
McCallum, R. W., P306
McDevitt, P. J., P529
McDougall, H. E., P998
McElreath, D. P., P816
McGuigan, J., P590
McKinley, J. M., P125
McLaughlin, R., 64
Mega, M., P726
Mega, S., P398
Mee, A. S., P878
Mee, P. D., P914
Mehboob, S., P129, P678, P802
Mehendiratta, V., P354
Meha, N., P342
Meier, R. D., P972
Meiner, J., P25, P36, 46, 55, P110
Minhas, Z. M., P97
Minocha, A., P131
Mishkin, D. S., P127, P349
Misra, P., P811
Mitani, T., P717
Mitchell, M. C., P182, P483
Mitra, D., P929
Mitchell, R. A., P206
Mital, A., P748
Mittal, S., P781, P960
Miyazaki, M., P737
Mizrahi, F., P779
Modha, F. M., P819
Modi, R. J., P198
Mody, R., P593, P912
Mohammedi, A., P797
Mohamed, M., P106, P456
Molloy, P. J., P8
Momenni, M., P112, P171, P477
Montenegro, R., P460
Montenovo, M. I., P706
Morgan, M. E., P840
Morrissey, S. K., P518, P519
Moulis, H., P69
Mourad, W. A., P145
Muckova, N., P665
Muddana, V., P739
Muhammad, A., P307, P308, P309, P935
Muir, A. J., P92
Mukherjee, M., P465, P486
Mullin, J. M., P18
Mummadi, R. R., P179, P427, P656, P987
Mummid, S. R., P882
Munjipppa, P., P337, P667
Munoz, J. C., P457
Murthy, U., P470
Murthy, U. K., P142
Mustacchia, P. J., P406, P718
Muthavarapu, S. R., P327
Mutlu, E., P241
Nachhimi, J. S., 20, P93, P762
Naderi, N., P603
Nadimpalli, R. V., P119
Nagar, A., P871
Nagri, S. K., P385
Naik, A. K., P52
Naina, H. V. K., P192
Nanda, R., P71
Naniwadek, A., P798
Naniwadek, A., P798
Narayan, M., P231
Nathani, M. G., P186, P523, P872
Navarro, V. J., P81
Nawaz, A., P43, P404
Neff, G., P226, P508
Nelson, S. P., P586, P917
Neri, B., P277, P623
Neshitt, A. M., P611, P943, P956
Nesmith, G. P., P194
Neuhaus, H., P705
Neumann, I., P705
Neumann, D. A., P705
Ng, E., P265, P925
Nguyen, C. C., P572
Nguyen, M. H., P840
Nguyen, M. T., P710
Nguyen, T. M., P987
Nguyen, T. N., P495
Nicholas, T. J., P631
Nieves, P. J., P761
Nikoloff, M. A., P975
Nonaka, T., P96
Norris, W. E., P647
Nourani, S. M., P854
Novak, I., P334
Author Index

Nozawa, S., P377
Nyhus, M., P672
O'Connor, R. M., P845
O'Riordan, K., P636
Obideen, K., P94, P421, P533, P764
Oda, Y., P713
Oeschslager, B. K., P706
Oh, J., P661
Okolie, C. N., P258
Olfassson, S., P548
Olden, K. W., P191, P490, P561, P816
Olejeme, H., P205
Olivier, M., P87
Olowe, K., P703
Olson, B., P243
Oloyae, M., P310, P311, P448
Oosterveen, S., P647
Orlando, R. C., P371, P373
Orr, W., P592
Osama, H., P37
Osgrad, E. M., P874
Ostrinsky, Y., P320
Outlaw, W., P826
Ouyang, A., P446
Ouyang, Q., P416
Oxentenko, A. S., P196, P489
Ozick, L., P493
Padda, M., P557
Pahk, A. J., P129
Pais, S., P161
Pal, S. K., P466
Palanc, A. L., P552, P553, P554
Palsson, O. S., P970
Panaccione, R., P950
Pandi, C., P44
Panetta, J. D., P76
Pankaj, P. J., P300
Pannala, R., P154, P169
Panazarella, P. S., P850
Pare, P., P637
Paredes, A. H., P234
Parekh, S., P94
Park, D. I., P111
Park, S. K., P111
Park, T., P165, P499, P744
Parkman, H. P., S3, P292, P378, P447, P908
Pasharavesh, L., P751
Paschos, C. L., P931
Pasricha, P. J., P960
Patel, A., P401, P533
Patel, A. P., P193, P229
Patel, H., P660
Patel, J., P796
Patel, K., P438, P501, P654
Patel, K. K., P759
Patel, K. R., P71
Patel, M. B., P808
Patel, N. P., P407
Patel, S., P50
Patel, S. N., P166
Patel, V., P933
Patel, Y. J., P995
Paul, M., P142
Paul, N., P905
Pawa, R., P493
Pearson, A. N., P120, P403
Pedrazzoli, Jr., P42
Peery, A. F., P22
Pehlivanov, N., P415
Peloquin, J. M., P837
Penny, E., P677
Perez, J., P440
Perez, R., P450
Petersen, B. T., P257, P725
Petersen, J. M., P575
Peterson, K., P17, P363
Peterson, K., A. G., P972
Pham, B. V., P557
Phillips, J. O., P333
Pimentel, M., P15, P62, P295, P303
Piper, M., P130, P501
Piper, M. H., P174
Pitchumoni, C. S., P307, P308, P309, P395
Pleskow, D., P45
Pochapin, M. B., P323
Pocock, P., P854
Poddar, U., P335
Polson, J., P39
Poppers, D. M., P323
Potak, J. Z., P504
Pou, J. A., P988
Prasad, G. A., P154, P702
Pratha, V., P582
Prakaz, C. J., P818
Present, D. H., P948
Prindiville, T., P947
Prindiville, T. P., P940
Proctor, D., P599
Prosser, B. J., P182
Protiva, P., P822
Puli, S. R., P580, P721
Qadeer, M. A., P326
Qayed, E., P58, P394, P727
Qazi, B., P96, P636
Quander, C., P299, P679
Quigley, E. M. M., P52, P632, P964
Qureshi, E., P778
Qureshi, W. A., P780
Raddavi, H., P141, P173, P230
Rader, V. J., P187
Rahman, R., P55
Rahmani, R., P531, P776
Rajman, I., P67
Raju, G. S., P1, P463, P656, P780, P781
Raju, R. P., P740
Ralph, J. C., P986
Ramamurthy, S., P235
Ramdhaney, S., P515
Ramirez, C., P347, P698, P1005, P1006
Ramkumar, D. P., P5, P153, P157, P473
Ramos-De la Medina, A., P749
Raphael, A., P20
Rangnekar, A. S., P681
Rani, A., P695
Ransibrahmanakul, K., P947
Rao, K. V., P329
Rao, P. S., P51
Rao, P. K., P72
Rao, S., 1, 51, 54, P101, P969
Raskin, J. B., P484
Ravi, K., P19, P890, P942
Ravipati, M., P214
Reddy, J. A., P808
Reddy, V., P403
Reddymasu, S., S1, P351, P448, P738
Rehan, R., P724
Reid, P., P235
Reka, S., P185, P534
Remes-Troche, J., P969
Remes-Troche, J. M., P749, P966
Remy, P., P990
Remzi, F., P23
Rex, D. K., P453, P682
Rezaiahshakjani, M., P382
Rhee, P-L., P296
Rhum, A. D., P122, P997
Ribeiro, M. L., P711
Ricci, G., P91
Richter, J. E., P697
Ringold, D. A., P693, P982
Rivas, Y., P334
Rivera, M., P228
Rizvonn, K. M., P718
Robertson, D. M., P92
Robilliotti, J., P379
Robson, K. M., P16
Rodrigues, D. M., P2
Rodriguez-Stanley, S., S5, P36
Rodriguez-Torres, M., P785
Rogart, J. N., P871
Romagnuolo, J., P677
Romero-Marrero, C., P441
Roorda, A. P., P767
Rosenberg, M., P914
Roth, L., P617
Rothstein, K. D., P439
Rothstein, R. I., P700, P985
Rovito, V., P477
Roy, H. K., P340, P672
Roy, P. K., P44, P579, P580
Rubin, D. T., P823, P866
Rubin, G., P361
Rumi, G., P350
Russell, N., P454
Russo, M. A., P544
Saad, A., P560
Sabbagh, R., P803
Sachdeva, S., P99
Saeed, A., P991
Saeed, A. A., P104, P433, P452, P936
Saeed, M. A., P936
Saetete, T. M., P150
Safier, H., P494
Saha, S., P892
Said, E. M., P991
Saini, S. D., P7
Salcedo, J. A., P410
Salcedo, M., P386
Salman, T. A., P86, P770
Saltzman, J. R., P252, P559
Salvatore, L., P513
Salyers, Jr., P322
Samanta, A., P757, P765
Sampiliner, R. E., 63
Sanaka, M. K., P1003
Sanal, M. G., P84, P773
Sanchez, A. P., P156, P900
Sandar, N., P884
Sandborn, W., P8
Sandborn, W. J., 21, 24A, P275, P283, P613, P619, P948
Sandha, G., P31
Sands, B., P610
Sankari, M., P815
Sansone, N. S., P513
Shinoura, S., P54
Shirasaka, D., P17
Shiva Kumar, K., P217
Shruti, M., P479
Shudo, R., P436
Siao-Salera, R., P455
Siddiqui, A. M., P131
Siddiqui, A. A., P7
Siddiqui, J., P312
Siddiqui, S., P340
Sikka, S., P983
Silas, D., P143, P995
Silberg, D. G., P30, P359, P371, P373, P589, P594, P687
Silverman, A., P629, P818
Silverman, A. L., P5
Simmons, A., P421
Simpson, K. N., P62
Sing, J. T., P399
Singh, A., P546, P820, P999
Singh, D. K., P80
Singh, E. G., P1001
Singh, G., P382, P866
Singh, K., P64, P742
Singh, M., P139, P210
Singh, N., P514
Singh, P., P528, P530
Singh, S., P310
Singh, V., P653
Sivaparakasapillai, N. M., P538, P659
Skopic, A., P201
Slatkin, N. E., P794
Slavin, J. L., P103
Small, A. J., P27
Smith, A. D., P212, P222, P462
Smith, J., P822
Smith, J. W., P274
Smith, M. T., P116
Snyder, N., P430, P685
Socoloff, D. N., P170
Sodeman, T., P431
Sohagia, A. B., P724
Sohn, N., P657
Somay, K., P522
Sontag, S., P712
Sood, G., P978
Sood, G. K., P752, P801
Soood, S., P830
Soood, V., P118
Sooodi, N. M., P676
Sorser, S. A., P782
Spechler, S. J., P687
Spiegel, A. J., P161, P568
Spira, R., P292, P838
Spradlin, N. M., P615
Sprung, D. J., P746
Sreenarasimhaiah, J., P401
Srikureja, W., P864
Srinivasan, R., P65
Sriram, P. V. J., P118, P527
Srivastava, A. P., P419
Stark, M. E., P26
Stecevic, V., P517
Stepen, R., P635
Stepen, R. M., P671
Stepfer, K. O., P430
Stein, B. N., P683
Stephen, S., P809
Stephens, S., P956
Sterling, M. J., P163
Sterling, R. K., P771
Steven, F., P843
Steven, T., P722
Stewart, M. L., P103
Stiphon, S., P6
Stoffel, E. M., P542
Stone, L., P3
Storch, I., P132, P158
Strum, W. B., P1001
Stuppy, W. P., P147, P203
Suarez, E., P441
Subbiah, V., P8
Subbiah, Y., P630
Subei, I. A., P756
Sugimoto, M., P65, P357, P364, P768
Sukhwani, P., P378
Suleiman, Y., P574, P804, P821
Sultan, K. S., P181
Sun, G., P23
Sundaram, U., P55, P320, P328
Surapaneni, N. S., P767
Sussman, D. A., P204
Svoboda, R. P., P561
Swain, C. P., P985
Swales, C. T., P784
Swanson, G., P835
Swaroop, P. P., P625
Swetser, S., P860, P965
Syed, H., P766
Szabo, G., P425
Tack, J., P367
Tacopina, T. A., P511
Talley, N. J., P29, P298, P301, P968
Tamboli, C. P., P786
Tan, S., P285
Tanaka, T., P713
Tang, J. S., P215
Tannous, G. C., P508
Tapia, M., P186
Targan, S., P24
Taruga, V., P377
Tashkori, M., P339
Tatel, S. F., P237
Tenner, S., P143, P135, P146, P221
Tennyson, C. A., P497
Terry, S., P855
Thackery, E. W., P102
Thomas, K. L., P9
Thomas, T., P261
Thompson, H. C., P245, P922, P923, P924, P926, P927, P928
Thompson, S. E., P6
Thorne, N., P167
Tin, H. H. J., P146, P221
Tiwari, P., P164, P220
Tobi, M., P997
Tokayer, A. Z., P681
Tombazzi, C. R., P388
Tong, S., P519
Tong, S. K., P833
Torbey, C., P519
Torgeron, S. A., P536
Toro, D., P988
Toro, D. H., P386, P450, P761
Torres, D., P422
Torres, E. A., P502
Torres, V. J., P50, P166
Tremaine, W. J., P60, P824, P944
Triafadiopouloa, G., P26
<table>
<thead>
<tr>
<th>Author</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trivedi, C. D.</td>
<td>P279</td>
</tr>
<tr>
<td>Trudeau, W.</td>
<td>P115</td>
</tr>
<tr>
<td>Tsai, C.-J.</td>
<td>34</td>
</tr>
<tr>
<td>Tsai, J.</td>
<td>P551, P558</td>
</tr>
<tr>
<td>Tsang, T.-K.</td>
<td>P665, P694, P719</td>
</tr>
<tr>
<td>Tsang, W.</td>
<td>P155</td>
</tr>
<tr>
<td>Tsushima, M. M.</td>
<td>P864</td>
</tr>
<tr>
<td>Turner, K. J.</td>
<td>P775</td>
</tr>
<tr>
<td>Tyagi, P.</td>
<td>P83</td>
</tr>
<tr>
<td>Ueno, R.</td>
<td>P37</td>
</tr>
<tr>
<td>Ullah, A.</td>
<td>P846</td>
</tr>
<tr>
<td>Ullman, T.</td>
<td>P263, P946</td>
</tr>
<tr>
<td>Ullman, T. A.</td>
<td>P504</td>
</tr>
<tr>
<td>Ulrich, D. L.</td>
<td>P735</td>
</tr>
<tr>
<td>Umar, M.</td>
<td>P97</td>
</tr>
<tr>
<td>Uppalapati, S. S.</td>
<td>P33</td>
</tr>
<tr>
<td>Urita, Y.</td>
<td>P21, P65, P357, P364, P768</td>
</tr>
<tr>
<td>Vadee, A.</td>
<td>P444</td>
</tr>
<tr>
<td>Vadlamudi, R. S.</td>
<td>P474, P509</td>
</tr>
<tr>
<td>Vaezi, M.</td>
<td>P23</td>
</tr>
<tr>
<td>Vaezi, M. F.</td>
<td>P24</td>
</tr>
<tr>
<td>Vakil, N.</td>
<td>P594</td>
</tr>
<tr>
<td>Vallurupalli, S.</td>
<td>P126</td>
</tr>
<tr>
<td>Van Thiel, D.</td>
<td>P835</td>
</tr>
<tr>
<td>VanderHeyden, T.</td>
<td>P180</td>
</tr>
<tr>
<td>Vanderveldt, H. S.</td>
<td>P642</td>
</tr>
<tr>
<td>Vargo, J. J.</td>
<td>P326</td>
</tr>
<tr>
<td>Varriyam, E.</td>
<td>P527</td>
</tr>
<tr>
<td>Varshe Ney, S.</td>
<td>P769</td>
</tr>
<tr>
<td>Vasireddi, S. S.</td>
<td>P208</td>
</tr>
<tr>
<td>Vautier, G.</td>
<td>P469</td>
</tr>
<tr>
<td>Veerapan, G. R.</td>
<td>P116, P874</td>
</tr>
<tr>
<td>Vega, K. J.</td>
<td>P28</td>
</tr>
<tr>
<td>Vege, S. S.</td>
<td>P496, P906</td>
</tr>
<tr>
<td>Velamati, P. G.</td>
<td>P483</td>
</tr>
<tr>
<td>Velayos, P. S.</td>
<td>P958</td>
</tr>
<tr>
<td>Velayutham, A.</td>
<td>P425</td>
</tr>
<tr>
<td>Vera, H.</td>
<td>P667</td>
</tr>
<tr>
<td>Verma, A.</td>
<td>P41</td>
</tr>
<tr>
<td>Vermeire, S.</td>
<td>P951</td>
</tr>
<tr>
<td>Victor, D. W.</td>
<td>P225</td>
</tr>
<tr>
<td>Vijayapal, A. S.</td>
<td>P109</td>
</tr>
<tr>
<td>Viksoo, M. J.</td>
<td>P163, P827</td>
</tr>
<tr>
<td>Virk, A.</td>
<td>P159</td>
</tr>
<tr>
<td>von Renteln, D.</td>
<td>P324, P704</td>
</tr>
<tr>
<td>Vu, D. H.</td>
<td>P549</td>
</tr>
<tr>
<td>Waechter, A.</td>
<td>P77</td>
</tr>
<tr>
<td>Waechter, A. C.</td>
<td>P859</td>
</tr>
<tr>
<td>Waheed, S.</td>
<td>P311</td>
</tr>
<tr>
<td>Waltefish, A.</td>
<td>P813</td>
</tr>
<tr>
<td>Wallace, M. B.</td>
<td>P980</td>
</tr>
<tr>
<td>Walter, A. H.</td>
<td>P162</td>
</tr>
<tr>
<td>Walter, M.</td>
<td>P491</td>
</tr>
<tr>
<td>Walters, R. L.</td>
<td>53</td>
</tr>
<tr>
<td>Wang, C.</td>
<td>P699</td>
</tr>
<tr>
<td>Wang, K. K.</td>
<td>P702, P709, P877</td>
</tr>
<tr>
<td>Wang, W.</td>
<td>P329</td>
</tr>
<tr>
<td>Wang, Y.</td>
<td>P697, P908</td>
</tr>
<tr>
<td>Ward, G. J.</td>
<td>P729</td>
</tr>
<tr>
<td>Watanabe, T.</td>
<td>P21</td>
</tr>
<tr>
<td>Weeks, S.</td>
<td>P627</td>
</tr>
<tr>
<td>Wehbi, M.</td>
<td>P858</td>
</tr>
<tr>
<td>Wehbi, M. A.</td>
<td>P344</td>
</tr>
<tr>
<td>Weinshel, E.</td>
<td>38</td>
</tr>
<tr>
<td>Weinstein, W. M.</td>
<td>P359</td>
</tr>
<tr>
<td>Weiser, K. T.</td>
<td>2</td>
</tr>
<tr>
<td>Weiss, J.</td>
<td>P184</td>
</tr>
<tr>
<td>Weiss, S. H.</td>
<td>P680</td>
</tr>
<tr>
<td>Wellington, J. L.</td>
<td>P114, P507</td>
</tr>
<tr>
<td>Wells, D. D.</td>
<td>P414</td>
</tr>
<tr>
<td>Wells, D. S.</td>
<td>P414</td>
</tr>
<tr>
<td>Wenzke, J. T.</td>
<td>P505</td>
</tr>
<tr>
<td>Wessinger, S. B.</td>
<td>P971</td>
</tr>
<tr>
<td>Whitcomb, D. C.</td>
<td>P739</td>
</tr>
<tr>
<td>Whitehead, W. E.</td>
<td>P640, P970</td>
</tr>
<tr>
<td>Whitlock, D. A.</td>
<td>P597</td>
</tr>
<tr>
<td>Widjaja, D.</td>
<td>P995</td>
</tr>
<tr>
<td>Widmer, J.</td>
<td>P124</td>
</tr>
<tr>
<td>Widmer, J. L.</td>
<td>P814</td>
</tr>
<tr>
<td>Wiese, D.</td>
<td>P605</td>
</tr>
<tr>
<td>Wild, G. E.</td>
<td>P606</td>
</tr>
<tr>
<td>Wiles, M. B.</td>
<td>P212</td>
</tr>
<tr>
<td>Wilkins, T.</td>
<td>P1007</td>
</tr>
<tr>
<td>Williams, J.</td>
<td>P180</td>
</tr>
<tr>
<td>Williams, J. C.</td>
<td>P967</td>
</tr>
<tr>
<td>Wolf, A. T.</td>
<td>P252</td>
</tr>
<tr>
<td>Wolf, D. C.</td>
<td>24B, P568</td>
</tr>
<tr>
<td>Wollins, E. R.</td>
<td>P496</td>
</tr>
<tr>
<td>Wong, B. S.</td>
<td>P196</td>
</tr>
<tr>
<td>Wong, C. K. W.</td>
<td>P537</td>
</tr>
<tr>
<td>Wong, R. H.</td>
<td>P11</td>
</tr>
<tr>
<td>Wong, R. K. H.</td>
<td>P996</td>
</tr>
<tr>
<td>Wright, K.</td>
<td>P824</td>
</tr>
<tr>
<td>Wu, B. U.</td>
<td>P389, P390</td>
</tr>
<tr>
<td>Wu, J.</td>
<td>P365</td>
</tr>
<tr>
<td>Yakoob, J.</td>
<td>P714</td>
</tr>
<tr>
<td>Yalamanchili, V.</td>
<td>P901</td>
</tr>
<tr>
<td>Yang, J.</td>
<td>P232</td>
</tr>
<tr>
<td>Yang, J. T.</td>
<td>P117</td>
</tr>
<tr>
<td>Yang, Y.-X.</td>
<td>P584</td>
</tr>
<tr>
<td>Yarze, J. C.</td>
<td>P564, P831, P861, P862</td>
</tr>
<tr>
<td>Yao, R. P.</td>
<td>P707</td>
</tr>
<tr>
<td>Yeaton, P.</td>
<td>P46, P391</td>
</tr>
<tr>
<td>Yee, Jr., H. F.</td>
<td>P259</td>
</tr>
<tr>
<td>Yeh, C.</td>
<td>P244</td>
</tr>
<tr>
<td>Yeh, Y.-C.</td>
<td>P931</td>
</tr>
<tr>
<td>Yen, E. F.</td>
<td>P609</td>
</tr>
<tr>
<td>Yen, R. D.</td>
<td>P434, P678, P763, P1000</td>
</tr>
<tr>
<td>Yoo, J.</td>
<td>P472</td>
</tr>
<tr>
<td>Younes, M.</td>
<td>P692</td>
</tr>
<tr>
<td>Young, A.</td>
<td>P734</td>
</tr>
<tr>
<td>Young, B.</td>
<td>P387</td>
</tr>
<tr>
<td>Young, M.</td>
<td>P20</td>
</tr>
<tr>
<td>Young, M. F.</td>
<td>P509</td>
</tr>
<tr>
<td>Younossi, Z. M.</td>
<td>P85</td>
</tr>
<tr>
<td>Yuan, Y.</td>
<td>P35</td>
</tr>
<tr>
<td>Yun, L. H.</td>
<td>P881</td>
</tr>
<tr>
<td>Zafar, S.</td>
<td>P428</td>
</tr>
<tr>
<td>Zali, M.</td>
<td>P106, P456</td>
</tr>
<tr>
<td>Zali, M. R.</td>
<td>P107, P338, P339, P382, P751</td>
</tr>
<tr>
<td>Zancosky, K. L.</td>
<td>8</td>
</tr>
<tr>
<td>Zarghi, A.</td>
<td>P247</td>
</tr>
<tr>
<td>Zauber, A. G.</td>
<td>14</td>
</tr>
<tr>
<td>Zayat, E. N.</td>
<td>P322</td>
</tr>
<tr>
<td>Zfass, A.</td>
<td>P408</td>
</tr>
<tr>
<td>Zhang, R.</td>
<td>P280, P607</td>
</tr>
<tr>
<td>Zhang, Y.</td>
<td>P416</td>
</tr>
<tr>
<td>Zhao, X.</td>
<td>P420</td>
</tr>
<tr>
<td>Zubaidi, S.</td>
<td>P110</td>
</tr>
</tbody>
</table>
Subject Index

5 aminosalicylates, mesalamines, P279
5-aminosalicylic acid, P283, P614, P619, P949, P950, P953
6-mercaptopurine, P936
6-thioguanine, P940
6MP, P504
AAGLD guidelines for HBV treatment, P90
Abdominal bloating and visible distention, P631
Abdominal CT scan, P328
Abdominal mass, P176, P718
Abdominal pain, P122, P190, P629, P738, P820
Abdominal surgery, P776
Abernethy malformation, P844
Aberrant right subclavian artery, P126
Abnormal liver enzymes, P224
Abscess, P229, P419, P535
Accommodation, P292
Achalasia, P369, P697
Achalasia cardia, P571
Acid output, P582
Acid reflux, P15
Acid supression therapy, P583
Acid-suppressive therapy, P236
Acute cholangitis, P54
Acute esophageal necrosis, P569
Acute hemorrhagic colitis, P574
Acute liver failure, 39, P73, P217, P425
Acute pancreatitis, 10, P43, P154, P155, P389, P390, P724, P726, P866, P879
Acute upper gastrointestinal bleeding, P979
Adenoma, P680, P878, P1003
Adenoma detection, P995
Adenoma detection rate, P1002
Adenoma recurrence, 9
Adenomatosis, P226
Adenomatous polyp, P342
Adenomatous polyps, P258, P450
Adenovirus, P499
Adherence, 11, P741, P955, P959, P1006
Adhesions, P629
Adiponectin, P570
Administrative data, P253
Adoloscent, P962
Adult, P907
Adult T-cell leukemia/lymphoma, P195
Advanced age, 16
Advanced adenomatous polyps, 7
Adverse events, P610
African American, 4, P28
African Americans, P92
African-American, P78, P648
African-Americans, P678
Afro-Caribbeans, P281
Afternoon, P1003
Age, P690
Agenesis of the gallbladder, P162
AIDS, P798
Alcohol and substance abuse, P52
Alcohol, P752
Alcoholic hepatitis, P423
Alendronate, P935
Alfa fetoprotein, P214
Algorithm, P277, P623
Alimaxx stent, P553
Allopecia, P912
Alpha feto protein, P95
alpha1 antitrypsin deficiency, P231
alpha2 adrenergic genotypes, P965
Ambulatory care, P256
Ambulatory pH monitoring, P10, P26
Ambulatory surgical center, P59
Ambulatory wireless pH monitoring, P588
Amecic abscess, P492
Ameloma, P476
Aminotransferases, P753
Ampulla of vater, P523
Ampulla, papilla, P986
Amylin, P734
Amyloid, P146
Amyloidosis, P146, P806, P889
ANA, P461
Anal EMG, P447
Anal manometry, P447
Anal sphincter, P446
Anal sphincter hypotension, P449
Analgesics, P190
Anastomotic stricture, P530
Ancillary clinical support, P938
Anemia, P117, P309, P514
Anidulafungin, P856
Animal model, P774
Anisakiasis, P904
Annular pancreas, P168
Anorectal manometry, P448
Anorectal, P446
Anti-HBc, P97
Anti Xa factor, P436
Anti-incontinence magnetic device, P449
Anti-TNF, 24A, 58
Antibiotic prophylaxis, P651
Antibiotics, P43
Antigen processing and presentation, P79
Antineutrophil cytoplasmic antibody (ANCA), P416
Antiplatelet anticoagulation, P998
Antivirals, P891
Aortoduodenal fistula, P72
APACHE II, P390
APC, P533
Apiral balloonning, P879
Apoptosis, P437, P943
Appendiceal adenocarcinoma, P559
Appendiceal villous adenoma, P559
Appendicitis, P474
Argon plasma coagulation (APC), P329, P537
Argon plasma coagulation, P812
Arterial dissection, P489
Ascaris lumbricoides, P200
Ascites, P88, P221, P222, P422, P518
Asian Indian, P84
Aspergillus, P567
Aspiration, P123
Aspirin, P31
Assessment, P991
Assessment tools, P284
AST, P945
Asthma, P368
Atrial-esophageal fistulas, P14
Atrophic gastritis, P65
Attitudes, P598
Atypical symptoms and older women, P7
Authorship, 60
Autoimmune, P167, P865
Autoimmune disease, P742
Autoimmune hemolytic anemia, P212, P463
Autoimmune hepatitis, P460, P765, P771, P834, P847
Autoimmune pancreatitis, P942
Autoimmunity, P377
Autonomic nervous system dysfunction, P965
AZM, P220
Azathioprine, 59, P498, P829, P936, P954
Baclofen, P122
Bacterial overgrowth, P62, P65, P241
Balantidium coli, P534
Balloon dilation, P821
Balloon dilator, P573
Bariatric surgery, 12, P61, P85, P824
Bariatric surgery outcome, 38
Bariatrics, P985
Barium enema, P792
Barostat, P25
Barrett, 64
Barrett's, P688
Barrett's esophagus with high-grade dysplasia, P708
Barrett's esophagus, buried BE, P701
Barrett's esophagus, esophageal adenocarcinoma, P695
Barrett's esophagus, P127, P349, P685, P686, P687, P689, P691, P694, P703
Barrett's neoplasia, 63
Barretts esophagus, P709
Barriers, P662, P676
Bascue, P485
Basidiobolus ranarum, P188
BCS, P89
Beclomethasone dipropionate, P269
Behavioral program, P962
Behavioral therapy, P306
Beliefs, P634
Benefit risk, P610
Benign bile duct stricture, P730
Bilateral, P737
Bilberry, P471
Bile duct stone removal, P47
Bile duct stones, 19
Bile leak, P48, P875
Biliary, P55, P404
Biliary colic, P729
Biliary cyst, P406
Biliary cystadenocarcinoma, P857
Biliary leak, P320
Biliary leaks, P653
Biliary stent, P320, P524
Biliary stenting, P395
Biliary stricture, P57, P58, P873
Biliary strictures, P405
Biliary tract complications, P50
Biliary obstruction, P172
Billing codes, P258
Biloma, P402, P875
Bioelectrical impedance analysis, P422
Biomarker, P112
Biomarkers, 12, P695
Biopsy forceps, P653
Biopsychosocial concept, P630
Black esophagus, P4, P569
Bleeding, P181, P520, P532, P778, P916, P978
Bloating, P69, P971
Bloody diarrhea, P491
Blue rubber bleb nevus syndrome, P514
BMD, 22
Body mass index, P348, P370, P683, P782, P783
Boerhaaves syndrome, P553
Borchadt, P816
Botox, P556
Bouveret's syndrome, P871
Bowel ischemia, P148
Bowel obstruction, P196
Bowel prep, P483
Bowel preparation, P975, P990, P992
Brain-gut pathway, P969
Bravo capsule, P15, P316
Bravo capsule placement, P315
Bread bag clip, P519
Breast cancer, P190, P578
Breath test, P110, P768
Breath testing, P62
Broken heart syndrome, P879
Bronchiolitis obliterans syndrome, P22
Buried bumper syndrome, P143, P544
C diff, P777
C-reactive protein, P111, P625
CA 19-9, P735
Cadherin mutation, P810
cagA vacA s1a, P714
Calcium metabolism, P63
Calcium sensing receptor, P739
CAM, P601
Canasa, P804
Cancer, 23, 27, P684, P692, P859
Carcinoid, P179, P480
Carcinoma, P702
Carcinosarcoma, P859
Cardiac arrest, P753
Cardiomyopathy, P502
Cardiovascular, P304
Case report, P481
Caspase 3-generated cytokeratin 18, P437
CAT scan, P402
Catheter-free, P12
CBD strictures, P49
CCR9, P620
Cecal, P477, P485
Cecal ulcer, P472
Cecal intubation, P104
Cecal mass, P798
Celiac disease, 3, 11, P175, P203, P248, P666, P741, P742, P743, P744, P745, P746, P747, P895, P987
Celiac plexus blockade, P722
Celiac sprue, P189, P740, P746
Cerebral thromboembolism, P828
Cetrotixab pegol, P285, P286, P481, P611, P622, P943, P951, P956
CES E-score, P977
Changing demographics, P885
Chemo-prevention, 13
Chemoinfusion, P760
Chemokines, P632
Chemoprevention, P340, P672
Chemoradiotherapy, P696
Chemotherapy, 41, P53, P475, P839
Chest pain, P239
Chest pain of GI origin, P239
Child, P335
Children aged 2-15 years, P332
Children, P238, P544, P635, P664, P731
Chloride channels, P40
Cholangiocarcinoma, P53, P403, P406, P870, P877
Cholangioscopy, P393
Cholecystectomy, P165
Cholecystitis, P159, P550
Cholecystoscopy, P164
Choledochal cyst, P406
Choledochal volvulus, P160
Choledochocle, P869
Choledochoduodenal fistula, P171
Choledocholithiasis, P169
Choledocholithiasis, P58, P165, P173, P735
Choledocholithiasis, lithotripsy, P405
Cholelithiasis, lithotripsy, P405
Cholestasis hepatitis, P459
Cholestasis, P213, P588, P873
Chromodendoscopy, P984
Chromosomal instability (CIN), P106
Chromosome 1p36 deletion, P669
Chronic abdominal pain, P332
Chronic alcoholic pancreatitis, P64
Chronic constipation, 48, P628, P640, P970
Chronic diarrhea, P301, P557
Chronic hepatitis B, P772
Chronic hepatitis B virus, P840
Chronic hepatitis C, P210, P218, P424, P763
Chronic liver disease, P770
Chronic noninfectious diarrhea, P785
Chronic pancreatitis, 17, P517, P722
Chronic viral hepatitis, P79
Ciprofloxacin, P213
Cirrhosis, 40, 43, P61, P150, P223, P231, P427, P833, P854
Cirrhosis - pleural effusions, P862
Cisplatin, P475
Clinical remission, P948
Clinical sequelae, P929
Clinical trials, P92, P961
Clinicopathologic factor, P456
Clip, P546
Clips, P656
Clostridium difficile, 49, P156, P413, P452, P776, P777, P807
Clostridium difficile diarrhea, P451
CMV, P289, P793
CMV enteritis, P547
Coagulation tests, P234
Coagulopathy, P849
Cobiprostone, P37, P40
Coccidiomycosis, P117
Coil embolization, P169
Cofa, P819
Cold biopsy, P796
Colectomy, 21, 57, P618, P921, P926, P927
Colitis, P484, P488, P490, P534, P775, P776, P807
Collagenous colitis, P487, P543
Colocutaneous fistula, P656
Colon, P109, P480, P524, P540, P576, P802, P806
Colon adenomatous polyps, P98
Colon aneuplasia, P492
Colon cancer, P102, P112, P457, P476, P486, P602, P999, P1005
Colon cancer prevention, P1004
Colon cancer risk, P98
Colon cancer screening, 6, P342, P346, P675, P998
Colon mass, P793
Colon masses, P457
Colon perforation, P561
Colon polyp, P789
Colon polyp histology, P982
Colon polyps, 7, P124, P663, P674, P677, P781, P983
Colon prep, P779
Colonie, P647
Colonic cancer, P454
Colon diverticulosis, P787
Colon interposition, P124, P530
Colonie ischemia, P483
Colonie lipoma, P577
Colonie lymphoma, P412
Colonie mantle cell lymphoma, P796
Colonie mass causing hematochezia, P577
Colonie metastasis, P134
Colonie obstruction, 27
Colonie polyp, P482
Colonie polyps, P450
Colonie transit, 54, P101
Colonoscopy withdrawal time, P341
Colonoscopic surveillance, 9
Colonoscopy preparation, P657, P781
Colonoscopy scheduling times, P995
Colorectal, P684
Colorectal adena, P111
Colorectal cancer, 5, 13, P106, P107, P244, P339, P340, P454, P456, P596, P672, P677, P678, P679, P958, P1000, P1007
Colorectal cancer diagnosis, P1001
Colorectal cancer mortality, 14
Colorectal cancer screening, P343, P344, P345, P676, P680, P683, P748, P997, P1001
Colorectal cancer screening (CRC), P660
Colorectal neoplasms, P450
Colyte, P337
Common bile duct, P51, P523
Common bile duct obstruction, P163
Common variable immunodeficiency, P189, P487
Community hospital, P385, P995
Community-acquired pneumonia, P584
Comorbidities, P302
Comparative investigation, P394
Compassionate use, P951
Complete spontaneous bowel movement, P628
Compliance, P261, P325
Complication, P123, P828, P907, P989
Complication of laparoscopic cholecystectomy, P837
Complications, P8, P43, P154, P180, P308, P576
Complications of cirrhosis, P862
Complications of enteric, P116
Computed tomographic enterography, P267
Computed tomography, P242
Concerns, P634
Congenital, P5
Congenital absence of portal vein, P844
Subject Index to Abstracts

Conscious sedation, P52
Consensus interferon, P424
Conservative management, P607
Constipation, 50, 51, 54, P110, P294, P295, P302, P447, P633, P635, P638, P671, P794, P795, P915, P918, P929
Consulters vs non-consulters, P970
Continuing medical education (CME), P237
Copper deficiency, P140
Cortical evoked potentials, P969
Corticosteroid, P817
Cortisol, 55
Cost, 2, P747, P928, P929, P931, P934
Cost analysis, 49, P930
Cost burden of illness, P265, P925
Cost effectiveness, 62, P918
Cost effectiveness study, 33
Cost outcomes, P915
Costs, P922
Covered self expandable metal stent, P391
Covered stent, P443
COX-2, 31
CRADS or CTC reporting and data system, P996
Crohns, P484
Crohn's, P608, P621, P909, P911, P941, P957
Crohn's and ITP, P831
Cronkhite-Canada syndrome, P194, P557
CRP, P71, P624
Cryptococcus, P427
Cryptogenic cirrhosis, P757, P765
CSEMS, P46
CT colonography, P996
CT enterography, P906
CT PET, P403
Cutaneous manifestation visceral malignancy, P151
Cyanacrylate, P318
Cyanacrylate glue, P554
Cyclical vomiting, P967
Cycling, P366
Cystic duct remnant, P867
Cystic duct stenting, P150
Cystic duct stones, P150
Cysts, P216
Cytochrome P4502E1, P107
Cytogenetics, P901
Cytokines, P377, P606
Cytomegalovirus infection, P843
Danaparoid sodium, P436
DBE, P408
DDP 733, P29
De Quervain's syndrome, P551
Deep vein thrombosis, 40
Defecation, P446
Defibrotide, P462
Delayed HCV clearance, P861
Delivery device, P539
Demarcation line, P713
Dementia, P249
Demographic factors, P247
Demographic features of GERD, P7
Demographic predictors, P617
Demographics, P666
Dengue fever, P749
Dexamethasone, P293
Dextrose, P157
Diabetes, P387
Diabetes mellitus, 7, P244, P457, P863
Diabetic gastroparesis, P381
Diabetic ketoacidosis, P736
Diagnosis, P272, P416, P641
Diagnostic testing, P62
Diagnostic yield, P307, P309, P643, P740, P987
Diaphragm's disease, P888
Diarrhea, 15, P193, P464, P493, P543, P668, P850, P860
DIC, P133
 Diet, P601
 Diet adherence, P743
 Dietary fiber, P103
 Dietary risk factors, P786
 Dieulafoy's lesion, P385
 Dieulafoy's ulcer, P813
 Difficult, P775
 Difficult colonoscopy, P788
 Diffuse large B-cell lymphoma, P174
 Diffuse polyposis, P557
 Digital rectal examination, 51
 Dilatation, P51
 Dilatation, 19, P123
 Dipsticks, P433
 Direct and indirect costs, P265, P925
 Direct and indirect method, P316
 Direct, P315
 Disease extent, P949
 Disease severity and duration, P599
 Disease severity, P266, P617
 Disparities, P677
 Disrupted duct syndrome, P725
 Disseminated histoplasmosis, P491
 Dissolution therapy, P819
 Distal migration, P509
 Diverticular complications, P469
 Diverticular disease, P968
 Diverticulitis, P187, P681, P782, P783
 Diverticulum of Kommerell, P126
 Diverting ileostomy closure, P280
 DNA content, aneuploidy, diploidy, P701
 Domperidone, P982
 Doppler, P86
 Dose, P614
 Dosing, P584
 Double aortic arch, P115
 Double balloon enteroscopy, 26, P154, P408, P514, P552, P554
 Double-balloon enteroscopy, P560
 Double-balloon enteroscopy, P317, P547
 Downstaging, P99
 Drug induced enteropathy, P642
 Drug resistance, 49
 Drug utilization, P34
 Drug-induced liver injury, P219, P224
 Dual channel pH probe monitoring, P665
 Duct, P166
 Duodenal biopsies, P889
 Duodenal biopsy, P740, P987
 Duodenal bulb heterotopic gastric mucosa, P811
 Duodenal MALT lymphoma, P894
 Duodenal mucosa, P64
 Duodenal narrowing, P168
 Duodenal ulcer, P171, P649
 Duodenal varices, P846
 Duodenum, P182, P183, P905
 DVT, P626
 Dx-H probe, P24
 Dysmotility, P11, P294
 Dyspepsia, 30, P26, P382
Dysphagia lusoria, P126
Dysphagia, P3, P11, P17, P115, P119, P120, P121, P152, P351, P372, P568, P570
Dysphagia, weight loss, P814
Dysplasia, 32A, 32B, 64, P606, P595, P596, P600, P616, P686, P689, P946
Dysphagia, weight loss, P814
Dysphagia, weight loss, P814
Dysplasia, 32A, 32B, 64, P506, P595, P596, P600, P616, P686, P689, P946
Dysplasia, 32A, 32B, 64, P506, P595, P596, P600, P616, P686, P689, P946
Dyssynergia, 51, P105
Dyssynergic defecation, 48
EBV, P289
Economics, 2, P382
Ecstasy, MDMA, P836
Ectopic ileal varices, P554
Education, P261, P1005
Educational programs, P237
Educational video, P659
Effective, P453
Efficacy, 8, P956
EGD, P981
EGFR, P-Akt, P-Erk, P695
Eikenella corrodens, P837
Elderly, P299, P1001
Elderly octogenarian, P1000
Elderly patient, P199
Elderly people, P21, P65
Electrohydraulic lithotripsy, P164
Electronic database, P399
Electronic health record, P932
Electronic medical record, P932
Emesis, P903
Emphysematous gastritis, P142
Encapsulating peritoneal sclerosis, P222
End stage liver disease, P215
Endoanal ultrasonography, P448
Endolumenal anti-reflux therapy, P700
Endoluminal anti-reflux therapy, 45
Endometriosis, P221, P562, P795
Endomyosial antibody, 3
Endophthalmitis, P225
Endoscopic, P546
Endoscopic clip, 28
Endoscopic cryotherapy ablation, P708
Endoscopic drainage, P391
Endoscopic findings, P250
Endoscopic full-thickness plication, P324, P704, P705
Endoscopic injection sclerotherapy, P644
Endoscopic management of hematochezia, P511
Endoscopic marking/clipping, P564
Endoscopic mucosal resection, P525
Endoscopic prevention of ERCP-pancreatitis, P652
Endoscopic resection, P323, P527
Endoscopic retrograde choledangiogram, P867
Endoscopic retrograde choledangiopancreatography, P321, P394, P404, P653, P727, P729
Endoscopic sphincterotomy, P47
Endoscopic surveillance of GI lymphoma, P710
Endoscopic therapy, P555
Endoscopic treatment, P985
Endoscopic ultrasonography, P310, P644
Endoscopic ultrasonography, P311, P399, P401, P407, P517, P646, P650, P702, P722, P844, P868, P876
Endoscopic ultrasonography (EUS), P531
Endoscopic ultrasound, trucut biopsy, FNA, P522
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA), P549
Endoscopic variceal ligation, P209
Endoscopy findings, P195
Endoscopy training, P397
Endosonography, P312, P978
Endovascular vein embolization, P835
Enema, P657, P790
Entamoeba histolytica, P476
Entecavir resistance, P840
Enteritis, P413
Enterocutaneous fistula, P607
Enteroscopy, P411, P509
Environmental risk factors, P786
Environmental saporophyte, P188
Enzyme immunoassay (EIA), P451
Eosinophilia, P41, P482
Eosinophilic ascites, P201
Eosinophilic esophagitis, P11, P17, P19, P351, P352, P372, P568, P570
Eosinophilic gastroenteritis, P141, P201
Eosinophilic infiltration, P201
Eosinophilic esophagitis, P691
Eotaxin, P372
ePFT, 17
Epidemiology, P298, P441, P968
Epstein-Barr virus, P947
ERCP, P46, P48, P50, P52, P54, P55, P57, P59, P172, P173, P319, P320, P393, P397, P398, P651, P730, P731, P875, P878
ERCP-associated pancreatitis, P652
Erosion of duodenum, P177
Erosive esophagitis, P348, P373, P594
Erosion, P122
Erythropoietic protoporphyria, P73
ESD, P467
Esomeprazole, P687
Esophageal, P572
Esophageal atresia, P124, P358
Esophageal cancer, P696, P708
Esophageal capsule endoscopy, P9, P977
Esophageal dilation, P574
Esophageal dysmotility, P486
Esophageal eosinophilic, P19
Esophageal function studies, P13
Esophageal histology, P359
Esophageal hypersensitivity, 1
Esophageal infection, P567
Esophageal lipidoma, P2
Esophageal manometry, P28, P351
Esophageal motility, 46
Esophageal perforation, P8, P119, P513, P575
Esophageal pH, P362
Esophageal pH monitoring, P370
Esophageal rings, P121
Esophageal secretion, P353
Esophageal stent, P509
Esophageal stricture, P843
Esophageal ulcer, P117
Esophageal varices, P127
Esophageal varical hemorrhage, P439
Esophageal varices, P644, P835
Esophageal webs, P121
Esophagectomy, P702
Esophagitis, P9, P693
Esophagus, 45, 46, P3, P12, P23, P25, P118, P354, P516, P525, P568, P569, P688, P690, P698, P700
Ethnicity, P28, P783
EUS, 65, P2, P59, P220, P400, P512, P527, P562, P615, P645, P647, P869
EUS; biopsy fine needle, P312
Ewing sarcoma, P176
Excluded stomach, P532
Exenatide, 15
Exercise, P788
Exercise induced, P470
Expenditures, P916
Extraluminal anti-reflux therapy, 45
Extraluminal anti-reflux therapy, 45
Extra-hepatic portal vein obstruction, 42
Subject Index

Extra-intestinal manifestations, P822
Extracolonic findings, P996
Extrahepatic manifestations, P218

F-scale, P21
Familial adenomatous polyposis, 32A, 32B
Familial aggregation, P298
Familial mediterranean fever, P823
Fat wrapping, P827
Fatty liver, P430, P768
Fatty replacement of the pancreas, P542
FD, P380
Fecal incontinence, P105, P448, P449
Fecal occult blood test, P418, P988
Fecal occult blood testing, P998
Fecal occult blood tests, P386
Feeding, 10, P314
Feeding problem, P336
Feeding tubes, P249
Fellowship, P319
Female, P321, P683
Fever of unknown origin, P232, P845
FFH, P149
Fiber supplementation, P787
Fibrosis, P82, P430, P754
Fine needle aspiration, P645
Fine-needle aspiration biopsy, P407
Fistula healing, P608, P621
Fistulizing Crohn’s, P910
FL: fatty liver, P87, P767
Flavor, P337
Flexible sigmoidoscopy, P345
Flow cytometry (FCM), P710
Flucanazole, P504
Focal foveolar hyperplasia, P149
Focal liver lesion, P859
Foerster forceps, P521
FOLFOX, P4
Follow up of non cardiac chest pain, P239
Food, P360
Foreign body, P519, P521
Foreign body retrieval, P526
Frequency, P97, P986
Fully covered, P1
Fulminant hepatic failure, P219
Functional bowel clinic, P630
Functional bowel disorders, P297, P508, P639
Functional chest pain, 1
Functional dyspepsia, 2, 53, P292, P298, P634
Functional gastrointestinal disorders, 52, P964, P966
Functional heartburn, 47, 55
Functional vomiting, P306
Fundal varix, 43
Fundic gland polyps, 32A, 32B
Fungal infection, P45
Fusobacterium nucleatum, P407
GA, P380
Gabapentin, P113
Gall bladder, P173, P179
Gall bladder dyskinesia, P738
Gallbladder remnant, P674
Gallstone, 34
Gallstone ileus, P871
Gallstones, P728
Gangliocytic paraganglioma, P407
Ganglioneuroma, P473
Gangrene, P477
Gangrenous cholecystitis, P160
Gastrointestinal hemorrhage, P233
Gastric, P39, P130, P384, P808
Gastric abberant pancreas, P312
Gastric acid, P36
Gastric adenocarcinoma, P814
Gastric adenocarcinoma diagnosis, P712
Gastric adenocarcinoma staging, P712
Gastric adenocarcinoma survival, P712
Gastric and duodenal ulcers (GDUs), P35
Gastric antral vascular ectasia, P809, P980
Gastric balloon, P513
Gastric bezoar, P819
Gastric bypass, P36, P140, P574, P896
Gastric bypass surgery, P63, P66, P532, P817
Gastric cancer, P465, P711, P716, P721
Gastric cancer recurrence, P129
Gastric cancer surveillance, P129
Gastric carcinoma, P714
Gastric duplication cyst, P555
Gastric electric stimulation, 8
Gastric electrical stimulator, P138
Gastric emphysema, P142
Gastric emptying, P293, P300, P376
Gastric emptying scintigraphy, 53
Gastric emphysema, P142
Gastric emptying scintigraphy, 53
Gastric lymphoma, P718
Gastric mass, P545
Gastric melanoma, P132
Gastric metastasis, P134
Gastric mucosa-associated lymphoid tissue (MALtoma), P719
Gastric myeloma, P144
Gastric neoplasm, P128
Gastric outlet obstruction, P513, P563, P818, P827, P871
Gastric pacemaker, P381
Gastric perforation, P620
Gastric pH, P362
Gastric polyp, P132, P818
Gastric schwantosiasis, P136
Gastric stasis, P556
Gastric stimulator, P627
Gastric submucosal lesions, P310
Gastric telangiectasias, P812
Gastric ulcer, P148
Gastric ulceration, P38
Gastroenterologists’ patient instructions, P682
Gastroenterology practice, 35
Gastroesophageal junction (GEJ), P128
Gastroesophageal reflux, P20, P332, P665, P931
Gastroesophageal reflux disease, 45, 47, 61, P9, P24, P26, P30, P359, P368, P370, P371, P373, P374, P382, P566, P587, P590, P591, P592, P700, P706
Gastrointestinal, 31, P235, P916
Gastrointestinal bleeding, P139
Gastrointestinal bleeding, P135, P234, P250, P385, P490, P519, P547, P560, P566, P846
Gastrointestinal CMV, P891
Gastrointestinal hemorrhage, P72, P558, P796, P902
Gastrointestinal lymphoma, P412, P710
Gastrointestinal manifestations, P536, P749
Gastrointestinal plasma cell dyscrasia, P144
Gastrointestinal polyps, P323
Gastrointestinal prophylaxis, P583
Gastrointestinal stromal tumor, P197, P893
Subject Index

Gastrointestinal stromal tumors (GIST), P128
Gastrointestinal symptoms, P247
Gastrointestinal tract, P242
Gastrointestinal tumors, P197
Gastrointestinal bleeding, P440
Gastroptosis, 8, P146, P300, P376, P377, P378, P507, P626, P627, P633, p738, P908, P967
Gastroptosis, P38
Gastrostomy tube, P544
Gastrostomy, P314
GE, P380
Gemtuzumab, P462
Gender, P101, P353, P672
Gender and predictors of weight loss, 38
Gender differences, P272
Gender disparity, 35
Gender effect, P997
Gene expression, P711
Gene sequencing, P603
General characteristics in no-show patients, P327
Genetic mutation, P840
Genetic test, P747
Genetic testing, P810
Genetic typing, P627
GERD, P2, P6, P10, P21, P27, P29, P256, P294, P316, P364, P366, P582, P586, P638, P685, P704, P705, P707, P912, P917
GERD nighttime symptoms, P593
GERD treatment options, P116
GI bleeding, P191, P240, P527, P813, P981
GI hemorrhage localization, P564
GI hemorrhage, P564
GI tract ulceration, P191
GIST, P181
Gliadin antibody, salivary, P203
GLIPR1, P692
GLP-2, P415
Glucagon-like peptide-2, P414
Glucose breath test, 16
Glutathione S-transferases, P107
Gluten free diet, 11, P741
Gluten sensitivity, P745
Glycogen, P863
Gossypiboma, P563
Grading, P442
Graft versus host disease (GVHD), P74, P250
Grand mal seizure, P171
Granulocyte-monocyte apheresis, P830
Granulomatous hepatitis, P224, P845
Guidelines, P383
H. pylori, P479, P714
H2-receptor antagonists, P34
HBV genotype, P755
HBV infection, P755
HBV serology, P755
HBV treatment, P772
HBV, P82, P766
HCC, P760
HCV virologic response, P861
HCV, cirrhosis, P801
HCV, P428, P434, P756, P763
Head and neck cancer, P131, P243
Healing, P594
Health care cost, P264
Health care costs, P920
Health education, P260
Health outcomes, P924
Health resource utilization, P587
Health-related quality of life, P590, P591, P592, P971
Healthcare costs, P266
Healthcare resource utilization, P914
Healthcare utilization, P922, P926
Heartburn, P27, P30, P359, P371, P373
Heat stress, P470
Helicobacter pylori, 36, P42, P98, P130, P147, P253, P322, P357, P386, P694, P711, P717, P719, P720
Helicobacter pylori (H. pylori), P699
Helicobacter pylori infection, P33
Helicobacter pylori serology, P720
Heller myotomy, P697
HELLP syndrome, P96
Hemangioma, P802
Hemangiomas, P802
Hemangiomatosis, P802
Hemoglobin, P852, P877
Hemochromatosis, P227
Hemoclip, P558
Hemoconcentration, P389
Hemodynamics, 42
Hemorrhid, P804
Hemostasis, P318
Hepatitis B purpura, P496
Hepatitis C and B and therapy, P208
Hepatitis C therapy, P913
Hepatitis C virus, P174
Hepatitis C virus (HCV), P223
Hepatocellular carcinoma (HCC), P223
Hepatocellular carcinoma, P254, P752, P850, P852, P857
Hepatolithiasis, P737
Hepatomegaly, P863
Hepatorenal syndrome, P83
Hepatotoxicity, P829
Hepatitis B, 44, P335
Hepatitis B immunoglobulin, 44
Hepatitis B therapy, P939
Hepatitis B, chronic, P90
Hepatitis C, P75, P76, P78, P92, P93, P94, P97, P209, P260, P429, P750, P754, P758, P761, P762, P842, P848, P855, P861
Hepatitis C and B and therapy, P208
Hepatitis C therapy, P913
Hepatitis C virus, P174
Hepatitis C virus (HCV), P223
Hepatocellular carcinoma (HCC), P223
Hepatocellular carcinoma, P254, P752, P850, P852, P857
Hepatolithiasis, P737
Hepatomegaly, P863
Hepatorenal syndrome, P83
Hepatotoxicity, P829
Hereditary gastric cancer, P83
Hereditary polyposis colorectal cancer, P884
Hereditary nonpolyposis colorectal cancer (HNPPCC), P338
Herpes esophagitis, P113
Heterotopia, P808
Heterotopic gastric mucosa, P811
Hiatal hernia, P160, P866
Hiccups, P816
HIDA scan, P162
Hidradenitis suppurativa, P505
High contrast imaging, P983
High contrast imaging, P982
High definition endoscopy, P445
High fiber diet, P787
Highly selective vagotomy, 61
Hispanic, P648, P728, P761
Hispanics, P441
Hispanic veterans, P988
Histamine2 receptor antagonist, P581
Histology, P751
Histoplasma, P793
Histoplasmosis, P3, P490, P798, P905
HIV, P344
HIV patients, P343
HIV screening, P501
HIV-associated colitis, P785
HLA haplotypes, P212
Hodgkin’s lymphoma, P858
Hodgkins disease, P718
HOMA, P435
Hookworm, P70
Hospital length of stay, P921
Hospitalization, P911
Hospitalizations, P937
HRQOL and resource use, P937
HRQOL and work productivity, P912
HSV, P113
HVPG, P82
Hydrogen breath tests, P241
Hydrothorax, P228
Hyper infection syndrome, P885
Hypercoagulable, P626
Hyperemesis gravidarum, P892
Hyperlipidemia, 20
Hyperpigmentation, P210
Hyperplastic polyps, P149
Hyperthyroidism, P459
Hypertriglyceridemia, 20, P155
Hypertriglyceridemia induced pancreatitis, P157
Hypothalamic pituitary adrenal axis, P606
Hypoxemia, P326
Iatrogenic, P984
IBD, 22, P289, P496, P601, P623, P624, P669, P670, P822, P828, P933, P936, P954
IEM and GERD, P356
IgA deficiency, P897
IgG4, P865
IgG4 positive colitis, P942
Ileal intubation, P655
Ileal pouch, 23, P616
Ileal pouch anal anastomosis, P612
Ileal pouch-anal anastomosis, P952
Ileitis, P625
Ileocecal ulcer, P899
Ileoileal intussusception, P199
Ileostomy, P607
Ileum, P195
Ileus, P202
Image quality score, P977
Imaging, P410, P904
Immune suppression, P944
Immunization, P274
Immunocompetent, P491, P891
Immunocompetent, immunocomprised, P522
Immunosuppression, P251, P274
Impedance, P363, P369
Impedance pH monitoring, P10
Impedance pH testing, 62
Impedance planimetry, 1
Impedance study, P29
Impedance testing, P366
Impedance-pH measuring, P331
Improvement of service, P104
Imuran, P954
Incarcerated hernia, P206
Income, 35
Incomplete bowel preparation, P661
Indeterminate colitis, P935
Indeterminate eosphageal eosinophils, P19
Indications for proton pump inhibitors, P585
Indirect, P315
Indoleamine 2,3-dioxygenase, P78
Ineffective eosphageal motility, P356
Ineffective motility, P355
Infectious colitis, P499
Infectious enteritis, P203
Inferior mesenteric vein thrombosis, P60
Inferior pancreaticoduodenal artery, P902
Inferior vena cava, P402
Inferon, P211, P756
Inflammation, P111, P611
Inflammatory bowel disease, 5, 60, P245, P274, P281, P352, P494, P503, P598, P599, P600, P602, P612, P620, P624, P625, P667, P933, P938, P940, P942, P947, P959
Infliximab, 21, P217, P245, P264, P270, P423, P497, P502, P605, P823, P826, P914, P919, P923, P928
Infliximab failure, P276
Informed consent, P659
Ingrowth, P1
Inpatient, P780
Inpatient mortality, P439
Inpatients, P779
Insulin, P155, P157
Insulin resistance, P770
Insulin-like growth factor, P703
Insuline resistance, P91
Interferon, P76, P420, P421, P434, P750, P847, P855
Interferon induced thyroid disease, P842
Internal medicine resident knowledge, P636
Intervention, P649
Intestinal, P493
Intestinal gas, P510
Intestinal inflammation, P597
Intestinal lymphangiectasia, P906
Intestinal malrotation, P205, P898
Intestinal metaplasia, P715
Intestinal spirochetosis, P800
Intestinal tuberculosis, P791
Intestinotrophic activity, P414
Intra-abdominal tuberculosis, P522
Intragastric balloon, P91
Intramural hematoma, P896
Intraoperative enteroscopy, P317
Intravenous immunoglobulins, P452
Intussusception, P417, P792
Inverted fundic gland polyp, P529
IP, P5
Iran, P716, P751
Irritable bowel syndrome, P638
Iron, P38
Iron deficiency anaemia, P235, P454
Iron overload, P227, P758
Irregular microvascular pattern, P713
Irrigation pump, P990
Irritable bowel syndrome, 52, P296, P299, P301, P303, P630, P632, P636, P639, P640, P800, P960, P961, P962, P963, P964, P965, P966, P968, P970, P972
Irritable bowel syndrome (IBS), P305
Irritable bowel syndrome with constipation, P302, P915
<table>
<thead>
<tr>
<th>Subject Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemia, P153, P180, P488</td>
</tr>
<tr>
<td>Ischemic, P388</td>
</tr>
<tr>
<td>Ischemic colitis, P470, P475</td>
</tr>
<tr>
<td>Ischemic hepatitis, P230, P753</td>
</tr>
<tr>
<td>Ischemic necrosis of colon, P882</td>
</tr>
<tr>
<td>Ischemis colitis, P489</td>
</tr>
<tr>
<td>Isolated gastric varices, P815</td>
</tr>
<tr>
<td>IVC filters, P177</td>
</tr>
<tr>
<td>Jaundice, P311, P735</td>
</tr>
<tr>
<td>Jejunal, P187</td>
</tr>
<tr>
<td>Jejunal ulcerations, P518</td>
</tr>
<tr>
<td>Jejunal varices, P178</td>
</tr>
<tr>
<td>Jejunostomy tube leakage, P548</td>
</tr>
<tr>
<td>Jejunostomy tube, P200</td>
</tr>
<tr>
<td>Jejunum, P186</td>
</tr>
<tr>
<td>Journal impact factor, 60</td>
</tr>
<tr>
<td>Kapoﬁ’s sarcoma, P417</td>
</tr>
<tr>
<td>Kayexalate, P882</td>
</tr>
<tr>
<td>Keeffe’s US algorithm for HBV treatment, P90</td>
</tr>
<tr>
<td>Kidney transplant, P516</td>
</tr>
<tr>
<td>Klebsiella pneumoniae, P225</td>
</tr>
<tr>
<td>Klippel-Trenauny-Weber syndrome, P478</td>
</tr>
<tr>
<td>Lactic acidosis, P839</td>
</tr>
<tr>
<td>Lactobacillus reuteri, P103</td>
</tr>
<tr>
<td>Lactose intolerance, P241</td>
</tr>
<tr>
<td>Lactulose, P233</td>
</tr>
<tr>
<td>Ladd’s band, P898</td>
</tr>
<tr>
<td>Language, P259</td>
</tr>
<tr>
<td>Lansoprazole, 30, P687</td>
</tr>
<tr>
<td>Laparascopic cholecystectomy, P48</td>
</tr>
<tr>
<td>Laparoscopic Heller myotomy, P697</td>
</tr>
<tr>
<td>Laparoscopic resection, P323</td>
</tr>
<tr>
<td>Large volume paracentesis, P438</td>
</tr>
<tr>
<td>Laryngitis, P580</td>
</tr>
<tr>
<td>Latin American, P680</td>
</tr>
<tr>
<td>Laxatives, P640</td>
</tr>
<tr>
<td>Learning curve, 26</td>
</tr>
<tr>
<td>Leptin, P387</td>
</tr>
<tr>
<td>Leser-Trelat, P151</td>
</tr>
<tr>
<td>Leukocyte esterase reagent strips, P433</td>
</tr>
<tr>
<td>Leukocyte esterase reagent strips, P88</td>
</tr>
<tr>
<td>Leukopenia, chronic kidney disease, P279</td>
</tr>
<tr>
<td>Limited systemic scleroderma, P890</td>
</tr>
<tr>
<td>Linaclotide, P628</td>
</tr>
<tr>
<td>Linear erosions, P799</td>
</tr>
<tr>
<td>Lipase, P158</td>
</tr>
<tr>
<td>Lipoma, P576</td>
</tr>
<tr>
<td>Lipoma mimicking carcinoma, P577</td>
</tr>
<tr>
<td>Lisinopril, P873</td>
</tr>
<tr>
<td>Literacy, P260</td>
</tr>
<tr>
<td>Lithotripsy, P165</td>
</tr>
<tr>
<td>Liver, P74, P80, P95, P216, P231, P246, P419, P769, P838, P853, P854</td>
</tr>
<tr>
<td>Liver abnormalities, P749</td>
</tr>
<tr>
<td>Liver abscess, P574, P837, P851</td>
</tr>
<tr>
<td>Liver biopsy, P429, P430, P772</td>
</tr>
<tr>
<td>Liver cancer, P441</td>
</tr>
<tr>
<td>Liver cirrhosis, P422</td>
</tr>
<tr>
<td>Liver disease, P742</td>
</tr>
<tr>
<td>Liver disease in pregnancy, P96</td>
</tr>
<tr>
<td>Liver failure, P836</td>
</tr>
<tr>
<td>Liver function, P768</td>
</tr>
<tr>
<td>Liver histology, P426</td>
</tr>
<tr>
<td>Liver lesions, P220</td>
</tr>
<tr>
<td>Liver mass, P841</td>
</tr>
<tr>
<td>Liver resection, P841</td>
</tr>
<tr>
<td>Liver transplant, P764</td>
</tr>
<tr>
<td>Liver transplant patients, P424</td>
</tr>
<tr>
<td>Liver transplantation, 4, 39, P50, P75, P77, P217, P440, P843, P856</td>
</tr>
<tr>
<td>Liver tumor, P226</td>
</tr>
<tr>
<td>Lobular breast carcinoma, P134</td>
</tr>
<tr>
<td>Long-segment Barrett’s esophagus (LSBE), P699</td>
</tr>
<tr>
<td>Long term, P707</td>
</tr>
<tr>
<td>Long-term efficacy, P622</td>
</tr>
<tr>
<td>Long-term follow-up, P635</td>
</tr>
<tr>
<td>Long-term outcome, P47</td>
</tr>
<tr>
<td>Long-term safety, P279</td>
</tr>
<tr>
<td>Loratidine, P834</td>
</tr>
<tr>
<td>Lower esophageal sphincter, P355</td>
</tr>
<tr>
<td>Lubiprostone, P918</td>
</tr>
<tr>
<td>Luminal Crohn’s disease, P276</td>
</tr>
<tr>
<td>Lung, P186</td>
</tr>
<tr>
<td>Lung abscess, P571</td>
</tr>
<tr>
<td>Lung cancer, P645, P805</td>
</tr>
<tr>
<td>Lung cancer staging, 65</td>
</tr>
<tr>
<td>Lung transplant, P22</td>
</tr>
<tr>
<td>Lupus nephritis, P472</td>
</tr>
<tr>
<td>Lymphadenopathy, P175, P218</td>
</tr>
<tr>
<td>Lymphangioma, P572</td>
</tr>
<tr>
<td>Lymphocytic collagenous microscopic colitis, P786</td>
</tr>
<tr>
<td>Lymphoma, P206, P815, P872</td>
</tr>
<tr>
<td>Lymphomatoid papulosis, P826</td>
</tr>
<tr>
<td>Lymphomatous colitis, P797</td>
</tr>
<tr>
<td>Liver transplant patients, P424</td>
</tr>
<tr>
<td>Magnetic resonance cholangiopancreatography, P58, P162, P394, P727</td>
</tr>
<tr>
<td>Magnifying endoscopy, P713</td>
</tr>
<tr>
<td>Malabsorption, P746, P883, P897</td>
</tr>
<tr>
<td>Malakoplakia, P130</td>
</tr>
<tr>
<td>Malignancy, P4, P646, P850</td>
</tr>
<tr>
<td>Malignant biliary obstruction, P49</td>
</tr>
<tr>
<td>Mallory Weiss tear, P648</td>
</tr>
<tr>
<td>Malnutrition, P883</td>
</tr>
<tr>
<td>Malpractice, 37</td>
</tr>
<tr>
<td>MALT lymphoma, P182, P463, P479, P525</td>
</tr>
<tr>
<td>Manometry, P354, P369, P671</td>
</tr>
<tr>
<td>Mantle cell lymphoma, P412</td>
</tr>
<tr>
<td>Maryland, P396</td>
</tr>
<tr>
<td>Mass, P477</td>
</tr>
<tr>
<td>Maternal inheritance, P967</td>
</tr>
<tr>
<td>Meat impaction, P573</td>
</tr>
<tr>
<td>Mechanical ERCP simulator, P56, P395</td>
</tr>
<tr>
<td>Meckel diverticulum, P907</td>
</tr>
<tr>
<td>Meckel’s diverticulum, P196, P199, P880, P887</td>
</tr>
<tr>
<td>Median annual income, P313</td>
</tr>
<tr>
<td>Mediastinal cyst, P152</td>
</tr>
<tr>
<td>Mediastinal lymph nodes, P646</td>
</tr>
<tr>
<td>Mediastinal lymphadenopathy, 65</td>
</tr>
<tr>
<td>Mediastinal mass, P531</td>
</tr>
<tr>
<td>Medical management, P187</td>
</tr>
<tr>
<td>Medicare population, P27</td>
</tr>
<tr>
<td>Medication constipation, 50</td>
</tr>
<tr>
<td>Medication lists, P255</td>
</tr>
<tr>
<td>Medication preference, P599</td>
</tr>
<tr>
<td>Melanoma, P135, P198</td>
</tr>
<tr>
<td>Melanosis duodeni, P881</td>
</tr>
<tr>
<td>MELD, P440</td>
</tr>
<tr>
<td>MELD score, P439</td>
</tr>
<tr>
<td>Melena, P894</td>
</tr>
<tr>
<td>Mental health side effects, P913</td>
</tr>
<tr>
<td>Mesalamine, 5, P269, P275, P278, P290, P785, P948, P955</td>
</tr>
<tr>
<td>Mesalazine, P963</td>
</tr>
<tr>
<td>Mesenteric ischemia, P403</td>
</tr>
<tr>
<td>Meta-analysis, P44, P579, P721</td>
</tr>
<tr>
<td>Metabolic syndrome waist circumference dominant determinant of NAFLD, P84</td>
</tr>
<tr>
<td>Metabolic syndrome, P85</td>
</tr>
<tr>
<td>Metal stent, P329</td>
</tr>
</tbody>
</table>
Metallothionein, P717
Metastasis, P118, P186, P578, P803, P805
Metastasis to liver, P859
Metastatic, P135
Metastatic carcinoma, P864
Metastatic gastric cancer, P465
Metastatic melanoma, P132, P886
Metastatic to scapula, P870
Methadone, P51
Methamphetamine, P903
Methane, P110, P295
Methimazole, P459
Methotrexate, P460
Methylene blue, P984
Methylnaltrexone, P794
Microsatellite instability, P338
Microsatellite instability (MSI), P106
Microscopic colitis, P248, P487
Migrated stent, P526
MII-pH, P355
Mild, 10
Mild or moderate, P950
Mini-MAZE, P8
Mismatch repair, P338
Mismatch repair proteins, P456
Missed appointments, P662
Missed cancer, P999
Missing endoscopy procedures, P327
Modified barium swallow, P120
Molecular analysis, P400
Monotherapy, 24B
Morphology & function, P64
Mortality, P389, P390, P726
Motility, P207, P354, P379, P381
MR enterography, P941
MRCP, 17, P55, P57
MRI, P941
MS, P435
MUC5AC, P715
Mucosal immunology, P632
Multichannel intraluminal esophageal impedance, P706
Multichannel intraluminal impedance, P22
Multiple biliary stents, P330
Multiple endocrine neoplasia-1, P137
Multiple endocrine neoplasm, P814
Multiple gastrointestinal carcinomas, P884
Multiple myeloma and pancreatic plasmacytoma, P161
Multiple myeloma, P853
Multiplex PCR, P694, P719
Muscle cramps, P192
Mycobacterium abscessus, P845
Mycobacterium avium complex, P183
Mycobacterium avium complex (MAC), P72
Mycoplasma mofetil, P472, P771
Myoclonus, P905
MyD88, P425
Myocardial infarction, P31, P981
N-butyl-2-cyanoacrylate, 43
NAFLD, 12, P431
NAFLD metabolic syndrome Asian Indians, P773
NAFLD, asymptomatic, ALT values could be deceptive, late presentation, P84
NAFLD: non alcoholic fatty liver disease, P767
NAFLD: non-alcoholic fatty liver disease, P87
NACMACS, P256
Naproxen-diphenhydramine sleeping aid, P114
Narrow band imaging, 6, P444, P541, P693, P982, P983
Nasal regurgitation, P125
NASH, P426, P435
NASH questionnaire, P431
NASH: non alcoholic steatohepatitis, P767
NASH: non-alcoholic steatohepatitis, P87
Natalizumab, 24A, 24B, 58, P847
Native American, P20
Naturopathy, P208
Nausea, 53
NBI, P445
Neuroendocrine tumor, P158
Neurofibroma, P138
Neurofibromatosis type 1, P893
Neuromuscular disorders, P969
Neuropathy, P834
Neutralizing antibodies, P956
Neutropenic enterocolitis, P792, P807
Neutrophilic dermatosis, P825
Newborns, P331
New device, P411
New technology, P393
Newborn, P336
Nighttime symptoms, P912
Nissen fundoplication, 61, P566
Nitazoxanide, P67, P68, P69, P147, P668, P848
No show, P327
Nocturnal gastroesophageal acid reflux, P356
NOD2, P287
NOD2/CARD15, P630
Nodular regenerative hyperplasia, P940
Non alcoholic steatohepatitis, P751, P765
Non erosive reflux disease, P693
Nonneoplastic polyps, P444
Non-alcoholic steatohepatitis, P774
Non-cardiac chest pain, P6
Non-cholesterol, P745
Non-cutaneous, P243
Non-Hodgkin, P872
Non-invasive, P432
Non-melanoma skin cancer, P944
Non-steroidal anti-inflammatory drug, 33
Non-steroidal anti-inflammatory drugs (NSAIDs), P35
Non-variceal acute UGI bleeding, 28
Nonacid reflux, P363
Nonalcoholic fatty liver disease, P85, P833
Nonalcoholic steatohepatitis, P80, P757, P759, P833
Noncardiac chest pain, P363
Noncholelasis, P829
Nonsteroidal anti-inflammatory, 63
Nonsteroidal anti-inflammatory drugs, 30
Nonsteroidal anti-inflammatory drugs, P141
Nonvariceal upper gastrointestinal bleeding (NVUGIB), P383
Normative data, P23
NOTES, P324
NSAID use, P33
NSAID-induced ulcer, P40
NSAID, P32, P204, P589
NSAI, P255
Nurse experience, P262
Nurse practitioner, P438
Nurses evaluation, P45
Nutritional changes, P605
Nutritional status, P71
Oatmeal, P507
Obesity, P30, P91, P326, P594, P684, P703, P757, P782, P788, P824, P993
Obesity screening, P748
Objective quality control, P994
Obstructive jaundice, P145
Occlusion, P179
Obstructive jaundice, P161
Occlusion, P179
Octreotide, P179
Odynophagia, P114, P567
Ohio, P431
Omeprazole, P18
Once daily, P275
Ongoing reflux despite PPI, P375
Open access colonoscopy, P346
Ophthalmologic complications, P76
Opioids, P794
Opportunistic infections, P501
Oral sodium phosphate solution, P682
Organ transplant, P243
Oro-nasal fistula, P125
Oseltamivir, P464
Osler-Weber-Rendu (HHT), P133
Osler-Weber-Rendu syndrome, P812
Osteopenia, P282
Osteoporosis, P895
Outcome, P45
Outcomes, P238, P246, P249, P254, P257, P259, P698, P937, P973
Outcomes research, P240, P587, P908, P917
P2x, P960
Paclitaxel, P466
Paid day off, P675
Pancreatitis, P729
Pancreas, 18, P872
Pancreas cyst, P723
Pancreas divisum, P876
Pancreatic, P166
Pancreatic abscess, P650
Pancreatic cancer, P311, P392, P399
Pancreatic cyst, 18, P392
Pancreatic cystic neoplasm, P392
Pancreatic cysts, P163, P400, P401
Pancreatic duct, P523
Pancreatic duct stone, P876
Pancreatic exocrine insufficiency, P542, P890
Pancreatic herniation, P866
Pancreatic mass, P161, P868
Pancreatic neoplasm, P723
Pancreatic pseudocyst, P152
Pancreatico-jejunostomy, P560
Pancreaticobiliary disorders, P727
Pancreatitis, 20, P45, P158, P167, P202, P731, P733, P734, P736, P739,
P864, P865, P894
Pancreatitis complications, P725
Pandisaccharidase, P897
Pantoprazole, P350, P367
Papilla, P878
Paracellular, P18
Paracentesis, P849
Paraneoplastic syndrome, P151, P463, P486
Parasite identification, P538
Parathyromone (PTH) assay, P549
Parathyroid adenoma, P549
Patency, P832
Patency capsule, P539
Pathogenesis of heterotopic gastric mucosa, P811
Pathologic reflux, 46
Patient education, P639
Patient reporting, P255
Patient-reported outcomes, P909, P910
Payor perspective, P919
PCR, P428
Pediatric, 3, P273, P304, P337, P398, P545, P668
Pediatric achalasia, P334
Pediatric Crohn’s disease, P922
Pediatrics, P352, P354, P666, P667, P917, P974
PEG complications, P131
PEG-IFN and ribavirin, P801
PEG-polyethylene glycol, P992
Peginterferon alpha-2a, P210
Pegylated electrolyte lavage solution, P1002
Pegylated interferon, P75, P209
Penetrating ulcer, P145
Pentoxifylline, P83, P426
Peptic ulcer, P168
Peptic ulcer bleeding, P31
Peptic ulcer disease, P33, P145, P148, P170, P322
Perceptions, P396
Percutaneous endoscopic gastrostomy, P313, P540, P579
Percutaneous gastrostomy tubes, P143
Perforation, 37, P467, P468, P524, P535, P540, P790
Performance, P991
Periampullary carcinoma, P172
Periampullary diverticula, P54
Perianal fistulas, P615
Peripancreatic abscess, P474
Perinatal, P335, P766
Periodic acid-Schiff (PAS) positive macrophages, P185
Perirectal abscess, P196
Peritonitis, P427
pH, P16
pH metry impact scale, P588
pH metry symptoms scale, P588
pH monitoring, P6, P15, P931
pH testing, P12
Pharmacodynamics, P360, P365
Pharmacokinetics, P275, P333, P365
Pharmacologic prevention of ERCP-pancreatitis, P652
Phase 1 clinical trial, P642
Phenotype, P281
Pneumothorax, P758
Phone calls, P930
Photodynamic therapy, P709, P877
Photodynamic therapy, PDT, P701
Physician adherence, P748
Physician workforce, P1007
Physicians, P673
Pigmentation of duodenal mucosa, P881
Pill esophagitis, P114
Pkg pharmacokinetics, P415
Placebo, P35
Plasmacytoma, P144
Plasmapheresis, P73
Plastic removable stents, P575
Plicator, P324, P704, P705
Pneumatic dilation, P334
Pneumatic dilation, P334
Pneumoperitoneum, P327
Pneumothorax, P881
Pill esophagitis, P114
Pkg pharmacokinetics, P415
Placebo, P35
Plasmacytoma, P144
Plasmapheresis, P73
Plastic removable stents, P575
Plicator, P324, P704, P705
Pneumatic dilation, P334
Pneumothorax, P202
Pneumotosis cystoides intestinalis, P890
Pneumotosis intestinalis, P142, P510, P670
Polaprezinc, P717
Polyethylene glycol laxative, 50
Polyethylene glycol, P340
Polyflex stent, P528, P530, P553, P575
Polymer migration, P116
Polymorphism, P339
Subject Index

Polymyalgia rheumatica and complications of steroid therapy, P469
Polymyositis, P211
Polyp, P458, P681
Polyp detection, P262, P660, P784
Polyp recurrence, P1004
Polypectomy, P535, P663, P1004
Polypoid, P473
Poor outcome, P358
Poor preps, P780
Population study, P679
Porous diaphragm syndrome, P228
Porphyria cutanea tarda, P227
Portal, P153
Portal hypertension, P86, P860
Portal vein thrombosis, 42, P60
Portal venous thrombosis, P436
Positive predictive value, P744
Post cholecystectomy pain, P974
Post cholecystectomy syndrome, P874
Postcholecystectomy, P653
Post polypectomy, 9
Post polypectomy hemorrhage, P778
Post-cholecystectomy syndrome, P867
Post-operative complications, 57
Post-operative ileus, P921
Post-prostatic biopsy hematochezia, P511
Post-operative ileus, P921
Post-cholecystectomy, P653
Post cholecystectomy syndrome, P874
Post cholecystectomy pain, P874
Portal venous thrombosis, P436
Portal hypertension, P86, P860
Porta venosa, P207
Porous diaphragm syndrome, P228
Pre-albumin, P71
Pre hepatorenal, P83
Practice variation, P938
Practice, P396
PPI, P580
Pouchitis, P945, P952
Pre-procedural counseling, P325
Pregabalin, P629
Prediction of polyp histology, P445
Predictive factors, P358, P618
Predictors, P30, P432
Predictors of response, P300
Pregnancy, P100, P205, P892
Prevalence, P20, P247, P299, P631, P685
Preventive health care, P598
Previous steroid use, P290
Primary carcinoïd tumor, P95
Primary carcinoid carcinoïd tumor, P214
Primary prevention, P32
Primary sclerosing cholangitis, 4, P102, P212, P764, P853
Prior gastric surgery, P556
Probiotics, P305, P963
Procedure times, P993
Prognosis, 39, P53
Prognostic marker, P724
Progression, P733
Prokinetics, P376, P975, P979
Prolonged therapy, P953
Prophylactic antibiotic, P579
Prophylactic antibiotics, P44
Prophylaxis of hepatitis B, 41
Propofol, P654
Prostate biopsy complications, P511
Prostate biopsy, P558
Prostatic biopsy, P520
Protein, P112
Protein C, P488
Protein losing enteropathy, P883, P906
Proton pump inhibitor, 63, P333, P374, P582, P589, P818
Proton pump inhibitors, P34, P141, P362, P581, P585, P586
Proton-pump inhibitors, P584
Proximal black esophagus, P565
Proximal channel pH probe indices, P665
Prurigo nodularis, P838
PSC, P669
Pseudomembranous colitis, P777
Pseudotumor, P841
Pseudoankylostoma elasticum, P813
Psychological distress, P374
Psychological stress, P606
Psychology, P913
Psychosocial assessment, P972
Psychosocial factors, P973
PTFE, P89
PTLD, P516
Pulmonary emboli, 40
Pulmonary fibrosis, P211
Pulmonary hypertension, P835, P900
Pulmonary manifestations in inflammatory bowel disease, P495
Pulmonary nodules, P495
Pylephlebitis, P60, P232
Pyloric stenosis, P821
Pyogenic liver abscess, P225, P851
Quality of life outcomes, P637
R- verapamil, 52
Rabeprazole sodium, P368
Rabeprazole, P348
Racial/ethnic, P676
Radiation, P321
Radiation colitis, P537
Radiation therapy, P696
Radiofrequency, P769
Radiofrequency ablation, P852, P980
Radionuclide gastric emptying, P507
Rapid urease test, P270
Rare presentation, P870
Ray, P734
Rat-toothed forceps, P529
Reactivation of hepatitis B, 41
Real-time, automated video capture, P994
Rebamipide, P364
Rebleed, P649
Rebleeding, P252
Recombinant hepatitis B vaccine, 44
Rectal, P520
Rectal bleeding, P537, P806
Rectal cancer, P99, P533, P803
Rectal foreign body, P521
Rectal pain, P329
Rectal prolapse, P561
Rectal stent, P533
Rectal tumor, P479
Rectal ulcer, P804
Rectal varices, P478
Rectum, P578, P790, P808
Rectus sheath hematoma, P649
Recurrence, P280
Recurrence in small bowel, P129

Subject Index to Abstracts S13

Recurrence, P221
Recurrent abdominal pain, P238
Recurrent hepatitis C, P77
Reflux, P16, P333, P580, P691
Reflux disease, P331
Reflux episodes, P375
Reflux esophagitis, P349, P357
Reflux related chronic cough, 62
Refractory antibiotic-associated diarrhea, P508
Refractory Crohn’s adalimumab, P831
Refractory GERD, P13
Refractory, P460
Relapse, P283
Relative risk, cholangitis, sepsis, P651
Remicade, P501
Remission maintenance, P604
Remission, P619, P771
Renal cell carcinoma, P197, P552
Renal failure, P213, P222
Repeat procedures, P257
ReQuestTM, P367
ReQuest in practice, P361
Sodium polystyrene sulfonate, P882
Sodium phosphate lavage solution, P1002
Sodium polystyrene, P483
Socioeconomic stratum, P313
Small intestine, P207, P410, P417, P901, P904
Small intestinal stricture, P976
Small intestinal bacterial overgrowth, P61, P63, P66, P68, P303
Small bowel transit time, P643
Small bowel thickening, P175
Small bowel obstruction, P204, P280, P976
Small bowel malignancy, P418
Small bowel carcinoma, P184
Small bowel thickening, P175
Small bowel transit time, P643
Sensitivity thresholds, P25
Sex hormone, P296
Sexual abuse, P966
Sexual dysfunction, P933
Septic complications, P251
Septic thrombophlebitis, P232
Sequential therapy, 36
Serum albumin, P724
Serum aminotransferases, P759
Serum adiponectin paradoxically decreased in lean NAFLD, P773
Serum cortisol, P654
Serum leptin, P353
Serotonin, P961
Serology, P623
Serologic markers, P612
Sex hormone, P296
Sexual abuse, P966
Sexual dysfunction, P933
Sharp angle efferent limb, P548
Short bowel syndrome, 15, P414
Short-chain fatty acid, P103
Short-segment Barrett’s esophagus (SSBE), P699
Show rate, P325
Shwachman-Diamond syndrome, P542
SIBO, P67, P68, P69
Sickle cell disease, P171, P230
Sickle thalassemia, P230
Sedation on-demand, P455
Sedation, P453, P658
Sedation on-demand, P455
Seizure, P654
Self expanding metal stents, P1
Self expanding plastic esophageal stent, P526
Self-expanding metal stent, 27
Sensitivity thresholds, P25
Septic complications, P251
Septic thrombophlebitis, P232
Sequential therapy, 36
Serologic markers, P612
Serologic tests, P743
Serology, P623
Serotonin, P961
Serotonin receptor, P353
Serologic markers, P612
Socioeconomic stratum, P313
Sodium polystyrene sulfonate, P882
Sodium phosphate, P483
Sodium phosphate lavage solution, P1002
Sodium polystyrene sulfonate, P882
Recurrent hepatitis C, P77
Remission maintenance, P604
Remission, P619, P771
Renal cell carcinoma, P197, P552
Renal failure, P213, P222
Repeat procedures, P257
ReQuestTM, P367
ReQuest in practice, P361
Sodium polystyrene sulfonate, P882
Sodium phosphate lavage solution, P1002
Sodium polystyrene sulfonate, P882
Subject Index

Soehendra dilator, P573
SOFA score, P726
Specialty care utilization, P259
Sphincterotomy, 19, P869
SPINK1, P739
Spirochetes, P800
Splanchnic haemodynamics, P86
Spleen, P215, P419
Splendore-Hoeppli phenomenon, P188
Splenectomy, P515
Splenectomy, P545
Spontaneous bacterial empyema, P228
Spontaneous bacterial peritonitis, P88, P433
Spontaneous multiperforation, P797
SpyGlass, cholangiopancreatoscopy, P405
SSRI, P240
Standard therapy, 36
Standardized morbidity ratios, P248
Staphylococcus aureus, P851
Statin, 34, P421, P763
Statins, P244, P434
Steatosis, P93, P215, P754, P762
Stent, P109
Stents, P46
Steroid, 22
Steroid discontinuation, P920
Steroid injection, P821
Steroids, P245
Stigma, P972
Stomal ulcer, P387, P980
Stones, P166
Stool occult blood, P805
Straight to test service, 25
Stress model, indomethacin model, P37
Stress ulcer prophylaxis, P585
Stress-ulcer prophylaxis, P236
Stretta, P707
Subepithelial, P384
Submucosal colonic polyps, P510
Submucosal lesion, P529, P562, P572
Submucosal lesions, P647
Subspecialty ambulatory training, P636
Superior mesenteric artery syndrome, P903
Surgery, P723
Surgical complications, P119
Surgical therapy, P137
Surveillance, 23, P506, P616, P686, P689
Surveillance colonoscopy, 14, 37, P263, P342, P674, P946
Surveillance intervals, P661
Survey, P236, P254
Survey among gastroenterologists, P682
Survival, P99, P764
Survival analysis, P716
Sustained viral response, P93, P761
Sustained virological response, P77
SVR, P428
Sweet’s syndrome, P825
Sweets syndrome, P498
Symptom questionnaire, P971
Symptom relief, P350
Symptom resolution, P371
Symptom severity, P590
Symptomatic cholecystolithiasis, P164
Symptoms, P378, P671
Synchronous tumors, P884
Systematic review, 59, P305, P721
Systemic diseases, P889
Systemic mastocytosis, P860
T-fasteners, P39
TACE, P760
TAK-390MR, P360, P365
Tandem colonoscopy, 6
Taxane, P466
TB, P484, P989
Teduglutide, P415
Tegaserod, P303, P304
Telangiectasia (AVM), P133
Tenosynovitis, P551
Terminal ileal ulcer, P190
Testing, P16
TFF1, P715
Therapies, P934
Therapy, P609, P945
Thermocoagulation, 28
Three-dimensional cT, P115
Thrombocytopenia, P94
Thyroid disease and hepatitis C, P842
Thyrotoxicosis, P219
Tight junction, P18
TIPS, P89, P443, P846
Tissue biopsy, P214
Tissue penetration, P611
Tissue transglutaminase, P744
TNF, P423
Toll-like receptor, P425
Tonsillar cancer, P125
Toxic megacolon, P468
Toxocara, P857
Trainee participation, P784
Training, P56, P319, P395, P974
Transit times of gastrointestinal tract, P379
Transjugular intrahepatic portosystemic shunt (TIPS), P832
Transmission, P766
Transplantation, P246
Treatment, P42
Treatment impact, P284
Treatment outcome, P613
Treatment patterns, P586
Treatment response, P420
Trichobezoar, P820
Trichuris trichiura, P534
Tropheryma whippelii, P185, P900
Tropical pancreatitis, P517
Tuberculoma, P512
Tuberculosis, P512
Tumor necrosis factor, P339
Tumor necrosis factor (TNF), P74
Tunnel biopsy, P384
Turmeric, milk thistle, schisandra, bupleurum, ginseng, P208
Twins, P5
Type D personality, P297
UGI cancer, 25
Ulcer, P39, P252
Ulcer complications, P32
Ulcer inhibition, P37
Uncorrective proctitis, P269
Ulcers, P388
Ultrasoundography, P404
Umbilical hernia, P206
Uninsured, P345
Upper airway collapse, P658
Upper endoscopy, P386
Upper esophageal sphincter, P13
Upper gastrointestinal bleeding, P252, P815
Upper gastrointestinal diseases, P908
Upper gastrointestinal lesions, P641, P988
Upper GI bleed, P581
Upper GI bleeding, P515
Upper GI series, P205
Upper nasal endoscope, P548
Uremic pericarditis, P571
Ureter, P803
Urinary dysfunction, P633
Utility scores, P285
Uveitis, P288
Vaccinium myrtillus, P471
Validation, P361
Vanishing bile duct syndrome, P858
Variceal bleeding, P832
Varices, P432, P442
Vasoactive intestinal peptide, P193
Venous thromboembolism, P494
Video capsule endoscopy, P538, P974
Villous blunting, P189
VIPoma, P193
Viral hepatitis, P420
Viral load, P947
Visceral hypersensitivity, P960
Vitamin D, P282
Vitamin E and C, P759
Volvulus, P485, P898
Vomiting, P41, P627
Von Hippel-Lindau disease, P163
Water infusion colonoscopy, P455
Watermelon colon, P799
Watermelon stomach, P809
Web based education, P237
Weight gain, P66, P270
Weight loss and gender, 38
Whipple's disease, P185, P900
Whipple's, P183
Wireless capsule endoscopy, P204, P642, P886
Withdrawal time, P458, P789
Women, 34
WPAI, P613
Young male, P296
Young, P728
Zeaxanthin, P774
Zenker's bezoar, P120
Zinc, P61, P140
Zollinger Ellison syndrome, P137, P170